atazanavir|abacavir|2|Significant - Monitor Closely|atazanavir and abacavir both increase  risk of immune reconstitution syndrome. Potential for interaction, monitor.
darunavir|abacavir|2|Significant - Monitor Closely|darunavir and abacavir both increase  risk of immune reconstitution syndrome. Potential for interaction, monitor.
ethanol|abacavir|1|Minor|ethanol increases levels of abacavir by decreasing metabolism. Minor or non-significant interaction. Interaction usually not clinically significant.
fosamprenavir|abacavir|2|Significant - Monitor Closely|fosamprenavir and abacavir both increase  risk of immune reconstitution syndrome. Potential for interaction, monitor.
ganciclovir|abacavir|20|Serious - Use Alternative|ganciclovir, abacavir.Either increases toxicity of the other by Other (see comment). Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available. Comment: Increased risk of hematologic toxicity.
indinavir|abacavir|2|Significant - Monitor Closely|indinavir and abacavir both increase  risk of immune reconstitution syndrome. Potential for interaction, monitor.
nelfinavir|abacavir|2|Significant - Monitor Closely|nelfinavir and abacavir both increase  risk of immune reconstitution syndrome. Potential for interaction, monitor.
ribavirin|abacavir|20|Serious - Use Alternative|ribavirin increases toxicity of abacavir by Other (see comment). Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available. Comment: Increased risk of lactic acidosis and hepatic decompensation.
ritonavir|abacavir|2|Significant - Monitor Closely|ritonavir and abacavir both increase  risk of immune reconstitution syndrome. Potential for interaction, monitor.
saquinavir|abacavir|2|Significant - Monitor Closely|saquinavir and abacavir both increase  risk of immune reconstitution syndrome. Potential for interaction, monitor.
tipranavir|abacavir|11|Significant - Monitor Closely|tipranavir decreases levels of abacavir by unspecified interaction mechanism. Significant interaction possible, monitor closely.
tipranavir|abacavir|2|Significant - Monitor Closely|tipranavir and abacavir both increase  risk of immune reconstitution syndrome. Potential for interaction, monitor.
valganciclovir|abacavir|20|Serious - Use Alternative|valganciclovir, abacavir.Either increases toxicity of the other by Other (see comment). Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available. Comment: Increased risk of hematologic toxicity.
abatacept|anakinra|21|Serious - Use Alternative|abatacept, anakinra. Mechanism: unspecified interaction mechanism. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available. Never use combination. Concomitant use not recommended (in mfr. info.).
abatacept|certolizumab pegol|20|Serious - Use Alternative|abatacept and certolizumab pegol both increase  immunosuppressive effects; risk of infection. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available. Avoid combination because of an increased risk of serious infection.
abatacept|denosumab|11|Significant - Monitor Closely|abatacept, denosumab. Other (see comment). Significant interaction possible, monitor closely. Comment: Caution should be taken in patients on concomitant immunosuppressants or with impaired immune systems because of increased risk for serious infections.
abatacept|etanercept|21|Serious - Use Alternative|abatacept, etanercept. Mechanism: pharmacodynamic synergism. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available. Never use combination. Increased risk of serious infection.
abatacept|infliximab|21|Serious - Use Alternative|abatacept, infliximab. Mechanism: pharmacodynamic synergism. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available. Never use combination. Increased risk of serious infection.
abatacept|sipuleucel-t|3|Significant - Monitor Closely|abatacept decreases effects of sipuleucel-t by pharmacodynamic antagonism. Potential for dangerous interaction. Use with caution and monitor closely.
abatacept|tocilizumab|21|Serious - Use Alternative|abatacept, tocilizumab. Mechanism: unspecified interaction mechanism. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available. Never use combination. Concomitant use not recommended (in mfr. info.).
abatacept|tofacitinib|20|Serious - Use Alternative|abatacept, tofacitinib.Either increases toxicity of the other by immunosuppressive effects; risk of infection. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
ginkgo biloba|abciximab|1|Minor|ginkgo biloba, abciximab. pharmacodynamic synergism. Minor or non-significant interaction. May prolong bleeding time.  Conflicting evidence.Ã¿ Use with caution.
atazanavir|abiraterone|11|Significant - Monitor Closely|atazanavir increases levels of abiraterone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely. Avoid or use with caution, strong inhibitors of 3A4 during abiraterone therapy.
abiraterone|bosutinib|20|Serious - Use Alternative|abiraterone increases levels of bosutinib by P-glycoprotein (MDR1) efflux transporter. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
carbamazepine|abiraterone|3|Significant - Monitor Closely|carbamazepine decreases levels of abiraterone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Potential for dangerous interaction. Use with caution and monitor closely.  Avoid coadministration of abiraterone with strong CYP3A4 inducers; if a strong CYP3A4 inducer must be used, increase abiraterone dosage frequency from once daily to twice daily.
clarithromycin|abiraterone|11|Significant - Monitor Closely|clarithromycin increases levels of abiraterone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely. Avoid or use with caution, strong inhibitors of 3A4 during abiraterone therapy.
abiraterone|dextromethorphan|11|Significant - Monitor Closely|abiraterone increases levels of dextromethorphan by affecting hepatic enzyme CYP2D6 metabolism. Significant interaction possible, monitor closely. Avoid coadministration of abiraterone with substrates of CYP2D6. If alternative therapy cannot be used, exercise caution and consider a dose reduction of the CYP2D6 substrate.
indinavir|abiraterone|11|Significant - Monitor Closely|indinavir increases levels of abiraterone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely. Avoid or use with caution, strong inhibitors of 3A4 during abiraterone therapy.
itraconazole|abiraterone|11|Significant - Monitor Closely|itraconazole increases levels of abiraterone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely. Avoid or use with caution, strong inhibitors of 3A4 during abiraterone therapy.
ketoconazole|abiraterone|11|Significant - Monitor Closely|ketoconazole increases levels of abiraterone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely. Avoid or use with caution, strong inhibitors of 3A4 during abiraterone therapy.
nefazodone|abiraterone|11|Significant - Monitor Closely|nefazodone increases levels of abiraterone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely. Avoid or use with caution, strong inhibitors of 3A4 during abiraterone therapy.
nelfinavir|abiraterone|11|Significant - Monitor Closely|nelfinavir increases levels of abiraterone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely. Avoid or use with caution, strong inhibitors of 3A4 during abiraterone therapy.
phenobarbital|abiraterone|3|Significant - Monitor Closely|phenobarbital decreases levels of abiraterone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Potential for dangerous interaction. Use with caution and monitor closely.  Avoid coadministration of abiraterone with strong CYP3A4 inducers; if a strong CYP3A4 inducer must be used, increase abiraterone dosage frequency from once daily to twice daily.
phenytoin|abiraterone|3|Significant - Monitor Closely|phenytoin decreases levels of abiraterone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Potential for dangerous interaction. Use with caution and monitor closely. Avoid coadministration of abiraterone with strong CYP3A4 inducers; if a strong CYP3A4 inducer must be used, increase abiraterone dosage frequency from once daily to twice daily.
rifabutin|abiraterone|3|Significant - Monitor Closely|rifabutin decreases levels of abiraterone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Potential for dangerous interaction. Use with caution and monitor closely.  Avoid coadministration of abiraterone with strong CYP3A4 inducers; if a strong CYP3A4 inducer must be used, increase abiraterone dosage frequency from once daily to twice daily.
rifapentine|abiraterone|3|Significant - Monitor Closely|rifapentine decreases levels of abiraterone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Potential for dangerous interaction. Use with caution and monitor closely. Avoid coadministration of abiraterone with strong CYP3A4 inducers; if a strong CYP3A4 inducer must be used, increase abiraterone dosage frequency from once daily to twice daily.
ritonavir|abiraterone|11|Significant - Monitor Closely|ritonavir increases levels of abiraterone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely. Avoid or use with caution, strong inhibitors of 3A4 during abiraterone therapy.
saquinavir|abiraterone|11|Significant - Monitor Closely|saquinavir increases levels of abiraterone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely. Avoid or use with caution, strong inhibitors of 3A4 during abiraterone therapy.
telithromycin|abiraterone|11|Significant - Monitor Closely|telithromycin increases levels of abiraterone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely. Avoid or use with caution, strong inhibitors of 3A4 during abiraterone therapy.
abiraterone|thioridazine|11|Significant - Monitor Closely|abiraterone increases levels of thioridazine by affecting hepatic enzyme CYP2D6 metabolism. Significant interaction possible, monitor closely. Avoid coadministration of abiraterone with substrates of CYP2D6. If alternative therapy cannot be used, exercise caution and consider a dose reduction of the CYP2D6 substrate.
voriconazole|abiraterone|11|Significant - Monitor Closely|voriconazole increases levels of abiraterone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely. Avoid or use with caution, strong inhibitors of 3A4 during abiraterone therapy.
acebutolol|clonidine|3|Significant - Monitor Closely|acebutolol, clonidine. Mechanism: pharmacodynamic synergism. Potential for dangerous interaction. Use with caution and monitor closely. Selective beta blocker administration during withdrawal from centrally acting alpha agonists may result in rebound hypertension.
dihydroergotamine|acebutolol|1|Minor|dihydroergotamine, acebutolol. Mechanism: pharmacodynamic synergism. Minor or non-significant interaction. Additive vasospasm.
acebutolol|epinephrine|11|Significant - Monitor Closely|acebutolol decreases effects of epinephrine by pharmacodynamic antagonism. Significant interaction possible, monitor closely.
acebutolol|epinephrine|2|Significant - Monitor Closely|acebutolol increases and epinephrine decreases serum potassium. Effect of interaction is not clear, use caution. Potential for interaction, monitor.
acebutolol|formoterol|11|Significant - Monitor Closely|acebutolol decreases effects of formoterol by pharmacodynamic antagonism. Significant interaction possible, monitor closely.
acebutolol|formoterol|2|Significant - Monitor Closely|acebutolol increases and formoterol decreases serum potassium. Effect of interaction is not clear, use caution. Potential for interaction, monitor.
ibuprofen|acebutolol|11|Significant - Monitor Closely|ibuprofen decreases effects of acebutolol by pharmacodynamic antagonism. Significant interaction possible, monitor closely. Long term (>1 wk) NSAID use.  NSAIDs decrease prostaglandin synthesis.
acebutolol|ibuprofen|2|Significant - Monitor Closely|acebutolol and ibuprofen both increase  serum potassium. Potential for interaction, monitor.
indomethacin|acebutolol|11|Significant - Monitor Closely|indomethacin decreases effects of acebutolol by pharmacodynamic antagonism. Significant interaction possible, monitor closely. Long term (>1 wk) NSAID use.  NSAIDs decrease prostaglandin synthesis.
acebutolol|indomethacin|2|Significant - Monitor Closely|acebutolol and indomethacin both increase  serum potassium. Potential for interaction, monitor.
acebutolol|pirbuterol|11|Significant - Monitor Closely|acebutolol decreases effects of pirbuterol by pharmacodynamic antagonism. Significant interaction possible, monitor closely.
acebutolol|pirbuterol|2|Significant - Monitor Closely|acebutolol increases and pirbuterol decreases serum potassium. Effect of interaction is not clear, use caution. Potential for interaction, monitor.
piroxicam|acebutolol|11|Significant - Monitor Closely|piroxicam decreases effects of acebutolol by pharmacodynamic antagonism. Significant interaction possible, monitor closely. Long term (>1 wk) NSAID use.  NSAIDs decrease prostaglandin synthesis.
acebutolol|piroxicam|2|Significant - Monitor Closely|acebutolol and piroxicam both increase  serum potassium. Potential for interaction, monitor.
prazosin|acebutolol|3|Significant - Monitor Closely|prazosin and acebutolol both increase  anti-hypertensive channel blocking. Potential for dangerous interaction. Use with caution and monitor closely. The severity and duration of hypotension following the first dose of prazosin may be enhanced.
acebutolol|salmeterol|11|Significant - Monitor Closely|acebutolol decreases effects of salmeterol by pharmacodynamic antagonism. Significant interaction possible, monitor closely.
acebutolol|salmeterol|2|Significant - Monitor Closely|acebutolol increases and salmeterol decreases serum potassium. Effect of interaction is not clear, use caution. Potential for interaction, monitor.
terazosin|acebutolol|3|Significant - Monitor Closely|terazosin and acebutolol both increase  anti-hypertensive channel blocking. Potential for dangerous interaction. Use with caution and monitor closely. Additive hypotensive effects may occur when terazosin is used in combination with acebutolol.
acebutolol|terbutaline|11|Significant - Monitor Closely|acebutolol decreases effects of terbutaline by pharmacodynamic antagonism. Significant interaction possible, monitor closely.
acebutolol|terbutaline|2|Significant - Monitor Closely|acebutolol increases and terbutaline decreases serum potassium. Effect of interaction is not clear, use caution. Potential for interaction, monitor.
treprostinil|acebutolol|1|Minor|treprostinil increases effects of acebutolol by pharmacodynamic synergism. Minor or non-significant interaction.
acebutolol|verapamil|3|Significant - Monitor Closely|acebutolol and verapamil both increase  anti-hypertensive channel blocking. Potential for dangerous interaction. Use with caution and monitor closely.
eltrombopag|acetaminophen|11|Significant - Monitor Closely|eltrombopag increases levels of acetaminophen by decreasing metabolism. Significant interaction possible, monitor closely. UGT inhibition; significance of interaction unclear.
imatinib|acetaminophen|3|Significant - Monitor Closely|imatinib decreases levels of acetaminophen by decreasing hepatic clearance. Potential for dangerous interaction. Use with caution and monitor closely. In vitro, imatinib was found to inhibit acetaminophen O-glucuronidation (Ki value of 58.5 micro-M) at therapeutic levels; avoid chronic acetaminophen therapy with imatinib; if occasional acetaminophen administered, do not exceed 1300 mg/day.
isoniazid|acetaminophen|11|Significant - Monitor Closely|isoniazid will increase the level or effect of acetaminophen by  affecting hepatic enzyme CYP2E1 metabolism. Significant interaction possible, monitor closely.
isoniazid|acetaminophen|1|Minor|isoniazid increases toxicity of acetaminophen by unknown mechanism. Minor or non-significant interaction.
liraglutide|acetaminophen|1|Minor|liraglutide decreases levels of acetaminophen by unspecified interaction mechanism. Minor or non-significant interaction.
acetaminophen|warfarin|2|Significant - Monitor Closely|acetaminophen increases effects of warfarin by unknown mechanism. Potential for interaction, monitor.
acetazolamide|aspirin|11|Significant - Monitor Closely|acetazolamide, aspirin.Either increases levels of the other by Other (see comment). Significant interaction possible, monitor closely. Comment: Carbonic anhydrase inhibitors (CAIs) and salicylates inhibit each other's renal tubular secretion, resulting in increased plasma levels.  CAIs also shift salicylates from plasma to the CNS, leading to potential neurotoxicity.
acetazolamide|aspirin|11|Significant - Monitor Closely|acetazolamide, aspirin. Mechanism: passive renal tubular reabsorption due to increased pH. Significant interaction possible, monitor closely. Salicylate levels increased at moderate doses; risk of CNS toxicity. Salicylate levels decreased at large doses (d/t increased renal excretion of unchanged salicylic acid).
acetazolamide|memantine|11|Significant - Monitor Closely|acetazolamide will increase the level or effect of memantine by  passive renal tubular reabsorption - basic urine. Significant interaction possible, monitor closely.
topiramate|acetazolamide|11|Significant - Monitor Closely|topiramate, acetazolamide.Either increases toxicity of the other by pharmacodynamic synergism. Significant interaction possible, monitor closely. Increased risk of kidney stone formation.
aspirin|chlorpropamide|11|Significant - Monitor Closely|aspirin increases effects of chlorpropamide by unknown mechanism. Significant interaction possible, monitor closely. Risk of hypoglycemia.
aspirin|chlorpropamide|1|Minor|aspirin will increase the level or effect of chlorpropamide by  acidic (anionic) drug competition for renal tubular clearance. Minor or non-significant interaction.
aspirin|chlorpropamide|1|Minor|aspirin increases effects of chlorpropamide by plasma protein binding competition. Minor or non-significant interaction. Large dose of salicylate.
aspirin|dexamethasone|11|Significant - Monitor Closely|aspirin, dexamethasone.Either increases toxicity of the other by pharmacodynamic synergism. Significant interaction possible, monitor closely. Increased risk of GI ulceration.
dexamethasone|aspirin|1|Minor|dexamethasone decreases levels of aspirin by increasing renal clearance. Minor or non-significant interaction.
aspirin|fludrocortisone|11|Significant - Monitor Closely|aspirin, fludrocortisone.Either increases toxicity of the other by pharmacodynamic synergism. Significant interaction possible, monitor closely. Increased risk of GI ulceration.
fludrocortisone|aspirin|1|Minor|fludrocortisone decreases levels of aspirin by increasing renal clearance. Minor or non-significant interaction.
aspirin|ginkgo biloba|2|Significant - Monitor Closely|aspirin and ginkgo biloba both increase  anticoagulation. Potential for interaction, monitor.
aspirin|glipizide|11|Significant - Monitor Closely|aspirin increases effects of glipizide by unknown mechanism. Significant interaction possible, monitor closely. Risk of hypoglycemia.
aspirin|glipizide|1|Minor|aspirin increases effects of glipizide by plasma protein binding competition. Minor or non-significant interaction. Large dose of salicylate.
aspirin|glyburide|11|Significant - Monitor Closely|aspirin increases effects of glyburide by unknown mechanism. Significant interaction possible, monitor closely. Risk of hypoglycemia.
aspirin|glyburide|1|Minor|aspirin increases effects of glyburide by plasma protein binding competition. Minor or non-significant interaction. Large dose of salicylate.
griseofulvin|aspirin|11|Significant - Monitor Closely|griseofulvin decreases levels of aspirin by unknown mechanism. Significant interaction possible, monitor closely.
aspirin|heparin|11|Significant - Monitor Closely|aspirin, heparin.Either increases toxicity of the other by anticoagulation. Significant interaction possible, monitor closely. The need for simultaneous use of low-dose aspirin and anticoagulant or antiplatelet agents are common for patients with cardiovascular disease; monitor closely.
heparin|aspirin|3|Significant - Monitor Closely|heparin and aspirin both increase  anticoagulation. Potential for dangerous interaction. Use with caution and monitor closely.
aspirin|hydrocortisone|11|Significant - Monitor Closely|aspirin, hydrocortisone.Either increases toxicity of the other by pharmacodynamic synergism. Significant interaction possible, monitor closely. Increased risk of GI ulceration.
hydrocortisone|aspirin|1|Minor|hydrocortisone decreases levels of aspirin by increasing renal clearance. Minor or non-significant interaction.
ibuprofen|aspirin|20|Serious - Use Alternative|ibuprofen decreases effects of aspirin by Other (see comment). Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available. Comment: Ibuprofen decreases the antiplatelet effects of aspirin by blocking the active site of platelet cyclooxygenase. The effect of other NSAIDs on aspirin is not established.
aspirin|ibuprofen|2|Significant - Monitor Closely|aspirin and ibuprofen both increase  anticoagulation. Potential for interaction, monitor.
aspirin|ibuprofen|2|Significant - Monitor Closely|aspirin and ibuprofen both increase  serum potassium. Potential for interaction, monitor.
aspirin|ibuprofen|1|Minor|aspirin will increase the level or effect of ibuprofen by  acidic (anionic) drug competition for renal tubular clearance. Minor or non-significant interaction.
aspirin|ketoprofen|2|Significant - Monitor Closely|aspirin and ketoprofen both increase  anticoagulation. Potential for interaction, monitor.
aspirin|ketoprofen|2|Significant - Monitor Closely|aspirin and ketoprofen both increase  serum potassium. Potential for interaction, monitor.
aspirin|ketoprofen|1|Minor|aspirin will increase the level or effect of ketoprofen by  acidic (anionic) drug competition for renal tubular clearance. Minor or non-significant interaction.
aspirin|ketorolac|21|Serious - Use Alternative|aspirin, ketorolac.Either increases toxicity of the other by pharmacodynamic synergism. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available. Never use combination.
aspirin|ketorolac|2|Significant - Monitor Closely|aspirin and ketorolac both increase  anticoagulation. Potential for interaction, monitor.
aspirin|ketorolac|2|Significant - Monitor Closely|aspirin and ketorolac both increase  serum potassium. Potential for interaction, monitor.
aspirin|ketorolac|1|Minor|aspirin will increase the level or effect of ketorolac by  acidic (anionic) drug competition for renal tubular clearance. Minor or non-significant interaction.
methazolamide|aspirin|11|Significant - Monitor Closely|methazolamide, aspirin.Either increases levels of the other by Other (see comment). Significant interaction possible, monitor closely. Comment: Carbonic anhydrase inhibitors (CAIs) and salicylates inhibit each other's renal tubular secretion, resulting in increased plasma levels.  CAIs also shift salicylates from plasma to the CNS, leading to potential neurotoxicity.
aspirin|methotrexate|20|Serious - Use Alternative|aspirin increases levels of methotrexate by decreasing renal clearance. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available. Caution should be exercised when salicylates are given in combination with methotrexate.  Risk for drug interactions with methotrexate is greatest during high-dose methotrexate therapy, it has been recommended that any of these drugs be used cautiously with methotrexate even when methotrexate is used in low doses.
aspirin|methylprednisolone|11|Significant - Monitor Closely|aspirin, methylprednisolone.Either increases toxicity of the other by pharmacodynamic synergism. Significant interaction possible, monitor closely. Increased risk of GI ulceration.
methylprednisolone|aspirin|1|Minor|methylprednisolone decreases levels of aspirin by increasing renal clearance. Minor or non-significant interaction.
aspirin|prednisolone|11|Significant - Monitor Closely|aspirin, prednisolone.Either increases toxicity of the other by pharmacodynamic synergism. Significant interaction possible, monitor closely. Increased risk of GI ulceration.
prednisolone|aspirin|1|Minor|prednisolone decreases levels of aspirin by increasing renal clearance. Minor or non-significant interaction.
aspirin|prednisone|11|Significant - Monitor Closely|aspirin, prednisone.Either increases toxicity of the other by pharmacodynamic synergism. Significant interaction possible, monitor closely. Increased risk of GI ulceration.
prednisone|aspirin|1|Minor|prednisone decreases levels of aspirin by increasing renal clearance. Minor or non-significant interaction.
aspirin|probenecid|20|Serious - Use Alternative|aspirin decreases effects of probenecid by acidic (anionic) drug competition for renal tubular clearance. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available. Aspirin decreases uricosuric action of probenecid.
aspirin|sulindac|2|Significant - Monitor Closely|aspirin and sulindac both increase  anticoagulation. Potential for interaction, monitor.
aspirin|sulindac|2|Significant - Monitor Closely|aspirin and sulindac both increase  serum potassium. Potential for interaction, monitor.
aspirin|sulindac|1|Minor|aspirin will increase the level or effect of sulindac by  acidic (anionic) drug competition for renal tubular clearance. Minor or non-significant interaction.
telmisartan|aspirin|11|Significant - Monitor Closely|telmisartan, aspirin.Either increases toxicity of the other by Other (see comment). Significant interaction possible, monitor closely. Comment: May result in renal function deterioration, particularly in elderly or volume depleted individuals.
aspirin|telmisartan|3|Significant - Monitor Closely|aspirin decreases effects of telmisartan by pharmacodynamic antagonism. Potential for dangerous interaction. Use with caution and monitor closely.  NSAIDs decrease synthesis of vasodilating renal prostaglandins, and thus affect fluid homeostasis and may diminish antihypertensive effect.
telmisartan|aspirin|2|Significant - Monitor Closely|telmisartan and aspirin both increase  serum potassium. Potential for interaction, monitor.
aspirin|ticlopidine|20|Serious - Use Alternative|aspirin increases effects of ticlopidine by pharmacodynamic synergism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available. Enhanced risk of hemorrhage.
aspirin|tolazamide|11|Significant - Monitor Closely|aspirin increases effects of tolazamide by unknown mechanism. Significant interaction possible, monitor closely. Risk of hypoglycemia.
aspirin|tolazamide|1|Minor|aspirin increases effects of tolazamide by plasma protein binding competition. Minor or non-significant interaction. Large dose of salicylate.
aspirin|tolbutamide|11|Significant - Monitor Closely|aspirin increases effects of tolbutamide by unknown mechanism. Significant interaction possible, monitor closely. Risk of hypoglycemia.
aspirin|tolbutamide|1|Minor|aspirin increases effects of tolbutamide by plasma protein binding competition. Minor or non-significant interaction. Large dose of salicylate.
aspirin|tolmetin|2|Significant - Monitor Closely|aspirin and tolmetin both increase  anticoagulation. Potential for interaction, monitor.
aspirin|tolmetin|2|Significant - Monitor Closely|aspirin and tolmetin both increase  serum potassium. Potential for interaction, monitor.
aspirin|tolmetin|1|Minor|aspirin will increase the level or effect of tolmetin by  acidic (anionic) drug competition for renal tubular clearance. Minor or non-significant interaction.
aspirin|trandolapril|1|Minor|aspirin decreases effects of trandolapril by pharmacodynamic antagonism. Minor or non-significant interaction. NSAIDs decrease prostaglandin synthesis.
aspirin|triamcinolone|11|Significant - Monitor Closely|aspirin, triamcinolone.Either increases toxicity of the other by pharmacodynamic synergism. Significant interaction possible, monitor closely. Increased risk of GI ulceration.
triamcinolone|aspirin|1|Minor|triamcinolone decreases levels of aspirin by increasing renal clearance. Minor or non-significant interaction.
aspirin|valproic acid|11|Significant - Monitor Closely|aspirin increases levels of valproic acid by plasma protein binding competition. Significant interaction possible, monitor closely.
warfarin|aspirin|3|Significant - Monitor Closely|warfarin and aspirin both increase  anticoagulation. Potential for dangerous interaction. Use with caution and monitor closely. The need for simultaneous use of low-dose aspirin and warfarin  are common for patients with cardiovascular disease; monitor closely.
demeclocycline|acitretin|33|Contraindicated|demeclocycline, acitretin. Other (see comment). Never use combination. Comment: Both acitretin and tetracyclines can cause increased intracranial pressure.
doxycycline|acitretin|33|Contraindicated|doxycycline, acitretin. Other (see comment). Never use combination. Comment: Both acitretin and tetracyclines can cause increased intracranial pressure.
acitretin|methotrexate|33|Contraindicated|acitretin, methotrexate.Either increases toxicity of the other by pharmacodynamic synergism. Never use combination. Risk of additive hepatotoxicity.
minocycline|acitretin|33|Contraindicated|minocycline, acitretin. Other (see comment). Never use combination. Comment: Both acitretin and tetracyclines can cause increased intracranial pressure.
acitretin|norethindrone|21|Serious - Use Alternative|acitretin decreases effects of norethindrone by unknown mechanism. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available. Never use combination. Contraceptive failure may result.
tetracycline|acitretin|33|Contraindicated|tetracycline, acitretin. Other (see comment). Never use combination. Comment: Both acitretin and tetracyclines can cause increased intracranial pressure.
acitretin|vitamin a|1|Minor|acitretin increases toxicity of vitamin a by pharmacodynamic synergism. Minor or non-significant interaction. (Vitamin A) Additive retinoid effects.
pramlintide|aclidinium|21|Serious - Use Alternative|pramlintide, aclidinium.Either increases effects of the other by pharmacodynamic synergism. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available. Never use combination. Synergistic inhibition of GI motility.
adalimumab|canakinumab|22|Serious - Use Alternative|adalimumab and canakinumab both increase  immunosuppressive effects; risk of infection. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available.
adalimumab|infliximab|22|Serious - Use Alternative|adalimumab and infliximab both increase  immunosuppressive effects; risk of infection. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available.
adalimumab|rilonacept|22|Serious - Use Alternative|adalimumab and rilonacept both increase  immunosuppressive effects; risk of infection. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available.
theophylline|adenosine|11|Significant - Monitor Closely|theophylline decreases effects of adenosine by pharmacodynamic antagonism. Significant interaction possible, monitor closely.
caffeine|adenosine|1|Minor|caffeine decreases effects of adenosine by pharmacodynamic antagonism. Minor or non-significant interaction.
dipyridamole|adenosine|11|Significant - Monitor Closely|dipyridamole increases levels of adenosine by decreasing metabolism. Significant interaction possible, monitor closely.
dyphylline|adenosine|11|Significant - Monitor Closely|dyphylline decreases effects of adenosine by pharmacodynamic antagonism. Significant interaction possible, monitor closely.
theophylline|adenosine|11|Significant - Monitor Closely|theophylline decreases effects of adenosine by pharmacodynamic antagonism. Significant interaction possible, monitor closely.
alefacept|canakinumab|22|Serious - Use Alternative|alefacept and canakinumab both increase  immunosuppressive effects; risk of infection. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available.
alefacept|rilonacept|22|Serious - Use Alternative|alefacept and rilonacept both increase  immunosuppressive effects; risk of infection. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available.
calcium acetate|alendronate|11|Significant - Monitor Closely|calcium acetate decreases levels of alendronate by inhibition of GI absorption. Applies only to oral form of both agents. Significant interaction possible, monitor closely. Separate by 30 minutes.
calcium chloride|alendronate|11|Significant - Monitor Closely|calcium chloride decreases levels of alendronate by inhibition of GI absorption. Applies only to oral form of both agents. Significant interaction possible, monitor closely. Separate by 30 minutes.
diclofenac|alendronate|1|Minor|diclofenac, alendronate.Either increases toxicity of the other by pharmacodynamic synergism. Minor or non-significant interaction. Increased risk of GI ulceration.
diflunisal|alendronate|1|Minor|diflunisal, alendronate.Either increases toxicity of the other by pharmacodynamic synergism. Minor or non-significant interaction. Increased risk of GI ulceration.
etodolac|alendronate|1|Minor|etodolac, alendronate.Either increases toxicity of the other by pharmacodynamic synergism. Minor or non-significant interaction. Increased risk of GI ulceration.
fenoprofen|alendronate|1|Minor|fenoprofen, alendronate.Either increases toxicity of the other by pharmacodynamic synergism. Minor or non-significant interaction. Increased risk of GI ulceration.
flurbiprofen|alendronate|1|Minor|flurbiprofen, alendronate.Either increases toxicity of the other by pharmacodynamic synergism. Minor or non-significant interaction. Increased risk of GI ulceration.
ibuprofen|alendronate|1|Minor|ibuprofen, alendronate.Either increases toxicity of the other by pharmacodynamic synergism. Minor or non-significant interaction. Increased risk of GI ulceration.
indomethacin|alendronate|1|Minor|indomethacin, alendronate.Either increases toxicity of the other by pharmacodynamic synergism. Minor or non-significant interaction. Increased risk of GI ulceration.
ketorolac|alendronate|1|Minor|ketorolac, alendronate.Either increases toxicity of the other by pharmacodynamic synergism. Minor or non-significant interaction. Increased risk of GI ulceration.
mefenamic acid|alendronate|1|Minor|mefenamic acid, alendronate.Either increases toxicity of the other by pharmacodynamic synergism. Minor or non-significant interaction. Increased risk of GI ulceration.
nabumetone|alendronate|1|Minor|nabumetone, alendronate.Either increases toxicity of the other by pharmacodynamic synergism. Minor or non-significant interaction. Increased risk of GI ulceration.
naproxen|alendronate|1|Minor|naproxen, alendronate.Either increases toxicity of the other by pharmacodynamic synergism. Minor or non-significant interaction. Increased risk of GI ulceration.
oxaprozin|alendronate|1|Minor|oxaprozin, alendronate.Either increases toxicity of the other by pharmacodynamic synergism. Minor or non-significant interaction. Increased risk of GI ulceration.
piroxicam|alendronate|1|Minor|piroxicam, alendronate.Either increases toxicity of the other by pharmacodynamic synergism. Minor or non-significant interaction. Increased risk of GI ulceration.
alvimopan|alfentanil|33|Contraindicated|alvimopan increases levels of alfentanil by receptor binding competition. Never use combination. Opioids must be d/c'ed at least 7 d prior to taking alvimopan.
cimetidine|alfentanil|2|Significant - Monitor Closely|cimetidine will increase the level or effect of alfentanil by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Potential for interaction, monitor.
fluconazole|alfentanil|1|Minor|fluconazole will increase the level or effect of alfentanil by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor or non-significant interaction.
itraconazole|alfentanil|2|Significant - Monitor Closely|itraconazole will increase the level or effect of alfentanil by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Potential for interaction, monitor.
ketoconazole|alfentanil|2|Significant - Monitor Closely|ketoconazole will increase the level or effect of alfentanil by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Potential for interaction, monitor.
telithromycin|alfentanil|1|Minor|telithromycin will increase the level or effect of alfentanil by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor or non-significant interaction.
tranylcypromine|alfentanil|20|Serious - Use Alternative|tranylcypromine increases toxicity of alfentanil by unknown mechanism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available. Risk of hypotension, hyperpyrexia, somnolence, or death; separate by 14 d.
triprolidine|alfentanil|2|Significant - Monitor Closely|triprolidine and alfentanil both increase  sedation. Potential for interaction, monitor.
voriconazole|alfentanil|11|Significant - Monitor Closely|voriconazole will increase the level or effect of alfentanil by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely. Dose reduction of fentanyl may be warranted
boceprevir|alfuzosin|33|Contraindicated|boceprevir increases levels of alfuzosin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Never use combination. Increased alfuzosin concentrations can result in hypotension.
conivaptan|alfuzosin|1|Minor|conivaptan will increase the level or effect of alfuzosin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor or non-significant interaction.
itraconazole|alfuzosin|33|Contraindicated|itraconazole increases levels of alfuzosin by decreasing metabolism. Never use combination.
itraconazole|alfuzosin|2|Significant - Monitor Closely|itraconazole will increase the level or effect of alfuzosin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Potential for interaction, monitor.
ketoconazole|alfuzosin|33|Contraindicated|ketoconazole increases levels of alfuzosin by decreasing metabolism. Never use combination.
ketoconazole|alfuzosin|2|Significant - Monitor Closely|ketoconazole will increase the level or effect of alfuzosin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Potential for interaction, monitor.
ritonavir|alfuzosin|33|Contraindicated|ritonavir will increase the level or effect of alfuzosin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Never use combination.
tadalafil|alfuzosin|11|Significant - Monitor Closely|tadalafil increases effects of alfuzosin by pharmacodynamic synergism. Significant interaction possible, monitor closely. Risk of hypotension.
alfuzosin|tamsulosin|20|Serious - Use Alternative|alfuzosin, tamsulosin.Either increases effects of the other by additive vasodilation. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available. Risk of hypotension.
telaprevir|alfuzosin|33|Contraindicated|telaprevir increases levels of alfuzosin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Never use combination. Contraindicated. Potential for hypotension or cardiac arrhythmia.
telithromycin|alfuzosin|1|Minor|telithromycin will increase the level or effect of alfuzosin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor or non-significant interaction.
alfuzosin|terazosin|2|Significant - Monitor Closely|alfuzosin and terazosin both increase  anti-hypertensive channel blocking. Potential for interaction, monitor.
vardenafil|alfuzosin|21|Serious - Use Alternative|vardenafil increases effects of alfuzosin by pharmacodynamic synergism. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available. Never use combination. Risk of hypotension.
voriconazole|alfuzosin|1|Minor|voriconazole will increase the level or effect of alfuzosin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor or non-significant interaction.
atorvastatin|aliskiren|11|Significant - Monitor Closely|atorvastatin increases levels of aliskiren by unspecified interaction mechanism. Significant interaction possible, monitor closely.
atorvastatin|aliskiren|2|Significant - Monitor Closely|atorvastatin will increase the level or effect of aliskiren by  P-glycoprotein (MDR1) efflux transporter. Potential for interaction, monitor.
aliskiren|canagliflozin|2|Significant - Monitor Closely|aliskiren and canagliflozin both increase  serum potassium. Potential for interaction, monitor.
cyclosporine|aliskiren|11|Significant - Monitor Closely|cyclosporine will increase the level or effect of aliskiren by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely. Avoid concurrent use. Coadministration of 200 mg and 600 mg cyclosporine, with 75 mg aliskiren resulted in an approximately 2.5-fold increase in Cmax and 5-fold increase in AUC of aliskiren
cyclosporine|aliskiren|11|Significant - Monitor Closely|cyclosporine will increase the level or effect of aliskiren by  P-glycoprotein (MDR1) efflux transporter. Significant interaction possible, monitor closely. Avoid concurrent use. Coadministration of 200 mg and 600 mg cyclosporine, with 75 mg aliskiren resulted in an approximately 2.5-fold increase in Cmax and 5-fold increase in AUC of aliskiren
aliskiren|furosemide|2|Significant - Monitor Closely|aliskiren decreases levels of furosemide by unspecified interaction mechanism. Potential for interaction, monitor.
itraconazole|aliskiren|11|Significant - Monitor Closely|itraconazole will increase the level or effect of aliskiren by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely. Concomitant use of itraconazole and aliskiren is not recommended, consider alternatives if possible.
itraconazole|aliskiren|11|Significant - Monitor Closely|itraconazole will increase the level or effect of aliskiren by  P-glycoprotein (MDR1) efflux transporter. Significant interaction possible, monitor closely. Concomitant use of itraconazole and aliskiren is not recommended, consider alternatives if possible.
ketoconazole|aliskiren|2|Significant - Monitor Closely|ketoconazole will increase the level or effect of aliskiren by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Potential for interaction, monitor.
ketoconazole|aliskiren|2|Significant - Monitor Closely|ketoconazole will increase the level or effect of aliskiren by  P-glycoprotein (MDR1) efflux transporter. Potential for interaction, monitor.
verapamil|aliskiren|2|Significant - Monitor Closely|verapamil will increase the level or effect of aliskiren by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Potential for interaction, monitor.
verapamil|aliskiren|2|Significant - Monitor Closely|verapamil will increase the level or effect of aliskiren by  P-glycoprotein (MDR1) efflux transporter. Potential for interaction, monitor.
allopurinol|azathioprine|20|Serious - Use Alternative|allopurinol increases levels of azathioprine by decreasing metabolism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available. Increased risk of bone marrow toxicity.
allopurinol|cyclosporine|1|Minor|allopurinol increases levels of cyclosporine by unknown mechanism. Minor or non-significant interaction.
allopurinol|mercaptopurine|11|Significant - Monitor Closely|allopurinol increases levels of mercaptopurine by decreasing metabolism. Significant interaction possible, monitor closely. Potential for increased myelosuppression.
allopurinol|warfarin|20|Serious - Use Alternative|allopurinol increases effects of warfarin by decreasing metabolism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
citalopram|almotriptan|20|Serious - Use Alternative|citalopram, almotriptan. Mechanism: unknown. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available. Combination may increase risk of serotonin syndrome. If concomitant treatment with citalopram and a triptan is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases.
conivaptan|almotriptan|11|Significant - Monitor Closely|conivaptan will increase the level or effect of almotriptan by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
almotriptan|desvenlafaxine|20|Serious - Use Alternative|almotriptan and desvenlafaxine both increase  serotonin levels. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
dihydroergotamine|almotriptan|33|Contraindicated|dihydroergotamine, almotriptan.Either increases toxicity of the other by pharmacodynamic synergism. Never use combination. Additive vasospasm.  Sep. by 24h.
almotriptan|dihydroergotamine|2|Significant - Monitor Closely|almotriptan and dihydroergotamine both increase  serotonin levels. Potential for interaction, monitor.
ergonovine|almotriptan|33|Contraindicated|ergonovine, almotriptan.Either increases toxicity of the other by pharmacodynamic synergism. Never use combination. Additive vasospasm.  Sep. by 24h.
ergotamine|almotriptan|33|Contraindicated|ergotamine, almotriptan.Either increases toxicity of the other by pharmacodynamic synergism. Never use combination. Additive vasospasm.  Sep. by 24h.
almotriptan|ergotamine|2|Significant - Monitor Closely|almotriptan and ergotamine both increase  serotonin levels. Potential for interaction, monitor.
almotriptan|escitalopram|3|Significant - Monitor Closely|almotriptan and escitalopram both increase  serotonin levels. Potential for dangerous interaction. Use with caution and monitor closely.
escitalopram|almotriptan|1|Minor|escitalopram, almotriptan. Mechanism: unknown. Minor or non-significant interaction. Risk of weakness, dyspnea, chest pain.
almotriptan|fluoxetine|3|Significant - Monitor Closely|almotriptan and fluoxetine both increase  serotonin levels. Potential for dangerous interaction. Use with caution and monitor closely.
fluoxetine|almotriptan|1|Minor|fluoxetine, almotriptan. Mechanism: unknown. Minor or non-significant interaction. Risk of weakness, dyspnea, chest pain.
fluvoxamine|almotriptan|20|Serious - Use Alternative|fluvoxamine will increase the level or effect of almotriptan by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
almotriptan|fluvoxamine|3|Significant - Monitor Closely|almotriptan and fluvoxamine both increase  serotonin levels. Potential for dangerous interaction. Use with caution and monitor closely.
fluvoxamine|almotriptan|1|Minor|fluvoxamine, almotriptan. Mechanism: unknown. Minor or non-significant interaction. Risk of weakness, dyspnea, chest pain.
almotriptan|isocarboxazid|22|Serious - Use Alternative|almotriptan and isocarboxazid both increase  serotonin levels. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available.
isocarboxazid|almotriptan|21|Serious - Use Alternative|isocarboxazid increases levels of almotriptan by decreasing metabolism. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available. Never use combination.
itraconazole|almotriptan|20|Serious - Use Alternative|itraconazole will increase the level or effect of almotriptan by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
ketoconazole|almotriptan|20|Serious - Use Alternative|ketoconazole will increase the level or effect of almotriptan by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
nefazodone|almotriptan|20|Serious - Use Alternative|nefazodone will increase the level or effect of almotriptan by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
almotriptan|nefazodone|3|Significant - Monitor Closely|almotriptan and nefazodone both increase  serotonin levels. Potential for dangerous interaction. Use with caution and monitor closely.
nefazodone|almotriptan|1|Minor|nefazodone, almotriptan. Mechanism: unknown. Minor or non-significant interaction. Risk of weakness, dyspnea, chest pain.
almotriptan|paroxetine|3|Significant - Monitor Closely|almotriptan and paroxetine both increase  serotonin levels. Potential for dangerous interaction. Use with caution and monitor closely.
paroxetine|almotriptan|1|Minor|paroxetine, almotriptan. Mechanism: unknown. Minor or non-significant interaction. Risk of weakness, dyspnea, chest pain.
almotriptan|phenelzine|22|Serious - Use Alternative|almotriptan and phenelzine both increase  serotonin levels. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available.
phenelzine|almotriptan|21|Serious - Use Alternative|phenelzine increases levels of almotriptan by decreasing metabolism. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available. Never use combination.
almotriptan|sertraline|3|Significant - Monitor Closely|almotriptan and sertraline both increase  serotonin levels. Potential for dangerous interaction. Use with caution and monitor closely.
sertraline|almotriptan|1|Minor|sertraline, almotriptan. Mechanism: unknown. Minor or non-significant interaction. Risk of weakness, dyspnea, chest pain.
almotriptan|tramadol|2|Significant - Monitor Closely|almotriptan and tramadol both increase  serotonin levels. Potential for interaction, monitor.
almotriptan|tranylcypromine|22|Serious - Use Alternative|almotriptan and tranylcypromine both increase  serotonin levels. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available.
tranylcypromine|almotriptan|21|Serious - Use Alternative|tranylcypromine increases levels of almotriptan by decreasing metabolism. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available. Never use combination.
almotriptan|trazodone|3|Significant - Monitor Closely|almotriptan and trazodone both increase  serotonin levels. Potential for dangerous interaction. Use with caution and monitor closely.
trazodone|almotriptan|1|Minor|trazodone, almotriptan. Mechanism: unknown. Minor or non-significant interaction. Risk of weakness, dyspnea, chest pain.
almotriptan|trimipramine|3|Significant - Monitor Closely|almotriptan and trimipramine both increase  serotonin levels. Potential for dangerous interaction. Use with caution and monitor closely.
almotriptan|venlafaxine|3|Significant - Monitor Closely|almotriptan and venlafaxine both increase  serotonin levels. Potential for dangerous interaction. Use with caution and monitor closely.
venlafaxine|almotriptan|1|Minor|venlafaxine, almotriptan. Mechanism: unknown. Minor or non-significant interaction. Risk of weakness, dyspnea, chest pain.
voriconazole|almotriptan|11|Significant - Monitor Closely|voriconazole will increase the level or effect of almotriptan by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
almotriptan|zolmitriptan|33|Contraindicated|almotriptan, zolmitriptan.Either increases toxicity of the other by pharmacodynamic synergism. Never use combination. Additive vasospasm.  Sep. by 24h.
almotriptan|zolmitriptan|2|Significant - Monitor Closely|almotriptan and zolmitriptan both increase  serotonin levels. Potential for interaction, monitor.
aprepitant|alprazolam|11|Significant - Monitor Closely|aprepitant will increase the level or effect of alprazolam by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
carbamazepine|alprazolam|20|Serious - Use Alternative|carbamazepine will decrease the level or effect of alprazolam by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
cimetidine|alprazolam|20|Serious - Use Alternative|cimetidine will increase the level or effect of alprazolam by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
clarithromycin|alprazolam|20|Serious - Use Alternative|clarithromycin will increase the level or effect of alprazolam by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
alprazolam|clozapine|2|Significant - Monitor Closely|alprazolam and clozapine both increase  sedation. Potential for interaction, monitor.
delavirdine|alprazolam|11|Significant - Monitor Closely|delavirdine will increase the level or effect of alprazolam by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
alprazolam|digoxin|11|Significant - Monitor Closely|alprazolam increases levels of digoxin by unknown mechanism. Significant interaction possible, monitor closely.
efavirenz|alprazolam|11|Significant - Monitor Closely|efavirenz will decrease the level or effect of alprazolam by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
ethotoin|alprazolam|11|Significant - Monitor Closely|ethotoin will decrease the level or effect of alprazolam by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
fluconazole|alprazolam|11|Significant - Monitor Closely|fluconazole will increase the level or effect of alprazolam by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
fosamprenavir|alprazolam|11|Significant - Monitor Closely|fosamprenavir will increase the level or effect of alprazolam by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
fosphenytoin|alprazolam|11|Significant - Monitor Closely|fosphenytoin will decrease the level or effect of alprazolam by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
indinavir|alprazolam|11|Significant - Monitor Closely|indinavir will increase the level or effect of alprazolam by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
itraconazole|alprazolam|33|Contraindicated|itraconazole increases levels of alprazolam by decreasing metabolism. Never use combination.
itraconazole|alprazolam|20|Serious - Use Alternative|itraconazole will increase the level or effect of alprazolam by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
ketoconazole|alprazolam|33|Contraindicated|ketoconazole increases levels of alprazolam by decreasing metabolism. Never use combination.
ketoconazole|alprazolam|20|Serious - Use Alternative|ketoconazole will increase the level or effect of alprazolam by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
nelfinavir|alprazolam|11|Significant - Monitor Closely|nelfinavir will increase the level or effect of alprazolam by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
omeprazole|alprazolam|1|Minor|omeprazole increases levels of alprazolam by decreasing metabolism. Minor or non-significant interaction.
phenytoin|alprazolam|11|Significant - Monitor Closely|phenytoin will decrease the level or effect of alprazolam by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
ritonavir|alprazolam|11|Significant - Monitor Closely|ritonavir will increase the level or effect of alprazolam by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
saquinavir|alprazolam|20|Serious - Use Alternative|saquinavir increases levels of alprazolam by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available. Potential for increased toxicity. Avoid coadministration. If need to use, decrease alprazolam dose.
telaprevir|alprazolam|11|Significant - Monitor Closely|telaprevir increases levels of alprazolam by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely. Concomitant use of alprazolam and telaprevir increases exposure to alprazolam. Clinical monitoring is warranted. .
telithromycin|alprazolam|11|Significant - Monitor Closely|telithromycin will increase the level or effect of alprazolam by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
tipranavir|alprazolam|33|Contraindicated|tipranavir increases levels of alprazolam by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Never use combination. Potential for increased toxicity. Tipranavir is used with ritonavir (boosted therapy) which is a potent CYP3A4 inhibitor.
triprolidine|alprazolam|2|Significant - Monitor Closely|triprolidine and alprazolam both increase  sedation. Potential for interaction, monitor.
voriconazole|alprazolam|11|Significant - Monitor Closely|voriconazole will increase the level or effect of alprazolam by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
alteplase|ginkgo biloba|3|Significant - Monitor Closely|alteplase and ginkgo biloba both increase  anticoagulation. Potential for dangerous interaction. Use with caution and monitor closely.
altretamine|amitriptyline|11|Significant - Monitor Closely|altretamine increases toxicity of amitriptyline by unknown mechanism. Significant interaction possible, monitor closely. Increased risk of orthostatic hypotension.
altretamine|amoxapine|11|Significant - Monitor Closely|altretamine increases toxicity of amoxapine by unknown mechanism. Significant interaction possible, monitor closely. Increased risk of orthostatic hypotension.
altretamine|clomipramine|11|Significant - Monitor Closely|altretamine increases toxicity of clomipramine by unknown mechanism. Significant interaction possible, monitor closely. Increased risk of orthostatic hypotension.
altretamine|desipramine|11|Significant - Monitor Closely|altretamine increases toxicity of desipramine by unknown mechanism. Significant interaction possible, monitor closely. Increased risk of orthostatic hypotension.
altretamine|doxepin|11|Significant - Monitor Closely|altretamine increases toxicity of doxepin by unknown mechanism. Significant interaction possible, monitor closely. Increased risk of orthostatic hypotension.
altretamine|imipramine|11|Significant - Monitor Closely|altretamine increases toxicity of imipramine by unknown mechanism. Significant interaction possible, monitor closely. Increased risk of orthostatic hypotension.
altretamine|isocarboxazid|11|Significant - Monitor Closely|altretamine increases toxicity of isocarboxazid by unknown mechanism. Significant interaction possible, monitor closely. Increased risk of orthostatic hypotension.
altretamine|nortriptyline|11|Significant - Monitor Closely|altretamine increases toxicity of nortriptyline by unknown mechanism. Significant interaction possible, monitor closely. Increased risk of orthostatic hypotension.
altretamine|phenelzine|11|Significant - Monitor Closely|altretamine increases toxicity of phenelzine by unknown mechanism. Significant interaction possible, monitor closely. Increased risk of orthostatic hypotension.
altretamine|rasagiline|11|Significant - Monitor Closely|altretamine increases toxicity of rasagiline by unknown mechanism. Significant interaction possible, monitor closely. Increased risk of orthostatic hypotension.
vitamin d|aluminum hydroxide|11|Significant - Monitor Closely|vitamin d increases levels of aluminum hydroxide by Other (see comment). Significant interaction possible, monitor closely. Comment: Avoid coadministration. Chronic use of aluminum-containing antacids in conjunction with vitamin D can lead to aluminum retention and possible toxicity.
deferiprone|aluminum hydroxide|11|Significant - Monitor Closely|deferiprone decreases levels of aluminum hydroxide by inhibition of GI absorption. Applies only to oral form of both agents. Significant interaction possible, monitor closely. Deferiprone chelates iron; its affinity for other minerals is unknown.
aluminum hydroxide|eltrombopag|21|Serious - Use Alternative|aluminum hydroxide decreases levels of eltrombopag by inhibition of GI absorption. Applies only to oral form of both agents. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available. Never use combination. Separate by at least 4 hours.
amiodarone|alvimopan|1|Minor|amiodarone will increase the level or effect of alvimopan by  P-glycoprotein (MDR1) efflux transporter. Minor or non-significant interaction.
atorvastatin|alvimopan|1|Minor|atorvastatin will increase the level or effect of alvimopan by  P-glycoprotein (MDR1) efflux transporter. Minor or non-significant interaction.
alvimopan|buprenorphine|33|Contraindicated|alvimopan increases levels of buprenorphine by receptor binding competition. Never use combination. Opioids must be d/c'ed at least 7 d prior to taking alvimopan.
alvimopan|butorphanol|33|Contraindicated|alvimopan increases levels of butorphanol by receptor binding competition. Never use combination. Opioids must be d/c'ed at least 7 d prior to taking alvimopan.
clarithromycin|alvimopan|1|Minor|clarithromycin will increase the level or effect of alvimopan by  P-glycoprotein (MDR1) efflux transporter. Minor or non-significant interaction.
clotrimazole|alvimopan|1|Minor|clotrimazole will decrease the level or effect of alvimopan by  P-glycoprotein (MDR1) efflux transporter. Minor or non-significant interaction.
alvimopan|codeine|33|Contraindicated|alvimopan increases levels of codeine by receptor binding competition. Never use combination. Opioids must be d/c'ed at least 7 d prior to taking alvimopan.
alvimopan|dextromoramide|33|Contraindicated|alvimopan increases levels of dextromoramide by receptor binding competition. Never use combination. Opioids must be d/c'ed at least 7 d prior to taking alvimopan.
alvimopan|dipipanone|33|Contraindicated|alvimopan increases levels of dipipanone by receptor binding competition. Never use combination. Opioids must be d/c'ed at least 7 d prior to taking alvimopan.
alvimopan|fentanyl|33|Contraindicated|alvimopan increases levels of fentanyl by receptor binding competition. Never use combination. Opioids must be d/c'ed at least 7 d prior to taking alvimopan.
alvimopan|hydrocodone|33|Contraindicated|alvimopan increases levels of hydrocodone by receptor binding competition. Never use combination. Opioids must be d/c'ed at least 7 d prior to taking alvimopan.
alvimopan|hydromorphone|33|Contraindicated|alvimopan increases levels of hydromorphone by receptor binding competition. Never use combination. Opioids must be d/c'ed at least 7 d prior to taking alvimopan.
ivacaftor|alvimopan|20|Serious - Use Alternative|ivacaftor increases levels of alvimopan by P-glycoprotein (MDR1) efflux transporter. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available. Ivacaftor and its M1 metabolite has the potential to inhibit P-gp, may significantly increase systemic exposure to P-gp substrates.
alvimopan|levorphanol|33|Contraindicated|alvimopan increases levels of levorphanol by receptor binding competition. Never use combination. Opioids must be d/c'ed at least 7 d prior to taking alvimopan.
alvimopan|methadone|33|Contraindicated|alvimopan increases levels of methadone by receptor binding competition. Never use combination. Opioids must be d/c'ed at least 7 d prior to taking alvimopan.
alvimopan|morphine|33|Contraindicated|alvimopan increases levels of morphine by receptor binding competition. Never use combination. Opioids must be d/c'ed at least 7 d prior to taking alvimopan.
alvimopan|nalbuphine|33|Contraindicated|alvimopan increases levels of nalbuphine by receptor binding competition. Never use combination. Opioids must be d/c'ed at least 7 d prior to taking alvimopan.
alvimopan|oxycodone|33|Contraindicated|alvimopan increases levels of oxycodone by receptor binding competition. Never use combination. Opioids must be d/c'ed at least 7 d prior to taking alvimopan.
alvimopan|oxymorphone|33|Contraindicated|alvimopan increases levels of oxymorphone by receptor binding competition. Never use combination. Opioids must be d/c'ed at least 7 d prior to taking alvimopan.
alvimopan|pentazocine|33|Contraindicated|alvimopan increases levels of pentazocine by receptor binding competition. Never use combination. Opioids must be d/c'ed at least 7 d prior to taking alvimopan.
alvimopan|meperidine|33|Contraindicated|alvimopan increases levels of meperidine by receptor binding competition. Never use combination. Opioids must be d/c'ed at least 7 d prior to taking alvimopan.
quinidine|alvimopan|2|Significant - Monitor Closely|quinidine will increase the level or effect of alvimopan by  P-glycoprotein (MDR1) efflux transporter. Potential for interaction, monitor.
alvimopan|sufentanil|33|Contraindicated|alvimopan increases levels of sufentanil by receptor binding competition. Never use combination. Opioids must be d/c'ed at least 7 d prior to taking alvimopan.
alvimopan|tapentadol|33|Contraindicated|alvimopan increases levels of tapentadol by receptor binding competition. Never use combination. Opioids must be d/c'ed at least 7 d prior to taking alvimopan.
alvimopan|tramadol|33|Contraindicated|alvimopan increases levels of tramadol by receptor binding competition. Never use combination. Opioids must be d/c'ed at least 7 d prior to taking alvimopan.
memantine|amantadine|11|Significant - Monitor Closely|memantine, amantadine.Either increases toxicity of the other by pharmacodynamic synergism. Significant interaction possible, monitor closely. Combination may lead to additive adverse effects. If coadministration cannot be avoided, monitor for increased adverse effects such as agitation, dizziness and other CNS events.
ambenonium|tacrine|20|Serious - Use Alternative|ambenonium increases effects of tacrine by pharmacodynamic synergism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available. Due to prolonged action of ambenonium, suspend all other cholinergic drugs until pt. stabilized on ambenonium.
tacrine|ambenonium|11|Significant - Monitor Closely|tacrine increases effects of ambenonium by pharmacodynamic synergism. Significant interaction possible, monitor closely.
ambenonium|tacrine|2|Significant - Monitor Closely|ambenonium and tacrine both increase  cholinergic effects/transmission. Potential for interaction, monitor.
telithromycin|ambrisentan|1|Minor|telithromycin will increase the level or effect of ambrisentan by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor or non-significant interaction.
voriconazole|ambrisentan|1|Minor|voriconazole will increase the level or effect of ambrisentan by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor or non-significant interaction.
amifostine|chlorothiazide|2|Significant - Monitor Closely|amifostine increases effects of chlorothiazide by pharmacodynamic synergism. Potential for interaction, monitor. Risk of hypotension.
amifostine|telmisartan|2|Significant - Monitor Closely|amifostine increases effects of telmisartan by pharmacodynamic synergism. Potential for interaction, monitor. Risk of hypotension.
amifostine|terazosin|2|Significant - Monitor Closely|amifostine increases effects of terazosin by pharmacodynamic synergism. Potential for interaction, monitor. Risk of hypotension.
amifostine|trandolapril|2|Significant - Monitor Closely|amifostine increases effects of trandolapril by pharmacodynamic synergism. Potential for interaction, monitor. Risk of hypotension.
amifostine|valsartan|2|Significant - Monitor Closely|amifostine increases effects of valsartan by pharmacodynamic synergism. Potential for interaction, monitor. Risk of hypotension.
amifostine|verapamil|2|Significant - Monitor Closely|amifostine increases effects of verapamil by pharmacodynamic synergism. Potential for interaction, monitor. Risk of hypotension.
amikacin|atracurium|20|Serious - Use Alternative|amikacin increases effects of atracurium by pharmacodynamic synergism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available. Risk of apnea.
bumetanide|amikacin|20|Serious - Use Alternative|bumetanide, amikacin.Either increases toxicity of the other by Mechanism: pharmacodynamic synergism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available. Increased risk of ototoxicity and nephrotoxicity.
amikacin|cisplatin|11|Significant - Monitor Closely|amikacin and cisplatin both increase  nephrotoxicity and/or ototoxicity. Significant interaction possible, monitor closely.
ethacrynic acid|amikacin|20|Serious - Use Alternative|ethacrynic acid, amikacin.Either increases toxicity of the other by Mechanism: pharmacodynamic synergism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available. Increased risk of ototoxicity and nephrotoxicity.
furosemide|amikacin|20|Serious - Use Alternative|furosemide, amikacin.Either increases toxicity of the other by Mechanism: pharmacodynamic synergism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available. Increased risk of ototoxicity and nephrotoxicity.
amikacin|pancuronium|20|Serious - Use Alternative|amikacin increases effects of pancuronium by pharmacodynamic synergism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available. Risk of apnea.
amikacin|rocuronium|20|Serious - Use Alternative|amikacin increases effects of rocuronium by pharmacodynamic synergism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available. Risk of apnea.
amikacin|succinylcholine|20|Serious - Use Alternative|amikacin increases effects of succinylcholine by pharmacodynamic synergism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available. Risk of apnea.
amikacin|tacrolimus|22|Serious - Use Alternative|amikacin and tacrolimus both increase  nephrotoxicity and/or ototoxicity. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available.
tacrolimus|amikacin|11|Significant - Monitor Closely|tacrolimus will increase the level or effect of amikacin by  P-glycoprotein (MDR1) efflux transporter. Significant interaction possible, monitor closely.
ticarcillin|amikacin|1|Minor|ticarcillin decreases effects of amikacin by altering metabolism. Minor or non-significant interaction. Increased risk in renal impairment.
amikacin|tubocurarine|20|Serious - Use Alternative|amikacin increases effects of tubocurarine by pharmacodynamic synergism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available. Risk of apnea.
amikacin|vecuronium|20|Serious - Use Alternative|amikacin increases effects of vecuronium by pharmacodynamic synergism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available. Risk of apnea.
benazepril|amiloride|11|Significant - Monitor Closely|benazepril, amiloride. Mechanism: pharmacodynamic synergism. Significant interaction possible, monitor closely. Risk of hyperkalemia.
candesartan|amiloride|3|Significant - Monitor Closely|candesartan and amiloride both increase  serum potassium. Potential for dangerous interaction. Use with caution and monitor closely.
captopril|amiloride|11|Significant - Monitor Closely|captopril, amiloride. Mechanism: pharmacodynamic synergism. Significant interaction possible, monitor closely. Risk of hyperkalemia.
enalapril|amiloride|11|Significant - Monitor Closely|enalapril, amiloride. Mechanism: pharmacodynamic synergism. Significant interaction possible, monitor closely. Risk of hyperkalemia.
amiloride|eplerenone|21|Serious - Use Alternative|amiloride, eplerenone. Mechanism: pharmacodynamic synergism. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available. Never use combination. Hyperkalemia.
eprosartan|amiloride|3|Significant - Monitor Closely|eprosartan and amiloride both increase  serum potassium. Potential for dangerous interaction. Use with caution and monitor closely.
fosinopril|amiloride|11|Significant - Monitor Closely|fosinopril, amiloride. Mechanism: pharmacodynamic synergism. Significant interaction possible, monitor closely. Risk of hyperkalemia.
irbesartan|amiloride|3|Significant - Monitor Closely|irbesartan and amiloride both increase  serum potassium. Potential for dangerous interaction. Use with caution and monitor closely.
lisinopril|amiloride|11|Significant - Monitor Closely|lisinopril, amiloride. Mechanism: pharmacodynamic synergism. Significant interaction possible, monitor closely. Risk of hyperkalemia.
losartan|amiloride|3|Significant - Monitor Closely|losartan and amiloride both increase  serum potassium. Potential for dangerous interaction. Use with caution and monitor closely.
moexipril|amiloride|11|Significant - Monitor Closely|moexipril, amiloride. Mechanism: pharmacodynamic synergism. Significant interaction possible, monitor closely. Risk of hyperkalemia.
perindopril|amiloride|11|Significant - Monitor Closely|perindopril, amiloride. Mechanism: pharmacodynamic synergism. Significant interaction possible, monitor closely. Risk of hyperkalemia.
quinapril|amiloride|11|Significant - Monitor Closely|quinapril, amiloride. Mechanism: pharmacodynamic synergism. Significant interaction possible, monitor closely. Risk of hyperkalemia.
amiloride|quinidine|11|Significant - Monitor Closely|amiloride, quinidine. Mechanism: unspecified interaction mechanism. Significant interaction possible, monitor closely. Increased risk of arrhythmias in pts. with ventricular tachycardia.
ramipril|amiloride|11|Significant - Monitor Closely|ramipril, amiloride. Mechanism: pharmacodynamic synergism. Significant interaction possible, monitor closely. Risk of hyperkalemia.
telmisartan|amiloride|3|Significant - Monitor Closely|telmisartan and amiloride both increase  serum potassium. Potential for dangerous interaction. Use with caution and monitor closely.
trandolapril|amiloride|11|Significant - Monitor Closely|trandolapril, amiloride. Mechanism: pharmacodynamic synergism. Significant interaction possible, monitor closely. Risk of hyperkalemia.
treprostinil|amiloride|1|Minor|treprostinil increases effects of amiloride by pharmacodynamic synergism. Minor or non-significant interaction.
valsartan|amiloride|3|Significant - Monitor Closely|valsartan and amiloride both increase  serum potassium. Potential for dangerous interaction. Use with caution and monitor closely.
amobarbital|theophylline|11|Significant - Monitor Closely|amobarbital will decrease the level or effect of theophylline by  affecting hepatic enzyme CYP1A2 metabolism. Significant interaction possible, monitor closely.
amobarbital|theophylline|11|Significant - Monitor Closely|amobarbital will decrease the level or effect of theophylline by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
butabarbital|theophylline|11|Significant - Monitor Closely|butabarbital will decrease the level or effect of theophylline by  affecting hepatic enzyme CYP1A2 metabolism. Significant interaction possible, monitor closely.
butabarbital|theophylline|11|Significant - Monitor Closely|butabarbital will decrease the level or effect of theophylline by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
butalbital|theophylline|11|Significant - Monitor Closely|butalbital will decrease the level or effect of theophylline by  affecting hepatic enzyme CYP1A2 metabolism. Significant interaction possible, monitor closely.
butalbital|theophylline|11|Significant - Monitor Closely|butalbital will decrease the level or effect of theophylline by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
carbamazepine|theophylline|20|Serious - Use Alternative|carbamazepine will decrease the level or effect of theophylline by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
theophylline|carbamazepine|20|Serious - Use Alternative|theophylline decreases levels of carbamazepine by increasing metabolism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
carbamazepine|theophylline|11|Significant - Monitor Closely|carbamazepine will decrease the level or effect of theophylline by  affecting hepatic enzyme CYP1A2 metabolism. Significant interaction possible, monitor closely.
cimetidine|theophylline|20|Serious - Use Alternative|cimetidine will increase the level or effect of theophylline by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
cimetidine|theophylline|11|Significant - Monitor Closely|cimetidine will increase the level or effect of theophylline by  affecting hepatic enzyme CYP1A2 metabolism. Significant interaction possible, monitor closely.
ciprofloxacin|theophylline|20|Serious - Use Alternative|ciprofloxacin will increase the level or effect of theophylline by  affecting hepatic enzyme CYP1A2 metabolism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available. Concomitant use of theophylline and ciprofloxacin has decreased theophylline clearance and increased plasma levels and symptoms of toxicity. Serious and fatal reactions have included cardiac arrest, seizure, status epilepticus, and respiratory failure. If concomitant use cannot be avoided, monitor theophylline levels and adjust dosage as needed.
ciprofloxacin|theophylline|20|Serious - Use Alternative|ciprofloxacin will increase the level or effect of theophylline by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available. Concomitant use of theophylline and ciprofloxacin has decreased theophylline clearance and increased plasma levels and symptoms of toxicity. Serious and fatal reactions have included cardiac arrest, seizure, status epilepticus, and respiratory failure. If concomitant use cannot be avoided, monitor theophylline levels and adjust dosage as needed.
clarithromycin|theophylline|20|Serious - Use Alternative|clarithromycin will increase the level or effect of theophylline by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
clarithromycin|theophylline|1|Minor|clarithromycin increases levels of theophylline by decreasing metabolism. Minor or non-significant interaction.
disulfiram|theophylline|1|Minor|disulfiram increases levels of theophylline by decreasing metabolism. Minor or non-significant interaction.
ethotoin|theophylline|11|Significant - Monitor Closely|ethotoin will decrease the level or effect of theophylline by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
fluvoxamine|theophylline|20|Serious - Use Alternative|fluvoxamine will increase the level or effect of theophylline by  affecting hepatic enzyme CYP1A2 metabolism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
fluvoxamine|theophylline|20|Serious - Use Alternative|fluvoxamine will increase the level or effect of theophylline by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
fosphenytoin|theophylline|11|Significant - Monitor Closely|fosphenytoin will decrease the level or effect of theophylline by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
hexobarbital|theophylline|11|Significant - Monitor Closely|hexobarbital will decrease the level or effect of theophylline by  affecting hepatic enzyme CYP1A2 metabolism. Significant interaction possible, monitor closely.
hexobarbital|theophylline|11|Significant - Monitor Closely|hexobarbital will decrease the level or effect of theophylline by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
isoniazid|theophylline|11|Significant - Monitor Closely|isoniazid will increase the level or effect of theophylline by  affecting hepatic enzyme CYP1A2 metabolism. Significant interaction possible, monitor closely.
isoniazid|theophylline|11|Significant - Monitor Closely|isoniazid will increase the level or effect of theophylline by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
theophylline|lithium|1|Minor|theophylline decreases levels of lithium by increasing renal clearance. Minor or non-significant interaction.
mexiletine|theophylline|11|Significant - Monitor Closely|mexiletine will increase the level or effect of theophylline by  affecting hepatic enzyme CYP1A2 metabolism. Significant interaction possible, monitor closely.
nadolol|theophylline|11|Significant - Monitor Closely|nadolol, theophylline. Other (see comment). Significant interaction possible, monitor closely. Comment: Beta blockers (esp. non selective) antagonize theophylline effects, while at the same time increasing theophylline levels and toxicity (mechanism: decreased theophylline metabolism). Smoking increases risk of interaction.
norfloxacin|theophylline|11|Significant - Monitor Closely|norfloxacin will increase the level or effect of theophylline by  affecting hepatic enzyme CYP1A2 metabolism. Significant interaction possible, monitor closely.
pefloxacin|theophylline|20|Serious - Use Alternative|pefloxacin will increase the level or effect of theophylline by  affecting hepatic enzyme CYP1A2 metabolism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
penbutolol|theophylline|11|Significant - Monitor Closely|penbutolol, theophylline. Other (see comment). Significant interaction possible, monitor closely. Comment: Beta blockers (esp. non selective) antagonize theophylline effects, while at the same time increasing theophylline levels and toxicity (mechanism: decreased theophylline metabolism). Smoking increases risk of interaction.
pentobarbital|theophylline|11|Significant - Monitor Closely|pentobarbital will decrease the level or effect of theophylline by  affecting hepatic enzyme CYP1A2 metabolism. Significant interaction possible, monitor closely.
pentobarbital|theophylline|11|Significant - Monitor Closely|pentobarbital will decrease the level or effect of theophylline by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
pentoxifylline|theophylline|1|Minor|pentoxifylline increases levels of theophylline by decreasing metabolism. Minor or non-significant interaction.
phenobarbital|theophylline|11|Significant - Monitor Closely|phenobarbital will decrease the level or effect of theophylline by  affecting hepatic enzyme CYP1A2 metabolism. Significant interaction possible, monitor closely.
phenobarbital|theophylline|11|Significant - Monitor Closely|phenobarbital will decrease the level or effect of theophylline by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
phenytoin|theophylline|11|Significant - Monitor Closely|phenytoin will decrease the level or effect of theophylline by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
pindolol|theophylline|11|Significant - Monitor Closely|pindolol, theophylline. Other (see comment). Significant interaction possible, monitor closely. Comment: Beta blockers (esp. non selective) antagonize theophylline effects, while at the same time increasing theophylline levels and toxicity (mechanism: decreased theophylline metabolism). Smoking increases risk of interaction.
primidone|theophylline|11|Significant - Monitor Closely|primidone will decrease the level or effect of theophylline by  affecting hepatic enzyme CYP1A2 metabolism. Significant interaction possible, monitor closely.
primidone|theophylline|11|Significant - Monitor Closely|primidone will decrease the level or effect of theophylline by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
propafenone|theophylline|1|Minor|propafenone increases levels of theophylline by decreasing renal clearance. Minor or non-significant interaction.
propranolol|theophylline|11|Significant - Monitor Closely|propranolol, theophylline. Other (see comment). Significant interaction possible, monitor closely. Comment: Beta blockers (esp. non selective) antagonize theophylline effects, while at the same time increasing theophylline levels and toxicity (mechanism: decreased theophylline metabolism). Smoking increases risk of interaction.
theophylline|regadenoson|22|Serious - Use Alternative|theophylline decreases effects of regadenoson by pharmacodynamic antagonism. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available. Avoid methylxanthines for 12 hours before regadenoson administration.
ritonavir|theophylline|11|Significant - Monitor Closely|ritonavir will increase the level or effect of theophylline by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
secobarbital|theophylline|11|Significant - Monitor Closely|secobarbital will decrease the level or effect of theophylline by  affecting hepatic enzyme CYP1A2 metabolism. Significant interaction possible, monitor closely.
secobarbital|theophylline|11|Significant - Monitor Closely|secobarbital will decrease the level or effect of theophylline by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
sotalol|theophylline|11|Significant - Monitor Closely|sotalol, theophylline. Other (see comment). Significant interaction possible, monitor closely. Comment: Beta blockers (esp. non selective) antagonize theophylline effects, while at the same time increasing theophylline levels and toxicity (mechanism: decreased theophylline metabolism). Smoking increases risk of interaction.
tacrine|theophylline|20|Serious - Use Alternative|tacrine increases levels of theophylline by decreasing metabolism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
tacrine|theophylline|11|Significant - Monitor Closely|tacrine will increase the level or effect of theophylline by  affecting hepatic enzyme CYP1A2 metabolism. Significant interaction possible, monitor closely.
ticlopidine|theophylline|1|Minor|ticlopidine increases levels of theophylline by decreasing metabolism. Minor or non-significant interaction.
timolol|theophylline|11|Significant - Monitor Closely|timolol, theophylline. Other (see comment). Significant interaction possible, monitor closely. Comment: Beta blockers (esp. non selective) antagonize theophylline effects, while at the same time increasing theophylline levels and toxicity (mechanism: decreased theophylline metabolism). Smoking increases risk of interaction.
troleandomycin|theophylline|11|Significant - Monitor Closely|troleandomycin will increase the level or effect of theophylline by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
verapamil|theophylline|11|Significant - Monitor Closely|verapamil will increase the level or effect of theophylline by  affecting hepatic enzyme CYP1A2 metabolism. Significant interaction possible, monitor closely.
verapamil|theophylline|11|Significant - Monitor Closely|verapamil will increase the level or effect of theophylline by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
zafirlukast|theophylline|11|Significant - Monitor Closely|zafirlukast will increase the level or effect of theophylline by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
theophylline|zafirlukast|1|Minor|theophylline decreases levels of zafirlukast by unknown mechanism. Minor or non-significant interaction.
zileuton|theophylline|11|Significant - Monitor Closely|zileuton will increase the level or effect of theophylline by  affecting hepatic enzyme CYP1A2 metabolism. Significant interaction possible, monitor closely.
atazanavir|amiodarone|22|Serious - Use Alternative|atazanavir will increase the level or effect of amiodarone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available.
amiodarone|atomoxetine|2|Significant - Monitor Closely|amiodarone will increase the level or effect of atomoxetine by  affecting hepatic enzyme CYP2D6 metabolism. Potential for interaction, monitor.
amiodarone|cisapride|33|Contraindicated|amiodarone and cisapride both increase  QTc interval. Never use combination.
clarithromycin|amiodarone|20|Serious - Use Alternative|clarithromycin will increase the level or effect of amiodarone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available. May result in prolongation of QT interval
amiodarone|clarithromycin|20|Serious - Use Alternative|amiodarone and clarithromycin both increase  QTc interval. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
cyclosporine|amiodarone|11|Significant - Monitor Closely|cyclosporine will increase the level or effect of amiodarone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
amiodarone|cyclosporine|11|Significant - Monitor Closely|amiodarone will increase the level or effect of cyclosporine by  P-glycoprotein (MDR1) efflux transporter. Significant interaction possible, monitor closely.
amiodarone|cyclosporine|1|Minor|amiodarone increases levels of cyclosporine by decreasing renal clearance. Minor or non-significant interaction.
amiodarone|digoxin|20|Serious - Use Alternative|amiodarone will increase the level or effect of digoxin by  P-glycoprotein (MDR1) efflux transporter. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available. Amiodarone increases PO digoxin serum concentrations by ~70% and IV digoxin by ~17%; measure digoxin levels before initiating amiodarone and reduce PO digoxin dose by 30-50%; decrease IV digoxin dose by 15-30%
amiodarone|digoxin|20|Serious - Use Alternative|amiodarone will increase the level or effect of digoxin by  basic (cationic) drug competition for renal tubular clearance. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available. Amiodarone increases PO digoxin serum concentrations by ~70% and IV digoxin by ~17%; measure digoxin levels before initiating amiodarone and reduce PO digoxin dose by 30-50%; decrease IV digoxin dose by 15-30%
diltiazem|amiodarone|11|Significant - Monitor Closely|diltiazem will increase the level or effect of amiodarone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
amiodarone|diltiazem|11|Significant - Monitor Closely|amiodarone will increase the level or effect of diltiazem by  basic (cationic) drug competition for renal tubular clearance. Significant interaction possible, monitor closely.
amiodarone|diltiazem|11|Significant - Monitor Closely|amiodarone, diltiazem. Mechanism: pharmacodynamic synergism. Significant interaction possible, monitor closely. Risk of cardiotoxicity with bradycardia.
amiodarone|eltrombopag|11|Significant - Monitor Closely|amiodarone will increase the level or effect of eltrombopag by  affecting hepatic enzyme CYP2C9/10 metabolism. Significant interaction possible, monitor closely.
amiodarone|ethotoin|11|Significant - Monitor Closely|amiodarone will increase the level or effect of ethotoin by  affecting hepatic enzyme CYP2C9/10 metabolism. Significant interaction possible, monitor closely.
ethotoin|amiodarone|11|Significant - Monitor Closely|ethotoin will decrease the level or effect of amiodarone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
etravirine|amiodarone|20|Serious - Use Alternative|etravirine will decrease the level or effect of amiodarone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
amiodarone|etravirine|11|Significant - Monitor Closely|amiodarone will increase the level or effect of etravirine by  affecting hepatic enzyme CYP2C9/10 metabolism. Significant interaction possible, monitor closely.
fingolimod|amiodarone|33|Contraindicated|fingolimod increases effects of amiodarone by pharmacodynamic synergism. Never use combination. Due to increased risk of bradycardia, AV block, and torsade de pointes, concomitant use is contraindicated.
amiodarone|flecainide|22|Serious - Use Alternative|amiodarone and flecainide both increase  QTc interval. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available.
amiodarone|flecainide|11|Significant - Monitor Closely|amiodarone will increase the level or effect of flecainide by  affecting hepatic enzyme CYP2D6 metabolism. Significant interaction possible, monitor closely. The flecainide dosage should be reduced by 50% during concurrent therapy with amiodarone. Carefully monitor the patient for adverse effects, including QT interval changes.
fosamprenavir|amiodarone|20|Serious - Use Alternative|fosamprenavir will increase the level or effect of amiodarone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
amiodarone|fosphenytoin|11|Significant - Monitor Closely|amiodarone will increase the level or effect of fosphenytoin by  affecting hepatic enzyme CYP2C9/10 metabolism. Significant interaction possible, monitor closely.
fosphenytoin|amiodarone|11|Significant - Monitor Closely|fosphenytoin will decrease the level or effect of amiodarone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
amiodarone|indinavir|33|Contraindicated|amiodarone will increase the level or effect of indinavir by  P-glycoprotein (MDR1) efflux transporter. Never use combination.
indinavir|amiodarone|20|Serious - Use Alternative|indinavir will increase the level or effect of amiodarone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
amiodarone|levofloxacin|22|Serious - Use Alternative|amiodarone and levofloxacin both increase  QTc interval. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available.
amiodarone|lumefantrine|20|Serious - Use Alternative|amiodarone and lumefantrine both increase  QTc interval. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
lumefantrine|amiodarone|11|Significant - Monitor Closely|lumefantrine increases effects of amiodarone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely. Additive QTc prolongation effects. Concomitant use of lumefantrine with other drugs that prolong the QT interval such as Class III antiarrhythmics should be avoided.
amiodarone|moxifloxacin|20|Serious - Use Alternative|amiodarone and moxifloxacin both increase  QTc interval. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
amiodarone|nelfinavir|33|Contraindicated|amiodarone will increase the level or effect of nelfinavir by  P-glycoprotein (MDR1) efflux transporter. Never use combination.
nelfinavir|amiodarone|21|Serious - Use Alternative|nelfinavir increases levels of amiodarone by decreasing metabolism. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available. Never use combination.
nelfinavir|amiodarone|20|Serious - Use Alternative|nelfinavir will increase the level or effect of amiodarone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
amiodarone|phenytoin|11|Significant - Monitor Closely|amiodarone will increase the level or effect of phenytoin by  affecting hepatic enzyme CYP2C9/10 metabolism. Significant interaction possible, monitor closely.
phenytoin|amiodarone|11|Significant - Monitor Closely|phenytoin will decrease the level or effect of amiodarone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely. An increased risk of phenytoin toxicity (ataxia, hyperreflexa, nystagmus, tremor) and/or decreased amiodarone concentrations.  Because of the long half-life of amiodarone, the full extent of this interaction may not be evident for several weeks; careful monitoring is required.
amiodarone|procainamide|33|Contraindicated|amiodarone and procainamide both increase  QTc interval. Never use combination.
amiodarone|procainamide|20|Serious - Use Alternative|amiodarone will increase the level or effect of procainamide by  basic (cationic) drug competition for renal tubular clearance. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
quinidine|amiodarone|20|Serious - Use Alternative|quinidine will increase the level or effect of amiodarone by  basic (cationic) drug competition for renal tubular clearance. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
quinidine|amiodarone|20|Serious - Use Alternative|quinidine and amiodarone both increase  QTc interval. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
amiodarone|ranolazine|22|Serious - Use Alternative|amiodarone and ranolazine both increase  QTc interval. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available.
ritonavir|amiodarone|33|Contraindicated|ritonavir will increase the level or effect of amiodarone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Never use combination.
amiodarone|ritonavir|33|Contraindicated|amiodarone will increase the level or effect of ritonavir by  P-glycoprotein (MDR1) efflux transporter. Never use combination.
ritonavir|amiodarone|33|Contraindicated|ritonavir increases levels of amiodarone by decreasing metabolism. Never use combination.
amiodarone|roflumilast|3|Significant - Monitor Closely|amiodarone increases levels of roflumilast by Other (see comment). Potential for dangerous interaction. Use with caution and monitor closely. Comment: Coadministration with dual inhibitors of CYP3A4 and CYP1A2 may increase systemic exposure and result in increased adverse reactions.
amiodarone|saquinavir|33|Contraindicated|amiodarone will increase the level or effect of saquinavir by  P-glycoprotein (MDR1) efflux transporter. Never use combination.
amiodarone|simvastatin|20|Serious - Use Alternative|amiodarone increases toxicity of simvastatin by decreasing metabolism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available. Do not exceed simvastatin 20 mg daily when given concurrently. Potential for increased risk of myopathy/rhabdomyolysis.
amiodarone|tacrolimus|11|Significant - Monitor Closely|amiodarone will increase the level or effect of tacrolimus by  P-glycoprotein (MDR1) efflux transporter. Significant interaction possible, monitor closely.
amiodarone|tacrolimus|1|Minor|amiodarone increases levels of tacrolimus by decreasing renal clearance. Minor or non-significant interaction.
amiodarone|tamoxifen|11|Significant - Monitor Closely|amiodarone, tamoxifen. affecting hepatic enzyme CYP2C9/10 metabolism. Significant interaction possible, monitor closely.  CYP2C9/10 inhibition decreases tamoxifen metabolism to active metabolites.
amiodarone|tamsulosin|2|Significant - Monitor Closely|amiodarone increases levels of tamsulosin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Potential for interaction, monitor. Dose reduction may be neeed for coadministered drugs that are predominantly metabolized by CYP3A.
amiodarone|tamsulosin|2|Significant - Monitor Closely|amiodarone increases levels of tamsulosin by affecting hepatic enzyme CYP2D6 metabolism. Potential for interaction, monitor.
amiodarone|telavancin|22|Serious - Use Alternative|amiodarone and telavancin both increase  QTc interval. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available.
amiodarone|telithromycin|22|Serious - Use Alternative|amiodarone and telithromycin both increase  QTc interval. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available.
telithromycin|amiodarone|11|Significant - Monitor Closely|telithromycin will increase the level or effect of amiodarone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely. The rare occurrence of arrhythmias resulting from the potential for additive QT prolongation should be considered as a possibility when amiodarone and telithromycin are coadministered. Telithromycin should be avoided if possible in patients that are treated amiodarone.
amiodarone|terfenadine|33|Contraindicated|amiodarone and terfenadine both increase  QTc interval. Never use combination.
thioridazine|amiodarone|33|Contraindicated|thioridazine and amiodarone both increase  QTc interval. Never use combination.
amiodarone|thioridazine|21|Serious - Use Alternative|amiodarone increases levels of thioridazine by decreasing metabolism. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available. Never use combination.
amiodarone|thioridazine|20|Serious - Use Alternative|amiodarone will increase the level or effect of thioridazine by  affecting hepatic enzyme CYP2D6 metabolism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
tipranavir|amiodarone|33|Contraindicated|tipranavir increases levels of amiodarone by decreasing metabolism. Never use combination.
amiodarone|tolterodine|1|Minor|amiodarone will increase the level or effect of tolterodine by  affecting hepatic enzyme CYP2D6 metabolism. Minor or non-significant interaction.
amiodarone|topotecan|22|Serious - Use Alternative|amiodarone will increase the level or effect of topotecan by  P-glycoprotein (MDR1) efflux transporter. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available. Product labeling for PO topotecan recommends avoiding concomitant use of P-gp inhibitors; the interaction with IV topotecan may be less severe but is still likely of clinical significance
amiodarone|toremifene|20|Serious - Use Alternative|amiodarone and toremifene both increase  QTc interval. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available. Concurrent use of toremifene with agents causing  QT prolongation should be avoided. If concomitant use is required it's recommended that toremifene be interrupted. If interruption not possible, patients requiring therapy with a drug that prolongs QT should be closely monitored. ECGs should be obtained for high risk patients.
amiodarone|tramadol|2|Significant - Monitor Closely|amiodarone decreases effects of tramadol by affecting hepatic enzyme CYP2D6 metabolism. Potential for interaction, monitor. Decreased conversion of tramadol to active metabolite.
amiodarone|tramadol|2|Significant - Monitor Closely|amiodarone decreases effects of tramadol by decreasing metabolism. Potential for interaction, monitor. Decreased conversion of tramadol to active metabolite.
trazodone|amiodarone|20|Serious - Use Alternative|trazodone and amiodarone both increase  QTc interval. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
trimipramine|amiodarone|20|Serious - Use Alternative|trimipramine and amiodarone both increase  QTc interval. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
verapamil|amiodarone|11|Significant - Monitor Closely|verapamil will increase the level or effect of amiodarone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
amiodarone|verapamil|11|Significant - Monitor Closely|amiodarone will increase the level or effect of verapamil by  basic (cationic) drug competition for renal tubular clearance. Significant interaction possible, monitor closely.
amiodarone|verapamil|11|Significant - Monitor Closely|amiodarone, verapamil. Mechanism: pharmacodynamic synergism. Significant interaction possible, monitor closely. Risk of cardiotoxicity with bradycardia.
amiodarone|voriconazole|22|Serious - Use Alternative|amiodarone and voriconazole both increase  QTc interval. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available.
voriconazole|amiodarone|11|Significant - Monitor Closely|voriconazole will increase the level or effect of amiodarone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
amiodarone|voriconazole|1|Minor|amiodarone will increase the level or effect of voriconazole by  affecting hepatic enzyme CYP2C9/10 metabolism. Minor or non-significant interaction.
amiodarone|warfarin|20|Serious - Use Alternative|amiodarone increases levels of warfarin by decreasing metabolism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
amiodarone|warfarin|11|Significant - Monitor Closely|amiodarone will increase the level or effect of warfarin by  affecting hepatic enzyme CYP2C9/10 metabolism. Significant interaction possible, monitor closely.
amiodarone|ziprasidone|33|Contraindicated|amiodarone and ziprasidone both increase  QTc interval. Never use combination.
atazanavir|amitriptyline|11|Significant - Monitor Closely|atazanavir increases levels of amitriptyline by unspecified interaction mechanism. Significant interaction possible, monitor closely.
atazanavir|amitriptyline|2|Significant - Monitor Closely|atazanavir will increase the level or effect of amitriptyline by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Potential for interaction, monitor.
butabarbital|amitriptyline|11|Significant - Monitor Closely|butabarbital will decrease the level or effect of amitriptyline by  affecting hepatic enzyme CYP2C19 metabolism. Significant interaction possible, monitor closely.
butabarbital|amitriptyline|3|Significant - Monitor Closely|butabarbital will decrease the level or effect of amitriptyline by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Potential for dangerous interaction. Use with caution and monitor closely.
butabarbital|amitriptyline|2|Significant - Monitor Closely|butabarbital and amitriptyline both increase  sedation. Potential for interaction, monitor.
butabarbital|amitriptyline|1|Minor|butabarbital, amitriptyline. Other (see comment). Minor or non-significant interaction. Comment: Barbiturates may increase adverse effects, including respiratory depression, produced by toxic doses of TCAs. With therapeutic doses of TCAs, barbiturates increase metabolism and decrease blood concentrations of TCAs.
butalbital|amitriptyline|11|Significant - Monitor Closely|butalbital will decrease the level or effect of amitriptyline by  affecting hepatic enzyme CYP2C19 metabolism. Significant interaction possible, monitor closely.
butalbital|amitriptyline|3|Significant - Monitor Closely|butalbital will decrease the level or effect of amitriptyline by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Potential for dangerous interaction. Use with caution and monitor closely.
butalbital|amitriptyline|2|Significant - Monitor Closely|butalbital and amitriptyline both increase  sedation. Potential for interaction, monitor.
butalbital|amitriptyline|1|Minor|butalbital, amitriptyline. Other (see comment). Minor or non-significant interaction. Comment: Barbiturates may increase adverse effects, including respiratory depression, produced by toxic doses of TCAs. With therapeutic doses of TCAs, barbiturates increase metabolism and decrease blood concentrations of TCAs.
carbamazepine|amitriptyline|2|Significant - Monitor Closely|carbamazepine will decrease the level or effect of amitriptyline by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Potential for interaction, monitor.
carbamazepine|amitriptyline|1|Minor|carbamazepine decreases levels of amitriptyline by increasing metabolism. Minor or non-significant interaction.
cimetidine|amitriptyline|2|Significant - Monitor Closely|cimetidine will increase the level or effect of amitriptyline by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Potential for interaction, monitor.
amitriptyline|cisapride|33|Contraindicated|amitriptyline and cisapride both increase  QTc interval. Never use combination.
amitriptyline|clonidine|20|Serious - Use Alternative|amitriptyline decreases effects of clonidine by Other (see comment). Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available. Comment: Inhibition of uptake by adrenergic neurons.
amitriptyline|desvenlafaxine|20|Serious - Use Alternative|amitriptyline and desvenlafaxine both increase  serotonin levels. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
amitriptyline|dobutamine|20|Serious - Use Alternative|amitriptyline, dobutamine. Other (see comment). Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available. Comment: Tricyclic antidepressants increase or decrease effects of sympathomimetics, by blocking reuptake of NE, or blocking uptake of indirect sympathomimetics into the adrenergic neuron.
amitriptyline|dobutamine|2|Significant - Monitor Closely|amitriptyline increases and dobutamine decreases sedation. Effect of interaction is not clear, use caution. Potential for interaction, monitor.
donepezil|amitriptyline|3|Significant - Monitor Closely|donepezil increases and amitriptyline decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Potential for dangerous interaction. Use with caution and monitor closely.
amitriptyline|dopamine|20|Serious - Use Alternative|amitriptyline, dopamine. Other (see comment). Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available. Comment: Tricyclic antidepressants increase or decrease effects of sympathomimetics, by blocking reuptake of NE, or blocking uptake of indirect sympathomimetics into the adrenergic neuron.
amitriptyline|dopamine|2|Significant - Monitor Closely|amitriptyline increases and dopamine decreases sedation. Effect of interaction is not clear, use caution. Potential for interaction, monitor.
duloxetine|amitriptyline|22|Serious - Use Alternative|duloxetine and amitriptyline both increase  serotonin levels. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available.
amitriptyline|ephedrine|20|Serious - Use Alternative|amitriptyline, ephedrine. Other (see comment). Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available. Comment: Tricyclic antidepressants increase or decrease effects of sympathomimetics, by blocking reuptake of NE, or blocking uptake of indirect sympathomimetics into the adrenergic neuron.
amitriptyline|ephedrine|11|Significant - Monitor Closely|amitriptyline increases effects of ephedrine by unknown mechanism. Significant interaction possible, monitor closely.
amitriptyline|ephedrine|2|Significant - Monitor Closely|amitriptyline increases and ephedrine decreases sedation. Effect of interaction is not clear, use caution. Potential for interaction, monitor.
epinephrine|amitriptyline|22|Serious - Use Alternative|epinephrine and amitriptyline both increase  QTc interval. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available.
amitriptyline|epinephrine|20|Serious - Use Alternative|amitriptyline, epinephrine. Other (see comment). Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available. Comment: Tricyclic antidepressants increase or decrease effects of sympathomimetics, by blocking reuptake of NE, or blocking uptake of indirect sympathomimetics into the adrenergic neuron.
amitriptyline|epinephrine|11|Significant - Monitor Closely|amitriptyline increases effects of epinephrine by unknown mechanism. Significant interaction possible, monitor closely.
amitriptyline|epinephrine|2|Significant - Monitor Closely|amitriptyline increases and epinephrine decreases sedation. Effect of interaction is not clear, use caution. Potential for interaction, monitor.
amitriptyline|fluconazole|22|Serious - Use Alternative|amitriptyline and fluconazole both increase  QTc interval. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available.
fluconazole|amitriptyline|11|Significant - Monitor Closely|fluconazole will increase the level or effect of amitriptyline by  affecting hepatic enzyme CYP2C19 metabolism. Significant interaction possible, monitor closely.
fluconazole|amitriptyline|2|Significant - Monitor Closely|fluconazole will increase the level or effect of amitriptyline by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Potential for interaction, monitor.
fluoxetine|amitriptyline|22|Serious - Use Alternative|fluoxetine and amitriptyline both increase  serotonin levels. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available.
fluoxetine|amitriptyline|20|Serious - Use Alternative|fluoxetine will increase the level or effect of amitriptyline by  affecting hepatic enzyme CYP2C19 metabolism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
amitriptyline|fluoxetine|3|Significant - Monitor Closely|amitriptyline and fluoxetine both increase  QTc interval. Potential for dangerous interaction. Use with caution and monitor closely.
fluvoxamine|amitriptyline|22|Serious - Use Alternative|fluvoxamine and amitriptyline both increase  serotonin levels. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available.
fluvoxamine|amitriptyline|20|Serious - Use Alternative|fluvoxamine will increase the level or effect of amitriptyline by  affecting hepatic enzyme CYP2C19 metabolism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
fluvoxamine|amitriptyline|3|Significant - Monitor Closely|fluvoxamine will increase the level or effect of amitriptyline by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Potential for dangerous interaction. Use with caution and monitor closely.
amitriptyline|fluvoxamine|3|Significant - Monitor Closely|amitriptyline and fluvoxamine both increase  QTc interval. Potential for dangerous interaction. Use with caution and monitor closely.
galantamine|amitriptyline|3|Significant - Monitor Closely|galantamine increases and amitriptyline decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Potential for dangerous interaction. Use with caution and monitor closely.
isocarboxazid|amitriptyline|33|Contraindicated|isocarboxazid and amitriptyline both increase  serotonin levels. Never use combination.
amitriptyline|ketoconazole|22|Serious - Use Alternative|amitriptyline and ketoconazole both increase  QTc interval. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available.
ketoconazole|amitriptyline|11|Significant - Monitor Closely|ketoconazole will increase the level or effect of amitriptyline by  P-glycoprotein (MDR1) efflux transporter. Significant interaction possible, monitor closely.
ketoconazole|amitriptyline|2|Significant - Monitor Closely|ketoconazole will increase the level or effect of amitriptyline by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Potential for interaction, monitor.
amitriptyline|lumefantrine|22|Serious - Use Alternative|amitriptyline and lumefantrine both increase  QTc interval. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available.
lumefantrine|amitriptyline|1|Minor|lumefantrine will decrease the level or effect of amitriptyline by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor or non-significant interaction.
amitriptyline|norepinephrine|20|Serious - Use Alternative|amitriptyline, norepinephrine. Other (see comment). Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available. Comment: Tricyclic antidepressants increase or decrease effects of sympathomimetics, by blocking reuptake of NE, or blocking uptake of indirect sympathomimetics into the adrenergic neuron.
amitriptyline|norepinephrine|11|Significant - Monitor Closely|amitriptyline increases effects of norepinephrine by unknown mechanism. Significant interaction possible, monitor closely.
amitriptyline|norepinephrine|2|Significant - Monitor Closely|amitriptyline increases and norepinephrine decreases sedation. Effect of interaction is not clear, use caution. Potential for interaction, monitor.
phenelzine|amitriptyline|33|Contraindicated|phenelzine and amitriptyline both increase  serotonin levels. Never use combination.
amitriptyline|phenylephrine|20|Serious - Use Alternative|amitriptyline, phenylephrine. Other (see comment). Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available. Comment: Tricyclic antidepressants increase or decrease effects of sympathomimetics, by blocking reuptake of NE, or blocking uptake of indirect sympathomimetics into the adrenergic neuron.
amitriptyline|phenylephrine|2|Significant - Monitor Closely|amitriptyline increases and phenylephrine decreases sedation. Effect of interaction is not clear, use caution. Potential for interaction, monitor.
amitriptyline|pirbuterol|20|Serious - Use Alternative|amitriptyline, pirbuterol. Other (see comment). Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available. Comment: Tricyclic antidepressants increase or decrease effects of sympathomimetics, by blocking reuptake of NE, or blocking uptake of indirect sympathomimetics into the adrenergic neuron.
amitriptyline|pirbuterol|2|Significant - Monitor Closely|amitriptyline increases and pirbuterol decreases sedation. Effect of interaction is not clear, use caution. Potential for interaction, monitor.
amitriptyline|pseudoephedrine|20|Serious - Use Alternative|amitriptyline, pseudoephedrine. Other (see comment). Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available. Comment: Tricyclic antidepressants increase or decrease effects of sympathomimetics, by blocking reuptake of NE, or blocking uptake of indirect sympathomimetics into the adrenergic neuron.
amitriptyline|pseudoephedrine|2|Significant - Monitor Closely|amitriptyline increases and pseudoephedrine decreases sedation. Effect of interaction is not clear, use caution. Potential for interaction, monitor.
quinidine|amitriptyline|33|Contraindicated|quinidine and amitriptyline both increase  QTc interval. Never use combination.
quinidine|amitriptyline|20|Serious - Use Alternative|quinidine will increase the level or effect of amitriptyline by  P-glycoprotein (MDR1) efflux transporter. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
rasagiline|amitriptyline|20|Serious - Use Alternative|rasagiline and amitriptyline both increase  serotonin levels. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available. Severe CNS toxicity associated with hyperpyrexia has been reported with the combined treatment of an antidepressant and rasagiline. Avoid combination within 14 days of MAOI use.
rifabutin|amitriptyline|11|Significant - Monitor Closely|rifabutin decreases levels of amitriptyline by increasing metabolism. Significant interaction possible, monitor closely.
rifabutin|amitriptyline|2|Significant - Monitor Closely|rifabutin will decrease the level or effect of amitriptyline by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Potential for interaction, monitor.
ritonavir|amitriptyline|11|Significant - Monitor Closely|ritonavir will increase the level or effect of amitriptyline by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
ritonavir|amitriptyline|11|Significant - Monitor Closely|ritonavir will increase the level or effect of amitriptyline by  P-glycoprotein (MDR1) efflux transporter. Significant interaction possible, monitor closely.
rivastigmine|amitriptyline|3|Significant - Monitor Closely|rivastigmine increases and amitriptyline decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Potential for dangerous interaction. Use with caution and monitor closely.
tacrine|amitriptyline|3|Significant - Monitor Closely|tacrine increases and amitriptyline decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Potential for dangerous interaction. Use with caution and monitor closely.
tacrolimus|amitriptyline|11|Significant - Monitor Closely|tacrolimus will increase the level or effect of amitriptyline by  P-glycoprotein (MDR1) efflux transporter. Significant interaction possible, monitor closely.
amitriptyline|terbutaline|20|Serious - Use Alternative|amitriptyline, terbutaline. Other (see comment). Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available. Comment: Tricyclic antidepressants increase or decrease effects of sympathomimetics, by blocking reuptake of NE, or blocking uptake of indirect sympathomimetics into the adrenergic neuron.
amitriptyline|terbutaline|2|Significant - Monitor Closely|amitriptyline increases and terbutaline decreases sedation. Effect of interaction is not clear, use caution. Potential for interaction, monitor.
amitriptyline|terfenadine|33|Contraindicated|amitriptyline and terfenadine both increase  QTc interval. Never use combination.
terfenadine|amitriptyline|2|Significant - Monitor Closely|terfenadine and amitriptyline both increase  sedation. Potential for interaction, monitor.
thioridazine|amitriptyline|22|Serious - Use Alternative|thioridazine and amitriptyline both increase  QTc interval. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available.
thioridazine|amitriptyline|2|Significant - Monitor Closely|thioridazine and amitriptyline both increase  sedation. Potential for interaction, monitor.
amitriptyline|thioridazine|1|Minor|amitriptyline, thioridazine.Either increases levels of the other by decreasing metabolism. Minor or non-significant interaction. Additive anticholinergic effects.
amitriptyline|thioridazine|1|Minor|amitriptyline, thioridazine.Either increases levels of the other by pharmacodynamic synergism. Minor or non-significant interaction. Additive anticholinergic effects.
thiothixene|amitriptyline|2|Significant - Monitor Closely|thiothixene and amitriptyline both increase  sedation. Potential for interaction, monitor.
amitriptyline|toremifene|20|Serious - Use Alternative|amitriptyline and toremifene both increase  QTc interval. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available. Concurrent use of toremifene with agents causing  QT prolongation should be avoided. If concomitant use is required it's recommended that toremifene be interrupted. If interruption not possible, patients requiring therapy with a drug that prolongs QT should be closely monitored. ECGs should be obtained for high risk patients.
amitriptyline|tramadol|3|Significant - Monitor Closely|amitriptyline and tramadol both increase  serotonin levels. Potential for dangerous interaction. Use with caution and monitor closely.
tramadol|amitriptyline|2|Significant - Monitor Closely|tramadol and amitriptyline both increase  sedation. Potential for interaction, monitor.
tranylcypromine|amitriptyline|33|Contraindicated|tranylcypromine and amitriptyline both increase  serotonin levels. Never use combination.
amitriptyline|trazodone|22|Serious - Use Alternative|amitriptyline and trazodone both increase  QTc interval. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available.
trazodone|amitriptyline|22|Serious - Use Alternative|trazodone and amitriptyline both increase  serotonin levels. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available.
trazodone|amitriptyline|11|Significant - Monitor Closely|trazodone will decrease the level or effect of amitriptyline by  P-glycoprotein (MDR1) efflux transporter. Significant interaction possible, monitor closely.
amitriptyline|trazodone|2|Significant - Monitor Closely|amitriptyline and trazodone both decrease  cholinergic effects/transmission. Potential for interaction, monitor.
amitriptyline|trazodone|2|Significant - Monitor Closely|amitriptyline and trazodone both increase  sedation. Potential for interaction, monitor.
amitriptyline|trimipramine|22|Serious - Use Alternative|amitriptyline and trimipramine both increase  QTc interval. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available.
amitriptyline|trimipramine|22|Serious - Use Alternative|amitriptyline and trimipramine both increase  serotonin levels. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available.
amitriptyline|trimipramine|2|Significant - Monitor Closely|amitriptyline and trimipramine both decrease  cholinergic effects/transmission. Potential for interaction, monitor.
amitriptyline|trimipramine|2|Significant - Monitor Closely|amitriptyline and trimipramine both increase  sedation. Potential for interaction, monitor.
triprolidine|amitriptyline|2|Significant - Monitor Closely|triprolidine and amitriptyline both increase  sedation. Potential for interaction, monitor.
venlafaxine|amitriptyline|22|Serious - Use Alternative|venlafaxine and amitriptyline both increase  serotonin levels. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available.
amitriptyline|venlafaxine|3|Significant - Monitor Closely|amitriptyline and venlafaxine both increase  QTc interval. Potential for dangerous interaction. Use with caution and monitor closely.
amitriptyline|vilazodone|22|Serious - Use Alternative|amitriptyline, vilazodone.Either increases toxicity of the other by serotonin levels. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available. Concomitant therapy should be discontinued immediately if signs or symptoms of serotonin syndrome emerge and supportive symptomatic treatment should be initiated.  .
voriconazole|amitriptyline|11|Significant - Monitor Closely|voriconazole will increase the level or effect of amitriptyline by  affecting hepatic enzyme CYP2C19 metabolism. Significant interaction possible, monitor closely.
amitriptyline|voriconazole|3|Significant - Monitor Closely|amitriptyline and voriconazole both increase  QTc interval. Potential for dangerous interaction. Use with caution and monitor closely.
voriconazole|amitriptyline|1|Minor|voriconazole will increase the level or effect of amitriptyline by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor or non-significant interaction.
amitriptyline|ziprasidone|22|Serious - Use Alternative|amitriptyline and ziprasidone both increase  QTc interval. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available.
ziprasidone|amitriptyline|2|Significant - Monitor Closely|ziprasidone and amitriptyline both increase  sedation. Potential for interaction, monitor.
zolmitriptan|amitriptyline|3|Significant - Monitor Closely|zolmitriptan and amitriptyline both increase  serotonin levels. Potential for dangerous interaction. Use with caution and monitor closely.
diltiazem|amlodipine|20|Serious - Use Alternative|diltiazem will increase the level or effect of amlodipine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available. Diltiazem increases amlodipine exposure by 60%; avoid use if possible
amlodipine|diltiazem|2|Significant - Monitor Closely|amlodipine and diltiazem both increase  anti-hypertensive channel blocking. Potential for interaction, monitor.
telaprevir|amlodipine|11|Significant - Monitor Closely|telaprevir increases levels of amlodipine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely. Exposure to amlodipine was increased when co-administered with telaprevir. Caution should be used and dose reduction for amlodipine should be considered. Clinical monitoring is recommended.
telithromycin|amlodipine|1|Minor|telithromycin will increase the level or effect of amlodipine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor or non-significant interaction.
tipranavir|amlodipine|11|Significant - Monitor Closely|tipranavir increases levels of amlodipine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely. Potential for increased toxicity. Tipranavir is used with ritonavir (boosted therapy) which is a potent CYP3A4 inhibitor.
tizanidine|amlodipine|1|Minor|tizanidine increases effects of amlodipine by pharmacodynamic synergism. Minor or non-significant interaction. Risk of hypotension.
treprostinil|amlodipine|1|Minor|treprostinil increases effects of amlodipine by pharmacodynamic synergism. Minor or non-significant interaction.
voriconazole|amlodipine|11|Significant - Monitor Closely|voriconazole increases levels of amlodipine by decreasing metabolism. Significant interaction possible, monitor closely.
voriconazole|amlodipine|1|Minor|voriconazole will increase the level or effect of amlodipine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor or non-significant interaction.
amobarbital|conjugated estrogens|11|Significant - Monitor Closely|amobarbital will decrease the level or effect of conjugated estrogens by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
amobarbital|cyclosporine|20|Serious - Use Alternative|amobarbital decreases levels of cyclosporine by increasing metabolism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
amobarbital|cyclosporine|11|Significant - Monitor Closely|amobarbital will decrease the level or effect of cyclosporine by  affecting hepatic enzyme CYP1A2 metabolism. Significant interaction possible, monitor closely.
amobarbital|cyclosporine|11|Significant - Monitor Closely|amobarbital will decrease the level or effect of cyclosporine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
amobarbital|dexamethasone|11|Significant - Monitor Closely|amobarbital will decrease the level or effect of dexamethasone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
amobarbital|doxycycline|11|Significant - Monitor Closely|amobarbital decreases levels of doxycycline by increasing metabolism. Significant interaction possible, monitor closely.
amobarbital|eltrombopag|11|Significant - Monitor Closely|amobarbital will decrease the level or effect of eltrombopag by  affecting hepatic enzyme CYP1A2 metabolism. Significant interaction possible, monitor closely.
amobarbital|eltrombopag|11|Significant - Monitor Closely|amobarbital will decrease the level or effect of eltrombopag by  affecting hepatic enzyme CYP2C9/10 metabolism. Significant interaction possible, monitor closely.
amobarbital|estradiol|11|Significant - Monitor Closely|amobarbital will decrease the level or effect of estradiol by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
amobarbital|felodipine|11|Significant - Monitor Closely|amobarbital will decrease the level or effect of felodipine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
amobarbital|fludrocortisone|11|Significant - Monitor Closely|amobarbital will decrease the level or effect of fludrocortisone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
amobarbital|griseofulvin|1|Minor|amobarbital decreases levels of griseofulvin by inhibition of GI absorption. Applies only to oral form of both agents. Minor or non-significant interaction.
amobarbital|hydrocortisone|11|Significant - Monitor Closely|amobarbital will decrease the level or effect of hydrocortisone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
amobarbital|methadone|11|Significant - Monitor Closely|amobarbital will decrease the level or effect of methadone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
amobarbital|methadone|2|Significant - Monitor Closely|amobarbital and methadone both increase  sedation. Potential for interaction, monitor.
amobarbital|nifedipine|1|Minor|amobarbital will decrease the level or effect of nifedipine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor or non-significant interaction.
amobarbital|prednisolone|11|Significant - Monitor Closely|amobarbital will decrease the level or effect of prednisolone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
amobarbital|prednisone|11|Significant - Monitor Closely|amobarbital will decrease the level or effect of prednisone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
amobarbital|quinidine|11|Significant - Monitor Closely|amobarbital will decrease the level or effect of quinidine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
amobarbital|theophylline|11|Significant - Monitor Closely|amobarbital will decrease the level or effect of theophylline by  affecting hepatic enzyme CYP1A2 metabolism. Significant interaction possible, monitor closely.
amobarbital|theophylline|11|Significant - Monitor Closely|amobarbital will decrease the level or effect of theophylline by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
amobarbital|triamcinolone|11|Significant - Monitor Closely|amobarbital will decrease the level or effect of triamcinolone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
amobarbital|trimipramine|2|Significant - Monitor Closely|amobarbital and trimipramine both increase  sedation. Potential for interaction, monitor.
amobarbital|trimipramine|1|Minor|amobarbital, trimipramine. Other (see comment). Minor or non-significant interaction. Comment: Barbiturates may increase adverse effects, including respiratory depression, produced by toxic doses of TCAs. With therapeutic doses of TCAs, barbiturates increase metabolism and decrease blood concentrations of TCAs.
triprolidine|amobarbital|2|Significant - Monitor Closely|triprolidine and amobarbital both increase  sedation. Potential for interaction, monitor.
amobarbital|verapamil|11|Significant - Monitor Closely|amobarbital will decrease the level or effect of verapamil by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
amobarbital|voriconazole|21|Serious - Use Alternative|amobarbital decreases levels of voriconazole by increasing metabolism. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available. Never use combination.
amobarbital|voriconazole|1|Minor|amobarbital will decrease the level or effect of voriconazole by  affecting hepatic enzyme CYP2C19 metabolism. Minor or non-significant interaction.
amobarbital|voriconazole|1|Minor|amobarbital will decrease the level or effect of voriconazole by  affecting hepatic enzyme CYP2C9/10 metabolism. Minor or non-significant interaction.
amobarbital|warfarin|20|Serious - Use Alternative|amobarbital decreases effects of warfarin by increasing metabolism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
amobarbital|warfarin|11|Significant - Monitor Closely|amobarbital will decrease the level or effect of warfarin by  affecting hepatic enzyme CYP1A2 metabolism. Significant interaction possible, monitor closely.
amobarbital|warfarin|11|Significant - Monitor Closely|amobarbital will decrease the level or effect of warfarin by  affecting hepatic enzyme CYP2C9/10 metabolism. Significant interaction possible, monitor closely.
amobarbital|warfarin|11|Significant - Monitor Closely|amobarbital will decrease the level or effect of warfarin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
amobarbital|warfarin|1|Minor|amobarbital will decrease the level or effect of warfarin by  affecting hepatic enzyme CYP2C19 metabolism. Minor or non-significant interaction.
atazanavir|amoxapine|11|Significant - Monitor Closely|atazanavir increases levels of amoxapine by unspecified interaction mechanism. Significant interaction possible, monitor closely.
butabarbital|amoxapine|2|Significant - Monitor Closely|butabarbital and amoxapine both increase  sedation. Potential for interaction, monitor.
butabarbital|amoxapine|1|Minor|butabarbital, amoxapine. Other (see comment). Minor or non-significant interaction. Comment: Barbiturates may increase adverse effects, including respiratory depression, produced by toxic doses of TCAs. With therapeutic doses of TCAs, barbiturates increase metabolism and decrease blood concentrations of TCAs.
butalbital|amoxapine|2|Significant - Monitor Closely|butalbital and amoxapine both increase  sedation. Potential for interaction, monitor.
butalbital|amoxapine|1|Minor|butalbital, amoxapine. Other (see comment). Minor or non-significant interaction. Comment: Barbiturates may increase adverse effects, including respiratory depression, produced by toxic doses of TCAs. With therapeutic doses of TCAs, barbiturates increase metabolism and decrease blood concentrations of TCAs.
amoxapine|cisapride|33|Contraindicated|amoxapine and cisapride both increase  QTc interval. Never use combination.
amoxapine|clonidine|20|Serious - Use Alternative|amoxapine decreases effects of clonidine by Other (see comment). Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available. Comment: Inhibition of uptake by adrenergic neurons.
amoxapine|desvenlafaxine|20|Serious - Use Alternative|amoxapine and desvenlafaxine both increase  serotonin levels. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
amoxapine|dobutamine|20|Serious - Use Alternative|amoxapine, dobutamine. Other (see comment). Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available. Comment: Tricyclic antidepressants increase or decrease effects of sympathomimetics, by blocking reuptake of NE, or blocking uptake of indirect sympathomimetics into the adrenergic neuron.
amoxapine|dobutamine|2|Significant - Monitor Closely|amoxapine increases and dobutamine decreases sedation. Effect of interaction is not clear, use caution. Potential for interaction, monitor.
donepezil|amoxapine|2|Significant - Monitor Closely|donepezil increases and amoxapine decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Potential for interaction, monitor.
amoxapine|dopamine|20|Serious - Use Alternative|amoxapine, dopamine. Other (see comment). Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available. Comment: Tricyclic antidepressants increase or decrease effects of sympathomimetics, by blocking reuptake of NE, or blocking uptake of indirect sympathomimetics into the adrenergic neuron.
amoxapine|dopamine|2|Significant - Monitor Closely|amoxapine increases and dopamine decreases sedation. Effect of interaction is not clear, use caution. Potential for interaction, monitor.
amoxapine|ephedrine|20|Serious - Use Alternative|amoxapine, ephedrine. Other (see comment). Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available. Comment: Tricyclic antidepressants increase or decrease effects of sympathomimetics, by blocking reuptake of NE, or blocking uptake of indirect sympathomimetics into the adrenergic neuron.
amoxapine|ephedrine|11|Significant - Monitor Closely|amoxapine increases effects of ephedrine by unknown mechanism. Significant interaction possible, monitor closely.
amoxapine|ephedrine|2|Significant - Monitor Closely|amoxapine increases and ephedrine decreases sedation. Effect of interaction is not clear, use caution. Potential for interaction, monitor.
epinephrine|amoxapine|22|Serious - Use Alternative|epinephrine and amoxapine both increase  QTc interval. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available.
amoxapine|epinephrine|20|Serious - Use Alternative|amoxapine, epinephrine. Other (see comment). Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available. Comment: Tricyclic antidepressants increase or decrease effects of sympathomimetics, by blocking reuptake of NE, or blocking uptake of indirect sympathomimetics into the adrenergic neuron.
amoxapine|epinephrine|11|Significant - Monitor Closely|amoxapine increases effects of epinephrine by unknown mechanism. Significant interaction possible, monitor closely.
amoxapine|epinephrine|2|Significant - Monitor Closely|amoxapine increases and epinephrine decreases sedation. Effect of interaction is not clear, use caution. Potential for interaction, monitor.
fluoxetine|amoxapine|22|Serious - Use Alternative|fluoxetine and amoxapine both increase  serotonin levels. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available.
amoxapine|fluoxetine|3|Significant - Monitor Closely|amoxapine and fluoxetine both increase  QTc interval. Potential for dangerous interaction. Use with caution and monitor closely.
fluvoxamine|amoxapine|22|Serious - Use Alternative|fluvoxamine and amoxapine both increase  serotonin levels. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available.
amoxapine|fluvoxamine|3|Significant - Monitor Closely|amoxapine and fluvoxamine both increase  QTc interval. Potential for dangerous interaction. Use with caution and monitor closely.
galantamine|amoxapine|2|Significant - Monitor Closely|galantamine increases and amoxapine decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Potential for interaction, monitor.
isocarboxazid|amoxapine|33|Contraindicated|isocarboxazid and amoxapine both increase  serotonin levels. Never use combination.
amoxapine|lumefantrine|22|Serious - Use Alternative|amoxapine and lumefantrine both increase  QTc interval. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available.
amoxapine|norepinephrine|20|Serious - Use Alternative|amoxapine, norepinephrine. Other (see comment). Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available. Comment: Tricyclic antidepressants increase or decrease effects of sympathomimetics, by blocking reuptake of NE, or blocking uptake of indirect sympathomimetics into the adrenergic neuron.
amoxapine|norepinephrine|11|Significant - Monitor Closely|amoxapine increases effects of norepinephrine by unknown mechanism. Significant interaction possible, monitor closely.
amoxapine|norepinephrine|2|Significant - Monitor Closely|amoxapine increases and norepinephrine decreases sedation. Effect of interaction is not clear, use caution. Potential for interaction, monitor.
phenelzine|amoxapine|33|Contraindicated|phenelzine and amoxapine both increase  serotonin levels. Never use combination.
amoxapine|phenylephrine|20|Serious - Use Alternative|amoxapine, phenylephrine. Other (see comment). Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available. Comment: Tricyclic antidepressants increase or decrease effects of sympathomimetics, by blocking reuptake of NE, or blocking uptake of indirect sympathomimetics into the adrenergic neuron.
amoxapine|phenylephrine|2|Significant - Monitor Closely|amoxapine increases and phenylephrine decreases sedation. Effect of interaction is not clear, use caution. Potential for interaction, monitor.
amoxapine|pirbuterol|20|Serious - Use Alternative|amoxapine, pirbuterol. Other (see comment). Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available. Comment: Tricyclic antidepressants increase or decrease effects of sympathomimetics, by blocking reuptake of NE, or blocking uptake of indirect sympathomimetics into the adrenergic neuron.
amoxapine|pirbuterol|2|Significant - Monitor Closely|amoxapine increases and pirbuterol decreases sedation. Effect of interaction is not clear, use caution. Potential for interaction, monitor.
amoxapine|pseudoephedrine|20|Serious - Use Alternative|amoxapine, pseudoephedrine. Other (see comment). Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available. Comment: Tricyclic antidepressants increase or decrease effects of sympathomimetics, by blocking reuptake of NE, or blocking uptake of indirect sympathomimetics into the adrenergic neuron.
amoxapine|pseudoephedrine|2|Significant - Monitor Closely|amoxapine increases and pseudoephedrine decreases sedation. Effect of interaction is not clear, use caution. Potential for interaction, monitor.
rasagiline|amoxapine|20|Serious - Use Alternative|rasagiline and amoxapine both increase  serotonin levels. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available. Severe CNS toxicity associated with hyperpyrexia has been reported with the combined treatment of an antidepressant and rasagiline. Avoid combination within 14 days of MAOI use.
rifabutin|amoxapine|11|Significant - Monitor Closely|rifabutin decreases levels of amoxapine by increasing metabolism. Significant interaction possible, monitor closely.
tacrine|amoxapine|2|Significant - Monitor Closely|tacrine increases and amoxapine decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Potential for interaction, monitor.
amoxapine|terbutaline|20|Serious - Use Alternative|amoxapine, terbutaline. Other (see comment). Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available. Comment: Tricyclic antidepressants increase or decrease effects of sympathomimetics, by blocking reuptake of NE, or blocking uptake of indirect sympathomimetics into the adrenergic neuron.
amoxapine|terbutaline|2|Significant - Monitor Closely|amoxapine increases and terbutaline decreases sedation. Effect of interaction is not clear, use caution. Potential for interaction, monitor.
amoxapine|terfenadine|33|Contraindicated|amoxapine and terfenadine both increase  QTc interval. Never use combination.
terfenadine|amoxapine|2|Significant - Monitor Closely|terfenadine and amoxapine both increase  sedation. Potential for interaction, monitor.
thiothixene|amoxapine|11|Significant - Monitor Closely|thiothixene and amoxapine both increase  antidopaminergic effects, including extrapyramidal symptoms and neuroleptic malignant syndrome. Significant interaction possible, monitor closely.
thiothixene|amoxapine|2|Significant - Monitor Closely|thiothixene and amoxapine both increase  sedation. Potential for interaction, monitor.
amoxapine|tramadol|3|Significant - Monitor Closely|amoxapine and tramadol both increase  serotonin levels. Potential for dangerous interaction. Use with caution and monitor closely.
tramadol|amoxapine|2|Significant - Monitor Closely|tramadol and amoxapine both increase  sedation. Potential for interaction, monitor.
tranylcypromine|amoxapine|33|Contraindicated|tranylcypromine and amoxapine both increase  serotonin levels. Never use combination.
amoxapine|trazodone|22|Serious - Use Alternative|amoxapine and trazodone both increase  QTc interval. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available.
trazodone|amoxapine|22|Serious - Use Alternative|trazodone and amoxapine both increase  serotonin levels. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available.
amoxapine|trazodone|2|Significant - Monitor Closely|amoxapine and trazodone both decrease  cholinergic effects/transmission. Potential for interaction, monitor.
amoxapine|trazodone|2|Significant - Monitor Closely|amoxapine and trazodone both increase  sedation. Potential for interaction, monitor.
amoxapine|trimipramine|22|Serious - Use Alternative|amoxapine and trimipramine both increase  QTc interval. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available.
amoxapine|trimipramine|22|Serious - Use Alternative|amoxapine and trimipramine both increase  serotonin levels. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available.
amoxapine|trimipramine|2|Significant - Monitor Closely|amoxapine and trimipramine both decrease  cholinergic effects/transmission. Potential for interaction, monitor.
amoxapine|trimipramine|2|Significant - Monitor Closely|amoxapine and trimipramine both increase  sedation. Potential for interaction, monitor.
triprolidine|amoxapine|2|Significant - Monitor Closely|triprolidine and amoxapine both increase  sedation. Potential for interaction, monitor.
venlafaxine|amoxapine|22|Serious - Use Alternative|venlafaxine and amoxapine both increase  serotonin levels. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available.
amoxapine|venlafaxine|3|Significant - Monitor Closely|amoxapine and venlafaxine both increase  QTc interval. Potential for dangerous interaction. Use with caution and monitor closely.
amoxapine|voriconazole|3|Significant - Monitor Closely|amoxapine and voriconazole both increase  QTc interval. Potential for dangerous interaction. Use with caution and monitor closely.
ziprasidone|amoxapine|33|Contraindicated|ziprasidone and amoxapine both increase  antidopaminergic effects, including extrapyramidal symptoms and neuroleptic malignant syndrome. Never use combination.
amoxapine|ziprasidone|22|Serious - Use Alternative|amoxapine and ziprasidone both increase  QTc interval. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available.
ziprasidone|amoxapine|2|Significant - Monitor Closely|ziprasidone and amoxapine both increase  sedation. Potential for interaction, monitor.
zolmitriptan|amoxapine|3|Significant - Monitor Closely|zolmitriptan and amoxapine both increase  serotonin levels. Potential for dangerous interaction. Use with caution and monitor closely.
demeclocycline|amoxicillin|20|Serious - Use Alternative|demeclocycline decreases effects of amoxicillin by pharmacodynamic antagonism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
doxycycline|amoxicillin|20|Serious - Use Alternative|doxycycline decreases effects of amoxicillin by pharmacodynamic antagonism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
amoxicillin|mestranol|2|Significant - Monitor Closely|amoxicillin will decrease the level or effect of mestranol by  altering intestinal flora. Applies only to oral forms of hormone. Low risk of contraceptive failure. Potential for interaction, monitor.
amoxicillin|methotrexate|11|Significant - Monitor Closely|amoxicillin increases levels of methotrexate by decreasing renal clearance. Significant interaction possible, monitor closely. Increased serum concentrations of methotrexate with concomitant hematologic and gastrointestinal toxicity have been observed with concurrent administration of high or low doses of methotrexate and penicillins.
minocycline|amoxicillin|20|Serious - Use Alternative|minocycline decreases effects of amoxicillin by pharmacodynamic antagonism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
tetracycline|amoxicillin|20|Serious - Use Alternative|tetracycline decreases effects of amoxicillin by pharmacodynamic antagonism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
ampicillin|atenolol|1|Minor|ampicillin decreases levels of atenolol by inhibition of GI absorption. Applies only to oral form of both agents. Minor or non-significant interaction.
demeclocycline|ampicillin|20|Serious - Use Alternative|demeclocycline decreases effects of ampicillin by pharmacodynamic antagonism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
doxycycline|ampicillin|20|Serious - Use Alternative|doxycycline decreases effects of ampicillin by pharmacodynamic antagonism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
ampicillin|mestranol|2|Significant - Monitor Closely|ampicillin will decrease the level or effect of mestranol by  altering intestinal flora. Applies only to oral forms of hormone. Low risk of contraceptive failure. Potential for interaction, monitor.
ampicillin|methotrexate|11|Significant - Monitor Closely|ampicillin increases levels of methotrexate by decreasing renal clearance. Significant interaction possible, monitor closely. Increased serum concentrations of methotrexate with concomitant hematologic and gastrointestinal toxicity have been observed with concurrent administration of high or low doses of methotrexate and penicillins.
minocycline|ampicillin|20|Serious - Use Alternative|minocycline decreases effects of ampicillin by pharmacodynamic antagonism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
oxytetracycline|ampicillin|20|Serious - Use Alternative|oxytetracycline decreases effects of ampicillin by pharmacodynamic antagonism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
tetracycline|ampicillin|20|Serious - Use Alternative|tetracycline decreases effects of ampicillin by pharmacodynamic antagonism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
amyl nitrite|ergotamine|20|Serious - Use Alternative|amyl nitrite increases effects of ergotamine by decreasing metabolism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available. Risk of increased SBP, angina pectoris.
ginkgo biloba|anagrelide|1|Minor|ginkgo biloba, anagrelide. pharmacodynamic synergism. Minor or non-significant interaction. May prolong bleeding time.  Conflicting evidence.Ã¿ Use with caution.
anakinra|canakinumab|22|Serious - Use Alternative|anakinra and canakinumab both increase  immunosuppressive effects; risk of infection. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available.
anakinra|certolizumab pegol|20|Serious - Use Alternative|anakinra and certolizumab pegol both increase  immunosuppressive effects; risk of infection. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available. Avoid combination because of an increased risk of serious infection.
anakinra|etanercept|22|Serious - Use Alternative|anakinra and etanercept both increase  immunosuppressive effects; risk of infection. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available.
anakinra|etanercept|20|Serious - Use Alternative|anakinra, etanercept.Either increases effects of the other by pharmacodynamic synergism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available. Additive immunosuppression; risk of serious infection.
anakinra|golimumab|22|Serious - Use Alternative|anakinra and golimumab both increase  immunosuppressive effects; risk of infection. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available.
anakinra|infliximab|22|Serious - Use Alternative|anakinra and infliximab both increase  immunosuppressive effects; risk of infection. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available.
anakinra|rilonacept|22|Serious - Use Alternative|anakinra and rilonacept both increase  immunosuppressive effects; risk of infection. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available.
anakinra|thalidomide|33|Contraindicated|anakinra increases toxicity of thalidomide by Other (see comment). Never use combination. Comment: Avoid concomitant use due to increased risk of infection.
enoxaparin|apixaban|22|Serious - Use Alternative|enoxaparin and apixaban both increase  anticoagulation. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available.
eptifibatide|apixaban|22|Serious - Use Alternative|eptifibatide and apixaban both increase  anticoagulation. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available.
itraconazole|apixaban|20|Serious - Use Alternative|itraconazole will increase the level or effect of apixaban by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available. If taking apixaban dose >2.5 mg BID, decrease dose by 50% if coadministered with strong dual inhibitors of CYP3A4 and P-gp; if currently taking apixaban 2.5 mg PO BID, avoid coadministration with strong dual inhibitors of CYP3A4 and P-gp
ketoconazole|apixaban|20|Serious - Use Alternative|ketoconazole will increase the level or effect of apixaban by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available. If taking apixaban dose >2.5 mg BID, decrease dose by 50% if coadministered with strong dual inhibitors of CYP3A4 and P-gp; if currently taking apixaban 2.5 mg PO BID, avoid coadministration with strong dual inhibitors of CYP3A4 and P-gp
posaconazole|apixaban|20|Serious - Use Alternative|posaconazole will increase the level or effect of apixaban by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available. If taking apixaban dose >2.5 mg BID, decrease dose by 50% if coadministered with strong dual inhibitors of CYP3A4 and P-gp; if currently taking apixaban 2.5 mg PO BID, avoid coadministration with strong dual inhibitors of CYP3A4 and P-gp
ritonavir|apixaban|20|Serious - Use Alternative|ritonavir will increase the level or effect of apixaban by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available. If taking apixaban dose >2.5 mg BID, decrease dose by 50% if coadministered with strong dual inhibitors of CYP3A4 and P-gp; if currently taking apixaban 2.5 mg PO BID, avoid coadministration with strong dual inhibitors of CYP3A4 and P-gp
rivaroxaban|apixaban|22|Serious - Use Alternative|rivaroxaban and apixaban both increase  anticoagulation. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available.
entacapone|apomorphine|2|Significant - Monitor Closely|entacapone increases effects of apomorphine by pharmacodynamic synergism. Potential for interaction, monitor.
paliperidone|apomorphine|20|Serious - Use Alternative|paliperidone decreases effects of apomorphine by pharmacodynamic antagonism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
paliperidone|apomorphine|2|Significant - Monitor Closely|paliperidone and apomorphine both increase  sedation. Potential for interaction, monitor.
thiothixene|apomorphine|20|Serious - Use Alternative|thiothixene decreases effects of apomorphine by pharmacodynamic antagonism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
thiothixene|apomorphine|2|Significant - Monitor Closely|thiothixene and apomorphine both increase  sedation. Potential for interaction, monitor.
apomorphine|toremifene|20|Serious - Use Alternative|apomorphine and toremifene both increase  QTc interval. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available. Concurrent use of toremifene with agents causing  QT prolongation should be avoided. If concomitant use is required it's recommended that toremifene be interrupted. If interruption not possible, patients requiring therapy with a drug that prolongs QT should be closely monitored. ECGs should be obtained for high risk patients.
ziprasidone|apomorphine|20|Serious - Use Alternative|ziprasidone decreases effects of apomorphine by pharmacodynamic antagonism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
apraclonidine|tranylcypromine|33|Contraindicated|apraclonidine, tranylcypromine. Mechanism: unknown. Never use combination. Contraindicated in mfr. prescribing info.
tranylcypromine|apraclonidine|33|Contraindicated|tranylcypromine, apraclonidine. Mechanism: unknown. Never use combination. Contraindicated in mfr prescribing info.
aprepitant|astemizole|33|Contraindicated|aprepitant increases levels of astemizole by decreasing metabolism. Never use combination. Risk of QT interval prolongation.
aprepitant|astemizole|21|Serious - Use Alternative|aprepitant will increase the level or effect of astemizole by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available. Never use combination.
carbamazepine|aprepitant|20|Serious - Use Alternative|carbamazepine will decrease the level or effect of aprepitant by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
aprepitant|carbamazepine|3|Significant - Monitor Closely|aprepitant will increase the level or effect of carbamazepine by  decreasing metabolism. Potential for dangerous interaction. Use with caution and monitor closely. Monitor plasma levels when used concomitantly
aprepitant|cisapride|33|Contraindicated|aprepitant increases levels of cisapride by decreasing metabolism. Never use combination. Risk of QT interval prolongation.
aprepitant|cisapride|21|Serious - Use Alternative|aprepitant will increase the level or effect of cisapride by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available. Never use combination.
clarithromycin|aprepitant|20|Serious - Use Alternative|clarithromycin will increase the level or effect of aprepitant by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
aprepitant|clarithromycin|1|Minor|aprepitant will increase the level or effect of clarithromycin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor or non-significant interaction.
aprepitant|dexamethasone|11|Significant - Monitor Closely|aprepitant will increase the level or effect of dexamethasone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
dexamethasone|aprepitant|11|Significant - Monitor Closely|dexamethasone will decrease the level or effect of aprepitant by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
aprepitant|diltiazem|11|Significant - Monitor Closely|aprepitant will increase the level or effect of diltiazem by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
diltiazem|aprepitant|11|Significant - Monitor Closely|diltiazem will increase the level or effect of aprepitant by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
aprepitant|docetaxel|1|Minor|aprepitant will increase the level or effect of docetaxel by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor or non-significant interaction.
ethotoin|aprepitant|11|Significant - Monitor Closely|ethotoin will decrease the level or effect of aprepitant by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
aprepitant|etoposide|2|Significant - Monitor Closely|aprepitant will increase the level or effect of etoposide by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Potential for interaction, monitor.
fosphenytoin|aprepitant|11|Significant - Monitor Closely|fosphenytoin will decrease the level or effect of aprepitant by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
aprepitant|imatinib|1|Minor|aprepitant will increase the level or effect of imatinib by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor or non-significant interaction.
aprepitant|irinotecan|20|Serious - Use Alternative|aprepitant will increase the level or effect of irinotecan by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
itraconazole|aprepitant|20|Serious - Use Alternative|itraconazole will increase the level or effect of aprepitant by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
aprepitant|itraconazole|1|Minor|aprepitant will increase the level or effect of itraconazole by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor or non-significant interaction.
ketoconazole|aprepitant|20|Serious - Use Alternative|ketoconazole will increase the level or effect of aprepitant by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
aprepitant|ketoconazole|1|Minor|aprepitant will increase the level or effect of ketoconazole by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor or non-significant interaction.
aprepitant|mestranol|11|Significant - Monitor Closely|aprepitant will increase the level or effect of mestranol by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
aprepitant|mestranol|1|Minor|aprepitant decreases levels of mestranol by increasing metabolism. Minor or non-significant interaction.
aprepitant|methylprednisolone|11|Significant - Monitor Closely|aprepitant will increase the level or effect of methylprednisolone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
methylprednisolone|aprepitant|11|Significant - Monitor Closely|methylprednisolone will decrease the level or effect of aprepitant by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
aprepitant|midazolam|11|Significant - Monitor Closely|aprepitant will increase the level or effect of midazolam by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
nefazodone|aprepitant|20|Serious - Use Alternative|nefazodone will increase the level or effect of aprepitant by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
aprepitant|nelfinavir|11|Significant - Monitor Closely|aprepitant will increase the level or effect of nelfinavir by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
nelfinavir|aprepitant|11|Significant - Monitor Closely|nelfinavir will increase the level or effect of aprepitant by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
aprepitant|paclitaxel|1|Minor|aprepitant will increase the level or effect of paclitaxel by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor or non-significant interaction.
phenytoin|aprepitant|11|Significant - Monitor Closely|phenytoin will decrease the level or effect of aprepitant by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
aprepitant|pimozide|33|Contraindicated|aprepitant increases levels of pimozide by decreasing metabolism. Never use combination. Risk of QT interval prolongation.
aprepitant|pimozide|1|Minor|aprepitant will increase the level or effect of pimozide by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor or non-significant interaction.
aprepitant|ritonavir|11|Significant - Monitor Closely|aprepitant will increase the level or effect of ritonavir by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
aprepitant|tamsulosin|2|Significant - Monitor Closely|aprepitant increases levels of tamsulosin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Potential for interaction, monitor. Dose reduction may be needed for coadministered drugs that are predominantly metabolized by CYP3A.
telithromycin|aprepitant|11|Significant - Monitor Closely|telithromycin will increase the level or effect of aprepitant by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
aprepitant|telithromycin|1|Minor|aprepitant will increase the level or effect of telithromycin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor or non-significant interaction.
aprepitant|terfenadine|33|Contraindicated|aprepitant increases levels of terfenadine by decreasing metabolism. Never use combination. Risk of QT interval prolongation.
aprepitant|terfenadine|21|Serious - Use Alternative|aprepitant will increase the level or effect of terfenadine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available. Never use combination.
aprepitant|tolterodine|11|Significant - Monitor Closely|aprepitant will increase the level or effect of tolterodine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
aprepitant|trazodone|11|Significant - Monitor Closely|aprepitant will increase the level or effect of trazodone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
aprepitant|triazolam|11|Significant - Monitor Closely|aprepitant will increase the level or effect of triazolam by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
troleandomycin|aprepitant|11|Significant - Monitor Closely|troleandomycin will increase the level or effect of aprepitant by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
aprepitant|troleandomycin|1|Minor|aprepitant will increase the level or effect of troleandomycin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor or non-significant interaction.
primidone|felodipine|11|Significant - Monitor Closely|primidone will decrease the level or effect of felodipine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
secobarbital|felodipine|11|Significant - Monitor Closely|secobarbital will decrease the level or effect of felodipine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
felodipine|tacrolimus|11|Significant - Monitor Closely|felodipine will increase the level or effect of tacrolimus by  P-glycoprotein (MDR1) efflux transporter. Significant interaction possible, monitor closely.
telithromycin|felodipine|11|Significant - Monitor Closely|telithromycin will increase the level or effect of felodipine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
tipranavir|felodipine|11|Significant - Monitor Closely|tipranavir, felodipine. Other (see comment). Significant interaction possible, monitor closely. Comment: Felodipine levels may incr or decr, due to contradictory effects of tipranavir on hepatic CYP3A4 and P glycoprotein.
treprostinil|felodipine|1|Minor|treprostinil increases effects of felodipine by pharmacodynamic synergism. Minor or non-significant interaction.
voriconazole|felodipine|11|Significant - Monitor Closely|voriconazole will increase the level or effect of felodipine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
voriconazole|felodipine|11|Significant - Monitor Closely|voriconazole increases levels of felodipine by decreasing metabolism. Significant interaction possible, monitor closely.
felodipine|voriconazole|1|Minor|felodipine will increase the level or effect of voriconazole by  affecting hepatic enzyme CYP2C19 metabolism. Minor or non-significant interaction.
fluoxetine|fenfluramine|3|Significant - Monitor Closely|fluoxetine and fenfluramine both increase  serotonin levels. Potential for dangerous interaction. Use with caution and monitor closely.
fluphenazine|fenfluramine|11|Significant - Monitor Closely|fluphenazine, fenfluramine. Mechanism: unknown. Significant interaction possible, monitor closely. Risk of cardiac arrhythmia or sudden death, more likely w/thioridazine than other phenothiazines.  Interaction more likely in certain predisposed pts. only.
fluphenazine|fenfluramine|2|Significant - Monitor Closely|fluphenazine increases and fenfluramine decreases sedation. Effect of interaction is not clear, use caution. Potential for interaction, monitor.
fluvoxamine|fenfluramine|3|Significant - Monitor Closely|fluvoxamine and fenfluramine both increase  serotonin levels. Potential for dangerous interaction. Use with caution and monitor closely.
fenfluramine|insulin aspart|11|Significant - Monitor Closely|fenfluramine increases effects of insulin aspart by Other (see comment). Significant interaction possible, monitor closely. Comment: Fenfluramine enhances glucose uptake in peripheral tissue, increasing risk of hypoglycemia.
fenfluramine|insulin detemir|11|Significant - Monitor Closely|fenfluramine increases effects of insulin detemir by Other (see comment). Significant interaction possible, monitor closely. Comment: Fenfluramine enhances glucose uptake in peripheral tissue, increasing risk of hypoglycemia.
fenfluramine|insulin glulisine|11|Significant - Monitor Closely|fenfluramine increases effects of insulin glulisine by Other (see comment). Significant interaction possible, monitor closely. Comment: Fenfluramine enhances glucose uptake in peripheral tissue, increasing risk of hypoglycemia.
isocarboxazid|fenfluramine|33|Contraindicated|isocarboxazid increases effects of fenfluramine by pharmacodynamic synergism. Never use combination. Risk of acute hypertensive episode.
isocarboxazid|fenfluramine|22|Serious - Use Alternative|isocarboxazid and fenfluramine both increase  serotonin levels. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available.
paroxetine|fenfluramine|3|Significant - Monitor Closely|paroxetine and fenfluramine both increase  serotonin levels. Potential for dangerous interaction. Use with caution and monitor closely.
perphenazine|fenfluramine|11|Significant - Monitor Closely|perphenazine, fenfluramine. Mechanism: unknown. Significant interaction possible, monitor closely. Risk of cardiac arrhythmia or sudden death, more likely w/thioridazine than other phenothiazines.  Interaction more likely in certain predisposed pts. only.
perphenazine|fenfluramine|2|Significant - Monitor Closely|perphenazine increases and fenfluramine decreases sedation. Effect of interaction is not clear, use caution. Potential for interaction, monitor.
phenelzine|fenfluramine|33|Contraindicated|phenelzine increases effects of fenfluramine by pharmacodynamic synergism. Never use combination. Risk of acute hypertensive episode.
phenelzine|fenfluramine|22|Serious - Use Alternative|phenelzine and fenfluramine both increase  serotonin levels. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available.
prochlorperazine|fenfluramine|11|Significant - Monitor Closely|prochlorperazine, fenfluramine. Mechanism: unknown. Significant interaction possible, monitor closely. Risk of cardiac arrhythmia or sudden death, more likely w/thioridazine than other phenothiazines.  Interaction more likely in certain predisposed pts. only.
prochlorperazine|fenfluramine|2|Significant - Monitor Closely|prochlorperazine increases and fenfluramine decreases sedation. Effect of interaction is not clear, use caution. Potential for interaction, monitor.
promazine|fenfluramine|11|Significant - Monitor Closely|promazine, fenfluramine. Mechanism: unknown. Significant interaction possible, monitor closely. Risk of cardiac arrhythmia or sudden death, more likely w/thioridazine than other phenothiazines.  Interaction more likely in certain predisposed pts. only.
promethazine|fenfluramine|11|Significant - Monitor Closely|promethazine, fenfluramine. Mechanism: unknown. Significant interaction possible, monitor closely. Risk of cardiac arrhythmia or sudden death, more likely w/thioridazine than other phenothiazines.  Interaction more likely in certain predisposed pts. only.
promethazine|fenfluramine|2|Significant - Monitor Closely|promethazine increases and fenfluramine decreases sedation. Effect of interaction is not clear, use caution. Potential for interaction, monitor.
thioridazine|fenfluramine|11|Significant - Monitor Closely|thioridazine, fenfluramine. Mechanism: unknown. Significant interaction possible, monitor closely. Risk of cardiac arrhythmia or sudden death, more likely w/thioridazine than other phenothiazines.  Interaction more likely in certain predisposed pts. only.
thioridazine|fenfluramine|2|Significant - Monitor Closely|thioridazine increases and fenfluramine decreases sedation. Effect of interaction is not clear, use caution. Potential for interaction, monitor.
tranylcypromine|fenfluramine|33|Contraindicated|tranylcypromine increases effects of fenfluramine by pharmacodynamic synergism. Never use combination. Risk of acute hypertensive episode.
tranylcypromine|fenfluramine|22|Serious - Use Alternative|tranylcypromine and fenfluramine both increase  serotonin levels. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available.
trifluoperazine|fenfluramine|11|Significant - Monitor Closely|trifluoperazine, fenfluramine. Mechanism: unknown. Significant interaction possible, monitor closely. Risk of cardiac arrhythmia or sudden death, more likely w/thioridazine than other phenothiazines.  Interaction more likely in certain predisposed pts. only.
trifluoperazine|fenfluramine|2|Significant - Monitor Closely|trifluoperazine increases and fenfluramine decreases sedation. Effect of interaction is not clear, use caution. Potential for interaction, monitor.
venlafaxine|fenfluramine|3|Significant - Monitor Closely|venlafaxine and fenfluramine both increase  serotonin levels. Potential for dangerous interaction. Use with caution and monitor closely.
fenofibrate|fluvastatin|20|Serious - Use Alternative|fenofibrate, fluvastatin.Either increases effects of the other by pharmacodynamic synergism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available. Fenofibrate may further increase risk for rhabdomyolysis when added to optimal statin regimen to further decrease TG and increase HDLs.
fenofibrate|insulin lispro|11|Significant - Monitor Closely|fenofibrate increases effects of insulin lispro by unspecified interaction mechanism. Significant interaction possible, monitor closely. Hypoglycemia; increased risk in hypoalbuminemia.
fenofibrate|lovastatin|20|Serious - Use Alternative|fenofibrate, lovastatin.Either increases effects of the other by pharmacodynamic synergism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available. Fenofibrate may further increase risk for rhabdomyolysis when added to optimal statin regimen to further decrease TG and increase HDLs. Do not exceed 20 mg/day of lovastatin.
fenofibrate|pitavastatin|20|Serious - Use Alternative|fenofibrate, pitavastatin.Either increases effects of the other by pharmacodynamic synergism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available. Fenofibrate may further increase risk for rhabdomyolysis when added to optimal statin regimen to further decrease TG and increase HDLs.
fenofibrate|pravastatin|20|Serious - Use Alternative|fenofibrate, pravastatin.Either increases effects of the other by pharmacodynamic synergism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available. Fenofibrate may further increase risk for rhabdomyolysis when added to optimal statin regimen to further decrease TG and increase HDLs.
fenofibrate|rosuvastatin|20|Serious - Use Alternative|fenofibrate, rosuvastatin.Either increases effects of the other by pharmacodynamic synergism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available. Fenofibrate may further increase risk for rhabdomyolysis when added to optimal statin regimen to further decrease TG and increase HDLs.
fenofibrate|simvastatin|20|Serious - Use Alternative|fenofibrate, simvastatin.Either increases effects of the other by pharmacodynamic synergism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available. Fenofibrate may further increase risk for rhabdomyolysis when added to optimal statin regimen to further decrease TG and increase HDLs.
fenofibrate|warfarin|20|Serious - Use Alternative|fenofibrate increases effects of warfarin by pharmacodynamic synergism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
fenofibrate|warfarin|20|Serious - Use Alternative|fenofibrate increases effects of warfarin by plasma protein binding competition. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
fenoprofen|ginkgo biloba|2|Significant - Monitor Closely|fenoprofen and ginkgo biloba both increase  anticoagulation. Potential for interaction, monitor.
fenoprofen|methotrexate|20|Serious - Use Alternative|fenoprofen increases levels of methotrexate by decreasing renal clearance. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available. Concomitant administration of NSAIDs with high dose methotrexate has been reported to elevate and prolong serum methotrexate levels, resulting in deaths from severe hematologic and GI toxicity. NSAIDs may reduce tubular secretion of methotrexate and enhance toxicity. .
fenoprofen|pralatrexate|11|Significant - Monitor Closely|fenoprofen increases levels of pralatrexate by decreasing renal clearance. Significant interaction possible, monitor closely. NSAIDs may delay pralatrexate clearance, increasing drug exposure. Adjust the pralatrexate dose as needed.
telmisartan|fenoprofen|11|Significant - Monitor Closely|telmisartan, fenoprofen.Either increases toxicity of the other by Other (see comment). Significant interaction possible, monitor closely. Comment: May result in renal function deterioration, particularly in elderly or volume depleted individuals.
fenoprofen|telmisartan|3|Significant - Monitor Closely|fenoprofen decreases effects of telmisartan by pharmacodynamic antagonism. Potential for dangerous interaction. Use with caution and monitor closely.  NSAIDs decrease synthesis of vasodilating renal prostaglandins, and thus affect fluid homeostasis and may diminish antihypertensive effect.
telmisartan|fenoprofen|2|Significant - Monitor Closely|telmisartan and fenoprofen both increase  serum potassium. Potential for interaction, monitor.
fenoprofen|timolol|11|Significant - Monitor Closely|fenoprofen decreases effects of timolol by pharmacodynamic antagonism. Significant interaction possible, monitor closely. Long term (>1 wk) NSAID use.  NSAIDs decrease prostaglandin synthesis.
timolol|fenoprofen|2|Significant - Monitor Closely|timolol and fenoprofen both increase  serum potassium. Potential for interaction, monitor.
trandolapril|fenoprofen|11|Significant - Monitor Closely|trandolapril, fenoprofen.Either increases toxicity of the other by Other (see comment). Significant interaction possible, monitor closely. Comment: May result in renal function deterioration, particularly in elderly or volume depleted individuals.
fenoprofen|trandolapril|3|Significant - Monitor Closely|fenoprofen decreases effects of trandolapril by pharmacodynamic antagonism. Potential for dangerous interaction. Use with caution and monitor closely. NSAIDs decrease synthesis of vasodilating renal prostaglandins, and thus affect fluid homeostasis and may diminish antihypertenisve effect.
warfarin|fenoprofen|3|Significant - Monitor Closely|warfarin and fenoprofen both increase  anticoagulation. Potential for dangerous interaction. Use with caution and monitor closely.
fluconazole|fentanyl|1|Minor|fluconazole will increase the level or effect of fentanyl by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor or non-significant interaction.
fosamprenavir|fentanyl|1|Minor|fosamprenavir will increase the level or effect of fentanyl by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor or non-significant interaction.
indinavir|fentanyl|1|Minor|indinavir will increase the level or effect of fentanyl by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor or non-significant interaction.
itraconazole|fentanyl|2|Significant - Monitor Closely|itraconazole will increase the level or effect of fentanyl by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Potential for interaction, monitor.
ketoconazole|fentanyl|2|Significant - Monitor Closely|ketoconazole will increase the level or effect of fentanyl by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Potential for interaction, monitor.
nelfinavir|fentanyl|1|Minor|nelfinavir will increase the level or effect of fentanyl by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor or non-significant interaction.
ritonavir|fentanyl|11|Significant - Monitor Closely|ritonavir will increase the level or effect of fentanyl by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely. Monitor carefully for respiratory depression and consider decreasing fentanyl dose. Ritonavir is a strong CYP3A4 inhibitor
telithromycin|fentanyl|1|Minor|telithromycin will increase the level or effect of fentanyl by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor or non-significant interaction.
tranylcypromine|fentanyl|22|Serious - Use Alternative|tranylcypromine and fentanyl both increase  serotonin levels. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available.
tranylcypromine|fentanyl|20|Serious - Use Alternative|tranylcypromine increases toxicity of fentanyl by unknown mechanism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available. Risk of hypotension, hyperpyrexia, somnolence, or death; separate by 14 d.
triprolidine|fentanyl|2|Significant - Monitor Closely|triprolidine and fentanyl both increase  sedation. Potential for interaction, monitor.
voriconazole|fentanyl|11|Significant - Monitor Closely|voriconazole will increase the level or effect of fentanyl by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely. Dose reduction of fentanyl may be warranted
fluconazole|fesoterodine|11|Significant - Monitor Closely|fluconazole will increase the level or effect of fesoterodine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
ketoconazole|fesoterodine|20|Serious - Use Alternative|ketoconazole will increase the level or effect of fesoterodine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
fingolimod|ibutilide|33|Contraindicated|fingolimod increases effects of ibutilide by pharmacodynamic synergism. Never use combination. Due to increased risk of bradycardia, AV block, and torsade de pointes, concomitant use is contraindicated.
ketoconazole|fingolimod|11|Significant - Monitor Closely|ketoconazole increases levels of fingolimod by Other (see comment). Significant interaction possible, monitor closely. Comment: Mechanism: affecting hepatic enzyme CYP4F2 metabolism  Monitor for adverse events of fingolimod when concomitantly used with ketoconazole.
fingolimod|procainamide|33|Contraindicated|fingolimod increases effects of procainamide by pharmacodynamic synergism. Never use combination. Due to increased risk of bradycardia, AV block, and torsade de pointes, concomitant use is contraindicated.
fingolimod|quinidine|33|Contraindicated|fingolimod increases effects of quinidine by pharmacodynamic synergism. Never use combination. Due to increased risk of bradycardia, AV block, and torsade de pointes, concomitant use is contraindicated.
fingolimod|sotalol|33|Contraindicated|fingolimod increases effects of sotalol by pharmacodynamic synergism. Never use combination. Due to increased risk of bradycardia, AV block, and torsade de pointes, concomitant use is contraindicated.
galantamine|flavoxate|2|Significant - Monitor Closely|galantamine increases and flavoxate decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Potential for interaction, monitor.
galantamine|flavoxate|1|Minor|galantamine decreases effects of flavoxate by pharmacodynamic antagonism. Minor or non-significant interaction.
tacrine|flavoxate|2|Significant - Monitor Closely|tacrine increases and flavoxate decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Potential for interaction, monitor.
tacrine|flavoxate|1|Minor|tacrine decreases effects of flavoxate by pharmacodynamic antagonism. Minor or non-significant interaction.
lumefantrine|flecainide|20|Serious - Use Alternative|lumefantrine will increase the level or effect of flecainide by  affecting hepatic enzyme CYP2D6 metabolism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
flecainide|lumefantrine|3|Significant - Monitor Closely|flecainide and lumefantrine both increase  QTc interval. Potential for dangerous interaction. Use with caution and monitor closely.
mirabegron|flecainide|2|Significant - Monitor Closely|mirabegron will increase the level or effect of flecainide by  affecting hepatic enzyme CYP2D6 metabolism. Potential for interaction, monitor.
ritonavir|flecainide|21|Serious - Use Alternative|ritonavir will increase the level or effect of flecainide by  affecting hepatic enzyme CYP2D6 metabolism. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available. Never use combination. Concurrent use of flecainide and ritonavir is contraindicated.
ritonavir|flecainide|21|Serious - Use Alternative|ritonavir increases levels of flecainide by decreasing metabolism. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available. Never use combination.
flecainide|terfenadine|22|Serious - Use Alternative|flecainide and terfenadine both increase  QTc interval. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available.
thioridazine|flecainide|11|Significant - Monitor Closely|thioridazine will increase the level or effect of flecainide by  affecting hepatic enzyme CYP2D6 metabolism. Significant interaction possible, monitor closely.
thioridazine|flecainide|3|Significant - Monitor Closely|thioridazine and flecainide both increase  QTc interval. Potential for dangerous interaction. Use with caution and monitor closely.
tipranavir|flecainide|33|Contraindicated|tipranavir will increase the level or effect of flecainide by  affecting hepatic enzyme CYP2D6 metabolism. Never use combination. Coadministration may result in flecainide-induced QT prolongation
trimipramine|flecainide|3|Significant - Monitor Closely|trimipramine and flecainide both increase  QTc interval. Potential for dangerous interaction. Use with caution and monitor closely.
flecainide|voriconazole|2|Significant - Monitor Closely|flecainide and voriconazole both increase  QTc interval. Potential for interaction, monitor.
flecainide|ziprasidone|3|Significant - Monitor Closely|flecainide and ziprasidone both increase  QTc interval. Potential for dangerous interaction. Use with caution and monitor closely.
flucloxacillin|mestranol|2|Significant - Monitor Closely|flucloxacillin will decrease the level or effect of mestranol by  altering intestinal flora. Applies only to oral forms of hormone. Low risk of contraceptive failure. Potential for interaction, monitor.
minocycline|flucloxacillin|20|Serious - Use Alternative|minocycline decreases effects of flucloxacillin by pharmacodynamic antagonism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
oxytetracycline|flucloxacillin|20|Serious - Use Alternative|oxytetracycline decreases effects of flucloxacillin by pharmacodynamic antagonism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
tetracycline|flucloxacillin|20|Serious - Use Alternative|tetracycline decreases effects of flucloxacillin by pharmacodynamic antagonism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
fluconazole|fluvastatin|1|Minor|fluconazole will increase the level or effect of fluvastatin by  affecting hepatic enzyme CYP2C9/10 metabolism. Minor or non-significant interaction.
fluconazole|fosphenytoin|11|Significant - Monitor Closely|fluconazole will increase the level or effect of fosphenytoin by  affecting hepatic enzyme CYP2C9/10 metabolism. Significant interaction possible, monitor closely.
fluconazole|haloperidol|22|Serious - Use Alternative|fluconazole and haloperidol both increase  QTc interval. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available.
imipramine|fluconazole|22|Serious - Use Alternative|imipramine and fluconazole both increase  QTc interval. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available.
fluconazole|imipramine|20|Serious - Use Alternative|fluconazole will increase the level or effect of imipramine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
fluconazole|imipramine|11|Significant - Monitor Closely|fluconazole will increase the level or effect of imipramine by  affecting hepatic enzyme CYP2C19 metabolism. Significant interaction possible, monitor closely.
fluconazole|ivacaftor|11|Significant - Monitor Closely|fluconazole increases levels of ivacaftor by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely. Reduce ivacaftor dose to 150 mg once daily when coadministered with moderate CYP3A4 inhibitors.
fluconazole|lovastatin|21|Serious - Use Alternative|fluconazole will increase the level or effect of lovastatin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available. Never use combination.
fluconazole|lumefantrine|22|Serious - Use Alternative|fluconazole and lumefantrine both increase  QTc interval. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available.
fluconazole|lumefantrine|11|Significant - Monitor Closely|fluconazole will increase the level or effect of lumefantrine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
fluconazole|midazolam|11|Significant - Monitor Closely|fluconazole will increase the level or effect of midazolam by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
nortriptyline|fluconazole|22|Serious - Use Alternative|nortriptyline and fluconazole both increase  QTc interval. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available.
fluconazole|ospemifene|3|Significant - Monitor Closely|fluconazole increases levels of ospemifene by affecting hepatic enzyme CYP2C19 metabolism. Potential for dangerous interaction. Use with caution and monitor closely.
fluconazole|ospemifene|3|Significant - Monitor Closely|fluconazole increases levels of ospemifene by affecting hepatic enzyme CYP2C9/10 metabolism. Potential for dangerous interaction. Use with caution and monitor closely.
fluconazole|phenytoin|11|Significant - Monitor Closely|fluconazole will increase the level or effect of phenytoin by  affecting hepatic enzyme CYP2C9/10 metabolism. Significant interaction possible, monitor closely.
fluconazole|pimozide|33|Contraindicated|fluconazole and pimozide both increase  QTc interval. Never use combination.
fluconazole|pimozide|33|Contraindicated|fluconazole increases levels of pimozide by decreasing metabolism. Never use combination. Risk of QT interval prolongation.
fluconazole|pimozide|1|Minor|fluconazole will increase the level or effect of pimozide by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor or non-significant interaction.
fluconazole|ramelteon|1|Minor|fluconazole will increase the level or effect of ramelteon by  affecting hepatic enzyme CYP2C9/10 metabolism. Minor or non-significant interaction.
fluconazole|ramelteon|1|Minor|fluconazole will increase the level or effect of ramelteon by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor or non-significant interaction.
fluconazole|ranolazine|21|Serious - Use Alternative|fluconazole will increase the level or effect of ranolazine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available. Never use combination.
fluconazole|ranolazine|3|Significant - Monitor Closely|fluconazole and ranolazine both increase  QTc interval. Potential for dangerous interaction. Use with caution and monitor closely.
rifabutin|fluconazole|1|Minor|rifabutin decreases levels of fluconazole by increasing metabolism. Minor or non-significant interaction.
fluconazole|silodosin|21|Serious - Use Alternative|fluconazole will increase the level or effect of silodosin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available. Never use combination.
fluconazole|simvastatin|21|Serious - Use Alternative|fluconazole will increase the level or effect of simvastatin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available. Never use combination.
fluconazole|tacrolimus|11|Significant - Monitor Closely|fluconazole will increase the level or effect of tacrolimus by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
fluconazole|tamoxifen|11|Significant - Monitor Closely|fluconazole, tamoxifen. affecting hepatic enzyme CYP2C9/10 metabolism. Significant interaction possible, monitor closely. CYP2C9/10 inhibition decreases tamoxifen metabolism to active metabolites.
fluconazole|tamoxifen|1|Minor|fluconazole, tamoxifen. affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor or non-significant interaction. CYP3A4 inhibition decreases metabolism of tamoxifen to N-desmethyl tamoxifen (active metabolite with similar biologic activity).
fluconazole|tamsulosin|2|Significant - Monitor Closely|fluconazole increases levels of tamsulosin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Potential for interaction, monitor. Dose reduction may be needed for coadministered drugs that are predominantly metabolized by CYP3A.
fluconazole|terfenadine|33|Contraindicated|fluconazole and terfenadine both increase  QTc interval. Never use combination.
fluconazole|terfenadine|33|Contraindicated|fluconazole increases levels of terfenadine by decreasing metabolism. Never use combination. Risk of QT interval prolongation.
fluconazole|terfenadine|21|Serious - Use Alternative|fluconazole will increase the level or effect of terfenadine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available. Never use combination.
fluconazole|tipranavir|11|Significant - Monitor Closely|fluconazole will increase the level or effect of tipranavir by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
fluconazole|tofacitinib|20|Serious - Use Alternative|fluconazole increases levels of tofacitinib by decreasing metabolism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available. Reduce tofacitinib dose to 5 mg qDay when coadministered with 1 or more concomitant medications that result in both moderate CYP3A4 inhibition and potent CYP2C19 inhibition.
fluconazole|tofacitinib|2|Significant - Monitor Closely|fluconazole increases levels of tofacitinib by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Potential for interaction, monitor. No specific dose adjustment recommended when tofacitinib coadministered with moderate CYP3A4 inhibitors; decrease tofacitinib dose if coadministered with both moderate CYP3A4 and potent CYP2C19 inhibitors.
fluconazole|tofacitinib|2|Significant - Monitor Closely|fluconazole increases levels of tofacitinib by affecting hepatic enzyme CYP2C19 metabolism. Potential for interaction, monitor. No specific dose adjustment recommended when tofacitinib coadministered with potent CYP2C19 inhibitors; decrease tofacitinib dose if coadministered with both moderate CYP3A4 and potent CYP2C19 inhibitors .
fluconazole|tolbutamide|11|Significant - Monitor Closely|fluconazole increases levels of tolbutamide by decreasing metabolism. Significant interaction possible, monitor closely.
fluconazole|tolbutamide|1|Minor|fluconazole will increase the level or effect of tolbutamide by  affecting hepatic enzyme CYP2C9/10 metabolism. Minor or non-significant interaction.
fluconazole|tolterodine|11|Significant - Monitor Closely|fluconazole will increase the level or effect of tolterodine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
fluconazole|tolvaptan|21|Serious - Use Alternative|fluconazole will increase the level or effect of tolvaptan by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available. Never use combination.
trazodone|fluconazole|22|Serious - Use Alternative|trazodone and fluconazole both increase  QTc interval. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available.
fluconazole|trazodone|2|Significant - Monitor Closely|fluconazole will increase the level or effect of trazodone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Potential for interaction, monitor.
fluconazole|triazolam|11|Significant - Monitor Closely|fluconazole will increase the level or effect of triazolam by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
fluconazole|trimethoprim|3|Significant - Monitor Closely|fluconazole and trimethoprim both increase  QTc interval. Potential for dangerous interaction. Use with caution and monitor closely.
trimipramine|fluconazole|22|Serious - Use Alternative|trimipramine and fluconazole both increase  QTc interval. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available.
fluconazole|verapamil|11|Significant - Monitor Closely|fluconazole will increase the level or effect of verapamil by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
fluconazole|vinblastine|1|Minor|fluconazole will increase the level or effect of vinblastine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor or non-significant interaction.
fluconazole|vincristine|1|Minor|fluconazole will increase the level or effect of vincristine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor or non-significant interaction.
fluconazole|voriconazole|3|Significant - Monitor Closely|fluconazole and voriconazole both increase  QTc interval. Potential for dangerous interaction. Use with caution and monitor closely.
fluconazole|voriconazole|1|Minor|fluconazole will increase the level or effect of voriconazole by  affecting hepatic enzyme CYP2C19 metabolism. Minor or non-significant interaction.
fluconazole|voriconazole|1|Minor|fluconazole will increase the level or effect of voriconazole by  affecting hepatic enzyme CYP2C9/10 metabolism. Minor or non-significant interaction.
fluconazole|warfarin|20|Serious - Use Alternative|fluconazole increases levels of warfarin by decreasing metabolism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
fluconazole|warfarin|11|Significant - Monitor Closely|fluconazole will increase the level or effect of warfarin by  affecting hepatic enzyme CYP2C9/10 metabolism. Significant interaction possible, monitor closely.
fluconazole|warfarin|11|Significant - Monitor Closely|fluconazole will increase the level or effect of warfarin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
fluconazole|warfarin|1|Minor|fluconazole will increase the level or effect of warfarin by  affecting hepatic enzyme CYP2C19 metabolism. Minor or non-significant interaction.
fluconazole|ziprasidone|22|Serious - Use Alternative|fluconazole and ziprasidone both increase  QTc interval. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available.
fluconazole|ziprasidone|1|Minor|fluconazole will increase the level or effect of ziprasidone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor or non-significant interaction.
fluconazole|zolpidem|1|Minor|fluconazole will increase the level or effect of zolpidem by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor or non-significant interaction.
fludarabine|pentostatin|33|Contraindicated|fludarabine, pentostatin.Either increases toxicity of the other by unknown mechanism. Never use combination. Risk of pulmonary toxicity.
fosphenytoin|fludrocortisone|11|Significant - Monitor Closely|fosphenytoin will decrease the level or effect of fludrocortisone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
fosphenytoin|fludrocortisone|11|Significant - Monitor Closely|fosphenytoin will decrease the level or effect of fludrocortisone by  P-glycoprotein (MDR1) efflux transporter. Significant interaction possible, monitor closely.
hexobarbital|fludrocortisone|11|Significant - Monitor Closely|hexobarbital will decrease the level or effect of fludrocortisone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
pentobarbital|fludrocortisone|11|Significant - Monitor Closely|pentobarbital will decrease the level or effect of fludrocortisone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
phenobarbital|fludrocortisone|11|Significant - Monitor Closely|phenobarbital will decrease the level or effect of fludrocortisone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
phenobarbital|fludrocortisone|11|Significant - Monitor Closely|phenobarbital will decrease the level or effect of fludrocortisone by  P-glycoprotein (MDR1) efflux transporter. Significant interaction possible, monitor closely.
phenytoin|fludrocortisone|11|Significant - Monitor Closely|phenytoin will decrease the level or effect of fludrocortisone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
phenytoin|fludrocortisone|11|Significant - Monitor Closely|phenytoin will decrease the level or effect of fludrocortisone by  P-glycoprotein (MDR1) efflux transporter. Significant interaction possible, monitor closely.
primidone|fludrocortisone|11|Significant - Monitor Closely|primidone will decrease the level or effect of fludrocortisone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
salsalate|fludrocortisone|11|Significant - Monitor Closely|salsalate, fludrocortisone.Either increases toxicity of the other by pharmacodynamic synergism. Significant interaction possible, monitor closely. Increased risk of GI ulceration.
fludrocortisone|salsalate|1|Minor|fludrocortisone decreases levels of salsalate by increasing renal clearance. Minor or non-significant interaction.
secobarbital|fludrocortisone|11|Significant - Monitor Closely|secobarbital will decrease the level or effect of fludrocortisone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
fludrocortisone|warfarin|11|Significant - Monitor Closely|fludrocortisone will decrease the level or effect of warfarin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
fludrocortisone|warfarin|11|Significant - Monitor Closely|fludrocortisone, warfarin. Other (see comment). Significant interaction possible, monitor closely. Comment: Corticosteroids may decrease anticoagulant effects by increasing blood coagulability; conversely, they may impair vascular integrity, thus increasing bleeding risk.  Monitor INR closely.
fluorouracil|fosphenytoin|11|Significant - Monitor Closely|fluorouracil increases levels of fosphenytoin by unknown mechanism. Significant interaction possible, monitor closely. Based on case reports.
metronidazole|fluorouracil|11|Significant - Monitor Closely|metronidazole increases toxicity of fluorouracil by decreasing elimination. Significant interaction possible, monitor closely.
fluorouracil|phenytoin|11|Significant - Monitor Closely|fluorouracil increases levels of phenytoin by unknown mechanism. Significant interaction possible, monitor closely. Based on case reports.
fluorouracil|warfarin|2|Significant - Monitor Closely|fluorouracil increases effects of warfarin by unspecified interaction mechanism. Potential for interaction, monitor. Due to the thrombocytopenic effects of fluorouracil, an additive risk of bleeding may be seen in patients receiving concomitant anticoagulants.
fluoxetine|fosphenytoin|11|Significant - Monitor Closely|fluoxetine will increase the level or effect of fosphenytoin by  affecting hepatic enzyme CYP2C9/10 metabolism. Significant interaction possible, monitor closely.
frovatriptan|fluoxetine|3|Significant - Monitor Closely|frovatriptan and fluoxetine both increase  serotonin levels. Potential for dangerous interaction. Use with caution and monitor closely.
fluoxetine|frovatriptan|1|Minor|fluoxetine, frovatriptan. Mechanism: unknown. Minor or non-significant interaction. Risk of weakness, dyspnea, chest pain.
fluoxetine|iloperidone|20|Serious - Use Alternative|fluoxetine will increase the level or effect of iloperidone by  affecting hepatic enzyme CYP2D6 metabolism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
fluoxetine|iloperidone|2|Significant - Monitor Closely|fluoxetine and iloperidone both increase  QTc interval. Potential for interaction, monitor.
fluoxetine|imipramine|22|Serious - Use Alternative|fluoxetine and imipramine both increase  serotonin levels. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available.
fluoxetine|imipramine|20|Serious - Use Alternative|fluoxetine will increase the level or effect of imipramine by  affecting hepatic enzyme CYP2C19 metabolism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
fluoxetine|imipramine|20|Serious - Use Alternative|fluoxetine will increase the level or effect of imipramine by  affecting hepatic enzyme CYP2D6 metabolism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
imipramine|fluoxetine|3|Significant - Monitor Closely|imipramine and fluoxetine both increase  QTc interval. Potential for dangerous interaction. Use with caution and monitor closely.
isocarboxazid|fluoxetine|33|Contraindicated|isocarboxazid and fluoxetine both increase  serotonin levels. Never use combination.
fluoxetine|ketoprofen|11|Significant - Monitor Closely|fluoxetine, ketoprofen.Either increases toxicity of the other by pharmacodynamic synergism. Significant interaction possible, monitor closely. Increased risk of upper GI bleeding. SSRIs inhib. serotonin uptake by platelets.
linezolid|fluoxetine|33|Contraindicated|linezolid and fluoxetine both increase  serotonin levels. Never use combination. Linezolid may increase serotonin as a result of MAO-A inhibition. If linezolid must be administered, discontinue serotonergic drug immediately and monitor for CNS toxicity. Serotonergic therapy may be resumed 24 hours after last linezolid dose or after 5 weeks of monitoring, whichever comes first.
fluoxetine|lithium|3|Significant - Monitor Closely|fluoxetine and lithium both increase  serotonin levels. Potential for dangerous interaction. Use with caution and monitor closely.
fluoxetine|lithium|1|Minor|fluoxetine, lithium. Mechanism: unknown. Minor or non-significant interaction. Risk of neurotoxicity.
lumefantrine|fluoxetine|33|Contraindicated|lumefantrine will increase the level or effect of fluoxetine by  affecting hepatic enzyme CYP2D6 metabolism. Never use combination.
fluoxetine|lumefantrine|3|Significant - Monitor Closely|fluoxetine and lumefantrine both increase  QTc interval. Potential for dangerous interaction. Use with caution and monitor closely.
fluoxetine|methamphetamine|20|Serious - Use Alternative|fluoxetine will increase the level or effect of methamphetamine by  affecting hepatic enzyme CYP2D6 metabolism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
fluoxetine|metoprolol|20|Serious - Use Alternative|fluoxetine will increase the level or effect of metoprolol by  affecting hepatic enzyme CYP2D6 metabolism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
naratriptan|fluoxetine|3|Significant - Monitor Closely|naratriptan and fluoxetine both increase  serotonin levels. Potential for dangerous interaction. Use with caution and monitor closely.
fluoxetine|naratriptan|1|Minor|fluoxetine, naratriptan. Mechanism: unknown. Minor or non-significant interaction. Risk of weakness, dyspnea, chest pain.
fluoxetine|nortriptyline|22|Serious - Use Alternative|fluoxetine and nortriptyline both increase  serotonin levels. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available.
fluoxetine|nortriptyline|20|Serious - Use Alternative|fluoxetine will increase the level or effect of nortriptyline by  affecting hepatic enzyme CYP2D6 metabolism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
nortriptyline|fluoxetine|3|Significant - Monitor Closely|nortriptyline and fluoxetine both increase  QTc interval. Potential for dangerous interaction. Use with caution and monitor closely.
oxycodone|fluoxetine|20|Serious - Use Alternative|oxycodone will increase the level or effect of fluoxetine by  affecting hepatic enzyme CYP2D6 metabolism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available. Opioids may enhance the serotonergic effects of SSRIs and increase risk for serotonergic syndrome
phenelzine|fluoxetine|33|Contraindicated|phenelzine and fluoxetine both increase  serotonin levels. Never use combination.
fluoxetine|phentermine|20|Serious - Use Alternative|fluoxetine, phentermine.Either increases toxicity of the other by Mechanism: unknown. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available. Risk of serotonin syndrome.
fluoxetine|phenytoin|11|Significant - Monitor Closely|fluoxetine will increase the level or effect of phenytoin by  affecting hepatic enzyme CYP2C9/10 metabolism. Significant interaction possible, monitor closely.
propafenone|fluoxetine|22|Serious - Use Alternative|propafenone and fluoxetine both increase  QTc interval. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available.
fluoxetine|propafenone|20|Serious - Use Alternative|fluoxetine will increase the level or effect of propafenone by  affecting hepatic enzyme CYP2D6 metabolism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
propafenone|fluoxetine|20|Serious - Use Alternative|propafenone will increase the level or effect of fluoxetine by  affecting hepatic enzyme CYP2D6 metabolism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
fluoxetine|propranolol|20|Serious - Use Alternative|fluoxetine will increase the level or effect of propranolol by  affecting hepatic enzyme CYP2D6 metabolism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
fluoxetine|protriptyline|22|Serious - Use Alternative|fluoxetine and protriptyline both increase  serotonin levels. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available.
protriptyline|fluoxetine|3|Significant - Monitor Closely|protriptyline and fluoxetine both increase  QTc interval. Potential for dangerous interaction. Use with caution and monitor closely.
rasagiline|fluoxetine|20|Serious - Use Alternative|rasagiline and fluoxetine both increase  serotonin levels. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available. evere CNS toxicity associated with hyperpyrexia has been reported with the combined treatment of an antidepressant and rasagiline. Avoid combination within 14 days of MAOI use.
fluoxetine|risperidone|20|Serious - Use Alternative|fluoxetine will increase the level or effect of risperidone by  affecting hepatic enzyme CYP2D6 metabolism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
fluoxetine|risperidone|2|Significant - Monitor Closely|fluoxetine and risperidone both increase  QTc interval. Potential for interaction, monitor.
ritonavir|fluoxetine|1|Minor|ritonavir will increase the level or effect of fluoxetine by  affecting hepatic enzyme CYP2D6 metabolism. Minor or non-significant interaction.
rizatriptan|fluoxetine|3|Significant - Monitor Closely|rizatriptan and fluoxetine both increase  serotonin levels. Potential for dangerous interaction. Use with caution and monitor closely.
fluoxetine|rizatriptan|1|Minor|fluoxetine, rizatriptan. Mechanism: unknown. Minor or non-significant interaction. Risk of weakness, dyspnea, chest pain.
selegiline|fluoxetine|33|Contraindicated|selegiline and fluoxetine both increase  serotonin levels. Never use combination. At least 5 weeks should elapse between discontinuation of fluoxetine and initiation of selegiline.
sumatriptan|fluoxetine|3|Significant - Monitor Closely|sumatriptan and fluoxetine both increase  serotonin levels. Potential for dangerous interaction. Use with caution and monitor closely.
fluoxetine|sumatriptan|1|Minor|fluoxetine, sumatriptan. Mechanism: unknown. Minor or non-significant interaction. Risk of weakness, dyspnea, chest pain.
fluoxetine|tamoxifen|11|Significant - Monitor Closely|fluoxetine will decrease the level or effect of tamoxifen by  decreasing metabolism. Significant interaction possible, monitor closely. Inhibition of CYP2D6 metabolism to tamoxifen's active metabolite, endoxifen.
fluoxetine|tamsulosin|2|Significant - Monitor Closely|fluoxetine increases levels of tamsulosin by affecting hepatic enzyme CYP2D6 metabolism. Potential for interaction, monitor.
fluoxetine|tetrabenazine|11|Significant - Monitor Closely|fluoxetine increases effects of tetrabenazine by affecting hepatic enzyme CYP2D6 metabolism. Significant interaction possible, monitor closely. Decrease tetrabenazine dose by 50% when coadministered with strong CYP2D6 inhibitors.
thioridazine|fluoxetine|33|Contraindicated|thioridazine will increase the level or effect of fluoxetine by  affecting hepatic enzyme CYP2D6 metabolism. Never use combination.
thioridazine|fluoxetine|33|Contraindicated|thioridazine and fluoxetine both increase  QTc interval. Never use combination.
fluoxetine|thioridazine|33|Contraindicated|fluoxetine increases levels of thioridazine by decreasing metabolism. Never use combination. Risk of long QT syndrome.
fluoxetine|thioridazine|22|Serious - Use Alternative|fluoxetine will increase the level or effect of thioridazine by  affecting hepatic enzyme CYP2D6 metabolism. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available.
thiothixene|fluoxetine|3|Significant - Monitor Closely|thiothixene and fluoxetine both increase  QTc interval. Potential for dangerous interaction. Use with caution and monitor closely.
tipranavir|fluoxetine|20|Serious - Use Alternative|tipranavir will increase the level or effect of fluoxetine by  affecting hepatic enzyme CYP2D6 metabolism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
fluoxetine|tolbutamide|11|Significant - Monitor Closely|fluoxetine will increase the level or effect of tolbutamide by  affecting hepatic enzyme CYP2C9/10 metabolism. Significant interaction possible, monitor closely.
fluoxetine|tolbutamide|11|Significant - Monitor Closely|fluoxetine increases effects of tolbutamide by unspecified interaction mechanism. Significant interaction possible, monitor closely. Risk of hypoglycemia.
fluoxetine|tolmetin|11|Significant - Monitor Closely|fluoxetine, tolmetin.Either increases toxicity of the other by pharmacodynamic synergism. Significant interaction possible, monitor closely. Increased risk of upper GI bleeding. SSRIs inhib. serotonin uptake by platelets.
fluoxetine|tolterodine|20|Serious - Use Alternative|fluoxetine will increase the level or effect of tolterodine by  affecting hepatic enzyme CYP2D6 metabolism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
toremifene|fluoxetine|3|Significant - Monitor Closely|toremifene and fluoxetine both increase  QTc interval. Potential for dangerous interaction. Use with caution and monitor closely.
fluoxetine|tramadol|3|Significant - Monitor Closely|fluoxetine and tramadol both increase  serotonin levels. Potential for dangerous interaction. Use with caution and monitor closely.
tranylcypromine|fluoxetine|33|Contraindicated|tranylcypromine and fluoxetine both increase  serotonin levels. Never use combination.
fluoxetine|trazodone|22|Serious - Use Alternative|fluoxetine and trazodone both increase  serotonin levels. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available.
trazodone|fluoxetine|3|Significant - Monitor Closely|trazodone and fluoxetine both increase  QTc interval. Potential for dangerous interaction. Use with caution and monitor closely.
fluoxetine|trimipramine|22|Serious - Use Alternative|fluoxetine and trimipramine both increase  serotonin levels. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available.
trimipramine|fluoxetine|3|Significant - Monitor Closely|trimipramine and fluoxetine both increase  QTc interval. Potential for dangerous interaction. Use with caution and monitor closely.
fluoxetine|venlafaxine|22|Serious - Use Alternative|fluoxetine and venlafaxine both increase  serotonin levels. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available.
fluoxetine|venlafaxine|2|Significant - Monitor Closely|fluoxetine and venlafaxine both increase  QTc interval. Potential for interaction, monitor.
venlafaxine|fluoxetine|1|Minor|venlafaxine will increase the level or effect of fluoxetine by  affecting hepatic enzyme CYP2D6 metabolism. Minor or non-significant interaction.
fluoxetine|voriconazole|20|Serious - Use Alternative|fluoxetine will increase the level or effect of voriconazole by  affecting hepatic enzyme CYP2C19 metabolism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
fluoxetine|voriconazole|11|Significant - Monitor Closely|fluoxetine will increase the level or effect of voriconazole by  affecting hepatic enzyme CYP2C9/10 metabolism. Significant interaction possible, monitor closely.
fluoxetine|voriconazole|2|Significant - Monitor Closely|fluoxetine and voriconazole both increase  QTc interval. Potential for interaction, monitor.
vorinostat|fluoxetine|3|Significant - Monitor Closely|vorinostat and fluoxetine both increase  QTc interval. Potential for dangerous interaction. Use with caution and monitor closely.
fluoxetine|warfarin|20|Serious - Use Alternative|fluoxetine increases levels of warfarin by decreasing metabolism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
fluoxetine|warfarin|11|Significant - Monitor Closely|fluoxetine will increase the level or effect of warfarin by  affecting hepatic enzyme CYP2C19 metabolism. Significant interaction possible, monitor closely.
fluoxetine|warfarin|2|Significant - Monitor Closely|fluoxetine will increase the level or effect of warfarin by  affecting hepatic enzyme CYP2C9/10 metabolism. Potential for interaction, monitor.
fluoxetine|ziprasidone|3|Significant - Monitor Closely|fluoxetine and ziprasidone both increase  QTc interval. Potential for dangerous interaction. Use with caution and monitor closely.
zolmitriptan|fluoxetine|3|Significant - Monitor Closely|zolmitriptan and fluoxetine both increase  serotonin levels. Potential for dangerous interaction. Use with caution and monitor closely.
fluoxetine|zolmitriptan|1|Minor|fluoxetine, zolmitriptan. Mechanism: unknown. Minor or non-significant interaction. Risk of weakness, dyspnea, chest pain.
fluoxymesterone|warfarin|20|Serious - Use Alternative|fluoxymesterone increases levels of warfarin by decreasing metabolism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
fluphenazine|levofloxacin|3|Significant - Monitor Closely|fluphenazine and levofloxacin both increase  QTc interval. Potential for dangerous interaction. Use with caution and monitor closely.
fluphenazine|methamphetamine|11|Significant - Monitor Closely|fluphenazine, methamphetamine. Mechanism: unknown. Significant interaction possible, monitor closely. Risk of cardiac arrhythmia or sudden death, more likely w/thioridazine than other phenothiazines.  Interaction more likely in certain predisposed pts. only.
fluphenazine|methamphetamine|2|Significant - Monitor Closely|fluphenazine increases and methamphetamine decreases sedation. Effect of interaction is not clear, use caution. Potential for interaction, monitor.
fluphenazine|metrizamide|33|Contraindicated|fluphenazine, metrizamide. Mechanism: unknown. Never use combination. Risk of seizure.  D/C phenothiazine 24h before admin. of metrizamide.
fluphenazine|phendimetrazine|11|Significant - Monitor Closely|fluphenazine, phendimetrazine. Mechanism: unknown. Significant interaction possible, monitor closely. Risk of cardiac arrhythmia or sudden death, more likely w/thioridazine than other phenothiazines.  Interaction more likely in certain predisposed pts. only.
fluphenazine|phendimetrazine|2|Significant - Monitor Closely|fluphenazine increases and phendimetrazine decreases sedation. Effect of interaction is not clear, use caution. Potential for interaction, monitor.
fluphenazine|phentermine|11|Significant - Monitor Closely|fluphenazine, phentermine. Mechanism: unknown. Significant interaction possible, monitor closely. Risk of cardiac arrhythmia or sudden death, more likely w/thioridazine than other phenothiazines.  Interaction more likely in certain predisposed pts. only.
fluphenazine|phentermine|2|Significant - Monitor Closely|fluphenazine increases and phentermine decreases sedation. Effect of interaction is not clear, use caution. Potential for interaction, monitor.
fluphenazine|terfenadine|33|Contraindicated|fluphenazine and terfenadine both increase  QTc interval. Never use combination.
terfenadine|fluphenazine|2|Significant - Monitor Closely|terfenadine and fluphenazine both increase  sedation. Potential for interaction, monitor.
fluphenazine|tetrabenazine|3|Significant - Monitor Closely|fluphenazine and tetrabenazine both increase  antidopaminergic effects, including extrapyramidal symptoms and neuroleptic malignant syndrome. Potential for dangerous interaction. Use with caution and monitor closely.
triprolidine|fluphenazine|2|Significant - Monitor Closely|triprolidine and fluphenazine both increase  sedation. Potential for interaction, monitor.
fosamprenavir|flurazepam|3|Significant - Monitor Closely|fosamprenavir increases levels of flurazepam by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Potential for dangerous interaction. Use with caution and monitor closely. Use alternatives if available. Consider lowering benzodiazepine dose.
indinavir|flurazepam|3|Significant - Monitor Closely|indinavir increases levels of flurazepam by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Potential for dangerous interaction. Use with caution and monitor closely. Potential for increased toxicity. Use alternatives if available. Consider lowering benzodiazepine dose.
nelfinavir|flurazepam|3|Significant - Monitor Closely|nelfinavir increases levels of flurazepam by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Potential for dangerous interaction. Use with caution and monitor closely. Use alternatives if available. Consider lowering benzodiazepine dose.
omeprazole|flurazepam|1|Minor|omeprazole increases levels of flurazepam by decreasing metabolism. Minor or non-significant interaction.
ritonavir|flurazepam|3|Significant - Monitor Closely|ritonavir increases levels of flurazepam by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Potential for dangerous interaction. Use with caution and monitor closely. Use alternatives if available. Consider lowering benzodiazepine dose.
saquinavir|flurazepam|3|Significant - Monitor Closely|saquinavir increases levels of flurazepam by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Potential for dangerous interaction. Use with caution and monitor closely. Use alternatives if available. Consider lowering benzodiazepine dose.
tipranavir|flurazepam|3|Significant - Monitor Closely|tipranavir increases levels of flurazepam by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Potential for dangerous interaction. Use with caution and monitor closely. Use alternatives if available. Consider lowering benzodiazepine dose.
triprolidine|flurazepam|2|Significant - Monitor Closely|triprolidine and flurazepam both increase  sedation. Potential for interaction, monitor.
flurbiprofen|ginkgo biloba|2|Significant - Monitor Closely|flurbiprofen and ginkgo biloba both increase  anticoagulation. Potential for interaction, monitor.
flurbiprofen|methotrexate|20|Serious - Use Alternative|flurbiprofen increases levels of methotrexate by decreasing renal clearance. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available. Concomitant administration of NSAIDs with high dose methotrexate has been reported to elevate and prolong serum methotrexate levels, resulting in deaths from severe hematologic and GI toxicity. NSAIDs may reduce tubular secretion of methotrexate and enhance toxicity. .
flurbiprofen|pralatrexate|11|Significant - Monitor Closely|flurbiprofen increases levels of pralatrexate by decreasing renal clearance. Significant interaction possible, monitor closely. NSAIDs may delay pralatrexate clearance, increasing drug exposure. Adjust the pralatrexate dose as needed.
telmisartan|flurbiprofen|11|Significant - Monitor Closely|telmisartan, flurbiprofen.Either increases toxicity of the other by Other (see comment). Significant interaction possible, monitor closely. Comment: May result in renal function deterioration, particularly in elderly or volume depleted individuals.
flurbiprofen|telmisartan|3|Significant - Monitor Closely|flurbiprofen decreases effects of telmisartan by pharmacodynamic antagonism. Potential for dangerous interaction. Use with caution and monitor closely.  NSAIDs decrease synthesis of vasodilating renal prostaglandins, and thus affect fluid homeostasis and may diminish antihypertensive effect.
telmisartan|flurbiprofen|2|Significant - Monitor Closely|telmisartan and flurbiprofen both increase  serum potassium. Potential for interaction, monitor.
flurbiprofen|timolol|11|Significant - Monitor Closely|flurbiprofen decreases effects of timolol by pharmacodynamic antagonism. Significant interaction possible, monitor closely. Long term (>1 wk) NSAID use.  NSAIDs decrease prostaglandin synthesis.
timolol|flurbiprofen|2|Significant - Monitor Closely|timolol and flurbiprofen both increase  serum potassium. Potential for interaction, monitor.
flurbiprofen|tolbutamide|11|Significant - Monitor Closely|flurbiprofen increases effects of tolbutamide by unknown mechanism. Significant interaction possible, monitor closely. Risk of hypoglycemia.
flurbiprofen|trandolapril|1|Minor|flurbiprofen decreases effects of trandolapril by pharmacodynamic antagonism. Minor or non-significant interaction. NSAIDs decrease prostaglandin synthesis.
voriconazole|flurbiprofen|1|Minor|voriconazole will increase the level or effect of flurbiprofen by  affecting hepatic enzyme CYP2C9/10 metabolism. Minor or non-significant interaction.
warfarin|flurbiprofen|3|Significant - Monitor Closely|warfarin and flurbiprofen both increase  anticoagulation. Potential for dangerous interaction. Use with caution and monitor closely.
gemfibrozil|fluvastatin|20|Serious - Use Alternative|gemfibrozil, fluvastatin.Either increases effects of the other by pharmacodynamic synergism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available. Gemfibrozil may further increase risk for rhabdomyolysis when added to optimal statin regimen to further decrease TG and increase HDLs.
fluvastatin|warfarin|11|Significant - Monitor Closely|fluvastatin increases effects of warfarin by affecting hepatic enzyme CYP2C9/10 metabolism. Significant interaction possible, monitor closely.
fluvoxamine|fosphenytoin|11|Significant - Monitor Closely|fluvoxamine will increase the level or effect of fosphenytoin by  affecting hepatic enzyme CYP2C9/10 metabolism. Significant interaction possible, monitor closely.
frovatriptan|fluvoxamine|3|Significant - Monitor Closely|frovatriptan and fluvoxamine both increase  serotonin levels. Potential for dangerous interaction. Use with caution and monitor closely.
fluvoxamine|frovatriptan|2|Significant - Monitor Closely|fluvoxamine will increase the level or effect of frovatriptan by  affecting hepatic enzyme CYP1A2 metabolism. Potential for interaction, monitor.
fluvoxamine|frovatriptan|1|Minor|fluvoxamine, frovatriptan. Mechanism: unknown. Minor or non-significant interaction. Risk of weakness, dyspnea, chest pain.
fluvoxamine|imipramine|22|Serious - Use Alternative|fluvoxamine and imipramine both increase  serotonin levels. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available.
fluvoxamine|imipramine|20|Serious - Use Alternative|fluvoxamine will increase the level or effect of imipramine by  affecting hepatic enzyme CYP1A2 metabolism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
fluvoxamine|imipramine|20|Serious - Use Alternative|fluvoxamine will increase the level or effect of imipramine by  affecting hepatic enzyme CYP2C19 metabolism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
fluvoxamine|imipramine|3|Significant - Monitor Closely|fluvoxamine will increase the level or effect of imipramine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Potential for dangerous interaction. Use with caution and monitor closely.
imipramine|fluvoxamine|3|Significant - Monitor Closely|imipramine and fluvoxamine both increase  QTc interval. Potential for dangerous interaction. Use with caution and monitor closely.
isocarboxazid|fluvoxamine|33|Contraindicated|isocarboxazid and fluvoxamine both increase  serotonin levels. Never use combination.
fluvoxamine|ketoprofen|11|Significant - Monitor Closely|fluvoxamine, ketoprofen.Either increases toxicity of the other by pharmacodynamic synergism. Significant interaction possible, monitor closely. Increased risk of upper GI bleeding. SSRIs inhib. serotonin uptake by platelets.
linezolid|fluvoxamine|22|Serious - Use Alternative|linezolid and fluvoxamine both increase  serotonin levels. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available. Linezolid may increase serotonin as a result of MAO-A inhibition. If linezolid must be administered, discontinue serotonergic drug immediately and monitor for CNS toxicity. Serotonergic therapy may be resumed 24 hours after last linezolid dose or after 2 weeks of monitoring, whichever comes first.
fluvoxamine|lithium|3|Significant - Monitor Closely|fluvoxamine and lithium both increase  serotonin levels. Potential for dangerous interaction. Use with caution and monitor closely.
fluvoxamine|lithium|1|Minor|fluvoxamine, lithium. Mechanism: unknown. Minor or non-significant interaction. Risk of neurotoxicity.
fluvoxamine|methadone|11|Significant - Monitor Closely|fluvoxamine will increase the level or effect of methadone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
fluvoxamine|methadone|2|Significant - Monitor Closely|fluvoxamine and methadone both increase  QTc interval. Potential for interaction, monitor.
fluvoxamine|mexiletine|20|Serious - Use Alternative|fluvoxamine will increase the level or effect of mexiletine by  affecting hepatic enzyme CYP1A2 metabolism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
fluvoxamine|mirtazapine|3|Significant - Monitor Closely|fluvoxamine and mirtazapine both increase  serotonin levels. Potential for dangerous interaction. Use with caution and monitor closely.
naratriptan|fluvoxamine|3|Significant - Monitor Closely|naratriptan and fluvoxamine both increase  serotonin levels. Potential for dangerous interaction. Use with caution and monitor closely.
fluvoxamine|naratriptan|1|Minor|fluvoxamine, naratriptan. Mechanism: unknown. Minor or non-significant interaction. Risk of weakness, dyspnea, chest pain.
fluvoxamine|nortriptyline|22|Serious - Use Alternative|fluvoxamine and nortriptyline both increase  serotonin levels. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available.
nortriptyline|fluvoxamine|3|Significant - Monitor Closely|nortriptyline and fluvoxamine both increase  QTc interval. Potential for dangerous interaction. Use with caution and monitor closely.
fluvoxamine|olanzapine|20|Serious - Use Alternative|fluvoxamine will increase the level or effect of olanzapine by  affecting hepatic enzyme CYP1A2 metabolism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
oxycodone|fluvoxamine|3|Significant - Monitor Closely|oxycodone increases effects of fluvoxamine by pharmacodynamic synergism. Potential for dangerous interaction. Use with caution and monitor closely. Opioids may enhance the serotonergic effects of SSRIs and increase risk for serotonergic syndrome.
phenelzine|fluvoxamine|33|Contraindicated|phenelzine and fluvoxamine both increase  serotonin levels. Never use combination.
fluvoxamine|phentermine|20|Serious - Use Alternative|fluvoxamine, phentermine.Either increases toxicity of the other by Mechanism: unknown. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available. Risk of serotonin syndrome.
fluvoxamine|phenytoin|11|Significant - Monitor Closely|fluvoxamine will increase the level or effect of phenytoin by  affecting hepatic enzyme CYP2C9/10 metabolism. Significant interaction possible, monitor closely.
fluvoxamine|protriptyline|22|Serious - Use Alternative|fluvoxamine and protriptyline both increase  serotonin levels. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available.
protriptyline|fluvoxamine|3|Significant - Monitor Closely|protriptyline and fluvoxamine both increase  QTc interval. Potential for dangerous interaction. Use with caution and monitor closely.
fluvoxamine|ramelteon|33|Contraindicated|fluvoxamine will increase the level or effect of ramelteon by  affecting hepatic enzyme CYP1A2 metabolism. Never use combination.
fluvoxamine|ramelteon|33|Contraindicated|fluvoxamine will increase the level or effect of ramelteon by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Never use combination.
fluvoxamine|ramelteon|21|Serious - Use Alternative|fluvoxamine increases levels of ramelteon by decreasing metabolism. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available. Never use combination.
fluvoxamine|ramelteon|2|Significant - Monitor Closely|fluvoxamine will increase the level or effect of ramelteon by  affecting hepatic enzyme CYP2C9/10 metabolism. Potential for interaction, monitor.
fluvoxamine|rasagiline|20|Serious - Use Alternative|fluvoxamine will increase the level or effect of rasagiline by  affecting hepatic enzyme CYP1A2 metabolism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available. Recommended dose of rasagiline is 0.5mg daily in combination with CYP1A2 inhibitors.
rasagiline|fluvoxamine|20|Serious - Use Alternative|rasagiline and fluvoxamine both increase  serotonin levels. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available. Severe CNS toxicity associated with hyperpyrexia has been reported with the combined treatment of an antidepressant and rasagiline. Avoid combination within 14 days of MAOI use.
rizatriptan|fluvoxamine|3|Significant - Monitor Closely|rizatriptan and fluvoxamine both increase  serotonin levels. Potential for dangerous interaction. Use with caution and monitor closely.
fluvoxamine|rizatriptan|1|Minor|fluvoxamine, rizatriptan. Mechanism: unknown. Minor or non-significant interaction. Risk of weakness, dyspnea, chest pain.
fluvoxamine|roflumilast|3|Significant - Monitor Closely|fluvoxamine increases levels of roflumilast by Other (see comment). Potential for dangerous interaction. Use with caution and monitor closely. Comment: Coadministration with dual inhibitors of CYP3A4 and CYP1A2 may increase systemic exposure and result in increased adverse reactions.
fluvoxamine|ropinirole|20|Serious - Use Alternative|fluvoxamine will increase the level or effect of ropinirole by  affecting hepatic enzyme CYP1A2 metabolism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
selegiline|fluvoxamine|33|Contraindicated|selegiline and fluvoxamine both increase  serotonin levels. Never use combination. At least 14 days should elapse between discontinuation of selegiline and initiation of treatment with a serotonergic drug.
sumatriptan|fluvoxamine|3|Significant - Monitor Closely|sumatriptan and fluvoxamine both increase  serotonin levels. Potential for dangerous interaction. Use with caution and monitor closely.
fluvoxamine|sumatriptan|1|Minor|fluvoxamine, sumatriptan. Mechanism: unknown. Minor or non-significant interaction. Risk of weakness, dyspnea, chest pain.
fluvoxamine|tacrine|11|Significant - Monitor Closely|fluvoxamine increases levels of tacrine by decreasing metabolism. Significant interaction possible, monitor closely.
fluvoxamine|tacrine|2|Significant - Monitor Closely|fluvoxamine will increase the level or effect of tacrine by  affecting hepatic enzyme CYP1A2 metabolism. Potential for interaction, monitor.
fluvoxamine|terfenadine|33|Contraindicated|fluvoxamine increases levels of terfenadine by decreasing metabolism. Never use combination. Risk of QT interval prolongation.
fluvoxamine|terfenadine|22|Serious - Use Alternative|fluvoxamine and terfenadine both increase  QTc interval. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available.
fluvoxamine|terfenadine|21|Serious - Use Alternative|fluvoxamine will increase the level or effect of terfenadine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available. Never use combination.
fluvoxamine|theophylline|20|Serious - Use Alternative|fluvoxamine will increase the level or effect of theophylline by  affecting hepatic enzyme CYP1A2 metabolism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
fluvoxamine|theophylline|20|Serious - Use Alternative|fluvoxamine will increase the level or effect of theophylline by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
thioridazine|fluvoxamine|33|Contraindicated|thioridazine will increase the level or effect of fluvoxamine by  affecting hepatic enzyme CYP2D6 metabolism. Never use combination.
thioridazine|fluvoxamine|33|Contraindicated|thioridazine and fluvoxamine both increase  QTc interval. Never use combination.
fluvoxamine|thioridazine|33|Contraindicated|fluvoxamine increases levels of thioridazine by decreasing metabolism. Never use combination. Risk of long QT syndrome.
fluvoxamine|tizanidine|22|Serious - Use Alternative|fluvoxamine will increase the level or effect of tizanidine by  affecting hepatic enzyme CYP1A2 metabolism. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available.
fluvoxamine|tolmetin|11|Significant - Monitor Closely|fluvoxamine, tolmetin.Either increases toxicity of the other by pharmacodynamic synergism. Significant interaction possible, monitor closely. Increased risk of upper GI bleeding. SSRIs inhib. serotonin uptake by platelets.
fluvoxamine|tramadol|3|Significant - Monitor Closely|fluvoxamine and tramadol both increase  serotonin levels. Potential for dangerous interaction. Use with caution and monitor closely.
tranylcypromine|fluvoxamine|33|Contraindicated|tranylcypromine and fluvoxamine both increase  serotonin levels. Never use combination.
fluvoxamine|trazodone|22|Serious - Use Alternative|fluvoxamine and trazodone both increase  serotonin levels. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available.
fluvoxamine|trazodone|20|Serious - Use Alternative|fluvoxamine will increase the level or effect of trazodone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
trazodone|fluvoxamine|3|Significant - Monitor Closely|trazodone and fluvoxamine both increase  QTc interval. Potential for dangerous interaction. Use with caution and monitor closely.
fluvoxamine|trimipramine|22|Serious - Use Alternative|fluvoxamine and trimipramine both increase  serotonin levels. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available.
trimipramine|fluvoxamine|3|Significant - Monitor Closely|trimipramine and fluvoxamine both increase  QTc interval. Potential for dangerous interaction. Use with caution and monitor closely.
fluvoxamine|venlafaxine|22|Serious - Use Alternative|fluvoxamine and venlafaxine both increase  serotonin levels. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available.
venlafaxine|fluvoxamine|20|Serious - Use Alternative|venlafaxine will increase the level or effect of fluvoxamine by  affecting hepatic enzyme CYP2D6 metabolism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
fluvoxamine|venlafaxine|2|Significant - Monitor Closely|fluvoxamine and venlafaxine both increase  QTc interval. Potential for interaction, monitor.
fluvoxamine|warfarin|20|Serious - Use Alternative|fluvoxamine will increase the level or effect of warfarin by  affecting hepatic enzyme CYP1A2 metabolism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
fluvoxamine|warfarin|20|Serious - Use Alternative|fluvoxamine increases levels of warfarin by decreasing metabolism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
fluvoxamine|warfarin|11|Significant - Monitor Closely|fluvoxamine will increase the level or effect of warfarin by  affecting hepatic enzyme CYP2C19 metabolism. Significant interaction possible, monitor closely.
fluvoxamine|warfarin|11|Significant - Monitor Closely|fluvoxamine will increase the level or effect of warfarin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
fluvoxamine|warfarin|2|Significant - Monitor Closely|fluvoxamine will increase the level or effect of warfarin by  affecting hepatic enzyme CYP2C9/10 metabolism. Potential for interaction, monitor.
zolmitriptan|fluvoxamine|3|Significant - Monitor Closely|zolmitriptan and fluvoxamine both increase  serotonin levels. Potential for dangerous interaction. Use with caution and monitor closely.
fluvoxamine|zolmitriptan|1|Minor|fluvoxamine, zolmitriptan. Mechanism: unknown. Minor or non-significant interaction. Risk of weakness, dyspnea, chest pain.
folic acid|fosphenytoin|1|Minor|folic acid decreases levels of fosphenytoin by increasing metabolism. Minor or non-significant interaction. Large doses of folic acid (>10 mg/day).
folic acid|phenobarbital|1|Minor|folic acid decreases levels of phenobarbital by increasing metabolism. Minor or non-significant interaction.
phenobarbital|folic acid|1|Minor|phenobarbital decreases levels of folic acid by inhibition of GI absorption. Applies only to oral form of both agents. Minor or non-significant interaction.
folic acid|phenytoin|1|Minor|folic acid decreases levels of phenytoin by increasing metabolism. Minor or non-significant interaction. Large doses of folic acid (>10 mg/day).
folic acid|primidone|1|Minor|folic acid decreases levels of primidone by increasing metabolism. Minor or non-significant interaction.
primidone|folic acid|1|Minor|primidone decreases levels of folic acid by inhibition of GI absorption. Applies only to oral form of both agents. Minor or non-significant interaction.
labetalol|formoterol|11|Significant - Monitor Closely|labetalol decreases effects of formoterol by pharmacodynamic antagonism. Significant interaction possible, monitor closely.
labetalol|formoterol|2|Significant - Monitor Closely|labetalol increases and formoterol decreases serum potassium. Effect of interaction is not clear, use caution. Potential for interaction, monitor.
metoprolol|formoterol|11|Significant - Monitor Closely|metoprolol decreases effects of formoterol by pharmacodynamic antagonism. Significant interaction possible, monitor closely.
metoprolol|formoterol|2|Significant - Monitor Closely|metoprolol increases and formoterol decreases serum potassium. Effect of interaction is not clear, use caution. Potential for interaction, monitor.
nadolol|formoterol|11|Significant - Monitor Closely|nadolol decreases effects of formoterol by pharmacodynamic antagonism. Significant interaction possible, monitor closely.
nadolol|formoterol|2|Significant - Monitor Closely|nadolol increases and formoterol decreases serum potassium. Effect of interaction is not clear, use caution. Potential for interaction, monitor.
penbutolol|formoterol|11|Significant - Monitor Closely|penbutolol decreases effects of formoterol by pharmacodynamic antagonism. Significant interaction possible, monitor closely.
penbutolol|formoterol|2|Significant - Monitor Closely|penbutolol increases and formoterol decreases serum potassium. Effect of interaction is not clear, use caution. Potential for interaction, monitor.
pindolol|formoterol|11|Significant - Monitor Closely|pindolol decreases effects of formoterol by pharmacodynamic antagonism. Significant interaction possible, monitor closely.
pindolol|formoterol|2|Significant - Monitor Closely|pindolol increases and formoterol decreases serum potassium. Effect of interaction is not clear, use caution. Potential for interaction, monitor.
propranolol|formoterol|11|Significant - Monitor Closely|propranolol decreases effects of formoterol by pharmacodynamic antagonism. Significant interaction possible, monitor closely.
propranolol|formoterol|2|Significant - Monitor Closely|propranolol increases and formoterol decreases serum potassium. Effect of interaction is not clear, use caution. Potential for interaction, monitor.
formoterol|sotalol|33|Contraindicated|formoterol and sotalol both increase  QTc interval. Never use combination. Drugs known to prolong the QTc interval may potentiate the cardiovascular effects of formoterol.
sotalol|formoterol|33|Contraindicated|sotalol and formoterol both increase  QTc interval. Never use combination. Drugs known to prolong the QTc interval may potentiate the cardiovascular effects of formoterol.
sotalol|formoterol|11|Significant - Monitor Closely|sotalol decreases effects of formoterol by pharmacodynamic antagonism. Significant interaction possible, monitor closely.
sotalol|formoterol|2|Significant - Monitor Closely|sotalol increases and formoterol decreases serum potassium. Effect of interaction is not clear, use caution. Potential for interaction, monitor.
timolol|formoterol|11|Significant - Monitor Closely|timolol decreases effects of formoterol by pharmacodynamic antagonism. Significant interaction possible, monitor closely.
timolol|formoterol|2|Significant - Monitor Closely|timolol increases and formoterol decreases serum potassium. Effect of interaction is not clear, use caution. Potential for interaction, monitor.
fosamprenavir|lovastatin|33|Contraindicated|fosamprenavir will increase the level or effect of lovastatin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Never use combination. Strong CYP3A4 inhibitors increase systemic statin exposure and risk of myopathy, including rhabdomyolysis
fosamprenavir|lurasidone|33|Contraindicated|fosamprenavir increases levels of lurasidone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Never use combination. Coadministration of lurasidone and strong CYP3A4 inhibitors is contraindicated.
fosamprenavir|methadone|11|Significant - Monitor Closely|fosamprenavir will increase the level or effect of methadone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
fosamprenavir|midazolam|21|Serious - Use Alternative|fosamprenavir increases levels of midazolam by decreasing metabolism. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available. Never use combination.
fosamprenavir|midazolam|11|Significant - Monitor Closely|fosamprenavir will increase the level or effect of midazolam by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
fosamprenavir|pimozide|33|Contraindicated|fosamprenavir increases levels of pimozide by decreasing metabolism. Never use combination. Risk of QT interval prolongation.
fosamprenavir|pimozide|1|Minor|fosamprenavir will increase the level or effect of pimozide by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor or non-significant interaction.
fosamprenavir|ranolazine|21|Serious - Use Alternative|fosamprenavir will increase the level or effect of ranolazine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available. Never use combination.
rifabutin|fosamprenavir|20|Serious - Use Alternative|rifabutin will decrease the level or effect of fosamprenavir by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
fosamprenavir|sildenafil|11|Significant - Monitor Closely|fosamprenavir will increase the level or effect of sildenafil by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
fosamprenavir|simvastatin|33|Contraindicated|fosamprenavir will increase the level or effect of simvastatin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Never use combination. Contraindicated. Increased risk for rhabdomyolysis with drugs that increase simvastatin systemic exposure
fosamprenavir|tacrolimus|11|Significant - Monitor Closely|fosamprenavir will increase the level or effect of tacrolimus by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
fosamprenavir|tadalafil|20|Serious - Use Alternative|fosamprenavir will increase the level or effect of tadalafil by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available. Stop tadalafil >24 hours prior to protease inhibitor (PI) initiation, restart 7 days after PI initiation at 20 mg once daily, and increase to 40 mg once daily based on tolerability.
fosamprenavir|tamoxifen|20|Serious - Use Alternative|fosamprenavir, tamoxifen. affecting hepatic/intestinal enzyme CYP3A4 metabolism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available. CYP3A4 inhibition decreases metabolism of tamoxifen to N-desmethyl tamoxifen (active metabolite with similar biologic activity).
fosamprenavir|tamsulosin|20|Serious - Use Alternative|fosamprenavir increases levels of tamsulosin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
telithromycin|fosamprenavir|11|Significant - Monitor Closely|telithromycin will increase the level or effect of fosamprenavir by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
fosamprenavir|telithromycin|1|Minor|fosamprenavir will increase the level or effect of telithromycin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor or non-significant interaction.
fosamprenavir|temsirolimus|11|Significant - Monitor Closely|fosamprenavir will increase the level or effect of temsirolimus by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
fosamprenavir|terfenadine|33|Contraindicated|fosamprenavir increases levels of terfenadine by decreasing metabolism. Never use combination. Risk of QT interval prolongation.
fosamprenavir|terfenadine|21|Serious - Use Alternative|fosamprenavir will increase the level or effect of terfenadine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available. Never use combination.
fosamprenavir|tipranavir|11|Significant - Monitor Closely|fosamprenavir will increase the level or effect of tipranavir by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
fosamprenavir|tipranavir|2|Significant - Monitor Closely|fosamprenavir and tipranavir both increase  risk of immune reconstitution syndrome. Potential for interaction, monitor.
fosamprenavir|tolterodine|11|Significant - Monitor Closely|fosamprenavir will increase the level or effect of tolterodine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
fosamprenavir|trazodone|20|Serious - Use Alternative|fosamprenavir increases levels of trazodone by decreasing metabolism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
fosamprenavir|trazodone|3|Significant - Monitor Closely|fosamprenavir will increase the level or effect of trazodone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Potential for dangerous interaction. Use with caution and monitor closely.
fosamprenavir|triazolam|21|Serious - Use Alternative|fosamprenavir increases levels of triazolam by decreasing metabolism. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available. Never use combination.
fosamprenavir|triazolam|11|Significant - Monitor Closely|fosamprenavir will increase the level or effect of triazolam by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
fosamprenavir|trimipramine|20|Serious - Use Alternative|fosamprenavir increases levels of trimipramine by decreasing metabolism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
fosamprenavir|vardenafil|11|Significant - Monitor Closely|fosamprenavir will increase the level or effect of vardenafil by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
fosamprenavir|verapamil|11|Significant - Monitor Closely|fosamprenavir will increase the level or effect of verapamil by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
fosamprenavir|vinblastine|1|Minor|fosamprenavir will increase the level or effect of vinblastine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor or non-significant interaction.
fosamprenavir|vincristine|1|Minor|fosamprenavir will increase the level or effect of vincristine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor or non-significant interaction.
fosamprenavir|vinorelbine|1|Minor|fosamprenavir will increase the level or effect of vinorelbine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor or non-significant interaction.
voriconazole|fosamprenavir|20|Serious - Use Alternative|voriconazole will increase the level or effect of fosamprenavir by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
fosamprenavir|warfarin|11|Significant - Monitor Closely|fosamprenavir will increase the level or effect of warfarin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
fosamprenavir|zolpidem|1|Minor|fosamprenavir will increase the level or effect of zolpidem by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor or non-significant interaction.
fosamprenavir|zonisamide|1|Minor|fosamprenavir will increase the level or effect of zonisamide by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor or non-significant interaction.
foscarnet|lumefantrine|3|Significant - Monitor Closely|foscarnet and lumefantrine both increase  QTc interval. Potential for dangerous interaction. Use with caution and monitor closely.
norfloxacin|foscarnet|1|Minor|norfloxacin, foscarnet. Mechanism: unknown. Minor or non-significant interaction. Risk of tonic clonic seizure.
foscarnet|ofloxacin|2|Significant - Monitor Closely|foscarnet and ofloxacin both increase  QTc interval. Potential for interaction, monitor.
ofloxacin|foscarnet|1|Minor|ofloxacin, foscarnet. Mechanism: unknown. Minor or non-significant interaction. Risk of tonic clonic seizure.
foscarnet|tacrolimus|2|Significant - Monitor Closely|foscarnet and tacrolimus both increase  nephrotoxicity and/or ototoxicity. Potential for interaction, monitor.
trimipramine|foscarnet|3|Significant - Monitor Closely|trimipramine and foscarnet both increase  QTc interval. Potential for dangerous interaction. Use with caution and monitor closely.
foscarnet|voriconazole|2|Significant - Monitor Closely|foscarnet and voriconazole both increase  QTc interval. Potential for interaction, monitor.
foscarnet|ziprasidone|3|Significant - Monitor Closely|foscarnet and ziprasidone both increase  QTc interval. Potential for dangerous interaction. Use with caution and monitor closely.
icatibant|fosinopril|2|Significant - Monitor Closely|icatibant decreases effects of fosinopril by pharmacodynamic antagonism. Potential for interaction, monitor. Icatibant has potential to have a pharmacodynamic interaction with ACE inhibitors where it may attenuate the antihypertensive effect of ACE inhibitors.
fosinopril|lithium|11|Significant - Monitor Closely|fosinopril increases toxicity of lithium by unknown mechanism. Significant interaction possible, monitor closely. ACE inhibitor induced Na+ depletion may increase reabsorption of lithium from renal tubule.
fosinopril|spironolactone|11|Significant - Monitor Closely|fosinopril, spironolactone. Mechanism: pharmacodynamic synergism. Significant interaction possible, monitor closely. Risk of hyperkalemia.
tizanidine|fosinopril|1|Minor|tizanidine increases effects of fosinopril by pharmacodynamic synergism. Minor or non-significant interaction. Risk of hypotension.
treprostinil|fosinopril|1|Minor|treprostinil increases effects of fosinopril by pharmacodynamic synergism. Minor or non-significant interaction.
fosinopril|triamterene|11|Significant - Monitor Closely|fosinopril, triamterene. Mechanism: pharmacodynamic synergism. Significant interaction possible, monitor closely. Risk of hyperkalemia.
fosphenytoin|furosemide|1|Minor|fosphenytoin decreases levels of furosemide by inhibition of GI absorption. Applies only to oral form of both agents. Minor or non-significant interaction.
fosphenytoin|hydrocortisone|11|Significant - Monitor Closely|fosphenytoin will decrease the level or effect of hydrocortisone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
fosphenytoin|hydrocortisone|11|Significant - Monitor Closely|fosphenytoin will decrease the level or effect of hydrocortisone by  P-glycoprotein (MDR1) efflux transporter. Significant interaction possible, monitor closely.
imatinib|fosphenytoin|11|Significant - Monitor Closely|imatinib will increase the level or effect of fosphenytoin by  affecting hepatic enzyme CYP2C9/10 metabolism. Significant interaction possible, monitor closely.
fosphenytoin|imatinib|11|Significant - Monitor Closely|fosphenytoin will decrease the level or effect of imatinib by  P-glycoprotein (MDR1) efflux transporter. Significant interaction possible, monitor closely.
fosphenytoin|imatinib|1|Minor|fosphenytoin will decrease the level or effect of imatinib by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor or non-significant interaction.
fosphenytoin|irinotecan|22|Serious - Use Alternative|fosphenytoin will decrease the level or effect of irinotecan by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available.
isoniazid|fosphenytoin|1|Minor|isoniazid increases levels of fosphenytoin by decreasing metabolism. Minor or non-significant interaction.
fosphenytoin|itraconazole|20|Serious - Use Alternative|fosphenytoin decreases levels of itraconazole by increasing metabolism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
itraconazole|fosphenytoin|11|Significant - Monitor Closely|itraconazole will increase the level or effect of fosphenytoin by  affecting hepatic enzyme CYP2C9/10 metabolism. Significant interaction possible, monitor closely.
fosphenytoin|itraconazole|11|Significant - Monitor Closely|fosphenytoin will decrease the level or effect of itraconazole by  P-glycoprotein (MDR1) efflux transporter. Significant interaction possible, monitor closely.
fosphenytoin|itraconazole|1|Minor|fosphenytoin will decrease the level or effect of itraconazole by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor or non-significant interaction.
fosphenytoin|lamotrigine|11|Significant - Monitor Closely|fosphenytoin decreases levels of lamotrigine by increasing metabolism. Significant interaction possible, monitor closely.
fosphenytoin|lopinavir|11|Significant - Monitor Closely|fosphenytoin will decrease the level or effect of lopinavir by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
fosphenytoin|lurasidone|33|Contraindicated|fosphenytoin decreases levels of lurasidone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Never use combination. Contraindicated; decreases lurasidone Cmax by ~85%.
lurasidone|fosphenytoin|11|Significant - Monitor Closely|lurasidone, fosphenytoin.Either increases toxicity of the other by Other (see comment). Significant interaction possible, monitor closely. Comment: Potential for increased CNS depressant effects when used concurrently; monitor for increased adverse effects and toxicity.
fosphenytoin|mebendazole|21|Serious - Use Alternative|fosphenytoin decreases levels of mebendazole by increasing metabolism. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available. Never use combination.
fosphenytoin|mestranol|20|Serious - Use Alternative|fosphenytoin decreases levels of mestranol by increasing metabolism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available. May result in contraceptive failure.
fosphenytoin|mestranol|11|Significant - Monitor Closely|fosphenytoin will decrease the level or effect of mestranol by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
fosphenytoin|mestranol|11|Significant - Monitor Closely|fosphenytoin will decrease the level or effect of mestranol by  P-glycoprotein (MDR1) efflux transporter. Significant interaction possible, monitor closely.
mestranol|fosphenytoin|11|Significant - Monitor Closely|mestranol decreases effects of fosphenytoin by decreasing metabolism. Significant interaction possible, monitor closely.
fosphenytoin|methadone|21|Serious - Use Alternative|fosphenytoin decreases levels of methadone by increasing metabolism. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available. Never use combination.
fosphenytoin|methadone|11|Significant - Monitor Closely|fosphenytoin will decrease the level or effect of methadone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
fosphenytoin|methotrexate|2|Significant - Monitor Closely|fosphenytoin increases toxicity of methotrexate by Other (see comment). Potential for interaction, monitor. Comment: Methotrexate is partially bound to serum albumin, and toxicity may be increased because of displacement by certain drugs.
fosphenytoin|methylprednisolone|11|Significant - Monitor Closely|fosphenytoin will decrease the level or effect of methylprednisolone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
fosphenytoin|methylprednisolone|11|Significant - Monitor Closely|fosphenytoin will decrease the level or effect of methylprednisolone by  P-glycoprotein (MDR1) efflux transporter. Significant interaction possible, monitor closely.
fosphenytoin|metyrapone|11|Significant - Monitor Closely|fosphenytoin decreases levels of metyrapone by increasing metabolism. Significant interaction possible, monitor closely.
fosphenytoin|mexiletine|11|Significant - Monitor Closely|fosphenytoin decreases levels of mexiletine by increasing metabolism. Significant interaction possible, monitor closely.
fosphenytoin|midazolam|11|Significant - Monitor Closely|fosphenytoin will decrease the level or effect of midazolam by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
fosphenytoin|nisoldipine|11|Significant - Monitor Closely|fosphenytoin will decrease the level or effect of nisoldipine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
omeprazole|fosphenytoin|11|Significant - Monitor Closely|omeprazole will increase the level or effect of fosphenytoin by  affecting hepatic enzyme CYP2C9/10 metabolism. Significant interaction possible, monitor closely.
oxcarbazepine|fosphenytoin|2|Significant - Monitor Closely|oxcarbazepine will increase the level or effect of fosphenytoin by  affecting hepatic enzyme CYP2C19 metabolism. Potential for interaction, monitor.
fosphenytoin|oxcarbazepine|1|Minor|fosphenytoin decreases levels of oxcarbazepine by increasing metabolism. Minor or non-significant interaction.
fosphenytoin|pancuronium|3|Significant - Monitor Closely|fosphenytoin decreases effects of pancuronium by pharmacodynamic antagonism. Potential for dangerous interaction. Use with caution and monitor closely. Monitor closely for more rapid recovery from neuromuscular blockade than expected; infusion rate requirements may be higher.
fosphenytoin|posaconazole|11|Significant - Monitor Closely|fosphenytoin will decrease the level or effect of posaconazole by  P-glycoprotein (MDR1) efflux transporter. Significant interaction possible, monitor closely.
fosphenytoin|posaconazole|11|Significant - Monitor Closely|fosphenytoin decreases levels of posaconazole by increasing metabolism. Significant interaction possible, monitor closely.
fosphenytoin|prednisolone|11|Significant - Monitor Closely|fosphenytoin will decrease the level or effect of prednisolone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
fosphenytoin|prednisolone|11|Significant - Monitor Closely|fosphenytoin will decrease the level or effect of prednisolone by  P-glycoprotein (MDR1) efflux transporter. Significant interaction possible, monitor closely.
fosphenytoin|prednisone|11|Significant - Monitor Closely|fosphenytoin will decrease the level or effect of prednisone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
fosphenytoin|prednisone|11|Significant - Monitor Closely|fosphenytoin will decrease the level or effect of prednisone by  P-glycoprotein (MDR1) efflux transporter. Significant interaction possible, monitor closely.
fosphenytoin|quetiapine|11|Significant - Monitor Closely|fosphenytoin will decrease the level or effect of quetiapine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
fosphenytoin|quinidine|11|Significant - Monitor Closely|fosphenytoin will decrease the level or effect of quinidine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
fosphenytoin|quinidine|11|Significant - Monitor Closely|fosphenytoin decreases levels of quinidine by increasing metabolism. Significant interaction possible, monitor closely.
fosphenytoin|roflumilast|33|Contraindicated|fosphenytoin will decrease the level or effect of roflumilast by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Never use combination. Coadministration not recommended; strong cytochrome P450 enzyme inducers decrease systemic exposure to roflumilast and may reduce the therapeutic effectiveness
sertraline|fosphenytoin|2|Significant - Monitor Closely|sertraline increases levels of fosphenytoin by decreasing metabolism. Potential for interaction, monitor.
fosphenytoin|sirolimus|21|Serious - Use Alternative|fosphenytoin will decrease the level or effect of sirolimus by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available. Never use combination.
fosphenytoin|sirolimus|11|Significant - Monitor Closely|fosphenytoin will decrease the level or effect of sirolimus by  P-glycoprotein (MDR1) efflux transporter. Significant interaction possible, monitor closely.
sucralfate|fosphenytoin|1|Minor|sucralfate decreases levels of fosphenytoin by inhibition of GI absorption. Applies only to oral form of both agents. Minor or non-significant interaction.
sulfadiazine|fosphenytoin|1|Minor|sulfadiazine increases levels of fosphenytoin by decreasing metabolism. Minor or non-significant interaction.
fosphenytoin|tacrolimus|11|Significant - Monitor Closely|fosphenytoin will decrease the level or effect of tacrolimus by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
fosphenytoin|tacrolimus|11|Significant - Monitor Closely|fosphenytoin will decrease the level or effect of tacrolimus by  P-glycoprotein (MDR1) efflux transporter. Significant interaction possible, monitor closely.
fosphenytoin|telithromycin|1|Minor|fosphenytoin will decrease the level or effect of telithromycin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor or non-significant interaction.
fosphenytoin|temsirolimus|11|Significant - Monitor Closely|fosphenytoin will decrease the level or effect of temsirolimus by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
fosphenytoin|theophylline|11|Significant - Monitor Closely|fosphenytoin will decrease the level or effect of theophylline by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
ticlopidine|fosphenytoin|11|Significant - Monitor Closely|ticlopidine will increase the level or effect of fosphenytoin by  affecting hepatic enzyme CYP2C9/10 metabolism. Significant interaction possible, monitor closely.
tolbutamide|fosphenytoin|1|Minor|tolbutamide increases levels of fosphenytoin by plasma protein binding competition. Minor or non-significant interaction.
fosphenytoin|tolbutamide|1|Minor|fosphenytoin decreases effects of tolbutamide by pharmacodynamic antagonism. Minor or non-significant interaction.
fosphenytoin|topiramate|11|Significant - Monitor Closely|fosphenytoin decreases levels of topiramate by increasing metabolism. Significant interaction possible, monitor closely.
topiramate|fosphenytoin|1|Minor|topiramate increases levels of fosphenytoin by decreasing metabolism. Minor or non-significant interaction.
fosphenytoin|tramadol|11|Significant - Monitor Closely|fosphenytoin will decrease the level or effect of tramadol by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely. Decreased AUC  of tramadol and the active metabolite (O-desmethyltramadol) when coadministered with strong CYP3A4 and CYP2B6 inducers
fosphenytoin|trazodone|2|Significant - Monitor Closely|fosphenytoin will decrease the level or effect of trazodone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Potential for interaction, monitor.
trazodone|fosphenytoin|1|Minor|trazodone increases levels of fosphenytoin by unspecified interaction mechanism. Minor or non-significant interaction.
fosphenytoin|triamcinolone|11|Significant - Monitor Closely|fosphenytoin will decrease the level or effect of triamcinolone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
fosphenytoin|triamcinolone|11|Significant - Monitor Closely|fosphenytoin will decrease the level or effect of triamcinolone by  P-glycoprotein (MDR1) efflux transporter. Significant interaction possible, monitor closely.
fosphenytoin|triazolam|11|Significant - Monitor Closely|fosphenytoin will decrease the level or effect of triazolam by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
fosphenytoin|tubocurarine|1|Minor|fosphenytoin decreases effects of tubocurarine by pharmacodynamic antagonism. Minor or non-significant interaction.
fosphenytoin|vandetanib|33|Contraindicated|fosphenytoin decreases levels of vandetanib by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Never use combination. Avoid coadministration with potent CYP3A4 inducers; these drugs reduce exposure to vandetanib by up to 40%.
fosphenytoin|vecuronium|3|Significant - Monitor Closely|fosphenytoin decreases effects of vecuronium by pharmacodynamic antagonism. Potential for dangerous interaction. Use with caution and monitor closely. Monitor closely for more rapid recovery from neuromuscular blockade than expected; infusion rate requirements may be higher.
vigabatrin|fosphenytoin|1|Minor|vigabatrin decreases levels of fosphenytoin by unknown mechanism. Minor or non-significant interaction.
fosphenytoin|vinblastine|11|Significant - Monitor Closely|fosphenytoin will decrease the level or effect of vinblastine by  P-glycoprotein (MDR1) efflux transporter. Significant interaction possible, monitor closely.
vinblastine|fosphenytoin|11|Significant - Monitor Closely|vinblastine decreases levels of fosphenytoin by inhibition of GI absorption. Applies only to oral form of both agents. Significant interaction possible, monitor closely.
vinblastine|fosphenytoin|11|Significant - Monitor Closely|vinblastine decreases levels of fosphenytoin by increasing metabolism. Significant interaction possible, monitor closely.
fosphenytoin|vinblastine|1|Minor|fosphenytoin will decrease the level or effect of vinblastine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor or non-significant interaction.
voriconazole|fosphenytoin|11|Significant - Monitor Closely|voriconazole will increase the level or effect of fosphenytoin by  affecting hepatic enzyme CYP2C9/10 metabolism. Significant interaction possible, monitor closely.
fosphenytoin|voriconazole|1|Minor|fosphenytoin decreases levels of voriconazole by increasing metabolism. Minor or non-significant interaction.
fosphenytoin|warfarin|11|Significant - Monitor Closely|fosphenytoin will decrease the level or effect of warfarin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
warfarin|fosphenytoin|11|Significant - Monitor Closely|warfarin increases levels of fosphenytoin by unknown mechanism. Significant interaction possible, monitor closely.
fosphenytoin|warfarin|11|Significant - Monitor Closely|fosphenytoin, warfarin. Other (see comment). Significant interaction possible, monitor closely. Comment: Hydantoin anticonvulsants increase anticoagulant effects at first, then decrease those effects with continued use (2+ wks).  There are multiple mechanisms involved, including enzyme induction, plasma protein binding site competition, and additive effects on prothrombin time.
frovatriptan|nefazodone|3|Significant - Monitor Closely|frovatriptan and nefazodone both increase  serotonin levels. Potential for dangerous interaction. Use with caution and monitor closely.
nefazodone|frovatriptan|1|Minor|nefazodone, frovatriptan. Mechanism: unknown. Minor or non-significant interaction. Risk of weakness, dyspnea, chest pain.
frovatriptan|paroxetine|3|Significant - Monitor Closely|frovatriptan and paroxetine both increase  serotonin levels. Potential for dangerous interaction. Use with caution and monitor closely.
paroxetine|frovatriptan|1|Minor|paroxetine, frovatriptan. Mechanism: unknown. Minor or non-significant interaction. Risk of weakness, dyspnea, chest pain.
frovatriptan|sertraline|3|Significant - Monitor Closely|frovatriptan and sertraline both increase  serotonin levels. Potential for dangerous interaction. Use with caution and monitor closely.
sertraline|frovatriptan|1|Minor|sertraline, frovatriptan. Mechanism: unknown. Minor or non-significant interaction. Risk of weakness, dyspnea, chest pain.
frovatriptan|tramadol|2|Significant - Monitor Closely|frovatriptan and tramadol both increase  serotonin levels. Potential for interaction, monitor.
frovatriptan|tranylcypromine|22|Serious - Use Alternative|frovatriptan and tranylcypromine both increase  serotonin levels. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available.
tranylcypromine|frovatriptan|21|Serious - Use Alternative|tranylcypromine increases levels of frovatriptan by decreasing metabolism. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available. Never use combination.
frovatriptan|trazodone|3|Significant - Monitor Closely|frovatriptan and trazodone both increase  serotonin levels. Potential for dangerous interaction. Use with caution and monitor closely.
trazodone|frovatriptan|1|Minor|trazodone, frovatriptan. Mechanism: unknown. Minor or non-significant interaction. Risk of weakness, dyspnea, chest pain.
frovatriptan|trimipramine|3|Significant - Monitor Closely|frovatriptan and trimipramine both increase  serotonin levels. Potential for dangerous interaction. Use with caution and monitor closely.
frovatriptan|venlafaxine|3|Significant - Monitor Closely|frovatriptan and venlafaxine both increase  serotonin levels. Potential for dangerous interaction. Use with caution and monitor closely.
venlafaxine|frovatriptan|1|Minor|venlafaxine, frovatriptan. Mechanism: unknown. Minor or non-significant interaction. Risk of weakness, dyspnea, chest pain.
frovatriptan|zolmitriptan|33|Contraindicated|frovatriptan, zolmitriptan.Either increases toxicity of the other by pharmacodynamic synergism. Never use combination. Additive vasospasm.  Sep. by 24h.
frovatriptan|zolmitriptan|2|Significant - Monitor Closely|frovatriptan and zolmitriptan both increase  serotonin levels. Potential for interaction, monitor.
furosemide|gentamicin|20|Serious - Use Alternative|furosemide, gentamicin.Either increases toxicity of the other by Mechanism: pharmacodynamic synergism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available. Increased risk of ototoxicity and nephrotoxicity.
furosemide|gentamicin|2|Significant - Monitor Closely|furosemide and gentamicin both decrease  serum potassium. Potential for interaction, monitor.
ibuprofen|furosemide|2|Significant - Monitor Closely|ibuprofen increases and furosemide decreases serum potassium. Effect of interaction is not clear, use caution. Potential for interaction, monitor.
ibuprofen|furosemide|1|Minor|ibuprofen decreases effects of furosemide by pharmacodynamic antagonism. Minor or non-significant interaction. NSAIDs decrease prostaglandin synthesis.
indomethacin|furosemide|2|Significant - Monitor Closely|indomethacin increases and furosemide decreases serum potassium. Effect of interaction is not clear, use caution. Potential for interaction, monitor.
indomethacin|furosemide|1|Minor|indomethacin decreases effects of furosemide by pharmacodynamic antagonism. Minor or non-significant interaction. NSAIDs decrease prostaglandin synthesis.
furosemide|kanamycin|20|Serious - Use Alternative|furosemide, kanamycin.Either increases toxicity of the other by Mechanism: pharmacodynamic synergism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available. Increased risk of ototoxicity and nephrotoxicity.
furosemide|netilmicin|20|Serious - Use Alternative|furosemide, netilmicin.Either increases toxicity of the other by Mechanism: pharmacodynamic synergism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available. Increased risk of ototoxicity and nephrotoxicity.
phenytoin|furosemide|1|Minor|phenytoin decreases levels of furosemide by inhibition of GI absorption. Applies only to oral form of both agents. Minor or non-significant interaction.
furosemide|streptomycin|20|Serious - Use Alternative|furosemide, streptomycin.Either increases toxicity of the other by Mechanism: pharmacodynamic synergism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available. Increased risk of ototoxicity and nephrotoxicity.
sulindac|furosemide|2|Significant - Monitor Closely|sulindac increases and furosemide decreases serum potassium. Effect of interaction is not clear, use caution. Potential for interaction, monitor.
sulindac|furosemide|1|Minor|sulindac decreases effects of furosemide by pharmacodynamic antagonism. Minor or non-significant interaction. NSAIDs decrease prostaglandin synthesis.
furosemide|tobramycin|20|Serious - Use Alternative|furosemide, tobramycin.Either increases toxicity of the other by Mechanism: pharmacodynamic synergism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available. Increased risk of ototoxicity and nephrotoxicity.
trandolapril|furosemide|11|Significant - Monitor Closely|trandolapril, furosemide. Mechanism: pharmacodynamic synergism. Significant interaction possible, monitor closely. Risk of acute hypotension, renal insufficiency.
treprostinil|furosemide|1|Minor|treprostinil increases effects of furosemide by pharmacodynamic synergism. Minor or non-significant interaction.
galantamine|glycopyrrolate|2|Significant - Monitor Closely|galantamine increases and glycopyrrolate decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Potential for interaction, monitor.
galantamine|glycopyrrolate|1|Minor|galantamine decreases effects of glycopyrrolate by pharmacodynamic antagonism. Minor or non-significant interaction.
galantamine|hyoscyamine|2|Significant - Monitor Closely|galantamine increases and hyoscyamine decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Potential for interaction, monitor.
galantamine|hyoscyamine|1|Minor|galantamine decreases effects of hyoscyamine by pharmacodynamic antagonism. Minor or non-significant interaction.
galantamine|imipramine|2|Significant - Monitor Closely|galantamine increases and imipramine decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Potential for interaction, monitor.
ketoconazole|galantamine|2|Significant - Monitor Closely|ketoconazole will increase the level or effect of galantamine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Potential for interaction, monitor.
galantamine|maprotiline|2|Significant - Monitor Closely|galantamine increases and maprotiline decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Potential for interaction, monitor.
galantamine|meclizine|2|Significant - Monitor Closely|galantamine increases and meclizine decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Potential for interaction, monitor.
galantamine|meclizine|1|Minor|galantamine decreases effects of meclizine by pharmacodynamic antagonism. Minor or non-significant interaction.
galantamine|nortriptyline|2|Significant - Monitor Closely|galantamine increases and nortriptyline decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Potential for interaction, monitor.
galantamine|orphenadrine|2|Significant - Monitor Closely|galantamine increases and orphenadrine decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Potential for interaction, monitor.
galantamine|oxybutynin|2|Significant - Monitor Closely|galantamine increases and oxybutynin decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Potential for interaction, monitor.
galantamine|oxybutynin|1|Minor|galantamine decreases effects of oxybutynin by pharmacodynamic antagonism. Minor or non-significant interaction.
paroxetine|galantamine|2|Significant - Monitor Closely|paroxetine will increase the level or effect of galantamine by  affecting hepatic enzyme CYP2D6 metabolism. Potential for interaction, monitor.
perphenazine|galantamine|1|Minor|perphenazine will increase the level or effect of galantamine by  affecting hepatic enzyme CYP2D6 metabolism. Minor or non-significant interaction.
procainamide|galantamine|1|Minor|procainamide decreases effects of galantamine by pharmacodynamic antagonism. Minor or non-significant interaction.
galantamine|propantheline|2|Significant - Monitor Closely|galantamine increases and propantheline decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Potential for interaction, monitor.
galantamine|propantheline|1|Minor|galantamine decreases effects of propantheline by pharmacodynamic antagonism. Minor or non-significant interaction.
galantamine|protriptyline|11|Significant - Monitor Closely|galantamine increases and protriptyline decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Significant interaction possible, monitor closely.
quinidine|galantamine|2|Significant - Monitor Closely|quinidine will increase the level or effect of galantamine by  affecting hepatic enzyme CYP2D6 metabolism. Potential for interaction, monitor.
galantamine|scopolamine|2|Significant - Monitor Closely|galantamine increases and scopolamine decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Potential for interaction, monitor.
galantamine|scopolamine|1|Minor|galantamine decreases effects of scopolamine by pharmacodynamic antagonism. Minor or non-significant interaction.
sertraline|galantamine|1|Minor|sertraline will increase the level or effect of galantamine by  affecting hepatic enzyme CYP2D6 metabolism. Minor or non-significant interaction.
galantamine|solifenacin|2|Significant - Monitor Closely|galantamine increases and solifenacin decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Potential for interaction, monitor.
galantamine|solifenacin|1|Minor|galantamine decreases effects of solifenacin by pharmacodynamic antagonism. Minor or non-significant interaction.
thioridazine|galantamine|1|Minor|thioridazine will increase the level or effect of galantamine by  affecting hepatic enzyme CYP2D6 metabolism. Minor or non-significant interaction.
galantamine|tolterodine|2|Significant - Monitor Closely|galantamine increases and tolterodine decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Potential for interaction, monitor.
galantamine|tolterodine|1|Minor|galantamine decreases effects of tolterodine by pharmacodynamic antagonism. Minor or non-significant interaction.
galantamine|trazodone|1|Minor|galantamine increases and trazodone decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Minor or non-significant interaction.
galantamine|trihexyphenidyl|2|Significant - Monitor Closely|galantamine decreases effects of trihexyphenidyl by pharmacodynamic antagonism. Potential for interaction, monitor.
galantamine|trimipramine|2|Significant - Monitor Closely|galantamine increases and trimipramine decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Potential for interaction, monitor.
ganciclovir|probenecid|11|Significant - Monitor Closely|ganciclovir will increase the level or effect of probenecid by  acidic (anionic) drug competition for renal tubular clearance. Significant interaction possible, monitor closely.
ganciclovir|zidovudine|21|Serious - Use Alternative|ganciclovir increases toxicity of zidovudine by pharmacodynamic synergism. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available. Never use combination.
gemcitabine|warfarin|11|Significant - Monitor Closely|gemcitabine increases effects of warfarin by unspecified interaction mechanism. Significant interaction possible, monitor closely. The anticoagulant effect of warfarin may be increased.
gemfibrozil|glimepiride|11|Significant - Monitor Closely|gemfibrozil increases effects of glimepiride by plasma protein binding competition. Significant interaction possible, monitor closely. Hypoglycemia; increased risk in hypoalbuminemia.
gemfibrozil|lovastatin|20|Serious - Use Alternative|gemfibrozil, lovastatin.Either increases effects of the other by Mechanism: pharmacodynamic synergism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available. Gemfibrozil may further increase risk for rhabdomyolysis when added to optimal statin regimen to further decrease TG and increase HDLs. Do not exceed 20 mg/day of lovastatin.
gemfibrozil|pitavastatin|20|Serious - Use Alternative|gemfibrozil, pitavastatin.Either increases effects of the other by pharmacodynamic synergism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available. Gemfibrozil may further increase risk for rhabdomyolysis when added to optimal statin regimen to further decrease TG and increase HDLs.
gemfibrozil|pravastatin|20|Serious - Use Alternative|gemfibrozil, pravastatin.Either increases effects of the other by pharmacodynamic synergism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available. Gemfibrozil may further increase risk for rhabdomyolysis when added to optimal statin regimen to further decrease TG and increase HDLs.
gemfibrozil|repaglinide|33|Contraindicated|gemfibrozil will increase the level or effect of repaglinide by  Other (see comment). Never use combination. Repaglinide  is a substrate of CYP2C8 hepatic enzyme; cyclosporine inhibits this enzyme and substantially increases levels of repaglinide
gemfibrozil|repaglinide|20|Serious - Use Alternative|gemfibrozil increases levels of repaglinide by decreasing metabolism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available. Hepatic cytochrome P450 2C8.
gemfibrozil|rosuvastatin|20|Serious - Use Alternative|gemfibrozil, rosuvastatin.Either increases effects of the other by pharmacodynamic synergism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available. Gemfibrozil may further increase risk for rhabdomyolysis when added to optimal statin regimen to further decrease TG and increase HDLs.
gemfibrozil|simvastatin|33|Contraindicated|gemfibrozil, simvastatin.Either increases effects of the other by pharmacodynamic synergism. Never use combination. Contraindicated with other lipid-lowering drugs that can cause myopathy.
gemfibrozil|tolbutamide|11|Significant - Monitor Closely|gemfibrozil increases effects of tolbutamide by plasma protein binding competition. Significant interaction possible, monitor closely. Hypoglycemia; increased risk in hypoalbuminemia.
gemfibrozil|warfarin|20|Serious - Use Alternative|gemfibrozil increases effects of warfarin by pharmacodynamic synergism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
gemfibrozil|warfarin|20|Serious - Use Alternative|gemfibrozil increases effects of warfarin by plasma protein binding competition. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
magnesium oxide|gemifloxacin|11|Significant - Monitor Closely|magnesium oxide decreases levels of gemifloxacin by inhibition of GI absorption. Applies only to oral form of both agents. Significant interaction possible, monitor closely. Separate by 2 hours.
sucralfate|gemifloxacin|11|Significant - Monitor Closely|sucralfate decreases levels of gemifloxacin by inhibition of GI absorption. Applies only to oral form of both agents. Significant interaction possible, monitor closely.
gentamicin|pancuronium|20|Serious - Use Alternative|gentamicin increases effects of pancuronium by pharmacodynamic synergism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available. Risk of apnea.
gentamicin|rocuronium|20|Serious - Use Alternative|gentamicin increases effects of rocuronium by pharmacodynamic synergism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available. Risk of apnea.
gentamicin|succinylcholine|20|Serious - Use Alternative|gentamicin increases effects of succinylcholine by pharmacodynamic synergism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available. Risk of apnea.
succinylcholine|gentamicin|2|Significant - Monitor Closely|succinylcholine increases and gentamicin decreases serum potassium. Effect of interaction is not clear, use caution. Potential for interaction, monitor.
tacrolimus|gentamicin|11|Significant - Monitor Closely|tacrolimus will increase the level or effect of gentamicin by  P-glycoprotein (MDR1) efflux transporter. Significant interaction possible, monitor closely.
gentamicin|tacrolimus|3|Significant - Monitor Closely|gentamicin and tacrolimus both increase  nephrotoxicity and/or ototoxicity. Potential for dangerous interaction. Use with caution and monitor closely.
ticarcillin|gentamicin|1|Minor|ticarcillin decreases effects of gentamicin by altering metabolism. Minor or non-significant interaction. Increased risk in renal impairment.
gentamicin|tubocurarine|20|Serious - Use Alternative|gentamicin increases effects of tubocurarine by pharmacodynamic synergism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available. Risk of apnea.
gentamicin|vecuronium|20|Serious - Use Alternative|gentamicin increases effects of vecuronium by pharmacodynamic synergism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available. Risk of apnea.
heparin|ginkgo biloba|3|Significant - Monitor Closely|heparin and ginkgo biloba both increase  anticoagulation. Potential for dangerous interaction. Use with caution and monitor closely.
ibuprofen|ginkgo biloba|2|Significant - Monitor Closely|ibuprofen and ginkgo biloba both increase  anticoagulation. Potential for interaction, monitor.
indomethacin|ginkgo biloba|2|Significant - Monitor Closely|indomethacin and ginkgo biloba both increase  anticoagulation. Potential for interaction, monitor.
ketoprofen|ginkgo biloba|2|Significant - Monitor Closely|ketoprofen and ginkgo biloba both increase  anticoagulation. Potential for interaction, monitor.
ketorolac|ginkgo biloba|2|Significant - Monitor Closely|ketorolac and ginkgo biloba both increase  anticoagulation. Potential for interaction, monitor.
lepirudin|ginkgo biloba|3|Significant - Monitor Closely|lepirudin and ginkgo biloba both increase  anticoagulation. Potential for dangerous interaction. Use with caution and monitor closely.
meloxicam|ginkgo biloba|2|Significant - Monitor Closely|meloxicam and ginkgo biloba both increase  anticoagulation. Potential for interaction, monitor.
nabumetone|ginkgo biloba|2|Significant - Monitor Closely|nabumetone and ginkgo biloba both increase  anticoagulation. Potential for interaction, monitor.
naproxen|ginkgo biloba|2|Significant - Monitor Closely|naproxen and ginkgo biloba both increase  anticoagulation. Potential for interaction, monitor.
oxaprozin|ginkgo biloba|2|Significant - Monitor Closely|oxaprozin and ginkgo biloba both increase  anticoagulation. Potential for interaction, monitor.
piroxicam|ginkgo biloba|2|Significant - Monitor Closely|piroxicam and ginkgo biloba both increase  anticoagulation. Potential for interaction, monitor.
ginkgo biloba|prasugrel|1|Minor|ginkgo biloba, prasugrel. pharmacodynamic synergism. Minor or non-significant interaction. May prolong bleeding time.  Conflicting evidence.Ã¿ Use with caution.
reteplase|ginkgo biloba|3|Significant - Monitor Closely|reteplase and ginkgo biloba both increase  anticoagulation. Potential for dangerous interaction. Use with caution and monitor closely.
sulindac|ginkgo biloba|2|Significant - Monitor Closely|sulindac and ginkgo biloba both increase  anticoagulation. Potential for interaction, monitor.
tenecteplase|ginkgo biloba|3|Significant - Monitor Closely|tenecteplase and ginkgo biloba both increase  anticoagulation. Potential for dangerous interaction. Use with caution and monitor closely.
ginkgo biloba|ticlopidine|1|Minor|ginkgo biloba, ticlopidine. pharmacodynamic synergism. Minor or non-significant interaction. May prolong bleeding time.  Conflicting evidence. Use with caution.
ginkgo biloba|tirofiban|1|Minor|ginkgo biloba, tirofiban. pharmacodynamic synergism. Minor or non-significant interaction. May prolong bleeding time.  Conflicting evidence. Use with caution.
tolmetin|ginkgo biloba|2|Significant - Monitor Closely|tolmetin and ginkgo biloba both increase  anticoagulation. Potential for interaction, monitor.
warfarin|ginkgo biloba|3|Significant - Monitor Closely|warfarin and ginkgo biloba both increase  anticoagulation. Potential for dangerous interaction. Use with caution and monitor closely.
ketoconazole|glimepiride|11|Significant - Monitor Closely|ketoconazole increases levels of glimepiride by decreasing metabolism. Significant interaction possible, monitor closely.
nadolol|glipizide|11|Significant - Monitor Closely|nadolol decreases effects of glipizide by pharmacodynamic antagonism. Significant interaction possible, monitor closely. Non selective beta blockers may also mask the symptoms of hypoglycemia.
pindolol|glipizide|11|Significant - Monitor Closely|pindolol decreases effects of glipizide by pharmacodynamic antagonism. Significant interaction possible, monitor closely. Non selective beta blockers may also mask the symptoms of hypoglycemia.
propranolol|glipizide|11|Significant - Monitor Closely|propranolol decreases effects of glipizide by pharmacodynamic antagonism. Significant interaction possible, monitor closely. Non selective beta blockers may also mask the symptoms of hypoglycemia.
timolol|glipizide|11|Significant - Monitor Closely|timolol decreases effects of glipizide by pharmacodynamic antagonism. Significant interaction possible, monitor closely. Non selective beta blockers may also mask the symptoms of hypoglycemia.
glucarpidase|leucovorin|3|Significant - Monitor Closely|glucarpidase will decrease the level or effect of leucovorin by  increasing metabolism. Potential for dangerous interaction. Use with caution and monitor closely. Leucorvorin, reduced folates, and folate antimetabolites are substrates for glucarpidase (hydrolyzes glutamate residue from folic acid and antifolates)
nadolol|glyburide|11|Significant - Monitor Closely|nadolol decreases effects of glyburide by pharmacodynamic antagonism. Significant interaction possible, monitor closely. Non selective beta blockers may also mask the symptoms of hypoglycemia.
pindolol|glyburide|11|Significant - Monitor Closely|pindolol decreases effects of glyburide by pharmacodynamic antagonism. Significant interaction possible, monitor closely. Non selective beta blockers may also mask the symptoms of hypoglycemia.
propranolol|glyburide|11|Significant - Monitor Closely|propranolol decreases effects of glyburide by pharmacodynamic antagonism. Significant interaction possible, monitor closely. Non selective beta blockers may also mask the symptoms of hypoglycemia.
salsalate|glyburide|11|Significant - Monitor Closely|salsalate increases effects of glyburide by unknown mechanism. Significant interaction possible, monitor closely. Risk of hypoglycemia.
salsalate|glyburide|1|Minor|salsalate increases effects of glyburide by plasma protein binding competition. Minor or non-significant interaction. Large dose of salicylate.
timolol|glyburide|11|Significant - Monitor Closely|timolol decreases effects of glyburide by pharmacodynamic antagonism. Significant interaction possible, monitor closely. Non selective beta blockers may also mask the symptoms of hypoglycemia.
haloperidol|glycerol phenylbutyrate|2|Significant - Monitor Closely|haloperidol decreases effects of glycerol phenylbutyrate by Other (see comment). Potential for interaction, monitor. Comment: Haloperidol may induce hyperammonemia; monitor ammonia levels closely when coadministered with glycerol phenylbutyrate.
prednisone|glycerol phenylbutyrate|2|Significant - Monitor Closely|prednisone decreases effects of glycerol phenylbutyrate by Other (see comment). Potential for interaction, monitor. Comment: Corticosteroids may cause the breakdown of body protein and increase plasma ammonia levels; monitor ammonia levels closely when glycerol phenylbutyrate is coadministered with corticosteroids.
probenecid|glycerol phenylbutyrate|2|Significant - Monitor Closely|probenecid, glycerol phenylbutyrate. decreasing renal clearance. Potential for interaction, monitor. Probenecid may inhibit the renal excretion glycerol phenylbutyrate metabolites PAA and PAGN; caution when adjusting doses based on these metabolite levels.
valproic acid|glycerol phenylbutyrate|2|Significant - Monitor Closely|valproic acid decreases effects of glycerol phenylbutyrate by Other (see comment). Potential for interaction, monitor. Comment: Valproic acid may induce hyperammonemia; monitor ammonia levels closely when coadministered with glycerol phenylbutyrate.
haloperidol|glycopyrrolate|2|Significant - Monitor Closely|haloperidol increases effects of glycopyrrolate by pharmacodynamic synergism. Potential for interaction, monitor. Additive anticholinergic effects, possible hypoglycemia.
tacrine|glycopyrrolate|2|Significant - Monitor Closely|tacrine increases and glycopyrrolate decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Potential for interaction, monitor.
tacrine|glycopyrrolate|1|Minor|tacrine decreases effects of glycopyrrolate by pharmacodynamic antagonism. Minor or non-significant interaction.
golimumab|infliximab|22|Serious - Use Alternative|golimumab and infliximab both increase  immunosuppressive effects; risk of infection. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available.
golimumab|rilonacept|22|Serious - Use Alternative|golimumab and rilonacept both increase  immunosuppressive effects; risk of infection. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available.
golimumab|tacrolimus|22|Serious - Use Alternative|golimumab and tacrolimus both increase  immunosuppressive effects; risk of infection. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available.
tocilizumab|golimumab|22|Serious - Use Alternative|tocilizumab and golimumab both increase  immunosuppressive effects; risk of infection. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available.
hexobarbital|griseofulvin|1|Minor|hexobarbital decreases levels of griseofulvin by inhibition of GI absorption. Applies only to oral form of both agents. Minor or non-significant interaction.
griseofulvin|mestranol|11|Significant - Monitor Closely|griseofulvin will decrease the level or effect of mestranol by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
griseofulvin|mestranol|1|Minor|griseofulvin decreases effects of mestranol by increasing metabolism. Minor or non-significant interaction. May also cause menstrual irregularities.
pentobarbital|griseofulvin|1|Minor|pentobarbital decreases levels of griseofulvin by inhibition of GI absorption. Applies only to oral form of both agents. Minor or non-significant interaction.
phenobarbital|griseofulvin|1|Minor|phenobarbital decreases levels of griseofulvin by inhibition of GI absorption. Applies only to oral form of both agents. Minor or non-significant interaction.
primidone|griseofulvin|1|Minor|primidone decreases levels of griseofulvin by inhibition of GI absorption. Applies only to oral form of both agents. Minor or non-significant interaction.
secobarbital|griseofulvin|1|Minor|secobarbital decreases levels of griseofulvin by inhibition of GI absorption. Applies only to oral form of both agents. Minor or non-significant interaction.
griseofulvin|ulipristal|20|Serious - Use Alternative|griseofulvin will decrease the level or effect of ulipristal by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
griseofulvin|warfarin|11|Significant - Monitor Closely|griseofulvin will decrease the level or effect of warfarin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
treprostinil|guanabenz|1|Minor|treprostinil increases effects of guanabenz by pharmacodynamic synergism. Minor or non-significant interaction.
trimipramine|guanabenz|20|Serious - Use Alternative|trimipramine decreases effects of guanabenz by Other (see comment). Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available. Comment: Inhibition of uptake by adrenergic neurons.
treprostinil|guanfacine|1|Minor|treprostinil increases effects of guanfacine by pharmacodynamic synergism. Minor or non-significant interaction.
trimipramine|guanfacine|20|Serious - Use Alternative|trimipramine decreases effects of guanfacine by Other (see comment). Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available. Comment: Inhibition of uptake by adrenergic neurons.
hyoscyamine|haloperidol|11|Significant - Monitor Closely|hyoscyamine decreases levels of haloperidol by inhibition of GI absorption. Applies only to oral form of both agents. Significant interaction possible, monitor closely.
hyoscyamine|haloperidol|11|Significant - Monitor Closely|hyoscyamine decreases levels of haloperidol by pharmacodynamic antagonism. Significant interaction possible, monitor closely.
haloperidol|hyoscyamine|11|Significant - Monitor Closely|haloperidol increases effects of hyoscyamine by pharmacodynamic synergism. Significant interaction possible, monitor closely. Additive anticholinergic effects, possible hypoglycemia.
haloperidol|itraconazole|22|Serious - Use Alternative|haloperidol and itraconazole both increase  QTc interval. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available.
haloperidol|ketoconazole|22|Serious - Use Alternative|haloperidol and ketoconazole both increase  QTc interval. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available.
lithium|haloperidol|11|Significant - Monitor Closely|lithium, haloperidol. Other (see comment). Significant interaction possible, monitor closely. Comment: Risk of neurotoxicity.  Multiple mechanisms involved.
haloperidol|lumefantrine|22|Serious - Use Alternative|haloperidol and lumefantrine both increase  QTc interval. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available.
lumefantrine|haloperidol|20|Serious - Use Alternative|lumefantrine will increase the level or effect of haloperidol by  affecting hepatic enzyme CYP2D6 metabolism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
mepenzolate|haloperidol|11|Significant - Monitor Closely|mepenzolate decreases levels of haloperidol by inhibition of GI absorption. Applies only to oral form of both agents. Significant interaction possible, monitor closely.
mepenzolate|haloperidol|11|Significant - Monitor Closely|mepenzolate decreases levels of haloperidol by pharmacodynamic antagonism. Significant interaction possible, monitor closely.
haloperidol|mepenzolate|11|Significant - Monitor Closely|haloperidol increases effects of mepenzolate by pharmacodynamic synergism. Significant interaction possible, monitor closely. Additive anticholinergic effects, possible hypoglycemia.
haloperidol|methyldopa|21|Serious - Use Alternative|haloperidol decreases effects of methyldopa by pharmacodynamic antagonism. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available. Never use combination.
orphenadrine|haloperidol|2|Significant - Monitor Closely|orphenadrine and haloperidol both increase  sedation. Potential for interaction, monitor.
propantheline|haloperidol|11|Significant - Monitor Closely|propantheline decreases levels of haloperidol by inhibition of GI absorption. Applies only to oral form of both agents. Significant interaction possible, monitor closely.
propantheline|haloperidol|11|Significant - Monitor Closely|propantheline decreases levels of haloperidol by pharmacodynamic antagonism. Significant interaction possible, monitor closely.
haloperidol|propantheline|11|Significant - Monitor Closely|haloperidol increases effects of propantheline by pharmacodynamic synergism. Significant interaction possible, monitor closely. Additive anticholinergic effects, possible hypoglycemia.
haloperidol|propranolol|11|Significant - Monitor Closely|haloperidol will increase the level or effect of propranolol by  affecting hepatic enzyme CYP2D6 metabolism. Significant interaction possible, monitor closely. If concurrent use cannot be avoided, cautious dosing and telemetric monitoring is advised. Coadministration of beta-blockers and haloperidol may cause an unexpected severe hypotensive reaction.
scopolamine|haloperidol|11|Significant - Monitor Closely|scopolamine decreases levels of haloperidol by inhibition of GI absorption. Applies only to oral form of both agents. Significant interaction possible, monitor closely.
scopolamine|haloperidol|11|Significant - Monitor Closely|scopolamine decreases levels of haloperidol by pharmacodynamic antagonism. Significant interaction possible, monitor closely.
haloperidol|scopolamine|11|Significant - Monitor Closely|haloperidol increases effects of scopolamine by pharmacodynamic synergism. Significant interaction possible, monitor closely. Additive anticholinergic effects, possible hypoglycemia.
haloperidol|tacrolimus|2|Significant - Monitor Closely|haloperidol and tacrolimus both increase  QTc interval. Potential for interaction, monitor.
haloperidol|tamoxifen|11|Significant - Monitor Closely|haloperidol decreases effects of tamoxifen by decreasing metabolism. Significant interaction possible, monitor closely. Inhibition of CYP2D6 metabolism to tamoxifen's active metabolite, endoxifen.
haloperidol|tamsulosin|2|Significant - Monitor Closely|haloperidol increases levels of tamsulosin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Potential for interaction, monitor. Dose reduction may be needed for coadministered drugs that are predominantly metabolized by CYP3A.
haloperidol|tamsulosin|2|Significant - Monitor Closely|haloperidol increases levels of tamsulosin by affecting hepatic enzyme CYP2D6 metabolism. Potential for interaction, monitor.
haloperidol|telithromycin|3|Significant - Monitor Closely|haloperidol and telithromycin both increase  QTc interval. Potential for dangerous interaction. Use with caution and monitor closely.
haloperidol|tetrabenazine|3|Significant - Monitor Closely|haloperidol and tetrabenazine both increase  antidopaminergic effects, including extrapyramidal symptoms and neuroleptic malignant syndrome. Potential for dangerous interaction. Use with caution and monitor closely.
thioridazine|haloperidol|22|Serious - Use Alternative|thioridazine and haloperidol both increase  QTc interval. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available.
haloperidol|thioridazine|20|Serious - Use Alternative|haloperidol will increase the level or effect of thioridazine by  affecting hepatic enzyme CYP2D6 metabolism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
thioridazine|haloperidol|11|Significant - Monitor Closely|thioridazine will increase the level or effect of haloperidol by  affecting hepatic enzyme CYP2D6 metabolism. Significant interaction possible, monitor closely.
haloperidol|thioridazine|2|Significant - Monitor Closely|haloperidol and thioridazine both increase  antidopaminergic effects, including extrapyramidal symptoms and neuroleptic malignant syndrome. Potential for interaction, monitor.
haloperidol|thioridazine|2|Significant - Monitor Closely|haloperidol and thioridazine both increase  sedation. Potential for interaction, monitor.
haloperidol|thiothixene|2|Significant - Monitor Closely|haloperidol and thiothixene both increase  antidopaminergic effects, including extrapyramidal symptoms and neuroleptic malignant syndrome. Potential for interaction, monitor.
haloperidol|thiothixene|2|Significant - Monitor Closely|haloperidol and thiothixene both increase  sedation. Potential for interaction, monitor.
haloperidol|thiothixene|2|Significant - Monitor Closely|haloperidol and thiothixene both increase  QTc interval. Potential for interaction, monitor.
tolterodine|haloperidol|11|Significant - Monitor Closely|tolterodine decreases levels of haloperidol by inhibition of GI absorption. Applies only to oral form of both agents. Significant interaction possible, monitor closely.
tolterodine|haloperidol|11|Significant - Monitor Closely|tolterodine decreases levels of haloperidol by pharmacodynamic antagonism. Significant interaction possible, monitor closely.
haloperidol|tolterodine|11|Significant - Monitor Closely|haloperidol increases effects of tolterodine by pharmacodynamic synergism. Significant interaction possible, monitor closely. Additive anticholinergic effects, possible hypoglycemia.
haloperidol|tolterodine|1|Minor|haloperidol will increase the level or effect of tolterodine by  affecting hepatic enzyme CYP2D6 metabolism. Minor or non-significant interaction.
haloperidol|toremifene|20|Serious - Use Alternative|haloperidol and toremifene both increase  QTc interval. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available. Concurrent use of toremifene with agents causing  QT prolongation should be avoided. If concomitant use is required it's recommended that toremifene be interrupted. If interruption not possible, patients requiring therapy with a drug that prolongs QT should be closely monitored. ECGs should be obtained for high risk patients.
tramadol|haloperidol|2|Significant - Monitor Closely|tramadol and haloperidol both increase  sedation. Potential for interaction, monitor.
trazodone|haloperidol|22|Serious - Use Alternative|trazodone and haloperidol both increase  QTc interval. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available.
haloperidol|trazodone|2|Significant - Monitor Closely|haloperidol and trazodone both increase  sedation. Potential for interaction, monitor.
haloperidol|trihexyphenidyl|2|Significant - Monitor Closely|haloperidol increases effects of trihexyphenidyl by pharmacodynamic synergism. Potential for interaction, monitor. Potential for additive anticholinergic effects.
trimipramine|haloperidol|22|Serious - Use Alternative|trimipramine and haloperidol both increase  QTc interval. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available.
haloperidol|trimipramine|2|Significant - Monitor Closely|haloperidol and trimipramine both increase  sedation. Potential for interaction, monitor.
triprolidine|haloperidol|2|Significant - Monitor Closely|triprolidine and haloperidol both increase  sedation. Potential for interaction, monitor.
haloperidol|voriconazole|3|Significant - Monitor Closely|haloperidol and voriconazole both increase  QTc interval. Potential for dangerous interaction. Use with caution and monitor closely.
haloperidol|vorinostat|2|Significant - Monitor Closely|haloperidol and vorinostat both increase  QTc interval. Potential for interaction, monitor.
haloperidol|ziprasidone|22|Serious - Use Alternative|haloperidol and ziprasidone both increase  QTc interval. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available.
haloperidol|ziprasidone|2|Significant - Monitor Closely|haloperidol and ziprasidone both increase  antidopaminergic effects, including extrapyramidal symptoms and neuroleptic malignant syndrome. Potential for interaction, monitor.
haloperidol|ziprasidone|2|Significant - Monitor Closely|haloperidol and ziprasidone both increase  sedation. Potential for interaction, monitor.
heparin|ticlopidine|21|Serious - Use Alternative|heparin, ticlopidine.Either increases effects of the other by pharmacodynamic synergism. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available. Never use combination. Enhanced risk of hemorrhage.
hexobarbital|hydrocortisone|11|Significant - Monitor Closely|hexobarbital will decrease the level or effect of hydrocortisone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
hexobarbital|methadone|11|Significant - Monitor Closely|hexobarbital will decrease the level or effect of methadone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
hexobarbital|methadone|2|Significant - Monitor Closely|hexobarbital and methadone both increase  sedation. Potential for interaction, monitor.
hexobarbital|nifedipine|1|Minor|hexobarbital will decrease the level or effect of nifedipine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor or non-significant interaction.
hexobarbital|prednisolone|11|Significant - Monitor Closely|hexobarbital will decrease the level or effect of prednisolone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
hexobarbital|prednisone|11|Significant - Monitor Closely|hexobarbital will decrease the level or effect of prednisone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
hexobarbital|quinidine|11|Significant - Monitor Closely|hexobarbital will decrease the level or effect of quinidine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
hexobarbital|theophylline|11|Significant - Monitor Closely|hexobarbital will decrease the level or effect of theophylline by  affecting hepatic enzyme CYP1A2 metabolism. Significant interaction possible, monitor closely.
hexobarbital|theophylline|11|Significant - Monitor Closely|hexobarbital will decrease the level or effect of theophylline by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
hexobarbital|triamcinolone|11|Significant - Monitor Closely|hexobarbital will decrease the level or effect of triamcinolone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
hydralazine|metoprolol|2|Significant - Monitor Closely|hydralazine increases effects of metoprolol by pharmacodynamic synergism. Potential for interaction, monitor. Additive hypotensive effects.
hydralazine|propranolol|2|Significant - Monitor Closely|hydralazine increases effects of propranolol by pharmacodynamic synergism. Potential for interaction, monitor. Additive hypotensive effects.
hydralazine|treprostinil|11|Significant - Monitor Closely|hydralazine, treprostinil.Either increases effects of the other by pharmacodynamic synergism. Significant interaction possible, monitor closely.
treprostinil|hydralazine|1|Minor|treprostinil increases effects of hydralazine by pharmacodynamic synergism. Minor or non-significant interaction.
hydrochlorothiazide|insulin lispro|1|Minor|hydrochlorothiazide decreases effects of insulin lispro by pharmacodynamic antagonism. Minor or non-significant interaction. Thiazide dosage >50 mg/day may increase blood glucose.
hydrochlorothiazide|lithium|11|Significant - Monitor Closely|hydrochlorothiazide increases toxicity of lithium by decreasing elimination. Significant interaction possible, monitor closely.
treprostinil|hydrochlorothiazide|1|Minor|treprostinil increases effects of hydrochlorothiazide by pharmacodynamic synergism. Minor or non-significant interaction.
triprolidine|hydrocodone|2|Significant - Monitor Closely|triprolidine and hydrocodone both increase  sedation. Potential for interaction, monitor.
hydrocortisone|linagliptin|11|Significant - Monitor Closely|hydrocortisone will increase the level or effect of linagliptin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely. Use of alternative treatments is strongly recommended when linagliptin is to be administered with a CYP3A4 inducer
pentobarbital|hydrocortisone|11|Significant - Monitor Closely|pentobarbital will decrease the level or effect of hydrocortisone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
phenobarbital|hydrocortisone|11|Significant - Monitor Closely|phenobarbital will decrease the level or effect of hydrocortisone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
phenobarbital|hydrocortisone|11|Significant - Monitor Closely|phenobarbital will decrease the level or effect of hydrocortisone by  P-glycoprotein (MDR1) efflux transporter. Significant interaction possible, monitor closely.
phenytoin|hydrocortisone|11|Significant - Monitor Closely|phenytoin will decrease the level or effect of hydrocortisone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
phenytoin|hydrocortisone|11|Significant - Monitor Closely|phenytoin will decrease the level or effect of hydrocortisone by  P-glycoprotein (MDR1) efflux transporter. Significant interaction possible, monitor closely.
primidone|hydrocortisone|11|Significant - Monitor Closely|primidone will decrease the level or effect of hydrocortisone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
salsalate|hydrocortisone|11|Significant - Monitor Closely|salsalate, hydrocortisone.Either increases toxicity of the other by pharmacodynamic synergism. Significant interaction possible, monitor closely. Increased risk of GI ulceration.
hydrocortisone|salsalate|1|Minor|hydrocortisone decreases levels of salsalate by increasing renal clearance. Minor or non-significant interaction.
secobarbital|hydrocortisone|11|Significant - Monitor Closely|secobarbital will decrease the level or effect of hydrocortisone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
hydrocortisone|warfarin|11|Significant - Monitor Closely|hydrocortisone will decrease the level or effect of warfarin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
hydrocortisone|warfarin|11|Significant - Monitor Closely|hydrocortisone, warfarin. Other (see comment). Significant interaction possible, monitor closely. Comment: Corticosteroids may decrease anticoagulant effects by increasing blood coagulability; conversely, they may impair vascular integrity, thus increasing bleeding risk.  Monitor INR closely.
triprolidine|hydromorphone|2|Significant - Monitor Closely|triprolidine and hydromorphone both increase  sedation. Potential for interaction, monitor.
hydroxyzine|triprolidine|2|Significant - Monitor Closely|hydroxyzine and triprolidine both increase  sedation. Potential for interaction, monitor.
tacrine|hyoscyamine|2|Significant - Monitor Closely|tacrine increases and hyoscyamine decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Potential for interaction, monitor.
tacrine|hyoscyamine|1|Minor|tacrine decreases effects of hyoscyamine by pharmacodynamic antagonism. Minor or non-significant interaction.
magnesium oxide|ibandronate|1|Minor|magnesium oxide decreases levels of ibandronate by inhibition of GI absorption. Applies only to oral form of both agents. Minor or non-significant interaction.
ibuprofen|labetalol|11|Significant - Monitor Closely|ibuprofen decreases effects of labetalol by pharmacodynamic antagonism. Significant interaction possible, monitor closely. Long term (>1 wk) NSAID use.  NSAIDs decrease prostaglandin synthesis.
labetalol|ibuprofen|2|Significant - Monitor Closely|labetalol and ibuprofen both increase  serum potassium. Potential for interaction, monitor.
ibuprofen|lithium|11|Significant - Monitor Closely|ibuprofen increases levels of lithium by decreasing renal clearance. Significant interaction possible, monitor closely.
ibuprofen|methotrexate|20|Serious - Use Alternative|ibuprofen increases levels of methotrexate by decreasing renal clearance. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available. Concomitant administration of NSAIDs with high dose methotrexate has been reported to elevate and prolong serum methotrexate levels, resulting in deaths from severe hematologic and GI toxicity. NSAIDs may reduce tubular secretion of methotrexate and enhance toxicity. .
ibuprofen|metoprolol|11|Significant - Monitor Closely|ibuprofen decreases effects of metoprolol by pharmacodynamic antagonism. Significant interaction possible, monitor closely. Long term (>1 wk) NSAID use.  NSAIDs decrease prostaglandin synthesis.
metoprolol|ibuprofen|2|Significant - Monitor Closely|metoprolol and ibuprofen both increase  serum potassium. Potential for interaction, monitor.
ibuprofen|nadolol|11|Significant - Monitor Closely|ibuprofen decreases effects of nadolol by pharmacodynamic antagonism. Significant interaction possible, monitor closely. Long term (>1 wk) NSAID use.  NSAIDs decrease prostaglandin synthesis.
nadolol|ibuprofen|2|Significant - Monitor Closely|nadolol and ibuprofen both increase  serum potassium. Potential for interaction, monitor.
ibuprofen|penbutolol|11|Significant - Monitor Closely|ibuprofen decreases effects of penbutolol by pharmacodynamic antagonism. Significant interaction possible, monitor closely. Long term (>1 wk) NSAID use.  NSAIDs decrease prostaglandin synthesis.
penbutolol|ibuprofen|2|Significant - Monitor Closely|penbutolol and ibuprofen both increase  serum potassium. Potential for interaction, monitor.
ibuprofen|pindolol|11|Significant - Monitor Closely|ibuprofen decreases effects of pindolol by pharmacodynamic antagonism. Significant interaction possible, monitor closely. Long term (>1 wk) NSAID use.  NSAIDs decrease prostaglandin synthesis.
pindolol|ibuprofen|2|Significant - Monitor Closely|pindolol and ibuprofen both increase  serum potassium. Potential for interaction, monitor.
procainamide|donepezil|1|Minor|procainamide decreases effects of donepezil by pharmacodynamic antagonism. Minor or non-significant interaction.
donepezil|propantheline|2|Significant - Monitor Closely|donepezil increases and propantheline decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Potential for interaction, monitor.
donepezil|propantheline|1|Minor|donepezil decreases effects of propantheline by pharmacodynamic antagonism. Minor or non-significant interaction.
donepezil|protriptyline|11|Significant - Monitor Closely|donepezil increases and protriptyline decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Significant interaction possible, monitor closely.
quinidine|donepezil|2|Significant - Monitor Closely|quinidine will increase the level or effect of donepezil by  affecting hepatic enzyme CYP2D6 metabolism. Potential for interaction, monitor.
donepezil|scopolamine|2|Significant - Monitor Closely|donepezil increases and scopolamine decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Potential for interaction, monitor.
donepezil|scopolamine|1|Minor|donepezil decreases effects of scopolamine by pharmacodynamic antagonism. Minor or non-significant interaction.
sertraline|donepezil|1|Minor|sertraline will increase the level or effect of donepezil by  affecting hepatic enzyme CYP2D6 metabolism. Minor or non-significant interaction.
donepezil|solifenacin|2|Significant - Monitor Closely|donepezil increases and solifenacin decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Potential for interaction, monitor.
donepezil|solifenacin|1|Minor|donepezil decreases effects of solifenacin by pharmacodynamic antagonism. Minor or non-significant interaction.
thioridazine|donepezil|1|Minor|thioridazine will increase the level or effect of donepezil by  affecting hepatic enzyme CYP2D6 metabolism. Minor or non-significant interaction.
donepezil|tolterodine|2|Significant - Monitor Closely|donepezil increases and tolterodine decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Potential for interaction, monitor.
donepezil|tolterodine|1|Minor|donepezil decreases effects of tolterodine by pharmacodynamic antagonism. Minor or non-significant interaction.
donepezil|trazodone|1|Minor|donepezil increases and trazodone decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Minor or non-significant interaction.
donepezil|trihexyphenidyl|2|Significant - Monitor Closely|donepezil decreases effects of trihexyphenidyl by pharmacodynamic antagonism. Potential for interaction, monitor.
donepezil|trimipramine|2|Significant - Monitor Closely|donepezil increases and trimipramine decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Potential for interaction, monitor.
doxepin|dopamine|20|Serious - Use Alternative|doxepin, dopamine. Other (see comment). Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available. Comment: Tricyclic antidepressants increase or decrease effects of sympathomimetics, by blocking reuptake of NE, or blocking uptake of indirect sympathomimetics into the adrenergic neuron.
doxepin|dopamine|2|Significant - Monitor Closely|doxepin increases and dopamine decreases sedation. Effect of interaction is not clear, use caution. Potential for interaction, monitor.
entacapone|dopamine|11|Significant - Monitor Closely|entacapone increases effects of dopamine by pharmacodynamic synergism. Significant interaction possible, monitor closely.
fosphenytoin|dopamine|20|Serious - Use Alternative|fosphenytoin, dopamine. Mechanism: pharmacodynamic synergism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available. Increased risk of hypotension.
imipramine|dopamine|20|Serious - Use Alternative|imipramine, dopamine. Other (see comment). Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available. Comment: Tricyclic antidepressants increase or decrease effects of sympathomimetics, by blocking reuptake of NE, or blocking uptake of indirect sympathomimetics into the adrenergic neuron.
imipramine|dopamine|2|Significant - Monitor Closely|imipramine increases and dopamine decreases sedation. Effect of interaction is not clear, use caution. Potential for interaction, monitor.
isocarboxazid|dopamine|33|Contraindicated|isocarboxazid increases effects of dopamine by pharmacodynamic synergism. Never use combination. Risk of acute hypertensive episode.
linezolid|dopamine|33|Contraindicated|linezolid increases effects of dopamine by pharmacodynamic synergism. Never use combination. Risk of acute hypertensive episode.
dopamine|lurasidone|33|Contraindicated|dopamine increases toxicity of lurasidone by Other (see comment). Never use combination. Comment: Interaction applies only in setting of acute lurasidone overdose. Epinephrine may enhance hypotensive effects of lurasidone in overdose setting.
methyldopa|dopamine|11|Significant - Monitor Closely|methyldopa increases effects of dopamine by unknown mechanism. Significant interaction possible, monitor closely.
dopamine|methyldopa|2|Significant - Monitor Closely|dopamine and methyldopa both increase  dopaminergic effects. Potential for interaction, monitor.
dopamine|midodrine|2|Significant - Monitor Closely|dopamine and midodrine both decrease  sedation. Potential for interaction, monitor.
dopamine|midodrine|2|Significant - Monitor Closely|dopamine and midodrine both increase  sympathetic (adrenergic) effects, including increased blood pressure and heart rate. Potential for interaction, monitor.
nortriptyline|dopamine|20|Serious - Use Alternative|nortriptyline, dopamine. Other (see comment). Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available. Comment: Tricyclic antidepressants increase or decrease effects of sympathomimetics, by blocking reuptake of NE, or blocking uptake of indirect sympathomimetics into the adrenergic neuron.
nortriptyline|dopamine|2|Significant - Monitor Closely|nortriptyline increases and dopamine decreases sedation. Effect of interaction is not clear, use caution. Potential for interaction, monitor.
phenelzine|dopamine|33|Contraindicated|phenelzine increases effects of dopamine by pharmacodynamic synergism. Never use combination. Risk of acute hypertensive episode.
phenytoin|dopamine|20|Serious - Use Alternative|phenytoin, dopamine. Mechanism: pharmacodynamic synergism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available. Increased risk of hypotension.
rasagiline|dopamine|11|Significant - Monitor Closely|rasagiline increases effects of dopamine by pharmacodynamic synergism. Significant interaction possible, monitor closely. Risk of acute hypertensive episode.
tadalafil|doxazosin|11|Significant - Monitor Closely|tadalafil increases effects of doxazosin by pharmacodynamic synergism. Significant interaction possible, monitor closely. Risk of hypotension.
doxazosin|tamsulosin|20|Serious - Use Alternative|doxazosin, tamsulosin.Either increases effects of the other by additive vasodilation. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available. Risk of hypotension.
treprostinil|doxazosin|1|Minor|treprostinil increases effects of doxazosin by pharmacodynamic synergism. Minor or non-significant interaction.
vardenafil|doxazosin|21|Serious - Use Alternative|vardenafil increases effects of doxazosin by pharmacodynamic synergism. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available. Never use combination. Risk of hypotension.
doxepin|ephedrine|20|Serious - Use Alternative|doxepin, ephedrine. Other (see comment). Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available. Comment: Tricyclic antidepressants increase or decrease effects of sympathomimetics, by blocking reuptake of NE, or blocking uptake of indirect sympathomimetics into the adrenergic neuron.
doxepin|ephedrine|11|Significant - Monitor Closely|doxepin increases effects of ephedrine by unknown mechanism. Significant interaction possible, monitor closely.
doxepin|ephedrine|2|Significant - Monitor Closely|doxepin increases and ephedrine decreases sedation. Effect of interaction is not clear, use caution. Potential for interaction, monitor.
epinephrine|doxepin|22|Serious - Use Alternative|epinephrine and doxepin both increase  QTc interval. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available.
doxepin|epinephrine|20|Serious - Use Alternative|doxepin, epinephrine. Other (see comment). Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available. Comment: Tricyclic antidepressants increase or decrease effects of sympathomimetics, by blocking reuptake of NE, or blocking uptake of indirect sympathomimetics into the adrenergic neuron.
doxepin|epinephrine|11|Significant - Monitor Closely|doxepin increases effects of epinephrine by unknown mechanism. Significant interaction possible, monitor closely.
doxepin|epinephrine|2|Significant - Monitor Closely|doxepin increases and epinephrine decreases sedation. Effect of interaction is not clear, use caution. Potential for interaction, monitor.
fluoxetine|doxepin|22|Serious - Use Alternative|fluoxetine and doxepin both increase  serotonin levels. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available.
fluoxetine|doxepin|20|Serious - Use Alternative|fluoxetine will increase the level or effect of doxepin by  affecting hepatic enzyme CYP2D6 metabolism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
doxepin|fluoxetine|3|Significant - Monitor Closely|doxepin and fluoxetine both increase  QTc interval. Potential for dangerous interaction. Use with caution and monitor closely.
fluvoxamine|doxepin|22|Serious - Use Alternative|fluvoxamine and doxepin both increase  serotonin levels. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available.
doxepin|fluvoxamine|3|Significant - Monitor Closely|doxepin and fluvoxamine both increase  QTc interval. Potential for dangerous interaction. Use with caution and monitor closely.
galantamine|doxepin|11|Significant - Monitor Closely|galantamine increases and doxepin decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Significant interaction possible, monitor closely.
isocarboxazid|doxepin|33|Contraindicated|isocarboxazid and doxepin both increase  serotonin levels. Never use combination.
doxepin|lumefantrine|22|Serious - Use Alternative|doxepin and lumefantrine both increase  QTc interval. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available.
lumefantrine|doxepin|20|Serious - Use Alternative|lumefantrine will increase the level or effect of doxepin by  affecting hepatic enzyme CYP2D6 metabolism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
doxepin|norepinephrine|20|Serious - Use Alternative|doxepin, norepinephrine. Other (see comment). Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available. Comment: Tricyclic antidepressants increase or decrease effects of sympathomimetics, by blocking reuptake of NE, or blocking uptake of indirect sympathomimetics into the adrenergic neuron.
doxepin|norepinephrine|11|Significant - Monitor Closely|doxepin increases effects of norepinephrine by unknown mechanism. Significant interaction possible, monitor closely.
doxepin|norepinephrine|2|Significant - Monitor Closely|doxepin increases and norepinephrine decreases sedation. Effect of interaction is not clear, use caution. Potential for interaction, monitor.
phenelzine|doxepin|33|Contraindicated|phenelzine and doxepin both increase  serotonin levels. Never use combination.
doxepin|phenylephrine|20|Serious - Use Alternative|doxepin, phenylephrine. Other (see comment). Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available. Comment: Tricyclic antidepressants increase or decrease effects of sympathomimetics, by blocking reuptake of NE, or blocking uptake of indirect sympathomimetics into the adrenergic neuron.
doxepin|phenylephrine|2|Significant - Monitor Closely|doxepin increases and phenylephrine decreases sedation. Effect of interaction is not clear, use caution. Potential for interaction, monitor.
doxepin|pirbuterol|20|Serious - Use Alternative|doxepin, pirbuterol. Other (see comment). Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available. Comment: Tricyclic antidepressants increase or decrease effects of sympathomimetics, by blocking reuptake of NE, or blocking uptake of indirect sympathomimetics into the adrenergic neuron.
doxepin|pirbuterol|2|Significant - Monitor Closely|doxepin increases and pirbuterol decreases sedation. Effect of interaction is not clear, use caution. Potential for interaction, monitor.
doxepin|pseudoephedrine|20|Serious - Use Alternative|doxepin, pseudoephedrine. Other (see comment). Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available. Comment: Tricyclic antidepressants increase or decrease effects of sympathomimetics, by blocking reuptake of NE, or blocking uptake of indirect sympathomimetics into the adrenergic neuron.
doxepin|pseudoephedrine|2|Significant - Monitor Closely|doxepin increases and pseudoephedrine decreases sedation. Effect of interaction is not clear, use caution. Potential for interaction, monitor.
quinidine|doxepin|33|Contraindicated|quinidine and doxepin both increase  QTc interval. Never use combination.
quinidine|doxepin|20|Serious - Use Alternative|quinidine will increase the level or effect of doxepin by  affecting hepatic enzyme CYP2D6 metabolism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available. Both agents increase QTc interval.
rasagiline|doxepin|20|Serious - Use Alternative|rasagiline and doxepin both increase  serotonin levels. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available. Severe CNS toxicity associated with hyperpyrexia has been reported with the combined treatment of an antidepressant and rasagiline. Avoid combination within 14 days of MAOI use.
rifabutin|doxepin|11|Significant - Monitor Closely|rifabutin decreases levels of doxepin by increasing metabolism. Significant interaction possible, monitor closely.
ritonavir|doxepin|11|Significant - Monitor Closely|ritonavir will increase the level or effect of doxepin by  affecting hepatic enzyme CYP2D6 metabolism. Significant interaction possible, monitor closely.
rivastigmine|doxepin|11|Significant - Monitor Closely|rivastigmine increases and doxepin decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Significant interaction possible, monitor closely.
tacrine|doxepin|11|Significant - Monitor Closely|tacrine increases and doxepin decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Significant interaction possible, monitor closely.
doxepin|telithromycin|3|Significant - Monitor Closely|doxepin and telithromycin both increase  QTc interval. Potential for dangerous interaction. Use with caution and monitor closely.
doxepin|terbutaline|20|Serious - Use Alternative|doxepin, terbutaline. Other (see comment). Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available. Comment: Tricyclic antidepressants increase or decrease effects of sympathomimetics, by blocking reuptake of NE, or blocking uptake of indirect sympathomimetics into the adrenergic neuron.
doxepin|terbutaline|2|Significant - Monitor Closely|doxepin increases and terbutaline decreases sedation. Effect of interaction is not clear, use caution. Potential for interaction, monitor.
doxepin|terfenadine|33|Contraindicated|doxepin and terfenadine both increase  QTc interval. Never use combination.
terfenadine|doxepin|2|Significant - Monitor Closely|terfenadine and doxepin both increase  sedation. Potential for interaction, monitor.
thioridazine|doxepin|33|Contraindicated|thioridazine will increase the level or effect of doxepin by  affecting hepatic enzyme CYP2D6 metabolism. Never use combination.
thioridazine|doxepin|22|Serious - Use Alternative|thioridazine and doxepin both increase  QTc interval. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available.
thioridazine|doxepin|2|Significant - Monitor Closely|thioridazine and doxepin both increase  sedation. Potential for interaction, monitor.
doxepin|thioridazine|1|Minor|doxepin, thioridazine.Either increases levels of the other by decreasing metabolism. Minor or non-significant interaction. Additive anticholinergic effects.
doxepin|thioridazine|1|Minor|doxepin, thioridazine.Either increases levels of the other by pharmacodynamic synergism. Minor or non-significant interaction. Additive anticholinergic effects.
thiothixene|doxepin|2|Significant - Monitor Closely|thiothixene and doxepin both increase  sedation. Potential for interaction, monitor.
doxepin|toremifene|20|Serious - Use Alternative|doxepin and toremifene both increase  QTc interval. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available. Concurrent use of toremifene with agents causing  QT prolongation should be avoided. If concomitant use is required it's recommended that toremifene be interrupted. If interruption not possible, patients requiring therapy with a drug that prolongs QT should be closely monitored. ECGs should be obtained for high risk patients.
doxepin|tramadol|3|Significant - Monitor Closely|doxepin and tramadol both increase  serotonin levels. Potential for dangerous interaction. Use with caution and monitor closely.
tramadol|doxepin|2|Significant - Monitor Closely|tramadol and doxepin both increase  sedation. Potential for interaction, monitor.
tranylcypromine|doxepin|33|Contraindicated|tranylcypromine and doxepin both increase  serotonin levels. Never use combination.
doxepin|trazodone|22|Serious - Use Alternative|doxepin and trazodone both increase  QTc interval. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available.
trazodone|doxepin|22|Serious - Use Alternative|trazodone and doxepin both increase  serotonin levels. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available.
doxepin|trazodone|2|Significant - Monitor Closely|doxepin and trazodone both decrease  cholinergic effects/transmission. Potential for interaction, monitor.
doxepin|trazodone|2|Significant - Monitor Closely|doxepin and trazodone both increase  sedation. Potential for interaction, monitor.
doxepin|trimipramine|22|Serious - Use Alternative|doxepin and trimipramine both increase  QTc interval. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available.
doxepin|trimipramine|22|Serious - Use Alternative|doxepin and trimipramine both increase  serotonin levels. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available.
doxepin|trimipramine|2|Significant - Monitor Closely|doxepin and trimipramine both decrease  cholinergic effects/transmission. Potential for interaction, monitor.
doxepin|trimipramine|2|Significant - Monitor Closely|doxepin and trimipramine both increase  sedation. Potential for interaction, monitor.
triprolidine|doxepin|2|Significant - Monitor Closely|triprolidine and doxepin both increase  sedation. Potential for interaction, monitor.
venlafaxine|doxepin|22|Serious - Use Alternative|venlafaxine and doxepin both increase  serotonin levels. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available.
venlafaxine|doxepin|20|Serious - Use Alternative|venlafaxine will increase the level or effect of doxepin by  affecting hepatic enzyme CYP2D6 metabolism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
doxepin|venlafaxine|3|Significant - Monitor Closely|doxepin and venlafaxine both increase  QTc interval. Potential for dangerous interaction. Use with caution and monitor closely.
doxepin|voriconazole|3|Significant - Monitor Closely|doxepin and voriconazole both increase  QTc interval. Potential for dangerous interaction. Use with caution and monitor closely.
doxepin|ziprasidone|22|Serious - Use Alternative|doxepin and ziprasidone both increase  QTc interval. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available.
ziprasidone|doxepin|2|Significant - Monitor Closely|ziprasidone and doxepin both increase  sedation. Potential for interaction, monitor.
zolmitriptan|doxepin|3|Significant - Monitor Closely|zolmitriptan and doxepin both increase  serotonin levels. Potential for dangerous interaction. Use with caution and monitor closely.
telithromycin|doxorubicin|2|Significant - Monitor Closely|telithromycin will increase the level or effect of doxorubicin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Potential for interaction, monitor.
voriconazole|doxorubicin|2|Significant - Monitor Closely|voriconazole will increase the level or effect of doxorubicin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Potential for interaction, monitor.
doxorubicin|zidovudine|11|Significant - Monitor Closely|doxorubicin decreases effects of zidovudine by Other (see comment). Significant interaction possible, monitor closely.
zidovudine|doxorubicin|2|Significant - Monitor Closely|zidovudine increases toxicity of doxorubicin by pharmacodynamic synergism. Potential for interaction, monitor. Inreased risk of myelosuppression.
ethotoin|doxycycline|1|Minor|ethotoin decreases levels of doxycycline by increasing metabolism. Minor or non-significant interaction.
doxycycline|flucloxacillin|20|Serious - Use Alternative|doxycycline decreases effects of flucloxacillin by pharmacodynamic antagonism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
fosphenytoin|doxycycline|1|Minor|fosphenytoin decreases levels of doxycycline by increasing metabolism. Minor or non-significant interaction.
hexobarbital|doxycycline|11|Significant - Monitor Closely|hexobarbital decreases levels of doxycycline by increasing metabolism. Significant interaction possible, monitor closely.
isotretinoin|doxycycline|21|Serious - Use Alternative|isotretinoin, doxycycline. Mechanism: unknown. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available. Never use combination. Risk of pseudotumor cerebri.
magnesium oxide|doxycycline|20|Serious - Use Alternative|magnesium oxide decreases levels of doxycycline by inhibition of GI absorption. Applies only to oral form of both agents. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
doxycycline|mestranol|2|Significant - Monitor Closely|doxycycline will decrease the level or effect of mestranol by  altering intestinal flora. Applies only to oral forms of hormone. Low risk of contraceptive failure. Potential for interaction, monitor.
doxycycline|methotrexate|2|Significant - Monitor Closely|doxycycline increases levels of methotrexate by decreasing elimination. Potential for interaction, monitor. Tetracyclines may decrease intestinal absorption of methotrexate or interfere with the enterohepatic circulation by inhibiting bowel flora and suppressing metabolism of the drug by bacteria.
doxycycline|nafcillin|20|Serious - Use Alternative|doxycycline decreases effects of nafcillin by pharmacodynamic antagonism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available. bacteriostatic antibiotics may interfere with the bactericidal actions of penicillins.
doxycycline|oxacillin|20|Serious - Use Alternative|doxycycline decreases effects of oxacillin by pharmacodynamic antagonism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available. bacteriostatic agents may inhibit the effects of bactericidal agents.
pentobarbital|doxycycline|11|Significant - Monitor Closely|pentobarbital decreases levels of doxycycline by increasing metabolism. Significant interaction possible, monitor closely.
phenobarbital|doxycycline|11|Significant - Monitor Closely|phenobarbital decreases levels of doxycycline by increasing metabolism. Significant interaction possible, monitor closely.
phenytoin|doxycycline|1|Minor|phenytoin decreases levels of doxycycline by increasing metabolism. Minor or non-significant interaction.
doxycycline|piperacillin|11|Significant - Monitor Closely|doxycycline decreases effects of piperacillin by pharmacodynamic antagonism. Significant interaction possible, monitor closely. bacteriostatic agents may inhibit the effects of bactericidal agents.
doxycycline|pivmecillinam|20|Serious - Use Alternative|doxycycline decreases effects of pivmecillinam by pharmacodynamic antagonism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
primidone|doxycycline|11|Significant - Monitor Closely|primidone decreases levels of doxycycline by increasing metabolism. Significant interaction possible, monitor closely.
rifabutin|doxycycline|1|Minor|rifabutin decreases levels of doxycycline by increasing metabolism. Minor or non-significant interaction.
secobarbital|doxycycline|11|Significant - Monitor Closely|secobarbital decreases levels of doxycycline by increasing metabolism. Significant interaction possible, monitor closely.
doxycycline|tamsulosin|2|Significant - Monitor Closely|doxycycline increases levels of tamsulosin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Potential for interaction, monitor. Dose reduction may be needed for coadministered drugs that are predominantly metabolized by CYP3A.
doxycycline|ticarcillin|20|Serious - Use Alternative|doxycycline decreases effects of ticarcillin by pharmacodynamic antagonism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
doxycycline|tretinoin|33|Contraindicated|doxycycline, tretinoin.Either increases toxicity of the other by unspecified interaction mechanism. Never use combination. Both tretinoin and tetracyclines can cause increased intracranial pressure.
doxycycline|tretinoin|20|Serious - Use Alternative|doxycycline, tretinoin.Either increases levels of the other by Mechanism: pharmacodynamic synergism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available. Increased phototoxicity.
doxycycline|warfarin|1|Minor|doxycycline increases effects of warfarin by pharmacodynamic synergism. Minor or non-significant interaction.
triprolidine|doxylamine|2|Significant - Monitor Closely|triprolidine and doxylamine both increase  sedation. Potential for interaction, monitor.
etravirine|dronedarone|21|Serious - Use Alternative|etravirine will decrease the level or effect of dronedarone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available. Never use combination.
dronedarone|etravirine|11|Significant - Monitor Closely|dronedarone will increase the level or effect of etravirine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
fingolimod|dronedarone|33|Contraindicated|fingolimod increases effects of dronedarone by pharmacodynamic synergism. Never use combination. Due to increased risk of bradycardia, AV block, and torsade de pointes, concomitant use is contraindicated.
dronedarone|itraconazole|33|Contraindicated|dronedarone, itraconazole.Either increases levels of the other by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Never use combination.
dronedarone|itraconazole|33|Contraindicated|dronedarone will increase the level or effect of itraconazole by  P-glycoprotein (MDR1) efflux transporter. Never use combination.
dronedarone|itraconazole|33|Contraindicated|dronedarone and itraconazole both increase  QTc interval. Never use combination.
ketoconazole|dronedarone|33|Contraindicated|ketoconazole will increase the level or effect of dronedarone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Never use combination.
dronedarone|ketoconazole|33|Contraindicated|dronedarone and ketoconazole both increase  QTc interval. Never use combination.
dronedarone|lumefantrine|22|Serious - Use Alternative|dronedarone and lumefantrine both increase  QTc interval. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available.
lumefantrine|dronedarone|21|Serious - Use Alternative|lumefantrine will decrease the level or effect of dronedarone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available. Never use combination.
dronedarone|lumefantrine|11|Significant - Monitor Closely|dronedarone will increase the level or effect of lumefantrine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
dronedarone|metoprolol|11|Significant - Monitor Closely|dronedarone will increase the level or effect of metoprolol by  affecting hepatic enzyme CYP2D6 metabolism. Significant interaction possible, monitor closely.
nefazodone|dronedarone|33|Contraindicated|nefazodone will increase the level or effect of dronedarone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Never use combination.
dronedarone|propranolol|11|Significant - Monitor Closely|dronedarone will increase the level or effect of propranolol by  affecting hepatic enzyme CYP2D6 metabolism. Significant interaction possible, monitor closely.
dronedarone|ritonavir|22|Serious - Use Alternative|dronedarone will increase the level or effect of ritonavir by  P-glycoprotein (MDR1) efflux transporter. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available.
ritonavir|dronedarone|21|Serious - Use Alternative|ritonavir will increase the level or effect of dronedarone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available. Never use combination.
dronedarone|ritonavir|11|Significant - Monitor Closely|dronedarone will increase the level or effect of ritonavir by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
dronedarone|simvastatin|11|Significant - Monitor Closely|dronedarone will increase the level or effect of simvastatin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely. Monitor for signs and symptoms of myopathy in patients receiving dronedarone concurrently with simvastatin
dronedarone|sirolimus|11|Significant - Monitor Closely|dronedarone will increase the level or effect of sirolimus by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely. Monitor for sirolimus toxicity and adjust dose as needed.
dronedarone|sirolimus|11|Significant - Monitor Closely|dronedarone will increase the level or effect of sirolimus by  P-glycoprotein (MDR1) efflux transporter. Significant interaction possible, monitor closely. If given together, monitor for sirolimus toxicity and adjust dose as needed.
dronedarone|tacrolimus|22|Serious - Use Alternative|dronedarone will increase the level or effect of tacrolimus by  P-glycoprotein (MDR1) efflux transporter. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available. The use of dronedarone in combination with other medications that can prolong the QT interval is considered contraindicated.
dronedarone|tacrolimus|11|Significant - Monitor Closely|dronedarone will increase the level or effect of tacrolimus by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
dronedarone|telithromycin|21|Serious - Use Alternative|dronedarone will increase the level or effect of telithromycin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available. Never use combination.
telithromycin|dronedarone|21|Serious - Use Alternative|telithromycin will increase the level or effect of dronedarone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available. Never use combination.
dronedarone|telithromycin|3|Significant - Monitor Closely|dronedarone and telithromycin both increase  QTc interval. Potential for dangerous interaction. Use with caution and monitor closely.
verapamil|dronedarone|21|Serious - Use Alternative|verapamil will increase the level or effect of dronedarone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available. Never use combination.
dronedarone|verapamil|11|Significant - Monitor Closely|dronedarone will increase the level or effect of verapamil by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
voriconazole|dronedarone|21|Serious - Use Alternative|voriconazole will increase the level or effect of dronedarone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available. Never use combination.
dronedarone|voriconazole|3|Significant - Monitor Closely|dronedarone and voriconazole both increase  QTc interval. Potential for dangerous interaction. Use with caution and monitor closely.
dronedarone|warfarin|11|Significant - Monitor Closely|dronedarone will increase the level or effect of warfarin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
dronedarone|ziprasidone|22|Serious - Use Alternative|dronedarone and ziprasidone both increase  QTc interval. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available.
dronedarone|ziprasidone|21|Serious - Use Alternative|dronedarone will increase the level or effect of ziprasidone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available. Never use combination.
droperidol|lumefantrine|22|Serious - Use Alternative|droperidol and lumefantrine both increase  QTc interval. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available.
droperidol|tetrabenazine|3|Significant - Monitor Closely|droperidol and tetrabenazine both increase  antidopaminergic effects, including extrapyramidal symptoms and neuroleptic malignant syndrome. Potential for dangerous interaction. Use with caution and monitor closely.
droperidol|thiothixene|2|Significant - Monitor Closely|droperidol and thiothixene both increase  antidopaminergic effects, including extrapyramidal symptoms and neuroleptic malignant syndrome. Potential for interaction, monitor.
droperidol|thiothixene|2|Significant - Monitor Closely|droperidol and thiothixene both increase  sedation. Potential for interaction, monitor.
trimipramine|droperidol|22|Serious - Use Alternative|trimipramine and droperidol both increase  QTc interval. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available.
droperidol|trimipramine|2|Significant - Monitor Closely|droperidol and trimipramine both increase  sedation. Potential for interaction, monitor.
triprolidine|droperidol|2|Significant - Monitor Closely|triprolidine and droperidol both increase  sedation. Potential for interaction, monitor.
droperidol|voriconazole|3|Significant - Monitor Closely|droperidol and voriconazole both increase  QTc interval. Potential for dangerous interaction. Use with caution and monitor closely.
droperidol|ziprasidone|22|Serious - Use Alternative|droperidol and ziprasidone both increase  QTc interval. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available.
droperidol|ziprasidone|2|Significant - Monitor Closely|droperidol and ziprasidone both increase  antidopaminergic effects, including extrapyramidal symptoms and neuroleptic malignant syndrome. Potential for interaction, monitor.
droperidol|ziprasidone|2|Significant - Monitor Closely|droperidol and ziprasidone both increase  sedation. Potential for interaction, monitor.
enalapril|drospirenone|11|Significant - Monitor Closely|enalapril, drospirenone. Mechanism: pharmacodynamic synergism. Significant interaction possible, monitor closely. Risk of hyperkalemia.
eprosartan|drospirenone|3|Significant - Monitor Closely|eprosartan and drospirenone both increase  serum potassium. Potential for dangerous interaction. Use with caution and monitor closely.
fosinopril|drospirenone|11|Significant - Monitor Closely|fosinopril, drospirenone. Mechanism: pharmacodynamic synergism. Significant interaction possible, monitor closely. Risk of hyperkalemia.
irbesartan|drospirenone|3|Significant - Monitor Closely|irbesartan and drospirenone both increase  serum potassium. Potential for dangerous interaction. Use with caution and monitor closely.
lisinopril|drospirenone|11|Significant - Monitor Closely|lisinopril, drospirenone. Mechanism: pharmacodynamic synergism. Significant interaction possible, monitor closely. Risk of hyperkalemia.
losartan|drospirenone|3|Significant - Monitor Closely|losartan and drospirenone both increase  serum potassium. Potential for dangerous interaction. Use with caution and monitor closely.
olmesartan|drospirenone|3|Significant - Monitor Closely|olmesartan and drospirenone both increase  serum potassium. Potential for dangerous interaction. Use with caution and monitor closely.
perindopril|drospirenone|11|Significant - Monitor Closely|perindopril, drospirenone. Mechanism: pharmacodynamic synergism. Significant interaction possible, monitor closely. Risk of hyperkalemia.
quinapril|drospirenone|11|Significant - Monitor Closely|quinapril, drospirenone. Mechanism: pharmacodynamic synergism. Significant interaction possible, monitor closely. Risk of hyperkalemia.
ramipril|drospirenone|11|Significant - Monitor Closely|ramipril, drospirenone. Mechanism: pharmacodynamic synergism. Significant interaction possible, monitor closely. Risk of hyperkalemia.
telmisartan|drospirenone|3|Significant - Monitor Closely|telmisartan and drospirenone both increase  serum potassium. Potential for dangerous interaction. Use with caution and monitor closely.
trandolapril|drospirenone|11|Significant - Monitor Closely|trandolapril, drospirenone. Mechanism: pharmacodynamic synergism. Significant interaction possible, monitor closely. Risk of hyperkalemia.
treprostinil|drospirenone|1|Minor|treprostinil increases effects of drospirenone by pharmacodynamic synergism. Minor or non-significant interaction.
drospirenone|triamterene|22|Serious - Use Alternative|drospirenone and triamterene both increase  serum potassium. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available.
drospirenone|triamterene|21|Serious - Use Alternative|drospirenone, triamterene.Either increases effects of the other by pharmacodynamic synergism. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available. Never use combination. Hyperkalemia.
duloxetine|flecainide|1|Minor|duloxetine will increase the level or effect of flecainide by  affecting hepatic enzyme CYP2D6 metabolism. Minor or non-significant interaction.
fluvoxamine|duloxetine|22|Serious - Use Alternative|fluvoxamine will increase the level or effect of duloxetine by  affecting hepatic enzyme CYP1A2 metabolism. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available.
duloxetine|fluvoxamine|22|Serious - Use Alternative|duloxetine and fluvoxamine both increase  serotonin levels. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available.
duloxetine|fluvoxamine|1|Minor|duloxetine will increase the level or effect of fluvoxamine by  affecting hepatic enzyme CYP2D6 metabolism. Minor or non-significant interaction.
duloxetine|imipramine|22|Serious - Use Alternative|duloxetine and imipramine both increase  serotonin levels. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available.
duloxetine|imipramine|3|Significant - Monitor Closely|duloxetine will increase the level or effect of imipramine by  affecting hepatic enzyme CYP2D6 metabolism. Potential for dangerous interaction. Use with caution and monitor closely.
isocarboxazid|duloxetine|33|Contraindicated|isocarboxazid and duloxetine both increase  serotonin levels. Never use combination.
duloxetine|nortriptyline|22|Serious - Use Alternative|duloxetine and nortriptyline both increase  serotonin levels. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available.
duloxetine|nortriptyline|11|Significant - Monitor Closely|duloxetine will increase the level or effect of nortriptyline by  affecting hepatic enzyme CYP2D6 metabolism. Significant interaction possible, monitor closely.
phenelzine|duloxetine|33|Contraindicated|phenelzine and duloxetine both increase  serotonin levels. Never use combination.
duloxetine|propafenone|11|Significant - Monitor Closely|duloxetine will increase the level or effect of propafenone by  affecting hepatic enzyme CYP2D6 metabolism. Significant interaction possible, monitor closely.
propafenone|duloxetine|11|Significant - Monitor Closely|propafenone will increase the level or effect of duloxetine by  affecting hepatic enzyme CYP2D6 metabolism. Significant interaction possible, monitor closely.
rasagiline|duloxetine|20|Serious - Use Alternative|rasagiline and duloxetine both increase  serotonin levels. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available. Severe CNS toxicity associated with hyperpyrexia has been reported with the combined treatment of an antidepressant and rasagiline. Avoid combination within 14 days of MAOI use.
duloxetine|tamoxifen|11|Significant - Monitor Closely|duloxetine decreases effects of tamoxifen by decreasing metabolism. Significant interaction possible, monitor closely. Inhibition of CYP2D6 metabolism to tamoxifen's active metabolite, endoxifen.
duloxetine|tamsulosin|2|Significant - Monitor Closely|duloxetine increases levels of tamsulosin by affecting hepatic enzyme CYP2D6 metabolism. Potential for interaction, monitor.
duloxetine|thioridazine|21|Serious - Use Alternative|duloxetine will increase the level or effect of thioridazine by  affecting hepatic enzyme CYP2D6 metabolism. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available. Never use combination.
thioridazine|duloxetine|21|Serious - Use Alternative|thioridazine will increase the level or effect of duloxetine by  affecting hepatic enzyme CYP2D6 metabolism. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available. Never use combination.
duloxetine|tramadol|20|Serious - Use Alternative|duloxetine will increase the level or effect of tramadol by  affecting hepatic enzyme CYP2D6 metabolism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
duloxetine|tramadol|3|Significant - Monitor Closely|duloxetine and tramadol both increase  serotonin levels. Potential for dangerous interaction. Use with caution and monitor closely.
tranylcypromine|duloxetine|33|Contraindicated|tranylcypromine and duloxetine both increase  serotonin levels. Never use combination.
duloxetine|trazodone|22|Serious - Use Alternative|duloxetine and trazodone both increase  serotonin levels. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available.
duloxetine|trimipramine|22|Serious - Use Alternative|duloxetine and trimipramine both increase  serotonin levels. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available.
duloxetine|venlafaxine|22|Serious - Use Alternative|duloxetine and venlafaxine both increase  serotonin levels. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available.
venlafaxine|duloxetine|11|Significant - Monitor Closely|venlafaxine will increase the level or effect of duloxetine by  affecting hepatic enzyme CYP2D6 metabolism. Significant interaction possible, monitor closely.
zolmitriptan|duloxetine|3|Significant - Monitor Closely|zolmitriptan and duloxetine both increase  serotonin levels. Potential for dangerous interaction. Use with caution and monitor closely.
duloxetine|zolmitriptan|1|Minor|duloxetine, zolmitriptan. Mechanism: unknown. Minor or non-significant interaction. Risk of weakness, dyspnea, chest pain.
fluvoxamine|dyphylline|20|Serious - Use Alternative|fluvoxamine will increase the level or effect of dyphylline by  affecting hepatic enzyme CYP1A2 metabolism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
fluvoxamine|dyphylline|20|Serious - Use Alternative|fluvoxamine will increase the level or effect of dyphylline by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
fosphenytoin|dyphylline|11|Significant - Monitor Closely|fosphenytoin will decrease the level or effect of dyphylline by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
isoniazid|dyphylline|11|Significant - Monitor Closely|isoniazid will increase the level or effect of dyphylline by  affecting hepatic enzyme CYP1A2 metabolism. Significant interaction possible, monitor closely.
isoniazid|dyphylline|11|Significant - Monitor Closely|isoniazid will increase the level or effect of dyphylline by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
dyphylline|lithium|1|Minor|dyphylline decreases levels of lithium by increasing renal clearance. Minor or non-significant interaction.
mexiletine|dyphylline|11|Significant - Monitor Closely|mexiletine will increase the level or effect of dyphylline by  affecting hepatic enzyme CYP1A2 metabolism. Significant interaction possible, monitor closely.
nadolol|dyphylline|11|Significant - Monitor Closely|nadolol, dyphylline. Other (see comment). Significant interaction possible, monitor closely. Comment: Beta blockers (esp. non selective) antagonize theophylline effects, while at the same time increasing theophylline levels and toxicity (mechanism: decreased theophylline metabolism). Smoking increases risk of interaction.
norfloxacin|dyphylline|11|Significant - Monitor Closely|norfloxacin will increase the level or effect of dyphylline by  affecting hepatic enzyme CYP1A2 metabolism. Significant interaction possible, monitor closely.
pentoxifylline|dyphylline|1|Minor|pentoxifylline increases levels of dyphylline by decreasing metabolism. Minor or non-significant interaction.
phenobarbital|dyphylline|11|Significant - Monitor Closely|phenobarbital will decrease the level or effect of dyphylline by  affecting hepatic enzyme CYP1A2 metabolism. Significant interaction possible, monitor closely.
phenobarbital|dyphylline|11|Significant - Monitor Closely|phenobarbital will decrease the level or effect of dyphylline by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
phenytoin|dyphylline|11|Significant - Monitor Closely|phenytoin will decrease the level or effect of dyphylline by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
pindolol|dyphylline|11|Significant - Monitor Closely|pindolol, dyphylline. Other (see comment). Significant interaction possible, monitor closely. Comment: Beta blockers (esp. non selective) antagonize theophylline effects, while at the same time increasing theophylline levels and toxicity (mechanism: decreased theophylline metabolism). Smoking increases risk of interaction.
primidone|dyphylline|11|Significant - Monitor Closely|primidone will decrease the level or effect of dyphylline by  affecting hepatic enzyme CYP1A2 metabolism. Significant interaction possible, monitor closely.
primidone|dyphylline|11|Significant - Monitor Closely|primidone will decrease the level or effect of dyphylline by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
propafenone|dyphylline|1|Minor|propafenone increases levels of dyphylline by decreasing renal clearance. Minor or non-significant interaction.
propranolol|dyphylline|11|Significant - Monitor Closely|propranolol, dyphylline. Other (see comment). Significant interaction possible, monitor closely. Comment: Beta blockers (esp. non selective) antagonize theophylline effects, while at the same time increasing theophylline levels and toxicity (mechanism: decreased theophylline metabolism). Smoking increases risk of interaction.
ticlopidine|dyphylline|1|Minor|ticlopidine increases levels of dyphylline by decreasing metabolism. Minor or non-significant interaction.
timolol|dyphylline|11|Significant - Monitor Closely|timolol, dyphylline. Other (see comment). Significant interaction possible, monitor closely. Comment: Beta blockers (esp. non selective) antagonize theophylline effects, while at the same time increasing theophylline levels and toxicity (mechanism: decreased theophylline metabolism). Smoking increases risk of interaction.
tacrine|edrophonium|11|Significant - Monitor Closely|tacrine increases effects of edrophonium by pharmacodynamic synergism. Significant interaction possible, monitor closely.
edrophonium|tacrine|2|Significant - Monitor Closely|edrophonium and tacrine both increase  cholinergic effects/transmission. Potential for interaction, monitor.
efavirenz|eltrombopag|20|Serious - Use Alternative|efavirenz will increase the level or effect of eltrombopag by  affecting hepatic enzyme CYP2C9/10 metabolism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
efavirenz|ergotamine|21|Serious - Use Alternative|efavirenz will decrease the level or effect of ergotamine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available. Never use combination.
efavirenz|ergotamine|20|Serious - Use Alternative|efavirenz increases levels of ergotamine by decreasing metabolism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available. Competitive inhibition of CYP3A4 might lead to vasospasm and ischemia.
efavirenz|etravirine|33|Contraindicated|efavirenz decreases levels of etravirine by increasing metabolism. Never use combination. Mfr.'s PI recommends not combining etravirine with other NNRTIs.
efavirenz|etravirine|20|Serious - Use Alternative|efavirenz will increase the level or effect of etravirine by  affecting hepatic enzyme CYP2C9/10 metabolism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
efavirenz|etravirine|11|Significant - Monitor Closely|efavirenz will increase the level or effect of etravirine by  affecting hepatic enzyme CYP2C19 metabolism. Significant interaction possible, monitor closely.
efavirenz|etravirine|11|Significant - Monitor Closely|efavirenz will decrease the level or effect of etravirine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
etravirine|efavirenz|1|Minor|etravirine will decrease the level or effect of efavirenz by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor or non-significant interaction.
efavirenz|indinavir|20|Serious - Use Alternative|efavirenz will decrease the level or effect of indinavir by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
indinavir|efavirenz|2|Significant - Monitor Closely|indinavir and efavirenz both increase  risk of immune reconstitution syndrome. Potential for interaction, monitor.
indinavir|efavirenz|1|Minor|indinavir will increase the level or effect of efavirenz by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor or non-significant interaction.
efavirenz|lovastatin|20|Serious - Use Alternative|efavirenz will decrease the level or effect of lovastatin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
efavirenz|methadone|11|Significant - Monitor Closely|efavirenz will decrease the level or effect of methadone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
efavirenz|midazolam|11|Significant - Monitor Closely|efavirenz will decrease the level or effect of midazolam by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
efavirenz|rilpivirine|33|Contraindicated|efavirenz decreases levels of rilpivirine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Never use combination. Contraindicated. Rilpivirine should not be used in combination with NNRTIs.
efavirenz|roflumilast|11|Significant - Monitor Closely|efavirenz will decrease the level or effect of roflumilast by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely. Coadministration not recommended; strong cytochrome P450 enzyme inducers decrease systemic exposure to roflumilast and may reduce the therapeutic effectiveness
efavirenz|saquinavir|11|Significant - Monitor Closely|efavirenz will decrease the level or effect of saquinavir by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
saquinavir|efavirenz|2|Significant - Monitor Closely|saquinavir and efavirenz both increase  risk of immune reconstitution syndrome. Potential for interaction, monitor.
efavirenz|simvastatin|11|Significant - Monitor Closely|efavirenz will decrease the level or effect of simvastatin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
efavirenz|tamsulosin|11|Significant - Monitor Closely|efavirenz increases levels of tamsulosin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely. Dose reduction may be needed for coadministered drugs that are predominantly metabolized by CYP3A.
efavirenz|telaprevir|20|Serious - Use Alternative|efavirenz decreases levels of telaprevir by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available. Coadministration of telaprevir with CYP3A inducers may significantly reduce telaprevir plasma concentrations resulting in reduced efficacy; efavirenz levels are also reported to be reduced by telaprevir.
telithromycin|efavirenz|1|Minor|telithromycin will increase the level or effect of efavirenz by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor or non-significant interaction.
efavirenz|temsirolimus|11|Significant - Monitor Closely|efavirenz will decrease the level or effect of temsirolimus by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
efavirenz|terfenadine|21|Serious - Use Alternative|efavirenz will decrease the level or effect of terfenadine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available. Never use combination.
efavirenz|terfenadine|21|Serious - Use Alternative|efavirenz increases levels of terfenadine by decreasing metabolism. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available. Never use combination.
efavirenz|tipranavir|11|Significant - Monitor Closely|efavirenz will decrease the level or effect of tipranavir by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
tipranavir|efavirenz|2|Significant - Monitor Closely|tipranavir and efavirenz both increase  risk of immune reconstitution syndrome. Potential for interaction, monitor.
efavirenz|tolterodine|11|Significant - Monitor Closely|efavirenz will decrease the level or effect of tolterodine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
efavirenz|tramadol|2|Significant - Monitor Closely|efavirenz will decrease the level or effect of tramadol by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Potential for interaction, monitor.
efavirenz|trazodone|11|Significant - Monitor Closely|efavirenz will decrease the level or effect of trazodone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
efavirenz|triazolam|21|Serious - Use Alternative|efavirenz increases levels of triazolam by decreasing metabolism. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available. Never use combination.
efavirenz|triazolam|11|Significant - Monitor Closely|efavirenz will decrease the level or effect of triazolam by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
efavirenz|vandetanib|20|Serious - Use Alternative|efavirenz decreases levels of vandetanib by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available. Avoid coadministration with potent CYP3A4 inducers; these drugs reduce exposure to vandetanib by up to 40%.
voriconazole|efavirenz|20|Serious - Use Alternative|voriconazole will increase the level or effect of efavirenz by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
efavirenz|voriconazole|20|Serious - Use Alternative|efavirenz decreases effects of voriconazole by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available. Efavirenz doses =400 mg/day induces CYP3A4 resulting in decreased voriconazole levels.
ergonovine|eletriptan|33|Contraindicated|ergonovine, eletriptan.Either increases toxicity of the other by pharmacodynamic synergism. Never use combination. Additive vasospasm.  Sep. by 24h.
ergotamine|eletriptan|33|Contraindicated|ergotamine, eletriptan.Either increases toxicity of the other by pharmacodynamic synergism. Never use combination. Additive vasospasm.  Sep. by 24h.
eletriptan|ergotamine|2|Significant - Monitor Closely|eletriptan and ergotamine both increase  serotonin levels. Potential for interaction, monitor.
eletriptan|escitalopram|3|Significant - Monitor Closely|eletriptan and escitalopram both increase  serotonin levels. Potential for dangerous interaction. Use with caution and monitor closely.
escitalopram|eletriptan|1|Minor|escitalopram, eletriptan. Mechanism: unknown. Minor or non-significant interaction. Risk of weakness, dyspnea, chest pain.
eletriptan|fluoxetine|3|Significant - Monitor Closely|eletriptan and fluoxetine both increase  serotonin levels. Potential for dangerous interaction. Use with caution and monitor closely.
fluoxetine|eletriptan|1|Minor|fluoxetine, eletriptan. Mechanism: unknown. Minor or non-significant interaction. Risk of weakness, dyspnea, chest pain.
fluvoxamine|eletriptan|11|Significant - Monitor Closely|fluvoxamine will increase the level or effect of eletriptan by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
eletriptan|fluvoxamine|3|Significant - Monitor Closely|eletriptan and fluvoxamine both increase  serotonin levels. Potential for dangerous interaction. Use with caution and monitor closely.
fluvoxamine|eletriptan|1|Minor|fluvoxamine, eletriptan. Mechanism: unknown. Minor or non-significant interaction. Risk of weakness, dyspnea, chest pain.
itraconazole|eletriptan|21|Serious - Use Alternative|itraconazole increases levels of eletriptan by decreasing metabolism. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available. Never use combination. Separate by 72 hours.
itraconazole|eletriptan|20|Serious - Use Alternative|itraconazole will increase the level or effect of eletriptan by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
ketoconazole|eletriptan|21|Serious - Use Alternative|ketoconazole increases levels of eletriptan by decreasing metabolism. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available. Never use combination. Separate by 72 hours.
ketoconazole|eletriptan|20|Serious - Use Alternative|ketoconazole will increase the level or effect of eletriptan by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
nefazodone|eletriptan|21|Serious - Use Alternative|nefazodone increases levels of eletriptan by decreasing metabolism. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available. Never use combination. Separate by 72 hours.
nefazodone|eletriptan|20|Serious - Use Alternative|nefazodone will increase the level or effect of eletriptan by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
eletriptan|nefazodone|3|Significant - Monitor Closely|eletriptan and nefazodone both increase  serotonin levels. Potential for dangerous interaction. Use with caution and monitor closely.
nefazodone|eletriptan|1|Minor|nefazodone, eletriptan. Mechanism: unknown. Minor or non-significant interaction. Risk of weakness, dyspnea, chest pain.
nelfinavir|eletriptan|21|Serious - Use Alternative|nelfinavir increases levels of eletriptan by decreasing metabolism. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available. Never use combination. Separate by 72 hours.
nelfinavir|eletriptan|11|Significant - Monitor Closely|nelfinavir will increase the level or effect of eletriptan by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
eletriptan|paroxetine|3|Significant - Monitor Closely|eletriptan and paroxetine both increase  serotonin levels. Potential for dangerous interaction. Use with caution and monitor closely.
paroxetine|eletriptan|1|Minor|paroxetine, eletriptan. Mechanism: unknown. Minor or non-significant interaction. Risk of weakness, dyspnea, chest pain.
ritonavir|eletriptan|21|Serious - Use Alternative|ritonavir increases levels of eletriptan by decreasing metabolism. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available. Never use combination. Separate by 72 hours.
ritonavir|eletriptan|11|Significant - Monitor Closely|ritonavir will increase the level or effect of eletriptan by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
eletriptan|sertraline|3|Significant - Monitor Closely|eletriptan and sertraline both increase  serotonin levels. Potential for dangerous interaction. Use with caution and monitor closely.
sertraline|eletriptan|1|Minor|sertraline, eletriptan. Mechanism: unknown. Minor or non-significant interaction. Risk of weakness, dyspnea, chest pain.
telithromycin|eletriptan|11|Significant - Monitor Closely|telithromycin will increase the level or effect of eletriptan by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
eletriptan|tramadol|2|Significant - Monitor Closely|eletriptan and tramadol both increase  serotonin levels. Potential for interaction, monitor.
eletriptan|tranylcypromine|22|Serious - Use Alternative|eletriptan and tranylcypromine both increase  serotonin levels. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available.
tranylcypromine|eletriptan|21|Serious - Use Alternative|tranylcypromine increases levels of eletriptan by decreasing metabolism. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available. Never use combination.
eletriptan|trazodone|3|Significant - Monitor Closely|eletriptan and trazodone both increase  serotonin levels. Potential for dangerous interaction. Use with caution and monitor closely.
trazodone|eletriptan|1|Minor|trazodone, eletriptan. Mechanism: unknown. Minor or non-significant interaction. Risk of weakness, dyspnea, chest pain.
eletriptan|trimipramine|3|Significant - Monitor Closely|eletriptan and trimipramine both increase  serotonin levels. Potential for dangerous interaction. Use with caution and monitor closely.
troleandomycin|eletriptan|21|Serious - Use Alternative|troleandomycin increases levels of eletriptan by decreasing metabolism. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available. Never use combination. Separate by 72 hours.
troleandomycin|eletriptan|11|Significant - Monitor Closely|troleandomycin will increase the level or effect of eletriptan by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
eletriptan|venlafaxine|3|Significant - Monitor Closely|eletriptan and venlafaxine both increase  serotonin levels. Potential for dangerous interaction. Use with caution and monitor closely.
venlafaxine|eletriptan|1|Minor|venlafaxine, eletriptan. Mechanism: unknown. Minor or non-significant interaction. Risk of weakness, dyspnea, chest pain.
voriconazole|eletriptan|11|Significant - Monitor Closely|voriconazole will increase the level or effect of eletriptan by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
eletriptan|zolmitriptan|33|Contraindicated|eletriptan, zolmitriptan.Either increases toxicity of the other by pharmacodynamic synergism. Never use combination. Additive vasospasm.  Sep. by 24h.
eletriptan|zolmitriptan|2|Significant - Monitor Closely|eletriptan and zolmitriptan both increase  serotonin levels. Potential for interaction, monitor.
eltrombopag|etodolac|11|Significant - Monitor Closely|eltrombopag increases levels of etodolac by decreasing metabolism. Significant interaction possible, monitor closely. UGT inhibition; significance of interaction unclear.
eltrombopag|fenoprofen|11|Significant - Monitor Closely|eltrombopag increases levels of fenoprofen by decreasing metabolism. Significant interaction possible, monitor closely. UGT inhibition; significance of interaction unclear.
eltrombopag|flurbiprofen|11|Significant - Monitor Closely|eltrombopag increases levels of flurbiprofen by decreasing metabolism. Significant interaction possible, monitor closely. UGT inhibition; significance of interaction unclear.
eltrombopag|fluvastatin|11|Significant - Monitor Closely|eltrombopag increases levels of fluvastatin by decreasing metabolism. Significant interaction possible, monitor closely. OATP transporter protein inhibition.
fluvoxamine|eltrombopag|20|Serious - Use Alternative|fluvoxamine will increase the level or effect of eltrombopag by  affecting hepatic enzyme CYP1A2 metabolism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
fluvoxamine|eltrombopag|11|Significant - Monitor Closely|fluvoxamine will increase the level or effect of eltrombopag by  affecting hepatic enzyme CYP2C9/10 metabolism. Significant interaction possible, monitor closely.
eltrombopag|hydrocodone|11|Significant - Monitor Closely|eltrombopag increases levels of hydrocodone by decreasing metabolism. Significant interaction possible, monitor closely. UGT inhibition; significance of interaction unclear.
eltrombopag|hydromorphone|11|Significant - Monitor Closely|eltrombopag increases levels of hydromorphone by decreasing metabolism. Significant interaction possible, monitor closely. UGT inhibition; significance of interaction unclear.
eltrombopag|ibuprofen|11|Significant - Monitor Closely|eltrombopag increases levels of ibuprofen by decreasing metabolism. Significant interaction possible, monitor closely. UGT inhibition; significance of interaction unclear.
eltrombopag|indomethacin|11|Significant - Monitor Closely|eltrombopag increases levels of indomethacin by decreasing metabolism. Significant interaction possible, monitor closely. UGT inhibition; significance of interaction unclear.
iron sucrose|eltrombopag|21|Serious - Use Alternative|iron sucrose decreases levels of eltrombopag by inhibition of GI absorption. Applies only to oral form of both agents. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available. Never use combination. Separate by at least 4 hours.
isoniazid|eltrombopag|11|Significant - Monitor Closely|isoniazid will increase the level or effect of eltrombopag by  affecting hepatic enzyme CYP1A2 metabolism. Significant interaction possible, monitor closely.
eltrombopag|ketoprofen|11|Significant - Monitor Closely|eltrombopag increases levels of ketoprofen by decreasing metabolism. Significant interaction possible, monitor closely. UGT inhibition; significance of interaction unclear.
eltrombopag|ketorolac|11|Significant - Monitor Closely|eltrombopag increases levels of ketorolac by decreasing metabolism. Significant interaction possible, monitor closely. UGT inhibition; significance of interaction unclear.
leflunomide|eltrombopag|11|Significant - Monitor Closely|leflunomide will increase the level or effect of eltrombopag by  affecting hepatic enzyme CYP2C9/10 metabolism. Significant interaction possible, monitor closely.
eltrombopag|levorphanol|11|Significant - Monitor Closely|eltrombopag increases levels of levorphanol by decreasing metabolism. Significant interaction possible, monitor closely. UGT inhibition; significance of interaction unclear.
magnesium sulfate|eltrombopag|21|Serious - Use Alternative|magnesium sulfate decreases levels of eltrombopag by inhibition of GI absorption. Applies only to oral form of both agents. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available. Never use combination. Separate by at least 4 hours.
eltrombopag|mefenamic acid|11|Significant - Monitor Closely|eltrombopag increases levels of mefenamic acid by decreasing metabolism. Significant interaction possible, monitor closely. UGT inhibition; significance of interaction unclear.
eltrombopag|meloxicam|11|Significant - Monitor Closely|eltrombopag increases levels of meloxicam by decreasing metabolism. Significant interaction possible, monitor closely. UGT inhibition; significance of interaction unclear.
eltrombopag|methadone|11|Significant - Monitor Closely|eltrombopag increases levels of methadone by decreasing metabolism. Significant interaction possible, monitor closely. UGT inhibition; significance of interaction unclear.
eltrombopag|methotrexate|2|Significant - Monitor Closely|eltrombopag increases levels of methotrexate by decreasing metabolism. Potential for interaction, monitor. OATP transporter protein inhibition.
mexiletine|eltrombopag|11|Significant - Monitor Closely|mexiletine will increase the level or effect of eltrombopag by  affecting hepatic enzyme CYP1A2 metabolism. Significant interaction possible, monitor closely.
eltrombopag|morphine|11|Significant - Monitor Closely|eltrombopag increases levels of morphine by decreasing metabolism. Significant interaction possible, monitor closely. UGT inhibition; significance of interaction unclear.
eltrombopag|meperidine|11|Significant - Monitor Closely|eltrombopag increases levels of meperidine by decreasing metabolism. Significant interaction possible, monitor closely. UGT inhibition; significance of interaction unclear.
sodium bicarbonate|eltrombopag|21|Serious - Use Alternative|sodium bicarbonate decreases levels of eltrombopag by inhibition of GI absorption. Applies only to oral form of both agents. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available. Never use combination. Separate by at least 4 hours.
eltrombopag|valsartan|2|Significant - Monitor Closely|eltrombopag will decrease the level or effect of valsartan by  Other (see comment). Potential for interaction, monitor. The results from an in vitro study with human liver tissue indicate that valsartan is a substrate of the hepatic uptake transporter OATP1B1; coadministration with OATP1B1 inhibitors may increase valsartan systemic exposure
zileuton|eltrombopag|11|Significant - Monitor Closely|zileuton will increase the level or effect of eltrombopag by  affecting hepatic enzyme CYP1A2 metabolism. Significant interaction possible, monitor closely.
valganciclovir|emtricitabine|11|Significant - Monitor Closely|valganciclovir increases levels of emtricitabine by Other (see comment). Significant interaction possible, monitor closely. Comment: Coadministration of emtricitabine with drugs that reduce renal function or compete for active tubular secretion may increase serum concentrations of emtricitabine.
valganciclovir|emtricitabine|3|Significant - Monitor Closely|valganciclovir, emtricitabine.Either increases toxicity of the other by pharmacodynamic synergism. Potential for dangerous interaction. Use with caution and monitor closely. Use alternatives if available. Increased risk of hematologic toxicity.
icatibant|enalapril|2|Significant - Monitor Closely|icatibant decreases effects of enalapril by pharmacodynamic antagonism. Potential for interaction, monitor. Icatibant has potential to have a pharmacodynamic interaction with ACE inhibitors where it may attenuate the antihypertensive effect of ACE inhibitors.
enalapril|insulin lispro|11|Significant - Monitor Closely|enalapril increases effects of insulin lispro by pharmacodynamic synergism. Significant interaction possible, monitor closely.
enalapril|lithium|11|Significant - Monitor Closely|enalapril increases toxicity of lithium by unknown mechanism. Significant interaction possible, monitor closely. ACE inhibitor induced Na+ depletion may increase reabsorption of lithium from renal tubule.
enalapril|spironolactone|11|Significant - Monitor Closely|enalapril, spironolactone. Mechanism: pharmacodynamic synergism. Significant interaction possible, monitor closely. Risk of hyperkalemia.
tizanidine|enalapril|1|Minor|tizanidine increases effects of enalapril by pharmacodynamic synergism. Minor or non-significant interaction. Risk of hypotension.
treprostinil|enalapril|1|Minor|treprostinil increases effects of enalapril by pharmacodynamic synergism. Minor or non-significant interaction.
enalapril|triamterene|11|Significant - Monitor Closely|enalapril, triamterene. Mechanism: pharmacodynamic synergism. Significant interaction possible, monitor closely. Risk of hyperkalemia.
enflurane|labetalol|11|Significant - Monitor Closely|enflurane, labetalol.Either increases effects of the other by pharmacodynamic synergism. Significant interaction possible, monitor closely. Risk of hypotension.
enflurane|rotigotine|2|Significant - Monitor Closely|enflurane and rotigotine both increase  sedation. Potential for interaction, monitor.
enoxaparin|ginkgo biloba|3|Significant - Monitor Closely|enoxaparin and ginkgo biloba both increase  anticoagulation. Potential for dangerous interaction. Use with caution and monitor closely.
entacapone|epinephrine|11|Significant - Monitor Closely|entacapone increases effects of epinephrine by pharmacodynamic synergism. Significant interaction possible, monitor closely.
entacapone|isocarboxazid|21|Serious - Use Alternative|entacapone increases effects of isocarboxazid by pharmacodynamic synergism. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available. Never use combination.
entacapone|methyldopa|11|Significant - Monitor Closely|entacapone increases effects of methyldopa by pharmacodynamic synergism. Significant interaction possible, monitor closely.
entacapone|norepinephrine|11|Significant - Monitor Closely|entacapone increases effects of norepinephrine by pharmacodynamic synergism. Significant interaction possible, monitor closely.
entacapone|phenelzine|21|Serious - Use Alternative|entacapone increases effects of phenelzine by pharmacodynamic synergism. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available. Never use combination.
entacapone|tranylcypromine|21|Serious - Use Alternative|entacapone increases effects of tranylcypromine by pharmacodynamic synergism. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available. Never use combination.
imipramine|ephedrine|20|Serious - Use Alternative|imipramine, ephedrine. Other (see comment). Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available. Comment: Tricyclic antidepressants increase or decrease effects of sympathomimetics, by blocking reuptake of NE, or blocking uptake of indirect sympathomimetics into the adrenergic neuron.
imipramine|ephedrine|11|Significant - Monitor Closely|imipramine increases effects of ephedrine by unknown mechanism. Significant interaction possible, monitor closely.
imipramine|ephedrine|2|Significant - Monitor Closely|imipramine increases and ephedrine decreases sedation. Effect of interaction is not clear, use caution. Potential for interaction, monitor.
isocarboxazid|ephedrine|33|Contraindicated|isocarboxazid increases effects of ephedrine by pharmacodynamic synergism. Never use combination. Risk of acute hypertensive episode.
linezolid|ephedrine|33|Contraindicated|linezolid increases effects of ephedrine by pharmacodynamic synergism. Never use combination. Risk of acute hypertensive episode.
methyldopa|ephedrine|11|Significant - Monitor Closely|methyldopa increases effects of ephedrine by unknown mechanism. Significant interaction possible, monitor closely.
ephedrine|midodrine|11|Significant - Monitor Closely|ephedrine, midodrine.Either increases effects of the other by pharmacodynamic synergism. Significant interaction possible, monitor closely.
ephedrine|midodrine|2|Significant - Monitor Closely|ephedrine and midodrine both decrease  sedation. Potential for interaction, monitor.
ephedrine|midodrine|2|Significant - Monitor Closely|ephedrine and midodrine both increase  sympathetic (adrenergic) effects, including increased blood pressure and heart rate. Potential for interaction, monitor.
nortriptyline|ephedrine|20|Serious - Use Alternative|nortriptyline, ephedrine. Other (see comment). Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available. Comment: Tricyclic antidepressants increase or decrease effects of sympathomimetics, by blocking reuptake of NE, or blocking uptake of indirect sympathomimetics into the adrenergic neuron.
nortriptyline|ephedrine|11|Significant - Monitor Closely|nortriptyline increases effects of ephedrine by unknown mechanism. Significant interaction possible, monitor closely.
nortriptyline|ephedrine|2|Significant - Monitor Closely|nortriptyline increases and ephedrine decreases sedation. Effect of interaction is not clear, use caution. Potential for interaction, monitor.
phenelzine|ephedrine|33|Contraindicated|phenelzine increases effects of ephedrine by pharmacodynamic synergism. Never use combination. Risk of acute hypertensive episode.
rasagiline|ephedrine|33|Contraindicated|rasagiline increases effects of ephedrine by pharmacodynamic synergism. Never use combination. Risk of acute hypertensive episode.
tranylcypromine|ephedrine|33|Contraindicated|tranylcypromine increases effects of ephedrine by pharmacodynamic synergism. Never use combination. Risk of acute hypertensive episode.
ergonovine|epinephrine|21|Serious - Use Alternative|ergonovine, epinephrine. Mechanism: pharmacodynamic synergism. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available. Never use combination. Additive vasospasm; risk of hypertension.
esmolol|epinephrine|11|Significant - Monitor Closely|esmolol decreases effects of epinephrine by pharmacodynamic antagonism. Significant interaction possible, monitor closely.
esmolol|epinephrine|2|Significant - Monitor Closely|esmolol increases and epinephrine decreases serum potassium. Effect of interaction is not clear, use caution. Potential for interaction, monitor.
epinephrine|imipramine|22|Serious - Use Alternative|epinephrine and imipramine both increase  QTc interval. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available.
imipramine|epinephrine|20|Serious - Use Alternative|imipramine, epinephrine. Other (see comment). Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available. Comment: Tricyclic antidepressants increase or decrease effects of sympathomimetics, by blocking reuptake of NE, or blocking uptake of indirect sympathomimetics into the adrenergic neuron.
imipramine|epinephrine|11|Significant - Monitor Closely|imipramine increases effects of epinephrine by unknown mechanism. Significant interaction possible, monitor closely.
imipramine|epinephrine|2|Significant - Monitor Closely|imipramine increases and epinephrine decreases sedation. Effect of interaction is not clear, use caution. Potential for interaction, monitor.
isocarboxazid|epinephrine|33|Contraindicated|isocarboxazid increases effects of epinephrine by pharmacodynamic synergism. Never use combination. Risk of acute hypertensive episode.
labetalol|epinephrine|11|Significant - Monitor Closely|labetalol decreases effects of epinephrine by pharmacodynamic antagonism. Significant interaction possible, monitor closely.
labetalol|epinephrine|2|Significant - Monitor Closely|labetalol increases and epinephrine decreases serum potassium. Effect of interaction is not clear, use caution. Potential for interaction, monitor.
linezolid|epinephrine|33|Contraindicated|linezolid increases effects of epinephrine by pharmacodynamic synergism. Never use combination. Risk of acute hypertensive episode.
epinephrine|lurasidone|33|Contraindicated|epinephrine increases toxicity of lurasidone by pharmacodynamic synergism. Never use combination. Interaction applies only in setting of acute lurasidone overdose. Epinephrine may enhance hypotensive effects of lurasidone in overdose setting.
methyldopa|epinephrine|11|Significant - Monitor Closely|methyldopa increases effects of epinephrine by unknown mechanism. Significant interaction possible, monitor closely.
metoprolol|epinephrine|11|Significant - Monitor Closely|metoprolol decreases effects of epinephrine by pharmacodynamic antagonism. Significant interaction possible, monitor closely.
metoprolol|epinephrine|2|Significant - Monitor Closely|metoprolol increases and epinephrine decreases serum potassium. Effect of interaction is not clear, use caution. Potential for interaction, monitor.
epinephrine|midodrine|2|Significant - Monitor Closely|epinephrine and midodrine both decrease  sedation. Potential for interaction, monitor.
epinephrine|midodrine|2|Significant - Monitor Closely|epinephrine and midodrine both increase  sympathetic (adrenergic) effects, including increased blood pressure and heart rate. Potential for interaction, monitor.
nadolol|epinephrine|20|Serious - Use Alternative|nadolol increases effects of epinephrine by pharmacodynamic synergism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available. Risk of hypertension and bradycardia.  Consider selective beta 1 blocker (e.g., metoprolol).
nadolol|epinephrine|11|Significant - Monitor Closely|nadolol decreases effects of epinephrine by pharmacodynamic antagonism. Significant interaction possible, monitor closely.
nadolol|epinephrine|2|Significant - Monitor Closely|nadolol increases and epinephrine decreases serum potassium. Effect of interaction is not clear, use caution. Potential for interaction, monitor.
epinephrine|nortriptyline|22|Serious - Use Alternative|epinephrine and nortriptyline both increase  QTc interval. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available.
nortriptyline|epinephrine|20|Serious - Use Alternative|nortriptyline, epinephrine. Other (see comment). Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available. Comment: Tricyclic antidepressants increase or decrease effects of sympathomimetics, by blocking reuptake of NE, or blocking uptake of indirect sympathomimetics into the adrenergic neuron.
nortriptyline|epinephrine|11|Significant - Monitor Closely|nortriptyline increases effects of epinephrine by unknown mechanism. Significant interaction possible, monitor closely.
nortriptyline|epinephrine|2|Significant - Monitor Closely|nortriptyline increases and epinephrine decreases sedation. Effect of interaction is not clear, use caution. Potential for interaction, monitor.
oxytocin|epinephrine|11|Significant - Monitor Closely|oxytocin increases effects of epinephrine by pharmacodynamic synergism. Significant interaction possible, monitor closely.
penbutolol|epinephrine|11|Significant - Monitor Closely|penbutolol decreases effects of epinephrine by pharmacodynamic antagonism. Significant interaction possible, monitor closely.
penbutolol|epinephrine|2|Significant - Monitor Closely|penbutolol increases and epinephrine decreases serum potassium. Effect of interaction is not clear, use caution. Potential for interaction, monitor.
phenelzine|epinephrine|33|Contraindicated|phenelzine increases effects of epinephrine by pharmacodynamic synergism. Never use combination. Risk of acute hypertensive episode.
pindolol|epinephrine|20|Serious - Use Alternative|pindolol increases effects of epinephrine by pharmacodynamic synergism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available. Risk of hypertension and bradycardia.  Consider selective beta 1 blocker (e.g., metoprolol).
pindolol|epinephrine|11|Significant - Monitor Closely|pindolol decreases effects of epinephrine by pharmacodynamic antagonism. Significant interaction possible, monitor closely.
pindolol|epinephrine|2|Significant - Monitor Closely|pindolol increases and epinephrine decreases serum potassium. Effect of interaction is not clear, use caution. Potential for interaction, monitor.
propranolol|epinephrine|20|Serious - Use Alternative|propranolol increases effects of epinephrine by pharmacodynamic synergism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available. Risk of hypertension and bradycardia.  Consider selective beta 1 blocker (e.g., metoprolol).
propranolol|epinephrine|11|Significant - Monitor Closely|propranolol decreases effects of epinephrine by pharmacodynamic antagonism. Significant interaction possible, monitor closely.
propranolol|epinephrine|2|Significant - Monitor Closely|propranolol increases and epinephrine decreases serum potassium. Effect of interaction is not clear, use caution. Potential for interaction, monitor.
epinephrine|protriptyline|22|Serious - Use Alternative|epinephrine and protriptyline both increase  QTc interval. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available.
protriptyline|epinephrine|20|Serious - Use Alternative|protriptyline, epinephrine. Other (see comment). Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available. Comment: Tricyclic antidepressants increase or decrease effects of sympathomimetics, by blocking reuptake of NE, or blocking uptake of indirect sympathomimetics into the adrenergic neuron.
protriptyline|epinephrine|11|Significant - Monitor Closely|protriptyline increases effects of epinephrine by unknown mechanism. Significant interaction possible, monitor closely.
protriptyline|epinephrine|2|Significant - Monitor Closely|protriptyline increases and epinephrine decreases sedation. Effect of interaction is not clear, use caution. Potential for interaction, monitor.
rasagiline|epinephrine|11|Significant - Monitor Closely|rasagiline increases effects of epinephrine by pharmacodynamic synergism. Significant interaction possible, monitor closely. Avoid concomitant use if possible. Caution is advised.
epinephrine|sotalol|33|Contraindicated|epinephrine and sotalol both increase  QTc interval. Never use combination.
sotalol|epinephrine|11|Significant - Monitor Closely|sotalol decreases effects of epinephrine by pharmacodynamic antagonism. Significant interaction possible, monitor closely.
sotalol|epinephrine|2|Significant - Monitor Closely|sotalol increases and epinephrine decreases serum potassium. Effect of interaction is not clear, use caution. Potential for interaction, monitor.
timolol|epinephrine|20|Serious - Use Alternative|timolol increases effects of epinephrine by pharmacodynamic synergism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available. Risk of hypertension and bradycardia.  Consider selective beta 1 blocker (e.g., metoprolol).
timolol|epinephrine|11|Significant - Monitor Closely|timolol decreases effects of epinephrine by pharmacodynamic antagonism. Significant interaction possible, monitor closely.
timolol|epinephrine|2|Significant - Monitor Closely|timolol increases and epinephrine decreases serum potassium. Effect of interaction is not clear, use caution. Potential for interaction, monitor.
tranylcypromine|epinephrine|33|Contraindicated|tranylcypromine increases effects of epinephrine by pharmacodynamic synergism. Never use combination. Risk of acute hypertensive episode.
epinephrine|trimipramine|22|Serious - Use Alternative|epinephrine and trimipramine both increase  QTc interval. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available.
trimipramine|epinephrine|20|Serious - Use Alternative|trimipramine, epinephrine. Other (see comment). Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available. Comment: Tricyclic antidepressants increase or decrease effects of sympathomimetics, by blocking reuptake of NE, or blocking uptake of indirect sympathomimetics into the adrenergic neuron.
trimipramine|epinephrine|11|Significant - Monitor Closely|trimipramine increases effects of epinephrine by unknown mechanism. Significant interaction possible, monitor closely.
trimipramine|epinephrine|2|Significant - Monitor Closely|trimipramine increases and epinephrine decreases sedation. Effect of interaction is not clear, use caution. Potential for interaction, monitor.
epinephrine|venlafaxine|3|Significant - Monitor Closely|epinephrine and venlafaxine both increase  QTc interval. Potential for dangerous interaction. Use with caution and monitor closely.
fluconazole|eplerenone|1|Minor|fluconazole will increase the level or effect of eplerenone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor or non-significant interaction.
itraconazole|eplerenone|33|Contraindicated|itraconazole will increase the level or effect of eplerenone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Never use combination. May increase the  risk of hyperkalemia and  hypotension
ketoconazole|eplerenone|21|Serious - Use Alternative|ketoconazole increases levels of eplerenone by decreasing metabolism. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available. Never use combination.
ketoconazole|eplerenone|2|Significant - Monitor Closely|ketoconazole will increase the level or effect of eplerenone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Potential for interaction, monitor.
nefazodone|eplerenone|33|Contraindicated|nefazodone will increase the level or effect of eplerenone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Never use combination.
nelfinavir|eplerenone|1|Minor|nelfinavir will increase the level or effect of eplerenone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor or non-significant interaction.
ritonavir|eplerenone|1|Minor|ritonavir will increase the level or effect of eplerenone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor or non-significant interaction.
saquinavir|eplerenone|33|Contraindicated|saquinavir increases levels of eplerenone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Never use combination. Potential for increased toxicity. .
spironolactone|eplerenone|21|Serious - Use Alternative|spironolactone, eplerenone. Mechanism: pharmacodynamic synergism. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available. Never use combination. Hyperkalemia.
telithromycin|eplerenone|1|Minor|telithromycin will increase the level or effect of eplerenone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor or non-significant interaction.
trandolapril|eplerenone|11|Significant - Monitor Closely|trandolapril, eplerenone. Mechanism: pharmacodynamic synergism. Significant interaction possible, monitor closely. Risk of hyperkalemia.
treprostinil|eplerenone|1|Minor|treprostinil increases effects of eplerenone by pharmacodynamic synergism. Minor or non-significant interaction.
triamterene|eplerenone|21|Serious - Use Alternative|triamterene, eplerenone. Mechanism: pharmacodynamic synergism. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available. Never use combination. Hyperkalemia.
troleandomycin|eplerenone|1|Minor|troleandomycin will increase the level or effect of eplerenone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor or non-significant interaction.
verapamil|eplerenone|11|Significant - Monitor Closely|verapamil will increase the level or effect of eplerenone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely. Plasma concentrations and pharmacologic or toxic effects of eplerenone may be increased by verapamil.
voriconazole|eplerenone|1|Minor|voriconazole will increase the level or effect of eplerenone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor or non-significant interaction.
eprosartan|lithium|20|Serious - Use Alternative|eprosartan increases toxicity of lithium by decreasing renal clearance. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
eprosartan|spironolactone|3|Significant - Monitor Closely|eprosartan and spironolactone both increase  serum potassium. Potential for dangerous interaction. Use with caution and monitor closely.
eprosartan|trandolapril|20|Serious - Use Alternative|eprosartan, trandolapril.Either increases toxicity of the other by pharmacodynamic synergism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available. Dual blockade of renin-angiotensin system increases risks of hypotension, hyperkalemia, and renal impairment.
treprostinil|eprosartan|2|Significant - Monitor Closely|treprostinil increases effects of eprosartan by pharmacodynamic synergism. Potential for interaction, monitor.
eprosartan|triamterene|3|Significant - Monitor Closely|eprosartan and triamterene both increase  serum potassium. Potential for dangerous interaction. Use with caution and monitor closely.
ginkgo biloba|eptifibatide|1|Minor|ginkgo biloba, eptifibatide. pharmacodynamic synergism. Minor or non-significant interaction. May prolong bleeding time.  Conflicting evidence. Use with caution.
rivaroxaban|eptifibatide|11|Significant - Monitor Closely|rivaroxaban, eptifibatide.Either increases effects of the other by anticoagulation. Significant interaction possible, monitor closely. Avoid concurrent use of rivaroxaban with other anticoagulants due to increased bleeding risk other than during therapeutic transition periods where patients should be observed closely. Monitor for signs/symptoms of blood loss.
ergonovine|frovatriptan|33|Contraindicated|ergonovine, frovatriptan.Either increases toxicity of the other by pharmacodynamic synergism. Never use combination. Additive vasospasm.  Sep. by 24h.
isosorbide dinitrate|ergonovine|20|Serious - Use Alternative|isosorbide dinitrate increases effects of ergonovine by decreasing metabolism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available. Risk of increased SBP, angina pectoris.
isosorbide mononitrate|ergonovine|20|Serious - Use Alternative|isosorbide mononitrate increases effects of ergonovine by decreasing metabolism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available. Risk of increased SBP, angina pectoris.
ergonovine|naratriptan|33|Contraindicated|ergonovine, naratriptan.Either increases toxicity of the other by pharmacodynamic synergism. Never use combination. Additive vasospasm.  Sep. by 24h.
pentaerythritol tetranitrate|ergonovine|20|Serious - Use Alternative|pentaerythritol tetranitrate increases effects of ergonovine by decreasing metabolism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available. Risk of increased SBP, angina pectoris.
ergonovine|phenylephrine|21|Serious - Use Alternative|ergonovine, phenylephrine. Mechanism: pharmacodynamic synergism. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available. Never use combination. Additive vasospasm; risk of hypertension.
ergonovine|telithromycin|21|Serious - Use Alternative|ergonovine, telithromycin. Mechanism: pharmacodynamic synergism. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available. Never use combination. Additive vasospasm.
tipranavir|ergonovine|21|Serious - Use Alternative|tipranavir increases levels of ergonovine by decreasing metabolism. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available. Never use combination.
ergonovine|zolmitriptan|33|Contraindicated|ergonovine, zolmitriptan.Either increases toxicity of the other by pharmacodynamic synergism. Never use combination. Additive vasospasm.  Sep. by 24h.
fluconazole|ergotamine|21|Serious - Use Alternative|fluconazole will increase the level or effect of ergotamine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available. Never use combination.
fluoxetine|ergotamine|3|Significant - Monitor Closely|fluoxetine and ergotamine both increase  serotonin levels. Potential for dangerous interaction. Use with caution and monitor closely.
fluvoxamine|ergotamine|21|Serious - Use Alternative|fluvoxamine will increase the level or effect of ergotamine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available. Never use combination.
fluvoxamine|ergotamine|3|Significant - Monitor Closely|fluvoxamine and ergotamine both increase  serotonin levels. Potential for dangerous interaction. Use with caution and monitor closely.
fosamprenavir|ergotamine|21|Serious - Use Alternative|fosamprenavir will increase the level or effect of ergotamine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available. Never use combination.
fosamprenavir|ergotamine|21|Serious - Use Alternative|fosamprenavir increases levels of ergotamine by decreasing metabolism. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available. Never use combination.
ergotamine|frovatriptan|33|Contraindicated|ergotamine, frovatriptan.Either increases toxicity of the other by pharmacodynamic synergism. Never use combination. Additive vasospasm.  Sep. by 24h.
frovatriptan|ergotamine|2|Significant - Monitor Closely|frovatriptan and ergotamine both increase  serotonin levels. Potential for interaction, monitor.
indinavir|ergotamine|21|Serious - Use Alternative|indinavir increases levels of ergotamine by decreasing metabolism. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available. Never use combination.
indinavir|ergotamine|20|Serious - Use Alternative|indinavir will increase the level or effect of ergotamine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
isosorbide dinitrate|ergotamine|20|Serious - Use Alternative|isosorbide dinitrate increases effects of ergotamine by decreasing metabolism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available. Risk of increased SBP, angina pectoris.
isosorbide mononitrate|ergotamine|20|Serious - Use Alternative|isosorbide mononitrate increases effects of ergotamine by decreasing metabolism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available. Risk of increased SBP, angina pectoris.
itraconazole|ergotamine|33|Contraindicated|itraconazole will increase the level or effect of ergotamine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Never use combination. Increased risk of ergotism leading to cerebral ischemia and/or ischemia of the extremities
ketoconazole|ergotamine|22|Serious - Use Alternative|ketoconazole will increase the level or effect of ergotamine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available.
ergotamine|naratriptan|33|Contraindicated|ergotamine, naratriptan.Either increases toxicity of the other by pharmacodynamic synergism. Never use combination. Additive vasospasm.  Sep. by 24h.
naratriptan|ergotamine|2|Significant - Monitor Closely|naratriptan and ergotamine both increase  serotonin levels. Potential for interaction, monitor.
nefazodone|ergotamine|22|Serious - Use Alternative|nefazodone will increase the level or effect of ergotamine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available.
nefazodone|ergotamine|3|Significant - Monitor Closely|nefazodone and ergotamine both increase  serotonin levels. Potential for dangerous interaction. Use with caution and monitor closely.
nelfinavir|ergotamine|21|Serious - Use Alternative|nelfinavir increases levels of ergotamine by decreasing metabolism. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available. Never use combination.
nelfinavir|ergotamine|20|Serious - Use Alternative|nelfinavir will increase the level or effect of ergotamine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
pentaerythritol tetranitrate|ergotamine|20|Serious - Use Alternative|pentaerythritol tetranitrate increases effects of ergotamine by decreasing metabolism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available. Risk of increased SBP, angina pectoris.
posaconazole|ergotamine|20|Serious - Use Alternative|posaconazole will increase the level or effect of ergotamine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
ritonavir|ergotamine|21|Serious - Use Alternative|ritonavir will increase the level or effect of ergotamine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available. Never use combination.
ritonavir|ergotamine|21|Serious - Use Alternative|ritonavir increases levels of ergotamine by decreasing metabolism. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available. Never use combination.
ergotamine|rizatriptan|33|Contraindicated|ergotamine, rizatriptan.Either increases toxicity of the other by pharmacodynamic synergism. Never use combination. Additive vasospasm.  Sep. by 24h.
rizatriptan|ergotamine|2|Significant - Monitor Closely|rizatriptan and ergotamine both increase  serotonin levels. Potential for interaction, monitor.
saquinavir|ergotamine|21|Serious - Use Alternative|saquinavir increases levels of ergotamine by decreasing metabolism. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available. Never use combination.
ergotamine|sumatriptan|33|Contraindicated|ergotamine, sumatriptan.Either increases toxicity of the other by pharmacodynamic synergism. Never use combination. Additive vasospasm.  Sep. by 24h.
sumatriptan|ergotamine|2|Significant - Monitor Closely|sumatriptan and ergotamine both increase  serotonin levels. Potential for interaction, monitor.
telaprevir|ergotamine|33|Contraindicated|telaprevir increases levels of ergotamine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Never use combination. Contraindicated. Potential for acute ergot toxicity characterized by peripheral vasospasm or ischemia.
telithromycin|ergotamine|21|Serious - Use Alternative|telithromycin will increase the level or effect of ergotamine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available. Never use combination.
ergotamine|telithromycin|21|Serious - Use Alternative|ergotamine, telithromycin. Mechanism: pharmacodynamic synergism. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available. Never use combination. Additive vasospasm.
tipranavir|ergotamine|21|Serious - Use Alternative|tipranavir increases levels of ergotamine by decreasing metabolism. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available. Never use combination.
ergotamine|tramadol|2|Significant - Monitor Closely|ergotamine and tramadol both increase  serotonin levels. Potential for interaction, monitor.
tranylcypromine|ergotamine|22|Serious - Use Alternative|tranylcypromine and ergotamine both increase  serotonin levels. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available.
trazodone|ergotamine|3|Significant - Monitor Closely|trazodone and ergotamine both increase  serotonin levels. Potential for dangerous interaction. Use with caution and monitor closely.
trimipramine|ergotamine|3|Significant - Monitor Closely|trimipramine and ergotamine both increase  serotonin levels. Potential for dangerous interaction. Use with caution and monitor closely.
troleandomycin|ergotamine|21|Serious - Use Alternative|troleandomycin will increase the level or effect of ergotamine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available. Never use combination.
venlafaxine|ergotamine|3|Significant - Monitor Closely|venlafaxine and ergotamine both increase  serotonin levels. Potential for dangerous interaction. Use with caution and monitor closely.
voriconazole|ergotamine|33|Contraindicated|voriconazole will increase the level or effect of ergotamine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Never use combination.
ergotamine|zolmitriptan|33|Contraindicated|ergotamine, zolmitriptan.Either increases toxicity of the other by pharmacodynamic synergism. Never use combination. Additive vasospasm.  Sep. by 24h.
zolmitriptan|ergotamine|2|Significant - Monitor Closely|zolmitriptan and ergotamine both increase  serotonin levels. Potential for interaction, monitor.
indinavir|erlotinib|11|Significant - Monitor Closely|indinavir will increase the level or effect of erlotinib by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
indinavir|erlotinib|11|Significant - Monitor Closely|indinavir will increase the level or effect of erlotinib by  P-glycoprotein (MDR1) efflux transporter. Significant interaction possible, monitor closely.
itraconazole|erlotinib|20|Serious - Use Alternative|itraconazole will increase the level or effect of erlotinib by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
itraconazole|erlotinib|11|Significant - Monitor Closely|itraconazole will increase the level or effect of erlotinib by  P-glycoprotein (MDR1) efflux transporter. Significant interaction possible, monitor closely.
ketoconazole|erlotinib|20|Serious - Use Alternative|ketoconazole will increase the level or effect of erlotinib by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
ketoconazole|erlotinib|11|Significant - Monitor Closely|ketoconazole will increase the level or effect of erlotinib by  P-glycoprotein (MDR1) efflux transporter. Significant interaction possible, monitor closely.
nefazodone|erlotinib|20|Serious - Use Alternative|nefazodone will increase the level or effect of erlotinib by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
nefazodone|erlotinib|11|Significant - Monitor Closely|nefazodone will decrease the level or effect of erlotinib by  P-glycoprotein (MDR1) efflux transporter. Significant interaction possible, monitor closely.
nelfinavir|erlotinib|11|Significant - Monitor Closely|nelfinavir will increase the level or effect of erlotinib by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
rifabutin|erlotinib|20|Serious - Use Alternative|rifabutin will decrease the level or effect of erlotinib by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
rifapentine|erlotinib|11|Significant - Monitor Closely|rifapentine will decrease the level or effect of erlotinib by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
ritonavir|erlotinib|11|Significant - Monitor Closely|ritonavir will increase the level or effect of erlotinib by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
telithromycin|erlotinib|11|Significant - Monitor Closely|telithromycin will increase the level or effect of erlotinib by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
troleandomycin|erlotinib|11|Significant - Monitor Closely|troleandomycin will increase the level or effect of erlotinib by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
voriconazole|erlotinib|11|Significant - Monitor Closely|voriconazole will increase the level or effect of erlotinib by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
frovatriptan|escitalopram|3|Significant - Monitor Closely|frovatriptan and escitalopram both increase  serotonin levels. Potential for dangerous interaction. Use with caution and monitor closely.
escitalopram|frovatriptan|1|Minor|escitalopram, frovatriptan. Mechanism: unknown. Minor or non-significant interaction. Risk of weakness, dyspnea, chest pain.
isocarboxazid|escitalopram|33|Contraindicated|isocarboxazid and escitalopram both increase  serotonin levels. Never use combination.
escitalopram|ketoprofen|11|Significant - Monitor Closely|escitalopram, ketoprofen.Either increases toxicity of the other by pharmacodynamic synergism. Significant interaction possible, monitor closely. Increased risk of upper GI bleeding. SSRIs inhib. serotonin uptake by platelets.
linezolid|escitalopram|22|Serious - Use Alternative|linezolid and escitalopram both increase  serotonin levels. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available. Linezolid may increase serotonin as a result of MAO-A inhibition. If linezolid must be administered, discontinue serotonergic drug immediately and monitor for CNS toxicity. Serotonergic therapy may be resumed 24 hours after last linezolid dose or after 2 weeks of monitoring, whichever comes first.
escitalopram|metoprolol|1|Minor|escitalopram increases levels of metoprolol by decreasing metabolism. Minor or non-significant interaction.
naratriptan|escitalopram|3|Significant - Monitor Closely|naratriptan and escitalopram both increase  serotonin levels. Potential for dangerous interaction. Use with caution and monitor closely.
escitalopram|naratriptan|1|Minor|escitalopram, naratriptan. Mechanism: unknown. Minor or non-significant interaction. Risk of weakness, dyspnea, chest pain.
oxycodone|escitalopram|3|Significant - Monitor Closely|oxycodone increases effects of escitalopram by pharmacodynamic synergism. Potential for dangerous interaction. Use with caution and monitor closely. Opioids may enhance the serotonergic effects of SSRIs and increase risk for serotonergic syndrome.
phenelzine|escitalopram|33|Contraindicated|phenelzine and escitalopram both increase  serotonin levels. Never use combination.
pimozide|escitalopram|21|Serious - Use Alternative|pimozide, escitalopram. Mechanism: unknown. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available. Never use combination. Risk of long QT syndrome.
escitalopram|propranolol|1|Minor|escitalopram increases levels of propranolol by decreasing metabolism. Minor or non-significant interaction.
rasagiline|escitalopram|20|Serious - Use Alternative|rasagiline and escitalopram both increase  serotonin levels. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available. Severe CNS toxicity associated with hyperpyrexia has been reported with the combined treatment of an antidepressant and rasagiline. Avoid combination within 14 days of MAOI use.
rizatriptan|escitalopram|3|Significant - Monitor Closely|rizatriptan and escitalopram both increase  serotonin levels. Potential for dangerous interaction. Use with caution and monitor closely.
escitalopram|rizatriptan|1|Minor|escitalopram, rizatriptan. Mechanism: unknown. Minor or non-significant interaction. Risk of weakness, dyspnea, chest pain.
selegiline|escitalopram|33|Contraindicated|selegiline and escitalopram both increase  serotonin levels. Never use combination. At least 14 days should elapse between discontinuation of selegiline and initiation of treatment with a serotonergic drug.
sumatriptan|escitalopram|3|Significant - Monitor Closely|sumatriptan and escitalopram both increase  serotonin levels. Potential for dangerous interaction. Use with caution and monitor closely.
escitalopram|sumatriptan|1|Minor|escitalopram, sumatriptan. Mechanism: unknown. Minor or non-significant interaction. Risk of weakness, dyspnea, chest pain.
telaprevir|escitalopram|11|Significant - Monitor Closely|telaprevir, escitalopram. Other (see comment). Significant interaction possible, monitor closely. Comment: Concentrations of escitalopram were decreased when co-administered with telaprevir. Selective serotonin reuptake inhibitors such as escitalopram have a wide therapeutic index, but doses may need to be adjusted when combined with telaprevir.
escitalopram|tolmetin|11|Significant - Monitor Closely|escitalopram, tolmetin.Either increases toxicity of the other by pharmacodynamic synergism. Significant interaction possible, monitor closely. Increased risk of upper GI bleeding. SSRIs inhib. serotonin uptake by platelets.
escitalopram|tramadol|3|Significant - Monitor Closely|escitalopram and tramadol both increase  serotonin levels. Potential for dangerous interaction. Use with caution and monitor closely.
tranylcypromine|escitalopram|33|Contraindicated|tranylcypromine and escitalopram both increase  serotonin levels. Never use combination.
escitalopram|trazodone|22|Serious - Use Alternative|escitalopram and trazodone both increase  serotonin levels. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available.
escitalopram|trimipramine|22|Serious - Use Alternative|escitalopram and trimipramine both increase  serotonin levels. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available.
escitalopram|venlafaxine|22|Serious - Use Alternative|escitalopram and venlafaxine both increase  serotonin levels. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available.
voriconazole|escitalopram|11|Significant - Monitor Closely|voriconazole will increase the level or effect of escitalopram by  affecting hepatic enzyme CYP2C19 metabolism. Significant interaction possible, monitor closely.
escitalopram|ziprasidone|3|Significant - Monitor Closely|escitalopram and ziprasidone both decrease  QTc interval. Potential for dangerous interaction. Use with caution and monitor closely.
zolmitriptan|escitalopram|3|Significant - Monitor Closely|zolmitriptan and escitalopram both increase  serotonin levels. Potential for dangerous interaction. Use with caution and monitor closely.
escitalopram|zolmitriptan|1|Minor|escitalopram, zolmitriptan. Mechanism: unknown. Minor or non-significant interaction. Risk of weakness, dyspnea, chest pain.
esmolol|formoterol|11|Significant - Monitor Closely|esmolol decreases effects of formoterol by pharmacodynamic antagonism. Significant interaction possible, monitor closely.
esmolol|formoterol|2|Significant - Monitor Closely|esmolol increases and formoterol decreases serum potassium. Effect of interaction is not clear, use caution. Potential for interaction, monitor.
ibuprofen|esmolol|11|Significant - Monitor Closely|ibuprofen decreases effects of esmolol by pharmacodynamic antagonism. Significant interaction possible, monitor closely. Long term (>1 wk) NSAID use.  NSAIDs decrease prostaglandin synthesis.
esmolol|ibuprofen|2|Significant - Monitor Closely|esmolol and ibuprofen both increase  serum potassium. Potential for interaction, monitor.
indomethacin|esmolol|11|Significant - Monitor Closely|indomethacin decreases effects of esmolol by pharmacodynamic antagonism. Significant interaction possible, monitor closely. Long term (>1 wk) NSAID use.  NSAIDs decrease prostaglandin synthesis.
esmolol|indomethacin|2|Significant - Monitor Closely|esmolol and indomethacin both increase  serum potassium. Potential for interaction, monitor.
esmolol|pirbuterol|11|Significant - Monitor Closely|esmolol decreases effects of pirbuterol by pharmacodynamic antagonism. Significant interaction possible, monitor closely.
esmolol|pirbuterol|2|Significant - Monitor Closely|esmolol increases and pirbuterol decreases serum potassium. Effect of interaction is not clear, use caution. Potential for interaction, monitor.
piroxicam|esmolol|11|Significant - Monitor Closely|piroxicam decreases effects of esmolol by pharmacodynamic antagonism. Significant interaction possible, monitor closely. Long term (>1 wk) NSAID use.  NSAIDs decrease prostaglandin synthesis.
esmolol|piroxicam|2|Significant - Monitor Closely|esmolol and piroxicam both increase  serum potassium. Potential for interaction, monitor.
prazosin|esmolol|3|Significant - Monitor Closely|prazosin and esmolol both increase  anti-hypertensive channel blocking. Potential for dangerous interaction. Use with caution and monitor closely. The severity and duration of hypotension following the first dose of prazosin may be enhanced.
esmolol|salmeterol|11|Significant - Monitor Closely|esmolol decreases effects of salmeterol by pharmacodynamic antagonism. Significant interaction possible, monitor closely.
esmolol|salmeterol|2|Significant - Monitor Closely|esmolol increases and salmeterol decreases serum potassium. Effect of interaction is not clear, use caution. Potential for interaction, monitor.
terazosin|esmolol|3|Significant - Monitor Closely|terazosin and esmolol both increase  anti-hypertensive channel blocking. Potential for dangerous interaction. Use with caution and monitor closely. Additive hypotensive effects may occur when terazosin is used in combination with esmolol.
esmolol|terbutaline|11|Significant - Monitor Closely|esmolol decreases effects of terbutaline by pharmacodynamic antagonism. Significant interaction possible, monitor closely.
esmolol|terbutaline|2|Significant - Monitor Closely|esmolol increases and terbutaline decreases serum potassium. Effect of interaction is not clear, use caution. Potential for interaction, monitor.
treprostinil|esmolol|1|Minor|treprostinil increases effects of esmolol by pharmacodynamic synergism. Minor or non-significant interaction.
verapamil|esmolol|20|Serious - Use Alternative|verapamil, esmolol.Either increases toxicity of the other by unspecified interaction mechanism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available. Can increase risk of bradycardia.
esmolol|verapamil|3|Significant - Monitor Closely|esmolol and verapamil both increase  anti-hypertensive channel blocking. Potential for dangerous interaction. Use with caution and monitor closely.
esomeprazole|indinavir|20|Serious - Use Alternative|esomeprazole will decrease the level or effect of indinavir by  increasing gastric pH. Applies only to oral form of both agents. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
esomeprazole|itraconazole|20|Serious - Use Alternative|esomeprazole will decrease the level or effect of itraconazole by  increasing gastric pH. Applies only to oral form of both agents. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
esomeprazole|ketoconazole|20|Serious - Use Alternative|esomeprazole will decrease the level or effect of ketoconazole by  increasing gastric pH. Applies only to oral form of both agents. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
esomeprazole|rilpivirine|33|Contraindicated|esomeprazole decreases levels of rilpivirine by increasing gastric pH. Applies only to oral form of both agents. Never use combination. Contraindicated. Concurrent use may cause treatment failure and/or the development of rilpivirine or NNRTI resistance. Coadministration of a PPI and rilpivirine may result in decreased rilpivirine plasma concentrations, which could cause impaired virologic response to rilpivirine.
itraconazole|estazolam|3|Significant - Monitor Closely|itraconazole will increase the level or effect of estazolam by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Potential for dangerous interaction. Use with caution and monitor closely.
omeprazole|estazolam|1|Minor|omeprazole increases levels of estazolam by decreasing metabolism. Minor or non-significant interaction.
triprolidine|estazolam|2|Significant - Monitor Closely|triprolidine and estazolam both increase  sedation. Potential for interaction, monitor.
ethotoin|estradiol|11|Significant - Monitor Closely|ethotoin will decrease the level or effect of estradiol by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
ethotoin|estradiol|11|Significant - Monitor Closely|ethotoin will decrease the level or effect of estradiol by  P-glycoprotein (MDR1) efflux transporter. Significant interaction possible, monitor closely.
fosphenytoin|estradiol|11|Significant - Monitor Closely|fosphenytoin will decrease the level or effect of estradiol by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
fosphenytoin|estradiol|11|Significant - Monitor Closely|fosphenytoin will decrease the level or effect of estradiol by  P-glycoprotein (MDR1) efflux transporter. Significant interaction possible, monitor closely.
griseofulvin|estradiol|11|Significant - Monitor Closely|griseofulvin will decrease the level or effect of estradiol by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
hexobarbital|estradiol|11|Significant - Monitor Closely|hexobarbital will decrease the level or effect of estradiol by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
pentobarbital|estradiol|11|Significant - Monitor Closely|pentobarbital will decrease the level or effect of estradiol by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
phenobarbital|estradiol|11|Significant - Monitor Closely|phenobarbital will decrease the level or effect of estradiol by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
phenobarbital|estradiol|11|Significant - Monitor Closely|phenobarbital will decrease the level or effect of estradiol by  P-glycoprotein (MDR1) efflux transporter. Significant interaction possible, monitor closely.
phenytoin|estradiol|11|Significant - Monitor Closely|phenytoin will decrease the level or effect of estradiol by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
phenytoin|estradiol|11|Significant - Monitor Closely|phenytoin will decrease the level or effect of estradiol by  P-glycoprotein (MDR1) efflux transporter. Significant interaction possible, monitor closely.
prednisolone|estradiol|11|Significant - Monitor Closely|prednisolone will decrease the level or effect of estradiol by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
prednisone|estradiol|11|Significant - Monitor Closely|prednisone will decrease the level or effect of estradiol by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
primidone|estradiol|11|Significant - Monitor Closely|primidone will decrease the level or effect of estradiol by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
secobarbital|estradiol|11|Significant - Monitor Closely|secobarbital will decrease the level or effect of estradiol by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
fosphenytoin|estropipate|11|Significant - Monitor Closely|fosphenytoin will decrease the level or effect of estropipate by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
fosphenytoin|estropipate|11|Significant - Monitor Closely|fosphenytoin will decrease the level or effect of estropipate by  P-glycoprotein (MDR1) efflux transporter. Significant interaction possible, monitor closely.
griseofulvin|estropipate|11|Significant - Monitor Closely|griseofulvin will decrease the level or effect of estropipate by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
phenobarbital|estropipate|11|Significant - Monitor Closely|phenobarbital will decrease the level or effect of estropipate by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
phenobarbital|estropipate|11|Significant - Monitor Closely|phenobarbital will decrease the level or effect of estropipate by  P-glycoprotein (MDR1) efflux transporter. Significant interaction possible, monitor closely.
phenytoin|estropipate|11|Significant - Monitor Closely|phenytoin will decrease the level or effect of estropipate by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
phenytoin|estropipate|11|Significant - Monitor Closely|phenytoin will decrease the level or effect of estropipate by  P-glycoprotein (MDR1) efflux transporter. Significant interaction possible, monitor closely.  If the estrogen is being used for contraception then loss of contraception may occur.
prednisolone|estropipate|11|Significant - Monitor Closely|prednisolone will decrease the level or effect of estropipate by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
prednisone|estropipate|11|Significant - Monitor Closely|prednisone will decrease the level or effect of estropipate by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
primidone|estropipate|11|Significant - Monitor Closely|primidone will decrease the level or effect of estropipate by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
voriconazole|eszopiclone|3|Significant - Monitor Closely|voriconazole increases levels of eszopiclone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Potential for dangerous interaction. Use with caution and monitor closely. Reduce eszopiclone starting dose to 1 mg/day.
etanercept|infliximab|22|Serious - Use Alternative|etanercept and infliximab both increase  immunosuppressive effects; risk of infection. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available.
etanercept|leflunomide|22|Serious - Use Alternative|etanercept and leflunomide both increase  immunosuppressive effects; risk of infection. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available.
etanercept|rilonacept|22|Serious - Use Alternative|etanercept and rilonacept both increase  immunosuppressive effects; risk of infection. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available.
etanercept|sipuleucel-t|3|Significant - Monitor Closely|etanercept decreases effects of sipuleucel-t by pharmacodynamic antagonism. Potential for dangerous interaction. Use with caution and monitor closely.
etanercept|tacrolimus|22|Serious - Use Alternative|etanercept and tacrolimus both increase  immunosuppressive effects; risk of infection. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available.
tocilizumab|etanercept|22|Serious - Use Alternative|tocilizumab and etanercept both increase  immunosuppressive effects; risk of infection. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available.
tocilizumab|etanercept|20|Serious - Use Alternative|tocilizumab, etanercept.Either increases effects of the other by pharmacodynamic synergism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available. Additive immunosuppression; risk of serious infection.
etanercept|tofacitinib|20|Serious - Use Alternative|etanercept, tofacitinib.Either increases toxicity of the other by immunosuppressive effects; risk of infection. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
ethacrynic acid|gentamicin|20|Serious - Use Alternative|ethacrynic acid, gentamicin.Either increases toxicity of the other by Mechanism: pharmacodynamic synergism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available. Increased risk of ototoxicity and nephrotoxicity.
ethacrynic acid|gentamicin|2|Significant - Monitor Closely|ethacrynic acid and gentamicin both decrease  serum potassium. Potential for interaction, monitor.
ibuprofen|ethacrynic acid|2|Significant - Monitor Closely|ibuprofen increases and ethacrynic acid decreases serum potassium. Effect of interaction is not clear, use caution. Potential for interaction, monitor.
indomethacin|ethacrynic acid|2|Significant - Monitor Closely|indomethacin increases and ethacrynic acid decreases serum potassium. Effect of interaction is not clear, use caution. Potential for interaction, monitor.
ethacrynic acid|kanamycin|20|Serious - Use Alternative|ethacrynic acid, kanamycin.Either increases toxicity of the other by Mechanism: pharmacodynamic synergism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available. Increased risk of ototoxicity and nephrotoxicity.
ethacrynic acid|netilmicin|20|Serious - Use Alternative|ethacrynic acid, netilmicin.Either increases toxicity of the other by Mechanism: pharmacodynamic synergism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available. Increased risk of ototoxicity and nephrotoxicity.
ethacrynic acid|streptomycin|20|Serious - Use Alternative|ethacrynic acid, streptomycin.Either increases toxicity of the other by Mechanism: pharmacodynamic synergism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available. Increased risk of ototoxicity and nephrotoxicity.
sulindac|ethacrynic acid|2|Significant - Monitor Closely|sulindac increases and ethacrynic acid decreases serum potassium. Effect of interaction is not clear, use caution. Potential for interaction, monitor.
ethacrynic acid|tobramycin|20|Serious - Use Alternative|ethacrynic acid, tobramycin.Either increases toxicity of the other by Mechanism: pharmacodynamic synergism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available. Increased risk of ototoxicity and nephrotoxicity.
trandolapril|ethacrynic acid|11|Significant - Monitor Closely|trandolapril, ethacrynic acid. Mechanism: pharmacodynamic synergism. Significant interaction possible, monitor closely. Risk of acute hypotension, renal insufficiency.
treprostinil|ethacrynic acid|1|Minor|treprostinil increases effects of ethacrynic acid by pharmacodynamic synergism. Minor or non-significant interaction.
perampanel|ethanol|11|Significant - Monitor Closely|perampanel and ethanol both increase  sedation. Significant interaction possible, monitor closely.
triprolidine|ethanol|2|Significant - Monitor Closely|triprolidine and ethanol both increase  sedation. Potential for interaction, monitor.
felbamate|ethotoin|11|Significant - Monitor Closely|felbamate will increase the level or effect of ethotoin by  affecting hepatic enzyme CYP2C9/10 metabolism. Significant interaction possible, monitor closely.
ethotoin|felbamate|1|Minor|ethotoin decreases levels of felbamate by increasing metabolism. Minor or non-significant interaction. Toxicity increased with combination.
ethotoin|felodipine|11|Significant - Monitor Closely|ethotoin will decrease the level or effect of felodipine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
ethotoin|felodipine|11|Significant - Monitor Closely|ethotoin decreases levels of felodipine by increasing metabolism. Significant interaction possible, monitor closely.
fluconazole|ethotoin|11|Significant - Monitor Closely|fluconazole will increase the level or effect of ethotoin by  affecting hepatic enzyme CYP2C9/10 metabolism. Significant interaction possible, monitor closely.
ethotoin|fludrocortisone|11|Significant - Monitor Closely|ethotoin will decrease the level or effect of fludrocortisone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
ethotoin|fludrocortisone|11|Significant - Monitor Closely|ethotoin will decrease the level or effect of fludrocortisone by  P-glycoprotein (MDR1) efflux transporter. Significant interaction possible, monitor closely.
fluorouracil|ethotoin|11|Significant - Monitor Closely|fluorouracil increases levels of ethotoin by unknown mechanism. Significant interaction possible, monitor closely. Based on case reports.
fluoxetine|ethotoin|11|Significant - Monitor Closely|fluoxetine will increase the level or effect of ethotoin by  affecting hepatic enzyme CYP2C9/10 metabolism. Significant interaction possible, monitor closely.
fluvoxamine|ethotoin|11|Significant - Monitor Closely|fluvoxamine will increase the level or effect of ethotoin by  affecting hepatic enzyme CYP2C9/10 metabolism. Significant interaction possible, monitor closely.
folic acid|ethotoin|1|Minor|folic acid decreases levels of ethotoin by increasing metabolism. Minor or non-significant interaction. Large doses of folic acid (>10 mg/day).
ethotoin|furosemide|1|Minor|ethotoin decreases levels of furosemide by inhibition of GI absorption. Applies only to oral form of both agents. Minor or non-significant interaction.
ethotoin|hydrocortisone|11|Significant - Monitor Closely|ethotoin will decrease the level or effect of hydrocortisone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
ethotoin|hydrocortisone|11|Significant - Monitor Closely|ethotoin will decrease the level or effect of hydrocortisone by  P-glycoprotein (MDR1) efflux transporter. Significant interaction possible, monitor closely.
imatinib|ethotoin|11|Significant - Monitor Closely|imatinib will increase the level or effect of ethotoin by  affecting hepatic enzyme CYP2C9/10 metabolism. Significant interaction possible, monitor closely.
ethotoin|imatinib|11|Significant - Monitor Closely|ethotoin will decrease the level or effect of imatinib by  P-glycoprotein (MDR1) efflux transporter. Significant interaction possible, monitor closely.
ethotoin|imatinib|1|Minor|ethotoin will decrease the level or effect of imatinib by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor or non-significant interaction.
isoniazid|ethotoin|1|Minor|isoniazid increases levels of ethotoin by decreasing metabolism. Minor or non-significant interaction.
ethotoin|itraconazole|20|Serious - Use Alternative|ethotoin decreases levels of itraconazole by increasing metabolism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
itraconazole|ethotoin|11|Significant - Monitor Closely|itraconazole will increase the level or effect of ethotoin by  affecting hepatic enzyme CYP2C9/10 metabolism. Significant interaction possible, monitor closely.
ethotoin|itraconazole|11|Significant - Monitor Closely|ethotoin will decrease the level or effect of itraconazole by  P-glycoprotein (MDR1) efflux transporter. Significant interaction possible, monitor closely.
ethotoin|itraconazole|1|Minor|ethotoin will decrease the level or effect of itraconazole by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor or non-significant interaction.
ethotoin|lamotrigine|11|Significant - Monitor Closely|ethotoin decreases levels of lamotrigine by increasing metabolism. Significant interaction possible, monitor closely.
ethotoin|mebendazole|21|Serious - Use Alternative|ethotoin decreases levels of mebendazole by increasing metabolism. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available. Never use combination.
ethotoin|methadone|21|Serious - Use Alternative|ethotoin decreases levels of methadone by increasing metabolism. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available. Never use combination.
ethotoin|methadone|11|Significant - Monitor Closely|ethotoin will decrease the level or effect of methadone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
ethotoin|mexiletine|11|Significant - Monitor Closely|ethotoin decreases levels of mexiletine by increasing metabolism. Significant interaction possible, monitor closely.
ethotoin|midazolam|11|Significant - Monitor Closely|ethotoin will decrease the level or effect of midazolam by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
ethotoin|oxcarbazepine|1|Minor|ethotoin decreases levels of oxcarbazepine by increasing metabolism. Minor or non-significant interaction.
ethotoin|prednisolone|11|Significant - Monitor Closely|ethotoin will decrease the level or effect of prednisolone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
ethotoin|prednisolone|11|Significant - Monitor Closely|ethotoin will decrease the level or effect of prednisolone by  P-glycoprotein (MDR1) efflux transporter. Significant interaction possible, monitor closely.
ethotoin|prednisone|11|Significant - Monitor Closely|ethotoin will decrease the level or effect of prednisone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
ethotoin|prednisone|11|Significant - Monitor Closely|ethotoin will decrease the level or effect of prednisone by  P-glycoprotein (MDR1) efflux transporter. Significant interaction possible, monitor closely.
ethotoin|quetiapine|11|Significant - Monitor Closely|ethotoin will decrease the level or effect of quetiapine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
ethotoin|theophylline|11|Significant - Monitor Closely|ethotoin will decrease the level or effect of theophylline by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
ticlopidine|ethotoin|11|Significant - Monitor Closely|ticlopidine will increase the level or effect of ethotoin by  affecting hepatic enzyme CYP2C9/10 metabolism. Significant interaction possible, monitor closely.
ethotoin|triamcinolone|11|Significant - Monitor Closely|ethotoin will decrease the level or effect of triamcinolone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
ethotoin|triamcinolone|11|Significant - Monitor Closely|ethotoin will decrease the level or effect of triamcinolone by  P-glycoprotein (MDR1) efflux transporter. Significant interaction possible, monitor closely.
ethotoin|triazolam|11|Significant - Monitor Closely|ethotoin will decrease the level or effect of triazolam by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
etodolac|ginkgo biloba|2|Significant - Monitor Closely|etodolac and ginkgo biloba both increase  anticoagulation. Potential for interaction, monitor.
etodolac|methotrexate|20|Serious - Use Alternative|etodolac increases levels of methotrexate by decreasing renal clearance. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available. Concomitant administration of NSAIDs with high dose methotrexate has been reported to elevate and prolong serum methotrexate levels, resulting in deaths from severe hematologic and GI toxicity. NSAIDs may reduce tubular secretion of methotrexate and enhance toxicity. .
etodolac|pralatrexate|11|Significant - Monitor Closely|etodolac increases levels of pralatrexate by decreasing renal clearance. Significant interaction possible, monitor closely. NSAIDs may delay pralatrexate clearance, increasing drug exposure. Adjust the pralatrexate dose as needed.
etodolac|timolol|11|Significant - Monitor Closely|etodolac decreases effects of timolol by pharmacodynamic antagonism. Significant interaction possible, monitor closely. Long term (>1 wk) NSAID use.  NSAIDs decrease prostaglandin synthesis.
timolol|etodolac|2|Significant - Monitor Closely|timolol and etodolac both increase  serum potassium. Potential for interaction, monitor.
trandolapril|etodolac|11|Significant - Monitor Closely|trandolapril, etodolac.Either increases toxicity of the other by Other (see comment). Significant interaction possible, monitor closely. Comment: May result in renal function deterioration, particularly in elderly or volume depleted individuals.
etodolac|trandolapril|3|Significant - Monitor Closely|etodolac decreases effects of trandolapril by pharmacodynamic antagonism. Potential for dangerous interaction. Use with caution and monitor closely. NSAIDs decrease synthesis of vasodilating renal prostaglandins, and thus affect fluid homeostasis and may diminish antihypertenisve effect.
warfarin|etodolac|3|Significant - Monitor Closely|warfarin and etodolac both increase  anticoagulation. Potential for dangerous interaction. Use with caution and monitor closely.
telithromycin|etoposide|2|Significant - Monitor Closely|telithromycin will increase the level or effect of etoposide by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Potential for interaction, monitor.
voriconazole|etoposide|2|Significant - Monitor Closely|voriconazole will increase the level or effect of etoposide by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Potential for interaction, monitor.
etoricoxib|lithium|11|Significant - Monitor Closely|etoricoxib increases levels of lithium by decreasing renal clearance. Significant interaction possible, monitor closely.
warfarin|etoricoxib|3|Significant - Monitor Closely|warfarin and etoricoxib both increase  anticoagulation. Potential for dangerous interaction. Use with caution and monitor closely.
etravirine|everolimus|21|Serious - Use Alternative|etravirine will decrease the level or effect of everolimus by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available. Never use combination.
etravirine|exemestane|2|Significant - Monitor Closely|etravirine will decrease the level or effect of exemestane by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Potential for interaction, monitor.
etravirine|fluvastatin|1|Minor|etravirine will increase the level or effect of fluvastatin by  affecting hepatic enzyme CYP2C9/10 metabolism. Minor or non-significant interaction.
etravirine|fosamprenavir|33|Contraindicated|etravirine increases levels of fosamprenavir by decreasing metabolism. Never use combination. Etravirine should not be co-administered with fosamprenavir, either with or without low-dose ritonavir.
fosamprenavir|etravirine|11|Significant - Monitor Closely|fosamprenavir will increase the level or effect of etravirine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
etravirine|fosphenytoin|11|Significant - Monitor Closely|etravirine will increase the level or effect of fosphenytoin by  affecting hepatic enzyme CYP2C9/10 metabolism. Significant interaction possible, monitor closely.
fosphenytoin|etravirine|11|Significant - Monitor Closely|fosphenytoin will decrease the level or effect of etravirine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
etravirine|guanfacine|11|Significant - Monitor Closely|etravirine will decrease the level or effect of guanfacine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
etravirine|ifosfamide|11|Significant - Monitor Closely|etravirine increases levels of ifosfamide by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely. Potential for increased toxicity. CYP inducers may accelerate conversion of ifosfamide to active metabolite and increase toxicity. .
imatinib|etravirine|11|Significant - Monitor Closely|imatinib will increase the level or effect of etravirine by  affecting hepatic enzyme CYP2C9/10 metabolism. Significant interaction possible, monitor closely.
etravirine|imatinib|1|Minor|etravirine will decrease the level or effect of imatinib by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor or non-significant interaction.
etravirine|ivacaftor|22|Serious - Use Alternative|etravirine decreases levels of ivacaftor by affecting hepatic/intestinal enzyme CYP3A4 metabolism. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available. Avoid coadministration with strong CYP3A4 inducers; systemic exposure of ivacaftor substantially reduced (ie, ~9-fold).
ivacaftor|etravirine|20|Serious - Use Alternative|ivacaftor increases levels of etravirine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available. Ivacaftor and its M1 metabolite has the potential to inhibit CYP3A4, may significantly increase systemic exposure to CYP3A4 substrates.
ketoconazole|etravirine|20|Serious - Use Alternative|ketoconazole will increase the level or effect of etravirine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
ketoconazole|etravirine|11|Significant - Monitor Closely|ketoconazole will increase the level or effect of etravirine by  affecting hepatic enzyme CYP2C9/10 metabolism. Significant interaction possible, monitor closely.
etravirine|ketoconazole|1|Minor|etravirine will decrease the level or effect of ketoconazole by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor or non-significant interaction.
lapatinib|etravirine|11|Significant - Monitor Closely|lapatinib will increase the level or effect of etravirine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
etravirine|linagliptin|11|Significant - Monitor Closely|etravirine will decrease the level or effect of linagliptin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
etravirine|lopinavir|11|Significant - Monitor Closely|etravirine will decrease the level or effect of lopinavir by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
etravirine|lovastatin|20|Serious - Use Alternative|etravirine will decrease the level or effect of lovastatin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
etravirine|lurasidone|33|Contraindicated|etravirine decreases levels of lurasidone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Never use combination. Contraindicated; decreases lurasidone Cmax by ~85%.
etravirine|maraviroc|11|Significant - Monitor Closely|etravirine will decrease the level or effect of maraviroc by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
etravirine|methadone|11|Significant - Monitor Closely|etravirine will decrease the level or effect of methadone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
etravirine|mifepristone|11|Significant - Monitor Closely|etravirine will decrease the level or effect of mifepristone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely. CYP3A4 inducers have not been studied, coadministration not recommended by manufacturer
nevirapine|etravirine|33|Contraindicated|nevirapine decreases levels of etravirine by increasing metabolism. Never use combination. Mfr.'s PI recommends not combining etravirine with other NNRTIs.
nevirapine|etravirine|11|Significant - Monitor Closely|nevirapine will decrease the level or effect of etravirine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
nifedipine|etravirine|11|Significant - Monitor Closely|nifedipine will increase the level or effect of etravirine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
etravirine|nifedipine|3|Significant - Monitor Closely|etravirine will decrease the level or effect of nifedipine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Potential for dangerous interaction. Use with caution and monitor closely.
nilotinib|etravirine|11|Significant - Monitor Closely|nilotinib will increase the level or effect of etravirine by  affecting hepatic enzyme CYP2C9/10 metabolism. Significant interaction possible, monitor closely.
nilotinib|etravirine|11|Significant - Monitor Closely|nilotinib will increase the level or effect of etravirine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
etravirine|nisoldipine|11|Significant - Monitor Closely|etravirine will decrease the level or effect of nisoldipine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
etravirine|paclitaxel|1|Minor|etravirine will decrease the level or effect of paclitaxel by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor or non-significant interaction.
etravirine|pazopanib|11|Significant - Monitor Closely|etravirine will decrease the level or effect of pazopanib by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
etravirine|perampanel|20|Serious - Use Alternative|etravirine will decrease the level or effect of perampanel by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
phenobarbital|etravirine|33|Contraindicated|phenobarbital decreases levels of etravirine by increasing metabolism. Never use combination.
phenobarbital|etravirine|11|Significant - Monitor Closely|phenobarbital will decrease the level or effect of etravirine by  affecting hepatic enzyme CYP2C19 metabolism. Significant interaction possible, monitor closely.
phenobarbital|etravirine|11|Significant - Monitor Closely|phenobarbital will decrease the level or effect of etravirine by  affecting hepatic enzyme CYP2C9/10 metabolism. Significant interaction possible, monitor closely.
phenobarbital|etravirine|11|Significant - Monitor Closely|phenobarbital will decrease the level or effect of etravirine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
phenytoin|etravirine|20|Serious - Use Alternative|phenytoin will decrease the level or effect of etravirine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available. Etravirine and phenytoin should not be coadministered. Concomitant use of etravirine and phenytoin may result in decreased etravirine plasma concentrations and loss of therapeutic effect of etravirine.
phenytoin|etravirine|20|Serious - Use Alternative|phenytoin will decrease the level or effect of etravirine by  increasing metabolism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available. Concomitant use of etravirine and phenytoin may result in decreased etravirine plasma concentrations and loss of therapeutic effect of etravirine.
etravirine|phenytoin|20|Serious - Use Alternative|etravirine will increase the level or effect of phenytoin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available. Etravirine and phenytoin should not be coadministered. Concomitant use of etravirine and phenytoin may result in decreased etravirine plasma concentrations and loss of therapeutic effect of etravirine. In addition, etravirine may inhibit the CYP metabolism of phenytoin, resulting in increased phenytoin concentrations.
phenytoin|etravirine|20|Serious - Use Alternative|phenytoin will decrease the level or effect of etravirine by  affecting hepatic enzyme CYP2C9/10 metabolism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
etravirine|praziquantel|33|Contraindicated|etravirine will decrease the level or effect of praziquantel by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Never use combination. Etravirine should be discontinued 2 weeks prior to starting praziquantel. Etravirine may be restarted one day after last praziquantel dose.
primidone|etravirine|11|Significant - Monitor Closely|primidone will decrease the level or effect of etravirine by  affecting hepatic enzyme CYP2C19 metabolism. Significant interaction possible, monitor closely.
primidone|etravirine|11|Significant - Monitor Closely|primidone will decrease the level or effect of etravirine by  affecting hepatic enzyme CYP2C9/10 metabolism. Significant interaction possible, monitor closely.
primidone|etravirine|11|Significant - Monitor Closely|primidone will decrease the level or effect of etravirine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
etravirine|propafenone|1|Minor|etravirine will decrease the level or effect of propafenone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor or non-significant interaction.
etravirine|quetiapine|11|Significant - Monitor Closely|etravirine will decrease the level or effect of quetiapine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
etravirine|quinidine|11|Significant - Monitor Closely|etravirine will decrease the level or effect of quinidine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
rifabutin|etravirine|20|Serious - Use Alternative|rifabutin will decrease the level or effect of etravirine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
etravirine|rilpivirine|33|Contraindicated|etravirine decreases levels of rilpivirine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Never use combination. Contraindicated. Rilpivirine should not be used in combination with NNRTIs.
etravirine|roflumilast|33|Contraindicated|etravirine will decrease the level or effect of roflumilast by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Never use combination. Coadministration not recommended; strong cytochrome P450 enzyme inducers decrease systemic exposure to roflumilast and may reduce the therapeutic effectiveness
etravirine|romidepsin|22|Serious - Use Alternative|etravirine will decrease the level or effect of romidepsin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available. Coadministration with strong 3A4 inducers should be avoided if possible.
etravirine|saquinavir|11|Significant - Monitor Closely|etravirine will decrease the level or effect of saquinavir by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
etravirine|sildenafil|20|Serious - Use Alternative|etravirine will decrease the level or effect of sildenafil by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available. Potent CYP3A4 inducers are expected to cause substantial decreases in sildenafil plasma levels
etravirine|simvastatin|20|Serious - Use Alternative|etravirine will decrease the level or effect of simvastatin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
etravirine|sorafenib|11|Significant - Monitor Closely|etravirine will decrease the level or effect of sorafenib by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
etravirine|telaprevir|20|Serious - Use Alternative|etravirine decreases levels of telaprevir by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
etravirine|ticagrelor|11|Significant - Monitor Closely|etravirine decreases levels of ticagrelor by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely. Avoid use of ticagrelor with potent CYP3A inducers.
tipranavir|etravirine|33|Contraindicated|tipranavir will decrease the level or effect of etravirine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Never use combination. Tipranavir boosted with ritonavir may cause a significant decrease in the plasma concentrations of etravirine and loss of therapeutic effect
etravirine|tolterodine|11|Significant - Monitor Closely|etravirine will decrease the level or effect of tolterodine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
etravirine|tolvaptan|21|Serious - Use Alternative|etravirine will decrease the level or effect of tolvaptan by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available. Never use combination.
etravirine|toremifene|11|Significant - Monitor Closely|etravirine decreases levels of toremifene by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely. CYP3A4 inducers increase rate of toremifene metabolism, lowering the steady-state concentration in serum.
etravirine|tramadol|2|Significant - Monitor Closely|etravirine will decrease the level or effect of tramadol by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Potential for interaction, monitor.
etravirine|trazodone|22|Serious - Use Alternative|etravirine will decrease the level or effect of trazodone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available.
etravirine|vandetanib|33|Contraindicated|etravirine decreases levels of vandetanib by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Never use combination. Avoid coadministration with potent CYP3A4 inducers; these drugs reduce exposure to vandetanib by up to 40%.
etravirine|vincristine|1|Minor|etravirine will decrease the level or effect of vincristine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor or non-significant interaction.
voriconazole|etravirine|20|Serious - Use Alternative|voriconazole will increase the level or effect of etravirine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
voriconazole|etravirine|11|Significant - Monitor Closely|voriconazole will increase the level or effect of etravirine by  affecting hepatic enzyme CYP2C19 metabolism. Significant interaction possible, monitor closely.
voriconazole|etravirine|11|Significant - Monitor Closely|voriconazole will increase the level or effect of etravirine by  affecting hepatic enzyme CYP2C9/10 metabolism. Significant interaction possible, monitor closely.
etravirine|voriconazole|1|Minor|etravirine will increase the level or effect of voriconazole by  affecting hepatic enzyme CYP2C19 metabolism. Minor or non-significant interaction.
etravirine|voriconazole|1|Minor|etravirine will increase the level or effect of voriconazole by  affecting hepatic enzyme CYP2C9/10 metabolism. Minor or non-significant interaction.
fluconazole|everolimus|21|Serious - Use Alternative|fluconazole will increase the level or effect of everolimus by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available. Never use combination.
itraconazole|everolimus|22|Serious - Use Alternative|itraconazole will increase the level or effect of everolimus by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available.
itraconazole|everolimus|21|Serious - Use Alternative|itraconazole will increase the level or effect of everolimus by  P-glycoprotein (MDR1) efflux transporter. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available. Never use combination.
ketoconazole|everolimus|22|Serious - Use Alternative|ketoconazole will increase the level or effect of everolimus by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available.
ketoconazole|everolimus|21|Serious - Use Alternative|ketoconazole will increase the level or effect of everolimus by  P-glycoprotein (MDR1) efflux transporter. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available. Never use combination.
everolimus|rilonacept|22|Serious - Use Alternative|everolimus and rilonacept both increase  immunosuppressive effects; risk of infection. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available.
verapamil|everolimus|11|Significant - Monitor Closely|verapamil will increase the level or effect of everolimus by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely. Concomitant use of a moderate 3A4 inhibitor such as verapamil may significantly increase the plasma concentrations of everolimus following oral administration.
verapamil|everolimus|11|Significant - Monitor Closely|verapamil will increase the level or effect of everolimus by  P-glycoprotein (MDR1) efflux transporter. Significant interaction possible, monitor closely. Everolimus prescribing information lists indication-specific dosing recommendations.
everolimus|verapamil|11|Significant - Monitor Closely|everolimus will increase the level or effect of verapamil by  P-glycoprotein (MDR1) efflux transporter. Significant interaction possible, monitor closely. Everolimus prescribing information lists indication-specific dosing recommendations.
voriconazole|everolimus|21|Serious - Use Alternative|voriconazole will increase the level or effect of everolimus by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available. Never use combination.
ezogabine|lamotrigine|1|Minor|ezogabine decreases levels of lamotrigine by Other (see comment). Minor or non-significant interaction. Comment: Ezogabine may induce glucuronidation that results in small decreases of trough levels.
ezogabine|ondansetron|20|Serious - Use Alternative|ezogabine and ondansetron both increase  QTc interval. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.  Avoid with congenital long QT syndrome; ECG monitoring recommended with concomitant medications that prolong QT interval, electrolyte abnormalities, CHF, or bradyarrhythmias.
phenytoin|ezogabine|1|Minor|phenytoin decreases levels of ezogabine by Mechanism: unknown. Minor or non-significant interaction. Upon discontinuation of phenytoin, ezogabine clearance decreased by approximately 30%. Consider an increase in the ezogabine dose during concurrent use.
famotidine|itraconazole|20|Serious - Use Alternative|famotidine will decrease the level or effect of itraconazole by  increasing gastric pH. Applies only to oral form of both agents. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
famotidine|ketoconazole|20|Serious - Use Alternative|famotidine will decrease the level or effect of ketoconazole by  increasing gastric pH. Applies only to oral form of both agents. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
famotidine|rilpivirine|11|Significant - Monitor Closely|famotidine, rilpivirine. increasing gastric pH. Applies only to oral form of both agents. Significant interaction possible, monitor closely. Combination of rilpivirine and H2-receptor antagonists should be used with caution as coadministration may cause significant decreases in rilpivirine plasma concentrations (increase in gastric pH). Administer famotidine at least 12 hours before or at least 4 hours after rilpivirine.
febuxostat|mercaptopurine|33|Contraindicated|febuxostat increases levels of mercaptopurine by decreasing metabolism. Never use combination. Potential for increased myelosuppression.
febuxostat|theophylline|33|Contraindicated|febuxostat increases levels of theophylline by decreasing metabolism. Never use combination.
felbamate|fosphenytoin|11|Significant - Monitor Closely|felbamate will increase the level or effect of fosphenytoin by  affecting hepatic enzyme CYP2C9/10 metabolism. Significant interaction possible, monitor closely.
fosphenytoin|felbamate|1|Minor|fosphenytoin decreases levels of felbamate by increasing metabolism. Minor or non-significant interaction. Toxicity increased with combination.
felbamate|phenobarbital|1|Minor|felbamate increases levels of phenobarbital by decreasing metabolism. Minor or non-significant interaction.
felbamate|phenytoin|11|Significant - Monitor Closely|felbamate will increase the level or effect of phenytoin by  affecting hepatic enzyme CYP2C9/10 metabolism. Significant interaction possible, monitor closely.
phenytoin|felbamate|1|Minor|phenytoin decreases levels of felbamate by increasing metabolism. Minor or non-significant interaction. Toxicity increased with combination.
felbamate|ulipristal|20|Serious - Use Alternative|felbamate will decrease the level or effect of ulipristal by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
valproic acid|felbamate|1|Minor|valproic acid increases levels of felbamate by decreasing metabolism. Minor or non-significant interaction.
felbamate|voriconazole|1|Minor|felbamate will increase the level or effect of voriconazole by  affecting hepatic enzyme CYP2C19 metabolism. Minor or non-significant interaction.
felbamate|voriconazole|1|Minor|felbamate will increase the level or effect of voriconazole by  affecting hepatic enzyme CYP2C9/10 metabolism. Minor or non-significant interaction.
fosphenytoin|felodipine|11|Significant - Monitor Closely|fosphenytoin will decrease the level or effect of felodipine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
fosphenytoin|felodipine|11|Significant - Monitor Closely|fosphenytoin decreases levels of felodipine by increasing metabolism. Significant interaction possible, monitor closely.
hexobarbital|felodipine|11|Significant - Monitor Closely|hexobarbital will decrease the level or effect of felodipine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
itraconazole|felodipine|33|Contraindicated|itraconazole will increase the level or effect of felodipine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Never use combination. CCBs elicit negative inotropic effects which may be additive to those of itraconazole;  additionally, itraconazole can inhibit the metabolism of calcium channel blockers; coadministration may increase risk of CHF
felodipine|itraconazole|33|Contraindicated|felodipine will increase the level or effect of itraconazole by  P-glycoprotein (MDR1) efflux transporter. Never use combination.
nelfinavir|felodipine|11|Significant - Monitor Closely|nelfinavir will increase the level or effect of felodipine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
felodipine|nelfinavir|11|Significant - Monitor Closely|felodipine will increase the level or effect of nelfinavir by  P-glycoprotein (MDR1) efflux transporter. Significant interaction possible, monitor closely.
oxcarbazepine|felodipine|11|Significant - Monitor Closely|oxcarbazepine will decrease the level or effect of felodipine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
pentobarbital|felodipine|11|Significant - Monitor Closely|pentobarbital will decrease the level or effect of felodipine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
phenobarbital|felodipine|11|Significant - Monitor Closely|phenobarbital will decrease the level or effect of felodipine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
phenytoin|felodipine|11|Significant - Monitor Closely|phenytoin will decrease the level or effect of felodipine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely. When possible, avoid coadministration of these drugs and consider alternative therapy. When an alternative therapy is not possible, patients should be monitored for the desired cardiovascular effects such as heart rate, chest pain, or blood pressure.
phenytoin|felodipine|11|Significant - Monitor Closely|phenytoin decreases levels of felodipine by increasing metabolism. Significant interaction possible, monitor closely.
aprepitant|vinblastine|1|Minor|aprepitant will increase the level or effect of vinblastine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor or non-significant interaction.
aprepitant|vincristine|1|Minor|aprepitant will increase the level or effect of vincristine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor or non-significant interaction.
aprepitant|vinorelbine|1|Minor|aprepitant will increase the level or effect of vinorelbine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor or non-significant interaction.
voriconazole|aprepitant|11|Significant - Monitor Closely|voriconazole will increase the level or effect of aprepitant by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
aprepitant|warfarin|3|Significant - Monitor Closely|aprepitant will decrease the level or effect of warfarin by  affecting hepatic enzyme CYP2C9/10 metabolism. Potential for dangerous interaction. Use with caution and monitor closely. Aprepitant is a CYP2C9 inducer so coadministration with warfarin may result in a clinically significant decrease in INR. Monitor INR closely in patients on chronic warfarin therapy.
aprotinin|captopril|1|Minor|aprotinin decreases effects of captopril by unspecified interaction mechanism. Minor or non-significant interaction.
aprotinin|heparin|1|Minor|aprotinin increases effects of heparin by unspecified interaction mechanism. Minor or non-significant interaction.
argatroban|ginkgo biloba|3|Significant - Monitor Closely|argatroban and ginkgo biloba both increase  anticoagulation. Potential for dangerous interaction. Use with caution and monitor closely.
carbamazepine|aripiprazole|20|Serious - Use Alternative|carbamazepine will decrease the level or effect of aripiprazole by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available. If carbamazepine is started in a patient already taking aripiprazole, the aripiprazole dose should be doubled; reduce aripiprazole dose if carbamazepine is discontinued
etravirine|aripiprazole|11|Significant - Monitor Closely|etravirine will decrease the level or effect of aripiprazole by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
itraconazole|aripiprazole|20|Serious - Use Alternative|itraconazole will increase the level or effect of aripiprazole by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
ketoconazole|aripiprazole|20|Serious - Use Alternative|ketoconazole will increase the level or effect of aripiprazole by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
quinidine|aripiprazole|2|Significant - Monitor Closely|quinidine will increase the level or effect of aripiprazole by  affecting hepatic enzyme CYP2D6 metabolism. Potential for interaction, monitor.
telithromycin|aripiprazole|11|Significant - Monitor Closely|telithromycin will increase the level or effect of aripiprazole by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
aripiprazole|tetrabenazine|3|Significant - Monitor Closely|aripiprazole and tetrabenazine both increase  antidopaminergic effects, including extrapyramidal symptoms and neuroleptic malignant syndrome. Potential for dangerous interaction. Use with caution and monitor closely.
triprolidine|aripiprazole|2|Significant - Monitor Closely|triprolidine and aripiprazole both increase  sedation. Potential for interaction, monitor.
voriconazole|aripiprazole|11|Significant - Monitor Closely|voriconazole will increase the level or effect of aripiprazole by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
armodafinil|roflumilast|3|Significant - Monitor Closely|armodafinil will decrease the level or effect of roflumilast by  affecting hepatic enzyme CYP1A2 metabolism. Potential for dangerous interaction. Use with caution and monitor closely. Concomitant therapy may reduce therapeutic effectiveness.
telithromycin|armodafinil|1|Minor|telithromycin will increase the level or effect of armodafinil by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor or non-significant interaction.
armodafinil|telithromycin|1|Minor|armodafinil will decrease the level or effect of telithromycin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor or non-significant interaction.
armodafinil|voriconazole|1|Minor|armodafinil will increase the level or effect of voriconazole by  affecting hepatic enzyme CYP2C19 metabolism. Minor or non-significant interaction.
voriconazole|armodafinil|1|Minor|voriconazole will increase the level or effect of armodafinil by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor or non-significant interaction.
arsenic trioxide|telavancin|20|Serious - Use Alternative|arsenic trioxide and telavancin both increase  QTc interval. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
arsenic trioxide|toremifene|20|Serious - Use Alternative|arsenic trioxide and toremifene both increase  QTc interval. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available. Concurrent use of toremifene with agents causing  QT prolongation should be avoided. If concomitant use is required it's recommended that toremifene be interrupted. If interruption not possible, patients requiring therapy with a drug that prolongs QT should be closely monitored. ECGs should be obtained for high risk patients.
trimipramine|arsenic trioxide|20|Serious - Use Alternative|trimipramine and arsenic trioxide both increase  QTc interval. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
arsenic trioxide|voriconazole|20|Serious - Use Alternative|arsenic trioxide and voriconazole both increase  QTc interval. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
arsenic trioxide|ziprasidone|33|Contraindicated|arsenic trioxide and ziprasidone both increase  QTc interval. Never use combination.
haloperidol|artemether|2|Significant - Monitor Closely|haloperidol and artemether both increase  QTc interval. Potential for interaction, monitor.
mefloquine|artemether|22|Serious - Use Alternative|mefloquine increases toxicity of artemether by QTc interval. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available. Mefloquine may enhance the QTc prolonging effect of high risk QTc prolonging agents.
saquinavir|artemether|22|Serious - Use Alternative|saquinavir increases levels of artemether by affecting hepatic/intestinal enzyme CYP3A4 metabolism. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available. Potential for increased toxicity. Increased risk of QT prolongation and cardiac arrhythmias.
carbamazepine|asenapine|1|Minor|carbamazepine will decrease the level or effect of asenapine by  affecting hepatic enzyme CYP1A2 metabolism. Minor or non-significant interaction.
fluvoxamine|asenapine|2|Significant - Monitor Closely|fluvoxamine will increase the level or effect of asenapine by  affecting hepatic enzyme CYP1A2 metabolism. Potential for interaction, monitor.
asenapine|fluvoxamine|2|Significant - Monitor Closely|asenapine will increase the level or effect of fluvoxamine by  affecting hepatic enzyme CYP2D6 metabolism. Potential for interaction, monitor.
asenapine|ondansetron|20|Serious - Use Alternative|asenapine and ondansetron both increase  QTc interval. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.  Avoid with congenital long QT syndrome; ECG monitoring recommended with concomitant medications that prolong QT interval, electrolyte abnormalities, CHF, or bradyarrhythmias.
asenapine|paroxetine|2|Significant - Monitor Closely|asenapine will increase the level or effect of paroxetine by  affecting hepatic enzyme CYP2D6 metabolism. Potential for interaction, monitor.
phenobarbital|asenapine|1|Minor|phenobarbital will decrease the level or effect of asenapine by  affecting hepatic enzyme CYP1A2 metabolism. Minor or non-significant interaction.
primidone|asenapine|1|Minor|primidone will decrease the level or effect of asenapine by  affecting hepatic enzyme CYP1A2 metabolism. Minor or non-significant interaction.
saquinavir|asenapine|22|Serious - Use Alternative|saquinavir, asenapine.Either increases toxicity of the other by pharmacodynamic synergism. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available. Increased risk of QT prolongation and cardiac arrhythmias.
sildenafil|asenapine|20|Serious - Use Alternative|sildenafil increases effects of asenapine by pharmacodynamic synergism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available. Risk of hypotension; separate sildenafil >25mg from alpha blocker by 4hr.
asenapine|thioridazine|20|Serious - Use Alternative|asenapine will increase the level or effect of thioridazine by  affecting hepatic enzyme CYP2D6 metabolism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
asenapine|toremifene|20|Serious - Use Alternative|asenapine and toremifene both increase  QTc interval. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available. Concurrent use of toremifene with agents causing  QT prolongation should be avoided. If concomitant use is required it's recommended that toremifene be interrupted. If interruption not possible, patients requiring therapy with a drug that prolongs QT should be closely monitored. ECGs should be obtained for high risk patients.
cimetidine|astemizole|33|Contraindicated|cimetidine increases levels of astemizole by decreasing metabolism. Never use combination. Risk of QT interval prolongation.
cimetidine|astemizole|22|Serious - Use Alternative|cimetidine will increase the level or effect of astemizole by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available.
astemizole|cisapride|33|Contraindicated|astemizole and cisapride both increase  QTc interval. Never use combination.
astemizole|clarithromycin|33|Contraindicated|astemizole and clarithromycin both increase  QTc interval. Never use combination.
clarithromycin|astemizole|33|Contraindicated|clarithromycin increases levels of astemizole by decreasing metabolism. Never use combination. Risk of QT interval prolongation.
clarithromycin|astemizole|22|Serious - Use Alternative|clarithromycin will increase the level or effect of astemizole by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available.
delavirdine|astemizole|21|Serious - Use Alternative|delavirdine increases levels of astemizole by decreasing metabolism. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available. Never use combination. Risk of QT interval prolongation.
delavirdine|astemizole|20|Serious - Use Alternative|delavirdine will increase the level or effect of astemizole by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
efavirenz|astemizole|21|Serious - Use Alternative|efavirenz will decrease the level or effect of astemizole by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available. Never use combination.
efavirenz|astemizole|21|Serious - Use Alternative|efavirenz increases levels of astemizole by decreasing metabolism. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available. Never use combination.
fluoxetine|astemizole|33|Contraindicated|fluoxetine increases levels of astemizole by decreasing metabolism. Never use combination. Risk of QT interval prolongation.
fluvoxamine|astemizole|33|Contraindicated|fluvoxamine increases levels of astemizole by decreasing metabolism. Never use combination. Risk of QT interval prolongation.
astemizole|fluvoxamine|22|Serious - Use Alternative|astemizole and fluvoxamine both increase  QTc interval. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available.
fluvoxamine|astemizole|21|Serious - Use Alternative|fluvoxamine will increase the level or effect of astemizole by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available. Never use combination.
fosamprenavir|astemizole|33|Contraindicated|fosamprenavir increases levels of astemizole by decreasing metabolism. Never use combination. Risk of QT interval prolongation.
fosamprenavir|astemizole|21|Serious - Use Alternative|fosamprenavir will increase the level or effect of astemizole by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available. Never use combination.
indinavir|astemizole|21|Serious - Use Alternative|indinavir increases levels of astemizole by decreasing metabolism. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available. Never use combination. Risk of QT interval prolongation.
indinavir|astemizole|20|Serious - Use Alternative|indinavir will increase the level or effect of astemizole by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
astemizole|itraconazole|33|Contraindicated|astemizole and itraconazole both increase  QTc interval. Never use combination.
itraconazole|astemizole|33|Contraindicated|itraconazole increases levels of astemizole by decreasing metabolism. Never use combination. Risk of QT interval prolongation.
itraconazole|astemizole|22|Serious - Use Alternative|itraconazole will increase the level or effect of astemizole by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available.
astemizole|ketoconazole|33|Contraindicated|astemizole and ketoconazole both increase  QTc interval. Never use combination.
ketoconazole|astemizole|33|Contraindicated|ketoconazole increases levels of astemizole by decreasing metabolism. Never use combination. Risk of QT interval prolongation.
ketoconazole|astemizole|22|Serious - Use Alternative|ketoconazole will increase the level or effect of astemizole by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available.
mibefradil|astemizole|33|Contraindicated|mibefradil increases levels of astemizole by decreasing metabolism. Never use combination. Risk of QT interval prolongation.
mibefradil|astemizole|21|Serious - Use Alternative|mibefradil will increase the level or effect of astemizole by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available. Never use combination.
nefazodone|astemizole|33|Contraindicated|nefazodone increases levels of astemizole by decreasing metabolism. Never use combination. Risk of QT interval prolongation.
nefazodone|astemizole|22|Serious - Use Alternative|nefazodone will increase the level or effect of astemizole by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available.
nelfinavir|astemizole|21|Serious - Use Alternative|nelfinavir increases levels of astemizole by decreasing metabolism. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available. Never use combination. Risk of QT interval prolongation.
nelfinavir|astemizole|20|Serious - Use Alternative|nelfinavir will increase the level or effect of astemizole by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
astemizole|posaconazole|22|Serious - Use Alternative|astemizole and posaconazole both increase  QTc interval. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available.
posaconazole|astemizole|21|Serious - Use Alternative|posaconazole increases levels of astemizole by decreasing metabolism. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available. Never use combination. Risk of QT interval prolongation.
posaconazole|astemizole|20|Serious - Use Alternative|posaconazole will increase the level or effect of astemizole by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
quinine|astemizole|21|Serious - Use Alternative|quinine increases levels of astemizole by decreasing metabolism. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available. Never use combination. Risk of prolonged QTc interval.
ritonavir|astemizole|33|Contraindicated|ritonavir increases levels of astemizole by decreasing metabolism. Never use combination. Risk of QT interval prolongation.
ritonavir|astemizole|21|Serious - Use Alternative|ritonavir will increase the level or effect of astemizole by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available. Never use combination.
astemizole|telavancin|22|Serious - Use Alternative|astemizole and telavancin both increase  QTc interval. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available.
telithromycin|astemizole|33|Contraindicated|telithromycin increases levels of astemizole by decreasing metabolism. Never use combination. Risk of QT interval prolongation.
astemizole|telithromycin|22|Serious - Use Alternative|astemizole and telithromycin both increase  QTc interval. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available.
telithromycin|astemizole|21|Serious - Use Alternative|telithromycin will increase the level or effect of astemizole by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available. Never use combination.
thioridazine|astemizole|33|Contraindicated|thioridazine and astemizole both increase  QTc interval. Never use combination.
tipranavir|astemizole|33|Contraindicated|tipranavir increases levels of astemizole by decreasing metabolism. Never use combination. Risk of QT interval prolongation.
troleandomycin|astemizole|33|Contraindicated|troleandomycin increases levels of astemizole by decreasing metabolism. Never use combination. Risk of QT interval prolongation.
troleandomycin|astemizole|21|Serious - Use Alternative|troleandomycin will increase the level or effect of astemizole by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available. Never use combination.
voriconazole|astemizole|33|Contraindicated|voriconazole increases levels of astemizole by decreasing metabolism. Never use combination. Risk of QT interval prolongation.
astemizole|voriconazole|22|Serious - Use Alternative|astemizole and voriconazole both increase  QTc interval. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available.
voriconazole|astemizole|21|Serious - Use Alternative|voriconazole will increase the level or effect of astemizole by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available. Never use combination.
atazanavir|atorvastatin|11|Significant - Monitor Closely|atazanavir will increase the level or effect of atorvastatin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
atazanavir|buprenorphine|3|Significant - Monitor Closely|atazanavir increases levels of buprenorphine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Potential for dangerous interaction. Use with caution and monitor closely. Potential for increased toxicity.
atazanavir|cabazitaxel|3|Significant - Monitor Closely|atazanavir increases levels of cabazitaxel by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Potential for dangerous interaction. Use with caution and monitor closely. Potential for increased toxicity. Avoid coadministration.
cimetidine|atazanavir|20|Serious - Use Alternative|cimetidine will decrease the level or effect of atazanavir by  increasing gastric pH. Applies only to oral form of both agents. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
cimetidine|atazanavir|2|Significant - Monitor Closely|cimetidine will increase the level or effect of atazanavir by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Potential for interaction, monitor.
atazanavir|cisapride|33|Contraindicated|atazanavir increases levels of cisapride by decreasing metabolism. Never use combination. Risk of QT interval prolongation.
atazanavir|cisapride|21|Serious - Use Alternative|atazanavir will increase the level or effect of cisapride by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available. Never use combination.
clarithromycin|atazanavir|2|Significant - Monitor Closely|clarithromycin will increase the level or effect of atazanavir by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Potential for interaction, monitor.
atazanavir|clarithromycin|1|Minor|atazanavir will increase the level or effect of clarithromycin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor or non-significant interaction.
atazanavir|clomipramine|11|Significant - Monitor Closely|atazanavir increases levels of clomipramine by unspecified interaction mechanism. Significant interaction possible, monitor closely.
atazanavir|clomipramine|2|Significant - Monitor Closely|atazanavir will increase the level or effect of clomipramine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Potential for interaction, monitor.
atazanavir|cyclosporine|11|Significant - Monitor Closely|atazanavir will increase the level or effect of cyclosporine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
cyclosporine|atazanavir|1|Minor|cyclosporine will increase the level or effect of atazanavir by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor or non-significant interaction.
atazanavir|desipramine|11|Significant - Monitor Closely|atazanavir increases levels of desipramine by unspecified interaction mechanism. Significant interaction possible, monitor closely.
atazanavir|desipramine|2|Significant - Monitor Closely|atazanavir will increase the level or effect of desipramine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Potential for interaction, monitor.
atazanavir|dihydroergotamine|33|Contraindicated|atazanavir will increase the level or effect of dihydroergotamine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Never use combination.
atazanavir|diltiazem|11|Significant - Monitor Closely|atazanavir will increase the level or effect of diltiazem by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
diltiazem|atazanavir|1|Minor|diltiazem will increase the level or effect of atazanavir by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor or non-significant interaction.
atazanavir|doxepin|11|Significant - Monitor Closely|atazanavir increases levels of doxepin by unspecified interaction mechanism. Significant interaction possible, monitor closely.
atazanavir|efavirenz|2|Significant - Monitor Closely|atazanavir and efavirenz both increase  risk of immune reconstitution syndrome. Potential for interaction, monitor.
atazanavir|efavirenz|1|Minor|atazanavir will increase the level or effect of efavirenz by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor or non-significant interaction.
efavirenz|atazanavir|1|Minor|efavirenz decreases levels of atazanavir by unspecified interaction mechanism. Minor or non-significant interaction. May be coadministered; see atazanavir monograph for dosing info.
atazanavir|eltrombopag|11|Significant - Monitor Closely|atazanavir increases levels of eltrombopag by decreasing metabolism. Significant interaction possible, monitor closely. UGT inhibition; significance of interaction unclear.
atazanavir|ergotamine|21|Serious - Use Alternative|atazanavir will increase the level or effect of ergotamine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available. Never use combination.
atazanavir|ergotamine|21|Serious - Use Alternative|atazanavir increases levels of ergotamine by decreasing metabolism. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available. Never use combination.
atazanavir|erlotinib|11|Significant - Monitor Closely|atazanavir will increase the level or effect of erlotinib by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
esomeprazole|atazanavir|20|Serious - Use Alternative|esomeprazole will decrease the level or effect of atazanavir by  increasing gastric pH. Applies only to oral form of both agents. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
atazanavir|etravirine|11|Significant - Monitor Closely|atazanavir will increase the level or effect of etravirine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
etravirine|atazanavir|1|Minor|etravirine will decrease the level or effect of atazanavir by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor or non-significant interaction. Packaging labeling states that etravirine and atazanavir/ritonavir can be coadministered without dose adjustments. Decrease in atazanavir not clinically relevant when all three drugs are used.
famotidine|atazanavir|20|Serious - Use Alternative|famotidine will decrease the level or effect of atazanavir by  increasing gastric pH. Applies only to oral form of both agents. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
atazanavir|imipramine|11|Significant - Monitor Closely|atazanavir increases levels of imipramine by unspecified interaction mechanism. Significant interaction possible, monitor closely.
atazanavir|imipramine|2|Significant - Monitor Closely|atazanavir will increase the level or effect of imipramine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Potential for interaction, monitor.
atazanavir|indinavir|20|Serious - Use Alternative|atazanavir, indinavir. Mechanism: pharmacodynamic synergism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available. Potential for additive hyperbilirubinemia; concomitant use not recommended.
atazanavir|indinavir|11|Significant - Monitor Closely|atazanavir will increase the level or effect of indinavir by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
atazanavir|indinavir|2|Significant - Monitor Closely|atazanavir and indinavir both increase  risk of immune reconstitution syndrome. Potential for interaction, monitor.
indinavir|atazanavir|1|Minor|indinavir will increase the level or effect of atazanavir by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor or non-significant interaction.
atazanavir|irinotecan|22|Serious - Use Alternative|atazanavir will increase the level or effect of irinotecan by  decreasing metabolism. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available. UGT1A1 inhibitors decrease irinotecan metabolism
lansoprazole|atazanavir|20|Serious - Use Alternative|lansoprazole will decrease the level or effect of atazanavir by  increasing gastric pH. Applies only to oral form of both agents. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
atazanavir|lansoprazole|1|Minor|atazanavir will increase the level or effect of lansoprazole by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor or non-significant interaction.
atazanavir|lovastatin|33|Contraindicated|atazanavir will increase the level or effect of lovastatin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Never use combination. Strong CYP3A4 inhibitors increase systemic statin exposure and risk of myopathy, including rhabdomyolysis
atazanavir|lurasidone|33|Contraindicated|atazanavir will increase the level or effect of lurasidone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Never use combination. Coadministration of lurasidone and strong CYP3A4 inhibitors is contraindicated.
atazanavir|midazolam|21|Serious - Use Alternative|atazanavir increases levels of midazolam by decreasing metabolism. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available. Never use combination.
atazanavir|midazolam|11|Significant - Monitor Closely|atazanavir will increase the level or effect of midazolam by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
atazanavir|nevirapine|2|Significant - Monitor Closely|atazanavir and nevirapine both increase  risk of immune reconstitution syndrome. Potential for interaction, monitor.
nevirapine|atazanavir|1|Minor|nevirapine will decrease the level or effect of atazanavir by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor or non-significant interaction.
nizatidine|atazanavir|20|Serious - Use Alternative|nizatidine will decrease the level or effect of atazanavir by  increasing gastric pH. Applies only to oral form of both agents. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
atazanavir|nortriptyline|11|Significant - Monitor Closely|atazanavir increases levels of nortriptyline by unspecified interaction mechanism. Significant interaction possible, monitor closely.
omeprazole|atazanavir|20|Serious - Use Alternative|omeprazole will decrease the level or effect of atazanavir by  increasing gastric pH. Applies only to oral form of both agents. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
pantoprazole|atazanavir|20|Serious - Use Alternative|pantoprazole will decrease the level or effect of atazanavir by  increasing gastric pH. Applies only to oral form of both agents. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
atazanavir|pimozide|33|Contraindicated|atazanavir increases levels of pimozide by decreasing metabolism. Never use combination. Risk of QT interval prolongation.
atazanavir|pimozide|1|Minor|atazanavir will increase the level or effect of pimozide by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor or non-significant interaction.
atazanavir|pitavastatin|33|Contraindicated|atazanavir increases levels of pitavastatin by unknown mechanism. Never use combination. Potential for increased toxicity. .
atazanavir|protriptyline|11|Significant - Monitor Closely|atazanavir increases levels of protriptyline by unspecified interaction mechanism. Significant interaction possible, monitor closely.
atazanavir|quinidine|11|Significant - Monitor Closely|atazanavir will increase the level or effect of quinidine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
rabeprazole|atazanavir|20|Serious - Use Alternative|rabeprazole will decrease the level or effect of atazanavir by  increasing gastric pH. Applies only to oral form of both agents. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
atazanavir|rabeprazole|1|Minor|atazanavir will increase the level or effect of rabeprazole by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor or non-significant interaction.
atazanavir|ramelteon|1|Minor|atazanavir will increase the level or effect of ramelteon by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor or non-significant interaction.
ranitidine|atazanavir|20|Serious - Use Alternative|ranitidine will decrease the level or effect of atazanavir by  increasing gastric pH. Applies only to oral form of both agents. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
atazanavir|ranolazine|21|Serious - Use Alternative|atazanavir will increase the level or effect of ranolazine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available. Never use combination.
rifabutin|atazanavir|2|Significant - Monitor Closely|rifabutin will decrease the level or effect of atazanavir by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Potential for interaction, monitor.
atazanavir|ritonavir|11|Significant - Monitor Closely|atazanavir will increase the level or effect of ritonavir by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
atazanavir|ritonavir|2|Significant - Monitor Closely|atazanavir and ritonavir both increase  risk of immune reconstitution syndrome. Potential for interaction, monitor.
ritonavir|atazanavir|1|Minor|ritonavir will increase the level or effect of atazanavir by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor or non-significant interaction.
atazanavir|sildenafil|33|Contraindicated|atazanavir will increase the level or effect of sildenafil by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Never use combination. Never use combination with chronic sildenafil for PAH
atazanavir|sildenafil|11|Significant - Monitor Closely|atazanavir increases levels of sildenafil by decreasing metabolism. Significant interaction possible, monitor closely.
atazanavir|simvastatin|33|Contraindicated|atazanavir will increase the level or effect of simvastatin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Never use combination. Contraindicated. Increased risk for rhabdomyolysis with drugs that increase simvastatin systemic exposure
atazanavir|sirolimus|21|Serious - Use Alternative|atazanavir will increase the level or effect of sirolimus by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available. Never use combination.
sodium bicarbonate|atazanavir|20|Serious - Use Alternative|sodium bicarbonate will decrease the level or effect of atazanavir by  increasing gastric pH. Applies only to oral form of both agents. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
atazanavir|sunitinib|11|Significant - Monitor Closely|atazanavir will increase the level or effect of sunitinib by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
atazanavir|tacrolimus|11|Significant - Monitor Closely|atazanavir will increase the level or effect of tacrolimus by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
atazanavir|tadalafil|22|Serious - Use Alternative|atazanavir will increase the level or effect of tadalafil by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available. Stop tadalafil >24 hours prior to protease inhibitor (PI) initiation, restart 7 days after PI initiation at 20 mg once daily, and increase to 40 mg once daily based on tolerability.
atazanavir|tadalafil|11|Significant - Monitor Closely|atazanavir increases levels of tadalafil by decreasing metabolism. Significant interaction possible, monitor closely. Stop tadalafil >24 hours prior to protease inhibitor (PI) initiation, restart 7 days after PI initiation at 20 mg once daily, and increase to 40 mg once daily based on tolerability.
atazanavir|tamoxifen|20|Serious - Use Alternative|atazanavir, tamoxifen. affecting hepatic/intestinal enzyme CYP3A4 metabolism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available. CYP3A4 inhibition decreases metabolism of tamoxifen to N-desmethyl tamoxifen (active metabolite with similar biologic activity).
atazanavir|tamsulosin|20|Serious - Use Alternative|atazanavir increases levels of tamsulosin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available. Potential for increased toxicity. .
atazanavir|telithromycin|1|Minor|atazanavir will increase the level or effect of telithromycin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor or non-significant interaction.
atazanavir|temsirolimus|11|Significant - Monitor Closely|atazanavir will increase the level or effect of temsirolimus by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
atazanavir|teniposide|11|Significant - Monitor Closely|atazanavir increases levels of teniposide by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely. Potential for increased toxicity. .
atazanavir|tipranavir|11|Significant - Monitor Closely|atazanavir will increase the level or effect of tipranavir by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
atazanavir|tipranavir|2|Significant - Monitor Closely|atazanavir and tipranavir both increase  risk of immune reconstitution syndrome. Potential for interaction, monitor.
atazanavir|tolterodine|11|Significant - Monitor Closely|atazanavir will increase the level or effect of tolterodine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
atazanavir|tramadol|11|Significant - Monitor Closely|atazanavir increases levels of tramadol by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely. Potential for increased toxicity. .
atazanavir|trazodone|11|Significant - Monitor Closely|atazanavir will increase the level or effect of trazodone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
atazanavir|trazodone|11|Significant - Monitor Closely|atazanavir increases levels of trazodone by unspecified interaction mechanism. Significant interaction possible, monitor closely.
atazanavir|triazolam|21|Serious - Use Alternative|atazanavir increases levels of triazolam by decreasing metabolism. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available. Never use combination.
atazanavir|triazolam|11|Significant - Monitor Closely|atazanavir will increase the level or effect of triazolam by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
atazanavir|trimipramine|11|Significant - Monitor Closely|atazanavir increases levels of trimipramine by unspecified interaction mechanism. Significant interaction possible, monitor closely.
atazanavir|vardenafil|11|Significant - Monitor Closely|atazanavir will increase the level or effect of vardenafil by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
atazanavir|vardenafil|11|Significant - Monitor Closely|atazanavir increases levels of vardenafil by decreasing metabolism. Significant interaction possible, monitor closely.
atazanavir|vemurafenib|20|Serious - Use Alternative|atazanavir increases levels of vemurafenib by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
atazanavir|verapamil|11|Significant - Monitor Closely|atazanavir will increase the level or effect of verapamil by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
verapamil|atazanavir|11|Significant - Monitor Closely|verapamil will increase the level or effect of atazanavir by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely. Caution advised, may increase risk of AV block
atazanavir|vilazodone|20|Serious - Use Alternative|atazanavir increases levels of vilazodone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available. Strong CYP3A4 inhibitors may increase vilazodone plasma levels by 50% - Reduce daily dose  to 20 mg.
atazanavir|vinblastine|1|Minor|atazanavir will increase the level or effect of vinblastine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor or non-significant interaction.
atazanavir|vincristine|1|Minor|atazanavir will increase the level or effect of vincristine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor or non-significant interaction.
atazanavir|vinorelbine|1|Minor|atazanavir will increase the level or effect of vinorelbine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor or non-significant interaction.
voriconazole|atazanavir|20|Serious - Use Alternative|voriconazole will increase the level or effect of atazanavir by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
atazanavir|warfarin|11|Significant - Monitor Closely|atazanavir will increase the level or effect of warfarin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
atazanavir|zolpidem|1|Minor|atazanavir will increase the level or effect of zolpidem by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor or non-significant interaction.
atazanavir|zonisamide|1|Minor|atazanavir will increase the level or effect of zonisamide by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor or non-significant interaction.
clonidine|atenolol|20|Serious - Use Alternative|clonidine, atenolol.Either increases toxicity of the other by unspecified interaction mechanism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available. Can increase risk of bradycardia.
clonidine|atenolol|11|Significant - Monitor Closely|clonidine, atenolol.Either increases toxicity of the other by pharmacodynamic synergism. Significant interaction possible, monitor closely. Sympatholytic action may worsen sinus node dysfunction and atrioventricular (AV) block.
atenolol|clonidine|3|Significant - Monitor Closely|atenolol, clonidine. Mechanism: pharmacodynamic synergism. Potential for dangerous interaction. Use with caution and monitor closely. Selective beta blocker administration during withdrawal from centrally acting alpha agonists may result in rebound hypertension.
dihydroergotamine|atenolol|1|Minor|dihydroergotamine, atenolol. Mechanism: pharmacodynamic synergism. Minor or non-significant interaction. Additive vasospasm.
diltiazem|atenolol|20|Serious - Use Alternative|diltiazem, atenolol.Either increases toxicity of the other by unspecified interaction mechanism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available. Can increase risk of bradycardia.
atenolol|diltiazem|3|Significant - Monitor Closely|atenolol and diltiazem both increase  anti-hypertensive channel blocking. Potential for dangerous interaction. Use with caution and monitor closely.
atenolol|disopyramide|11|Significant - Monitor Closely|atenolol increases effects of disopyramide by pharmacodynamic synergism. Significant interaction possible, monitor closely. Additive negative inotropic effects.
atenolol|epinephrine|11|Significant - Monitor Closely|atenolol decreases effects of epinephrine by pharmacodynamic antagonism. Significant interaction possible, monitor closely.
atenolol|epinephrine|2|Significant - Monitor Closely|atenolol increases and epinephrine decreases serum potassium. Effect of interaction is not clear, use caution. Potential for interaction, monitor.
atenolol|formoterol|11|Significant - Monitor Closely|atenolol decreases effects of formoterol by pharmacodynamic antagonism. Significant interaction possible, monitor closely.
atenolol|formoterol|2|Significant - Monitor Closely|atenolol increases and formoterol decreases serum potassium. Effect of interaction is not clear, use caution. Potential for interaction, monitor.
ibuprofen|atenolol|11|Significant - Monitor Closely|ibuprofen decreases effects of atenolol by pharmacodynamic antagonism. Significant interaction possible, monitor closely. Long term (>1 wk) NSAID use.  NSAIDs decrease prostaglandin synthesis.
atenolol|ibuprofen|2|Significant - Monitor Closely|atenolol and ibuprofen both increase  serum potassium. Potential for interaction, monitor.
indomethacin|atenolol|11|Significant - Monitor Closely|indomethacin decreases effects of atenolol by pharmacodynamic antagonism. Significant interaction possible, monitor closely. Long term (>1 wk) NSAID use.  NSAIDs decrease prostaglandin synthesis.
atenolol|indomethacin|2|Significant - Monitor Closely|atenolol and indomethacin both increase  serum potassium. Potential for interaction, monitor.
atenolol|pirbuterol|11|Significant - Monitor Closely|atenolol decreases effects of pirbuterol by pharmacodynamic antagonism. Significant interaction possible, monitor closely.
atenolol|pirbuterol|2|Significant - Monitor Closely|atenolol increases and pirbuterol decreases serum potassium. Effect of interaction is not clear, use caution. Potential for interaction, monitor.
piroxicam|atenolol|11|Significant - Monitor Closely|piroxicam decreases effects of atenolol by pharmacodynamic antagonism. Significant interaction possible, monitor closely. Long term (>1 wk) NSAID use.  NSAIDs decrease prostaglandin synthesis.
atenolol|piroxicam|2|Significant - Monitor Closely|atenolol and piroxicam both increase  serum potassium. Potential for interaction, monitor.
prazosin|atenolol|3|Significant - Monitor Closely|prazosin and atenolol both increase  anti-hypertensive channel blocking. Potential for dangerous interaction. Use with caution and monitor closely.
atenolol|salmeterol|11|Significant - Monitor Closely|atenolol decreases effects of salmeterol by pharmacodynamic antagonism. Significant interaction possible, monitor closely.
atenolol|salmeterol|2|Significant - Monitor Closely|atenolol increases and salmeterol decreases serum potassium. Effect of interaction is not clear, use caution. Potential for interaction, monitor.
terazosin|atenolol|3|Significant - Monitor Closely|terazosin and atenolol both increase  anti-hypertensive channel blocking. Potential for dangerous interaction. Use with caution and monitor closely.
atenolol|terbutaline|11|Significant - Monitor Closely|atenolol decreases effects of terbutaline by pharmacodynamic antagonism. Significant interaction possible, monitor closely.
atenolol|terbutaline|2|Significant - Monitor Closely|atenolol increases and terbutaline decreases serum potassium. Effect of interaction is not clear, use caution. Potential for interaction, monitor.
treprostinil|atenolol|1|Minor|treprostinil increases effects of atenolol by pharmacodynamic synergism. Minor or non-significant interaction.
verapamil|atenolol|20|Serious - Use Alternative|verapamil, atenolol.Either increases toxicity of the other by unspecified interaction mechanism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available. Can increase risk of bradycardia.
atenolol|verapamil|3|Significant - Monitor Closely|atenolol and verapamil both increase  anti-hypertensive channel blocking. Potential for dangerous interaction. Use with caution and monitor closely.
chloroquine|atomoxetine|2|Significant - Monitor Closely|chloroquine will increase the level or effect of atomoxetine by  affecting hepatic enzyme CYP2D6 metabolism. Potential for interaction, monitor.
diphenhydramine|atomoxetine|2|Significant - Monitor Closely|diphenhydramine will increase the level or effect of atomoxetine by  affecting hepatic enzyme CYP2D6 metabolism. Potential for interaction, monitor.
fluoxetine|atomoxetine|11|Significant - Monitor Closely|fluoxetine will increase the level or effect of atomoxetine by  affecting hepatic enzyme CYP2D6 metabolism. Significant interaction possible, monitor closely. Reduced initial doses of atomoxetine are recommended with strong CYP2D6 inhibitors.
haloperidol|atomoxetine|2|Significant - Monitor Closely|haloperidol will increase the level or effect of atomoxetine by  affecting hepatic enzyme CYP2D6 metabolism. Potential for interaction, monitor.
isocarboxazid|atomoxetine|33|Contraindicated|isocarboxazid increases effects of atomoxetine by pharmacodynamic synergism. Never use combination. The use of atomoxetine with monoamine oxidase inhibitors (MAOIs) is contraindicated. Risk of acute hypertensive episode.
paroxetine|atomoxetine|11|Significant - Monitor Closely|paroxetine will increase the level or effect of atomoxetine by  affecting hepatic enzyme CYP2D6 metabolism. Significant interaction possible, monitor closely. Reduced initial doses of atomoxetine are recommended with strong CYP2D6 inhibitors.
perphenazine|atomoxetine|2|Significant - Monitor Closely|perphenazine will increase the level or effect of atomoxetine by  affecting hepatic enzyme CYP2D6 metabolism. Potential for interaction, monitor.
phenelzine|atomoxetine|33|Contraindicated|phenelzine increases effects of atomoxetine by pharmacodynamic synergism. Never use combination. The use of atomoxetine with monoamine oxidase inhibitors (MAOIs) is contraindicated. Risk of acute hypertensive episode.
quinidine|atomoxetine|11|Significant - Monitor Closely|quinidine will increase the level or effect of atomoxetine by  affecting hepatic enzyme CYP2D6 metabolism. Significant interaction possible, monitor closely. Reduced initial doses of atomoxetine are recommended with strong CYP2D6 inhibitors.
rasagiline|atomoxetine|33|Contraindicated|rasagiline increases effects of atomoxetine by pharmacodynamic synergism. Never use combination. The use of atomoxetine with monoamine oxidase inhibitors (MAOIs) is contraindicated. Risk of acute hypertensive episode.
ritonavir|atomoxetine|2|Significant - Monitor Closely|ritonavir will increase the level or effect of atomoxetine by  affecting hepatic enzyme CYP2D6 metabolism. Potential for interaction, monitor.
thioridazine|atomoxetine|2|Significant - Monitor Closely|thioridazine will increase the level or effect of atomoxetine by  affecting hepatic enzyme CYP2D6 metabolism. Potential for interaction, monitor.
tranylcypromine|atomoxetine|33|Contraindicated|tranylcypromine increases effects of atomoxetine by pharmacodynamic synergism. Never use combination. The use of atomoxetine with monoamine oxidase inhibitors (MAOIs) is contraindicated. Risk of acute hypertensive episode.
bezafibrate|atorvastatin|21|Serious - Use Alternative|bezafibrate, atorvastatin.Either increases toxicity of the other by pharmacodynamic synergism. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available. Never use combination. Increased risk of rhabdomyolysis.
boceprevir|atorvastatin|11|Significant - Monitor Closely|boceprevir increases levels of atorvastatin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely. Titrate atorvastatin dose carefully and do not exceed maximum daily dose of 40 mg during coadministration with boceprevir.
bosentan|atorvastatin|11|Significant - Monitor Closely|bosentan will decrease the level or effect of atorvastatin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
carbamazepine|atorvastatin|20|Serious - Use Alternative|carbamazepine will decrease the level or effect of atorvastatin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
clarithromycin|atorvastatin|22|Serious - Use Alternative|clarithromycin will increase the level or effect of atorvastatin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available. Do not exceed atorvastatin dose of 20 mg/day when coadministered with clarithromycin
clarithromycin|atorvastatin|22|Serious - Use Alternative|clarithromycin will increase the level or effect of atorvastatin by  P-glycoprotein (MDR1) efflux transporter. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available. Do not exceed atorvastatin dose of 20 mg/day when coadministered with clarithromycin
colchicine|atorvastatin|20|Serious - Use Alternative|colchicine, atorvastatin.Either increases toxicity of the other by pharmacodynamic synergism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available. Increased risk of rhabdomyolysis (incl a fatality).
atorvastatin|colchicine|11|Significant - Monitor Closely|atorvastatin will increase the level or effect of colchicine by  P-glycoprotein (MDR1) efflux transporter. Significant interaction possible, monitor closely.
cyclosporine|atorvastatin|22|Serious - Use Alternative|cyclosporine will increase the level or effect of atorvastatin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available. Coadministration increases risk of statin-associated myopathy including rhabdomyolysis
delavirdine|atorvastatin|11|Significant - Monitor Closely|delavirdine will increase the level or effect of atorvastatin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
diltiazem|atorvastatin|11|Significant - Monitor Closely|diltiazem will increase the level or effect of atorvastatin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely. If concurrent therapy is required, monitor the patient for signs and symptoms of myopathy or rhabdomyolysis (muscle pain, tenderness, or weakness, or discolored urine). If myopathy or rhabdomyolysis is diagnosed or suspected, monitor creatine kinase (CK) levels and discontinue use if CK levels show a marked increase.
dronedarone|atorvastatin|11|Significant - Monitor Closely|dronedarone will increase the level or effect of atorvastatin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
dronedarone|atorvastatin|11|Significant - Monitor Closely|dronedarone will increase the level or effect of atorvastatin by  P-glycoprotein (MDR1) efflux transporter. Significant interaction possible, monitor closely.
efavirenz|atorvastatin|11|Significant - Monitor Closely|efavirenz will decrease the level or effect of atorvastatin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
eltrombopag|atorvastatin|11|Significant - Monitor Closely|eltrombopag increases levels of atorvastatin by decreasing metabolism. Significant interaction possible, monitor closely. OATP transporter protein inhibition.
etravirine|atorvastatin|11|Significant - Monitor Closely|etravirine will decrease the level or effect of atorvastatin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
fenofibrate|atorvastatin|20|Serious - Use Alternative|fenofibrate, atorvastatin.Either increases effects of the other by pharmacodynamic synergism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available. Fenofibrate may further increase risk for rhabdomyolysis when added to optimal statin regimen to further decrease TG and increase HDLs.
fluconazole|atorvastatin|11|Significant - Monitor Closely|fluconazole will increase the level or effect of atorvastatin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
fosamprenavir|atorvastatin|20|Serious - Use Alternative|fosamprenavir will increase the level or effect of atorvastatin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available. Limit atorvastatin dose to 20 mg/day
gemfibrozil|atorvastatin|20|Serious - Use Alternative|gemfibrozil, atorvastatin.Either increases effects of the other by pharmacodynamic synergism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available. Gemfibrozil may further increase risk for rhabdomyolysis when added to optimal statin regimen to further decrease TG and increase HDLs.
atorvastatin|imatinib|11|Significant - Monitor Closely|atorvastatin will increase the level or effect of imatinib by  P-glycoprotein (MDR1) efflux transporter. Significant interaction possible, monitor closely.
indinavir|atorvastatin|20|Serious - Use Alternative|indinavir increases toxicity of atorvastatin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available. Risk of myopathy and rhabdomyolysis increased when atorvastatin coadministered with CYP3A4 inhibitors; use lowest statin dose possible.
atorvastatin|indinavir|11|Significant - Monitor Closely|atorvastatin will increase the level or effect of indinavir by  P-glycoprotein (MDR1) efflux transporter. Significant interaction possible, monitor closely.
itraconazole|atorvastatin|20|Serious - Use Alternative|itraconazole will increase the level or effect of atorvastatin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available. Limit atorvastatin dose to 20 mg/day
atorvastatin|itraconazole|11|Significant - Monitor Closely|atorvastatin will increase the level or effect of itraconazole by  P-glycoprotein (MDR1) efflux transporter. Significant interaction possible, monitor closely.
ketoconazole|atorvastatin|20|Serious - Use Alternative|ketoconazole will increase the level or effect of atorvastatin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
ketoconazole|atorvastatin|11|Significant - Monitor Closely|ketoconazole will increase the level or effect of atorvastatin by  P-glycoprotein (MDR1) efflux transporter. Significant interaction possible, monitor closely.
liraglutide|atorvastatin|2|Significant - Monitor Closely|liraglutide will decrease the level or effect of atorvastatin by  Other (see comment). Potential for interaction, monitor. Based on pharmacokinetic studies liraglutide decreased atorvastatin Cmax by 38% and median Tmax delayed from 1h to 3h with liraglutide and the AUC did not change.
atorvastatin|lomitapide|11|Significant - Monitor Closely|atorvastatin increases levels of lomitapide by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely. Lomitapide dose should not exceed 30 mg/day.
lomitapide|atorvastatin|3|Significant - Monitor Closely|lomitapide increases levels of atorvastatin by P-glycoprotein (MDR1) efflux transporter. Potential for dangerous interaction. Use with caution and monitor closely. Consider reducing dose when used concomitantly with lomitapide.
nefazodone|atorvastatin|22|Serious - Use Alternative|nefazodone will increase the level or effect of atorvastatin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available.
nefazodone|atorvastatin|11|Significant - Monitor Closely|nefazodone will decrease the level or effect of atorvastatin by  P-glycoprotein (MDR1) efflux transporter. Significant interaction possible, monitor closely.
atorvastatin|nelfinavir|11|Significant - Monitor Closely|atorvastatin will increase the level or effect of nelfinavir by  P-glycoprotein (MDR1) efflux transporter. Significant interaction possible, monitor closely.
nelfinavir|atorvastatin|3|Significant - Monitor Closely|nelfinavir will increase the level or effect of atorvastatin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Potential for dangerous interaction. Use with caution and monitor closely. Limit atorvastatin dose to 40 mg/day
nevirapine|atorvastatin|11|Significant - Monitor Closely|nevirapine will decrease the level or effect of atorvastatin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
rifabutin|atorvastatin|20|Serious - Use Alternative|rifabutin will decrease the level or effect of atorvastatin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
ritonavir|atorvastatin|11|Significant - Monitor Closely|ritonavir will increase the level or effect of atorvastatin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
atorvastatin|ritonavir|11|Significant - Monitor Closely|atorvastatin will increase the level or effect of ritonavir by  P-glycoprotein (MDR1) efflux transporter. Significant interaction possible, monitor closely.
saquinavir|atorvastatin|20|Serious - Use Alternative|saquinavir will increase the level or effect of atorvastatin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available. Limit atorvastatin dose to 20 mg/day
atorvastatin|saquinavir|11|Significant - Monitor Closely|atorvastatin will increase the level or effect of saquinavir by  P-glycoprotein (MDR1) efflux transporter. Significant interaction possible, monitor closely.
telaprevir|atorvastatin|33|Contraindicated|telaprevir increases levels of atorvastatin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Never use combination. Contraindicated. Potential for myopathy including rhabdomyolysis.
telithromycin|atorvastatin|11|Significant - Monitor Closely|telithromycin will increase the level or effect of atorvastatin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
tipranavir|atorvastatin|33|Contraindicated|tipranavir increases levels of atorvastatin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Never use combination. This interaction is the net effect of tipranavir being coadministered with ritonavir (boosted therapy); increased risk of myopathy including rhabdomyolysis.
atorvastatin|topotecan|22|Serious - Use Alternative|atorvastatin will increase the level or effect of topotecan by  P-glycoprotein (MDR1) efflux transporter. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available. Product labeling for PO topotecan recommends avoiding concomitant use of P-gp inhibitors; the interaction with IV topotecan may be less severe but is still likely of clinical significance
verapamil|atorvastatin|11|Significant - Monitor Closely|verapamil will increase the level or effect of atorvastatin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
verapamil|atorvastatin|11|Significant - Monitor Closely|verapamil will increase the level or effect of atorvastatin by  P-glycoprotein (MDR1) efflux transporter. Significant interaction possible, monitor closely.
voriconazole|atorvastatin|11|Significant - Monitor Closely|voriconazole will increase the level or effect of atorvastatin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
rifabutin|atovaquone|11|Significant - Monitor Closely|rifabutin decreases levels of atovaquone by increasing metabolism. Significant interaction possible, monitor closely.
tetracycline|atovaquone|1|Minor|tetracycline decreases levels of atovaquone by inhibition of GI absorption. Applies only to oral form of both agents. Minor or non-significant interaction. Effect may be minor, due to pharmacodynamic synergism.
carbamazepine|atracurium|1|Minor|carbamazepine decreases effects of atracurium by pharmacodynamic antagonism. Minor or non-significant interaction.
clindamycin|atracurium|20|Serious - Use Alternative|clindamycin increases effects of atracurium by pharmacodynamic synergism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available. Risk of respiratory depression.
fosphenytoin|atracurium|1|Minor|fosphenytoin decreases effects of atracurium by pharmacodynamic antagonism. Minor or non-significant interaction.
gentamicin|atracurium|20|Serious - Use Alternative|gentamicin increases effects of atracurium by pharmacodynamic synergism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available. Risk of apnea.
lincomycin|atracurium|20|Serious - Use Alternative|lincomycin increases effects of atracurium by pharmacodynamic synergism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available. Risk of respiratory depression.
netilmicin|atracurium|20|Serious - Use Alternative|netilmicin increases effects of atracurium by pharmacodynamic synergism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available. Risk of apnea.
phenytoin|atracurium|1|Minor|phenytoin decreases effects of atracurium by pharmacodynamic antagonism. Minor or non-significant interaction.
quinidine|atracurium|1|Minor|quinidine increases effects of atracurium by pharmacodynamic synergism. Minor or non-significant interaction.
quinine|atracurium|21|Serious - Use Alternative|quinine increases effects of atracurium by pharmacodynamic synergism. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available. Never use combination. Risk of resp. depression.
tobramycin|atracurium|20|Serious - Use Alternative|tobramycin increases effects of atracurium by pharmacodynamic synergism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available. Risk of apnea.
donepezil|atropine|2|Significant - Monitor Closely|donepezil increases and atropine decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Potential for interaction, monitor.
donepezil|atropine|1|Minor|donepezil decreases effects of atropine by pharmacodynamic antagonism. Minor or non-significant interaction.
galantamine|atropine|2|Significant - Monitor Closely|galantamine increases and atropine decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Potential for interaction, monitor.
galantamine|atropine|1|Minor|galantamine decreases effects of atropine by pharmacodynamic antagonism. Minor or non-significant interaction.
atropine|haloperidol|11|Significant - Monitor Closely|atropine decreases levels of haloperidol by inhibition of GI absorption. Applies only to oral form of both agents. Significant interaction possible, monitor closely.
atropine|haloperidol|11|Significant - Monitor Closely|atropine decreases levels of haloperidol by pharmacodynamic antagonism. Significant interaction possible, monitor closely.
haloperidol|atropine|11|Significant - Monitor Closely|haloperidol increases effects of atropine by pharmacodynamic synergism. Significant interaction possible, monitor closely. Additive anticholinergic effects, possible hypoglycemia.
tacrine|atropine|2|Significant - Monitor Closely|tacrine increases and atropine decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Potential for interaction, monitor.
tacrine|atropine|1|Minor|tacrine decreases effects of atropine by pharmacodynamic antagonism. Minor or non-significant interaction.
desipramine|avanafil|11|Significant - Monitor Closely|desipramine will increase the level or effect of avanafil by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely. CYP3A4 inhibitors may reduce avanafil clearance increasing systemic exposure to avanafil; increased levels may result in increased associated adverse events; the maximum recommended dose of STENDRA is 50 mg, not to exceed once every 24 hours for patients taking concomitant moderate CYP3A4 inhibitors
isosorbide dinitrate|avanafil|33|Contraindicated|isosorbide dinitrate, avanafil.Either increases effects of the other by Mechanism: additive vasodilation. Never use combination. Contraindicated; potentially fatal hypotension.
isosorbide mononitrate|avanafil|33|Contraindicated|isosorbide mononitrate, avanafil.Either increases effects of the other by Mechanism: additive vasodilation. Never use combination. Potentially fatal hypotension.
ketoconazole|avanafil|22|Serious - Use Alternative|ketoconazole will increase the level or effect of avanafil by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available. CYP3A4 inhibitors may reduce avanafil clearance increasing systemic exposure to avanafil; significantly increased levels may result in significant adverse events including severe hypotension, syncope, visual changes, and priapism. Coadministration with strong CYP3A4 is contraindicated.
ritonavir|avanafil|22|Serious - Use Alternative|ritonavir will increase the level or effect of avanafil by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available. CYP3A4 inhibitors may reduce avanafil clearance increasing systemic exposure to avanafil; significantly increased levels may result in significant adverse events including severe hypotension, syncope, visual changes, and priapism. Coadministration with strong CYP3A4 is contraindicated.
clobazam|axitinib|22|Serious - Use Alternative|clobazam decreases levels of axitinib by affecting hepatic/intestinal enzyme CYP3A4 metabolism. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available. Selection of concomitant medication with no or minimal CYP3A4 induction potential is recommended.
etravirine|axitinib|22|Serious - Use Alternative|etravirine decreases levels of axitinib by affecting hepatic/intestinal enzyme CYP3A4 metabolism. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available. Selection of concomitant medication with no or minimal CYP3A4 induction potential is recommended.
paclitaxel|axitinib|2|Significant - Monitor Closely|paclitaxel decreases levels of axitinib by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Potential for interaction, monitor.
phenytoin|axitinib|22|Serious - Use Alternative|phenytoin decreases levels of axitinib by affecting hepatic/intestinal enzyme CYP3A4 metabolism. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available. Selection of concomitant medication with no or minimal CYP3A4 induction potential is recommended.
azathioprine|canakinumab|22|Serious - Use Alternative|azathioprine and canakinumab both increase  immunosuppressive effects; risk of infection. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available.
febuxostat|azathioprine|33|Contraindicated|febuxostat increases levels of azathioprine by decreasing metabolism. Never use combination.
azathioprine|rilonacept|22|Serious - Use Alternative|azathioprine and rilonacept both increase  immunosuppressive effects; risk of infection. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available.
trandolapril|azathioprine|11|Significant - Monitor Closely|trandolapril, azathioprine. Mechanism: pharmacodynamic synergism. Significant interaction possible, monitor closely. Risk of neutropenia.
azathioprine|warfarin|11|Significant - Monitor Closely|azathioprine decreases effects of warfarin by unknown mechanism. Significant interaction possible, monitor closely.
azelastine|triprolidine|2|Significant - Monitor Closely|azelastine and triprolidine both increase  sedation. Potential for interaction, monitor.
cyclosporine|azithromycin|11|Significant - Monitor Closely|cyclosporine will increase the level or effect of azithromycin by  P-glycoprotein (MDR1) efflux transporter. Significant interaction possible, monitor closely.
azithromycin|disopyramide|3|Significant - Monitor Closely|azithromycin and disopyramide both increase  QTc interval. Potential for dangerous interaction. Use with caution and monitor closely.
lovastatin|azithromycin|11|Significant - Monitor Closely|lovastatin will increase the level or effect of azithromycin by  P-glycoprotein (MDR1) efflux transporter. Significant interaction possible, monitor closely.
azithromycin|lumefantrine|2|Significant - Monitor Closely|azithromycin and lumefantrine both increase  QTc interval. Potential for interaction, monitor.
azithromycin|vismodegib|2|Significant - Monitor Closely|azithromycin will increase the level or effect of vismodegib by  P-glycoprotein (MDR1) efflux transporter. Potential for interaction, monitor. Vismodegib is a substrate of efflux transporter P-glycoprotein (P-gp); coadministration with P-gp inhibitors increase vismodegib systemic exposure
azithromycin|warfarin|20|Serious - Use Alternative|azithromycin increases effects of warfarin by decreasing metabolism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
azithromycin|ziprasidone|2|Significant - Monitor Closely|azithromycin and ziprasidone both increase  QTc interval. Potential for interaction, monitor.
basiliximab|canakinumab|22|Serious - Use Alternative|basiliximab and canakinumab both increase  immunosuppressive effects; risk of infection. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available.
basiliximab|rilonacept|22|Serious - Use Alternative|basiliximab and rilonacept both increase  immunosuppressive effects; risk of infection. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available.
ketoconazole|bedaquiline|22|Serious - Use Alternative|ketoconazole will increase the level or effect of bedaquiline by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available. Avoid coadministration of bedaquiline with strong CYP3A4 inhibitors for >14 consecutive days, unless the benefit of treatment outweighs the risk
belatacept|belimumab|2|Significant - Monitor Closely|belatacept and belimumab both increase  immunosuppressive effects; risk of infection. Potential for interaction, monitor.
belatacept|denosumab|2|Significant - Monitor Closely|belatacept and denosumab both increase  immunosuppressive effects; risk of infection. Potential for interaction, monitor.
belatacept|leflunomide|2|Significant - Monitor Closely|belatacept and leflunomide both increase  immunosuppressive effects; risk of infection. Potential for interaction, monitor.
belatacept|natalizumab|2|Significant - Monitor Closely|belatacept and natalizumab both increase  immunosuppressive effects; risk of infection. Potential for interaction, monitor.
belatacept|pralatrexate|2|Significant - Monitor Closely|belatacept and pralatrexate both increase  immunosuppressive effects; risk of infection. Potential for interaction, monitor.
belatacept|rilonacept|2|Significant - Monitor Closely|belatacept and rilonacept both increase  immunosuppressive effects; risk of infection. Potential for interaction, monitor.
belatacept|sipuleucel-t|20|Serious - Use Alternative|belatacept and sipuleucel-t both increase  immunosuppressive effects; risk of infection. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available. Concomitant use of sipuleucel-T and immunosuppressives should be avoided.
belatacept|sipuleucel-t|3|Significant - Monitor Closely|belatacept decreases effects of sipuleucel-t by pharmacodynamic antagonism. Potential for dangerous interaction. Use with caution and monitor closely.
belatacept|tacrolimus|2|Significant - Monitor Closely|belatacept and tacrolimus both increase  immunosuppressive effects; risk of infection. Potential for interaction, monitor.
belatacept|tofacitinib|20|Serious - Use Alternative|belatacept, tofacitinib.Either increases toxicity of the other by immunosuppressive effects; risk of infection. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
belimumab|denosumab|11|Significant - Monitor Closely|belimumab, denosumab. Other (see comment). Significant interaction possible, monitor closely. Comment: Caution should be taken in patients on concomitant immunosuppressants or with impaired immune systems because of increased risk for serious infections.
belimumab|fingolimod|3|Significant - Monitor Closely|belimumab increases effects of fingolimod by immunosuppressive effects; risk of infection. Potential for dangerous interaction. Use with caution and monitor closely. Concomitant therapy is expected to increase the risk of immunosuppression. Use caution when switching patients from long-acting therapies with immune effects. .
hydroxyurea|belimumab|2|Significant - Monitor Closely|hydroxyurea, belimumab. Other (see comment). Potential for interaction, monitor. Comment: Combination may increase risk of infection.
belimumab|sipuleucel-t|3|Significant - Monitor Closely|belimumab decreases effects of sipuleucel-t by pharmacodynamic antagonism. Potential for dangerous interaction. Use with caution and monitor closely.
benazepril|drospirenone|11|Significant - Monitor Closely|benazepril, drospirenone. Mechanism: pharmacodynamic synergism. Significant interaction possible, monitor closely. Risk of hyperkalemia.
icatibant|benazepril|2|Significant - Monitor Closely|icatibant decreases effects of benazepril by pharmacodynamic antagonism. Potential for interaction, monitor. Icatibant has potential to have a pharmacodynamic interaction with ACE inhibitors where it may attenuate the antihypertensive effect of ACE inhibitors.
benazepril|lithium|11|Significant - Monitor Closely|benazepril increases toxicity of lithium by unknown mechanism. Significant interaction possible, monitor closely. ACE inhibitor induced Na+ depletion may increase reabsorption of lithium from renal tubule.
benazepril|spironolactone|11|Significant - Monitor Closely|benazepril, spironolactone. Mechanism: pharmacodynamic synergism. Significant interaction possible, monitor closely. Risk of hyperkalemia.
tizanidine|benazepril|1|Minor|tizanidine increases effects of benazepril by pharmacodynamic synergism. Minor or non-significant interaction. Risk of hypotension.
treprostinil|benazepril|1|Minor|treprostinil increases effects of benazepril by pharmacodynamic synergism. Minor or non-significant interaction.
benazepril|triamterene|11|Significant - Monitor Closely|benazepril, triamterene. Mechanism: pharmacodynamic synergism. Significant interaction possible, monitor closely. Risk of hyperkalemia.
bendamustine|busulfan|11|Significant - Monitor Closely|bendamustine, busulfan.Either increases toxicity of the other by pharmacodynamic synergism. Significant interaction possible, monitor closely. Additive myelosuppression.
butabarbital|bendamustine|11|Significant - Monitor Closely|butabarbital decreases levels of bendamustine by affecting hepatic enzyme CYP1A2 metabolism. Significant interaction possible, monitor closely. Concentrations of active metabolites may be increased.
carbamazepine|bendamustine|11|Significant - Monitor Closely|carbamazepine decreases levels of bendamustine by affecting hepatic enzyme CYP1A2 metabolism. Significant interaction possible, monitor closely. Concentrations of active metabolites may be increased.
bendamustine|carboplatin|11|Significant - Monitor Closely|bendamustine, carboplatin.Either increases toxicity of the other by pharmacodynamic synergism. Significant interaction possible, monitor closely. Additive myelosuppression.
bendamustine|carmustine|11|Significant - Monitor Closely|bendamustine, carmustine.Either increases toxicity of the other by pharmacodynamic synergism. Significant interaction possible, monitor closely. Additive myelosuppression.
bendamustine|chlorambucil|11|Significant - Monitor Closely|bendamustine, chlorambucil.Either increases toxicity of the other by pharmacodynamic synergism. Significant interaction possible, monitor closely. Additive myelosuppression.
cimetidine|bendamustine|11|Significant - Monitor Closely|cimetidine increases levels of bendamustine by affecting hepatic enzyme CYP1A2 metabolism. Significant interaction possible, monitor closely. Decreased conversion of bendamustine to active metabolites. Concentration of active metabolites of bendamustine may be decreased.
ciprofloxacin|bendamustine|11|Significant - Monitor Closely|ciprofloxacin increases levels of bendamustine by decreasing metabolism. Significant interaction possible, monitor closely. Decreased conversion of bendamustine to active metabolites. Concurrent administration of a CYP1A2 inhibitor such as ciprofloxacin may increase bendamustine concentrations. .
bendamustine|cisplatin|11|Significant - Monitor Closely|bendamustine, cisplatin.Either increases toxicity of the other by pharmacodynamic synergism. Significant interaction possible, monitor closely. Additive myelosuppression.
bendamustine|cyclophosphamide|2|Significant - Monitor Closely|bendamustine, cyclophosphamide.Either increases toxicity of the other by pharmacodynamic synergism. Potential for interaction, monitor. Additive myelosuppression.
bendamustine|dacarbazine|11|Significant - Monitor Closely|bendamustine, dacarbazine.Either increases toxicity of the other by pharmacodynamic synergism. Significant interaction possible, monitor closely. Additive myelosuppression.
fluvoxamine|bendamustine|11|Significant - Monitor Closely|fluvoxamine increases levels of bendamustine by affecting hepatic enzyme CYP1A2 metabolism. Significant interaction possible, monitor closely. Decreased conversion of bendamustine to active metabolites. Concentration of active metabolites of bendamustine may be decreased.
bendamustine|hydroxyurea|2|Significant - Monitor Closely|bendamustine, hydroxyurea. Other (see comment). Potential for interaction, monitor. Comment: Combination may increase risk of myelosuppression.
bendamustine|ifosfamide|11|Significant - Monitor Closely|bendamustine, ifosfamide.Either increases toxicity of the other by pharmacodynamic synergism. Significant interaction possible, monitor closely. Additive myelosuppression.
ivacaftor|bendamustine|20|Serious - Use Alternative|ivacaftor increases levels of bendamustine by P-glycoprotein (MDR1) efflux transporter. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available. Ivacaftor and its M1 metabolite has the potential to inhibit P-gp, may significantly increase systemic exposure to P-gp substrates.
bendamustine|lomustine|11|Significant - Monitor Closely|bendamustine, lomustine.Either increases toxicity of the other by pharmacodynamic synergism. Significant interaction possible, monitor closely. Additive myelosuppression.
bendamustine|mechlorethamine|2|Significant - Monitor Closely|bendamustine, mechlorethamine.Either increases toxicity of the other by pharmacodynamic synergism. Potential for interaction, monitor. Additive myelosuppression.
bendamustine|melphalan|11|Significant - Monitor Closely|bendamustine, melphalan.Either increases toxicity of the other by pharmacodynamic synergism. Significant interaction possible, monitor closely. Additive myelosuppression.
mexiletine|bendamustine|11|Significant - Monitor Closely|mexiletine increases levels of bendamustine by affecting hepatic enzyme CYP1A2 metabolism. Significant interaction possible, monitor closely. Decreased conversion of bendamustine to active metabolites. Concentration of active metabolites of bendamustine may be decreased.
omeprazole|bendamustine|11|Significant - Monitor Closely|omeprazole decreases levels of bendamustine by affecting hepatic enzyme CYP1A2 metabolism. Significant interaction possible, monitor closely. Concentrations of active metabolites may be increased.
bendamustine|oxaliplatin|11|Significant - Monitor Closely|bendamustine, oxaliplatin.Either increases toxicity of the other by pharmacodynamic synergism. Significant interaction possible, monitor closely. Additive myelosuppression.
palifermin|bendamustine|22|Serious - Use Alternative|palifermin increases toxicity of bendamustine by Other (see comment). High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available. Comment: Palifermin should not be administered within 24 hours before, during infusion of, or within 24 hours after administration of antineoplastic agents. .
pentobarbital|bendamustine|11|Significant - Monitor Closely|pentobarbital decreases levels of bendamustine by affecting hepatic enzyme CYP1A2 metabolism. Significant interaction possible, monitor closely. Concentrations of active metabolites may be increased.
phenobarbital|bendamustine|11|Significant - Monitor Closely|phenobarbital decreases levels of bendamustine by affecting hepatic enzyme CYP1A2 metabolism. Significant interaction possible, monitor closely. Concentrations of active metabolites may be increased.
primidone|bendamustine|11|Significant - Monitor Closely|primidone decreases levels of bendamustine by affecting hepatic enzyme CYP1A2 metabolism. Significant interaction possible, monitor closely. Concentrations of active metabolites may be increased.
secobarbital|bendamustine|11|Significant - Monitor Closely|secobarbital increases effects of bendamustine by increasing metabolism. Significant interaction possible, monitor closely. Increased conversion of bendamustine to active metabolites.
secobarbital|bendamustine|11|Significant - Monitor Closely|secobarbital decreases levels of bendamustine by affecting hepatic enzyme CYP1A2 metabolism. Significant interaction possible, monitor closely. Concentrations of active metabolites may be increased.
bendamustine|streptozocin|11|Significant - Monitor Closely|bendamustine, streptozocin.Either increases toxicity of the other by pharmacodynamic synergism. Significant interaction possible, monitor closely. Additive myelosuppression.
bendamustine|thiotepa|11|Significant - Monitor Closely|bendamustine, thiotepa.Either increases toxicity of the other by pharmacodynamic synergism. Significant interaction possible, monitor closely. Additive myelosuppression.
zileuton|bendamustine|11|Significant - Monitor Closely|zileuton increases levels of bendamustine by affecting hepatic enzyme CYP1A2 metabolism. Significant interaction possible, monitor closely. Decreased conversion of bendamustine to active metabolites. Concentration of active metabolites of bendamustine may be decreased.
diazoxide|bendroflumethiazide|1|Minor|diazoxide, bendroflumethiazide. Mechanism: pharmacodynamic synergism. Minor or non-significant interaction. Risk of hyperglycemia.
bendroflumethiazide|digoxin|11|Significant - Monitor Closely|bendroflumethiazide increases effects of digoxin by pharmacodynamic synergism. Significant interaction possible, monitor closely. Hypokalemia increases digoxin effects.
digoxin|bendroflumethiazide|2|Significant - Monitor Closely|digoxin increases and bendroflumethiazide decreases serum potassium. Effect of interaction is not clear, use caution. Potential for interaction, monitor.
bendroflumethiazide|lithium|11|Significant - Monitor Closely|bendroflumethiazide increases toxicity of lithium by decreasing elimination. Significant interaction possible, monitor closely.
treprostinil|bendroflumethiazide|1|Minor|treprostinil increases effects of bendroflumethiazide by pharmacodynamic synergism. Minor or non-significant interaction.
chlorpromazine|benzphetamine|11|Significant - Monitor Closely|chlorpromazine, benzphetamine. Mechanism: unknown. Significant interaction possible, monitor closely. Risk of cardiac arrhythmia or sudden death, more likely w/thioridazine than other phenothiazines.  Interaction more likely in certain predisposed pts. only.
chlorpromazine|benzphetamine|2|Significant - Monitor Closely|chlorpromazine increases and benzphetamine decreases sedation. Effect of interaction is not clear, use caution. Potential for interaction, monitor.
fluphenazine|benzphetamine|11|Significant - Monitor Closely|fluphenazine, benzphetamine. Mechanism: unknown. Significant interaction possible, monitor closely. Risk of cardiac arrhythmia or sudden death, more likely w/thioridazine than other phenothiazines.  Interaction more likely in certain predisposed pts. only.
fluphenazine|benzphetamine|2|Significant - Monitor Closely|fluphenazine increases and benzphetamine decreases sedation. Effect of interaction is not clear, use caution. Potential for interaction, monitor.
isocarboxazid|benzphetamine|33|Contraindicated|isocarboxazid increases effects of benzphetamine by pharmacodynamic synergism. Never use combination. Risk of acute hypertensive episode.
perphenazine|benzphetamine|11|Significant - Monitor Closely|perphenazine, benzphetamine. Mechanism: unknown. Significant interaction possible, monitor closely. Risk of cardiac arrhythmia or sudden death, more likely w/thioridazine than other phenothiazines.  Interaction more likely in certain predisposed pts. only.
perphenazine|benzphetamine|2|Significant - Monitor Closely|perphenazine increases and benzphetamine decreases sedation. Effect of interaction is not clear, use caution. Potential for interaction, monitor.
phenelzine|benzphetamine|33|Contraindicated|phenelzine increases effects of benzphetamine by pharmacodynamic synergism. Never use combination. Risk of acute hypertensive episode.
prochlorperazine|benzphetamine|11|Significant - Monitor Closely|prochlorperazine, benzphetamine. Mechanism: unknown. Significant interaction possible, monitor closely. Risk of cardiac arrhythmia or sudden death, more likely w/thioridazine than other phenothiazines.  Interaction more likely in certain predisposed pts. only.
prochlorperazine|benzphetamine|2|Significant - Monitor Closely|prochlorperazine increases and benzphetamine decreases sedation. Effect of interaction is not clear, use caution. Potential for interaction, monitor.
promethazine|benzphetamine|11|Significant - Monitor Closely|promethazine, benzphetamine. Mechanism: unknown. Significant interaction possible, monitor closely. Risk of cardiac arrhythmia or sudden death, more likely w/thioridazine than other phenothiazines.  Interaction more likely in certain predisposed pts. only.
promethazine|benzphetamine|2|Significant - Monitor Closely|promethazine increases and benzphetamine decreases sedation. Effect of interaction is not clear, use caution. Potential for interaction, monitor.
sodium bicarbonate|benzphetamine|11|Significant - Monitor Closely|sodium bicarbonate will increase the level or effect of benzphetamine by  passive renal tubular reabsorption - basic urine. Significant interaction possible, monitor closely.
thioridazine|benzphetamine|11|Significant - Monitor Closely|thioridazine, benzphetamine. Mechanism: unknown. Significant interaction possible, monitor closely. Risk of cardiac arrhythmia or sudden death, more likely w/thioridazine than other phenothiazines.  Interaction more likely in certain predisposed pts. only.
thioridazine|benzphetamine|2|Significant - Monitor Closely|thioridazine increases and benzphetamine decreases sedation. Effect of interaction is not clear, use caution. Potential for interaction, monitor.
tramadol|benzphetamine|2|Significant - Monitor Closely|tramadol increases and benzphetamine decreases sedation. Effect of interaction is not clear, use caution. Potential for interaction, monitor.
tranylcypromine|benzphetamine|33|Contraindicated|tranylcypromine increases effects of benzphetamine by pharmacodynamic synergism. Never use combination. Risk of acute hypertensive episode.
trifluoperazine|benzphetamine|11|Significant - Monitor Closely|trifluoperazine, benzphetamine. Mechanism: unknown. Significant interaction possible, monitor closely. Risk of cardiac arrhythmia or sudden death, more likely w/thioridazine than other phenothiazines.  Interaction more likely in certain predisposed pts. only.
trifluoperazine|benzphetamine|2|Significant - Monitor Closely|trifluoperazine increases and benzphetamine decreases sedation. Effect of interaction is not clear, use caution. Potential for interaction, monitor.
triprolidine|benzphetamine|2|Significant - Monitor Closely|triprolidine increases and benzphetamine decreases sedation. Effect of interaction is not clear, use caution. Potential for interaction, monitor.
clonidine|betaxolol|20|Serious - Use Alternative|clonidine, betaxolol.Either increases toxicity of the other by unspecified interaction mechanism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available. Can increase risk of bradycardia.
clonidine|betaxolol|11|Significant - Monitor Closely|clonidine, betaxolol.Either increases toxicity of the other by pharmacodynamic synergism. Significant interaction possible, monitor closely. Additive sympatholytic action may worsen sinus node dysfunction and atrioventricular (AV) block.
betaxolol|clonidine|3|Significant - Monitor Closely|betaxolol, clonidine. Mechanism: pharmacodynamic synergism. Potential for dangerous interaction. Use with caution and monitor closely. Selective beta blocker administration during withdrawal from centrally acting alpha agonists may result in rebound hypertension.
dihydroergotamine|betaxolol|1|Minor|dihydroergotamine, betaxolol. Mechanism: pharmacodynamic synergism. Minor or non-significant interaction. Additive vasospasm.
betaxolol|epinephrine|11|Significant - Monitor Closely|betaxolol decreases effects of epinephrine by pharmacodynamic antagonism. Significant interaction possible, monitor closely.
betaxolol|epinephrine|2|Significant - Monitor Closely|betaxolol increases and epinephrine decreases serum potassium. Effect of interaction is not clear, use caution. Potential for interaction, monitor.
betaxolol|formoterol|11|Significant - Monitor Closely|betaxolol decreases effects of formoterol by pharmacodynamic antagonism. Significant interaction possible, monitor closely.
betaxolol|formoterol|2|Significant - Monitor Closely|betaxolol increases and formoterol decreases serum potassium. Effect of interaction is not clear, use caution. Potential for interaction, monitor.
ibuprofen|betaxolol|11|Significant - Monitor Closely|ibuprofen decreases effects of betaxolol by pharmacodynamic antagonism. Significant interaction possible, monitor closely. Long term (>1 wk) NSAID use.  NSAIDs decrease prostaglandin synthesis.
betaxolol|ibuprofen|2|Significant - Monitor Closely|betaxolol and ibuprofen both increase  serum potassium. Potential for interaction, monitor.
indomethacin|betaxolol|11|Significant - Monitor Closely|indomethacin decreases effects of betaxolol by pharmacodynamic antagonism. Significant interaction possible, monitor closely. Long term (>1 wk) NSAID use.  NSAIDs decrease prostaglandin synthesis.
betaxolol|indomethacin|2|Significant - Monitor Closely|betaxolol and indomethacin both increase  serum potassium. Potential for interaction, monitor.
piroxicam|betaxolol|11|Significant - Monitor Closely|piroxicam decreases effects of betaxolol by pharmacodynamic antagonism. Significant interaction possible, monitor closely. Long term (>1 wk) NSAID use.  NSAIDs decrease prostaglandin synthesis.
betaxolol|piroxicam|2|Significant - Monitor Closely|betaxolol and piroxicam both increase  serum potassium. Potential for interaction, monitor.
prazosin|betaxolol|3|Significant - Monitor Closely|prazosin and betaxolol both increase  anti-hypertensive channel blocking. Potential for dangerous interaction. Use with caution and monitor closely.
terazosin|betaxolol|3|Significant - Monitor Closely|terazosin and betaxolol both increase  anti-hypertensive channel blocking. Potential for dangerous interaction. Use with caution and monitor closely.
betaxolol|terbutaline|11|Significant - Monitor Closely|betaxolol decreases effects of terbutaline by pharmacodynamic antagonism. Significant interaction possible, monitor closely.
betaxolol|terbutaline|2|Significant - Monitor Closely|betaxolol increases and terbutaline decreases serum potassium. Effect of interaction is not clear, use caution. Potential for interaction, monitor.
treprostinil|betaxolol|1|Minor|treprostinil increases effects of betaxolol by pharmacodynamic synergism. Minor or non-significant interaction.
tacrine|bethanechol|11|Significant - Monitor Closely|tacrine increases effects of bethanechol by pharmacodynamic synergism. Significant interaction possible, monitor closely.
bethanechol|tacrine|2|Significant - Monitor Closely|bethanechol and tacrine both increase  cholinergic effects/transmission. Potential for interaction, monitor.
bevacizumab|irinotecan|2|Significant - Monitor Closely|bevacizumab, irinotecan. Other (see comment). Potential for interaction, monitor. Comment: Potential for increased risk of diarrhea and neutropenia during concomitant administration of  bevacizumab and irinotecan.
bevacizumab|sorafenib|2|Significant - Monitor Closely|bevacizumab, sorafenib. Other (see comment). Potential for interaction, monitor. Comment: Monitor for development of hand-foot skin reactions during combination therapy.
bevacizumab|sunitinib|20|Serious - Use Alternative|bevacizumab, sunitinib. Other (see comment). Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available. Comment: Coadministration of bevacizumab and sunitinib is not recommended. Cases of microangiopathic hemolytic anemia (MAHA) have been reported.  .
conivaptan|bexarotene|11|Significant - Monitor Closely|conivaptan will increase the level or effect of bexarotene by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely. Upon completion or discontinuation of conivaptan, allow at least 7 days before initiating therapy with CYP3A4 substrates.
gemfibrozil|bexarotene|11|Significant - Monitor Closely|gemfibrozil increases levels of bexarotene by unspecified interaction mechanism. Significant interaction possible, monitor closely.
bexarotene|vitamin a|11|Significant - Monitor Closely|bexarotene increases toxicity of vitamin a by pharmacodynamic synergism. Significant interaction possible, monitor closely. (Vitamin A) Additive retinoid effects. Avoid consuming vitamin-A containing supplements in amounts exceeding FDA recommended daily allowance.
cholestyramine|bezafibrate|11|Significant - Monitor Closely|cholestyramine decreases levels of bezafibrate by inhibition of GI absorption. Applies only to oral form of both agents. Significant interaction possible, monitor closely.
isocarboxazid|bezafibrate|33|Contraindicated|isocarboxazid, bezafibrate.Either increases toxicity of the other by pharmacodynamic synergism. Never use combination. Increased hepatotoxicity.
linezolid|bezafibrate|33|Contraindicated|linezolid, bezafibrate.Either increases toxicity of the other by pharmacodynamic synergism. Never use combination. Increased hepatotoxicity.
bezafibrate|lovastatin|21|Serious - Use Alternative|bezafibrate, lovastatin.Either increases toxicity of the other by pharmacodynamic synergism. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available. Never use combination. Increased risk of rhabdomyolysis.
phenelzine|bezafibrate|33|Contraindicated|phenelzine, bezafibrate.Either increases toxicity of the other by pharmacodynamic synergism. Never use combination. Increased hepatotoxicity.
bezafibrate|pravastatin|11|Significant - Monitor Closely|bezafibrate, pravastatin.Either increases toxicity of the other by pharmacodynamic synergism. Significant interaction possible, monitor closely. Increased risk of rhabdomyolysis.
tranylcypromine|bezafibrate|33|Contraindicated|tranylcypromine, bezafibrate.Either increases toxicity of the other by pharmacodynamic synergism. Never use combination. Increased hepatotoxicity.
bezafibrate|warfarin|20|Serious - Use Alternative|bezafibrate increases effects of warfarin by pharmacodynamic synergism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
bezafibrate|warfarin|20|Serious - Use Alternative|bezafibrate increases effects of warfarin by plasma protein binding competition. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
latanoprost|bimatoprost|20|Serious - Use Alternative|latanoprost will increase the level or effect of bimatoprost by  unknown mechanism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available. The drug combination may result in increased intraocular pressure.
bismuth subsalicylate|minocycline|20|Serious - Use Alternative|bismuth subsalicylate decreases levels of minocycline by inhibition of GI absorption. Applies only to oral form of both agents. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
bismuth subsalicylate|tetracycline|20|Serious - Use Alternative|bismuth subsalicylate decreases levels of tetracycline by inhibition of GI absorption. Applies only to oral form of both agents. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
clonidine|bisoprolol|20|Serious - Use Alternative|clonidine, bisoprolol.Either increases toxicity of the other by unspecified interaction mechanism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available. Can increase risk of bradycardia.
bisoprolol|clonidine|3|Significant - Monitor Closely|bisoprolol, clonidine. Mechanism: pharmacodynamic synergism. Potential for dangerous interaction. Use with caution and monitor closely. Selective beta blocker administration during withdrawal from centrally acting alpha agonists may result in rebound hypertension.
dihydroergotamine|bisoprolol|1|Minor|dihydroergotamine, bisoprolol. Mechanism: pharmacodynamic synergism. Minor or non-significant interaction. Additive vasospasm.
bisoprolol|epinephrine|11|Significant - Monitor Closely|bisoprolol decreases effects of epinephrine by pharmacodynamic antagonism. Significant interaction possible, monitor closely.
bisoprolol|epinephrine|2|Significant - Monitor Closely|bisoprolol increases and epinephrine decreases serum potassium. Effect of interaction is not clear, use caution. Potential for interaction, monitor.
bisoprolol|formoterol|11|Significant - Monitor Closely|bisoprolol decreases effects of formoterol by pharmacodynamic antagonism. Significant interaction possible, monitor closely.
bisoprolol|formoterol|2|Significant - Monitor Closely|bisoprolol increases and formoterol decreases serum potassium. Effect of interaction is not clear, use caution. Potential for interaction, monitor.
ibuprofen|bisoprolol|11|Significant - Monitor Closely|ibuprofen decreases effects of bisoprolol by pharmacodynamic antagonism. Significant interaction possible, monitor closely. Long term (>1 wk) NSAID use.  NSAIDs decrease prostaglandin synthesis.
bisoprolol|ibuprofen|2|Significant - Monitor Closely|bisoprolol and ibuprofen both increase  serum potassium. Potential for interaction, monitor.
indomethacin|bisoprolol|11|Significant - Monitor Closely|indomethacin decreases effects of bisoprolol by pharmacodynamic antagonism. Significant interaction possible, monitor closely. Long term (>1 wk) NSAID use.  NSAIDs decrease prostaglandin synthesis.
bisoprolol|indomethacin|2|Significant - Monitor Closely|bisoprolol and indomethacin both increase  serum potassium. Potential for interaction, monitor.
bisoprolol|pirbuterol|11|Significant - Monitor Closely|bisoprolol decreases effects of pirbuterol by pharmacodynamic antagonism. Significant interaction possible, monitor closely.
bisoprolol|pirbuterol|2|Significant - Monitor Closely|bisoprolol increases and pirbuterol decreases serum potassium. Effect of interaction is not clear, use caution. Potential for interaction, monitor.
piroxicam|bisoprolol|11|Significant - Monitor Closely|piroxicam decreases effects of bisoprolol by pharmacodynamic antagonism. Significant interaction possible, monitor closely. Long term (>1 wk) NSAID use.  NSAIDs decrease prostaglandin synthesis.
bisoprolol|piroxicam|2|Significant - Monitor Closely|bisoprolol and piroxicam both increase  serum potassium. Potential for interaction, monitor.
prazosin|bisoprolol|3|Significant - Monitor Closely|prazosin and bisoprolol both increase  anti-hypertensive channel blocking. Potential for dangerous interaction. Use with caution and monitor closely.
bisoprolol|salmeterol|11|Significant - Monitor Closely|bisoprolol decreases effects of salmeterol by pharmacodynamic antagonism. Significant interaction possible, monitor closely.
bisoprolol|salmeterol|2|Significant - Monitor Closely|bisoprolol increases and salmeterol decreases serum potassium. Effect of interaction is not clear, use caution. Potential for interaction, monitor.
terazosin|bisoprolol|3|Significant - Monitor Closely|terazosin and bisoprolol both increase  anti-hypertensive channel blocking. Potential for dangerous interaction. Use with caution and monitor closely.
bisoprolol|terbutaline|11|Significant - Monitor Closely|bisoprolol decreases effects of terbutaline by pharmacodynamic antagonism. Significant interaction possible, monitor closely.
bisoprolol|terbutaline|2|Significant - Monitor Closely|bisoprolol increases and terbutaline decreases serum potassium. Effect of interaction is not clear, use caution. Potential for interaction, monitor.
treprostinil|bisoprolol|1|Minor|treprostinil increases effects of bisoprolol by pharmacodynamic synergism. Minor or non-significant interaction.
verapamil|bisoprolol|20|Serious - Use Alternative|verapamil, bisoprolol.Either increases toxicity of the other by unspecified interaction mechanism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available. Can increase risk of bradycardia.
bisoprolol|verapamil|3|Significant - Monitor Closely|bisoprolol and verapamil both increase  anti-hypertensive channel blocking. Potential for dangerous interaction. Use with caution and monitor closely.
deferasirox|bivalirudin|2|Significant - Monitor Closely|deferasirox, bivalirudin. Other (see comment). Potential for interaction, monitor. Comment: Gastric ulceration and GI bleeding have been reported in patients taking deferasirox, use caution when coadministering with other drugs known to increase the risk of peptic ulcers or gastric hemorrhage including anticoagulants.
gemcitabine|bivalirudin|2|Significant - Monitor Closely|gemcitabine increases effects of bivalirudin by unspecified interaction mechanism. Potential for interaction, monitor. Due to the thrombocytopenic effects of gemcitabine, an additive risk of bleeding may be seen in patients receiving concomitant anticoagulants.
bivalirudin|ginkgo biloba|3|Significant - Monitor Closely|bivalirudin and ginkgo biloba both increase  anticoagulation. Potential for dangerous interaction. Use with caution and monitor closely.
rivaroxaban|bivalirudin|11|Significant - Monitor Closely|rivaroxaban, bivalirudin.Either increases effects of the other by anticoagulation. Significant interaction possible, monitor closely. Avoid concurrent use of rivaroxaban with other anticoagulants due to increased bleeding risk other than during therapeutic transition periods where patients should be observed closely. Monitor for signs/symptoms of blood loss.
brentuximab vedotin|bleomycin|33|Contraindicated|brentuximab vedotin and bleomycin both increase  Other (see comment). Never use combination. Contraindicated because of increased risk of pulmonary toxicity.
bleomycin|fosphenytoin|11|Significant - Monitor Closely|bleomycin decreases levels of fosphenytoin by increasing metabolism. Significant interaction possible, monitor closely.
bleomycin|phenytoin|11|Significant - Monitor Closely|bleomycin decreases levels of phenytoin by increasing metabolism. Significant interaction possible, monitor closely.
carbamazepine|boceprevir|33|Contraindicated|carbamazepine will decrease the level or effect of boceprevir by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Never use combination. Contraindicated. May lead to loss of virologic response to boceprevir.
boceprevir|cisapride|33|Contraindicated|boceprevir will increase the level or effect of cisapride by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Never use combination. Contraindicated. Potential for cardiac arrhythmias.
boceprevir|conivaptan|33|Contraindicated|boceprevir will increase the level or effect of conivaptan by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Never use combination. Coadministration of conivaptan with strong CYP3A4 inhibitors is contraindicated.
boceprevir|dihydroergotamine|33|Contraindicated|boceprevir increases levels of dihydroergotamine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Never use combination. Potential for acute ergot toxicity characterized by peripheral vasospasm and ischemia of the extremities and other tissues.
boceprevir|drospirenone|33|Contraindicated|boceprevir increases levels of drospirenone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Never use combination. Contraindicated. Potential for hyperkalemia.
boceprevir|etravirine|11|Significant - Monitor Closely|boceprevir increases levels of etravirine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely. Combination of etravirine and boceprevir can be used without dose adjustments; coadministration of etravirine and boceprevir not recommended in presence of other drugs which may further decrease etravirine exposure including but not limited to, darunavir/ritonavir, lopinavir/ritonavir, saquinavir/ritonavir, tenofovir disoproxil fumarate, or rifabutin .
fosphenytoin|boceprevir|33|Contraindicated|fosphenytoin will decrease the level or effect of boceprevir by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Never use combination. Contraindicated. May lead to loss of virologic response to boceprevir.
boceprevir|lomitapide|33|Contraindicated|boceprevir increases levels of lomitapide by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Never use combination. Increases lomitapide levels several folds .
boceprevir|midazolam|33|Contraindicated|boceprevir increases levels of midazolam by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Never use combination. Contraindicated. Concurrent use with oral midazolam may cause prolonged or increased sedation or respiratory depression. Concurrent use with boceprevir and IV midazolam may cause a  significant interaction; consider using a lower dose of IV midazolam. .
phenobarbital|boceprevir|33|Contraindicated|phenobarbital will decrease the level or effect of boceprevir by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Never use combination. Contraindicated. May lead to loss of virologic response to boceprevir.
phenytoin|boceprevir|33|Contraindicated|phenytoin will decrease the level or effect of boceprevir by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Never use combination. Contraindicated. May lead to loss of virologic response to boceprevir.
boceprevir|pimozide|33|Contraindicated|boceprevir increases levels of pimozide by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Never use combination. Contraindicated. Potential for cardiac arrhythmias.
boceprevir|ponatinib|20|Serious - Use Alternative|boceprevir increases levels of ponatinib by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available. Decrease ponatinib starting dose to 30 mg qDay if coadministration with strong CYP3A4 inhibitors cannot be avoided.
boceprevir|pravastatin|11|Significant - Monitor Closely|boceprevir increases levels of pravastatin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
boceprevir|sirolimus|11|Significant - Monitor Closely|boceprevir increases levels of sirolimus by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely. Plasma concentrations of sirolimus are expected to be increased significantly during coadministration with boceprevir. Close monitoring of immunosuppressant blood levels is recommended.
boceprevir|tacrolimus|11|Significant - Monitor Closely|boceprevir increases levels of tacrolimus by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely. Plasma concentrations of tacrolimus are expected to be increased significantly during coadministration with boceprevir. Close monitoring of immunosuppressant blood levels is recommended.
boceprevir|tadalafil|33|Contraindicated|boceprevir increases levels of tadalafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Never use combination. Contraindicated with chronic use for PAH.  Boceprevir can be used with tadalafil for ED; dose should be limited to 10 mg every 72 hr with increased monitoring for adverse reactions.
bortezomib|clopidogrel|11|Significant - Monitor Closely|bortezomib decreases effects of clopidogrel by decreasing metabolism. Significant interaction possible, monitor closely. Avoid concurrent use of CYP2C19 inhibitors with clopidogrel. Due to the thrombocytopenic effects of bortezomib, an additive risk of bleeding may be seen in patients receiving concomitant  platelet inhibitors.
bortezomib|etravirine|2|Significant - Monitor Closely|bortezomib will increase the level or effect of etravirine by  affecting hepatic enzyme CYP2C19 metabolism. Potential for interaction, monitor.
etravirine|bortezomib|2|Significant - Monitor Closely|etravirine will decrease the level or effect of bortezomib by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Potential for interaction, monitor.
telithromycin|bortezomib|2|Significant - Monitor Closely|telithromycin will increase the level or effect of bortezomib by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Potential for interaction, monitor.
voriconazole|bortezomib|2|Significant - Monitor Closely|voriconazole will increase the level or effect of bortezomib by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Potential for interaction, monitor.
bortezomib|voriconazole|1|Minor|bortezomib will increase the level or effect of voriconazole by  affecting hepatic enzyme CYP2C19 metabolism. Minor or non-significant interaction.
cyclosporine|bosentan|20|Serious - Use Alternative|cyclosporine will increase the level or effect of bosentan by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
bosentan|cyclosporine|20|Serious - Use Alternative|bosentan will decrease the level or effect of cyclosporine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
bosentan|glyburide|33|Contraindicated|bosentan, glyburide.Either decreases levels of the other by increasing metabolism. Never use combination.
bosentan|glyburide|33|Contraindicated|bosentan, glyburide.Either increases toxicity of the other by Other (see comment). Never use combination. Comment: Coadministration increases risk of liver enzyme elevations; alternative hypoglycemic agents should be considered.
bosentan|glyburide|2|Significant - Monitor Closely|bosentan decreases levels of glyburide by affecting hepatic enzyme CYP2C9/10 metabolism. Potential for interaction, monitor. Strong CYP2C9 inducers may increase glyburide metabolism.
itraconazole|bosentan|2|Significant - Monitor Closely|itraconazole will increase the level or effect of bosentan by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Potential for interaction, monitor.
itraconazole|bosentan|1|Minor|itraconazole will increase the level or effect of bosentan by  affecting hepatic enzyme CYP2C9/10 metabolism. Minor or non-significant interaction.
bosentan|itraconazole|1|Minor|bosentan will decrease the level or effect of itraconazole by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor or non-significant interaction.
ketoconazole|bosentan|2|Significant - Monitor Closely|ketoconazole will increase the level or effect of bosentan by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Potential for interaction, monitor.
ketoconazole|bosentan|1|Minor|ketoconazole will increase the level or effect of bosentan by  affecting hepatic enzyme CYP2C9/10 metabolism. Minor or non-significant interaction.
bosentan|ketoconazole|1|Minor|bosentan will decrease the level or effect of ketoconazole by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor or non-significant interaction.
bosentan|lovastatin|20|Serious - Use Alternative|bosentan will decrease the level or effect of lovastatin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
bosentan|lurasidone|33|Contraindicated|bosentan decreases levels of lurasidone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Never use combination. Contraindicated.
bosentan|mestranol|11|Significant - Monitor Closely|bosentan will decrease the level or effect of mestranol by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
bosentan|roflumilast|33|Contraindicated|bosentan will decrease the level or effect of roflumilast by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Never use combination. Coadministration not recommended; strong cytochrome P450 enzyme inducers decrease systemic exposure to roflumilast and may reduce the therapeutic effectiveness
bosentan|simvastatin|20|Serious - Use Alternative|bosentan will decrease the level or effect of simvastatin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
telithromycin|bosentan|1|Minor|telithromycin will increase the level or effect of bosentan by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor or non-significant interaction.
bosentan|telithromycin|1|Minor|bosentan will decrease the level or effect of telithromycin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor or non-significant interaction.
bosentan|temsirolimus|11|Significant - Monitor Closely|bosentan will decrease the level or effect of temsirolimus by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
bosentan|tolbutamide|1|Minor|bosentan will decrease the level or effect of tolbutamide by  affecting hepatic enzyme CYP2C9/10 metabolism. Minor or non-significant interaction.
bosentan|tramadol|11|Significant - Monitor Closely|bosentan will decrease the level or effect of tramadol by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely. Decreased AUC  of tramadol and the active metabolite (O-desmethyltramadol) when coadministered with strong CYP3A4 and CYP2B6 inducers
bosentan|trazodone|22|Serious - Use Alternative|bosentan will decrease the level or effect of trazodone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available.
bosentan|ulipristal|20|Serious - Use Alternative|bosentan will decrease the level or effect of ulipristal by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
bosentan|vandetanib|33|Contraindicated|bosentan decreases levels of vandetanib by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Never use combination. Avoid coadministration with potent CYP3A4 inducers; these drugs reduce exposure to vandetanib by up to 40%.
voriconazole|bosentan|1|Minor|voriconazole will increase the level or effect of bosentan by  affecting hepatic enzyme CYP2C9/10 metabolism. Minor or non-significant interaction.
bosentan|voriconazole|1|Minor|bosentan will decrease the level or effect of voriconazole by  affecting hepatic enzyme CYP2C9/10 metabolism. Minor or non-significant interaction.
voriconazole|bosentan|1|Minor|voriconazole will increase the level or effect of bosentan by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor or non-significant interaction.
bosentan|warfarin|11|Significant - Monitor Closely|bosentan will decrease the level or effect of warfarin by  affecting hepatic enzyme CYP2C9/10 metabolism. Significant interaction possible, monitor closely.
bosentan|warfarin|11|Significant - Monitor Closely|bosentan will decrease the level or effect of warfarin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
crizotinib|bosutinib|20|Serious - Use Alternative|crizotinib increases levels of bosutinib by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
bosutinib|digoxin|2|Significant - Monitor Closely|bosutinib increases levels of digoxin by P-glycoprotein (MDR1) efflux transporter. Potential for interaction, monitor.
etravirine|bosutinib|20|Serious - Use Alternative|etravirine decreases levels of bosutinib by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available. Strong CYP3A4 inducers decreased bosutinib plasma concentration by ~85%.
ketoconazole|bosutinib|20|Serious - Use Alternative|ketoconazole increases levels of bosutinib by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available. Strong CYP3A4 inhibitors increases bosutinib plasma concentration ~5-fold.
ketoconazole|bosutinib|20|Serious - Use Alternative|ketoconazole increases levels of bosutinib by P-glycoprotein (MDR1) efflux transporter. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
lansoprazole|bosutinib|11|Significant - Monitor Closely|lansoprazole decreases levels of bosutinib by Other (see comment). Significant interaction possible, monitor closely. Comment: PPIs may decrease bosutinib concentration by ~45%; bosutinib displays pH-dependent solubility.
brimonidine|droperidol|1|Minor|brimonidine increases effects of droperidol by pharmacodynamic synergism. Minor or non-significant interaction. Increased CNS depression.
isocarboxazid|brimonidine|33|Contraindicated|isocarboxazid, brimonidine. Mechanism: unknown. Never use combination. Contraindicated in mfr prescribing info.
linezolid|brimonidine|33|Contraindicated|linezolid, brimonidine. Mechanism: unknown. Never use combination. Contraindicated in mfr prescribing info.
phenelzine|brimonidine|33|Contraindicated|phenelzine, brimonidine. Mechanism: unknown. Never use combination. Contraindicated in mfr prescribing info.
procarbazine|brimonidine|33|Contraindicated|procarbazine, brimonidine. Mechanism: unknown. Never use combination.
rasagiline|brimonidine|33|Contraindicated|rasagiline, brimonidine. Mechanism: unknown. Never use combination. Brimonidine should not be used in patients receiving MAO inhibitors.
selegiline|brimonidine|33|Contraindicated|selegiline, brimonidine. Mechanism: unknown. Never use combination. Coadministration is contraindicated.
tranylcypromine|brimonidine|33|Contraindicated|tranylcypromine, brimonidine. Mechanism: unknown. Never use combination. Contraindicated in mfr prescribing info.
brimonidine|treprostinil|1|Minor|brimonidine increases effects of treprostinil by pharmacodynamic synergism. Minor or non-significant interaction.
topiramate|brinzolamide|11|Significant - Monitor Closely|topiramate, brinzolamide.Either increases toxicity of the other by pharmacodynamic synergism. Significant interaction possible, monitor closely. Increased risk of kidney stone formation.
chlorpromazine|bromocriptine|20|Serious - Use Alternative|chlorpromazine decreases effects of bromocriptine by pharmacodynamic antagonism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
fluphenazine|bromocriptine|20|Serious - Use Alternative|fluphenazine decreases effects of bromocriptine by pharmacodynamic antagonism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
paliperidone|bromocriptine|20|Serious - Use Alternative|paliperidone decreases effects of bromocriptine by pharmacodynamic antagonism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
perphenazine|bromocriptine|20|Serious - Use Alternative|perphenazine decreases effects of bromocriptine by pharmacodynamic antagonism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
prochlorperazine|bromocriptine|20|Serious - Use Alternative|prochlorperazine decreases effects of bromocriptine by pharmacodynamic antagonism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
promethazine|bromocriptine|20|Serious - Use Alternative|promethazine decreases effects of bromocriptine by pharmacodynamic antagonism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
bromocriptine|pseudoephedrine|11|Significant - Monitor Closely|bromocriptine, pseudoephedrine.Either increases effects of the other by pharmacodynamic synergism. Significant interaction possible, monitor closely. Hypertension, V tach.
bromocriptine|tacrolimus|11|Significant - Monitor Closely|bromocriptine increases levels of tacrolimus by decreasing metabolism. Significant interaction possible, monitor closely.
thioridazine|bromocriptine|20|Serious - Use Alternative|thioridazine decreases effects of bromocriptine by pharmacodynamic antagonism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
thiothixene|bromocriptine|20|Serious - Use Alternative|thiothixene decreases effects of bromocriptine by pharmacodynamic antagonism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
tipranavir|bromocriptine|11|Significant - Monitor Closely|tipranavir increases levels of bromocriptine by decreasing metabolism. Significant interaction possible, monitor closely. Increased levels possibly due to CYP3A4 inhibition.
trifluoperazine|bromocriptine|20|Serious - Use Alternative|trifluoperazine decreases effects of bromocriptine by pharmacodynamic antagonism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
ibuprofen|pralatrexate|11|Significant - Monitor Closely|ibuprofen increases levels of pralatrexate by decreasing renal clearance. Significant interaction possible, monitor closely. NSAIDs may delay pralatrexate clearance, increasing drug exposure. Adjust the pralatrexate dose as needed.
ibuprofen|propranolol|11|Significant - Monitor Closely|ibuprofen decreases effects of propranolol by pharmacodynamic antagonism. Significant interaction possible, monitor closely. Long term (>1 wk) NSAID use.  NSAIDs decrease prostaglandin synthesis.
propranolol|ibuprofen|2|Significant - Monitor Closely|propranolol and ibuprofen both increase  serum potassium. Potential for interaction, monitor.
ibuprofen|sotalol|11|Significant - Monitor Closely|ibuprofen decreases effects of sotalol by pharmacodynamic antagonism. Significant interaction possible, monitor closely. Long term (>1 wk) NSAID use.  NSAIDs decrease prostaglandin synthesis.
sotalol|ibuprofen|2|Significant - Monitor Closely|sotalol and ibuprofen both increase  serum potassium. Potential for interaction, monitor.
ibuprofen|tolbutamide|11|Significant - Monitor Closely|ibuprofen increases effects of tolbutamide by unknown mechanism. Significant interaction possible, monitor closely. Risk of hypoglycemia.
trandolapril|ibuprofen|11|Significant - Monitor Closely|trandolapril, ibuprofen.Either increases toxicity of the other by Other (see comment). Significant interaction possible, monitor closely. Comment: May result in renal function deterioration, particularly in elderly or volume depleted individuals.
ibuprofen|trandolapril|3|Significant - Monitor Closely|ibuprofen decreases effects of trandolapril by pharmacodynamic antagonism. Potential for dangerous interaction. Use with caution and monitor closely. NSAIDs decrease synthesis of vasodilating renal prostaglandins, and thus affect fluid homeostasis and may diminish antihypertenisve effect.
voriconazole|ibuprofen|1|Minor|voriconazole will increase the level or effect of ibuprofen by  affecting hepatic enzyme CYP2C9/10 metabolism. Minor or non-significant interaction.
warfarin|ibuprofen|3|Significant - Monitor Closely|warfarin and ibuprofen both increase  anticoagulation. Potential for dangerous interaction. Use with caution and monitor closely.
ibutilide|lumefantrine|33|Contraindicated|ibutilide and lumefantrine both increase  QTc interval. Never use combination.
ibutilide|ranolazine|22|Serious - Use Alternative|ibutilide and ranolazine both increase  QTc interval. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available.
ibutilide|telavancin|22|Serious - Use Alternative|ibutilide and telavancin both increase  QTc interval. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available.
ibutilide|toremifene|20|Serious - Use Alternative|ibutilide and toremifene both increase  QTc interval. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available. Concurrent use of toremifene with agents causing  QT prolongation should be avoided. If concomitant use is required it's recommended that toremifene be interrupted. If interruption not possible, patients requiring therapy with a drug that prolongs QT should be closely monitored. ECGs should be obtained for high risk patients.
trimipramine|ibutilide|33|Contraindicated|trimipramine and ibutilide both increase  QTc interval. Never use combination.
ibutilide|voriconazole|22|Serious - Use Alternative|ibutilide and voriconazole both increase  QTc interval. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available.
ibutilide|ziprasidone|33|Contraindicated|ibutilide and ziprasidone both increase  QTc interval. Never use combination.
icatibant|moexipril|2|Significant - Monitor Closely|icatibant decreases effects of moexipril by pharmacodynamic antagonism. Potential for interaction, monitor. Icatibant has potential to have a pharmacodynamic interaction with ACE inhibitors where it may attenuate the antihypertensive effect of ACE inhibitors.
icatibant|perindopril|2|Significant - Monitor Closely|icatibant decreases effects of perindopril by pharmacodynamic antagonism. Potential for interaction, monitor. Icatibant has potential to have a pharmacodynamic interaction with ACE inhibitors where it may attenuate the antihypertensive effect of ACE inhibitors.
icatibant|quinapril|2|Significant - Monitor Closely|icatibant decreases effects of quinapril by pharmacodynamic antagonism. Potential for interaction, monitor. Icatibant has potential to have a pharmacodynamic interaction with ACE inhibitors where it may attenuate the antihypertensive effect of ACE inhibitors.
icatibant|ramipril|2|Significant - Monitor Closely|icatibant decreases effects of ramipril by pharmacodynamic antagonism. Potential for interaction, monitor. Icatibant has potential to have a pharmacodynamic interaction with ACE inhibitors where it may attenuate the antihypertensive effect of ACE inhibitors.
icatibant|trandolapril|2|Significant - Monitor Closely|icatibant decreases effects of trandolapril by pharmacodynamic antagonism. Potential for interaction, monitor. Icatibant has potential to have a pharmacodynamic interaction with ACE inhibitors where it may attenuate the antihypertensive effect of ACE inhibitors.
trastuzumab|idarubicin|20|Serious - Use Alternative|trastuzumab increases toxicity of idarubicin by Other (see comment). Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available. Comment: May increase formation of toxic anthracycline metabolites in heart tissue.
ketoconazole|iloperidone|20|Serious - Use Alternative|ketoconazole will increase the level or effect of iloperidone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
iloperidone|ketoconazole|3|Significant - Monitor Closely|iloperidone and ketoconazole both increase  QTc interval. Potential for dangerous interaction. Use with caution and monitor closely.
lumefantrine|iloperidone|20|Serious - Use Alternative|lumefantrine will increase the level or effect of iloperidone by  affecting hepatic enzyme CYP2D6 metabolism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
lumefantrine|iloperidone|11|Significant - Monitor Closely|lumefantrine will decrease the level or effect of iloperidone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
iloperidone|lumefantrine|3|Significant - Monitor Closely|iloperidone and lumefantrine both increase  QTc interval. Potential for dangerous interaction. Use with caution and monitor closely.
paroxetine|iloperidone|20|Serious - Use Alternative|paroxetine will increase the level or effect of iloperidone by  affecting hepatic enzyme CYP2D6 metabolism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
iloperidone|paroxetine|2|Significant - Monitor Closely|iloperidone and paroxetine both increase  QTc interval. Potential for interaction, monitor.
iloperidone|ziprasidone|3|Significant - Monitor Closely|iloperidone and ziprasidone both increase  QTc interval. Potential for dangerous interaction. Use with caution and monitor closely.
iloperidone|ziprasidone|2|Significant - Monitor Closely|iloperidone and ziprasidone both increase  antidopaminergic effects, including extrapyramidal symptoms and neuroleptic malignant syndrome. Potential for interaction, monitor.
iloperidone|ziprasidone|2|Significant - Monitor Closely|iloperidone and ziprasidone both increase  sedation. Potential for interaction, monitor.
itraconazole|imatinib|11|Significant - Monitor Closely|itraconazole will increase the level or effect of imatinib by  P-glycoprotein (MDR1) efflux transporter. Significant interaction possible, monitor closely.
itraconazole|imatinib|2|Significant - Monitor Closely|itraconazole will increase the level or effect of imatinib by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Potential for interaction, monitor.
ketoconazole|imatinib|11|Significant - Monitor Closely|ketoconazole will increase the level or effect of imatinib by  P-glycoprotein (MDR1) efflux transporter. Significant interaction possible, monitor closely.
ketoconazole|imatinib|2|Significant - Monitor Closely|ketoconazole will increase the level or effect of imatinib by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Potential for interaction, monitor.
lovastatin|imatinib|11|Significant - Monitor Closely|lovastatin will increase the level or effect of imatinib by  P-glycoprotein (MDR1) efflux transporter. Significant interaction possible, monitor closely.
imatinib|lurasidone|33|Contraindicated|imatinib increases levels of lurasidone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Never use combination. Coadministration of lurasidone and strong CYP3A4 inhibitors is contraindicated.
nifedipine|imatinib|11|Significant - Monitor Closely|nifedipine will decrease the level or effect of imatinib by  P-glycoprotein (MDR1) efflux transporter. Significant interaction possible, monitor closely.
nifedipine|imatinib|1|Minor|nifedipine will increase the level or effect of imatinib by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor or non-significant interaction.
phenobarbital|imatinib|11|Significant - Monitor Closely|phenobarbital will decrease the level or effect of imatinib by  P-glycoprotein (MDR1) efflux transporter. Significant interaction possible, monitor closely.
phenobarbital|imatinib|1|Minor|phenobarbital will decrease the level or effect of imatinib by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor or non-significant interaction.
imatinib|phenytoin|11|Significant - Monitor Closely|imatinib will increase the level or effect of phenytoin by  affecting hepatic enzyme CYP2C9/10 metabolism. Significant interaction possible, monitor closely.
phenytoin|imatinib|11|Significant - Monitor Closely|phenytoin will decrease the level or effect of imatinib by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.  Alternatives to phenytoin, with less enzyme induction potential, should be considered.  Combo may decrease imatinib levels and efficacy.
phenytoin|imatinib|11|Significant - Monitor Closely|phenytoin will decrease the level or effect of imatinib by  P-glycoprotein (MDR1) efflux transporter. Significant interaction possible, monitor closely.
imatinib|pimozide|11|Significant - Monitor Closely|imatinib increases levels of pimozide by decreasing metabolism. Significant interaction possible, monitor closely.
tacrolimus|imatinib|11|Significant - Monitor Closely|tacrolimus will increase the level or effect of imatinib by  P-glycoprotein (MDR1) efflux transporter. Significant interaction possible, monitor closely.
imatinib|tadalafil|11|Significant - Monitor Closely|imatinib will increase the level or effect of tadalafil by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely. For ED limit tadalafil to max of 2.5 mg/day (for daily use) or 10 mg dose every 72 hr (for use as needed). Avoid concurrent use of tadalafil for pulmonary HTN in patients taking strong CYP3A4 inhibitors.
imatinib|tamoxifen|11|Significant - Monitor Closely|imatinib decreases effects of tamoxifen by decreasing metabolism. Significant interaction possible, monitor closely. Inhibition of CYP2D6 metabolism to tamoxifen's active metabolite, endoxifen.
imatinib|tamsulosin|20|Serious - Use Alternative|imatinib increases levels of tamsulosin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
imatinib|tamsulosin|2|Significant - Monitor Closely|imatinib increases levels of tamsulosin by affecting hepatic enzyme CYP2D6 metabolism. Potential for interaction, monitor.
telithromycin|imatinib|1|Minor|telithromycin will increase the level or effect of imatinib by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor or non-significant interaction.
imatinib|tolterodine|1|Minor|imatinib will increase the level or effect of tolterodine by  affecting hepatic enzyme CYP2D6 metabolism. Minor or non-significant interaction.
trazodone|imatinib|11|Significant - Monitor Closely|trazodone will decrease the level or effect of imatinib by  P-glycoprotein (MDR1) efflux transporter. Significant interaction possible, monitor closely.
verapamil|imatinib|11|Significant - Monitor Closely|verapamil will increase the level or effect of imatinib by  P-glycoprotein (MDR1) efflux transporter. Significant interaction possible, monitor closely.
verapamil|imatinib|1|Minor|verapamil will increase the level or effect of imatinib by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor or non-significant interaction.
imatinib|voriconazole|11|Significant - Monitor Closely|imatinib will increase the level or effect of voriconazole by  affecting hepatic enzyme CYP2C9/10 metabolism. Significant interaction possible, monitor closely.
voriconazole|imatinib|1|Minor|voriconazole will increase the level or effect of imatinib by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor or non-significant interaction.
imatinib|warfarin|21|Serious - Use Alternative|imatinib increases levels of warfarin by decreasing metabolism. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available. Never use combination.
imatinib|warfarin|3|Significant - Monitor Closely|imatinib will increase the level or effect of warfarin by  affecting hepatic enzyme CYP2C9/10 metabolism. Potential for dangerous interaction. Use with caution and monitor closely.
imatinib|warfarin|3|Significant - Monitor Closely|imatinib, warfarin.Either increases toxicity of the other by Other (see comment). Potential for dangerous interaction. Use with caution and monitor closely. Comment: Imatinib may cause thrombocytopenia; bleeding risk increased when imatinib is coadministered with anticoagulants, NSAIDs, platelet inhibitors, and thrombolytic agents; patients requiring anticoagulation while on imatinib should receive LMWH or unfractionated heparin instead of warfarin because of multiple interaction mechanisms of imatinib with warfarin.
imatinib|warfarin|3|Significant - Monitor Closely|imatinib, warfarin.Either increases toxicity of the other by plasma protein binding competition. Potential for dangerous interaction. Use with caution and monitor closely. Patients requiring anticoagulation while on imatinib should receive LMWH or unfractionated heparin instead of warfarin because of multiple interaction mechanisms of imatinib with warfarin.
isocarboxazid|imipramine|33|Contraindicated|isocarboxazid and imipramine both increase  serotonin levels. Never use combination.
imipramine|ketoconazole|22|Serious - Use Alternative|imipramine and ketoconazole both increase  QTc interval. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available.
ketoconazole|imipramine|2|Significant - Monitor Closely|ketoconazole will increase the level or effect of imipramine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Potential for interaction, monitor.
imipramine|lumefantrine|22|Serious - Use Alternative|imipramine and lumefantrine both increase  QTc interval. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available.
lumefantrine|imipramine|20|Serious - Use Alternative|lumefantrine will increase the level or effect of imipramine by  affecting hepatic enzyme CYP2D6 metabolism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
lumefantrine|imipramine|1|Minor|lumefantrine will decrease the level or effect of imipramine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor or non-significant interaction.
imipramine|norepinephrine|20|Serious - Use Alternative|imipramine, norepinephrine. Other (see comment). Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available. Comment: Tricyclic antidepressants increase or decrease effects of sympathomimetics, by blocking reuptake of NE, or blocking uptake of indirect sympathomimetics into the adrenergic neuron.
imipramine|norepinephrine|11|Significant - Monitor Closely|imipramine increases effects of norepinephrine by unknown mechanism. Significant interaction possible, monitor closely.
imipramine|norepinephrine|2|Significant - Monitor Closely|imipramine increases and norepinephrine decreases sedation. Effect of interaction is not clear, use caution. Potential for interaction, monitor.
phenelzine|imipramine|33|Contraindicated|phenelzine and imipramine both increase  serotonin levels. Never use combination.
imipramine|phenylephrine|20|Serious - Use Alternative|imipramine, phenylephrine. Other (see comment). Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available. Comment: Tricyclic antidepressants increase or decrease effects of sympathomimetics, by blocking reuptake of NE, or blocking uptake of indirect sympathomimetics into the adrenergic neuron.
imipramine|phenylephrine|2|Significant - Monitor Closely|imipramine increases and phenylephrine decreases sedation. Effect of interaction is not clear, use caution. Potential for interaction, monitor.
imipramine|pirbuterol|20|Serious - Use Alternative|imipramine, pirbuterol. Other (see comment). Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available. Comment: Tricyclic antidepressants increase or decrease effects of sympathomimetics, by blocking reuptake of NE, or blocking uptake of indirect sympathomimetics into the adrenergic neuron.
imipramine|pirbuterol|2|Significant - Monitor Closely|imipramine increases and pirbuterol decreases sedation. Effect of interaction is not clear, use caution. Potential for interaction, monitor.
imipramine|pseudoephedrine|20|Serious - Use Alternative|imipramine, pseudoephedrine. Other (see comment). Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available. Comment: Tricyclic antidepressants increase or decrease effects of sympathomimetics, by blocking reuptake of NE, or blocking uptake of indirect sympathomimetics into the adrenergic neuron.
imipramine|pseudoephedrine|2|Significant - Monitor Closely|imipramine increases and pseudoephedrine decreases sedation. Effect of interaction is not clear, use caution. Potential for interaction, monitor.
quinidine|imipramine|33|Contraindicated|quinidine and imipramine both increase  QTc interval. Never use combination.
quinidine|imipramine|20|Serious - Use Alternative|quinidine will increase the level or effect of imipramine by  affecting hepatic enzyme CYP2D6 metabolism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
rasagiline|imipramine|20|Serious - Use Alternative|rasagiline and imipramine both increase  serotonin levels. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available. Severe CNS toxicity associated with hyperpyrexia has been reported with the combined treatment of an antidepressant and rasagiline. Avoid combination within 14 days of MAOI use.
rifabutin|imipramine|11|Significant - Monitor Closely|rifabutin decreases levels of imipramine by increasing metabolism. Significant interaction possible, monitor closely.
rifabutin|imipramine|2|Significant - Monitor Closely|rifabutin will decrease the level or effect of imipramine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Potential for interaction, monitor.
ritonavir|imipramine|11|Significant - Monitor Closely|ritonavir will increase the level or effect of imipramine by  affecting hepatic enzyme CYP2D6 metabolism. Significant interaction possible, monitor closely.
ritonavir|imipramine|11|Significant - Monitor Closely|ritonavir will increase the level or effect of imipramine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
tacrine|imipramine|11|Significant - Monitor Closely|tacrine will increase the level or effect of imipramine by  affecting hepatic enzyme CYP1A2 metabolism. Significant interaction possible, monitor closely.
tacrine|imipramine|2|Significant - Monitor Closely|tacrine increases and imipramine decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Potential for interaction, monitor.
imipramine|tamsulosin|2|Significant - Monitor Closely|imipramine increases levels of tamsulosin by affecting hepatic enzyme CYP2D6 metabolism. Potential for interaction, monitor.
imipramine|terbutaline|20|Serious - Use Alternative|imipramine, terbutaline. Other (see comment). Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available. Comment: Tricyclic antidepressants increase or decrease effects of sympathomimetics, by blocking reuptake of NE, or blocking uptake of indirect sympathomimetics into the adrenergic neuron.
imipramine|terbutaline|2|Significant - Monitor Closely|imipramine increases and terbutaline decreases sedation. Effect of interaction is not clear, use caution. Potential for interaction, monitor.
imipramine|terfenadine|33|Contraindicated|imipramine and terfenadine both increase  QTc interval. Never use combination.
terfenadine|imipramine|2|Significant - Monitor Closely|terfenadine and imipramine both increase  sedation. Potential for interaction, monitor.
thioridazine|imipramine|33|Contraindicated|thioridazine will increase the level or effect of imipramine by  affecting hepatic enzyme CYP2D6 metabolism. Never use combination.
thioridazine|imipramine|22|Serious - Use Alternative|thioridazine and imipramine both increase  QTc interval. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available.
thioridazine|imipramine|2|Significant - Monitor Closely|thioridazine and imipramine both increase  sedation. Potential for interaction, monitor.
imipramine|thioridazine|1|Minor|imipramine, thioridazine.Either increases levels of the other by decreasing metabolism. Minor or non-significant interaction. Additive anticholinergic effects.
imipramine|thioridazine|1|Minor|imipramine, thioridazine.Either increases levels of the other by pharmacodynamic synergism. Minor or non-significant interaction. Additive anticholinergic effects.
thiothixene|imipramine|2|Significant - Monitor Closely|thiothixene and imipramine both increase  sedation. Potential for interaction, monitor.
imipramine|toremifene|20|Serious - Use Alternative|imipramine and toremifene both increase  QTc interval. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available. Concurrent use of toremifene with agents causing  QT prolongation should be avoided. If concomitant use is required it's recommended that toremifene be interrupted. If interruption not possible, patients requiring therapy with a drug that prolongs QT should be closely monitored. ECGs should be obtained for high risk patients.
imipramine|tramadol|3|Significant - Monitor Closely|imipramine and tramadol both increase  serotonin levels. Potential for dangerous interaction. Use with caution and monitor closely.
tramadol|imipramine|2|Significant - Monitor Closely|tramadol and imipramine both increase  sedation. Potential for interaction, monitor.
tranylcypromine|imipramine|33|Contraindicated|tranylcypromine and imipramine both increase  serotonin levels. Never use combination.
imipramine|trazodone|22|Serious - Use Alternative|imipramine and trazodone both increase  QTc interval. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available.
trazodone|imipramine|22|Serious - Use Alternative|trazodone and imipramine both increase  serotonin levels. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available.
imipramine|trazodone|2|Significant - Monitor Closely|imipramine and trazodone both decrease  cholinergic effects/transmission. Potential for interaction, monitor.
imipramine|trazodone|2|Significant - Monitor Closely|imipramine and trazodone both increase  sedation. Potential for interaction, monitor.
imipramine|trimipramine|22|Serious - Use Alternative|imipramine and trimipramine both increase  QTc interval. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available.
imipramine|trimipramine|22|Serious - Use Alternative|imipramine and trimipramine both increase  serotonin levels. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available.
imipramine|trimipramine|2|Significant - Monitor Closely|imipramine and trimipramine both decrease  cholinergic effects/transmission. Potential for interaction, monitor.
imipramine|trimipramine|2|Significant - Monitor Closely|imipramine and trimipramine both increase  sedation. Potential for interaction, monitor.
triprolidine|imipramine|2|Significant - Monitor Closely|triprolidine and imipramine both increase  sedation. Potential for interaction, monitor.
venlafaxine|imipramine|22|Serious - Use Alternative|venlafaxine and imipramine both increase  serotonin levels. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available.
venlafaxine|imipramine|11|Significant - Monitor Closely|venlafaxine will increase the level or effect of imipramine by  affecting hepatic enzyme CYP2D6 metabolism. Significant interaction possible, monitor closely.
imipramine|venlafaxine|3|Significant - Monitor Closely|imipramine and venlafaxine both increase  QTc interval. Potential for dangerous interaction. Use with caution and monitor closely.
voriconazole|imipramine|11|Significant - Monitor Closely|voriconazole will increase the level or effect of imipramine by  affecting hepatic enzyme CYP2C19 metabolism. Significant interaction possible, monitor closely.
imipramine|voriconazole|3|Significant - Monitor Closely|imipramine and voriconazole both increase  QTc interval. Potential for dangerous interaction. Use with caution and monitor closely.
voriconazole|imipramine|1|Minor|voriconazole will increase the level or effect of imipramine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor or non-significant interaction.
imipramine|ziprasidone|22|Serious - Use Alternative|imipramine and ziprasidone both increase  QTc interval. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available.
ziprasidone|imipramine|2|Significant - Monitor Closely|ziprasidone and imipramine both increase  sedation. Potential for interaction, monitor.
zolmitriptan|imipramine|3|Significant - Monitor Closely|zolmitriptan and imipramine both increase  serotonin levels. Potential for dangerous interaction. Use with caution and monitor closely.
indapamide|lithium|11|Significant - Monitor Closely|indapamide increases toxicity of lithium by decreasing elimination. Significant interaction possible, monitor closely.
indapamide|lumefantrine|33|Contraindicated|indapamide and lumefantrine both increase  QTc interval. Never use combination.
indapamide|telavancin|22|Serious - Use Alternative|indapamide and telavancin both increase  QTc interval. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available.
treprostinil|indapamide|1|Minor|treprostinil increases effects of indapamide by pharmacodynamic synergism. Minor or non-significant interaction.
trimipramine|indapamide|33|Contraindicated|trimipramine and indapamide both increase  QTc interval. Never use combination.
indapamide|voriconazole|22|Serious - Use Alternative|indapamide and voriconazole both increase  QTc interval. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available.
indapamide|ziprasidone|33|Contraindicated|indapamide and ziprasidone both increase  QTc interval. Never use combination.
ketoconazole|indinavir|20|Serious - Use Alternative|ketoconazole will increase the level or effect of indinavir by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
ketoconazole|indinavir|11|Significant - Monitor Closely|ketoconazole will increase the level or effect of indinavir by  P-glycoprotein (MDR1) efflux transporter. Significant interaction possible, monitor closely.
indinavir|ketoconazole|1|Minor|indinavir will increase the level or effect of ketoconazole by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor or non-significant interaction.
lansoprazole|indinavir|20|Serious - Use Alternative|lansoprazole will decrease the level or effect of indinavir by  increasing gastric pH. Applies only to oral form of both agents. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
indinavir|lansoprazole|1|Minor|indinavir will increase the level or effect of lansoprazole by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor or non-significant interaction.
indinavir|lovastatin|33|Contraindicated|indinavir will increase the level or effect of lovastatin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Never use combination.
indinavir|lovastatin|33|Contraindicated|indinavir will increase the level or effect of lovastatin by  P-glycoprotein (MDR1) efflux transporter. Never use combination.
indinavir|lurasidone|33|Contraindicated|indinavir will increase the level or effect of lurasidone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Never use combination. Coadministration of lurasidone and strong CYP3A4 inhibitors is contraindicated.
indinavir|midazolam|21|Serious - Use Alternative|indinavir increases levels of midazolam by decreasing metabolism. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available. Never use combination.
indinavir|midazolam|11|Significant - Monitor Closely|indinavir will increase the level or effect of midazolam by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
midazolam|indinavir|11|Significant - Monitor Closely|midazolam will decrease the level or effect of indinavir by  P-glycoprotein (MDR1) efflux transporter. Significant interaction possible, monitor closely.
omeprazole|indinavir|20|Serious - Use Alternative|omeprazole will decrease the level or effect of indinavir by  increasing gastric pH. Applies only to oral form of both agents. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
pantoprazole|indinavir|20|Serious - Use Alternative|pantoprazole will decrease the level or effect of indinavir by  increasing gastric pH. Applies only to oral form of both agents. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
indinavir|pimozide|21|Serious - Use Alternative|indinavir increases levels of pimozide by decreasing metabolism. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available. Never use combination. Risk of QT interval prolongation.
indinavir|pimozide|1|Minor|indinavir will increase the level or effect of pimozide by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor or non-significant interaction.
indinavir|ponatinib|20|Serious - Use Alternative|indinavir increases levels of ponatinib by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available. Decrease ponatinib starting dose to 30 mg qDay if coadministration with strong CYP3A4 inhibitors cannot be avoided.
ponatinib|indinavir|2|Significant - Monitor Closely|ponatinib increases levels of indinavir by P-glycoprotein (MDR1) efflux transporter. Potential for interaction, monitor.
rabeprazole|indinavir|20|Serious - Use Alternative|rabeprazole will decrease the level or effect of indinavir by  increasing gastric pH. Applies only to oral form of both agents. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
indinavir|rabeprazole|1|Minor|indinavir will increase the level or effect of rabeprazole by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor or non-significant interaction.
indinavir|ranolazine|20|Serious - Use Alternative|indinavir will increase the level or effect of ranolazine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
ranolazine|indinavir|11|Significant - Monitor Closely|ranolazine will increase the level or effect of indinavir by  P-glycoprotein (MDR1) efflux transporter. Significant interaction possible, monitor closely.
rifabutin|indinavir|20|Serious - Use Alternative|rifabutin will decrease the level or effect of indinavir by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
indinavir|rifabutin|11|Significant - Monitor Closely|indinavir increases levels of rifabutin by decreasing metabolism. Significant interaction possible, monitor closely.
indinavir|risperidone|11|Significant - Monitor Closely|indinavir will increase the level or effect of risperidone by  P-glycoprotein (MDR1) efflux transporter. Significant interaction possible, monitor closely.
indinavir|saquinavir|11|Significant - Monitor Closely|indinavir will increase the level or effect of saquinavir by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
indinavir|saquinavir|11|Significant - Monitor Closely|indinavir will increase the level or effect of saquinavir by  P-glycoprotein (MDR1) efflux transporter. Significant interaction possible, monitor closely.
indinavir|saquinavir|2|Significant - Monitor Closely|indinavir and saquinavir both increase  risk of immune reconstitution syndrome. Potential for interaction, monitor.
indinavir|saxagliptin|3|Significant - Monitor Closely|indinavir will increase the level or effect of saxagliptin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Potential for dangerous interaction. Use with caution and monitor closely. Limit saxagliptin dose to 2.5 mg/day when coadministered with strong CYP3A4 inhibitors
indinavir|sildenafil|11|Significant - Monitor Closely|indinavir will increase the level or effect of sildenafil by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
indinavir|silodosin|20|Serious - Use Alternative|indinavir will increase the level or effect of silodosin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
indinavir|silodosin|11|Significant - Monitor Closely|indinavir will increase the level or effect of silodosin by  P-glycoprotein (MDR1) efflux transporter. Significant interaction possible, monitor closely.
indinavir|sunitinib|11|Significant - Monitor Closely|indinavir will increase the level or effect of sunitinib by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
indinavir|tacrolimus|11|Significant - Monitor Closely|indinavir will increase the level or effect of tacrolimus by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
indinavir|tacrolimus|11|Significant - Monitor Closely|indinavir will increase the level or effect of tacrolimus by  P-glycoprotein (MDR1) efflux transporter. Significant interaction possible, monitor closely.
indinavir|tadalafil|20|Serious - Use Alternative|indinavir will increase the level or effect of tadalafil by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available. Stop tadalafil >24 hours prior to protease inhibitor (PI) initiation, restart 7 days after PI initiation at 20 mg once daily, and increase to 40 mg once daily based on tolerability.
indinavir|tamoxifen|20|Serious - Use Alternative|indinavir, tamoxifen. affecting hepatic/intestinal enzyme CYP3A4 metabolism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available. CYP3A4 inhibition decreases metabolism of tamoxifen to N-desmethyl tamoxifen (active metabolite with similar biologic activity).
indinavir|tamsulosin|20|Serious - Use Alternative|indinavir increases levels of tamsulosin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available. Potential for increased toxicity. .
telithromycin|indinavir|11|Significant - Monitor Closely|telithromycin will increase the level or effect of indinavir by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
indinavir|telithromycin|1|Minor|indinavir will increase the level or effect of telithromycin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor or non-significant interaction.
indinavir|temsirolimus|11|Significant - Monitor Closely|indinavir will increase the level or effect of temsirolimus by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
indinavir|terfenadine|21|Serious - Use Alternative|indinavir increases levels of terfenadine by decreasing metabolism. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available. Never use combination. Risk of QT interval prolongation.
indinavir|terfenadine|20|Serious - Use Alternative|indinavir will increase the level or effect of terfenadine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
indinavir|tolterodine|11|Significant - Monitor Closely|indinavir will increase the level or effect of tolterodine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
indinavir|tramadol|11|Significant - Monitor Closely|indinavir increases levels of tramadol by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely. Potential for increased toxicity. .
trazodone|indinavir|11|Significant - Monitor Closely|trazodone will decrease the level or effect of indinavir by  P-glycoprotein (MDR1) efflux transporter. Significant interaction possible, monitor closely.
indinavir|trazodone|3|Significant - Monitor Closely|indinavir will increase the level or effect of trazodone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Potential for dangerous interaction. Use with caution and monitor closely.
indinavir|triazolam|21|Serious - Use Alternative|indinavir increases levels of triazolam by decreasing metabolism. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available. Never use combination.
indinavir|triazolam|11|Significant - Monitor Closely|indinavir will increase the level or effect of triazolam by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
indinavir|vardenafil|11|Significant - Monitor Closely|indinavir will increase the level or effect of vardenafil by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
indinavir|vemurafenib|20|Serious - Use Alternative|indinavir increases levels of vemurafenib by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
vemurafenib|indinavir|2|Significant - Monitor Closely|vemurafenib increases levels of indinavir by P-glycoprotein (MDR1) efflux transporter. Potential for interaction, monitor.
indinavir|verapamil|11|Significant - Monitor Closely|indinavir will increase the level or effect of verapamil by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
verapamil|indinavir|11|Significant - Monitor Closely|verapamil will increase the level or effect of indinavir by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
verapamil|indinavir|11|Significant - Monitor Closely|verapamil will increase the level or effect of indinavir by  P-glycoprotein (MDR1) efflux transporter. Significant interaction possible, monitor closely.
indinavir|vinblastine|1|Minor|indinavir will increase the level or effect of vinblastine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor or non-significant interaction.
indinavir|vincristine|1|Minor|indinavir will increase the level or effect of vincristine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor or non-significant interaction.
indinavir|vinorelbine|1|Minor|indinavir will increase the level or effect of vinorelbine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor or non-significant interaction.
voriconazole|indinavir|20|Serious - Use Alternative|voriconazole will increase the level or effect of indinavir by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
indinavir|warfarin|11|Significant - Monitor Closely|indinavir will increase the level or effect of warfarin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
indinavir|zolpidem|1|Minor|indinavir will increase the level or effect of zolpidem by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor or non-significant interaction.
indinavir|zonisamide|1|Minor|indinavir will increase the level or effect of zonisamide by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor or non-significant interaction.
indomethacin|labetalol|11|Significant - Monitor Closely|indomethacin decreases effects of labetalol by pharmacodynamic antagonism. Significant interaction possible, monitor closely. Long term (>1 wk) NSAID use.  NSAIDs decrease prostaglandin synthesis.
labetalol|indomethacin|2|Significant - Monitor Closely|labetalol and indomethacin both increase  serum potassium. Potential for interaction, monitor.
indomethacin|lithium|11|Significant - Monitor Closely|indomethacin increases levels of lithium by decreasing renal clearance. Significant interaction possible, monitor closely.
losartan|indomethacin|11|Significant - Monitor Closely|losartan, indomethacin.Either increases toxicity of the other by Other (see comment). Significant interaction possible, monitor closely. Comment: May result in renal function deterioration, particularly in elderly or volume depleted individuals.
indomethacin|losartan|3|Significant - Monitor Closely|indomethacin decreases effects of losartan by pharmacodynamic antagonism. Potential for dangerous interaction. Use with caution and monitor closely.  NSAIDs decrease synthesis of vasodilating renal prostaglandins, and thus affect fluid homeostasis and may diminish antihypertensive effect.
losartan|indomethacin|2|Significant - Monitor Closely|losartan and indomethacin both increase  serum potassium. Potential for interaction, monitor.
indomethacin|methotrexate|20|Serious - Use Alternative|indomethacin increases levels of methotrexate by decreasing renal clearance. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available. Concomitant administration of NSAIDs with high dose methotrexate has been reported to elevate and prolong serum methotrexate levels, resulting in deaths from severe hematologic and GI toxicity. NSAIDs may reduce tubular secretion of methotrexate and enhance toxicity. .
indomethacin|metoprolol|11|Significant - Monitor Closely|indomethacin decreases effects of metoprolol by pharmacodynamic antagonism. Significant interaction possible, monitor closely. Long term (>1 wk) NSAID use.  NSAIDs decrease prostaglandin synthesis.
metoprolol|indomethacin|2|Significant - Monitor Closely|metoprolol and indomethacin both increase  serum potassium. Potential for interaction, monitor.
indomethacin|nadolol|11|Significant - Monitor Closely|indomethacin decreases effects of nadolol by pharmacodynamic antagonism. Significant interaction possible, monitor closely. Long term (>1 wk) NSAID use.  NSAIDs decrease prostaglandin synthesis.
nadolol|indomethacin|2|Significant - Monitor Closely|nadolol and indomethacin both increase  serum potassium. Potential for interaction, monitor.
indomethacin|penbutolol|11|Significant - Monitor Closely|indomethacin decreases effects of penbutolol by pharmacodynamic antagonism. Significant interaction possible, monitor closely. Long term (>1 wk) NSAID use.  NSAIDs decrease prostaglandin synthesis.
penbutolol|indomethacin|2|Significant - Monitor Closely|penbutolol and indomethacin both increase  serum potassium. Potential for interaction, monitor.
indomethacin|pindolol|11|Significant - Monitor Closely|indomethacin decreases effects of pindolol by pharmacodynamic antagonism. Significant interaction possible, monitor closely. Long term (>1 wk) NSAID use.  NSAIDs decrease prostaglandin synthesis.
pindolol|indomethacin|2|Significant - Monitor Closely|pindolol and indomethacin both increase  serum potassium. Potential for interaction, monitor.
indomethacin|pralatrexate|11|Significant - Monitor Closely|indomethacin increases levels of pralatrexate by decreasing renal clearance. Significant interaction possible, monitor closely. NSAIDs may delay pralatrexate clearance, increasing drug exposure. Adjust the pralatrexate dose as needed.
indomethacin|probenecid|11|Significant - Monitor Closely|indomethacin will increase the level or effect of probenecid by  acidic (anionic) drug competition for renal tubular clearance. Significant interaction possible, monitor closely.
indomethacin|propranolol|11|Significant - Monitor Closely|indomethacin decreases effects of propranolol by pharmacodynamic antagonism. Significant interaction possible, monitor closely. Long term (>1 wk) NSAID use.  NSAIDs decrease prostaglandin synthesis.
propranolol|indomethacin|2|Significant - Monitor Closely|propranolol and indomethacin both increase  serum potassium. Potential for interaction, monitor.
indomethacin|sotalol|11|Significant - Monitor Closely|indomethacin decreases effects of sotalol by pharmacodynamic antagonism. Significant interaction possible, monitor closely. Long term (>1 wk) NSAID use.  NSAIDs decrease prostaglandin synthesis.
sotalol|indomethacin|2|Significant - Monitor Closely|sotalol and indomethacin both increase  serum potassium. Potential for interaction, monitor.
telmisartan|indomethacin|11|Significant - Monitor Closely|telmisartan, indomethacin.Either increases toxicity of the other by Other (see comment). Significant interaction possible, monitor closely. Comment: May result in renal function deterioration, particularly in elderly or volume depleted individuals.
indomethacin|telmisartan|3|Significant - Monitor Closely|indomethacin decreases effects of telmisartan by pharmacodynamic antagonism. Potential for dangerous interaction. Use with caution and monitor closely.  NSAIDs decrease synthesis of vasodilating renal prostaglandins, and thus affect fluid homeostasis and may diminish antihypertensive effect.
telmisartan|indomethacin|2|Significant - Monitor Closely|telmisartan and indomethacin both increase  serum potassium. Potential for interaction, monitor.
indomethacin|timolol|11|Significant - Monitor Closely|indomethacin decreases effects of timolol by pharmacodynamic antagonism. Significant interaction possible, monitor closely. Long term (>1 wk) NSAID use.  NSAIDs decrease prostaglandin synthesis.
timolol|indomethacin|2|Significant - Monitor Closely|timolol and indomethacin both increase  serum potassium. Potential for interaction, monitor.
indomethacin|tolbutamide|11|Significant - Monitor Closely|indomethacin increases effects of tolbutamide by unknown mechanism. Significant interaction possible, monitor closely. Risk of hypoglycemia.
trandolapril|indomethacin|11|Significant - Monitor Closely|trandolapril, indomethacin.Either increases toxicity of the other by Other (see comment). Significant interaction possible, monitor closely. Comment: May result in renal function deterioration, particularly in elderly or volume depleted individuals.
indomethacin|trandolapril|3|Significant - Monitor Closely|indomethacin decreases effects of trandolapril by pharmacodynamic antagonism. Potential for dangerous interaction. Use with caution and monitor closely. NSAIDs decrease synthesis of vasodilating renal prostaglandins, and thus affect fluid homeostasis and may diminish antihypertenisve effect.
triamterene|indomethacin|3|Significant - Monitor Closely|triamterene and indomethacin both increase  serum potassium. Potential for dangerous interaction. Use with caution and monitor closely.
triamterene|indomethacin|1|Minor|triamterene, indomethacin. Other (see comment). Minor or non-significant interaction. Comment: Risk of acute renal failure.  Mechanism: NSAIDs decrease prostaglandin synthesis, which normally protect against nephrotoxicity.
indomethacin|triamterene|1|Minor|indomethacin increases toxicity of triamterene by pharmacodynamic antagonism. Minor or non-significant interaction. NSAIDs decrease prostaglandin synthesis, increasing the risk of nephrotoxicity.
warfarin|indomethacin|3|Significant - Monitor Closely|warfarin and indomethacin both increase  anticoagulation. Potential for dangerous interaction. Use with caution and monitor closely.
infliximab|leflunomide|22|Serious - Use Alternative|infliximab and leflunomide both increase  immunosuppressive effects; risk of infection. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available.
infliximab|rilonacept|22|Serious - Use Alternative|infliximab and rilonacept both increase  immunosuppressive effects; risk of infection. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available.
infliximab|sipuleucel-t|3|Significant - Monitor Closely|infliximab decreases effects of sipuleucel-t by pharmacodynamic antagonism. Potential for dangerous interaction. Use with caution and monitor closely.
infliximab|tacrolimus|22|Serious - Use Alternative|infliximab and tacrolimus both increase  immunosuppressive effects; risk of infection. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available.
tocilizumab|infliximab|22|Serious - Use Alternative|tocilizumab and infliximab both increase  immunosuppressive effects; risk of infection. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available.
infliximab|tofacitinib|20|Serious - Use Alternative|infliximab, tofacitinib.Either increases toxicity of the other by immunosuppressive effects; risk of infection. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
pegvisomant|insulin aspart|1|Minor|pegvisomant increases effects of insulin aspart by pharmacodynamic synergism. Minor or non-significant interaction.
nadolol|insulin glargine|11|Significant - Monitor Closely|nadolol, insulin glargine. Mechanism: pharmacodynamic antagonism. Significant interaction possible, monitor closely. Non selective beta blockers delay recovery of normoglycemia after insulin induced hypoglycemia; however, they also inhibit insulin secretion, so long term beta blocker Tx may result in reduced glucose tolerance.  Insulin induced hypoglycemia may induce hypertension during non selective beta blocker Tx.
pindolol|insulin glargine|11|Significant - Monitor Closely|pindolol, insulin glargine. Mechanism: pharmacodynamic antagonism. Significant interaction possible, monitor closely. Non selective beta blockers delay recovery of normoglycemia after insulin induced hypoglycemia; however, they also inhibit insulin secretion, so long term beta blocker Tx may result in reduced glucose tolerance.  Insulin induced hypoglycemia may induce hypertension during non selective beta blocker Tx.
propranolol|insulin glargine|11|Significant - Monitor Closely|propranolol, insulin glargine. Mechanism: pharmacodynamic antagonism. Significant interaction possible, monitor closely. Non selective beta blockers delay recovery of normoglycemia after insulin induced hypoglycemia; however, they also inhibit insulin secretion, so long term beta blocker Tx may result in reduced glucose tolerance.  Insulin induced hypoglycemia may induce hypertension during non selective beta blocker Tx.
timolol|insulin glargine|11|Significant - Monitor Closely|timolol, insulin glargine. Mechanism: pharmacodynamic antagonism. Significant interaction possible, monitor closely. Non selective beta blockers delay recovery of normoglycemia after insulin induced hypoglycemia; however, they also inhibit insulin secretion, so long term beta blocker Tx may result in reduced glucose tolerance.  Insulin induced hypoglycemia may induce hypertension during non selective beta blocker Tx.
timolol|insulin inhaled|3|Significant - Monitor Closely|timolol, insulin inhaled. Other (see comment). Potential for dangerous interaction. Use with caution and monitor closely. Comment: Beta-blockers may either increase or decrease the blood glucose lowering effect of insulin; beta-blockers can prolong hypoglycemia (interference with glycogenolysis) or cause hyperglycemia (insulin secretion inhibited).
insulin lispro|pramlintide|33|Contraindicated|insulin lispro, pramlintide. Mechanism: unspecified interaction mechanism. Never use combination. Must be administered separately.
prednisone|insulin lispro|1|Minor|prednisone decreases effects of insulin lispro by pharmacodynamic antagonism. Minor or non-significant interaction.
ramipril|insulin lispro|11|Significant - Monitor Closely|ramipril increases effects of insulin lispro by pharmacodynamic synergism. Significant interaction possible, monitor closely.
iodine|lithium|1|Minor|iodine, lithium. Mechanism: pharmacodynamic synergism. Minor or non-significant interaction. Additive hypothyroid effects.
ipilimumab|vemurafenib|3|Significant - Monitor Closely|ipilimumab, vemurafenib.Either increases toxicity of the other by Other (see comment). Potential for dangerous interaction. Use with caution and monitor closely. Comment: Grade 3 increases in transaminases and bilirubin observed in a majority of patients when coadministered.
irbesartan|lithium|20|Serious - Use Alternative|irbesartan increases toxicity of lithium by decreasing renal clearance. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
irbesartan|spironolactone|3|Significant - Monitor Closely|irbesartan and spironolactone both increase  serum potassium. Potential for dangerous interaction. Use with caution and monitor closely.
irbesartan|trandolapril|20|Serious - Use Alternative|irbesartan, trandolapril.Either increases toxicity of the other by pharmacodynamic synergism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available. Dual blockade of renin-angiotensin system increases risks of hypotension, hyperkalemia, and renal impairment.
treprostinil|irbesartan|2|Significant - Monitor Closely|treprostinil increases effects of irbesartan by pharmacodynamic synergism. Potential for interaction, monitor.
irbesartan|triamterene|3|Significant - Monitor Closely|irbesartan and triamterene both increase  serum potassium. Potential for dangerous interaction. Use with caution and monitor closely.
ketoconazole|irinotecan|22|Serious - Use Alternative|ketoconazole will increase the level or effect of irinotecan by  decreasing metabolism. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available. UGT1A1 inhibitors decrease irinotecan metabolism
ketoconazole|irinotecan|11|Significant - Monitor Closely|ketoconazole will increase the level or effect of irinotecan by  P-glycoprotein (MDR1) efflux transporter. Significant interaction possible, monitor closely.
phenytoin|irinotecan|22|Serious - Use Alternative|phenytoin will decrease the level or effect of irinotecan by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available.
regorafenib|irinotecan|11|Significant - Monitor Closely|regorafenib will increase the level or effect of irinotecan by  decreasing metabolism. Significant interaction possible, monitor closely. Regorafenib may inhibit UGT1A1-mediated metabolism of irinotican and its metabolite
telithromycin|irinotecan|22|Serious - Use Alternative|telithromycin will increase the level or effect of irinotecan by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available.
voriconazole|irinotecan|22|Serious - Use Alternative|voriconazole will increase the level or effect of irinotecan by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available.
isocarboxazid|l-tryptophan|22|Serious - Use Alternative|isocarboxazid and l-tryptophan both increase  serotonin levels. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available.
isocarboxazid|methamphetamine|33|Contraindicated|isocarboxazid increases effects of methamphetamine by pharmacodynamic synergism. Never use combination. Risk of acute hypertensive episode.
isocarboxazid|methylphenidate|33|Contraindicated|isocarboxazid increases effects of methylphenidate by pharmacodynamic synergism. Never use combination. Risk of acute hypertensive episode.
isocarboxazid|midodrine|33|Contraindicated|isocarboxazid increases effects of midodrine by pharmacodynamic synergism. Never use combination. Risk of acute hypertensive episode.
isocarboxazid|milnacipran|33|Contraindicated|isocarboxazid and milnacipran both increase  serotonin levels. Never use combination.
isocarboxazid|mirtazapine|22|Serious - Use Alternative|isocarboxazid and mirtazapine both increase  serotonin levels. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available.
naratriptan|isocarboxazid|22|Serious - Use Alternative|naratriptan and isocarboxazid both increase  serotonin levels. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available.
isocarboxazid|naratriptan|21|Serious - Use Alternative|isocarboxazid increases levels of naratriptan by decreasing metabolism. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available. Never use combination.
isocarboxazid|nefazodone|33|Contraindicated|isocarboxazid and nefazodone both increase  serotonin levels. Never use combination.
isocarboxazid|norepinephrine|33|Contraindicated|isocarboxazid increases effects of norepinephrine by pharmacodynamic synergism. Never use combination. Risk of acute hypertensive episode.
isocarboxazid|nortriptyline|33|Contraindicated|isocarboxazid and nortriptyline both increase  serotonin levels. Never use combination.
isocarboxazid|paroxetine|33|Contraindicated|isocarboxazid and paroxetine both increase  serotonin levels. Never use combination.
isocarboxazid|meperidine|33|Contraindicated|isocarboxazid and meperidine both increase  serotonin levels. Never use combination.
isocarboxazid|meperidine|33|Contraindicated|isocarboxazid increases toxicity of meperidine by unknown mechanism. Never use combination.
isocarboxazid|phendimetrazine|33|Contraindicated|isocarboxazid increases effects of phendimetrazine by pharmacodynamic synergism. Never use combination. Risk of acute hypertensive episode.
isocarboxazid|phentermine|33|Contraindicated|isocarboxazid increases effects of phentermine by pharmacodynamic synergism. Never use combination. Risk of acute hypertensive episode.
isocarboxazid|phenylephrine|33|Contraindicated|isocarboxazid increases effects of phenylephrine by pharmacodynamic synergism. Never use combination. Risk of acute hypertensive episode.
isocarboxazid|pirbuterol|21|Serious - Use Alternative|isocarboxazid increases effects of pirbuterol by pharmacodynamic synergism. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available. Never use combination. Risk of acute hypertensive episode.
isocarboxazid|protriptyline|33|Contraindicated|isocarboxazid and protriptyline both increase  serotonin levels. Never use combination.
isocarboxazid|pseudoephedrine|33|Contraindicated|isocarboxazid increases effects of pseudoephedrine by pharmacodynamic synergism. Never use combination. Risk of acute hypertensive episode.
rizatriptan|isocarboxazid|22|Serious - Use Alternative|rizatriptan and isocarboxazid both increase  serotonin levels. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available.
isocarboxazid|rizatriptan|21|Serious - Use Alternative|isocarboxazid increases levels of rizatriptan by decreasing metabolism. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available. Never use combination.
isocarboxazid|sertraline|33|Contraindicated|isocarboxazid and sertraline both increase  serotonin levels. Never use combination.
sumatriptan|isocarboxazid|22|Serious - Use Alternative|sumatriptan and isocarboxazid both increase  serotonin levels. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available.
isocarboxazid|sumatriptan|21|Serious - Use Alternative|isocarboxazid increases levels of sumatriptan by decreasing metabolism. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available. Never use combination.
isocarboxazid|terbutaline|21|Serious - Use Alternative|isocarboxazid increases effects of terbutaline by pharmacodynamic synergism. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available. Never use combination. Risk of acute hypertensive episode.
tetrabenazine|isocarboxazid|33|Contraindicated|tetrabenazine, isocarboxazid. Other (see comment). Never use combination. Comment: Risk of acute hypertensive episode; separate by 14 d.  Mechanism: MAOI causes accumulation of NE in neuron and tetrabenazine stimulates NE release.
tolcapone|isocarboxazid|21|Serious - Use Alternative|tolcapone increases effects of isocarboxazid by pharmacodynamic synergism. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available. Never use combination.
isocarboxazid|tramadol|22|Serious - Use Alternative|isocarboxazid and tramadol both increase  serotonin levels. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available.
isocarboxazid|tramadol|20|Serious - Use Alternative|isocarboxazid increases toxicity of tramadol by unknown mechanism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available. Risk of hypotension, hyperpyrexia, somnolence, or death; separate by 14 d.
isocarboxazid|tranylcypromine|33|Contraindicated|isocarboxazid and tranylcypromine both increase  serotonin levels. Never use combination.
isocarboxazid|trazodone|33|Contraindicated|isocarboxazid and trazodone both increase  serotonin levels. Never use combination.
isocarboxazid|trimipramine|33|Contraindicated|isocarboxazid and trimipramine both increase  serotonin levels. Never use combination.
isocarboxazid|venlafaxine|33|Contraindicated|isocarboxazid and venlafaxine both increase  serotonin levels. Never use combination.
isocarboxazid|vilazodone|33|Contraindicated|isocarboxazid, vilazodone.Either increases toxicity of the other by serotonin levels. Never use combination. Coadministration with MAO-A inhibitors are contraindicated. Do not prescribe vilazodone within 14 days of discontinuing or starting an MAO inhibitor.
zolmitriptan|isocarboxazid|22|Serious - Use Alternative|zolmitriptan and isocarboxazid both increase  serotonin levels. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available.
isocarboxazid|zolmitriptan|21|Serious - Use Alternative|isocarboxazid increases levels of zolmitriptan by decreasing metabolism. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available. Never use combination.
isoniazid|ketoconazole|33|Contraindicated|isoniazid decreases levels of ketoconazole by unspecified interaction mechanism. Never use combination.
isoniazid|ketoconazole|1|Minor|isoniazid will increase the level or effect of ketoconazole by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor or non-significant interaction.
isoniazid|meperidine|3|Significant - Monitor Closely|isoniazid and meperidine both increase  serotonin levels. Potential for dangerous interaction. Use with caution and monitor closely.
isoniazid|phenytoin|1|Minor|isoniazid increases levels of phenytoin by decreasing metabolism. Minor or non-significant interaction.
isoniazid|tacrolimus|11|Significant - Monitor Closely|isoniazid will increase the level or effect of tacrolimus by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
isoniazid|tadalafil|11|Significant - Monitor Closely|isoniazid will increase the level or effect of tadalafil by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely. For ED limit tadalafil to max of 2.5 mg/day (for daily use) or 10 mg dose every 72 hr (for use as needed). Avoid concurrent use of tadalafil for pulmonary HTN in patients taking strong CYP3A4 inhibitors.
isoniazid|tamoxifen|3|Significant - Monitor Closely|isoniazid, tamoxifen. affecting hepatic/intestinal enzyme CYP3A4 metabolism. Potential for dangerous interaction. Use with caution and monitor closely. CYP3A4 inhibition decreases metabolism of tamoxifen to N-desmethyl tamoxifen (active metabolite with similar biologic activity).
isoniazid|tamsulosin|20|Serious - Use Alternative|isoniazid increases levels of tamsulosin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
isoniazid|tamsulosin|2|Significant - Monitor Closely|isoniazid increases levels of tamsulosin by affecting hepatic enzyme CYP2D6 metabolism. Potential for interaction, monitor.
isoniazid|telithromycin|3|Significant - Monitor Closely|isoniazid will increase the level or effect of telithromycin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Potential for dangerous interaction. Use with caution and monitor closely.
isoniazid|temsirolimus|11|Significant - Monitor Closely|isoniazid will increase the level or effect of temsirolimus by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
isoniazid|theophylline|11|Significant - Monitor Closely|isoniazid will increase the level or effect of theophylline by  affecting hepatic enzyme CYP1A2 metabolism. Significant interaction possible, monitor closely.
isoniazid|theophylline|11|Significant - Monitor Closely|isoniazid will increase the level or effect of theophylline by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
isoniazid|tolterodine|11|Significant - Monitor Closely|isoniazid will increase the level or effect of tolterodine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
isoniazid|tramadol|2|Significant - Monitor Closely|isoniazid and tramadol both increase  serotonin levels. Potential for interaction, monitor.
isoniazid|trazodone|11|Significant - Monitor Closely|isoniazid will increase the level or effect of trazodone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
trazodone|isoniazid|3|Significant - Monitor Closely|trazodone and isoniazid both increase  serotonin levels. Potential for dangerous interaction. Use with caution and monitor closely.
trimipramine|isoniazid|3|Significant - Monitor Closely|trimipramine and isoniazid both increase  serotonin levels. Potential for dangerous interaction. Use with caution and monitor closely.
isoniazid|vardenafil|11|Significant - Monitor Closely|isoniazid will increase the level or effect of vardenafil by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
venlafaxine|isoniazid|3|Significant - Monitor Closely|venlafaxine and isoniazid both increase  serotonin levels. Potential for dangerous interaction. Use with caution and monitor closely.
isoniazid|verapamil|11|Significant - Monitor Closely|isoniazid will increase the level or effect of verapamil by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
isoniazid|vinblastine|11|Significant - Monitor Closely|isoniazid will increase the level or effect of vinblastine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
isoniazid|vincristine|11|Significant - Monitor Closely|isoniazid will increase the level or effect of vincristine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
isoniazid|vinorelbine|11|Significant - Monitor Closely|isoniazid will increase the level or effect of vinorelbine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
isoniazid|warfarin|11|Significant - Monitor Closely|isoniazid will increase the level or effect of warfarin by  affecting hepatic enzyme CYP1A2 metabolism. Significant interaction possible, monitor closely.
isoniazid|warfarin|11|Significant - Monitor Closely|isoniazid will increase the level or effect of warfarin by  affecting hepatic enzyme CYP2C19 metabolism. Significant interaction possible, monitor closely.
isoniazid|warfarin|11|Significant - Monitor Closely|isoniazid will increase the level or effect of warfarin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
isoniazid|zolpidem|1|Minor|isoniazid will increase the level or effect of zolpidem by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor or non-significant interaction.
isoniazid|zonisamide|11|Significant - Monitor Closely|isoniazid will increase the level or effect of zonisamide by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
isosorbide dinitrate|sildenafil|33|Contraindicated|isosorbide dinitrate, sildenafil. Mechanism: additive vasodilation. Never use combination. Potentially fatal hypotension.
isosorbide dinitrate|tadalafil|33|Contraindicated|isosorbide dinitrate, tadalafil. Mechanism: additive vasodilation. Never use combination. Contraindicated. Potentially fatal hypotension. Allow 48h after last tadalafil dose before nitrate administration.
isosorbide dinitrate|vardenafil|33|Contraindicated|isosorbide dinitrate, vardenafil. Mechanism: additive vasodilation. Never use combination. Potentially fatal hypotension.
isosorbide mononitrate|sildenafil|33|Contraindicated|isosorbide mononitrate, sildenafil. Mechanism: additive vasodilation. Never use combination. Potentially fatal hypotension.
isosorbide mononitrate|tadalafil|33|Contraindicated|isosorbide mononitrate, tadalafil. Mechanism: additive vasodilation. Never use combination. Contraindicated. Potentially fatal hypotension. Allow 48h after last tadalafil dose before nitrate administration.
isosorbide mononitrate|vardenafil|33|Contraindicated|isosorbide mononitrate, vardenafil. Mechanism: additive vasodilation. Never use combination. Potentially fatal hypotension.
isotretinoin|minocycline|21|Serious - Use Alternative|isotretinoin, minocycline. Mechanism: unknown. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available. Never use combination. Risk of pseudotumor cerebri.
isotretinoin|oxytetracycline|21|Serious - Use Alternative|isotretinoin, oxytetracycline. Mechanism: unknown. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available. Never use combination. Risk of pseudotumor cerebri.
isotretinoin|tetracycline|21|Serious - Use Alternative|isotretinoin, tetracycline. Mechanism: unknown. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available. Never use combination. Risk of pseudotumor cerebri.
isotretinoin|vitamin a|11|Significant - Monitor Closely|isotretinoin increases toxicity of vitamin a by pharmacodynamic synergism. Significant interaction possible, monitor closely. (Vitamin A) Additive retinoid effects.
lumefantrine|isradipine|1|Minor|lumefantrine will decrease the level or effect of isradipine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor or non-significant interaction.
telithromycin|isradipine|1|Minor|telithromycin will increase the level or effect of isradipine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor or non-significant interaction.
tipranavir|isradipine|11|Significant - Monitor Closely|tipranavir increases levels of isradipine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely. Potential for increased toxicity. .
treprostinil|isradipine|1|Minor|treprostinil increases effects of isradipine by pharmacodynamic synergism. Minor or non-significant interaction.
voriconazole|isradipine|11|Significant - Monitor Closely|voriconazole increases levels of isradipine by decreasing metabolism. Significant interaction possible, monitor closely.
voriconazole|isradipine|1|Minor|voriconazole will increase the level or effect of isradipine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor or non-significant interaction.
ivacaftor|itraconazole|20|Serious - Use Alternative|ivacaftor, itraconazole.Either increases levels of the other by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available. Ivacaftor and its M1 metabolite has the potential to inhibit CYP3A4, may significantly increase systemic exposure to CYP3A4 substrates; reduce ivacaftor dose to 150 mg twice-a-week when coadministered with strong CYP3A4 inhibitors.
lansoprazole|itraconazole|20|Serious - Use Alternative|lansoprazole will decrease the level or effect of itraconazole by  increasing gastric pH. Applies only to oral form of both agents. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
itraconazole|lansoprazole|2|Significant - Monitor Closely|itraconazole will increase the level or effect of lansoprazole by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Potential for interaction, monitor.
itraconazole|lovastatin|33|Contraindicated|itraconazole will increase the level or effect of lovastatin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Never use combination. Strong CYP3A4 inhibitors increase systemic statin exposure and risk of myopathy, including rhabdomyolysis
itraconazole|lovastatin|33|Contraindicated|itraconazole will increase the level or effect of lovastatin by  P-glycoprotein (MDR1) efflux transporter. Never use combination.
itraconazole|lurasidone|33|Contraindicated|itraconazole will increase the level or effect of lurasidone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Never use combination. Coadministration of lurasidone and strong CYP3A4 inhibitors is contraindicated.
itraconazole|mestranol|20|Serious - Use Alternative|itraconazole will increase the level or effect of mestranol by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
itraconazole|mestranol|11|Significant - Monitor Closely|itraconazole will increase the level or effect of mestranol by  P-glycoprotein (MDR1) efflux transporter. Significant interaction possible, monitor closely.
itraconazole|mestranol|1|Minor|itraconazole decreases effects of mestranol by increasing metabolism. Minor or non-significant interaction. May also cause menstrual irregularities.
itraconazole|methylprednisolone|20|Serious - Use Alternative|itraconazole will increase the level or effect of methylprednisolone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
itraconazole|methylprednisolone|11|Significant - Monitor Closely|itraconazole will increase the level or effect of methylprednisolone by  P-glycoprotein (MDR1) efflux transporter. Significant interaction possible, monitor closely.
methylprednisolone|itraconazole|1|Minor|methylprednisolone will decrease the level or effect of itraconazole by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor or non-significant interaction.
itraconazole|midazolam|33|Contraindicated|itraconazole will increase the level or effect of midazolam by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Never use combination. oral midazolam contraindicated; administered in some occasions if IV form used
midazolam|itraconazole|11|Significant - Monitor Closely|midazolam will decrease the level or effect of itraconazole by  P-glycoprotein (MDR1) efflux transporter. Significant interaction possible, monitor closely.
nizatidine|itraconazole|20|Serious - Use Alternative|nizatidine will decrease the level or effect of itraconazole by  increasing gastric pH. Applies only to oral form of both agents. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
omeprazole|itraconazole|20|Serious - Use Alternative|omeprazole will decrease the level or effect of itraconazole by  increasing gastric pH. Applies only to oral form of both agents. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
pantoprazole|itraconazole|20|Serious - Use Alternative|pantoprazole will decrease the level or effect of itraconazole by  increasing gastric pH. Applies only to oral form of both agents. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
itraconazole|pantoprazole|1|Minor|itraconazole will increase the level or effect of pantoprazole by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor or non-significant interaction.
itraconazole|pazopanib|20|Serious - Use Alternative|itraconazole will increase the level or effect of pazopanib by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available. Avoid coadministration of pazopanib with strong CYP3A4 inhibitors if possible; if must coadminister, decrease pazopanib dose to 400 mg/day
itraconazole|pazopanib|2|Significant - Monitor Closely|itraconazole and pazopanib both increase  QTc interval. Potential for interaction, monitor.
phenobarbital|itraconazole|11|Significant - Monitor Closely|phenobarbital will decrease the level or effect of itraconazole by  P-glycoprotein (MDR1) efflux transporter. Significant interaction possible, monitor closely.
phenobarbital|itraconazole|1|Minor|phenobarbital will decrease the level or effect of itraconazole by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor or non-significant interaction.
phenobarbital|itraconazole|1|Minor|phenobarbital decreases levels of itraconazole by inhibition of GI absorption. Applies only to oral form of both agents. Minor or non-significant interaction.
phenytoin|itraconazole|20|Serious - Use Alternative|phenytoin decreases levels of itraconazole by increasing metabolism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
itraconazole|phenytoin|11|Significant - Monitor Closely|itraconazole will increase the level or effect of phenytoin by  affecting hepatic enzyme CYP2C9/10 metabolism. Significant interaction possible, monitor closely.
phenytoin|itraconazole|11|Significant - Monitor Closely|phenytoin will decrease the level or effect of itraconazole by  P-glycoprotein (MDR1) efflux transporter. Significant interaction possible, monitor closely. Antifungal failure may occur due to clinically significant decreases in itraconazole serum concentrations when given with phenytoin. Increased itraconazole dosage may be needed.
phenytoin|itraconazole|1|Minor|phenytoin will decrease the level or effect of itraconazole by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor or non-significant interaction.
itraconazole|pimozide|33|Contraindicated|itraconazole will increase the level or effect of pimozide by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Never use combination. Both drugs will increase QT interval
itraconazole|pimozide|33|Contraindicated|itraconazole and pimozide both increase  QTc interval. Never use combination.
itraconazole|pimozide|33|Contraindicated|itraconazole increases levels of pimozide by decreasing metabolism. Never use combination. Risk of QT interval prolongation.
itraconazole|ponatinib|20|Serious - Use Alternative|itraconazole increases levels of ponatinib by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available. Decrease ponatinib starting dose to 30 mg qDay if coadministration with strong CYP3A4 inhibitors cannot be avoided.
itraconazole|prednisolone|20|Serious - Use Alternative|itraconazole will increase the level or effect of prednisolone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
itraconazole|prednisolone|11|Significant - Monitor Closely|itraconazole will increase the level or effect of prednisolone by  P-glycoprotein (MDR1) efflux transporter. Significant interaction possible, monitor closely.
prednisolone|itraconazole|1|Minor|prednisolone will decrease the level or effect of itraconazole by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor or non-significant interaction.
itraconazole|prednisone|20|Serious - Use Alternative|itraconazole will increase the level or effect of prednisone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
itraconazole|prednisone|11|Significant - Monitor Closely|itraconazole will increase the level or effect of prednisone by  P-glycoprotein (MDR1) efflux transporter. Significant interaction possible, monitor closely.
prednisone|itraconazole|1|Minor|prednisone will decrease the level or effect of itraconazole by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor or non-significant interaction.
itraconazole|quinidine|33|Contraindicated|itraconazole will increase the level or effect of quinidine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Never use combination. Both drugs will increase QT interval
quinidine|itraconazole|33|Contraindicated|quinidine will increase the level or effect of itraconazole by  P-glycoprotein (MDR1) efflux transporter. Never use combination. Both drugs will increase QT interval
quinidine|itraconazole|33|Contraindicated|quinidine and itraconazole both increase  QTc interval. Never use combination.
rabeprazole|itraconazole|20|Serious - Use Alternative|rabeprazole will decrease the level or effect of itraconazole by  increasing gastric pH. Applies only to oral form of both agents. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
itraconazole|rabeprazole|2|Significant - Monitor Closely|itraconazole will increase the level or effect of rabeprazole by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Potential for interaction, monitor.
ranitidine|itraconazole|20|Serious - Use Alternative|ranitidine will decrease the level or effect of itraconazole by  increasing gastric pH. Applies only to oral form of both agents. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
itraconazole|ranolazine|33|Contraindicated|itraconazole will increase the level or effect of ranolazine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Never use combination. May increase risk of cardiovascular events, including prolonged QTc
ranolazine|itraconazole|33|Contraindicated|ranolazine will increase the level or effect of itraconazole by  P-glycoprotein (MDR1) efflux transporter. Never use combination.
itraconazole|ranolazine|33|Contraindicated|itraconazole and ranolazine both increase  QTc interval. Never use combination.
itraconazole|regorafenib|33|Contraindicated|itraconazole, regorafenib. affecting hepatic/intestinal enzyme CYP3A4 metabolism. Never use combination. Strong CYP3A4 inhibitors increase regorafenib levels and decrease exposure of the active metabolites M-2 and M-5.
rifabutin|itraconazole|11|Significant - Monitor Closely|rifabutin decreases levels of itraconazole by increasing metabolism. Significant interaction possible, monitor closely.
rifabutin|itraconazole|2|Significant - Monitor Closely|rifabutin will decrease the level or effect of itraconazole by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Potential for interaction, monitor.
itraconazole|rifabutin|1|Minor|itraconazole increases levels of rifabutin by decreasing metabolism. Minor or non-significant interaction.
itraconazole|risperidone|11|Significant - Monitor Closely|itraconazole will increase the level or effect of risperidone by  P-glycoprotein (MDR1) efflux transporter. Significant interaction possible, monitor closely.
itraconazole|risperidone|3|Significant - Monitor Closely|itraconazole and risperidone both increase  QTc interval. Potential for dangerous interaction. Use with caution and monitor closely.
itraconazole|ritonavir|20|Serious - Use Alternative|itraconazole will increase the level or effect of ritonavir by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
itraconazole|ritonavir|11|Significant - Monitor Closely|itraconazole will increase the level or effect of ritonavir by  P-glycoprotein (MDR1) efflux transporter. Significant interaction possible, monitor closely.
ritonavir|itraconazole|1|Minor|ritonavir will increase the level or effect of itraconazole by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor or non-significant interaction.
itraconazole|rivaroxaban|11|Significant - Monitor Closely|itraconazole increases levels of rivaroxaban by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely. Avoid concomitant use of rivaroxaban and combined Pgp and strong CYP3A4 inhibitors. Combination may lead to significant increases in rivaroxaban levels and increase bleeding risk.
itraconazole|ruxolitinib|20|Serious - Use Alternative|itraconazole will increase the level or effect of ruxolitinib by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available. Reduce ruxolitinib starting dose to 10 mg BID with platelet count 100 X 10^9/L or more and concurrent use of strong CYP3A4 inhibitors; avoid with platelet counts <100 X 10^9/L
itraconazole|sildenafil|20|Serious - Use Alternative|itraconazole will increase the level or effect of sildenafil by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
itraconazole|silodosin|22|Serious - Use Alternative|itraconazole will increase the level or effect of silodosin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available.
itraconazole|silodosin|11|Significant - Monitor Closely|itraconazole will increase the level or effect of silodosin by  P-glycoprotein (MDR1) efflux transporter. Significant interaction possible, monitor closely.
itraconazole|simvastatin|33|Contraindicated|itraconazole will increase the level or effect of simvastatin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Never use combination. Contraindicated. Increased risk for rhabdomyolysis with drugs that increase simvastatin systemic exposure
simvastatin|itraconazole|11|Significant - Monitor Closely|simvastatin will increase the level or effect of itraconazole by  P-glycoprotein (MDR1) efflux transporter. Significant interaction possible, monitor closely.
itraconazole|sirolimus|22|Serious - Use Alternative|itraconazole will increase the level or effect of sirolimus by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available.
itraconazole|sirolimus|11|Significant - Monitor Closely|itraconazole will increase the level or effect of sirolimus by  P-glycoprotein (MDR1) efflux transporter. Significant interaction possible, monitor closely.
itraconazole|solifenacin|20|Serious - Use Alternative|itraconazole will increase the level or effect of solifenacin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
itraconazole|sunitinib|20|Serious - Use Alternative|itraconazole will increase the level or effect of sunitinib by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
itraconazole|tacrolimus|20|Serious - Use Alternative|itraconazole will increase the level or effect of tacrolimus by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
itraconazole|tacrolimus|11|Significant - Monitor Closely|itraconazole will increase the level or effect of tacrolimus by  P-glycoprotein (MDR1) efflux transporter. Significant interaction possible, monitor closely.
itraconazole|tadalafil|20|Serious - Use Alternative|itraconazole will increase the level or effect of tadalafil by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available. For ED limit tadalafil to max of 2.5 mg/day (for daily use) or 10 mg dose every 72 hr (for use as needed). Avoid concurrent use of tadalafil for pulmonary HTN in patients taking strong CYP3A4 inhibitors.
itraconazole|tamoxifen|2|Significant - Monitor Closely|itraconazole, tamoxifen. affecting hepatic/intestinal enzyme CYP3A4 metabolism. Potential for interaction, monitor. CYP3A4 inhibition decreases metabolism of tamoxifen to N-desmethyl tamoxifen (active metabolite with similar biologic activity).
itraconazole|tamsulosin|20|Serious - Use Alternative|itraconazole increases levels of tamsulosin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
itraconazole|telithromycin|3|Significant - Monitor Closely|itraconazole and telithromycin both increase  QTc interval. Potential for dangerous interaction. Use with caution and monitor closely.
itraconazole|telithromycin|2|Significant - Monitor Closely|itraconazole will increase the level or effect of telithromycin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Potential for interaction, monitor.
telithromycin|itraconazole|1|Minor|telithromycin will increase the level or effect of itraconazole by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor or non-significant interaction.
itraconazole|temsirolimus|20|Serious - Use Alternative|itraconazole will increase the level or effect of temsirolimus by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
itraconazole|teniposide|2|Significant - Monitor Closely|itraconazole will increase the level or effect of teniposide by  P-glycoprotein (MDR1) efflux transporter. Potential for interaction, monitor.
itraconazole|terfenadine|33|Contraindicated|itraconazole and terfenadine both increase  QTc interval. Never use combination.
itraconazole|terfenadine|33|Contraindicated|itraconazole increases levels of terfenadine by decreasing metabolism. Never use combination. Risk of QT interval prolongation.
itraconazole|terfenadine|22|Serious - Use Alternative|itraconazole will increase the level or effect of terfenadine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available.
itraconazole|tipranavir|20|Serious - Use Alternative|itraconazole will increase the level or effect of tipranavir by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
itraconazole|tolterodine|20|Serious - Use Alternative|itraconazole will increase the level or effect of tolterodine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
itraconazole|tolvaptan|22|Serious - Use Alternative|itraconazole will increase the level or effect of tolvaptan by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available.
itraconazole|tolvaptan|11|Significant - Monitor Closely|itraconazole will increase the level or effect of tolvaptan by  P-glycoprotein (MDR1) efflux transporter. Significant interaction possible, monitor closely.
tolvaptan|itraconazole|11|Significant - Monitor Closely|tolvaptan will increase the level or effect of itraconazole by  P-glycoprotein (MDR1) efflux transporter. Significant interaction possible, monitor closely.
itraconazole|topotecan|22|Serious - Use Alternative|itraconazole will increase the level or effect of topotecan by  P-glycoprotein (MDR1) efflux transporter. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available. Product labeling for PO topotecan recommends avoiding concomitant use of P-gp inhibitors; the interaction with IV topotecan may be less severe but is still likely of clinical significance
trazodone|itraconazole|22|Serious - Use Alternative|trazodone and itraconazole both increase  QTc interval. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available.
itraconazole|trazodone|20|Serious - Use Alternative|itraconazole will increase the level or effect of trazodone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
trazodone|itraconazole|11|Significant - Monitor Closely|trazodone will decrease the level or effect of itraconazole by  P-glycoprotein (MDR1) efflux transporter. Significant interaction possible, monitor closely.
itraconazole|triazolam|33|Contraindicated|itraconazole will increase the level or effect of triazolam by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Never use combination. Both drugs will increase QT interval
itraconazole|triazolam|33|Contraindicated|itraconazole increases levels of triazolam by decreasing metabolism. Never use combination.
trimipramine|itraconazole|22|Serious - Use Alternative|trimipramine and itraconazole both increase  QTc interval. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available.
itraconazole|vardenafil|21|Serious - Use Alternative|itraconazole increases levels of vardenafil by decreasing metabolism. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available. Never use combination. Greater risk in pts. over 75 yrs old.
itraconazole|vardenafil|20|Serious - Use Alternative|itraconazole will increase the level or effect of vardenafil by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
itraconazole|vemurafenib|20|Serious - Use Alternative|itraconazole increases levels of vemurafenib by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
itraconazole|vemurafenib|2|Significant - Monitor Closely|itraconazole increases levels of vemurafenib by P-glycoprotein (MDR1) efflux transporter. Potential for interaction, monitor.
itraconazole|venlafaxine|3|Significant - Monitor Closely|itraconazole and venlafaxine both increase  QTc interval. Potential for dangerous interaction. Use with caution and monitor closely.
itraconazole|verapamil|20|Serious - Use Alternative|itraconazole will increase the level or effect of verapamil by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available. Observe the patient for development of toxicity associated with verapamil (peripheral edema, dizziness, hypotension, flushing, headache). Consider reducing the dose of verapamil or withdrawing one of the agents.
verapamil|itraconazole|11|Significant - Monitor Closely|verapamil will increase the level or effect of itraconazole by  P-glycoprotein (MDR1) efflux transporter. Significant interaction possible, monitor closely.
verapamil|itraconazole|1|Minor|verapamil will increase the level or effect of itraconazole by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor or non-significant interaction.
itraconazole|vinblastine|11|Significant - Monitor Closely|itraconazole will increase the level or effect of vinblastine by  P-glycoprotein (MDR1) efflux transporter. Significant interaction possible, monitor closely.
itraconazole|vinblastine|2|Significant - Monitor Closely|itraconazole will increase the level or effect of vinblastine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Potential for interaction, monitor.
itraconazole|vincristine|11|Significant - Monitor Closely|itraconazole will increase the level or effect of vincristine by  P-glycoprotein (MDR1) efflux transporter. Significant interaction possible, monitor closely.
itraconazole|vincristine|2|Significant - Monitor Closely|itraconazole will increase the level or effect of vincristine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Potential for interaction, monitor.
itraconazole|vinorelbine|2|Significant - Monitor Closely|itraconazole will increase the level or effect of vinorelbine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Potential for interaction, monitor.
itraconazole|warfarin|20|Serious - Use Alternative|itraconazole will increase the level or effect of warfarin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
itraconazole|warfarin|20|Serious - Use Alternative|itraconazole increases levels of warfarin by decreasing metabolism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
itraconazole|warfarin|11|Significant - Monitor Closely|itraconazole will increase the level or effect of warfarin by  affecting hepatic enzyme CYP2C9/10 metabolism. Significant interaction possible, monitor closely.
itraconazole|zolpidem|2|Significant - Monitor Closely|itraconazole will increase the level or effect of zolpidem by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Potential for interaction, monitor.
itraconazole|zonisamide|2|Significant - Monitor Closely|itraconazole will increase the level or effect of zonisamide by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Potential for interaction, monitor.
ketoconazole|ivacaftor|20|Serious - Use Alternative|ketoconazole increases levels of ivacaftor by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available. Reduce ivacaftor dose to 150 mg twice-a-week when coadministered with strong CYP3A4 inhibitors.
ivacaftor|pazopanib|20|Serious - Use Alternative|ivacaftor increases levels of pazopanib by P-glycoprotein (MDR1) efflux transporter. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available. Ivacaftor and its M1 metabolite has the potential to inhibit P-gp, may significantly increase systemic exposure to P-gp substrates.
ivacaftor|pazopanib|20|Serious - Use Alternative|ivacaftor, pazopanib.Either increases levels of the other by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available. Ivacaftor and its M1 metabolite has the potential to inhibit CYP3A4, may significantly increase systemic exposure to CYP3A4 substrates.
phenobarbital|ivacaftor|22|Serious - Use Alternative|phenobarbital decreases levels of ivacaftor by affecting hepatic/intestinal enzyme CYP3A4 metabolism. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available. Avoid coadministration with strong CYP3A4 inducers; systemic exposure of ivacaftor substantially reduced (ie, ~9-fold).
phenytoin|ivacaftor|22|Serious - Use Alternative|phenytoin decreases levels of ivacaftor by affecting hepatic/intestinal enzyme CYP3A4 metabolism. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available. Avoid coadministration with strong CYP3A4 inducers; systemic exposure of ivacaftor substantially reduced (ie, ~9-fold).
ivacaftor|posaconazole|20|Serious - Use Alternative|ivacaftor increases levels of posaconazole by P-glycoprotein (MDR1) efflux transporter. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available. Ivacaftor and its M1 metabolite has the potential to inhibit P-gp, may significantly increase systemic exposure to P-gp substrates.
posaconazole|ivacaftor|11|Significant - Monitor Closely|posaconazole increases levels of ivacaftor by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely. Reduce ivacaftor dose to 150 mg twice-a-week when coadministered with strong CYP3A4 inhibitors.
rifabutin|ivacaftor|22|Serious - Use Alternative|rifabutin decreases levels of ivacaftor by affecting hepatic/intestinal enzyme CYP3A4 metabolism. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available. Avoid coadministration with strong CYP3A4 inducers; systemic exposure of ivacaftor substantially reduced (ie, ~9-fold).
ivacaftor|rifabutin|20|Serious - Use Alternative|ivacaftor increases levels of rifabutin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available. Ivacaftor and its M1 metabolite has the potential to inhibit CYP3A4, may significantly increase systemic exposure to CYP3A4 substrates.
ivacaftor|telithromycin|20|Serious - Use Alternative|ivacaftor, telithromycin.Either increases levels of the other by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available. Ivacaftor and its M1 metabolite has the potential to inhibit CYP3A4, may significantly increase systemic exposure to CYP3A4 substrates; reduce ivacaftor dose to 150 mg twice-a-week when coadministered with strong CYP3A4 inhibitors.
ivacaftor|vismodegib|20|Serious - Use Alternative|ivacaftor increases levels of vismodegib by P-glycoprotein (MDR1) efflux transporter. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available. Ivacaftor and its M1 metabolite has the potential to inhibit P-gp, may significantly increase systemic exposure to P-gp substrates.
voriconazole|ivacaftor|11|Significant - Monitor Closely|voriconazole increases levels of ivacaftor by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely. Reduce ivacaftor dose to 150 mg twice-a-week when coadministered with strong CYP3A4 inhibitors.
telithromycin|ixabepilone|11|Significant - Monitor Closely|telithromycin will increase the level or effect of ixabepilone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
voriconazole|ixabepilone|11|Significant - Monitor Closely|voriconazole will increase the level or effect of ixabepilone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
ticarcillin|kanamycin|1|Minor|ticarcillin decreases effects of kanamycin by altering metabolism. Minor or non-significant interaction. Increased risk in renal impairment.
memantine|ketamine|21|Serious - Use Alternative|memantine, ketamine.Either increases toxicity of the other by pharmacodynamic synergism. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available. Never use combination.
lansoprazole|ketoconazole|20|Serious - Use Alternative|lansoprazole will decrease the level or effect of ketoconazole by  increasing gastric pH. Applies only to oral form of both agents. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
ketoconazole|lansoprazole|2|Significant - Monitor Closely|ketoconazole will increase the level or effect of lansoprazole by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Potential for interaction, monitor.
ketoconazole|levomilnacipran|3|Significant - Monitor Closely|ketoconazole will increase the level or effect of levomilnacipran by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Potential for dangerous interaction. Use with caution and monitor closely. Do not exceed 80 mg/day of levomilnacipran when coadministered with strong CYP3A4 inhibitors
ketoconazole|lovastatin|33|Contraindicated|ketoconazole will increase the level or effect of lovastatin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Never use combination. Strong CYP3A4 inhibitors increase systemic statin exposure and risk of myopathy, including rhabdomyolysis
ketoconazole|lovastatin|11|Significant - Monitor Closely|ketoconazole will increase the level or effect of lovastatin by  P-glycoprotein (MDR1) efflux transporter. Significant interaction possible, monitor closely.
ketoconazole|lurasidone|33|Contraindicated|ketoconazole will increase the level or effect of lurasidone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Never use combination. Coadministration of lurasidone and strong CYP3A4 inhibitors is contraindicated.
ketoconazole|mestranol|20|Serious - Use Alternative|ketoconazole will increase the level or effect of mestranol by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
ketoconazole|mestranol|11|Significant - Monitor Closely|ketoconazole will increase the level or effect of mestranol by  P-glycoprotein (MDR1) efflux transporter. Significant interaction possible, monitor closely.
ketoconazole|mestranol|1|Minor|ketoconazole decreases effects of mestranol by increasing metabolism. Minor or non-significant interaction. May also cause menstrual irregularities.
ketoconazole|methylprednisolone|20|Serious - Use Alternative|ketoconazole will increase the level or effect of methylprednisolone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
ketoconazole|methylprednisolone|11|Significant - Monitor Closely|ketoconazole will increase the level or effect of methylprednisolone by  P-glycoprotein (MDR1) efflux transporter. Significant interaction possible, monitor closely.
methylprednisolone|ketoconazole|1|Minor|methylprednisolone will decrease the level or effect of ketoconazole by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor or non-significant interaction.
ketoconazole|midazolam|21|Serious - Use Alternative|ketoconazole increases levels of midazolam by decreasing metabolism. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available. Never use combination.
ketoconazole|midazolam|20|Serious - Use Alternative|ketoconazole will increase the level or effect of midazolam by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
nevirapine|ketoconazole|21|Serious - Use Alternative|nevirapine decreases levels of ketoconazole by increasing metabolism. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available. Never use combination.
nevirapine|ketoconazole|1|Minor|nevirapine will decrease the level or effect of ketoconazole by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor or non-significant interaction.
nizatidine|ketoconazole|20|Serious - Use Alternative|nizatidine will decrease the level or effect of ketoconazole by  increasing gastric pH. Applies only to oral form of both agents. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
nortriptyline|ketoconazole|22|Serious - Use Alternative|nortriptyline and ketoconazole both increase  QTc interval. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available.
ketoconazole|nortriptyline|11|Significant - Monitor Closely|ketoconazole will increase the level or effect of nortriptyline by  P-glycoprotein (MDR1) efflux transporter. Significant interaction possible, monitor closely.
omeprazole|ketoconazole|20|Serious - Use Alternative|omeprazole will decrease the level or effect of ketoconazole by  increasing gastric pH. Applies only to oral form of both agents. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
ketoconazole|ospemifene|3|Significant - Monitor Closely|ketoconazole increases levels of ospemifene by affecting hepatic enzyme CYP2C9/10 metabolism. Potential for dangerous interaction. Use with caution and monitor closely.
ketoconazole|ospemifene|3|Significant - Monitor Closely|ketoconazole increases levels of ospemifene by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Potential for dangerous interaction. Use with caution and monitor closely.
pantoprazole|ketoconazole|20|Serious - Use Alternative|pantoprazole will decrease the level or effect of ketoconazole by  increasing gastric pH. Applies only to oral form of both agents. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
ketoconazole|pantoprazole|1|Minor|ketoconazole will increase the level or effect of pantoprazole by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor or non-significant interaction.
ketoconazole|pantoprazole|1|Minor|ketoconazole will increase the level or effect of pantoprazole by  affecting hepatic enzyme CYP2C19 metabolism. Minor or non-significant interaction.
ketoconazole|pazopanib|20|Serious - Use Alternative|ketoconazole will increase the level or effect of pazopanib by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available. Avoid coadministration of pazopanib with strong CYP3A4 inhibitors if possible; if must coadminister, decrease pazopanib dose to 400 mg/day
ketoconazole|pazopanib|2|Significant - Monitor Closely|ketoconazole and pazopanib both increase  QTc interval. Potential for interaction, monitor.
ketoconazole|pimozide|33|Contraindicated|ketoconazole and pimozide both increase  QTc interval. Never use combination.
ketoconazole|pimozide|33|Contraindicated|ketoconazole increases levels of pimozide by decreasing metabolism. Never use combination. Risk of QT interval prolongation.
ketoconazole|pimozide|2|Significant - Monitor Closely|ketoconazole will increase the level or effect of pimozide by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Potential for interaction, monitor.
ketoconazole|pioglitazone|2|Significant - Monitor Closely|ketoconazole will increase the level or effect of pioglitazone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Potential for interaction, monitor.
ketoconazole|pomalidomide|20|Serious - Use Alternative|ketoconazole increases levels of pomalidomide by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
ketoconazole|pomalidomide|20|Serious - Use Alternative|ketoconazole increases levels of pomalidomide by affecting hepatic enzyme CYP1A2 metabolism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
ketoconazole|pomalidomide|20|Serious - Use Alternative|ketoconazole increases levels of pomalidomide by P-glycoprotein (MDR1) efflux transporter. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
ketoconazole|ponatinib|20|Serious - Use Alternative|ketoconazole increases levels of ponatinib by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available. Decrease ponatinib starting dose to 30 mg qDay if coadministration with strong CYP3A4 inhibitors cannot be avoided.
ketoconazole|prednisolone|20|Serious - Use Alternative|ketoconazole will increase the level or effect of prednisolone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
ketoconazole|prednisolone|11|Significant - Monitor Closely|ketoconazole will increase the level or effect of prednisolone by  P-glycoprotein (MDR1) efflux transporter. Significant interaction possible, monitor closely.
prednisolone|ketoconazole|1|Minor|prednisolone will decrease the level or effect of ketoconazole by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor or non-significant interaction.
ketoconazole|prednisone|20|Serious - Use Alternative|ketoconazole will increase the level or effect of prednisone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
ketoconazole|prednisone|11|Significant - Monitor Closely|ketoconazole will increase the level or effect of prednisone by  P-glycoprotein (MDR1) efflux transporter. Significant interaction possible, monitor closely.
prednisone|ketoconazole|1|Minor|prednisone will decrease the level or effect of ketoconazole by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor or non-significant interaction.
ketoconazole|quetiapine|20|Serious - Use Alternative|ketoconazole will increase the level or effect of quetiapine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
quinidine|ketoconazole|33|Contraindicated|quinidine and ketoconazole both increase  QTc interval. Never use combination.
ketoconazole|quinidine|20|Serious - Use Alternative|ketoconazole will increase the level or effect of quinidine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
rabeprazole|ketoconazole|20|Serious - Use Alternative|rabeprazole will decrease the level or effect of ketoconazole by  increasing gastric pH. Applies only to oral form of both agents. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
ketoconazole|rabeprazole|2|Significant - Monitor Closely|ketoconazole will increase the level or effect of rabeprazole by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Potential for interaction, monitor.
ketoconazole|ramelteon|2|Significant - Monitor Closely|ketoconazole will increase the level or effect of ramelteon by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Potential for interaction, monitor.
ketoconazole|ramelteon|1|Minor|ketoconazole will increase the level or effect of ramelteon by  affecting hepatic enzyme CYP2C9/10 metabolism. Minor or non-significant interaction.
ranitidine|ketoconazole|20|Serious - Use Alternative|ranitidine will decrease the level or effect of ketoconazole by  increasing gastric pH. Applies only to oral form of both agents. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
ketoconazole|ranolazine|33|Contraindicated|ketoconazole will increase the level or effect of ranolazine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Never use combination.
ketoconazole|ranolazine|33|Contraindicated|ketoconazole and ranolazine both increase  QTc interval. Never use combination.
ketoconazole|regorafenib|33|Contraindicated|ketoconazole, regorafenib. affecting hepatic/intestinal enzyme CYP3A4 metabolism. Never use combination. Strong CYP3A4 inhibitors increase regorafenib levels and decrease exposure of the active metabolites M-2 and M-5.
ketoconazole|ritonavir|20|Serious - Use Alternative|ketoconazole will increase the level or effect of ritonavir by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
ketoconazole|ritonavir|11|Significant - Monitor Closely|ketoconazole will increase the level or effect of ritonavir by  P-glycoprotein (MDR1) efflux transporter. Significant interaction possible, monitor closely.
ritonavir|ketoconazole|1|Minor|ritonavir will increase the level or effect of ketoconazole by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor or non-significant interaction.
ketoconazole|rivaroxaban|20|Serious - Use Alternative|ketoconazole increases levels of rivaroxaban by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available. Avoid concomitant use of rivaroxaban and combined Pgp and strong CYP3A4 inhibitors. Combination may lead to significant increases in rivaroxaban levels and increase bleeding risk.
ketoconazole|roflumilast|3|Significant - Monitor Closely|ketoconazole increases levels of roflumilast by Other (see comment). Potential for dangerous interaction. Use with caution and monitor closely. Comment: Coadministration with dual inhibitors of CYP3A4 and CYP1A2 may increase systemic exposure and result in increased adverse reactions.
ketoconazole|ruxolitinib|20|Serious - Use Alternative|ketoconazole will increase the level or effect of ruxolitinib by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available. Reduce ruxolitinib starting dose to 10 mg BID with platelet count 100 X 10^9/L or more and concurrent use of strong CYP3A4 inhibitors; avoid with platelet counts <100 X 10^9/L
ketoconazole|saquinavir|20|Serious - Use Alternative|ketoconazole will increase the level or effect of saquinavir by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
ketoconazole|saquinavir|11|Significant - Monitor Closely|ketoconazole will increase the level or effect of saquinavir by  P-glycoprotein (MDR1) efflux transporter. Significant interaction possible, monitor closely.
ketoconazole|saxagliptin|3|Significant - Monitor Closely|ketoconazole will increase the level or effect of saxagliptin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Potential for dangerous interaction. Use with caution and monitor closely. Limit saxagliptin dose to 2.5 mg/day when coadministered with strong CYP3A4 inhibitors
ketoconazole|sildenafil|20|Serious - Use Alternative|ketoconazole will increase the level or effect of sildenafil by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
ketoconazole|silodosin|22|Serious - Use Alternative|ketoconazole will increase the level or effect of silodosin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available.
ketoconazole|silodosin|11|Significant - Monitor Closely|ketoconazole will increase the level or effect of silodosin by  P-glycoprotein (MDR1) efflux transporter. Significant interaction possible, monitor closely.
ketoconazole|simvastatin|33|Contraindicated|ketoconazole will increase the level or effect of simvastatin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Never use combination. Contraindicated. Increased risk for rhabdomyolysis with drugs that increase simvastatin systemic exposure
ketoconazole|sirolimus|33|Contraindicated|ketoconazole increases levels of sirolimus by decreasing metabolism. Never use combination.
ketoconazole|sirolimus|22|Serious - Use Alternative|ketoconazole will increase the level or effect of sirolimus by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available.
ketoconazole|sirolimus|11|Significant - Monitor Closely|ketoconazole will increase the level or effect of sirolimus by  P-glycoprotein (MDR1) efflux transporter. Significant interaction possible, monitor closely.
ketoconazole|solifenacin|20|Serious - Use Alternative|ketoconazole will increase the level or effect of solifenacin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
sucralfate|ketoconazole|11|Significant - Monitor Closely|sucralfate decreases levels of ketoconazole by inhibition of GI absorption. Applies only to oral form of both agents. Significant interaction possible, monitor closely.
ketoconazole|sunitinib|20|Serious - Use Alternative|ketoconazole will increase the level or effect of sunitinib by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
ketoconazole|tacrolimus|20|Serious - Use Alternative|ketoconazole will increase the level or effect of tacrolimus by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
ketoconazole|tacrolimus|11|Significant - Monitor Closely|ketoconazole will increase the level or effect of tacrolimus by  P-glycoprotein (MDR1) efflux transporter. Significant interaction possible, monitor closely.
ketoconazole|tadalafil|22|Serious - Use Alternative|ketoconazole will increase the level or effect of tadalafil by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available. CYP3A4 inhibitors may reduce tadalafil clearance increasing systemic exposure to tadalafil; significantly increased levels may result in significant adverse events including severe hypotension, syncope, visual changes, and priapism.
ketoconazole|tamoxifen|11|Significant - Monitor Closely|ketoconazole, tamoxifen. affecting hepatic enzyme CYP2C9/10 metabolism. Significant interaction possible, monitor closely. CYP2C9/10 inhibition decreases tamoxifen metabolism to active metabolites.
ketoconazole|tamoxifen|2|Significant - Monitor Closely|ketoconazole, tamoxifen. affecting hepatic/intestinal enzyme CYP3A4 metabolism. Potential for interaction, monitor. CYP3A4 inhibition decreases metabolism of tamoxifen to N-desmethyl tamoxifen (active metabolite with similar biologic activity).
ketoconazole|tamsulosin|20|Serious - Use Alternative|ketoconazole increases levels of tamsulosin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available. Potential for increased toxicity.
ketoconazole|tamsulosin|2|Significant - Monitor Closely|ketoconazole increases levels of tamsulosin by affecting hepatic enzyme CYP2D6 metabolism. Potential for interaction, monitor.
ketoconazole|telaprevir|11|Significant - Monitor Closely|ketoconazole increases levels of telaprevir by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely. When co-administration is required, high doses of ketoconazole (greater than 200 mg/day) are not recommended. QT interval prolongation has been reported with ketoconazole.
telaprevir|ketoconazole|11|Significant - Monitor Closely|telaprevir increases levels of ketoconazole by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely. When co-administration is required, high doses of ketoconazole (greater than 200 mg/day) are not recommended. QT interval prolongation has been reported with ketoconazole.
ketoconazole|telithromycin|3|Significant - Monitor Closely|ketoconazole and telithromycin both increase  QTc interval. Potential for dangerous interaction. Use with caution and monitor closely.
ketoconazole|telithromycin|2|Significant - Monitor Closely|ketoconazole will increase the level or effect of telithromycin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Potential for interaction, monitor.
telithromycin|ketoconazole|1|Minor|telithromycin will increase the level or effect of ketoconazole by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor or non-significant interaction.
ketoconazole|temsirolimus|20|Serious - Use Alternative|ketoconazole will increase the level or effect of temsirolimus by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
ketoconazole|teniposide|2|Significant - Monitor Closely|ketoconazole will increase the level or effect of teniposide by  P-glycoprotein (MDR1) efflux transporter. Potential for interaction, monitor.
ketoconazole|terfenadine|33|Contraindicated|ketoconazole and terfenadine both increase  QTc interval. Never use combination.
ketoconazole|terfenadine|33|Contraindicated|ketoconazole increases levels of terfenadine by decreasing metabolism. Never use combination. Risk of QT interval prolongation.
ketoconazole|terfenadine|22|Serious - Use Alternative|ketoconazole will increase the level or effect of terfenadine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available.
ketoconazole|tipranavir|20|Serious - Use Alternative|ketoconazole will increase the level or effect of tipranavir by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
ketoconazole|tolbutamide|11|Significant - Monitor Closely|ketoconazole increases levels of tolbutamide by decreasing metabolism. Significant interaction possible, monitor closely.
ketoconazole|tolbutamide|1|Minor|ketoconazole will increase the level or effect of tolbutamide by  affecting hepatic enzyme CYP2C9/10 metabolism. Minor or non-significant interaction.
ketoconazole|tolterodine|20|Serious - Use Alternative|ketoconazole will increase the level or effect of tolterodine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
ketoconazole|tolvaptan|22|Serious - Use Alternative|ketoconazole will increase the level or effect of tolvaptan by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available.
ketoconazole|tolvaptan|11|Significant - Monitor Closely|ketoconazole will increase the level or effect of tolvaptan by  P-glycoprotein (MDR1) efflux transporter. Significant interaction possible, monitor closely.
ketoconazole|topotecan|22|Serious - Use Alternative|ketoconazole will increase the level or effect of topotecan by  P-glycoprotein (MDR1) efflux transporter. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available. Product labeling for PO topotecan recommends avoiding concomitant use of P-gp inhibitors; the interaction with IV topotecan may be less severe but is still likely of clinical significance
ketoconazole|tramadol|11|Significant - Monitor Closely|ketoconazole will increase the level or effect of tramadol by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely. May require decreased tramadol dose or adjustment of dosing interval; increased risk for serious adverse events including seizures and serotonin syndrome
trazodone|ketoconazole|22|Serious - Use Alternative|trazodone and ketoconazole both increase  QTc interval. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available.
ketoconazole|trazodone|20|Serious - Use Alternative|ketoconazole will increase the level or effect of trazodone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
ketoconazole|triazolam|33|Contraindicated|ketoconazole increases levels of triazolam by decreasing metabolism. Never use combination.
ketoconazole|triazolam|20|Serious - Use Alternative|ketoconazole will increase the level or effect of triazolam by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
ketoconazole|trimethoprim|3|Significant - Monitor Closely|ketoconazole and trimethoprim both increase  QTc interval. Potential for dangerous interaction. Use with caution and monitor closely.
trimipramine|ketoconazole|22|Serious - Use Alternative|trimipramine and ketoconazole both increase  QTc interval. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available.
ketoconazole|vardenafil|21|Serious - Use Alternative|ketoconazole increases levels of vardenafil by decreasing metabolism. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available. Never use combination. Greater risk in pts. over 75 yrs old.
ketoconazole|vardenafil|20|Serious - Use Alternative|ketoconazole will increase the level or effect of vardenafil by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
ketoconazole|vemurafenib|20|Serious - Use Alternative|ketoconazole increases levels of vemurafenib by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
ketoconazole|vemurafenib|2|Significant - Monitor Closely|ketoconazole increases levels of vemurafenib by P-glycoprotein (MDR1) efflux transporter. Potential for interaction, monitor.
ketoconazole|venlafaxine|3|Significant - Monitor Closely|ketoconazole and venlafaxine both increase  QTc interval. Potential for dangerous interaction. Use with caution and monitor closely.
ketoconazole|verapamil|20|Serious - Use Alternative|ketoconazole will increase the level or effect of verapamil by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
verapamil|ketoconazole|1|Minor|verapamil will increase the level or effect of ketoconazole by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor or non-significant interaction.
ketoconazole|vilazodone|20|Serious - Use Alternative|ketoconazole increases levels of vilazodone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available. Strong CYP3A4 inhibitors may increase vilazodone plasma levels by 50% - Reduce daily dose  to 20 mg.
ketoconazole|vinblastine|11|Significant - Monitor Closely|ketoconazole will increase the level or effect of vinblastine by  P-glycoprotein (MDR1) efflux transporter. Significant interaction possible, monitor closely.
ketoconazole|vinblastine|2|Significant - Monitor Closely|ketoconazole will increase the level or effect of vinblastine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Potential for interaction, monitor.
ketoconazole|vincristine|11|Significant - Monitor Closely|ketoconazole will increase the level or effect of vincristine by  P-glycoprotein (MDR1) efflux transporter. Significant interaction possible, monitor closely.
ketoconazole|vincristine|2|Significant - Monitor Closely|ketoconazole will increase the level or effect of vincristine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Potential for interaction, monitor.
ketoconazole|vinorelbine|2|Significant - Monitor Closely|ketoconazole will increase the level or effect of vinorelbine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Potential for interaction, monitor.
ketoconazole|voriconazole|3|Significant - Monitor Closely|ketoconazole and voriconazole both increase  QTc interval. Potential for dangerous interaction. Use with caution and monitor closely.
ketoconazole|voriconazole|1|Minor|ketoconazole will increase the level or effect of voriconazole by  affecting hepatic enzyme CYP2C9/10 metabolism. Minor or non-significant interaction.
voriconazole|ketoconazole|1|Minor|voriconazole will increase the level or effect of ketoconazole by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor or non-significant interaction.
ketoconazole|warfarin|20|Serious - Use Alternative|ketoconazole will increase the level or effect of warfarin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
ketoconazole|warfarin|20|Serious - Use Alternative|ketoconazole increases levels of warfarin by decreasing metabolism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
ketoconazole|warfarin|11|Significant - Monitor Closely|ketoconazole will increase the level or effect of warfarin by  affecting hepatic enzyme CYP2C9/10 metabolism. Significant interaction possible, monitor closely.
zafirlukast|ketoconazole|1|Minor|zafirlukast will increase the level or effect of ketoconazole by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor or non-significant interaction.
ketoconazole|ziprasidone|22|Serious - Use Alternative|ketoconazole and ziprasidone both increase  QTc interval. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available.
ketoconazole|ziprasidone|2|Significant - Monitor Closely|ketoconazole will increase the level or effect of ziprasidone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Potential for interaction, monitor.
ketoconazole|zolpidem|2|Significant - Monitor Closely|ketoconazole will increase the level or effect of zolpidem by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Potential for interaction, monitor.
ketoconazole|zonisamide|2|Significant - Monitor Closely|ketoconazole will increase the level or effect of zonisamide by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Potential for interaction, monitor.
ketoprofen|ketorolac|21|Serious - Use Alternative|ketoprofen, ketorolac.Either increases toxicity of the other by pharmacodynamic synergism. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available. Never use combination.
ketoprofen|ketorolac|2|Significant - Monitor Closely|ketoprofen and ketorolac both increase  anticoagulation. Potential for interaction, monitor.
ketoprofen|ketorolac|2|Significant - Monitor Closely|ketoprofen and ketorolac both increase  serum potassium. Potential for interaction, monitor.
ketoprofen|ketorolac|1|Minor|ketoprofen will increase the level or effect of ketorolac by  acidic (anionic) drug competition for renal tubular clearance. Minor or non-significant interaction.
ketoprofen|lithium|11|Significant - Monitor Closely|ketoprofen increases levels of lithium by decreasing renal clearance. Significant interaction possible, monitor closely.
ketoprofen|methotrexate|20|Serious - Use Alternative|ketoprofen increases levels of methotrexate by decreasing renal clearance. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available. Concomitant administration of NSAIDs with high dose methotrexate has been reported to elevate and prolong serum methotrexate levels, resulting in deaths from severe hematologic and GI toxicity. NSAIDs may reduce tubular secretion of methotrexate and enhance toxicity. .
paroxetine|ketoprofen|11|Significant - Monitor Closely|paroxetine, ketoprofen.Either increases toxicity of the other by pharmacodynamic synergism. Significant interaction possible, monitor closely. Increased risk of upper GI bleeding. SSRIs inhib. serotonin uptake by platelets.
ketoprofen|pemetrexed|20|Serious - Use Alternative|ketoprofen increases levels of pemetrexed by unspecified interaction mechanism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available. Interrupt dosing in all patients taking NSAIDs with long elimination half-lives for at least 5d before, the day of, and 2d following pemetrexed administration. If coadministration of an NSAID is necessary, closely monitor patients for toxicity, especially myelosuppression, renal toxicity, and GI toxicity.
sertraline|ketoprofen|11|Significant - Monitor Closely|sertraline, ketoprofen.Either increases toxicity of the other by pharmacodynamic synergism. Significant interaction possible, monitor closely. Increased risk of upper GI bleeding. SSRIs inhib. serotonin uptake by platelets.
telmisartan|ketoprofen|11|Significant - Monitor Closely|telmisartan, ketoprofen.Either increases toxicity of the other by Other (see comment). Significant interaction possible, monitor closely. Comment: May result in renal function deterioration, particularly in elderly or volume depleted individuals.
ketoprofen|telmisartan|3|Significant - Monitor Closely|ketoprofen decreases effects of telmisartan by pharmacodynamic antagonism. Potential for dangerous interaction. Use with caution and monitor closely.  NSAIDs decrease synthesis of vasodilating renal prostaglandins, and thus affect fluid homeostasis and may diminish antihypertensive effect.
telmisartan|ketoprofen|2|Significant - Monitor Closely|telmisartan and ketoprofen both increase  serum potassium. Potential for interaction, monitor.
ketoprofen|timolol|11|Significant - Monitor Closely|ketoprofen decreases effects of timolol by pharmacodynamic antagonism. Significant interaction possible, monitor closely. Long term (>1 wk) NSAID use.  NSAIDs decrease prostaglandin synthesis.
timolol|ketoprofen|2|Significant - Monitor Closely|timolol and ketoprofen both increase  serum potassium. Potential for interaction, monitor.
trandolapril|ketoprofen|11|Significant - Monitor Closely|trandolapril, ketoprofen.Either increases toxicity of the other by Other (see comment). Significant interaction possible, monitor closely. Comment: May result in renal function deterioration, particularly in elderly or volume depleted individuals.
ketoprofen|trandolapril|3|Significant - Monitor Closely|ketoprofen decreases effects of trandolapril by pharmacodynamic antagonism. Potential for dangerous interaction. Use with caution and monitor closely. NSAIDs decrease synthesis of vasodilating renal prostaglandins, and thus affect fluid homeostasis and may diminish antihypertenisve effect.
warfarin|ketoprofen|3|Significant - Monitor Closely|warfarin and ketoprofen both increase  anticoagulation. Potential for dangerous interaction. Use with caution and monitor closely.
ketorolac|lithium|11|Significant - Monitor Closely|ketorolac increases levels of lithium by decreasing renal clearance. Significant interaction possible, monitor closely.
ketorolac|methotrexate|20|Serious - Use Alternative|ketorolac increases levels of methotrexate by decreasing renal clearance. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available. Concomitant administration of NSAIDs with high dose methotrexate has been reported to elevate and prolong serum methotrexate levels, resulting in deaths from severe hematologic and GI toxicity. NSAIDs may reduce tubular secretion of methotrexate and enhance toxicity. .
probenecid|ketorolac|21|Serious - Use Alternative|probenecid increases levels of ketorolac by decreasing renal clearance. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available. Never use combination.
ketorolac|probenecid|11|Significant - Monitor Closely|ketorolac will increase the level or effect of probenecid by  acidic (anionic) drug competition for renal tubular clearance. Significant interaction possible, monitor closely.
sulindac|ketorolac|21|Serious - Use Alternative|sulindac, ketorolac.Either increases toxicity of the other by pharmacodynamic synergism. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available. Never use combination.
ketorolac|sulindac|2|Significant - Monitor Closely|ketorolac and sulindac both increase  anticoagulation. Potential for interaction, monitor.
ketorolac|sulindac|2|Significant - Monitor Closely|ketorolac and sulindac both increase  serum potassium. Potential for interaction, monitor.
ketorolac|sulindac|1|Minor|ketorolac will increase the level or effect of sulindac by  acidic (anionic) drug competition for renal tubular clearance. Minor or non-significant interaction.
telmisartan|ketorolac|11|Significant - Monitor Closely|telmisartan, ketorolac.Either increases toxicity of the other by Other (see comment). Significant interaction possible, monitor closely. Comment: May result in renal function deterioration, particularly in elderly or volume depleted individuals.
ketorolac|telmisartan|3|Significant - Monitor Closely|ketorolac decreases effects of telmisartan by pharmacodynamic antagonism. Potential for dangerous interaction. Use with caution and monitor closely.  NSAIDs decrease synthesis of vasodilating renal prostaglandins, and thus affect fluid homeostasis and may diminish antihypertensive effect.
telmisartan|ketorolac|2|Significant - Monitor Closely|telmisartan and ketorolac both increase  serum potassium. Potential for interaction, monitor.
ketorolac|timolol|11|Significant - Monitor Closely|ketorolac decreases effects of timolol by pharmacodynamic antagonism. Significant interaction possible, monitor closely. Long term (>1 wk) NSAID use.  NSAIDs decrease prostaglandin synthesis.
timolol|ketorolac|2|Significant - Monitor Closely|timolol and ketorolac both increase  serum potassium. Potential for interaction, monitor.
tolmetin|ketorolac|21|Serious - Use Alternative|tolmetin, ketorolac.Either increases toxicity of the other by pharmacodynamic synergism. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available. Never use combination.
ketorolac|tolmetin|2|Significant - Monitor Closely|ketorolac and tolmetin both increase  anticoagulation. Potential for interaction, monitor.
ketorolac|tolmetin|2|Significant - Monitor Closely|ketorolac and tolmetin both increase  serum potassium. Potential for interaction, monitor.
ketorolac|tolmetin|1|Minor|ketorolac will increase the level or effect of tolmetin by  acidic (anionic) drug competition for renal tubular clearance. Minor or non-significant interaction.
trandolapril|ketorolac|11|Significant - Monitor Closely|trandolapril, ketorolac.Either increases toxicity of the other by Other (see comment). Significant interaction possible, monitor closely. Comment: May result in renal function deterioration, particularly in elderly or volume depleted individuals.
ketorolac|trandolapril|3|Significant - Monitor Closely|ketorolac decreases effects of trandolapril by pharmacodynamic antagonism. Potential for dangerous interaction. Use with caution and monitor closely. NSAIDs decrease synthesis of vasodilating renal prostaglandins, and thus affect fluid homeostasis and may diminish antihypertenisve effect.
warfarin|ketorolac|3|Significant - Monitor Closely|warfarin and ketorolac both increase  anticoagulation. Potential for dangerous interaction. Use with caution and monitor closely.
l-tryptophan|vilazodone|22|Serious - Use Alternative|l-tryptophan, vilazodone.Either increases toxicity of the other by serotonin levels. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available. Concomitant use is not recommended.
zolmitriptan|l-tryptophan|2|Significant - Monitor Closely|zolmitriptan and l-tryptophan both increase  serotonin levels. Potential for interaction, monitor.
labetalol|pirbuterol|11|Significant - Monitor Closely|labetalol decreases effects of pirbuterol by pharmacodynamic antagonism. Significant interaction possible, monitor closely.
labetalol|pirbuterol|2|Significant - Monitor Closely|labetalol increases and pirbuterol decreases serum potassium. Effect of interaction is not clear, use caution. Potential for interaction, monitor.
piroxicam|labetalol|11|Significant - Monitor Closely|piroxicam decreases effects of labetalol by pharmacodynamic antagonism. Significant interaction possible, monitor closely. Long term (>1 wk) NSAID use.  NSAIDs decrease prostaglandin synthesis.
labetalol|piroxicam|2|Significant - Monitor Closely|labetalol and piroxicam both increase  serum potassium. Potential for interaction, monitor.
prazosin|labetalol|3|Significant - Monitor Closely|prazosin and labetalol both increase  anti-hypertensive channel blocking. Potential for dangerous interaction. Use with caution and monitor closely.
labetalol|salmeterol|11|Significant - Monitor Closely|labetalol decreases effects of salmeterol by pharmacodynamic antagonism. Significant interaction possible, monitor closely.
labetalol|salmeterol|2|Significant - Monitor Closely|labetalol increases and salmeterol decreases serum potassium. Effect of interaction is not clear, use caution. Potential for interaction, monitor.
terazosin|labetalol|3|Significant - Monitor Closely|terazosin and labetalol both increase  anti-hypertensive channel blocking. Potential for dangerous interaction. Use with caution and monitor closely.
labetalol|terbutaline|11|Significant - Monitor Closely|labetalol decreases effects of terbutaline by pharmacodynamic antagonism. Significant interaction possible, monitor closely.
labetalol|terbutaline|2|Significant - Monitor Closely|labetalol increases and terbutaline decreases serum potassium. Effect of interaction is not clear, use caution. Potential for interaction, monitor.
treprostinil|labetalol|1|Minor|treprostinil increases effects of labetalol by pharmacodynamic synergism. Minor or non-significant interaction.
labetalol|verapamil|3|Significant - Monitor Closely|labetalol and verapamil both increase  anti-hypertensive channel blocking. Potential for dangerous interaction. Use with caution and monitor closely.
valganciclovir|lamivudine|3|Significant - Monitor Closely|valganciclovir, lamivudine.Either increases toxicity of the other by pharmacodynamic synergism. Potential for dangerous interaction. Use with caution and monitor closely. Use alternatives if available.  Increased risk of hematologic toxicity.
mestranol|lamotrigine|11|Significant - Monitor Closely|mestranol decreases levels of lamotrigine by increasing hepatic clearance. Significant interaction possible, monitor closely.
phenytoin|lamotrigine|11|Significant - Monitor Closely|phenytoin decreases levels of lamotrigine by increasing metabolism. Significant interaction possible, monitor closely.
valproic acid|lamotrigine|11|Significant - Monitor Closely|valproic acid increases levels of lamotrigine by decreasing hepatic clearance. Significant interaction possible, monitor closely.
lansoprazole|rilpivirine|33|Contraindicated|lansoprazole decreases levels of rilpivirine by increasing gastric pH. Applies only to oral form of both agents. Never use combination. Contraindicated. Concurrent use may cause treatment failure and/or the development of rilpivirine or NNRTI resistance. Coadministration of a PPI and rilpivirine may result in decreased rilpivirine plasma concentrations, which could cause impaired virologic response to rilpivirine.
sucralfate|lansoprazole|1|Minor|sucralfate decreases levels of lansoprazole by inhibition of GI absorption. Applies only to oral form of both agents. Minor or non-significant interaction. Separate by 30 minutes.
lapatinib|lumefantrine|11|Significant - Monitor Closely|lapatinib will increase the level or effect of lumefantrine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
lapatinib|lumefantrine|3|Significant - Monitor Closely|lapatinib and lumefantrine both increase  QTc interval. Potential for dangerous interaction. Use with caution and monitor closely.
lapatinib|pazopanib|20|Serious - Use Alternative|lapatinib will increase the level or effect of pazopanib by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available. Avoid coadministration of pazopanib with strong CYP3A4 inhibitors if possible; if must coadminister, decrease pazopanib dose to 400 mg/day
lapatinib|pazopanib|1|Minor|lapatinib and pazopanib both increase  QTc interval. Minor or non-significant interaction.
lapatinib|tacrolimus|11|Significant - Monitor Closely|lapatinib will increase the level or effect of tacrolimus by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
lapatinib|tacrolimus|11|Significant - Monitor Closely|lapatinib will increase the level or effect of tacrolimus by  P-glycoprotein (MDR1) efflux transporter. Significant interaction possible, monitor closely.
lapatinib|tamsulosin|2|Significant - Monitor Closely|lapatinib increases levels of tamsulosin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Potential for interaction, monitor. Dose reduction may be needed for coadministered drugs that are predominantly metabolized by CYP3A.
telithromycin|lapatinib|11|Significant - Monitor Closely|telithromycin will increase the level or effect of lapatinib by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
lapatinib|telithromycin|2|Significant - Monitor Closely|lapatinib and telithromycin both increase  QTc interval. Potential for interaction, monitor.
lapatinib|telithromycin|1|Minor|lapatinib will increase the level or effect of telithromycin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor or non-significant interaction.
lapatinib|tolterodine|11|Significant - Monitor Closely|lapatinib will increase the level or effect of tolterodine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
lapatinib|topotecan|22|Serious - Use Alternative|lapatinib will increase the level or effect of topotecan by  P-glycoprotein (MDR1) efflux transporter. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available. Product labeling for PO topotecan recommends avoiding concomitant use of P-gp inhibitors; the interaction with IV topotecan may be less severe but is still likely of clinical significance
lapatinib|toremifene|20|Serious - Use Alternative|lapatinib and toremifene both increase  QTc interval. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available. Concurrent use of toremifene with agents causing  QT prolongation should be avoided. If concomitant use is required it's recommended that toremifene be interrupted. If interruption not possible, patients requiring therapy with a drug that prolongs QT should be closely monitored. ECGs should be obtained for high risk patients.
trazodone|lapatinib|11|Significant - Monitor Closely|trazodone will decrease the level or effect of lapatinib by  P-glycoprotein (MDR1) efflux transporter. Significant interaction possible, monitor closely.
trazodone|lapatinib|3|Significant - Monitor Closely|trazodone and lapatinib both increase  QTc interval. Potential for dangerous interaction. Use with caution and monitor closely.
lapatinib|trazodone|2|Significant - Monitor Closely|lapatinib will increase the level or effect of trazodone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Potential for interaction, monitor.
trimipramine|lapatinib|3|Significant - Monitor Closely|trimipramine and lapatinib both increase  QTc interval. Potential for dangerous interaction. Use with caution and monitor closely.
voriconazole|lapatinib|11|Significant - Monitor Closely|voriconazole will increase the level or effect of lapatinib by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
lapatinib|voriconazole|2|Significant - Monitor Closely|lapatinib and voriconazole both increase  QTc interval. Potential for interaction, monitor.
lapatinib|ziprasidone|3|Significant - Monitor Closely|lapatinib and ziprasidone both increase  QTc interval. Potential for dangerous interaction. Use with caution and monitor closely.
lapatinib|ziprasidone|1|Minor|lapatinib will increase the level or effect of ziprasidone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor or non-significant interaction.
leflunomide|rilonacept|22|Serious - Use Alternative|leflunomide and rilonacept both increase  immunosuppressive effects; risk of infection. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available.
leflunomide|tofacitinib|20|Serious - Use Alternative|leflunomide, tofacitinib.Either increases toxicity of the other by immunosuppressive effects; risk of infection. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
leflunomide|warfarin|11|Significant - Monitor Closely|leflunomide will increase the level or effect of warfarin by  affecting hepatic enzyme CYP2C9/10 metabolism. Significant interaction possible, monitor closely.
leucovorin|trimethoprim|20|Serious - Use Alternative|leucovorin decreases effects of trimethoprim by pharmacodynamic antagonism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available. Monitor for trimethoprim treatment failure or decreased efficacy when coadministered with leucovorin, especially when used with sulfamethoxazole for  Pneumocystis jiroveci pneumonia in patients who are HIV positive .
levofloxacin|lumefantrine|3|Significant - Monitor Closely|levofloxacin and lumefantrine both increase  QTc interval. Potential for dangerous interaction. Use with caution and monitor closely.
magnesium oxide|levofloxacin|11|Significant - Monitor Closely|magnesium oxide decreases levels of levofloxacin by inhibition of GI absorption. Applies only to oral form of both agents. Significant interaction possible, monitor closely. Separate by 2 hours.
perphenazine|levofloxacin|3|Significant - Monitor Closely|perphenazine and levofloxacin both increase  QTc interval. Potential for dangerous interaction. Use with caution and monitor closely.
levofloxacin|procainamide|22|Serious - Use Alternative|levofloxacin and procainamide both increase  QTc interval. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available.
prochlorperazine|levofloxacin|3|Significant - Monitor Closely|prochlorperazine and levofloxacin both increase  QTc interval. Potential for dangerous interaction. Use with caution and monitor closely.
promazine|levofloxacin|3|Significant - Monitor Closely|promazine and levofloxacin both increase  QTc interval. Potential for dangerous interaction. Use with caution and monitor closely.
promethazine|levofloxacin|3|Significant - Monitor Closely|promethazine and levofloxacin both increase  QTc interval. Potential for dangerous interaction. Use with caution and monitor closely.
quinidine|levofloxacin|22|Serious - Use Alternative|quinidine and levofloxacin both increase  QTc interval. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available.
levofloxacin|sotalol|22|Serious - Use Alternative|levofloxacin and sotalol both increase  QTc interval. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available.
sucralfate|levofloxacin|11|Significant - Monitor Closely|sucralfate decreases levels of levofloxacin by inhibition of GI absorption. Applies only to oral form of both agents. Significant interaction possible, monitor closely.
thioridazine|levofloxacin|3|Significant - Monitor Closely|thioridazine and levofloxacin both increase  QTc interval. Potential for dangerous interaction. Use with caution and monitor closely.
levofloxacin|toremifene|20|Serious - Use Alternative|levofloxacin and toremifene both increase  QTc interval. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available. Concurrent use of toremifene with agents causing  QT prolongation should be avoided. If concomitant use is required it's recommended that toremifene be interrupted. If interruption not possible, patients requiring therapy with a drug that prolongs QT should be closely monitored. ECGs should be obtained for high risk patients.
trifluoperazine|levofloxacin|3|Significant - Monitor Closely|trifluoperazine and levofloxacin both increase  QTc interval. Potential for dangerous interaction. Use with caution and monitor closely.
trimipramine|levofloxacin|3|Significant - Monitor Closely|trimipramine and levofloxacin both increase  QTc interval. Potential for dangerous interaction. Use with caution and monitor closely.
levofloxacin|voriconazole|2|Significant - Monitor Closely|levofloxacin and voriconazole both increase  QTc interval. Potential for interaction, monitor.
levofloxacin|warfarin|11|Significant - Monitor Closely|levofloxacin increases effects of warfarin by Other (see comment). Significant interaction possible, monitor closely. Comment: Decr vitamin K-producing intestinal flora may increase INR after a few days.
levofloxacin|warfarin|11|Significant - Monitor Closely|levofloxacin increases effects of warfarin by unknown mechanism. Significant interaction possible, monitor closely. Ciprofloxacin, norfloxacin, & ofloxacin are most likely to interact w/warfarin; data for other quinolones is conflicting.  Monitor INR closely.
levofloxacin|ziprasidone|3|Significant - Monitor Closely|levofloxacin and ziprasidone both increase  QTc interval. Potential for dangerous interaction. Use with caution and monitor closely.
triprolidine|levorphanol|2|Significant - Monitor Closely|triprolidine and levorphanol both increase  sedation. Potential for interaction, monitor.
raloxifene|levothyroxine|11|Significant - Monitor Closely|raloxifene decreases levels of levothyroxine by inhibition of GI absorption. Applies only to oral form of both agents. Significant interaction possible, monitor closely.
levothyroxine|warfarin|20|Serious - Use Alternative|levothyroxine increases effects of warfarin by pharmacodynamic synergism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
nadolol|lidocaine|11|Significant - Monitor Closely|nadolol, lidocaine. Mechanism: pharmacodynamic synergism. Significant interaction possible, monitor closely. Increased effects of epinephrine in anesthetic; risk of hypertension and bradycardia.  Do NOT D/C chronic beta blocker Tx prior to anesthetic administration.  Consider selective beta 1 blocker (e.g., metoprolol).
nadolol|lidocaine|11|Significant - Monitor Closely|nadolol increases levels of lidocaine by decreasing elimination. Significant interaction possible, monitor closely. Risk of hypertension and bradycardia.  Consider selective beta 1 blocker (e.g., metoprolol).
pindolol|lidocaine|11|Significant - Monitor Closely|pindolol, lidocaine. Mechanism: pharmacodynamic synergism. Significant interaction possible, monitor closely. Increased effects of epinephrine in anesthetic; risk of hypertension and bradycardia.  Do NOT D/C chronic beta blocker Tx prior to anesthetic administration.  Consider selective beta 1 blocker (e.g., metoprolol).
pindolol|lidocaine|11|Significant - Monitor Closely|pindolol increases levels of lidocaine by decreasing elimination. Significant interaction possible, monitor closely. Risk of hypertension and bradycardia.  Consider selective beta 1 blocker (e.g., metoprolol).
propranolol|lidocaine|11|Significant - Monitor Closely|propranolol, lidocaine. Mechanism: pharmacodynamic synergism. Significant interaction possible, monitor closely. Increased effects of epinephrine in anesthetic; risk of hypertension and bradycardia.  Do NOT D/C chronic beta blocker Tx prior to anesthetic administration.  Consider selective beta 1 blocker (e.g., metoprolol).
propranolol|lidocaine|11|Significant - Monitor Closely|propranolol increases levels of lidocaine by decreasing elimination. Significant interaction possible, monitor closely. Risk of hypertension and bradycardia.  Consider selective beta 1 blocker (e.g., metoprolol).
tacrine|lidocaine|11|Significant - Monitor Closely|tacrine will increase the level or effect of lidocaine by  affecting hepatic enzyme CYP1A2 metabolism. Significant interaction possible, monitor closely.
lidocaine|tamsulosin|2|Significant - Monitor Closely|lidocaine increases levels of tamsulosin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Potential for interaction, monitor. Dose reduction may be needed for coadministered drugs that are predominantly metabolized by CYP3A.
lidocaine|tamsulosin|2|Significant - Monitor Closely|lidocaine increases levels of tamsulosin by affecting hepatic enzyme CYP2D6 metabolism. Potential for interaction, monitor.
timolol|lidocaine|11|Significant - Monitor Closely|timolol, lidocaine. Mechanism: pharmacodynamic synergism. Significant interaction possible, monitor closely. Increased effects of epinephrine in anesthetic; risk of hypertension and bradycardia.  Do NOT D/C chronic beta blocker Tx prior to anesthetic administration.  Consider selective beta 1 blocker (e.g., metoprolol).
timolol|lidocaine|11|Significant - Monitor Closely|timolol increases levels of lidocaine by decreasing elimination. Significant interaction possible, monitor closely. Risk of hypertension and bradycardia.  Consider selective beta 1 blocker (e.g., metoprolol).
lidocaine|tramadol|1|Minor|lidocaine increases toxicity of tramadol by pharmacodynamic synergism. Minor or non-significant interaction. Risk of increased CNS depression.
prednisone|linagliptin|11|Significant - Monitor Closely|prednisone will increase the level or effect of linagliptin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely. Use of alternative treatments is strongly recommended when linagliptin is to be administered with a CYP3A4 inducer
ritonavir|linagliptin|11|Significant - Monitor Closely|ritonavir increases levels of linagliptin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely. Potential for increased toxicity. .
ritonavir|linagliptin|11|Significant - Monitor Closely|ritonavir decreases effects of linagliptin by Other (see comment). Significant interaction possible, monitor closely. Comment: Reports of hyperglycemia due to insulin resistance with protease inhibitors. .
lincomycin|pancuronium|20|Serious - Use Alternative|lincomycin increases effects of pancuronium by pharmacodynamic synergism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available. Risk of respiratory depression.
lincomycin|rocuronium|20|Serious - Use Alternative|lincomycin increases effects of rocuronium by pharmacodynamic synergism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available. Risk of respiratory depression.
lincomycin|succinylcholine|20|Serious - Use Alternative|lincomycin increases effects of succinylcholine by pharmacodynamic synergism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available. Risk of respiratory depression.
lincomycin|tubocurarine|20|Serious - Use Alternative|lincomycin increases effects of tubocurarine by pharmacodynamic synergism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available. Risk of respiratory depression.
lincomycin|vecuronium|20|Serious - Use Alternative|lincomycin increases effects of vecuronium by pharmacodynamic synergism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available. Risk of respiratory depression.
linezolid|nefazodone|22|Serious - Use Alternative|linezolid and nefazodone both increase  serotonin levels. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available. Linezolid may increase serotonin as a result of MAO-A inhibition. If linezolid must be administered, discontinue serotonergic drug immediately and monitor for CNS toxicity. Serotonergic therapy may be resumed 24 hours after last linezolid dose or after 2 weeks of monitoring, whichever comes first.
linezolid|norepinephrine|33|Contraindicated|linezolid increases effects of norepinephrine by pharmacodynamic synergism. Never use combination. Risk of acute hypertensive episode.
linezolid|paroxetine|22|Serious - Use Alternative|linezolid and paroxetine both increase  serotonin levels. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available. Linezolid may increase serotonin as a result of MAO-A inhibition. If linezolid must be administered, discontinue serotonergic drug immediately and monitor for CNS toxicity. Serotonergic therapy may be resumed 24 hours after last linezolid dose or after 2 weeks of monitoring, whichever comes first.
linezolid|phenylephrine|33|Contraindicated|linezolid increases effects of phenylephrine by pharmacodynamic synergism. Never use combination. Risk of acute hypertensive episode.
linezolid|pirbuterol|21|Serious - Use Alternative|linezolid increases effects of pirbuterol by pharmacodynamic synergism. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available. Never use combination. Risk of acute hypertensive episode.
linezolid|pseudoephedrine|33|Contraindicated|linezolid increases effects of pseudoephedrine by pharmacodynamic synergism. Never use combination. Risk of acute hypertensive episode.
linezolid|sertraline|22|Serious - Use Alternative|linezolid and sertraline both increase  serotonin levels. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available. Linezolid may increase serotonin as a result of MAO-A inhibition. If linezolid must be administered, discontinue serotonergic drug immediately and monitor for CNS toxicity. Serotonergic therapy may be resumed 24 hours after last linezolid dose or after 2 weeks of monitoring, whichever comes first.
linezolid|terbutaline|21|Serious - Use Alternative|linezolid increases effects of terbutaline by pharmacodynamic synergism. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available. Never use combination. Risk of acute hypertensive episode.
tetrabenazine|linezolid|33|Contraindicated|tetrabenazine, linezolid. Other (see comment). Never use combination. Comment: Risk of acute hypertensive episode; separate by 14 d.  Mechanism: MAOI causes accumulation of NE in neuron and tetrabenazine stimulates NE release.
tolcapone|linezolid|21|Serious - Use Alternative|tolcapone increases effects of linezolid by pharmacodynamic synergism. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available. Never use combination.
linezolid|tramadol|22|Serious - Use Alternative|linezolid and tramadol both increase  serotonin levels. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available. Linezolid may increase serotonin as a result of MAO-A inhibition. If linezolid must be administered, discontinue serotonergic drug immediately and monitor for CNS toxicity. Serotonergic therapy may be resumed 24 hours after last linezolid dose or after 2 weeks of monitoring, whichever comes first.
linezolid|tramadol|20|Serious - Use Alternative|linezolid increases toxicity of tramadol by unknown mechanism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available. Risk of hypotension, hyperpyrexia, somnolence, or death; separate by 14 d.
linezolid|tranylcypromine|22|Serious - Use Alternative|linezolid and tranylcypromine both increase  serotonin levels. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available. Linezolid may increase serotonin as a result of MAO-A inhibition. If linezolid must be administered, discontinue serotonergic drug immediately and monitor for CNS toxicity. Serotonergic therapy may be resumed 24 hours after last linezolid dose or after 2 weeks of monitoring, whichever comes first.
linezolid|trazodone|22|Serious - Use Alternative|linezolid and trazodone both increase  serotonin levels. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available. Linezolid may increase serotonin as a result of MAO-A inhibition. If linezolid must be administered, discontinue serotonergic drug immediately and monitor for CNS toxicity. Serotonergic therapy may be resumed 24 hours after last linezolid dose or after 2 weeks of monitoring, whichever comes first.
linezolid|trimipramine|22|Serious - Use Alternative|linezolid and trimipramine both increase  serotonin levels. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available. Linezolid may increase serotonin as a result of MAO-A inhibition. If linezolid must be administered, discontinue serotonergic drug immediately and monitor for CNS toxicity. Serotonergic therapy may be resumed 24 hours after last linezolid dose or after 2 weeks of monitoring, whichever comes first.
linezolid|venlafaxine|22|Serious - Use Alternative|linezolid and venlafaxine both increase  serotonin levels. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available. Linezolid may increase serotonin as a result of MAO-A inhibition. If linezolid must be administered, discontinue serotonergic drug immediately and monitor for CNS toxicity. Serotonergic therapy may be resumed 24 hours after last linezolid dose or after 2 weeks of monitoring, whichever comes first.
linezolid|vilazodone|22|Serious - Use Alternative|linezolid, vilazodone.Either increases toxicity of the other by serotonin levels. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available. Linezolid may increase serotonin as a result of MAO-A inhibition. If linezolid must be administered, discontinue serotonergic drug immediately and monitor for CNS toxicity. Serotonergic therapy may be resumed 24 hours after last linezolid dose or after 2 weeks of monitoring, whichever comes first.
zolmitriptan|linezolid|22|Serious - Use Alternative|zolmitriptan and linezolid both increase  serotonin levels. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available. Linezolid may increase serotonin as a result of MAO-A inhibition. If linezolid must be administered, discontinue serotonergic drug immediately and monitor for CNS toxicity. Serotonergic therapy may be resumed 24 hours after last linezolid dose or after 2 weeks of monitoring, whichever comes first.
linezolid|zolmitriptan|21|Serious - Use Alternative|linezolid increases levels of zolmitriptan by decreasing metabolism. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available. Never use combination.
liothyronine|warfarin|20|Serious - Use Alternative|liothyronine increases effects of warfarin by pharmacodynamic synergism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
tramadol|lisdexamfetamine|2|Significant - Monitor Closely|tramadol increases and lisdexamfetamine decreases sedation. Effect of interaction is not clear, use caution. Potential for interaction, monitor.
tranylcypromine|lisdexamfetamine|33|Contraindicated|tranylcypromine increases effects of lisdexamfetamine by pharmacodynamic synergism. Never use combination. Risk of acute hypertensive episode.
tranylcypromine|lisdexamfetamine|20|Serious - Use Alternative|tranylcypromine and lisdexamfetamine both increase  serotonin levels. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available. Tranylcypromine may increase serotonin as a result of MAO-A inhibition. If tranylcypromine must be administered, discontinue serotonergic drug immediately and monitor for CNS toxicity/hypertension. Serotonergic therapy may be resumed 24 hours after last tranylcypromine dose or after 2 weeks of monitoring, whichever comes first
triprolidine|lisdexamfetamine|2|Significant - Monitor Closely|triprolidine increases and lisdexamfetamine decreases sedation. Effect of interaction is not clear, use caution. Potential for interaction, monitor.
lisinopril|lithium|11|Significant - Monitor Closely|lisinopril increases toxicity of lithium by unknown mechanism. Significant interaction possible, monitor closely. ACE inhibitor induced Na+ depletion may increase reabsorption of lithium from renal tubule.
lisinopril|spironolactone|11|Significant - Monitor Closely|lisinopril, spironolactone. Mechanism: pharmacodynamic synergism. Significant interaction possible, monitor closely. Risk of hyperkalemia.
tizanidine|lisinopril|1|Minor|tizanidine increases effects of lisinopril by pharmacodynamic synergism. Minor or non-significant interaction. Risk of hypotension.
treprostinil|lisinopril|1|Minor|treprostinil increases effects of lisinopril by pharmacodynamic synergism. Minor or non-significant interaction.
lisinopril|triamterene|11|Significant - Monitor Closely|lisinopril, triamterene. Mechanism: pharmacodynamic synergism. Significant interaction possible, monitor closely. Risk of hyperkalemia.
losartan|lithium|20|Serious - Use Alternative|losartan increases toxicity of lithium by decreasing renal clearance. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
mefenamic acid|lithium|11|Significant - Monitor Closely|mefenamic acid increases levels of lithium by decreasing renal clearance. Significant interaction possible, monitor closely.
meloxicam|lithium|11|Significant - Monitor Closely|meloxicam increases levels of lithium by decreasing renal clearance. Significant interaction possible, monitor closely.
methyclothiazide|lithium|11|Significant - Monitor Closely|methyclothiazide increases toxicity of lithium by decreasing elimination. Significant interaction possible, monitor closely.
methyldopa|lithium|1|Minor|methyldopa increases toxicity of lithium by unknown mechanism. Minor or non-significant interaction.
metolazone|lithium|11|Significant - Monitor Closely|metolazone increases toxicity of lithium by decreasing elimination. Significant interaction possible, monitor closely.
metronidazole|lithium|1|Minor|metronidazole increases levels of lithium by decreasing metabolism. Minor or non-significant interaction.
moexipril|lithium|11|Significant - Monitor Closely|moexipril increases toxicity of lithium by unknown mechanism. Significant interaction possible, monitor closely. ACE inhibitor induced Na+ depletion may increase reabsorption of lithium from renal tubule.
naproxen|lithium|11|Significant - Monitor Closely|naproxen increases levels of lithium by decreasing renal clearance. Significant interaction possible, monitor closely.
perindopril|lithium|11|Significant - Monitor Closely|perindopril increases toxicity of lithium by unknown mechanism. Significant interaction possible, monitor closely. ACE inhibitor induced Na+ depletion may increase reabsorption of lithium from renal tubule.
piroxicam|lithium|11|Significant - Monitor Closely|piroxicam increases levels of lithium by decreasing renal clearance. Significant interaction possible, monitor closely.
quinapril|lithium|11|Significant - Monitor Closely|quinapril increases toxicity of lithium by unknown mechanism. Significant interaction possible, monitor closely. ACE inhibitor induced Na+ depletion may increase reabsorption of lithium from renal tubule.
ramipril|lithium|11|Significant - Monitor Closely|ramipril increases toxicity of lithium by unknown mechanism. Significant interaction possible, monitor closely. ACE inhibitor induced Na+ depletion may increase reabsorption of lithium from renal tubule.
sumatriptan|lithium|2|Significant - Monitor Closely|sumatriptan and lithium both increase  serotonin levels. Potential for interaction, monitor.
telmisartan|lithium|20|Serious - Use Alternative|telmisartan increases toxicity of lithium by decreasing renal clearance. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
theophylline|lithium|1|Minor|theophylline decreases levels of lithium by increasing renal clearance. Minor or non-significant interaction.
tolmetin|lithium|11|Significant - Monitor Closely|tolmetin increases levels of lithium by decreasing renal clearance. Significant interaction possible, monitor closely.
trandolapril|lithium|11|Significant - Monitor Closely|trandolapril increases toxicity of lithium by unknown mechanism. Significant interaction possible, monitor closely. ACE inhibitor induced Na+ depletion may increase reabsorption of lithium from renal tubule.
tranylcypromine|lithium|22|Serious - Use Alternative|tranylcypromine and lithium both increase  serotonin levels. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available.
lithium|tranylcypromine|11|Significant - Monitor Closely|lithium, tranylcypromine. Mechanism: unknown. Significant interaction possible, monitor closely. Risk of malignant hyperpyrexia.  Interactions esp. expected w/non selective MAOIs.
trazodone|lithium|3|Significant - Monitor Closely|trazodone and lithium both increase  serotonin levels. Potential for dangerous interaction. Use with caution and monitor closely.
lithium|trazodone|1|Minor|lithium, trazodone. Other (see comment). Minor or non-significant interaction. Comment: Risk of neurotoxicity in geriatric pts.  Multiple mechanisms involved.
trazodone|lithium|1|Minor|trazodone, lithium. Mechanism: unknown. Minor or non-significant interaction. Risk of neurotoxicity.
trimipramine|lithium|3|Significant - Monitor Closely|trimipramine and lithium both increase  serotonin levels. Potential for dangerous interaction. Use with caution and monitor closely.
lithium|trimipramine|1|Minor|lithium, trimipramine. Other (see comment). Minor or non-significant interaction. Comment: Risk of neurotoxicity in geriatric pts.  Multiple mechanisms involved.
valsartan|lithium|20|Serious - Use Alternative|valsartan increases toxicity of lithium by decreasing renal clearance. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
venlafaxine|lithium|3|Significant - Monitor Closely|venlafaxine and lithium both increase  serotonin levels. Potential for dangerous interaction. Use with caution and monitor closely.
venlafaxine|lithium|1|Minor|venlafaxine, lithium. Mechanism: unknown. Minor or non-significant interaction. Risk of neurotoxicity.
verapamil|lithium|1|Minor|verapamil increases toxicity of lithium by pharmacodynamic synergism. Minor or non-significant interaction. Increased risk of neurotoxicity.
zolmitriptan|lithium|2|Significant - Monitor Closely|zolmitriptan and lithium both increase  serotonin levels. Potential for interaction, monitor.
lomitapide|lovastatin|20|Serious - Use Alternative|lomitapide increases levels of lovastatin by decreasing metabolism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available. Reduce lovastatin dose by 50% when initiating lomitapide dosing.
lovastatin|lomitapide|11|Significant - Monitor Closely|lovastatin increases levels of lomitapide by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely. Lomitapide dose should not exceed 30 mg/day.
lomitapide|lovastatin|3|Significant - Monitor Closely|lomitapide increases levels of lovastatin by P-glycoprotein (MDR1) efflux transporter. Potential for dangerous interaction. Use with caution and monitor closely. Consider reducing dose when used concomitantly with lomitapide.
lomitapide|simvastatin|20|Serious - Use Alternative|lomitapide increases levels of simvastatin by decreasing metabolism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available. Reduce simvastatin dose by 50% when initiating lomitapide dosing.
telaprevir|lomitapide|33|Contraindicated|telaprevir increases levels of lomitapide by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Never use combination. Increases lomitapide levels several folds.
lomitapide|telaprevir|3|Significant - Monitor Closely|lomitapide increases levels of telaprevir by P-glycoprotein (MDR1) efflux transporter. Potential for dangerous interaction. Use with caution and monitor closely. Consider reducing dose when used concomitantly with lomitapide.
ticagrelor|lomitapide|33|Contraindicated|ticagrelor increases levels of lomitapide by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Never use combination. Increases lomitapide levels several folds.
lomitapide|warfarin|3|Significant - Monitor Closely|lomitapide will increase the level or effect of warfarin by  unspecified interaction mechanism. Potential for dangerous interaction. Use with caution and monitor closely. Increases plasma concentration of R(+)-warfarin and S(-)-warfarin and INR significantly. Monitor INR especially after changing lomitapide dosage.  Adjust warfarin dose as necessary.
phenytoin|lopinavir|11|Significant - Monitor Closely|phenytoin will decrease the level or effect of lopinavir by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
lopinavir|pitavastatin|33|Contraindicated|lopinavir increases levels of pitavastatin by decreasing metabolism. Never use combination.
lopinavir|ponatinib|20|Serious - Use Alternative|lopinavir increases levels of ponatinib by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available. Decrease ponatinib starting dose to 30 mg qDay if coadministration with strong CYP3A4 inhibitors cannot be avoided.
lopinavir|roflumilast|3|Significant - Monitor Closely|lopinavir will decrease the level or effect of roflumilast by  affecting hepatic enzyme CYP1A2 metabolism. Potential for dangerous interaction. Use with caution and monitor closely. Concomitant therapy may reduce therapeutic effectiveness.
lopinavir|tadalafil|20|Serious - Use Alternative|lopinavir will increase the level or effect of tadalafil by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available. CYP3A4 inhibitors may reduce tadalafil clearance increasing systemic exposure to tadalafil; significantly increased levels may result in significant adverse events including severe hypotension, syncope, visual changes, and priapism.
lopinavir|tamoxifen|20|Serious - Use Alternative|lopinavir, tamoxifen. affecting hepatic/intestinal enzyme CYP3A4 metabolism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available. CYP3A4 inhibition decreases metabolism of tamoxifen to N-desmethyl tamoxifen (active metabolite with similar biologic activity).
lopinavir|tamsulosin|20|Serious - Use Alternative|lopinavir increases levels of tamsulosin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available. Potential for increased toxicity.
lopinavir|tamsulosin|2|Significant - Monitor Closely|lopinavir increases levels of tamsulosin by affecting hepatic enzyme CYP2D6 metabolism. Potential for interaction, monitor.
telithromycin|lopinavir|11|Significant - Monitor Closely|telithromycin will increase the level or effect of lopinavir by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
tipranavir|lopinavir|20|Serious - Use Alternative|tipranavir decreases levels of lopinavir by unspecified interaction mechanism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
lopinavir|topotecan|22|Serious - Use Alternative|lopinavir will increase the level or effect of topotecan by  P-glycoprotein (MDR1) efflux transporter. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available. Product labeling for PO topotecan recommends avoiding concomitant use of P-gp inhibitors; the interaction with IV topotecan may be less severe but is still likely of clinical significance
lopinavir|venlafaxine|11|Significant - Monitor Closely|lopinavir increases levels of venlafaxine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely. Potential for increased toxicity.
verapamil|lopinavir|11|Significant - Monitor Closely|verapamil will increase the level or effect of lopinavir by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
voriconazole|lopinavir|11|Significant - Monitor Closely|voriconazole will increase the level or effect of lopinavir by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
nefazodone|loratadine|2|Significant - Monitor Closely|nefazodone will decrease the level or effect of loratadine by  P-glycoprotein (MDR1) efflux transporter. Potential for interaction, monitor.
nefazodone|loratadine|1|Minor|nefazodone will increase the level or effect of loratadine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor or non-significant interaction.
triprolidine|lorazepam|2|Significant - Monitor Closely|triprolidine and lorazepam both increase  sedation. Potential for interaction, monitor.
telaprevir|cyclosporine|11|Significant - Monitor Closely|telaprevir increases levels of cyclosporine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely. Significant dose reductions and prolongation of the dosing interval of the immunosuppressant to achieve the desired blood levels should be anticipated. Close monitoring of the immunosuppressant blood levels, and frequent assessments of renal function and immunosuppressant-related side effects are recommended when co-administered with telaprevir. .
cyclosporine|telithromycin|1|Minor|cyclosporine will increase the level or effect of telithromycin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor or non-significant interaction.
testosterone|cyclosporine|20|Serious - Use Alternative|testosterone increases effects of cyclosporine by decreasing metabolism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
ticlopidine|cyclosporine|1|Minor|ticlopidine decreases levels of cyclosporine by unspecified interaction mechanism. Minor or non-significant interaction.
cyclosporine|tipranavir|11|Significant - Monitor Closely|cyclosporine will increase the level or effect of tipranavir by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
tipranavir|cyclosporine|11|Significant - Monitor Closely|tipranavir, cyclosporine. Other (see comment). Significant interaction possible, monitor closely. Comment: Cyclosporine levels may incr or decr, due to contradictory effects of tipranavir on hepatic CYP3A4 and P glycoprotein.
cyclosporine|tobramycin|11|Significant - Monitor Closely|cyclosporine will increase the level or effect of tobramycin by  P-glycoprotein (MDR1) efflux transporter. Significant interaction possible, monitor closely.
cyclosporine|tobramycin|3|Significant - Monitor Closely|cyclosporine and tobramycin both increase  nephrotoxicity and/or ototoxicity. Potential for dangerous interaction. Use with caution and monitor closely.
cyclosporine|tofacitinib|20|Serious - Use Alternative|cyclosporine, tofacitinib.Either increases toxicity of the other by immunosuppressive effects; risk of infection. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
cyclosporine|tofacitinib|2|Significant - Monitor Closely|cyclosporine increases levels of tofacitinib by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Potential for interaction, monitor. No specific dose adjustment recommended when tofacitinib coadministered with moderate CYP3A4 inhibitors; decrease tofacitinib dose if coadministered with both moderate CYP3A4 and potent CYP2C19 inhibitors.
tolmetin|cyclosporine|3|Significant - Monitor Closely|tolmetin, cyclosporine.Either increases toxicity of the other by nephrotoxicity and/or ototoxicity. Potential for dangerous interaction. Use with caution and monitor closely.
cyclosporine|tolterodine|11|Significant - Monitor Closely|cyclosporine will increase the level or effect of tolterodine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
cyclosporine|topotecan|22|Serious - Use Alternative|cyclosporine will increase the level or effect of topotecan by  P-glycoprotein (MDR1) efflux transporter. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available. Product labeling for PO topotecan recommends avoiding concomitant use of P-gp inhibitors; the interaction with IV topotecan may be less severe but is still likely of clinical significance
trandolapril|cyclosporine|11|Significant - Monitor Closely|trandolapril, cyclosporine. Mechanism: unspecified interaction mechanism. Significant interaction possible, monitor closely. Risk of acute renal failure.
trazodone|cyclosporine|11|Significant - Monitor Closely|trazodone will decrease the level or effect of cyclosporine by  P-glycoprotein (MDR1) efflux transporter. Significant interaction possible, monitor closely.
cyclosporine|trazodone|2|Significant - Monitor Closely|cyclosporine will increase the level or effect of trazodone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Potential for interaction, monitor.
troglitazone|cyclosporine|11|Significant - Monitor Closely|troglitazone will decrease the level or effect of cyclosporine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
troleandomycin|cyclosporine|11|Significant - Monitor Closely|troleandomycin will increase the level or effect of cyclosporine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
cyclosporine|troleandomycin|1|Minor|cyclosporine will increase the level or effect of troleandomycin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor or non-significant interaction.
verapamil|cyclosporine|11|Significant - Monitor Closely|verapamil will increase the level or effect of cyclosporine by  affecting hepatic enzyme CYP1A2 metabolism. Significant interaction possible, monitor closely.
cyclosporine|verapamil|11|Significant - Monitor Closely|cyclosporine will increase the level or effect of verapamil by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
verapamil|cyclosporine|11|Significant - Monitor Closely|verapamil will increase the level or effect of cyclosporine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
verapamil|cyclosporine|11|Significant - Monitor Closely|verapamil will increase the level or effect of cyclosporine by  P-glycoprotein (MDR1) efflux transporter. Significant interaction possible, monitor closely.
fluoxetine|cyproheptadine|3|Significant - Monitor Closely|fluoxetine increases and cyproheptadine decreases serotonin levels. Effect of interaction is not clear, use caution. Potential for dangerous interaction. Use with caution and monitor closely.
cyproheptadine|metyrapone|33|Contraindicated|cyproheptadine decreases effects of metyrapone by pharmacodynamic antagonism. Never use combination.
cyproheptadine|triprolidine|2|Significant - Monitor Closely|cyproheptadine and triprolidine both increase  sedation. Potential for interaction, monitor.
cytarabine|digoxin|11|Significant - Monitor Closely|cytarabine decreases levels of digoxin by inhibition of GI absorption. Applies only to oral form of both agents. Significant interaction possible, monitor closely. Cytarabine may decrease digoxin absorption even several days after stopping chemotherapy. Digoxin capsules and digitoxin do not appear to be affected. .
gemfibrozil|dabrafenib|20|Serious - Use Alternative|gemfibrozil increases levels of dabrafenib by decreasing metabolism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available. Strong CYP2C8 inhibitors may increase dabrafenib levels.
ketoconazole|dabrafenib|20|Serious - Use Alternative|ketoconazole increases levels of dabrafenib by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
dabrafenib|midazolam|3|Significant - Monitor Closely|dabrafenib will decrease the level or effect of midazolam by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Potential for dangerous interaction. Use with caution and monitor closely.
nefazodone|dabrafenib|20|Serious - Use Alternative|nefazodone increases levels of dabrafenib by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
dabrafenib|nefazodone|3|Significant - Monitor Closely|dabrafenib will decrease the level or effect of nefazodone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Potential for dangerous interaction. Use with caution and monitor closely.
dabrafenib|pantoprazole|3|Significant - Monitor Closely|dabrafenib will decrease the level or effect of pantoprazole by  affecting hepatic enzyme CYP2C19 metabolism. Potential for dangerous interaction. Use with caution and monitor closely. Use alternative if available
pantoprazole|dabrafenib|2|Significant - Monitor Closely|pantoprazole will decrease the level or effect of dabrafenib by  increasing gastric pH. Applies only to oral form of both agents. Potential for interaction, monitor. Drugs that alter upper GI tract pH (eg, PPIs, H2-blockers, antacids) may decrease dabrafenib solubility and reduce its bioavailability
phenobarbital|dabrafenib|20|Serious - Use Alternative|phenobarbital decreases levels of dabrafenib by increasing metabolism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available. Strong CYP2C8 inducers may decrease dabrafenib levels.
phenobarbital|dabrafenib|20|Serious - Use Alternative|phenobarbital decreases levels of dabrafenib by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
phenytoin|dabrafenib|20|Serious - Use Alternative|phenytoin decreases levels of dabrafenib by increasing metabolism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available. Strong CYP2C8 inducers may decrease dabrafenib levels.
phenytoin|dabrafenib|20|Serious - Use Alternative|phenytoin decreases levels of dabrafenib by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
ranitidine|dabrafenib|2|Significant - Monitor Closely|ranitidine will decrease the level or effect of dabrafenib by  increasing gastric pH. Applies only to oral form of both agents. Potential for interaction, monitor. Drugs that alter upper GI tract pH (eg, PPIs, H2-blockers, antacids) may decrease dabrafenib solubility and reduce its bioavailability
danazol|insulin aspart|1|Minor|danazol increases effects of insulin aspart by pharmacodynamic synergism. Minor or non-significant interaction.
danazol|tacrolimus|1|Minor|danazol increases effects of tacrolimus by decreasing metabolism. Minor or non-significant interaction.
danazol|warfarin|20|Serious - Use Alternative|danazol increases levels of warfarin by decreasing metabolism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
dantrolene|nicardipine|33|Contraindicated|dantrolene, nicardipine.Either increases toxicity of the other by Mechanism: pharmacodynamic synergism. Never use combination. Rare incidence of cardiovascular collapse and marked hyperkalemia observed when coadministered; may be higher risk with nondihydropyridine calcium channel blockers.
lumefantrine|dapsone|1|Minor|lumefantrine will decrease the level or effect of dapsone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor or non-significant interaction.
rifabutin|dapsone|2|Significant - Monitor Closely|rifabutin will decrease the level or effect of dapsone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Potential for interaction, monitor.
telithromycin|dapsone|1|Minor|telithromycin will increase the level or effect of dapsone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor or non-significant interaction.
trimethoprim|dapsone|1|Minor|trimethoprim, dapsone.Either increases levels of the other by decreasing elimination. Minor or non-significant interaction.
voriconazole|dapsone|1|Minor|voriconazole will increase the level or effect of dapsone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor or non-significant interaction.
donepezil|darifenacin|2|Significant - Monitor Closely|donepezil increases and darifenacin decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Potential for interaction, monitor.
darifenacin|donepezil|1|Minor|darifenacin will increase the level or effect of donepezil by  affecting hepatic enzyme CYP2D6 metabolism. Minor or non-significant interaction.
darifenacin|donepezil|1|Minor|darifenacin will increase the level or effect of donepezil by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor or non-significant interaction.
donepezil|darifenacin|1|Minor|donepezil decreases effects of darifenacin by pharmacodynamic antagonism. Minor or non-significant interaction.
galantamine|darifenacin|2|Significant - Monitor Closely|galantamine increases and darifenacin decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Potential for interaction, monitor.
darifenacin|galantamine|1|Minor|darifenacin will increase the level or effect of galantamine by  affecting hepatic enzyme CYP2D6 metabolism. Minor or non-significant interaction.
darifenacin|galantamine|1|Minor|darifenacin will increase the level or effect of galantamine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor or non-significant interaction.
galantamine|darifenacin|1|Minor|galantamine decreases effects of darifenacin by pharmacodynamic antagonism. Minor or non-significant interaction.
itraconazole|darifenacin|20|Serious - Use Alternative|itraconazole will increase the level or effect of darifenacin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
darifenacin|itraconazole|1|Minor|darifenacin will increase the level or effect of itraconazole by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor or non-significant interaction.
ketoconazole|darifenacin|20|Serious - Use Alternative|ketoconazole will increase the level or effect of darifenacin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
darifenacin|ketoconazole|1|Minor|darifenacin will increase the level or effect of ketoconazole by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor or non-significant interaction.
nefazodone|darifenacin|20|Serious - Use Alternative|nefazodone will increase the level or effect of darifenacin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
darifenacin|nelfinavir|11|Significant - Monitor Closely|darifenacin will increase the level or effect of nelfinavir by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
darifenacin|ritonavir|11|Significant - Monitor Closely|darifenacin will increase the level or effect of ritonavir by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
ritonavir|darifenacin|11|Significant - Monitor Closely|ritonavir will increase the level or effect of darifenacin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
tacrine|darifenacin|2|Significant - Monitor Closely|tacrine increases and darifenacin decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Potential for interaction, monitor.
tacrine|darifenacin|1|Minor|tacrine decreases effects of darifenacin by pharmacodynamic antagonism. Minor or non-significant interaction.
darifenacin|tamsulosin|2|Significant - Monitor Closely|darifenacin increases levels of tamsulosin by affecting hepatic enzyme CYP2D6 metabolism. Potential for interaction, monitor.
telithromycin|darifenacin|11|Significant - Monitor Closely|telithromycin will increase the level or effect of darifenacin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
darifenacin|telithromycin|1|Minor|darifenacin will increase the level or effect of telithromycin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor or non-significant interaction.
darifenacin|tramadol|1|Minor|darifenacin will increase the level or effect of tramadol by  affecting hepatic enzyme CYP2D6 metabolism. Minor or non-significant interaction.
voriconazole|darifenacin|11|Significant - Monitor Closely|voriconazole will increase the level or effect of darifenacin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
darunavir|etravirine|11|Significant - Monitor Closely|darunavir will increase the level or effect of etravirine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
darunavir|lidocaine|11|Significant - Monitor Closely|darunavir increases levels of lidocaine by decreasing metabolism. Significant interaction possible, monitor closely.
lopinavir|darunavir|20|Serious - Use Alternative|lopinavir decreases levels of darunavir by increasing metabolism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
darunavir|lopinavir|11|Significant - Monitor Closely|darunavir will increase the level or effect of lopinavir by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
darunavir|lovastatin|33|Contraindicated|darunavir will increase the level or effect of lovastatin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Never use combination. Strong CYP3A4 inhibitors increase systemic statin exposure and risk of myopathy, including rhabdomyolysis
darunavir|lurasidone|33|Contraindicated|darunavir increases levels of lurasidone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Never use combination. Coadministration of lurasidone and strong CYP3A4 inhibitors is contraindicated.
saquinavir|darunavir|20|Serious - Use Alternative|saquinavir decreases levels of darunavir by increasing metabolism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
darunavir|saquinavir|11|Significant - Monitor Closely|darunavir will increase the level or effect of saquinavir by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
darunavir|saquinavir|2|Significant - Monitor Closely|darunavir and saquinavir both increase  risk of immune reconstitution syndrome. Potential for interaction, monitor.
darunavir|tacrolimus|11|Significant - Monitor Closely|darunavir will increase the level or effect of tacrolimus by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
darunavir|tadalafil|20|Serious - Use Alternative|darunavir will increase the level or effect of tadalafil by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available. Stop tadalafil >24 hours prior to protease inhibitor (PI) initiation, restart 7 days after PI initiation at 20 mg once daily, and increase to 40 mg once daily based on tolerability.
darunavir|tamoxifen|20|Serious - Use Alternative|darunavir, tamoxifen. affecting hepatic/intestinal enzyme CYP3A4 metabolism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available. CYP3A4 inhibition decreases metabolism of tamoxifen to N-desmethyl tamoxifen (active metabolite with similar biologic activity).
darunavir|tamsulosin|20|Serious - Use Alternative|darunavir increases levels of tamsulosin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
telithromycin|darunavir|11|Significant - Monitor Closely|telithromycin will increase the level or effect of darunavir by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
darunavir|telithromycin|1|Minor|darunavir will increase the level or effect of telithromycin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor or non-significant interaction.
darunavir|temsirolimus|11|Significant - Monitor Closely|darunavir will increase the level or effect of temsirolimus by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
darunavir|teniposide|2|Significant - Monitor Closely|darunavir will increase the level or effect of teniposide by  P-glycoprotein (MDR1) efflux transporter. Potential for interaction, monitor.
darunavir|tolterodine|11|Significant - Monitor Closely|darunavir will increase the level or effect of tolterodine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
darunavir|topotecan|22|Serious - Use Alternative|darunavir will increase the level or effect of topotecan by  P-glycoprotein (MDR1) efflux transporter. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available. Product labeling for PO topotecan recommends avoiding concomitant use of P-gp inhibitors; the interaction with IV topotecan may be less severe but is still likely of clinical significance
darunavir|trazodone|11|Significant - Monitor Closely|darunavir will increase the level or effect of trazodone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
darunavir|vardenafil|11|Significant - Monitor Closely|darunavir will increase the level or effect of vardenafil by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
darunavir|verapamil|11|Significant - Monitor Closely|darunavir will increase the level or effect of verapamil by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
darunavir|vinblastine|1|Minor|darunavir will increase the level or effect of vinblastine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor or non-significant interaction.
darunavir|vincristine|1|Minor|darunavir will increase the level or effect of vincristine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor or non-significant interaction.
darunavir|vinorelbine|1|Minor|darunavir will increase the level or effect of vinorelbine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor or non-significant interaction.
voriconazole|darunavir|33|Contraindicated|voriconazole will increase the level or effect of darunavir by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Never use combination.
darunavir|zolpidem|1|Minor|darunavir will increase the level or effect of zolpidem by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor or non-significant interaction.
darunavir|zonisamide|1|Minor|darunavir will increase the level or effect of zonisamide by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor or non-significant interaction.
dasatinib|etravirine|11|Significant - Monitor Closely|dasatinib will increase the level or effect of etravirine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
omeprazole|dasatinib|20|Serious - Use Alternative|omeprazole will decrease the level or effect of dasatinib by  increasing gastric pH. Applies only to oral form of both agents. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
pantoprazole|dasatinib|20|Serious - Use Alternative|pantoprazole will decrease the level or effect of dasatinib by  increasing gastric pH. Applies only to oral form of both agents. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
phenobarbital|dasatinib|11|Significant - Monitor Closely|phenobarbital will decrease the level or effect of dasatinib by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
phenytoin|dasatinib|11|Significant - Monitor Closely|phenytoin will decrease the level or effect of dasatinib by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely. Concomitant use will lead to decreased dasatinib plasma concentrations. Consider using alternative therapeutic agents with low enzyme induction potential for coadministration with dasatinib. However, if concomitant use with phenytoin is required, consider increasing the dasatinib dose and monitor the patient closely for dasatinib toxicity (myelosuppression, fluid retention, diarrhea, hemorrhage, or skin rash).
rabeprazole|dasatinib|20|Serious - Use Alternative|rabeprazole will decrease the level or effect of dasatinib by  increasing gastric pH. Applies only to oral form of both agents. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
dasatinib|rabeprazole|1|Minor|dasatinib will increase the level or effect of rabeprazole by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor or non-significant interaction.
ranitidine|dasatinib|20|Serious - Use Alternative|ranitidine will decrease the level or effect of dasatinib by  increasing gastric pH. Applies only to oral form of both agents. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
dasatinib|tacrolimus|11|Significant - Monitor Closely|dasatinib will increase the level or effect of tacrolimus by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
telithromycin|dasatinib|11|Significant - Monitor Closely|telithromycin will increase the level or effect of dasatinib by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
dasatinib|telithromycin|2|Significant - Monitor Closely|dasatinib and telithromycin both increase  QTc interval. Potential for interaction, monitor.
dasatinib|telithromycin|1|Minor|dasatinib will increase the level or effect of telithromycin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor or non-significant interaction.
dasatinib|toremifene|20|Serious - Use Alternative|dasatinib and toremifene both increase  QTc interval. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available. Concurrent use of toremifene with agents causing  QT prolongation should be avoided. If concomitant use is required it's recommended that toremifene be interrupted. If interruption not possible, patients requiring therapy with a drug that prolongs QT should be closely monitored. ECGs should be obtained for high risk patients.
trimipramine|dasatinib|3|Significant - Monitor Closely|trimipramine and dasatinib both increase  QTc interval. Potential for dangerous interaction. Use with caution and monitor closely.
voriconazole|dasatinib|11|Significant - Monitor Closely|voriconazole will increase the level or effect of dasatinib by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
dasatinib|voriconazole|2|Significant - Monitor Closely|dasatinib and voriconazole both increase  QTc interval. Potential for interaction, monitor.
dasatinib|ziprasidone|3|Significant - Monitor Closely|dasatinib and ziprasidone both increase  QTc interval. Potential for dangerous interaction. Use with caution and monitor closely.
dasatinib|ziprasidone|1|Minor|dasatinib will increase the level or effect of ziprasidone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor or non-significant interaction.
deferasirox|etravirine|2|Significant - Monitor Closely|deferasirox will decrease the level or effect of etravirine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Potential for interaction, monitor.
deferiprone|iron sucrose|11|Significant - Monitor Closely|deferiprone decreases levels of iron sucrose by inhibition of GI absorption. Applies only to oral form of both agents. Significant interaction possible, monitor closely. Deferiprone chelates iron.
deferiprone|sodium bicarbonate|11|Significant - Monitor Closely|deferiprone decreases levels of sodium bicarbonate by inhibition of GI absorption. Applies only to oral form of both agents. Significant interaction possible, monitor closely. Deferiprone chelates iron; its affinity for other minerals is unknown.
mifepristone|degarelix|3|Significant - Monitor Closely|mifepristone, degarelix. QTc interval. Potential for dangerous interaction. Use with caution and monitor closely. Use alternatives if available.
delavirdine|dihydroergotamine|33|Contraindicated|delavirdine will increase the level or effect of dihydroergotamine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Never use combination.
delavirdine|ergonovine|21|Serious - Use Alternative|delavirdine increases levels of ergonovine by decreasing metabolism. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available. Never use combination.
delavirdine|ergotamine|21|Serious - Use Alternative|delavirdine increases levels of ergotamine by decreasing metabolism. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available. Never use combination.
delavirdine|ergotamine|20|Serious - Use Alternative|delavirdine will increase the level or effect of ergotamine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
delavirdine|etravirine|33|Contraindicated|delavirdine increases levels of etravirine by decreasing metabolism. Never use combination. Mfr.'s PI recommends not combining etravirine with other NNRTIs.
delavirdine|etravirine|11|Significant - Monitor Closely|delavirdine will increase the level or effect of etravirine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
etravirine|delavirdine|1|Minor|etravirine will decrease the level or effect of delavirdine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor or non-significant interaction.
delavirdine|fosamprenavir|11|Significant - Monitor Closely|delavirdine will increase the level or effect of fosamprenavir by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
fosamprenavir|delavirdine|2|Significant - Monitor Closely|fosamprenavir and delavirdine both increase  risk of immune reconstitution syndrome. Potential for interaction, monitor.
fosamprenavir|delavirdine|1|Minor|fosamprenavir will increase the level or effect of delavirdine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor or non-significant interaction.
fosphenytoin|delavirdine|33|Contraindicated|fosphenytoin will decrease the level or effect of delavirdine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Never use combination. Potential for loss of virologic response and possible resistance to delavirdine
delavirdine|indinavir|11|Significant - Monitor Closely|delavirdine will increase the level or effect of indinavir by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely. Consider reducing indinavir dose to 600 mg TID when coadministered with delavirdine
indinavir|delavirdine|2|Significant - Monitor Closely|indinavir and delavirdine both increase  risk of immune reconstitution syndrome. Potential for interaction, monitor.
indinavir|delavirdine|1|Minor|indinavir will increase the level or effect of delavirdine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor or non-significant interaction.
delavirdine|lovastatin|33|Contraindicated|delavirdine will increase the level or effect of lovastatin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Never use combination. Strong CYP3A4 inhibitors increase systemic statin exposure and risk of myopathy, including rhabdomyolysis
delavirdine|lurasidone|33|Contraindicated|delavirdine will increase the level or effect of lurasidone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Never use combination. Coadministration of lurasidone and strong CYP3A4 inhibitors is contraindicated.
delavirdine|midazolam|11|Significant - Monitor Closely|delavirdine will increase the level or effect of midazolam by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
phenobarbital|delavirdine|33|Contraindicated|phenobarbital decreases levels of delavirdine by increasing metabolism. Never use combination.
phenobarbital|delavirdine|1|Minor|phenobarbital will decrease the level or effect of delavirdine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor or non-significant interaction.
phenytoin|delavirdine|33|Contraindicated|phenytoin will decrease the level or effect of delavirdine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Never use combination. Potential for loss of virologic response and possible resistance to delavirdine
rifabutin|delavirdine|21|Serious - Use Alternative|rifabutin decreases levels of delavirdine by increasing metabolism. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available. Never use combination.
delavirdine|rifabutin|21|Serious - Use Alternative|delavirdine increases levels of rifabutin by decreasing metabolism. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available. Never use combination.
rifabutin|delavirdine|2|Significant - Monitor Closely|rifabutin will decrease the level or effect of delavirdine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Potential for interaction, monitor.
delavirdine|rilpivirine|33|Contraindicated|delavirdine increases levels of rilpivirine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Never use combination. Contraindicated. Rilpivirine should not be used in combination with NNRTIs.
delavirdine|ritonavir|11|Significant - Monitor Closely|delavirdine will increase the level or effect of ritonavir by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
ritonavir|delavirdine|2|Significant - Monitor Closely|ritonavir and delavirdine both increase  risk of immune reconstitution syndrome. Potential for interaction, monitor.
ritonavir|delavirdine|1|Minor|ritonavir will increase the level or effect of delavirdine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor or non-significant interaction.
delavirdine|saquinavir|11|Significant - Monitor Closely|delavirdine will increase the level or effect of saquinavir by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely. Consider reducing saquinavir dose when coadministered with delavirdine
saquinavir|delavirdine|2|Significant - Monitor Closely|saquinavir and delavirdine both increase  risk of immune reconstitution syndrome. Potential for interaction, monitor.
delavirdine|simvastatin|33|Contraindicated|delavirdine will increase the level or effect of simvastatin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Never use combination.
delavirdine|tacrolimus|11|Significant - Monitor Closely|delavirdine will increase the level or effect of tacrolimus by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
delavirdine|tadalafil|11|Significant - Monitor Closely|delavirdine will increase the level or effect of tadalafil by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely. For ED limit tadalafil to max of 2.5 mg/day (for daily use) or 10 mg dose every 72 hr (for use as needed). Avoid concurrent use of tadalafil for pulmonary HTN in patients taking strong CYP3A4 inhibitors.
delavirdine|tamoxifen|11|Significant - Monitor Closely|delavirdine, tamoxifen. affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely. CYP3A4 inhibition decreases metabolism of tamoxifen to N-desmethyl tamoxifen (active metabolite with similar biologic activity).
delavirdine|tamoxifen|11|Significant - Monitor Closely|delavirdine, tamoxifen. affecting hepatic enzyme CYP2C9/10 metabolism. Significant interaction possible, monitor closely. CYP3A4 inhibition decreases metabolism of tamoxifen to N-desmethyl tamoxifen (active metabolite with similar biologic activity).
delavirdine|tamoxifen|11|Significant - Monitor Closely|delavirdine, tamoxifen. affecting hepatic enzyme CYP2D6 metabolism. Significant interaction possible, monitor closely. CYP2D6 inhibition decreases metabolism of tamoxifen to  hydroxytamoxifen, and N-desmethyl tamoxifen to endoxifen (active metabolites with 100-fold greater affinity for estrogen receptor); decreased endoxifen levels may result in poor clinical outcome.
delavirdine|tamsulosin|20|Serious - Use Alternative|delavirdine increases levels of tamsulosin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
delavirdine|tamsulosin|2|Significant - Monitor Closely|delavirdine increases levels of tamsulosin by affecting hepatic enzyme CYP2D6 metabolism. Potential for interaction, monitor.
delavirdine|telithromycin|1|Minor|delavirdine will increase the level or effect of telithromycin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor or non-significant interaction.
telithromycin|delavirdine|1|Minor|telithromycin will increase the level or effect of delavirdine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor or non-significant interaction.
delavirdine|temsirolimus|11|Significant - Monitor Closely|delavirdine will increase the level or effect of temsirolimus by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
delavirdine|terfenadine|21|Serious - Use Alternative|delavirdine increases levels of terfenadine by decreasing metabolism. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available. Never use combination. Risk of QT interval prolongation.
delavirdine|terfenadine|20|Serious - Use Alternative|delavirdine will increase the level or effect of terfenadine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
delavirdine|tipranavir|11|Significant - Monitor Closely|delavirdine will increase the level or effect of tipranavir by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
tipranavir|delavirdine|2|Significant - Monitor Closely|tipranavir and delavirdine both increase  risk of immune reconstitution syndrome. Potential for interaction, monitor.
delavirdine|tolterodine|11|Significant - Monitor Closely|delavirdine will increase the level or effect of tolterodine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
delavirdine|trazodone|3|Significant - Monitor Closely|delavirdine will increase the level or effect of trazodone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Potential for dangerous interaction. Use with caution and monitor closely.
delavirdine|triazolam|11|Significant - Monitor Closely|delavirdine will increase the level or effect of triazolam by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
delavirdine|vardenafil|11|Significant - Monitor Closely|delavirdine will increase the level or effect of vardenafil by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
delavirdine|verapamil|11|Significant - Monitor Closely|delavirdine will increase the level or effect of verapamil by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
verapamil|delavirdine|1|Minor|verapamil will increase the level or effect of delavirdine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor or non-significant interaction.
delavirdine|vinblastine|1|Minor|delavirdine will increase the level or effect of vinblastine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor or non-significant interaction.
delavirdine|vincristine|1|Minor|delavirdine will increase the level or effect of vincristine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor or non-significant interaction.
delavirdine|vinorelbine|1|Minor|delavirdine will increase the level or effect of vinorelbine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor or non-significant interaction.
voriconazole|delavirdine|20|Serious - Use Alternative|voriconazole will increase the level or effect of delavirdine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
delavirdine|warfarin|11|Significant - Monitor Closely|delavirdine will increase the level or effect of warfarin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
zafirlukast|delavirdine|1|Minor|zafirlukast will increase the level or effect of delavirdine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor or non-significant interaction.
delavirdine|zolpidem|1|Minor|delavirdine will increase the level or effect of zolpidem by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor or non-significant interaction.
delavirdine|zonisamide|1|Minor|delavirdine will increase the level or effect of zonisamide by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor or non-significant interaction.
demeclocycline|dicloxacillin|20|Serious - Use Alternative|demeclocycline decreases effects of dicloxacillin by pharmacodynamic antagonism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
demeclocycline|flucloxacillin|20|Serious - Use Alternative|demeclocycline decreases effects of flucloxacillin by pharmacodynamic antagonism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
isotretinoin|demeclocycline|21|Serious - Use Alternative|isotretinoin, demeclocycline. Mechanism: unknown. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available. Never use combination. Risk of pseudotumor cerebri.
magnesium oxide|demeclocycline|20|Serious - Use Alternative|magnesium oxide decreases levels of demeclocycline by inhibition of GI absorption. Applies only to oral form of both agents. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
demeclocycline|mestranol|2|Significant - Monitor Closely|demeclocycline will decrease the level or effect of mestranol by  altering intestinal flora. Applies only to oral forms of hormone. Low risk of contraceptive failure. Potential for interaction, monitor.
demeclocycline|methoxyflurane|20|Serious - Use Alternative|demeclocycline, methoxyflurane. Mechanism: pharmacodynamic synergism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available. Risk of nephrotoxicity.
demeclocycline|nafcillin|20|Serious - Use Alternative|demeclocycline decreases effects of nafcillin by pharmacodynamic antagonism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available. bacteriostatic antibiotics may interfere with the bactericidal actions of penicillins.
demeclocycline|oxacillin|20|Serious - Use Alternative|demeclocycline decreases effects of oxacillin by pharmacodynamic antagonism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available. bacteriostatic agents may inhibit the effects of bactericidal agentsba.
demeclocycline|piperacillin|11|Significant - Monitor Closely|demeclocycline decreases effects of piperacillin by pharmacodynamic antagonism. Significant interaction possible, monitor closely. bacteriostatic agents may inhibit the effects of bactericidal agents.
demeclocycline|pivmecillinam|20|Serious - Use Alternative|demeclocycline decreases effects of pivmecillinam by pharmacodynamic antagonism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
demeclocycline|ticarcillin|20|Serious - Use Alternative|demeclocycline decreases effects of ticarcillin by pharmacodynamic antagonism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
demeclocycline|tretinoin|20|Serious - Use Alternative|demeclocycline, tretinoin. Mechanism: pharmacodynamic synergism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available. Increased phototoxicity.
demeclocycline|warfarin|1|Minor|demeclocycline increases effects of warfarin by pharmacodynamic synergism. Minor or non-significant interaction.
etanercept|denosumab|11|Significant - Monitor Closely|etanercept, denosumab. Other (see comment). Significant interaction possible, monitor closely. Comment: Caution should be taken in patients on concomitant immunosuppressants or with impaired immune systems because of increased risk for serious infections.
infliximab|denosumab|11|Significant - Monitor Closely|infliximab, denosumab. Other (see comment). Significant interaction possible, monitor closely. Comment: Caution should be taken in patients on concomitant immunosuppressants or with impaired immune systems because of increased risk for serious infections.
pralatrexate|denosumab|11|Significant - Monitor Closely|pralatrexate, denosumab. Other (see comment). Significant interaction possible, monitor closely. Comment: Caution should be taken in patients on concomitant immunosuppressants or with impaired immune systems because of increased risk for serious infections.
rilonacept|denosumab|11|Significant - Monitor Closely|rilonacept, denosumab. Other (see comment). Significant interaction possible, monitor closely. Comment: Caution should be taken in patients on concomitant immunosuppressants or with impaired immune systems because of increased risk for serious infections.
desipramine|desvenlafaxine|20|Serious - Use Alternative|desipramine and desvenlafaxine both increase  serotonin levels. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
desvenlafaxine|desipramine|2|Significant - Monitor Closely|desvenlafaxine will increase the level or effect of desipramine by  affecting hepatic enzyme CYP2D6 metabolism. Potential for interaction, monitor. Desvenlafaxine inhibits CYP2D6; with higher desvenlafaxine doses (ie, 400 mg) decrease the CYP2D6 substrate dose by up to 50%; no dosage adjustment needed with desvenlafaxine doses <100 mg
desipramine|dobutamine|20|Serious - Use Alternative|desipramine, dobutamine. Other (see comment). Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available. Comment: Tricyclic antidepressants increase or decrease effects of sympathomimetics, by blocking reuptake of NE, or blocking uptake of indirect sympathomimetics into the adrenergic neuron.
desipramine|dobutamine|2|Significant - Monitor Closely|desipramine increases and dobutamine decreases sedation. Effect of interaction is not clear, use caution. Potential for interaction, monitor.
donepezil|desipramine|1|Minor|donepezil increases and desipramine decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Minor or non-significant interaction.
desipramine|dopamine|20|Serious - Use Alternative|desipramine, dopamine. Other (see comment). Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available. Comment: Tricyclic antidepressants increase or decrease effects of sympathomimetics, by blocking reuptake of NE, or blocking uptake of indirect sympathomimetics into the adrenergic neuron.
desipramine|dopamine|2|Significant - Monitor Closely|desipramine increases and dopamine decreases sedation. Effect of interaction is not clear, use caution. Potential for interaction, monitor.
duloxetine|desipramine|22|Serious - Use Alternative|duloxetine and desipramine both increase  serotonin levels. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available.
duloxetine|desipramine|11|Significant - Monitor Closely|duloxetine will increase the level or effect of desipramine by  affecting hepatic enzyme CYP2D6 metabolism. Significant interaction possible, monitor closely.
desipramine|ephedrine|20|Serious - Use Alternative|desipramine, ephedrine. Other (see comment). Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available. Comment: Tricyclic antidepressants increase or decrease effects of sympathomimetics, by blocking reuptake of NE, or blocking uptake of indirect sympathomimetics into the adrenergic neuron.
desipramine|ephedrine|11|Significant - Monitor Closely|desipramine increases effects of ephedrine by unknown mechanism. Significant interaction possible, monitor closely.
desipramine|ephedrine|2|Significant - Monitor Closely|desipramine increases and ephedrine decreases sedation. Effect of interaction is not clear, use caution. Potential for interaction, monitor.
epinephrine|desipramine|22|Serious - Use Alternative|epinephrine and desipramine both increase  QTc interval. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available.
desipramine|epinephrine|20|Serious - Use Alternative|desipramine, epinephrine. Other (see comment). Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available. Comment: Tricyclic antidepressants increase or decrease effects of sympathomimetics, by blocking reuptake of NE, or blocking uptake of indirect sympathomimetics into the adrenergic neuron.
desipramine|epinephrine|11|Significant - Monitor Closely|desipramine increases effects of epinephrine by unknown mechanism. Significant interaction possible, monitor closely.
desipramine|epinephrine|2|Significant - Monitor Closely|desipramine increases and epinephrine decreases sedation. Effect of interaction is not clear, use caution. Potential for interaction, monitor.
fluoxetine|desipramine|22|Serious - Use Alternative|fluoxetine and desipramine both increase  serotonin levels. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available.
fluoxetine|desipramine|20|Serious - Use Alternative|fluoxetine will increase the level or effect of desipramine by  affecting hepatic enzyme CYP2D6 metabolism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
desipramine|fluoxetine|3|Significant - Monitor Closely|desipramine and fluoxetine both increase  QTc interval. Potential for dangerous interaction. Use with caution and monitor closely.
fluvoxamine|desipramine|22|Serious - Use Alternative|fluvoxamine and desipramine both increase  serotonin levels. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available.
fluvoxamine|desipramine|3|Significant - Monitor Closely|fluvoxamine will increase the level or effect of desipramine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Potential for dangerous interaction. Use with caution and monitor closely.
desipramine|fluvoxamine|3|Significant - Monitor Closely|desipramine and fluvoxamine both increase  QTc interval. Potential for dangerous interaction. Use with caution and monitor closely.
galantamine|desipramine|1|Minor|galantamine increases and desipramine decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Minor or non-significant interaction.
isocarboxazid|desipramine|33|Contraindicated|isocarboxazid and desipramine both increase  serotonin levels. Never use combination.
mirabegron|desipramine|2|Significant - Monitor Closely|mirabegron will increase the level or effect of desipramine by  affecting hepatic enzyme CYP2D6 metabolism. Potential for interaction, monitor.
desipramine|norepinephrine|20|Serious - Use Alternative|desipramine, norepinephrine. Other (see comment). Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available. Comment: Tricyclic antidepressants increase or decrease effects of sympathomimetics, by blocking reuptake of NE, or blocking uptake of indirect sympathomimetics into the adrenergic neuron.
desipramine|norepinephrine|11|Significant - Monitor Closely|desipramine increases effects of norepinephrine by unknown mechanism. Significant interaction possible, monitor closely.
desipramine|norepinephrine|2|Significant - Monitor Closely|desipramine increases and norepinephrine decreases sedation. Effect of interaction is not clear, use caution. Potential for interaction, monitor.
phenelzine|desipramine|33|Contraindicated|phenelzine and desipramine both increase  serotonin levels. Never use combination.
desipramine|phenylephrine|20|Serious - Use Alternative|desipramine, phenylephrine. Other (see comment). Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available. Comment: Tricyclic antidepressants increase or decrease effects of sympathomimetics, by blocking reuptake of NE, or blocking uptake of indirect sympathomimetics into the adrenergic neuron.
desipramine|phenylephrine|2|Significant - Monitor Closely|desipramine increases and phenylephrine decreases sedation. Effect of interaction is not clear, use caution. Potential for interaction, monitor.
desipramine|pirbuterol|20|Serious - Use Alternative|desipramine, pirbuterol. Other (see comment). Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available. Comment: Tricyclic antidepressants increase or decrease effects of sympathomimetics, by blocking reuptake of NE, or blocking uptake of indirect sympathomimetics into the adrenergic neuron.
desipramine|pirbuterol|2|Significant - Monitor Closely|desipramine increases and pirbuterol decreases sedation. Effect of interaction is not clear, use caution. Potential for interaction, monitor.
desipramine|pseudoephedrine|20|Serious - Use Alternative|desipramine, pseudoephedrine. Other (see comment). Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available. Comment: Tricyclic antidepressants increase or decrease effects of sympathomimetics, by blocking reuptake of NE, or blocking uptake of indirect sympathomimetics into the adrenergic neuron.
desipramine|pseudoephedrine|2|Significant - Monitor Closely|desipramine increases and pseudoephedrine decreases sedation. Effect of interaction is not clear, use caution. Potential for interaction, monitor.
quinidine|desipramine|33|Contraindicated|quinidine and desipramine both increase  QTc interval. Never use combination.
quinidine|desipramine|20|Serious - Use Alternative|quinidine will increase the level or effect of desipramine by  affecting hepatic enzyme CYP2D6 metabolism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
rasagiline|desipramine|20|Serious - Use Alternative|rasagiline and desipramine both increase  serotonin levels. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available. Severe CNS toxicity associated with hyperpyrexia has been reported with the combined treatment of an antidepressant and rasagiline. Avoid combination within 14 days of MAOI use.
rifabutin|desipramine|11|Significant - Monitor Closely|rifabutin decreases levels of desipramine by increasing metabolism. Significant interaction possible, monitor closely.
rifabutin|desipramine|2|Significant - Monitor Closely|rifabutin will decrease the level or effect of desipramine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Potential for interaction, monitor.
ritonavir|desipramine|11|Significant - Monitor Closely|ritonavir will increase the level or effect of desipramine by  affecting hepatic enzyme CYP2D6 metabolism. Significant interaction possible, monitor closely.
ritonavir|desipramine|11|Significant - Monitor Closely|ritonavir will increase the level or effect of desipramine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
rivastigmine|desipramine|1|Minor|rivastigmine increases and desipramine decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Minor or non-significant interaction.
tacrine|desipramine|1|Minor|tacrine increases and desipramine decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Minor or non-significant interaction.
desipramine|tamsulosin|2|Significant - Monitor Closely|desipramine increases levels of tamsulosin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Potential for interaction, monitor. Dose reduction may be needed for coadministered drugs that are predominantly metabolized by CYP3A.
desipramine|tamsulosin|2|Significant - Monitor Closely|desipramine increases levels of tamsulosin by affecting hepatic enzyme CYP2D6 metabolism. Potential for interaction, monitor.
desipramine|terbutaline|20|Serious - Use Alternative|desipramine, terbutaline. Other (see comment). Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available. Comment: Tricyclic antidepressants increase or decrease effects of sympathomimetics, by blocking reuptake of NE, or blocking uptake of indirect sympathomimetics into the adrenergic neuron.
desipramine|terbutaline|2|Significant - Monitor Closely|desipramine increases and terbutaline decreases sedation. Effect of interaction is not clear, use caution. Potential for interaction, monitor.
desipramine|terfenadine|33|Contraindicated|desipramine and terfenadine both increase  QTc interval. Never use combination.
terfenadine|desipramine|2|Significant - Monitor Closely|terfenadine and desipramine both increase  sedation. Potential for interaction, monitor.
thiothixene|desipramine|2|Significant - Monitor Closely|thiothixene and desipramine both increase  sedation. Potential for interaction, monitor.
tipranavir|desipramine|11|Significant - Monitor Closely|tipranavir will increase the level or effect of desipramine by  affecting hepatic enzyme CYP2D6 metabolism. Significant interaction possible, monitor closely.
tolterodine|desipramine|2|Significant - Monitor Closely|tolterodine and desipramine both decrease  cholinergic effects/transmission. Potential for interaction, monitor.
desipramine|toremifene|20|Serious - Use Alternative|desipramine and toremifene both increase  QTc interval. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available. Concurrent use of toremifene with agents causing  QT prolongation should be avoided. If concomitant use is required it's recommended that toremifene be interrupted. If interruption not possible, patients requiring therapy with a drug that prolongs QT should be closely monitored. ECGs should be obtained for high risk patients.
desipramine|tramadol|3|Significant - Monitor Closely|desipramine and tramadol both increase  serotonin levels. Potential for dangerous interaction. Use with caution and monitor closely.
tramadol|desipramine|2|Significant - Monitor Closely|tramadol and desipramine both increase  sedation. Potential for interaction, monitor.
tranylcypromine|desipramine|33|Contraindicated|tranylcypromine and desipramine both increase  serotonin levels. Never use combination.
desipramine|trazodone|22|Serious - Use Alternative|desipramine and trazodone both increase  QTc interval. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available.
trazodone|desipramine|22|Serious - Use Alternative|trazodone and desipramine both increase  serotonin levels. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available.
desipramine|trazodone|2|Significant - Monitor Closely|desipramine and trazodone both decrease  cholinergic effects/transmission. Potential for interaction, monitor.
desipramine|trazodone|2|Significant - Monitor Closely|desipramine and trazodone both increase  sedation. Potential for interaction, monitor.
desipramine|trimipramine|22|Serious - Use Alternative|desipramine and trimipramine both increase  QTc interval. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available.
desipramine|trimipramine|22|Serious - Use Alternative|desipramine and trimipramine both increase  serotonin levels. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available.
desipramine|trimipramine|2|Significant - Monitor Closely|desipramine and trimipramine both decrease  cholinergic effects/transmission. Potential for interaction, monitor.
desipramine|trimipramine|2|Significant - Monitor Closely|desipramine and trimipramine both increase  sedation. Potential for interaction, monitor.
triprolidine|desipramine|2|Significant - Monitor Closely|triprolidine and desipramine both increase  sedation. Potential for interaction, monitor.
venlafaxine|desipramine|22|Serious - Use Alternative|venlafaxine and desipramine both increase  serotonin levels. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available.
venlafaxine|desipramine|11|Significant - Monitor Closely|venlafaxine will increase the level or effect of desipramine by  affecting hepatic enzyme CYP2D6 metabolism. Significant interaction possible, monitor closely.
desipramine|venlafaxine|3|Significant - Monitor Closely|desipramine and venlafaxine both increase  QTc interval. Potential for dangerous interaction. Use with caution and monitor closely.
desipramine|vilazodone|22|Serious - Use Alternative|desipramine, vilazodone.Either increases toxicity of the other by serotonin levels. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available. Concomitant therapy should be discontinued immediately if signs or symptoms of serotonin syndrome emerge and supportive symptomatic treatment should be initiated.  .
desipramine|voriconazole|3|Significant - Monitor Closely|desipramine and voriconazole both increase  QTc interval. Potential for dangerous interaction. Use with caution and monitor closely.
voriconazole|desipramine|1|Minor|voriconazole will increase the level or effect of desipramine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor or non-significant interaction.
desipramine|ziprasidone|22|Serious - Use Alternative|desipramine and ziprasidone both increase  QTc interval. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available.
ziprasidone|desipramine|2|Significant - Monitor Closely|ziprasidone and desipramine both increase  sedation. Potential for interaction, monitor.
zolmitriptan|desipramine|3|Significant - Monitor Closely|zolmitriptan and desipramine both increase  serotonin levels. Potential for dangerous interaction. Use with caution and monitor closely.
dextromethorphan|desvenlafaxine|20|Serious - Use Alternative|dextromethorphan and desvenlafaxine both increase  serotonin levels. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
desvenlafaxine|dextromethorphan|2|Significant - Monitor Closely|desvenlafaxine will increase the level or effect of dextromethorphan by  affecting hepatic enzyme CYP2D6 metabolism. Potential for interaction, monitor. Desvenlafaxine inhibits CYP2D6; with higher desvenlafaxine doses (ie, 400 mg) decrease the CYP2D6 substrate dose by up to 50%; no dosage adjustment needed with desvenlafaxine doses <100 mg
dihydroergotamine|desvenlafaxine|20|Serious - Use Alternative|dihydroergotamine and desvenlafaxine both increase  serotonin levels. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
doxepin|desvenlafaxine|20|Serious - Use Alternative|doxepin and desvenlafaxine both increase  serotonin levels. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
desvenlafaxine|doxepin|2|Significant - Monitor Closely|desvenlafaxine will increase the level or effect of doxepin by  affecting hepatic enzyme CYP2D6 metabolism. Potential for interaction, monitor. Desvenlafaxine inhibits CYP2D6; with higher desvenlafaxine doses (ie, 400 mg) decrease the CYP2D6 substrate dose by up to 50%; no dosage adjustment needed with desvenlafaxine doses <100 mg
duloxetine|desvenlafaxine|20|Serious - Use Alternative|duloxetine and desvenlafaxine both increase  serotonin levels. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
desvenlafaxine|duloxetine|2|Significant - Monitor Closely|desvenlafaxine will increase the level or effect of duloxetine by  affecting hepatic enzyme CYP2D6 metabolism. Potential for interaction, monitor. Desvenlafaxine inhibits CYP2D6; with higher desvenlafaxine doses (ie, 400 mg) decrease the CYP2D6 substrate dose by up to 50%; no dosage adjustment needed with desvenlafaxine doses <100 mg
eletriptan|desvenlafaxine|20|Serious - Use Alternative|eletriptan and desvenlafaxine both increase  serotonin levels. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
ergotamine|desvenlafaxine|20|Serious - Use Alternative|ergotamine and desvenlafaxine both increase  serotonin levels. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
escitalopram|desvenlafaxine|20|Serious - Use Alternative|escitalopram and desvenlafaxine both increase  serotonin levels. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
fluoxetine|desvenlafaxine|20|Serious - Use Alternative|fluoxetine and desvenlafaxine both increase  serotonin levels. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
desvenlafaxine|fluoxetine|2|Significant - Monitor Closely|desvenlafaxine will increase the level or effect of fluoxetine by  affecting hepatic enzyme CYP2D6 metabolism. Potential for interaction, monitor. Desvenlafaxine inhibits CYP2D6; with higher desvenlafaxine doses (ie, 400 mg) decrease the CYP2D6 substrate dose by up to 50%; no dosage adjustment needed with desvenlafaxine doses <100 mg
fluvoxamine|desvenlafaxine|20|Serious - Use Alternative|fluvoxamine and desvenlafaxine both increase  serotonin levels. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
desvenlafaxine|fluvoxamine|2|Significant - Monitor Closely|desvenlafaxine will increase the level or effect of fluvoxamine by  affecting hepatic enzyme CYP2D6 metabolism. Potential for interaction, monitor. Desvenlafaxine inhibits CYP2D6; with higher desvenlafaxine doses (ie, 400 mg) decrease the CYP2D6 substrate dose by up to 50%; no dosage adjustment needed with desvenlafaxine doses <100 mg
frovatriptan|desvenlafaxine|20|Serious - Use Alternative|frovatriptan and desvenlafaxine both increase  serotonin levels. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
imipramine|desvenlafaxine|20|Serious - Use Alternative|imipramine and desvenlafaxine both increase  serotonin levels. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
desvenlafaxine|imipramine|2|Significant - Monitor Closely|desvenlafaxine will increase the level or effect of imipramine by  affecting hepatic enzyme CYP2D6 metabolism. Potential for interaction, monitor. Desvenlafaxine inhibits CYP2D6; with higher desvenlafaxine doses (ie, 400 mg) decrease the CYP2D6 substrate dose by up to 50%; no dosage adjustment needed with desvenlafaxine doses <100 mg
isocarboxazid|desvenlafaxine|33|Contraindicated|isocarboxazid and desvenlafaxine both increase  serotonin levels. Never use combination. At least 14 days should elapse between discontinuation of MAOIs and initiation of treatment with a serotonergic drug
l-tryptophan|desvenlafaxine|20|Serious - Use Alternative|l-tryptophan and desvenlafaxine both increase  serotonin levels. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
linezolid|desvenlafaxine|33|Contraindicated|linezolid and desvenlafaxine both increase  serotonin levels. Never use combination. Linezolid may increase serotonin as a result of MAO-A inhibition. If linezolid must be administered, discontinue serotonergic drug immediately and monitor for CNS toxicity. Serotonergic therapy may be resumed 24 hours after last linezolid dose or after 2 weeks of monitoring, whichever comes first
lithium|desvenlafaxine|20|Serious - Use Alternative|lithium and desvenlafaxine both increase  serotonin levels. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
maprotiline|desvenlafaxine|20|Serious - Use Alternative|maprotiline and desvenlafaxine both increase  serotonin levels. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
milnacipran|desvenlafaxine|20|Serious - Use Alternative|milnacipran and desvenlafaxine both increase  serotonin levels. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
mirtazapine|desvenlafaxine|20|Serious - Use Alternative|mirtazapine and desvenlafaxine both increase  serotonin levels. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
naratriptan|desvenlafaxine|20|Serious - Use Alternative|naratriptan and desvenlafaxine both increase  serotonin levels. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
nefazodone|desvenlafaxine|20|Serious - Use Alternative|nefazodone and desvenlafaxine both increase  serotonin levels. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
nortriptyline|desvenlafaxine|20|Serious - Use Alternative|nortriptyline and desvenlafaxine both increase  serotonin levels. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
desvenlafaxine|nortriptyline|2|Significant - Monitor Closely|desvenlafaxine will increase the level or effect of nortriptyline by  affecting hepatic enzyme CYP2D6 metabolism. Potential for interaction, monitor. Desvenlafaxine inhibits CYP2D6; with higher desvenlafaxine doses (ie, 400 mg) decrease the CYP2D6 substrate dose by up to 50%; no dosage adjustment needed with desvenlafaxine doses <100 mg
paroxetine|desvenlafaxine|20|Serious - Use Alternative|paroxetine and desvenlafaxine both increase  serotonin levels. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
desvenlafaxine|paroxetine|2|Significant - Monitor Closely|desvenlafaxine will increase the level or effect of paroxetine by  affecting hepatic enzyme CYP2D6 metabolism. Potential for interaction, monitor. Desvenlafaxine inhibits CYP2D6; with higher desvenlafaxine doses (ie, 400 mg) decrease the CYP2D6 substrate dose by up to 50%; no dosage adjustment needed with desvenlafaxine doses <100 mg
meperidine|desvenlafaxine|20|Serious - Use Alternative|meperidine and desvenlafaxine both increase  serotonin levels. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
phenelzine|desvenlafaxine|33|Contraindicated|phenelzine and desvenlafaxine both increase  serotonin levels. Never use combination. At least 14 days should elapse between discontinuation of MAOIs and initiation of treatment with a serotonergic drug
procarbazine|desvenlafaxine|33|Contraindicated|procarbazine and desvenlafaxine both increase  serotonin levels. Never use combination. At least 14 days should elapse between discontinuation of MAOIs and initiation of treatment with a serotonergic drug
desvenlafaxine|promethazine|2|Significant - Monitor Closely|desvenlafaxine will increase the level or effect of promethazine by  affecting hepatic enzyme CYP2D6 metabolism. Potential for interaction, monitor. Desvenlafaxine inhibits CYP2D6; with higher desvenlafaxine doses (ie, 400 mg) decrease the CYP2D6 substrate dose by up to 50%; no dosage adjustment needed with desvenlafaxine doses <100 mg
protriptyline|desvenlafaxine|20|Serious - Use Alternative|protriptyline and desvenlafaxine both increase  serotonin levels. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
rasagiline|desvenlafaxine|33|Contraindicated|rasagiline and desvenlafaxine both increase  serotonin levels. Never use combination. At least 14 days should elapse between discontinuation of MAOIs and initiation of treatment with a serotonergic drug
rizatriptan|desvenlafaxine|20|Serious - Use Alternative|rizatriptan and desvenlafaxine both increase  serotonin levels. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
selegiline|desvenlafaxine|33|Contraindicated|selegiline and desvenlafaxine both increase  serotonin levels. Never use combination. At least 14 days should elapse between discontinuation of MAOIs and initiation of treatment with a serotonergic drug
sertraline|desvenlafaxine|20|Serious - Use Alternative|sertraline and desvenlafaxine both increase  serotonin levels. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
sumatriptan|desvenlafaxine|20|Serious - Use Alternative|sumatriptan and desvenlafaxine both increase  serotonin levels. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
desvenlafaxine|tapentadol|3|Significant - Monitor Closely|desvenlafaxine and tapentadol both increase  serotonin levels. Potential for dangerous interaction. Use with caution and monitor closely.
tramadol|desvenlafaxine|20|Serious - Use Alternative|tramadol and desvenlafaxine both increase  serotonin levels. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
desvenlafaxine|tramadol|2|Significant - Monitor Closely|desvenlafaxine will increase the level or effect of tramadol by  affecting hepatic enzyme CYP2D6 metabolism. Potential for interaction, monitor. Desvenlafaxine inhibits CYP2D6; with higher desvenlafaxine doses (ie, 400 mg) decrease the CYP2D6 substrate dose by up to 50%; no dosage adjustment needed with desvenlafaxine doses <100 mg
tranylcypromine|desvenlafaxine|33|Contraindicated|tranylcypromine and desvenlafaxine both increase  serotonin levels. Never use combination. At least 14 days should elapse between discontinuation of MAOIs and initiation of treatment with a serotonergic drug
trazodone|desvenlafaxine|20|Serious - Use Alternative|trazodone and desvenlafaxine both increase  serotonin levels. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
trimipramine|desvenlafaxine|20|Serious - Use Alternative|trimipramine and desvenlafaxine both increase  serotonin levels. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
zolmitriptan|desvenlafaxine|20|Serious - Use Alternative|zolmitriptan and desvenlafaxine both increase  serotonin levels. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
ethotoin|dexamethasone|11|Significant - Monitor Closely|ethotoin will decrease the level or effect of dexamethasone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
ethotoin|dexamethasone|11|Significant - Monitor Closely|ethotoin will decrease the level or effect of dexamethasone by  P-glycoprotein (MDR1) efflux transporter. Significant interaction possible, monitor closely.
fosphenytoin|dexamethasone|11|Significant - Monitor Closely|fosphenytoin will decrease the level or effect of dexamethasone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
fosphenytoin|dexamethasone|11|Significant - Monitor Closely|fosphenytoin will decrease the level or effect of dexamethasone by  P-glycoprotein (MDR1) efflux transporter. Significant interaction possible, monitor closely.
hexobarbital|dexamethasone|11|Significant - Monitor Closely|hexobarbital will decrease the level or effect of dexamethasone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
dexamethasone|imatinib|1|Minor|dexamethasone will decrease the level or effect of imatinib by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor or non-significant interaction.
dexamethasone|lurasidone|33|Contraindicated|dexamethasone decreases levels of lurasidone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Never use combination. Contraindicated; decreases lurasidone Cmax by ~85%.
pentobarbital|dexamethasone|11|Significant - Monitor Closely|pentobarbital will decrease the level or effect of dexamethasone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
phenobarbital|dexamethasone|11|Significant - Monitor Closely|phenobarbital will decrease the level or effect of dexamethasone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
phenobarbital|dexamethasone|11|Significant - Monitor Closely|phenobarbital will decrease the level or effect of dexamethasone by  P-glycoprotein (MDR1) efflux transporter. Significant interaction possible, monitor closely.
phenytoin|dexamethasone|11|Significant - Monitor Closely|phenytoin will decrease the level or effect of dexamethasone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
phenytoin|dexamethasone|11|Significant - Monitor Closely|phenytoin will decrease the level or effect of dexamethasone by  P-glycoprotein (MDR1) efflux transporter. Significant interaction possible, monitor closely.
primidone|dexamethasone|11|Significant - Monitor Closely|primidone will decrease the level or effect of dexamethasone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
dexamethasone|rilpivirine|33|Contraindicated|dexamethasone decreases levels of rilpivirine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Never use combination. Contraindicated. Rilpivirine should not be co-administered with strong CYP 3A4 inducers. Potential for loss of virologic response and possible resistance to rilpivirine or to the NNRTI class.
dexamethasone|roflumilast|33|Contraindicated|dexamethasone will decrease the level or effect of roflumilast by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Never use combination. Coadministration not recommended; strong cytochrome P450 enzyme inducers decrease systemic exposure to roflumilast and may reduce the therapeutic effectiveness
salsalate|dexamethasone|11|Significant - Monitor Closely|salsalate, dexamethasone.Either increases toxicity of the other by pharmacodynamic synergism. Significant interaction possible, monitor closely. Increased risk of GI ulceration.
dexamethasone|salsalate|1|Minor|dexamethasone decreases levels of salsalate by increasing renal clearance. Minor or non-significant interaction.
secobarbital|dexamethasone|11|Significant - Monitor Closely|secobarbital will decrease the level or effect of dexamethasone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
dexamethasone|sunitinib|11|Significant - Monitor Closely|dexamethasone will decrease the level or effect of sunitinib by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
telithromycin|dexamethasone|11|Significant - Monitor Closely|telithromycin will increase the level or effect of dexamethasone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
dexamethasone|telithromycin|1|Minor|dexamethasone will decrease the level or effect of telithromycin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor or non-significant interaction.
dexamethasone|temsirolimus|11|Significant - Monitor Closely|dexamethasone will decrease the level or effect of temsirolimus by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
dexamethasone|tramadol|11|Significant - Monitor Closely|dexamethasone will decrease the level or effect of tramadol by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely. Decreased AUC  of tramadol and the active metabolite (O-desmethyltramadol) when coadministered with strong CYP3A4 and CYP2B6 inducers
dexamethasone|trazodone|11|Significant - Monitor Closely|dexamethasone will decrease the level or effect of trazodone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
trazodone|dexamethasone|11|Significant - Monitor Closely|trazodone will decrease the level or effect of dexamethasone by  P-glycoprotein (MDR1) efflux transporter. Significant interaction possible, monitor closely.
dexamethasone|vandetanib|33|Contraindicated|dexamethasone decreases levels of vandetanib by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Never use combination. Avoid coadministration with potent CYP3A4 inducers; these drugs reduce exposure to vandetanib by up to 40%.
voriconazole|dexamethasone|11|Significant - Monitor Closely|voriconazole will increase the level or effect of dexamethasone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
dexamethasone|warfarin|11|Significant - Monitor Closely|dexamethasone will decrease the level or effect of warfarin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
dexamethasone|warfarin|11|Significant - Monitor Closely|dexamethasone, warfarin. Other (see comment). Significant interaction possible, monitor closely. Comment: Corticosteroids may decrease anticoagulant effects by increasing blood coagulability; conversely, they may impair vascular integrity, thus increasing bleeding risk.  Monitor INR closely.
fluoxetine|dexfenfluramine|3|Significant - Monitor Closely|fluoxetine and dexfenfluramine both increase  serotonin levels. Potential for dangerous interaction. Use with caution and monitor closely.
fluoxetine|dexfenfluramine|2|Significant - Monitor Closely|fluoxetine will increase the level or effect of dexfenfluramine by  affecting hepatic enzyme CYP2D6 metabolism. Potential for interaction, monitor.
fluphenazine|dexfenfluramine|11|Significant - Monitor Closely|fluphenazine, dexfenfluramine. Mechanism: unknown. Significant interaction possible, monitor closely. Risk of cardiac arrhythmia or sudden death, more likely w/thioridazine than other phenothiazines.  Interaction more likely in certain predisposed pts. only.
fluphenazine|dexfenfluramine|2|Significant - Monitor Closely|fluphenazine increases and dexfenfluramine decreases sedation. Effect of interaction is not clear, use caution. Potential for interaction, monitor.
fluvoxamine|dexfenfluramine|3|Significant - Monitor Closely|fluvoxamine and dexfenfluramine both increase  serotonin levels. Potential for dangerous interaction. Use with caution and monitor closely.
dexfenfluramine|insulin aspart|11|Significant - Monitor Closely|dexfenfluramine increases effects of insulin aspart by Other (see comment). Significant interaction possible, monitor closely. Comment: Dexfenfluramine enhances glucose uptake in peripheral tissue, increasing risk of hypoglycemia.
dexfenfluramine|insulin detemir|11|Significant - Monitor Closely|dexfenfluramine increases effects of insulin detemir by Other (see comment). Significant interaction possible, monitor closely. Comment: Dexfenfluramine enhances glucose uptake in peripheral tissue, increasing risk of hypoglycemia.
dexfenfluramine|insulin glulisine|11|Significant - Monitor Closely|dexfenfluramine increases effects of insulin glulisine by Other (see comment). Significant interaction possible, monitor closely. Comment: Dexfenfluramine enhances glucose uptake in peripheral tissue, increasing risk of hypoglycemia.
isocarboxazid|dexfenfluramine|33|Contraindicated|isocarboxazid increases effects of dexfenfluramine by pharmacodynamic synergism. Never use combination. Risk of acute hypertensive episode.
isocarboxazid|dexfenfluramine|22|Serious - Use Alternative|isocarboxazid and dexfenfluramine both increase  serotonin levels. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available.
paroxetine|dexfenfluramine|3|Significant - Monitor Closely|paroxetine and dexfenfluramine both increase  serotonin levels. Potential for dangerous interaction. Use with caution and monitor closely.
paroxetine|dexfenfluramine|2|Significant - Monitor Closely|paroxetine will increase the level or effect of dexfenfluramine by  affecting hepatic enzyme CYP2D6 metabolism. Potential for interaction, monitor.
perphenazine|dexfenfluramine|11|Significant - Monitor Closely|perphenazine, dexfenfluramine. Mechanism: unknown. Significant interaction possible, monitor closely. Risk of cardiac arrhythmia or sudden death, more likely w/thioridazine than other phenothiazines.  Interaction more likely in certain predisposed pts. only.
perphenazine|dexfenfluramine|2|Significant - Monitor Closely|perphenazine increases and dexfenfluramine decreases sedation. Effect of interaction is not clear, use caution. Potential for interaction, monitor.
perphenazine|dexfenfluramine|1|Minor|perphenazine will increase the level or effect of dexfenfluramine by  affecting hepatic enzyme CYP2D6 metabolism. Minor or non-significant interaction.
phenelzine|dexfenfluramine|33|Contraindicated|phenelzine increases effects of dexfenfluramine by pharmacodynamic synergism. Never use combination. Risk of acute hypertensive episode.
phenelzine|dexfenfluramine|22|Serious - Use Alternative|phenelzine and dexfenfluramine both increase  serotonin levels. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available.
prochlorperazine|dexfenfluramine|11|Significant - Monitor Closely|prochlorperazine, dexfenfluramine. Mechanism: unknown. Significant interaction possible, monitor closely. Risk of cardiac arrhythmia or sudden death, more likely w/thioridazine than other phenothiazines.  Interaction more likely in certain predisposed pts. only.
prochlorperazine|dexfenfluramine|2|Significant - Monitor Closely|prochlorperazine increases and dexfenfluramine decreases sedation. Effect of interaction is not clear, use caution. Potential for interaction, monitor.
promazine|dexfenfluramine|11|Significant - Monitor Closely|promazine, dexfenfluramine. Mechanism: unknown. Significant interaction possible, monitor closely. Risk of cardiac arrhythmia or sudden death, more likely w/thioridazine than other phenothiazines.  Interaction more likely in certain predisposed pts. only.
promethazine|dexfenfluramine|11|Significant - Monitor Closely|promethazine, dexfenfluramine. Mechanism: unknown. Significant interaction possible, monitor closely. Risk of cardiac arrhythmia or sudden death, more likely w/thioridazine than other phenothiazines.  Interaction more likely in certain predisposed pts. only.
promethazine|dexfenfluramine|2|Significant - Monitor Closely|promethazine increases and dexfenfluramine decreases sedation. Effect of interaction is not clear, use caution. Potential for interaction, monitor.
thioridazine|dexfenfluramine|11|Significant - Monitor Closely|thioridazine, dexfenfluramine. Mechanism: unknown. Significant interaction possible, monitor closely. Risk of cardiac arrhythmia or sudden death, more likely w/thioridazine than other phenothiazines.  Interaction more likely in certain predisposed pts. only.
thioridazine|dexfenfluramine|2|Significant - Monitor Closely|thioridazine increases and dexfenfluramine decreases sedation. Effect of interaction is not clear, use caution. Potential for interaction, monitor.
thioridazine|dexfenfluramine|1|Minor|thioridazine will increase the level or effect of dexfenfluramine by  affecting hepatic enzyme CYP2D6 metabolism. Minor or non-significant interaction.
tranylcypromine|dexfenfluramine|33|Contraindicated|tranylcypromine increases effects of dexfenfluramine by pharmacodynamic synergism. Never use combination. Risk of acute hypertensive episode.
tranylcypromine|dexfenfluramine|22|Serious - Use Alternative|tranylcypromine and dexfenfluramine both increase  serotonin levels. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available.
trifluoperazine|dexfenfluramine|11|Significant - Monitor Closely|trifluoperazine, dexfenfluramine. Mechanism: unknown. Significant interaction possible, monitor closely. Risk of cardiac arrhythmia or sudden death, more likely w/thioridazine than other phenothiazines.  Interaction more likely in certain predisposed pts. only.
trifluoperazine|dexfenfluramine|2|Significant - Monitor Closely|trifluoperazine increases and dexfenfluramine decreases sedation. Effect of interaction is not clear, use caution. Potential for interaction, monitor.
venlafaxine|dexfenfluramine|3|Significant - Monitor Closely|venlafaxine and dexfenfluramine both increase  serotonin levels. Potential for dangerous interaction. Use with caution and monitor closely.
venlafaxine|dexfenfluramine|1|Minor|venlafaxine will increase the level or effect of dexfenfluramine by  affecting hepatic enzyme CYP2D6 metabolism. Minor or non-significant interaction.
dexmedetomidine|trimipramine|2|Significant - Monitor Closely|dexmedetomidine and trimipramine both increase  sedation. Potential for interaction, monitor.
fluoxetine|dextroamphetamine|11|Significant - Monitor Closely|fluoxetine will increase the level or effect of dextroamphetamine by  affecting hepatic enzyme CYP2D6 metabolism. Significant interaction possible, monitor closely.
fluoxetine|dextroamphetamine|3|Significant - Monitor Closely|fluoxetine and dextroamphetamine both increase  serotonin levels. Potential for dangerous interaction. Use with caution and monitor closely.
fluphenazine|dextroamphetamine|11|Significant - Monitor Closely|fluphenazine, dextroamphetamine. Mechanism: unknown. Significant interaction possible, monitor closely. Risk of cardiac arrhythmia or sudden death, more likely w/thioridazine than other phenothiazines.  Interaction more likely in certain predisposed pts. only.
fluphenazine|dextroamphetamine|2|Significant - Monitor Closely|fluphenazine increases and dextroamphetamine decreases sedation. Effect of interaction is not clear, use caution. Potential for interaction, monitor.
fluvoxamine|dextroamphetamine|3|Significant - Monitor Closely|fluvoxamine and dextroamphetamine both increase  serotonin levels. Potential for dangerous interaction. Use with caution and monitor closely.
isocarboxazid|dextroamphetamine|33|Contraindicated|isocarboxazid increases effects of dextroamphetamine by pharmacodynamic synergism. Never use combination. Risk of acute hypertensive episode.
isocarboxazid|dextroamphetamine|22|Serious - Use Alternative|isocarboxazid and dextroamphetamine both increase  serotonin levels. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available.
paroxetine|dextroamphetamine|3|Significant - Monitor Closely|paroxetine and dextroamphetamine both increase  serotonin levels. Potential for dangerous interaction. Use with caution and monitor closely.
paroxetine|dextroamphetamine|2|Significant - Monitor Closely|paroxetine will increase the level or effect of dextroamphetamine by  affecting hepatic enzyme CYP2D6 metabolism. Potential for interaction, monitor.
perphenazine|dextroamphetamine|11|Significant - Monitor Closely|perphenazine, dextroamphetamine. Mechanism: unknown. Significant interaction possible, monitor closely. Risk of cardiac arrhythmia or sudden death, more likely w/thioridazine than other phenothiazines.  Interaction more likely in certain predisposed pts. only.
perphenazine|dextroamphetamine|2|Significant - Monitor Closely|perphenazine increases and dextroamphetamine decreases sedation. Effect of interaction is not clear, use caution. Potential for interaction, monitor.
perphenazine|dextroamphetamine|1|Minor|perphenazine will increase the level or effect of dextroamphetamine by  affecting hepatic enzyme CYP2D6 metabolism. Minor or non-significant interaction.
phenelzine|dextroamphetamine|33|Contraindicated|phenelzine increases effects of dextroamphetamine by pharmacodynamic synergism. Never use combination. Risk of acute hypertensive episode.
phenelzine|dextroamphetamine|22|Serious - Use Alternative|phenelzine and dextroamphetamine both increase  serotonin levels. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available.
prochlorperazine|dextroamphetamine|11|Significant - Monitor Closely|prochlorperazine, dextroamphetamine. Mechanism: unknown. Significant interaction possible, monitor closely. Risk of cardiac arrhythmia or sudden death, more likely w/thioridazine than other phenothiazines.  Interaction more likely in certain predisposed pts. only.
prochlorperazine|dextroamphetamine|2|Significant - Monitor Closely|prochlorperazine increases and dextroamphetamine decreases sedation. Effect of interaction is not clear, use caution. Potential for interaction, monitor.
promethazine|dextroamphetamine|11|Significant - Monitor Closely|promethazine, dextroamphetamine. Mechanism: unknown. Significant interaction possible, monitor closely. Risk of cardiac arrhythmia or sudden death, more likely w/thioridazine than other phenothiazines.  Interaction more likely in certain predisposed pts. only.
promethazine|dextroamphetamine|2|Significant - Monitor Closely|promethazine increases and dextroamphetamine decreases sedation. Effect of interaction is not clear, use caution. Potential for interaction, monitor.
rasagiline|dextroamphetamine|33|Contraindicated|rasagiline increases effects of dextroamphetamine by pharmacodynamic synergism. Never use combination. Risk of acute hypertensive episode. Coadministration is contraindicated during or within 14 days following the administration of MAOIs.
thioridazine|dextroamphetamine|11|Significant - Monitor Closely|thioridazine, dextroamphetamine. Mechanism: unknown. Significant interaction possible, monitor closely. Risk of cardiac arrhythmia or sudden death, more likely w/thioridazine than other phenothiazines.  Interaction more likely in certain predisposed pts. only.
thioridazine|dextroamphetamine|2|Significant - Monitor Closely|thioridazine increases and dextroamphetamine decreases sedation. Effect of interaction is not clear, use caution. Potential for interaction, monitor.
thioridazine|dextroamphetamine|1|Minor|thioridazine will increase the level or effect of dextroamphetamine by  affecting hepatic enzyme CYP2D6 metabolism. Minor or non-significant interaction.
tramadol|dextroamphetamine|2|Significant - Monitor Closely|tramadol increases and dextroamphetamine decreases sedation. Effect of interaction is not clear, use caution. Potential for interaction, monitor.
dextroamphetamine|tramadol|2|Significant - Monitor Closely|dextroamphetamine and tramadol both increase  serotonin levels. Potential for interaction, monitor.
dextroamphetamine|tramadol|1|Minor|dextroamphetamine increases effects of tramadol by unspecified interaction mechanism. Minor or non-significant interaction.
tranylcypromine|dextroamphetamine|33|Contraindicated|tranylcypromine increases effects of dextroamphetamine by pharmacodynamic synergism. Never use combination. Risk of acute hypertensive episode.
tranylcypromine|dextroamphetamine|22|Serious - Use Alternative|tranylcypromine and dextroamphetamine both increase  serotonin levels. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available.
trifluoperazine|dextroamphetamine|11|Significant - Monitor Closely|trifluoperazine, dextroamphetamine. Mechanism: unknown. Significant interaction possible, monitor closely. Risk of cardiac arrhythmia or sudden death, more likely w/thioridazine than other phenothiazines.  Interaction more likely in certain predisposed pts. only.
trifluoperazine|dextroamphetamine|2|Significant - Monitor Closely|trifluoperazine increases and dextroamphetamine decreases sedation. Effect of interaction is not clear, use caution. Potential for interaction, monitor.
triprolidine|dextroamphetamine|2|Significant - Monitor Closely|triprolidine increases and dextroamphetamine decreases sedation. Effect of interaction is not clear, use caution. Potential for interaction, monitor.
fluoxetine|dextromethorphan|22|Serious - Use Alternative|fluoxetine and dextromethorphan both increase  serotonin levels. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available.
fluoxetine|dextromethorphan|20|Serious - Use Alternative|fluoxetine will increase the level or effect of dextromethorphan by  affecting hepatic enzyme CYP2D6 metabolism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
isocarboxazid|dextromethorphan|33|Contraindicated|isocarboxazid and dextromethorphan both increase  serotonin levels. Never use combination.
paroxetine|dextromethorphan|22|Serious - Use Alternative|paroxetine and dextromethorphan both increase  serotonin levels. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available.
paroxetine|dextromethorphan|20|Serious - Use Alternative|paroxetine will increase the level or effect of dextromethorphan by  affecting hepatic enzyme CYP2D6 metabolism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
phenelzine|dextromethorphan|33|Contraindicated|phenelzine and dextromethorphan both increase  serotonin levels. Never use combination.
quinidine|dextromethorphan|2|Significant - Monitor Closely|quinidine will increase the level or effect of dextromethorphan by  affecting hepatic enzyme CYP2D6 metabolism. Potential for interaction, monitor.
rasagiline|dextromethorphan|33|Contraindicated|rasagiline and dextromethorphan both increase  serotonin levels. Never use combination. Risk of psychosis episodes or bizarre behavior.
selegiline|dextromethorphan|33|Contraindicated|selegiline and dextromethorphan both increase  serotonin levels. Never use combination.
terbinafine|dextromethorphan|1|Minor|terbinafine increases levels of dextromethorphan by decreasing metabolism. Minor or non-significant interaction.
dextromethorphan|tramadol|3|Significant - Monitor Closely|dextromethorphan and tramadol both increase  serotonin levels. Potential for dangerous interaction. Use with caution and monitor closely.
tranylcypromine|dextromethorphan|33|Contraindicated|tranylcypromine and dextromethorphan both increase  serotonin levels. Never use combination.
trazodone|dextromethorphan|22|Serious - Use Alternative|trazodone and dextromethorphan both increase  serotonin levels. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available.
trimipramine|dextromethorphan|22|Serious - Use Alternative|trimipramine and dextromethorphan both increase  serotonin levels. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available.
venlafaxine|dextromethorphan|22|Serious - Use Alternative|venlafaxine and dextromethorphan both increase  serotonin levels. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available.
venlafaxine|dextromethorphan|20|Serious - Use Alternative|venlafaxine will increase the level or effect of dextromethorphan by  affecting hepatic enzyme CYP2D6 metabolism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
dextromethorphan|vilazodone|22|Serious - Use Alternative|dextromethorphan, vilazodone.Either increases toxicity of the other by serotonin levels. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available. Concomitant therapy should be discontinued immediately if signs or symptoms of serotonin syndrome emerge and supportive symptomatic treatment should be initiated.  .
zolmitriptan|dextromethorphan|3|Significant - Monitor Closely|zolmitriptan and dextromethorphan both increase  serotonin levels. Potential for dangerous interaction. Use with caution and monitor closely.
ethotoin|diazepam|11|Significant - Monitor Closely|ethotoin will decrease the level or effect of diazepam by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
etravirine|diazepam|11|Significant - Monitor Closely|etravirine will decrease the level or effect of diazepam by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
etravirine|diazepam|1|Minor|etravirine will increase the level or effect of diazepam by  affecting hepatic enzyme CYP2C19 metabolism. Minor or non-significant interaction.
fluconazole|diazepam|11|Significant - Monitor Closely|fluconazole will increase the level or effect of diazepam by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
fluconazole|diazepam|1|Minor|fluconazole will increase the level or effect of diazepam by  affecting hepatic enzyme CYP2C19 metabolism. Minor or non-significant interaction.
fosamprenavir|diazepam|3|Significant - Monitor Closely|fosamprenavir increases levels of diazepam by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Potential for dangerous interaction. Use with caution and monitor closely. Use alternatives if available.
fosphenytoin|diazepam|11|Significant - Monitor Closely|fosphenytoin will decrease the level or effect of diazepam by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
indinavir|diazepam|3|Significant - Monitor Closely|indinavir increases levels of diazepam by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Potential for dangerous interaction. Use with caution and monitor closely. Potential for increased toxicity. Use alternatives if available. Consider lowering benzodiazepine dose.
itraconazole|diazepam|20|Serious - Use Alternative|itraconazole will increase the level or effect of diazepam by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
ketoconazole|diazepam|20|Serious - Use Alternative|ketoconazole will increase the level or effect of diazepam by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
nelfinavir|diazepam|3|Significant - Monitor Closely|nelfinavir increases levels of diazepam by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Potential for dangerous interaction. Use with caution and monitor closely. Use alternatives if available.
omeprazole|diazepam|1|Minor|omeprazole will increase the level or effect of diazepam by  affecting hepatic enzyme CYP2C19 metabolism. Minor or non-significant interaction.
phenytoin|diazepam|11|Significant - Monitor Closely|phenytoin will decrease the level or effect of diazepam by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
ritonavir|diazepam|3|Significant - Monitor Closely|ritonavir increases levels of diazepam by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Potential for dangerous interaction. Use with caution and monitor closely. Use alternatives if available.
saquinavir|diazepam|3|Significant - Monitor Closely|saquinavir increases levels of diazepam by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Potential for dangerous interaction. Use with caution and monitor closely. Use alternatives if available.
telithromycin|diazepam|11|Significant - Monitor Closely|telithromycin will increase the level or effect of diazepam by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
voriconazole|diazepam|11|Significant - Monitor Closely|voriconazole will increase the level or effect of diazepam by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
voriconazole|diazepam|1|Minor|voriconazole will increase the level or effect of diazepam by  affecting hepatic enzyme CYP2C19 metabolism. Minor or non-significant interaction.
diazoxide|fosphenytoin|1|Minor|diazoxide decreases levels of fosphenytoin by increasing metabolism. Minor or non-significant interaction.
diazoxide|hydrochlorothiazide|1|Minor|diazoxide, hydrochlorothiazide. Mechanism: pharmacodynamic synergism. Minor or non-significant interaction. Risk of hyperglycemia.
diazoxide|indapamide|1|Minor|diazoxide, indapamide. Mechanism: pharmacodynamic synergism. Minor or non-significant interaction. Risk of hyperglycemia.
diazoxide|phenytoin|1|Minor|diazoxide decreases levels of phenytoin by increasing metabolism. Minor or non-significant interaction.
eltrombopag|diclofenac|11|Significant - Monitor Closely|eltrombopag increases levels of diclofenac by decreasing metabolism. Significant interaction possible, monitor closely. UGT inhibition; significance of interaction unclear.
diclofenac|ginkgo biloba|2|Significant - Monitor Closely|diclofenac and ginkgo biloba both increase  anticoagulation. Potential for interaction, monitor.
diclofenac|lithium|11|Significant - Monitor Closely|diclofenac increases levels of lithium by decreasing renal clearance. Significant interaction possible, monitor closely.
diclofenac|methotrexate|20|Serious - Use Alternative|diclofenac increases levels of methotrexate by decreasing renal clearance. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available. Concomitant administration of NSAIDs with high dose methotrexate has been reported to elevate and prolong serum methotrexate levels, resulting in deaths from severe hematologic and GI toxicity. NSAIDs may reduce tubular secretion of methotrexate and enhance toxicity. .
diclofenac|pralatrexate|11|Significant - Monitor Closely|diclofenac increases levels of pralatrexate by decreasing renal clearance. Significant interaction possible, monitor closely. NSAIDs may delay pralatrexate clearance, increasing drug exposure. Adjust the pralatrexate dose as needed.
telmisartan|diclofenac|11|Significant - Monitor Closely|telmisartan, diclofenac.Either increases toxicity of the other by Other (see comment). Significant interaction possible, monitor closely. Comment: May result in renal function deterioration, particularly in elderly or volume depleted individuals.
diclofenac|telmisartan|3|Significant - Monitor Closely|diclofenac decreases effects of telmisartan by pharmacodynamic antagonism. Potential for dangerous interaction. Use with caution and monitor closely.  NSAIDs decrease synthesis of vasodilating renal prostaglandins, and thus affect fluid homeostasis and may diminish antihypertensive effect.
telmisartan|diclofenac|2|Significant - Monitor Closely|telmisartan and diclofenac both increase  serum potassium. Potential for interaction, monitor.
diclofenac|timolol|11|Significant - Monitor Closely|diclofenac decreases effects of timolol by pharmacodynamic antagonism. Significant interaction possible, monitor closely. Long term (>1 wk) NSAID use.  NSAIDs decrease prostaglandin synthesis.
timolol|diclofenac|2|Significant - Monitor Closely|timolol and diclofenac both increase  serum potassium. Potential for interaction, monitor.
trandolapril|diclofenac|11|Significant - Monitor Closely|trandolapril, diclofenac.Either increases toxicity of the other by Other (see comment). Significant interaction possible, monitor closely. Comment: May result in renal function deterioration, particularly in elderly or volume depleted individuals.
diclofenac|trandolapril|3|Significant - Monitor Closely|diclofenac decreases effects of trandolapril by pharmacodynamic antagonism. Potential for dangerous interaction. Use with caution and monitor closely. NSAIDs decrease synthesis of vasodilating renal prostaglandins, and thus affect fluid homeostasis and may diminish antihypertenisve effect.
voriconazole|diclofenac|11|Significant - Monitor Closely|voriconazole will increase the level or effect of diclofenac by  affecting hepatic enzyme CYP2C9/10 metabolism. Significant interaction possible, monitor closely. Do not exceed diclofenac dose of 50 mg BID
warfarin|diclofenac|3|Significant - Monitor Closely|warfarin and diclofenac both increase  anticoagulation. Potential for dangerous interaction. Use with caution and monitor closely.
doxycycline|dicloxacillin|20|Serious - Use Alternative|doxycycline decreases effects of dicloxacillin by pharmacodynamic antagonism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
dicloxacillin|mestranol|2|Significant - Monitor Closely|dicloxacillin will decrease the level or effect of mestranol by  altering intestinal flora. Applies only to oral forms of hormone. Low risk of contraceptive failure. Potential for interaction, monitor.
dicloxacillin|methotrexate|11|Significant - Monitor Closely|dicloxacillin increases levels of methotrexate by decreasing renal clearance. Significant interaction possible, monitor closely. Increased serum concentrations of methotrexate with concomitant hematologic and gastrointestinal toxicity have been observed with concurrent administration of high or low doses of methotrexate and penicillins.
minocycline|dicloxacillin|20|Serious - Use Alternative|minocycline decreases effects of dicloxacillin by pharmacodynamic antagonism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
tetracycline|dicloxacillin|20|Serious - Use Alternative|tetracycline decreases effects of dicloxacillin by pharmacodynamic antagonism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
dicloxacillin|warfarin|11|Significant - Monitor Closely|dicloxacillin decreases levels of warfarin by increasing metabolism. Significant interaction possible, monitor closely.
donepezil|dicyclomine|2|Significant - Monitor Closely|donepezil increases and dicyclomine decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Potential for interaction, monitor.
donepezil|dicyclomine|1|Minor|donepezil decreases effects of dicyclomine by pharmacodynamic antagonism. Minor or non-significant interaction.
galantamine|dicyclomine|2|Significant - Monitor Closely|galantamine increases and dicyclomine decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Potential for interaction, monitor.
galantamine|dicyclomine|1|Minor|galantamine decreases effects of dicyclomine by pharmacodynamic antagonism. Minor or non-significant interaction.
dicyclomine|haloperidol|11|Significant - Monitor Closely|dicyclomine decreases levels of haloperidol by inhibition of GI absorption. Applies only to oral form of both agents. Significant interaction possible, monitor closely.
dicyclomine|haloperidol|11|Significant - Monitor Closely|dicyclomine decreases levels of haloperidol by pharmacodynamic antagonism. Significant interaction possible, monitor closely.
haloperidol|dicyclomine|11|Significant - Monitor Closely|haloperidol increases effects of dicyclomine by pharmacodynamic synergism. Significant interaction possible, monitor closely. Additive anticholinergic effects, possible hypoglycemia.
tacrine|dicyclomine|2|Significant - Monitor Closely|tacrine increases and dicyclomine decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Potential for interaction, monitor.
tacrine|dicyclomine|1|Minor|tacrine decreases effects of dicyclomine by pharmacodynamic antagonism. Minor or non-significant interaction.
ganciclovir|didanosine|11|Significant - Monitor Closely|ganciclovir increases levels of didanosine by decreasing renal clearance. Significant interaction possible, monitor closely.
ganciclovir|didanosine|3|Significant - Monitor Closely|ganciclovir, didanosine.Either increases toxicity of the other by pharmacodynamic synergism. Potential for dangerous interaction. Use with caution and monitor closely. Use alternatives if available. Increased risk of hematologic toxicity.
tipranavir|didanosine|11|Significant - Monitor Closely|tipranavir decreases levels of didanosine by unspecified interaction mechanism. Significant interaction possible, monitor closely. Separate by at least 2 hrs.
tipranavir|didanosine|2|Significant - Monitor Closely|tipranavir and didanosine both increase  risk of immune reconstitution syndrome. Potential for interaction, monitor.
valganciclovir|didanosine|3|Significant - Monitor Closely|valganciclovir, didanosine.Either increases toxicity of the other by pharmacodynamic synergism. Potential for dangerous interaction. Use with caution and monitor closely. Use alternatives if available. Increased risk of hematologic toxicity.
valganciclovir|didanosine|1|Minor|valganciclovir increases levels of didanosine by decreasing renal clearance. Minor or non-significant interaction.
fluphenazine|diethylpropion|11|Significant - Monitor Closely|fluphenazine, diethylpropion. Mechanism: unknown. Significant interaction possible, monitor closely. Risk of cardiac arrhythmia or sudden death, more likely w/thioridazine than other phenothiazines.  Interaction more likely in certain predisposed pts. only.
fluphenazine|diethylpropion|2|Significant - Monitor Closely|fluphenazine increases and diethylpropion decreases sedation. Effect of interaction is not clear, use caution. Potential for interaction, monitor.
isocarboxazid|diethylpropion|33|Contraindicated|isocarboxazid increases effects of diethylpropion by pharmacodynamic synergism. Never use combination. Risk of acute hypertensive episode.
perphenazine|diethylpropion|11|Significant - Monitor Closely|perphenazine, diethylpropion. Mechanism: unknown. Significant interaction possible, monitor closely. Risk of cardiac arrhythmia or sudden death, more likely w/thioridazine than other phenothiazines.  Interaction more likely in certain predisposed pts. only.
perphenazine|diethylpropion|2|Significant - Monitor Closely|perphenazine increases and diethylpropion decreases sedation. Effect of interaction is not clear, use caution. Potential for interaction, monitor.
phenelzine|diethylpropion|33|Contraindicated|phenelzine increases effects of diethylpropion by pharmacodynamic synergism. Never use combination. Risk of acute hypertensive episode.
prochlorperazine|diethylpropion|11|Significant - Monitor Closely|prochlorperazine, diethylpropion. Mechanism: unknown. Significant interaction possible, monitor closely. Risk of cardiac arrhythmia or sudden death, more likely w/thioridazine than other phenothiazines.  Interaction more likely in certain predisposed pts. only.
prochlorperazine|diethylpropion|2|Significant - Monitor Closely|prochlorperazine increases and diethylpropion decreases sedation. Effect of interaction is not clear, use caution. Potential for interaction, monitor.
promazine|diethylpropion|11|Significant - Monitor Closely|promazine, diethylpropion. Mechanism: unknown. Significant interaction possible, monitor closely. Risk of cardiac arrhythmia or sudden death, more likely w/thioridazine than other phenothiazines.  Interaction more likely in certain predisposed pts. only.
promethazine|diethylpropion|11|Significant - Monitor Closely|promethazine, diethylpropion. Mechanism: unknown. Significant interaction possible, monitor closely. Risk of cardiac arrhythmia or sudden death, more likely w/thioridazine than other phenothiazines.  Interaction more likely in certain predisposed pts. only.
promethazine|diethylpropion|2|Significant - Monitor Closely|promethazine increases and diethylpropion decreases sedation. Effect of interaction is not clear, use caution. Potential for interaction, monitor.
rasagiline|diethylpropion|11|Significant - Monitor Closely|rasagiline increases effects of diethylpropion by pharmacodynamic synergism. Significant interaction possible, monitor closely. Risk of acute hypertensive episode.
thioridazine|diethylpropion|11|Significant - Monitor Closely|thioridazine, diethylpropion. Mechanism: unknown. Significant interaction possible, monitor closely. Risk of cardiac arrhythmia or sudden death, more likely w/thioridazine than other phenothiazines.  Interaction more likely in certain predisposed pts. only.
thioridazine|diethylpropion|2|Significant - Monitor Closely|thioridazine increases and diethylpropion decreases sedation. Effect of interaction is not clear, use caution. Potential for interaction, monitor.
tranylcypromine|diethylpropion|33|Contraindicated|tranylcypromine increases effects of diethylpropion by pharmacodynamic synergism. Never use combination. Risk of acute hypertensive episode.
trifluoperazine|diethylpropion|11|Significant - Monitor Closely|trifluoperazine, diethylpropion. Mechanism: unknown. Significant interaction possible, monitor closely. Risk of cardiac arrhythmia or sudden death, more likely w/thioridazine than other phenothiazines.  Interaction more likely in certain predisposed pts. only.
trifluoperazine|diethylpropion|2|Significant - Monitor Closely|trifluoperazine increases and diethylpropion decreases sedation. Effect of interaction is not clear, use caution. Potential for interaction, monitor.
eltrombopag|diflunisal|11|Significant - Monitor Closely|eltrombopag increases levels of diflunisal by decreasing metabolism. Significant interaction possible, monitor closely. UGT inhibition; significance of interaction unclear.
diflunisal|ginkgo biloba|2|Significant - Monitor Closely|diflunisal and ginkgo biloba both increase  anticoagulation. Potential for interaction, monitor.
diflunisal|indomethacin|2|Significant - Monitor Closely|diflunisal and indomethacin both increase  anticoagulation. Potential for interaction, monitor.
diflunisal|indomethacin|2|Significant - Monitor Closely|diflunisal and indomethacin both increase  serum potassium. Potential for interaction, monitor.
diflunisal|indomethacin|1|Minor|diflunisal will increase the level or effect of indomethacin by  acidic (anionic) drug competition for renal tubular clearance. Minor or non-significant interaction.
diflunisal|lithium|11|Significant - Monitor Closely|diflunisal increases levels of lithium by decreasing renal clearance. Significant interaction possible, monitor closely.
diflunisal|methotrexate|20|Serious - Use Alternative|diflunisal increases levels of methotrexate by decreasing renal clearance. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available. Concomitant administration of NSAIDs with high dose methotrexate has been reported to elevate and prolong serum methotrexate levels, resulting in deaths from severe hematologic and GI toxicity. NSAIDs may reduce tubular secretion of methotrexate and enhance toxicity. .
diflunisal|pralatrexate|11|Significant - Monitor Closely|diflunisal increases levels of pralatrexate by decreasing renal clearance. Significant interaction possible, monitor closely. NSAIDs may delay pralatrexate clearance, increasing drug exposure. Adjust the pralatrexate dose as needed.
diflunisal|probenecid|11|Significant - Monitor Closely|diflunisal will increase the level or effect of probenecid by  acidic (anionic) drug competition for renal tubular clearance. Significant interaction possible, monitor closely.
diflunisal|probenecid|11|Significant - Monitor Closely|diflunisal decreases effects of probenecid by unknown mechanism. Significant interaction possible, monitor closely.
telmisartan|diflunisal|11|Significant - Monitor Closely|telmisartan, diflunisal.Either increases toxicity of the other by Other (see comment). Significant interaction possible, monitor closely. Comment: May result in renal function deterioration, particularly in elderly or volume depleted individuals.
diflunisal|telmisartan|3|Significant - Monitor Closely|diflunisal decreases effects of telmisartan by pharmacodynamic antagonism. Potential for dangerous interaction. Use with caution and monitor closely.  NSAIDs decrease synthesis of vasodilating renal prostaglandins, and thus affect fluid homeostasis and may diminish antihypertensive effect.
telmisartan|diflunisal|2|Significant - Monitor Closely|telmisartan and diflunisal both increase  serum potassium. Potential for interaction, monitor.
diflunisal|timolol|11|Significant - Monitor Closely|diflunisal decreases effects of timolol by pharmacodynamic antagonism. Significant interaction possible, monitor closely. Long term (>1 wk) NSAID use.  NSAIDs decrease prostaglandin synthesis.
timolol|diflunisal|2|Significant - Monitor Closely|timolol and diflunisal both increase  serum potassium. Potential for interaction, monitor.
trandolapril|diflunisal|11|Significant - Monitor Closely|trandolapril, diflunisal.Either increases toxicity of the other by Other (see comment). Significant interaction possible, monitor closely. Comment: May result in renal function deterioration, particularly in elderly or volume depleted individuals.
diflunisal|trandolapril|3|Significant - Monitor Closely|diflunisal decreases effects of trandolapril by pharmacodynamic antagonism. Potential for dangerous interaction. Use with caution and monitor closely. NSAIDs decrease synthesis of vasodilating renal prostaglandins, and thus affect fluid homeostasis and may diminish antihypertenisve effect.
diflunisal|warfarin|11|Significant - Monitor Closely|diflunisal increases effects of warfarin by plasma protein binding competition. Significant interaction possible, monitor closely.
warfarin|diflunisal|3|Significant - Monitor Closely|warfarin and diflunisal both increase  anticoagulation. Potential for dangerous interaction. Use with caution and monitor closely.
doxorubicin|digoxin|2|Significant - Monitor Closely|doxorubicin decreases levels of digoxin by inhibition of GI absorption. Applies only to oral form of both agents. Potential for interaction, monitor.
digoxin|dronedarone|20|Serious - Use Alternative|digoxin increases toxicity of dronedarone by P-glycoprotein (MDR1) efflux transporter. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available. May cause increased risk of arrhythmic or sudden death; avoid use; if digoxin must be coadministered, decrease digoxin dose by 50%.
dronedarone|digoxin|11|Significant - Monitor Closely|dronedarone will increase the level or effect of digoxin by  P-glycoprotein (MDR1) efflux transporter. Significant interaction possible, monitor closely. If coadministered, consider reducing digoxin dose. Closely monitor serum digoxin levels and observe for digoxin toxicity.
ethacrynic acid|digoxin|11|Significant - Monitor Closely|ethacrynic acid increases effects of digoxin by pharmacodynamic synergism. Significant interaction possible, monitor closely. Hypokalemia increases digoxin effects.
digoxin|ethacrynic acid|2|Significant - Monitor Closely|digoxin increases and ethacrynic acid decreases serum potassium. Effect of interaction is not clear, use caution. Potential for interaction, monitor.
etravirine|digoxin|11|Significant - Monitor Closely|etravirine increases levels of digoxin by P-glycoprotein (MDR1) efflux transporter. Significant interaction possible, monitor closely. Potential for increased toxicity. .
furosemide|digoxin|11|Significant - Monitor Closely|furosemide increases effects of digoxin by pharmacodynamic synergism. Significant interaction possible, monitor closely. Hypokalemia increases digoxin effects.
digoxin|furosemide|2|Significant - Monitor Closely|digoxin increases and furosemide decreases serum potassium. Effect of interaction is not clear, use caution. Potential for interaction, monitor.
digoxin|hydrochlorothiazide|11|Significant - Monitor Closely|digoxin will increase the level or effect of hydrochlorothiazide by  basic (cationic) drug competition for renal tubular clearance. Significant interaction possible, monitor closely.
hydrochlorothiazide|digoxin|11|Significant - Monitor Closely|hydrochlorothiazide increases effects of digoxin by pharmacodynamic synergism. Significant interaction possible, monitor closely. Hypokalemia increases digoxin effects.
digoxin|hydrochlorothiazide|2|Significant - Monitor Closely|digoxin increases and hydrochlorothiazide decreases serum potassium. Effect of interaction is not clear, use caution. Potential for interaction, monitor.
indapamide|digoxin|11|Significant - Monitor Closely|indapamide increases effects of digoxin by pharmacodynamic synergism. Significant interaction possible, monitor closely. Hypokalemia increases digoxin effects.
digoxin|indapamide|2|Significant - Monitor Closely|digoxin increases and indapamide decreases serum potassium. Effect of interaction is not clear, use caution. Potential for interaction, monitor.
itraconazole|digoxin|11|Significant - Monitor Closely|itraconazole will increase the level or effect of digoxin by  P-glycoprotein (MDR1) efflux transporter. Significant interaction possible, monitor closely.
itraconazole|digoxin|11|Significant - Monitor Closely|itraconazole increases levels of digoxin by enhancing GI absorption. Applies only to oral form of both agents. Significant interaction possible, monitor closely.
itraconazole|digoxin|11|Significant - Monitor Closely|itraconazole increases levels of digoxin by decreasing renal clearance. Significant interaction possible, monitor closely.
levothyroxine|digoxin|11|Significant - Monitor Closely|levothyroxine decreases effects of digoxin by unknown mechanism. Significant interaction possible, monitor closely.
liothyronine|digoxin|11|Significant - Monitor Closely|liothyronine decreases effects of digoxin by unknown mechanism. Significant interaction possible, monitor closely.
liraglutide|digoxin|1|Minor|liraglutide decreases levels of digoxin by unspecified interaction mechanism. Minor or non-significant interaction.
methotrexate|digoxin|2|Significant - Monitor Closely|methotrexate decreases levels of digoxin by inhibition of GI absorption. Applies only to oral form of both agents. Potential for interaction, monitor. Serum levels of digoxin may be reduced and actions may be decreased. Monitor patient for signs of reduction in pharmacologic effect of digoxin and increase digoxin dose if necessary. Serum level monitoring may facilitate tailoring dosage.
digoxin|methyclothiazide|11|Significant - Monitor Closely|digoxin will increase the level or effect of methyclothiazide by  basic (cationic) drug competition for renal tubular clearance. Significant interaction possible, monitor closely.
methyclothiazide|digoxin|11|Significant - Monitor Closely|methyclothiazide increases effects of digoxin by pharmacodynamic synergism. Significant interaction possible, monitor closely. Hypokalemia increases digoxin effects.
digoxin|methyclothiazide|2|Significant - Monitor Closely|digoxin increases and methyclothiazide decreases serum potassium. Effect of interaction is not clear, use caution. Potential for interaction, monitor.  .
metolazone|digoxin|11|Significant - Monitor Closely|metolazone increases effects of digoxin by pharmacodynamic synergism. Significant interaction possible, monitor closely. Hypokalemia increases digoxin effects.
digoxin|metolazone|2|Significant - Monitor Closely|digoxin increases and metolazone decreases serum potassium. Effect of interaction is not clear, use caution. Potential for interaction, monitor.
mirabegron|digoxin|11|Significant - Monitor Closely|mirabegron will increase the level or effect of digoxin by  P-glycoprotein (MDR1) efflux transporter. Significant interaction possible, monitor closely.
penbutolol|digoxin|11|Significant - Monitor Closely|penbutolol increases effects of digoxin by pharmacodynamic synergism. Significant interaction possible, monitor closely. Enhanced bradycardia.
penbutolol|digoxin|2|Significant - Monitor Closely|penbutolol and digoxin both increase  serum potassium. Potential for interaction, monitor.
penicillamine|digoxin|1|Minor|penicillamine decreases levels of digoxin by unknown mechanism. Minor or non-significant interaction.
procarbazine|digoxin|2|Significant - Monitor Closely|procarbazine decreases levels of digoxin by inhibition of GI absorption. Applies only to oral form of both agents. Potential for interaction, monitor.
propafenone|digoxin|20|Serious - Use Alternative|propafenone increases levels of digoxin by decreasing renal clearance. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
quinidine|digoxin|20|Serious - Use Alternative|quinidine will increase the level or effect of digoxin by  P-glycoprotein (MDR1) efflux transporter. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
quinidine|digoxin|20|Serious - Use Alternative|quinidine will increase the level or effect of digoxin by  basic (cationic) drug competition for renal tubular clearance. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
digoxin|quinine|11|Significant - Monitor Closely|digoxin will increase the level or effect of quinine by  basic (cationic) drug competition for renal tubular clearance. Significant interaction possible, monitor closely.
rabeprazole|digoxin|20|Serious - Use Alternative|rabeprazole will increase the level or effect of digoxin by  increasing gastric pH. Applies only to oral form of both agents. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
rabeprazole|digoxin|2|Significant - Monitor Closely|rabeprazole increases toxicity of digoxin by Other (see comment). Potential for interaction, monitor. Comment: Prolonged use of PPIs may cause hypomagnesemia and increase risk for digoxin toxicity.
ranolazine|digoxin|11|Significant - Monitor Closely|ranolazine will increase the level or effect of digoxin by  P-glycoprotein (MDR1) efflux transporter. Significant interaction possible, monitor closely.
ranolazine|digoxin|11|Significant - Monitor Closely|ranolazine increases levels of digoxin by decreasing metabolism. Significant interaction possible, monitor closely. Ranolazine inhibits P glycoprotein.
ritonavir|digoxin|11|Significant - Monitor Closely|ritonavir will increase the level or effect of digoxin by  P-glycoprotein (MDR1) efflux transporter. Significant interaction possible, monitor closely. Plasma concentrations and pharmacologic effects of digoxin may be increased by ritonavir.  Monitor for increased effects of digoxin.
ritonavir|digoxin|11|Significant - Monitor Closely|ritonavir increases levels of digoxin by decreasing renal clearance. Significant interaction possible, monitor closely.
ritonavir|digoxin|11|Significant - Monitor Closely|ritonavir increases levels of digoxin by decreasing hepatic clearance. Significant interaction possible, monitor closely.
spironolactone|digoxin|11|Significant - Monitor Closely|spironolactone will increase the level or effect of digoxin by  P-glycoprotein (MDR1) efflux transporter. Significant interaction possible, monitor closely. Spironolactone  has been shown to increase the half-life of digoxin and subsequent toxicity may occur. Monitor carefully during coadministration
spironolactone|digoxin|11|Significant - Monitor Closely|spironolactone, digoxin. Mechanism: decreasing renal clearance. Significant interaction possible, monitor closely. False digoxin assay results may be obtained.
spironolactone|digoxin|11|Significant - Monitor Closely|spironolactone increases levels of digoxin by Other (see comment). Significant interaction possible, monitor closely. Comment: Spironolactone may cause false elevation of digoxin assay.
spironolactone|digoxin|3|Significant - Monitor Closely|spironolactone and digoxin both increase  serum potassium. Potential for dangerous interaction. Use with caution and monitor closely.
sulfasalazine|digoxin|11|Significant - Monitor Closely|sulfasalazine decreases levels of digoxin by inhibition of GI absorption. Applies only to oral form of both agents. Significant interaction possible, monitor closely. Sulfasalazine >2 g/day.
sulfasalazine|digoxin|2|Significant - Monitor Closely|sulfasalazine and digoxin both increase  serum potassium. Potential for interaction, monitor.
telaprevir|digoxin|11|Significant - Monitor Closely|telaprevir increases levels of digoxin by Other (see comment). Significant interaction possible, monitor closely. Comment: Concentrations of digoxin were increased when co-administered with telaprevir. The lowest dose of digoxin should be initially prescribed. The serum digoxin concentrations should be monitored and used for titration of digoxin dose to obtain the desired clinical effect.
telithromycin|digoxin|11|Significant - Monitor Closely|telithromycin will increase the level or effect of digoxin by  altering intestinal flora. Applies only to oral form of both agents. Significant interaction possible, monitor closely.
telithromycin|digoxin|1|Minor|telithromycin increases levels of digoxin by unspecified interaction mechanism. Minor or non-significant interaction.
telmisartan|digoxin|11|Significant - Monitor Closely|telmisartan increases levels of digoxin by unknown mechanism. Significant interaction possible, monitor closely.
telmisartan|digoxin|2|Significant - Monitor Closely|telmisartan and digoxin both increase  serum potassium. Potential for interaction, monitor.
tolvaptan|digoxin|11|Significant - Monitor Closely|tolvaptan will increase the level or effect of digoxin by  P-glycoprotein (MDR1) efflux transporter. Significant interaction possible, monitor closely.
digoxin|tolvaptan|2|Significant - Monitor Closely|digoxin and tolvaptan both increase  serum potassium. Potential for interaction, monitor.
verapamil|digoxin|20|Serious - Use Alternative|verapamil increases levels of digoxin by decreasing renal clearance. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
verapamil|digoxin|11|Significant - Monitor Closely|verapamil will increase the level or effect of digoxin by  P-glycoprotein (MDR1) efflux transporter. Significant interaction possible, monitor closely. Toxicity characterized by gastrointestinal and neuropsychiatric symptoms, and cardiac arrhythmias may result.
digoxin|verapamil|11|Significant - Monitor Closely|digoxin will increase the level or effect of verapamil by  basic (cationic) drug competition for renal tubular clearance. Significant interaction possible, monitor closely.
vincristine|digoxin|11|Significant - Monitor Closely|vincristine decreases levels of digoxin by inhibition of GI absorption. Applies only to oral form of both agents. Significant interaction possible, monitor closely.
efavirenz|dihydroergotamine|21|Serious - Use Alternative|efavirenz will decrease the level or effect of dihydroergotamine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available. Never use combination.
dihydroergotamine|eletriptan|33|Contraindicated|dihydroergotamine, eletriptan.Either increases toxicity of the other by pharmacodynamic synergism. Never use combination. Additive vasospasm.  Sep. by 24h.
eletriptan|dihydroergotamine|2|Significant - Monitor Closely|eletriptan and dihydroergotamine both increase  serotonin levels. Potential for interaction, monitor.
dihydroergotamine|esmolol|1|Minor|dihydroergotamine, esmolol. Mechanism: pharmacodynamic synergism. Minor or non-significant interaction. Additive vasospasm.
fluconazole|dihydroergotamine|21|Serious - Use Alternative|fluconazole will increase the level or effect of dihydroergotamine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available. Never use combination.
fluoxetine|dihydroergotamine|3|Significant - Monitor Closely|fluoxetine and dihydroergotamine both increase  serotonin levels. Potential for dangerous interaction. Use with caution and monitor closely.
fluvoxamine|dihydroergotamine|21|Serious - Use Alternative|fluvoxamine will increase the level or effect of dihydroergotamine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available. Never use combination.
fluvoxamine|dihydroergotamine|3|Significant - Monitor Closely|fluvoxamine and dihydroergotamine both increase  serotonin levels. Potential for dangerous interaction. Use with caution and monitor closely.
fosamprenavir|dihydroergotamine|33|Contraindicated|fosamprenavir will increase the level or effect of dihydroergotamine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Never use combination.
dihydroergotamine|frovatriptan|33|Contraindicated|dihydroergotamine, frovatriptan.Either increases toxicity of the other by pharmacodynamic synergism. Never use combination. Additive vasospasm.  Sep. by 24h.
frovatriptan|dihydroergotamine|2|Significant - Monitor Closely|frovatriptan and dihydroergotamine both increase  serotonin levels. Potential for interaction, monitor.
indinavir|dihydroergotamine|33|Contraindicated|indinavir will increase the level or effect of dihydroergotamine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Never use combination.
itraconazole|dihydroergotamine|33|Contraindicated|itraconazole will increase the level or effect of dihydroergotamine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Never use combination. Increased risk of ergotism leading to cerebral ischemia and/or ischemia of the extremities
ketoconazole|dihydroergotamine|33|Contraindicated|ketoconazole will increase the level or effect of dihydroergotamine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Never use combination.
dihydroergotamine|labetalol|1|Minor|dihydroergotamine, labetalol. Mechanism: pharmacodynamic synergism. Minor or non-significant interaction. Additive vasospasm.
dihydroergotamine|metoprolol|1|Minor|dihydroergotamine, metoprolol. Mechanism: pharmacodynamic synergism. Minor or non-significant interaction. Additive vasospasm.
dihydroergotamine|nadolol|1|Minor|dihydroergotamine, nadolol. Mechanism: pharmacodynamic synergism. Minor or non-significant interaction. Additive vasospasm.
dihydroergotamine|naratriptan|33|Contraindicated|dihydroergotamine, naratriptan.Either increases toxicity of the other by pharmacodynamic synergism. Never use combination. Additive vasospasm.  Sep. by 24h.
naratriptan|dihydroergotamine|2|Significant - Monitor Closely|naratriptan and dihydroergotamine both increase  serotonin levels. Potential for interaction, monitor.
nefazodone|dihydroergotamine|33|Contraindicated|nefazodone will increase the level or effect of dihydroergotamine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Never use combination.
nefazodone|dihydroergotamine|3|Significant - Monitor Closely|nefazodone and dihydroergotamine both increase  serotonin levels. Potential for dangerous interaction. Use with caution and monitor closely.
nelfinavir|dihydroergotamine|33|Contraindicated|nelfinavir will increase the level or effect of dihydroergotamine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Never use combination.
dihydroergotamine|penbutolol|1|Minor|dihydroergotamine, penbutolol. Mechanism: pharmacodynamic synergism. Minor or non-significant interaction. Additive vasospasm.
dihydroergotamine|pindolol|1|Minor|dihydroergotamine, pindolol. Mechanism: pharmacodynamic synergism. Minor or non-significant interaction. Additive vasospasm.
posaconazole|dihydroergotamine|33|Contraindicated|posaconazole will increase the level or effect of dihydroergotamine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Never use combination.
dihydroergotamine|propranolol|1|Minor|dihydroergotamine, propranolol. Mechanism: pharmacodynamic synergism. Minor or non-significant interaction. Additive vasospasm.
ritonavir|dihydroergotamine|33|Contraindicated|ritonavir will increase the level or effect of dihydroergotamine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Never use combination.
dihydroergotamine|rizatriptan|33|Contraindicated|dihydroergotamine, rizatriptan.Either increases toxicity of the other by pharmacodynamic synergism. Never use combination. Additive vasospasm.  Sep. by 24h.
rizatriptan|dihydroergotamine|2|Significant - Monitor Closely|rizatriptan and dihydroergotamine both increase  serotonin levels. Potential for interaction, monitor.
saquinavir|dihydroergotamine|33|Contraindicated|saquinavir increases levels of dihydroergotamine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Never use combination.
dihydroergotamine|sotalol|1|Minor|dihydroergotamine, sotalol. Mechanism: pharmacodynamic synergism. Minor or non-significant interaction. Additive vasospasm.
dihydroergotamine|sumatriptan|33|Contraindicated|dihydroergotamine, sumatriptan.Either increases toxicity of the other by pharmacodynamic synergism. Never use combination. Additive vasospasm.  Sep. by 24h.
sumatriptan|dihydroergotamine|2|Significant - Monitor Closely|sumatriptan and dihydroergotamine both increase  serotonin levels. Potential for interaction, monitor.
telaprevir|dihydroergotamine|33|Contraindicated|telaprevir increases levels of dihydroergotamine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Never use combination. Contraindicated. Potential for acute ergot toxicity characterized by peripheral vasospasm or ischemia.
telithromycin|dihydroergotamine|33|Contraindicated|telithromycin will increase the level or effect of dihydroergotamine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Never use combination.
dihydroergotamine|telithromycin|21|Serious - Use Alternative|dihydroergotamine, telithromycin. Mechanism: pharmacodynamic synergism. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available. Never use combination. Additive vasospasm.
dihydroergotamine|timolol|1|Minor|dihydroergotamine, timolol. Mechanism: pharmacodynamic synergism. Minor or non-significant interaction. Additive vasospasm.
tipranavir|dihydroergotamine|33|Contraindicated|tipranavir increases levels of dihydroergotamine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Never use combination.
dihydroergotamine|tramadol|2|Significant - Monitor Closely|dihydroergotamine and tramadol both increase  serotonin levels. Potential for interaction, monitor.
tranylcypromine|dihydroergotamine|22|Serious - Use Alternative|tranylcypromine and dihydroergotamine both increase  serotonin levels. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available.
trazodone|dihydroergotamine|3|Significant - Monitor Closely|trazodone and dihydroergotamine both increase  serotonin levels. Potential for dangerous interaction. Use with caution and monitor closely.
trimipramine|dihydroergotamine|3|Significant - Monitor Closely|trimipramine and dihydroergotamine both increase  serotonin levels. Potential for dangerous interaction. Use with caution and monitor closely.
troleandomycin|dihydroergotamine|21|Serious - Use Alternative|troleandomycin will increase the level or effect of dihydroergotamine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available. Never use combination.
venlafaxine|dihydroergotamine|3|Significant - Monitor Closely|venlafaxine and dihydroergotamine both increase  serotonin levels. Potential for dangerous interaction. Use with caution and monitor closely.
voriconazole|dihydroergotamine|33|Contraindicated|voriconazole will increase the level or effect of dihydroergotamine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Never use combination.
dihydroergotamine|zolmitriptan|33|Contraindicated|dihydroergotamine, zolmitriptan.Either increases toxicity of the other by pharmacodynamic synergism. Never use combination. Additive vasospasm.  Sep. by 24h.
zolmitriptan|dihydroergotamine|2|Significant - Monitor Closely|zolmitriptan and dihydroergotamine both increase  serotonin levels. Potential for interaction, monitor.
diltiazem|dronedarone|20|Serious - Use Alternative|diltiazem will increase the level or effect of dronedarone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
dronedarone|diltiazem|20|Serious - Use Alternative|dronedarone will increase the level or effect of diltiazem by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
diltiazem|eltrombopag|11|Significant - Monitor Closely|diltiazem will increase the level or effect of eltrombopag by  affecting hepatic enzyme CYP1A2 metabolism. Significant interaction possible, monitor closely.
diltiazem|lovastatin|20|Serious - Use Alternative|diltiazem will increase the level or effect of lovastatin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available. Do not exceed 20 mg/day of lovastatin
diltiazem|metoprolol|20|Serious - Use Alternative|diltiazem, metoprolol.Either increases toxicity of the other by unspecified interaction mechanism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available. Can increase risk of bradycardia.
metoprolol|diltiazem|3|Significant - Monitor Closely|metoprolol and diltiazem both increase  anti-hypertensive channel blocking. Potential for dangerous interaction. Use with caution and monitor closely.
diltiazem|midazolam|11|Significant - Monitor Closely|diltiazem will increase the level or effect of midazolam by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely. Midazolam dose adjustments may be necessary in patients receiving concomitant diltiazem and midazolam. Monitor for signs of midazolam toxicity (eg, sedation, somnolence, confusion, impaired coordination, diminished reflexes, coma).
pindolol|diltiazem|3|Significant - Monitor Closely|pindolol and diltiazem both increase  anti-hypertensive channel blocking. Potential for dangerous interaction. Use with caution and monitor closely.
diltiazem|propranolol|20|Serious - Use Alternative|diltiazem, propranolol.Either increases toxicity of the other by unspecified interaction mechanism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available. Can increase risk of bradycardia.
propranolol|diltiazem|3|Significant - Monitor Closely|propranolol and diltiazem both increase  anti-hypertensive channel blocking. Potential for dangerous interaction. Use with caution and monitor closely.
diltiazem|quinidine|11|Significant - Monitor Closely|diltiazem will increase the level or effect of quinidine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
quinidine|diltiazem|11|Significant - Monitor Closely|quinidine will increase the level or effect of diltiazem by  basic (cationic) drug competition for renal tubular clearance. Significant interaction possible, monitor closely.
diltiazem|ranolazine|11|Significant - Monitor Closely|diltiazem will increase the level or effect of ranolazine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely. Limit the dose of ranolazine to a maximum of 500 mg twice a day when used concomitantly with diltiazem.
diltiazem|ritonavir|11|Significant - Monitor Closely|diltiazem will increase the level or effect of ritonavir by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
ritonavir|diltiazem|11|Significant - Monitor Closely|ritonavir will increase the level or effect of diltiazem by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
diltiazem|ritonavir|11|Significant - Monitor Closely|diltiazem will increase the level or effect of ritonavir by  P-glycoprotein (MDR1) efflux transporter. Significant interaction possible, monitor closely.
diltiazem|saxagliptin|1|Minor|diltiazem will increase the level or effect of saxagliptin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor or non-significant interaction.
diltiazem|silodosin|20|Serious - Use Alternative|diltiazem will increase the level or effect of silodosin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
diltiazem|silodosin|11|Significant - Monitor Closely|diltiazem will increase the level or effect of silodosin by  P-glycoprotein (MDR1) efflux transporter. Significant interaction possible, monitor closely.
silodosin|diltiazem|2|Significant - Monitor Closely|silodosin and diltiazem both increase  anti-hypertensive channel blocking. Potential for interaction, monitor.
diltiazem|simvastatin|20|Serious - Use Alternative|diltiazem will increase the level or effect of simvastatin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available. Benefits of combination therapy should be carefully weighed against the potential risks of combination. Limit simvastatin dose to no more than 10 mg/day when used concurrently.
diltiazem|sirolimus|20|Serious - Use Alternative|diltiazem will increase the level or effect of sirolimus by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
diltiazem|sirolimus|11|Significant - Monitor Closely|diltiazem will increase the level or effect of sirolimus by  P-glycoprotein (MDR1) efflux transporter. Significant interaction possible, monitor closely.
diltiazem|tacrolimus|11|Significant - Monitor Closely|diltiazem will increase the level or effect of tacrolimus by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
diltiazem|tacrolimus|11|Significant - Monitor Closely|diltiazem will increase the level or effect of tacrolimus by  P-glycoprotein (MDR1) efflux transporter. Significant interaction possible, monitor closely.
diltiazem|tamsulosin|2|Significant - Monitor Closely|diltiazem increases levels of tamsulosin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Potential for interaction, monitor. Dose reduction may be needed for coadministered drugs that are predominantly metabolized by CYP3A.
telithromycin|diltiazem|11|Significant - Monitor Closely|telithromycin will increase the level or effect of diltiazem by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
diltiazem|telithromycin|1|Minor|diltiazem will increase the level or effect of telithromycin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor or non-significant interaction.
diltiazem|terfenadine|21|Serious - Use Alternative|diltiazem increases levels of terfenadine by decreasing metabolism. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available. Never use combination. Risk of QT interval prolongation.
diltiazem|terfenadine|20|Serious - Use Alternative|diltiazem will increase the level or effect of terfenadine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
diltiazem|timolol|20|Serious - Use Alternative|diltiazem, timolol.Either increases toxicity of the other by unspecified interaction mechanism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available. Can increase risk of bradycardia.
timolol|diltiazem|3|Significant - Monitor Closely|timolol and diltiazem both increase  anti-hypertensive channel blocking. Potential for dangerous interaction. Use with caution and monitor closely.
diltiazem|tipranavir|11|Significant - Monitor Closely|diltiazem will increase the level or effect of tipranavir by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
tipranavir|diltiazem|11|Significant - Monitor Closely|tipranavir, diltiazem. Other (see comment). Significant interaction possible, monitor closely. Comment: Diltiazem levels may incr or decr, due to contradictory effects of tipranavir on hepatic CYP3A4 and P glycoprotein.
diltiazem|tolterodine|11|Significant - Monitor Closely|diltiazem will increase the level or effect of tolterodine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
diltiazem|tolvaptan|20|Serious - Use Alternative|diltiazem will increase the level or effect of tolvaptan by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
diltiazem|tolvaptan|11|Significant - Monitor Closely|diltiazem will increase the level or effect of tolvaptan by  P-glycoprotein (MDR1) efflux transporter. Significant interaction possible, monitor closely.
diltiazem|trazodone|2|Significant - Monitor Closely|diltiazem will increase the level or effect of trazodone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Potential for interaction, monitor.
diltiazem|trazodone|1|Minor|diltiazem increases levels of trazodone by decreasing metabolism. Minor or non-significant interaction.
treprostinil|diltiazem|1|Minor|treprostinil increases effects of diltiazem by pharmacodynamic synergism. Minor or non-significant interaction.
diltiazem|triazolam|11|Significant - Monitor Closely|diltiazem will increase the level or effect of triazolam by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
voriconazole|diltiazem|11|Significant - Monitor Closely|voriconazole will increase the level or effect of diltiazem by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely. Combo may increase risk of hypotension, bradycardia, AV block.
voriconazole|diltiazem|11|Significant - Monitor Closely|voriconazole increases levels of diltiazem by decreasing metabolism. Significant interaction possible, monitor closely.
dimenhydrinate|triprolidine|2|Significant - Monitor Closely|dimenhydrinate and triprolidine both increase  sedation. Potential for interaction, monitor.
dinoprostone|oxytocin|11|Significant - Monitor Closely|dinoprostone increases effects of oxytocin by pharmacodynamic synergism. Significant interaction possible, monitor closely.
donepezil|diphenhydramine|2|Significant - Monitor Closely|donepezil increases and diphenhydramine decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Potential for interaction, monitor.
diphenhydramine|donepezil|1|Minor|diphenhydramine will increase the level or effect of donepezil by  affecting hepatic enzyme CYP2D6 metabolism. Minor or non-significant interaction.
donepezil|diphenhydramine|1|Minor|donepezil decreases effects of diphenhydramine by pharmacodynamic antagonism. Minor or non-significant interaction.
galantamine|diphenhydramine|2|Significant - Monitor Closely|galantamine increases and diphenhydramine decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Potential for interaction, monitor.
diphenhydramine|galantamine|1|Minor|diphenhydramine will increase the level or effect of galantamine by  affecting hepatic enzyme CYP2D6 metabolism. Minor or non-significant interaction.
galantamine|diphenhydramine|1|Minor|galantamine decreases effects of diphenhydramine by pharmacodynamic antagonism. Minor or non-significant interaction.
tacrine|diphenhydramine|2|Significant - Monitor Closely|tacrine increases and diphenhydramine decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Potential for interaction, monitor.
tacrine|diphenhydramine|1|Minor|tacrine decreases effects of diphenhydramine by pharmacodynamic antagonism. Minor or non-significant interaction.
diphenhydramine|tamoxifen|11|Significant - Monitor Closely|diphenhydramine decreases effects of tamoxifen by decreasing metabolism. Significant interaction possible, monitor closely. Inhibition of CYP2D6 metabolism to tamoxifen's active metabolite, endoxifen.
diphenhydramine|tamsulosin|2|Significant - Monitor Closely|diphenhydramine increases levels of tamsulosin by affecting hepatic enzyme CYP2D6 metabolism. Potential for interaction, monitor.
diphenhydramine|thioridazine|20|Serious - Use Alternative|diphenhydramine will increase the level or effect of thioridazine by  affecting hepatic enzyme CYP2D6 metabolism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
diphenhydramine|thioridazine|11|Significant - Monitor Closely|diphenhydramine decreases levels of thioridazine by inhibition of GI absorption. Applies only to oral form of both agents. Significant interaction possible, monitor closely.
diphenhydramine|thioridazine|11|Significant - Monitor Closely|diphenhydramine decreases levels of thioridazine by pharmacodynamic antagonism. Significant interaction possible, monitor closely.
thioridazine|diphenhydramine|11|Significant - Monitor Closely|thioridazine increases effects of diphenhydramine by pharmacodynamic synergism. Significant interaction possible, monitor closely. Additive anticholinergic effects, possible hypoglycemia.
diphenhydramine|thioridazine|2|Significant - Monitor Closely|diphenhydramine and thioridazine both increase  sedation. Potential for interaction, monitor.
diphenhydramine|tramadol|2|Significant - Monitor Closely|diphenhydramine decreases effects of tramadol by affecting hepatic enzyme CYP2D6 metabolism. Potential for interaction, monitor. Decreased conversion of tramadol to active metabolite.
diphenhydramine|tramadol|2|Significant - Monitor Closely|diphenhydramine and tramadol both increase  sedation. Potential for interaction, monitor.
diphenhydramine|tramadol|2|Significant - Monitor Closely|diphenhydramine decreases effects of tramadol by decreasing metabolism. Potential for interaction, monitor. Decreased conversion of tramadol to active metabolite.
diphenhydramine|triprolidine|2|Significant - Monitor Closely|diphenhydramine and triprolidine both increase  sedation. Potential for interaction, monitor.
ginkgo biloba|dipyridamole|1|Minor|ginkgo biloba, dipyridamole. pharmacodynamic synergism. Minor or non-significant interaction. May prolong bleeding time.  Conflicting evidence.Ã¿ Use with caution.
dipyridamole|regadenoson|21|Serious - Use Alternative|dipyridamole, regadenoson. Mechanism: unspecified interaction mechanism. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available. Never use combination. Regadenoson's effects may be changed; mfr. recommends avoiding dipyridamole for 2 days prior to administration.
dipyridamole|topotecan|22|Serious - Use Alternative|dipyridamole will increase the level or effect of topotecan by  P-glycoprotein (MDR1) efflux transporter. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available. Product labeling for PO topotecan recommends avoiding concomitant use of P-gp inhibitors; the interaction with IV topotecan may be less severe but is still likely of clinical significance
ethotoin|disopyramide|11|Significant - Monitor Closely|ethotoin increases toxicity of disopyramide by increasing metabolism. Significant interaction possible, monitor closely. Hydantoins decreases the level, but increases the toxicity, of disopyramide.
ethotoin|disopyramide|1|Minor|ethotoin will decrease the level or effect of disopyramide by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor or non-significant interaction.
etravirine|disopyramide|1|Minor|etravirine will decrease the level or effect of disopyramide by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor or non-significant interaction.
fingolimod|disopyramide|33|Contraindicated|fingolimod increases effects of disopyramide by pharmacodynamic synergism. Never use combination. Due to increased risk of bradycardia, AV block, and torsade de pointes, concomitant use is contraindicated.
fosphenytoin|disopyramide|11|Significant - Monitor Closely|fosphenytoin increases toxicity of disopyramide by increasing metabolism. Significant interaction possible, monitor closely. Hydantoins decreases the level, but increases the toxicity, of disopyramide.
fosphenytoin|disopyramide|1|Minor|fosphenytoin will decrease the level or effect of disopyramide by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor or non-significant interaction.
disopyramide|levofloxacin|22|Serious - Use Alternative|disopyramide and levofloxacin both increase  QTc interval. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available.
disopyramide|moxifloxacin|33|Contraindicated|disopyramide and moxifloxacin both increase  QTc interval. Never use combination.
phenobarbital|disopyramide|1|Minor|phenobarbital will decrease the level or effect of disopyramide by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor or non-significant interaction.
phenytoin|disopyramide|11|Significant - Monitor Closely|phenytoin will decrease the level or effect of disopyramide by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely. Phenytoin decreases the levels of disopyramide but can also increase the toxicity.
phenytoin|disopyramide|11|Significant - Monitor Closely|phenytoin increases toxicity of disopyramide by increasing metabolism. Significant interaction possible, monitor closely. Hydantoins decreases the level, but increases the toxicity, of disopyramide.
practolol|disopyramide|11|Significant - Monitor Closely|practolol increases effects of disopyramide by pharmacodynamic synergism. Significant interaction possible, monitor closely. Additive negative inotropic effects.
disopyramide|ranolazine|22|Serious - Use Alternative|disopyramide and ranolazine both increase  QTc interval. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available.
disopyramide|sotalol|33|Contraindicated|disopyramide and sotalol both increase  QTc interval. Never use combination.
disopyramide|telavancin|22|Serious - Use Alternative|disopyramide and telavancin both increase  QTc interval. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available.
disopyramide|telithromycin|22|Serious - Use Alternative|disopyramide and telithromycin both increase  QTc interval. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available.
telithromycin|disopyramide|1|Minor|telithromycin will increase the level or effect of disopyramide by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor or non-significant interaction.
disopyramide|terfenadine|33|Contraindicated|disopyramide and terfenadine both increase  QTc interval. Never use combination.
thioridazine|disopyramide|33|Contraindicated|thioridazine and disopyramide both increase  QTc interval. Never use combination.
disopyramide|toremifene|20|Serious - Use Alternative|disopyramide and toremifene both increase  QTc interval. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available. Concurrent use of toremifene with agents causing  QT prolongation should be avoided. If concomitant use is required it's recommended that toremifene be interrupted. If interruption not possible, patients requiring therapy with a drug that prolongs QT should be closely monitored. ECGs should be obtained for high risk patients.
trimipramine|disopyramide|33|Contraindicated|trimipramine and disopyramide both increase  QTc interval. Never use combination.
disopyramide|voriconazole|22|Serious - Use Alternative|disopyramide and voriconazole both increase  QTc interval. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available.
voriconazole|disopyramide|1|Minor|voriconazole will increase the level or effect of disopyramide by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor or non-significant interaction.
disopyramide|ziprasidone|33|Contraindicated|disopyramide and ziprasidone both increase  QTc interval. Never use combination.
disulfiram|ethotoin|11|Significant - Monitor Closely|disulfiram will increase the level or effect of ethotoin by  affecting hepatic enzyme CYP2C9/10 metabolism. Significant interaction possible, monitor closely.
disulfiram|ethotoin|1|Minor|disulfiram increases levels of ethotoin by decreasing metabolism. Minor or non-significant interaction.
disulfiram|fosphenytoin|11|Significant - Monitor Closely|disulfiram will increase the level or effect of fosphenytoin by  affecting hepatic enzyme CYP2C9/10 metabolism. Significant interaction possible, monitor closely.
disulfiram|fosphenytoin|1|Minor|disulfiram increases levels of fosphenytoin by decreasing metabolism. Minor or non-significant interaction.
disulfiram|isoniazid|11|Significant - Monitor Closely|disulfiram will increase the level or effect of isoniazid by  affecting hepatic enzyme CYP2E1 metabolism. Significant interaction possible, monitor closely.
isoniazid|disulfiram|11|Significant - Monitor Closely|isoniazid increases toxicity of disulfiram by decreasing metabolism. Significant interaction possible, monitor closely. Enhanced CNS toxicity.
disulfiram|metronidazole|21|Serious - Use Alternative|disulfiram increases toxicity of metronidazole by decreasing metabolism. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available. Never use combination. Enhanced CNS & cardiac toxicity.
disulfiram|phenytoin|11|Significant - Monitor Closely|disulfiram will increase the level or effect of phenytoin by  affecting hepatic enzyme CYP2C9/10 metabolism. Significant interaction possible, monitor closely.
disulfiram|phenytoin|1|Minor|disulfiram increases levels of phenytoin by decreasing metabolism. Minor or non-significant interaction.
disulfiram|theophylline|1|Minor|disulfiram increases levels of theophylline by decreasing metabolism. Minor or non-significant interaction.
disulfiram|tipranavir|22|Serious - Use Alternative|disulfiram, tipranavir. Mechanism: decreasing metabolism. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available. Risk of disulfiram reaction (tipranavir capsules contain alcohol).
disulfiram|warfarin|11|Significant - Monitor Closely|disulfiram will increase the level or effect of warfarin by  affecting hepatic enzyme CYP2C9/10 metabolism. Significant interaction possible, monitor closely.
disulfiram|warfarin|11|Significant - Monitor Closely|disulfiram increases effects of warfarin by unspecified interaction mechanism. Significant interaction possible, monitor closely.
doxepin|dobutamine|20|Serious - Use Alternative|doxepin, dobutamine. Other (see comment). Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available. Comment: Tricyclic antidepressants increase or decrease effects of sympathomimetics, by blocking reuptake of NE, or blocking uptake of indirect sympathomimetics into the adrenergic neuron.
doxepin|dobutamine|2|Significant - Monitor Closely|doxepin increases and dobutamine decreases sedation. Effect of interaction is not clear, use caution. Potential for interaction, monitor.
entacapone|dobutamine|11|Significant - Monitor Closely|entacapone increases effects of dobutamine by pharmacodynamic synergism. Significant interaction possible, monitor closely.
imipramine|dobutamine|20|Serious - Use Alternative|imipramine, dobutamine. Other (see comment). Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available. Comment: Tricyclic antidepressants increase or decrease effects of sympathomimetics, by blocking reuptake of NE, or blocking uptake of indirect sympathomimetics into the adrenergic neuron.
imipramine|dobutamine|2|Significant - Monitor Closely|imipramine increases and dobutamine decreases sedation. Effect of interaction is not clear, use caution. Potential for interaction, monitor.
isocarboxazid|dobutamine|33|Contraindicated|isocarboxazid increases effects of dobutamine by pharmacodynamic synergism. Never use combination. Risk of acute hypertensive episode.
linezolid|dobutamine|33|Contraindicated|linezolid increases effects of dobutamine by pharmacodynamic synergism. Never use combination. Risk of acute hypertensive episode.
methyldopa|dobutamine|11|Significant - Monitor Closely|methyldopa increases effects of dobutamine by unknown mechanism. Significant interaction possible, monitor closely.
dobutamine|midodrine|2|Significant - Monitor Closely|dobutamine and midodrine both decrease  sedation. Potential for interaction, monitor.
dobutamine|midodrine|2|Significant - Monitor Closely|dobutamine and midodrine both increase  sympathetic (adrenergic) effects, including increased blood pressure and heart rate. Potential for interaction, monitor.
nortriptyline|dobutamine|20|Serious - Use Alternative|nortriptyline, dobutamine. Other (see comment). Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available. Comment: Tricyclic antidepressants increase or decrease effects of sympathomimetics, by blocking reuptake of NE, or blocking uptake of indirect sympathomimetics into the adrenergic neuron.
nortriptyline|dobutamine|2|Significant - Monitor Closely|nortriptyline increases and dobutamine decreases sedation. Effect of interaction is not clear, use caution. Potential for interaction, monitor.
phenelzine|dobutamine|33|Contraindicated|phenelzine increases effects of dobutamine by pharmacodynamic synergism. Never use combination. Risk of acute hypertensive episode.
rasagiline|dobutamine|11|Significant - Monitor Closely|rasagiline increases effects of dobutamine by pharmacodynamic synergism. Significant interaction possible, monitor closely. Risk of acute hypertensive episode.
ketoconazole|docetaxel|11|Significant - Monitor Closely|ketoconazole will increase the level or effect of docetaxel by  P-glycoprotein (MDR1) efflux transporter. Significant interaction possible, monitor closely.
ketoconazole|docetaxel|2|Significant - Monitor Closely|ketoconazole will increase the level or effect of docetaxel by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Potential for interaction, monitor.
telithromycin|docetaxel|1|Minor|telithromycin will increase the level or effect of docetaxel by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor or non-significant interaction.
voriconazole|docetaxel|1|Minor|voriconazole will increase the level or effect of docetaxel by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor or non-significant interaction.
fingolimod|dofetilide|33|Contraindicated|fingolimod increases effects of dofetilide by pharmacodynamic synergism. Never use combination. Due to increased risk of bradycardia, AV block, and torsade de pointes, concomitant use is contraindicated.
hydrochlorothiazide|dofetilide|21|Serious - Use Alternative|hydrochlorothiazide increases levels of dofetilide by decreasing renal clearance. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available. Never use combination. Risk of prolonged QTc interval.
dofetilide|hydrochlorothiazide|11|Significant - Monitor Closely|dofetilide will increase the level or effect of hydrochlorothiazide by  basic (cationic) drug competition for renal tubular clearance. Significant interaction possible, monitor closely.
dofetilide|indapamide|33|Contraindicated|dofetilide and indapamide both increase  QTc interval. Never use combination.
dofetilide|itraconazole|33|Contraindicated|dofetilide and itraconazole both increase  QTc interval. Never use combination.
itraconazole|dofetilide|33|Contraindicated|itraconazole will increase the level or effect of dofetilide by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Never use combination. Both drugs will increase QT interval
dofetilide|ketoconazole|22|Serious - Use Alternative|dofetilide and ketoconazole both increase  QTc interval. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available.
dofetilide|ranolazine|3|Significant - Monitor Closely|dofetilide and ranolazine both increase  QTc interval. Potential for dangerous interaction. Use with caution and monitor closely.
dofetilide|telithromycin|3|Significant - Monitor Closely|dofetilide and telithromycin both increase  QTc interval. Potential for dangerous interaction. Use with caution and monitor closely.
thioridazine|dofetilide|22|Serious - Use Alternative|thioridazine and dofetilide both increase  QTc interval. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available.
dofetilide|toremifene|20|Serious - Use Alternative|dofetilide and toremifene both increase  QTc interval. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available. Concurrent use of toremifene with agents causing  QT prolongation should be avoided. If concomitant use is required it's recommended that toremifene be interrupted. If interruption not possible, patients requiring therapy with a drug that prolongs QT should be closely monitored. ECGs should be obtained for high risk patients.
dofetilide|trimethoprim|11|Significant - Monitor Closely|dofetilide will increase the level or effect of trimethoprim by  basic (cationic) drug competition for renal tubular clearance. Significant interaction possible, monitor closely.
dofetilide|trimethoprim|3|Significant - Monitor Closely|dofetilide and trimethoprim both increase  QTc interval. Potential for dangerous interaction. Use with caution and monitor closely.
trimipramine|dofetilide|22|Serious - Use Alternative|trimipramine and dofetilide both increase  QTc interval. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available.
dofetilide|verapamil|11|Significant - Monitor Closely|dofetilide will increase the level or effect of verapamil by  basic (cationic) drug competition for renal tubular clearance. Significant interaction possible, monitor closely.
dofetilide|voriconazole|3|Significant - Monitor Closely|dofetilide and voriconazole both increase  QTc interval. Potential for dangerous interaction. Use with caution and monitor closely.
dofetilide|ziprasidone|22|Serious - Use Alternative|dofetilide and ziprasidone both increase  QTc interval. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available.
dolasetron|toremifene|20|Serious - Use Alternative|dolasetron and toremifene both increase  QTc interval. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available. Concurrent use of toremifene with agents causing  QT prolongation should be avoided. If concomitant use is required it's recommended that toremifene be interrupted. If interruption not possible, patients requiring therapy with a drug that prolongs QT should be closely monitored. ECGs should be obtained for high risk patients.
dolasetron|trimipramine|20|Serious - Use Alternative|dolasetron, trimipramine.Either increases toxicity of the other by serotonin levels. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
trimipramine|dolasetron|3|Significant - Monitor Closely|trimipramine and dolasetron both increase  QTc interval. Potential for dangerous interaction. Use with caution and monitor closely.
dolasetron|voriconazole|2|Significant - Monitor Closely|dolasetron and voriconazole both increase  QTc interval. Potential for interaction, monitor.
dolasetron|ziprasidone|3|Significant - Monitor Closely|dolasetron and ziprasidone both increase  QTc interval. Potential for dangerous interaction. Use with caution and monitor closely.
donepezil|doxepin|11|Significant - Monitor Closely|donepezil increases and doxepin decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Significant interaction possible, monitor closely.
donepezil|flavoxate|2|Significant - Monitor Closely|donepezil increases and flavoxate decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Potential for interaction, monitor.
donepezil|flavoxate|1|Minor|donepezil decreases effects of flavoxate by pharmacodynamic antagonism. Minor or non-significant interaction.
donepezil|glycopyrrolate|2|Significant - Monitor Closely|donepezil increases and glycopyrrolate decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Potential for interaction, monitor.
donepezil|glycopyrrolate|1|Minor|donepezil decreases effects of glycopyrrolate by pharmacodynamic antagonism. Minor or non-significant interaction.
donepezil|hyoscyamine|2|Significant - Monitor Closely|donepezil increases and hyoscyamine decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Potential for interaction, monitor.
donepezil|hyoscyamine|1|Minor|donepezil decreases effects of hyoscyamine by pharmacodynamic antagonism. Minor or non-significant interaction.
donepezil|imipramine|2|Significant - Monitor Closely|donepezil increases and imipramine decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Potential for interaction, monitor.
donepezil|maprotiline|2|Significant - Monitor Closely|donepezil increases and maprotiline decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Potential for interaction, monitor.
donepezil|meclizine|2|Significant - Monitor Closely|donepezil increases and meclizine decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Potential for interaction, monitor.
donepezil|meclizine|1|Minor|donepezil decreases effects of meclizine by pharmacodynamic antagonism. Minor or non-significant interaction.
donepezil|nortriptyline|2|Significant - Monitor Closely|donepezil increases and nortriptyline decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Potential for interaction, monitor.
donepezil|orphenadrine|2|Significant - Monitor Closely|donepezil increases and orphenadrine decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Potential for interaction, monitor.
donepezil|oxybutynin|2|Significant - Monitor Closely|donepezil increases and oxybutynin decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Potential for interaction, monitor.
donepezil|oxybutynin|1|Minor|donepezil decreases effects of oxybutynin by pharmacodynamic antagonism. Minor or non-significant interaction.
perphenazine|donepezil|1|Minor|perphenazine will increase the level or effect of donepezil by  affecting hepatic enzyme CYP2D6 metabolism. Minor or non-significant interaction.
ziprasidone|bromocriptine|20|Serious - Use Alternative|ziprasidone decreases effects of bromocriptine by pharmacodynamic antagonism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
bromocriptine|zolmitriptan|33|Contraindicated|bromocriptine, zolmitriptan.Either increases toxicity of the other by pharmacodynamic synergism. Never use combination. Vasoconstrictive effects of triptans and bromocriptine may be additive. Drugs should not be used within 24h of one another.
brompheniramine|triprolidine|2|Significant - Monitor Closely|brompheniramine and triprolidine both increase  sedation. Potential for interaction, monitor.
clotrimazole|budesonide|11|Significant - Monitor Closely|clotrimazole will decrease the level or effect of budesonide by  P-glycoprotein (MDR1) efflux transporter. Significant interaction possible, monitor closely.
conivaptan|budesonide|11|Significant - Monitor Closely|conivaptan will increase the level or effect of budesonide by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
budesonide|conivaptan|11|Significant - Monitor Closely|budesonide will decrease the level or effect of conivaptan by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
itraconazole|budesonide|20|Serious - Use Alternative|itraconazole will increase the level or effect of budesonide by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
itraconazole|budesonide|11|Significant - Monitor Closely|itraconazole will increase the level or effect of budesonide by  P-glycoprotein (MDR1) efflux transporter. Significant interaction possible, monitor closely.
itraconazole|budesonide|11|Significant - Monitor Closely|itraconazole increases effects of budesonide by decreasing metabolism. Significant interaction possible, monitor closely.
budesonide|itraconazole|1|Minor|budesonide will decrease the level or effect of itraconazole by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor or non-significant interaction.
ketoconazole|budesonide|20|Serious - Use Alternative|ketoconazole will increase the level or effect of budesonide by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
ketoconazole|budesonide|11|Significant - Monitor Closely|ketoconazole will increase the level or effect of budesonide by  P-glycoprotein (MDR1) efflux transporter. Significant interaction possible, monitor closely.
ketoconazole|budesonide|11|Significant - Monitor Closely|ketoconazole increases effects of budesonide by decreasing metabolism. Significant interaction possible, monitor closely.
budesonide|ketoconazole|1|Minor|budesonide will decrease the level or effect of ketoconazole by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor or non-significant interaction.
telithromycin|budesonide|11|Significant - Monitor Closely|telithromycin will increase the level or effect of budesonide by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
budesonide|telithromycin|1|Minor|budesonide will decrease the level or effect of telithromycin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor or non-significant interaction.
budesonide|tipranavir|11|Significant - Monitor Closely|budesonide will decrease the level or effect of tipranavir by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
voriconazole|budesonide|11|Significant - Monitor Closely|voriconazole will increase the level or effect of budesonide by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
bumetanide|cisplatin|11|Significant - Monitor Closely|bumetanide, cisplatin.Either increases toxicity of the other by pharmacodynamic synergism. Significant interaction possible, monitor closely. Additive ototoxicity.
bumetanide|digoxin|11|Significant - Monitor Closely|bumetanide increases effects of digoxin by pharmacodynamic synergism. Significant interaction possible, monitor closely. Hypokalemia increases digoxin effects.
digoxin|bumetanide|2|Significant - Monitor Closely|digoxin increases and bumetanide decreases serum potassium. Effect of interaction is not clear, use caution. Potential for interaction, monitor.
bumetanide|gentamicin|20|Serious - Use Alternative|bumetanide, gentamicin.Either increases toxicity of the other by Mechanism: pharmacodynamic synergism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available. Increased risk of ototoxicity and nephrotoxicity.
bumetanide|gentamicin|2|Significant - Monitor Closely|bumetanide and gentamicin both decrease  serum potassium. Potential for interaction, monitor.
ibuprofen|bumetanide|11|Significant - Monitor Closely|ibuprofen decreases effects of bumetanide by pharmacodynamic antagonism. Significant interaction possible, monitor closely. NSAIDs decrease prostaglandin synthesis.
ibuprofen|bumetanide|2|Significant - Monitor Closely|ibuprofen increases and bumetanide decreases serum potassium. Effect of interaction is not clear, use caution. Potential for interaction, monitor.
indomethacin|bumetanide|11|Significant - Monitor Closely|indomethacin decreases effects of bumetanide by pharmacodynamic antagonism. Significant interaction possible, monitor closely. NSAIDs decrease prostaglandin synthesis.
indomethacin|bumetanide|2|Significant - Monitor Closely|indomethacin increases and bumetanide decreases serum potassium. Effect of interaction is not clear, use caution. Potential for interaction, monitor.
bumetanide|kanamycin|20|Serious - Use Alternative|bumetanide, kanamycin.Either increases toxicity of the other by Mechanism: pharmacodynamic synergism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available. Increased risk of ototoxicity and nephrotoxicity.
bumetanide|netilmicin|20|Serious - Use Alternative|bumetanide, netilmicin.Either increases toxicity of the other by Mechanism: pharmacodynamic synergism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available. Increased risk of ototoxicity and nephrotoxicity.
bumetanide|streptomycin|20|Serious - Use Alternative|bumetanide, streptomycin.Either increases toxicity of the other by Mechanism: pharmacodynamic synergism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available. Increased risk of ototoxicity and nephrotoxicity.
sulindac|bumetanide|11|Significant - Monitor Closely|sulindac decreases effects of bumetanide by pharmacodynamic antagonism. Significant interaction possible, monitor closely. NSAIDs decrease prostaglandin synthesis.
sulindac|bumetanide|2|Significant - Monitor Closely|sulindac increases and bumetanide decreases serum potassium. Effect of interaction is not clear, use caution. Potential for interaction, monitor.
bumetanide|tobramycin|20|Serious - Use Alternative|bumetanide, tobramycin.Either increases toxicity of the other by Mechanism: pharmacodynamic synergism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available. Increased risk of ototoxicity and nephrotoxicity.
trandolapril|bumetanide|11|Significant - Monitor Closely|trandolapril, bumetanide. Mechanism: pharmacodynamic synergism. Significant interaction possible, monitor closely. Risk of acute hypotension, renal insufficiency.
treprostinil|bumetanide|1|Minor|treprostinil increases effects of bumetanide by pharmacodynamic synergism. Minor or non-significant interaction.
buprenorphine|droperidol|2|Significant - Monitor Closely|buprenorphine and droperidol both increase  sedation. Potential for interaction, monitor.
etravirine|buprenorphine|11|Significant - Monitor Closely|etravirine will decrease the level or effect of buprenorphine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely. Etravirine induces CYP3A4; no dosage adjustment required initially, monitor closely for withdrawal symptoms if etravirine added to buprenorphine therapy; conversely, may need to decrease buprenorphine if etravirine discontinued
isocarboxazid|buprenorphine|20|Serious - Use Alternative|isocarboxazid increases toxicity of buprenorphine by unknown mechanism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available. Risk of hypotension, hyperpyrexia, somnolence, or death; separate by 14 d.
linezolid|buprenorphine|20|Serious - Use Alternative|linezolid increases toxicity of buprenorphine by unknown mechanism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available. Risk of hypotension, hyperpyrexia, somnolence, or death; separate by 14 d.
phenelzine|buprenorphine|20|Serious - Use Alternative|phenelzine increases toxicity of buprenorphine by unknown mechanism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available. Risk of hypotension, hyperpyrexia, somnolence, or death; separate by 14 d.
procarbazine|buprenorphine|20|Serious - Use Alternative|procarbazine increases toxicity of buprenorphine by unknown mechanism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available. Do not use within 14 days of MAOI use. .
selegiline|buprenorphine|20|Serious - Use Alternative|selegiline increases toxicity of buprenorphine by unknown mechanism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available. Buprenorphine transdermal is not recommended for in patients who have received MAOI within 14 days, because severe and unpredictable potentiation by MAO inhibitors has been reported with opioid analgesics.
tranylcypromine|buprenorphine|20|Serious - Use Alternative|tranylcypromine increases toxicity of buprenorphine by unknown mechanism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available. Risk of hypotension, hyperpyrexia, somnolence, or death; separate by 14 d.
triprolidine|buprenorphine|2|Significant - Monitor Closely|triprolidine and buprenorphine both increase  sedation. Potential for interaction, monitor.
carbamazepine|bupropion|1|Minor|carbamazepine decreases levels of bupropion by increasing metabolism. Minor or non-significant interaction.
cyclosporine|bupropion|11|Significant - Monitor Closely|cyclosporine increases toxicity of bupropion by unspecified interaction mechanism. Significant interaction possible, monitor closely. May lower seizure threshold; keep bupropion dose as low as possible.
bupropion|cyclosporine|1|Minor|bupropion decreases levels of cyclosporine by unknown mechanism. Minor or non-significant interaction. Case report only.
isocarboxazid|bupropion|33|Contraindicated|isocarboxazid and bupropion both increase  dopaminergic effects. Never use combination. Bupropion inhibits reuptake of dopamine and norepinephrine (NE), and MAOIs decrease metabolism of dopamine and NE; coadministration increases risk for hypertensive reactions; allow at least 14 days between discontinuation of MAOI and initiating bupropion
phenelzine|bupropion|33|Contraindicated|phenelzine and bupropion both increase  dopaminergic effects. Never use combination. Bupropion inhibits reuptake of dopamine and norepinephrine (NE), and MAOIs decrease metabolism of dopamine and NE; coadministration increases risk for hypertensive reactions; allow at least 14 days between discontinuation of MAOI and initiating bupropion
rasagiline|bupropion|33|Contraindicated|rasagiline and bupropion both increase  dopaminergic effects. Never use combination. Bupropion inhibits reuptake of dopamine and norepinephrine (NE), and MAOIs decrease metabolism of dopamine and NE; coadministration increases risk for hypertensive reactions; allow at least 14 days between discontinuation of MAOI and initiating bupropion
ritonavir|bupropion|11|Significant - Monitor Closely|ritonavir decreases levels of bupropion by affecting hepatic enzyme CYP2B6 metabolism. Significant interaction possible, monitor closely. Ritonavir decreases levels of bupropion by inducing CYP2B6. Bupropion levels decreased by 20-80%, increased doses of bupropion may be required .
bupropion|thioridazine|20|Serious - Use Alternative|bupropion will increase the level or effect of thioridazine by  affecting hepatic enzyme CYP2D6 metabolism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
thioridazine|bupropion|1|Minor|thioridazine increases toxicity of bupropion by unspecified interaction mechanism. Minor or non-significant interaction. May lower seizure threshold; keep bupropion dose as low as possible.
tranylcypromine|bupropion|33|Contraindicated|tranylcypromine and bupropion both increase  dopaminergic effects. Never use combination. Bupropion inhibits reuptake of dopamine and norepinephrine (NE), and MAOIs decrease metabolism of dopamine and NE; coadministration increases risk for hypertensive reactions; allow at least 14 days between discontinuation of MAOI and initiating bupropion
clarithromycin|buspirone|20|Serious - Use Alternative|clarithromycin will increase the level or effect of buspirone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
buspirone|desvenlafaxine|20|Serious - Use Alternative|buspirone and desvenlafaxine both increase  serotonin levels. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
diltiazem|buspirone|11|Significant - Monitor Closely|diltiazem will increase the level or effect of buspirone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
isocarboxazid|buspirone|33|Contraindicated|isocarboxazid and buspirone both increase  serotonin levels. Never use combination.
isocarboxazid|buspirone|33|Contraindicated|isocarboxazid, buspirone. Mechanism: pharmacodynamic synergism. Never use combination. Risk of acute hypertensive episode.
nefazodone|buspirone|22|Serious - Use Alternative|nefazodone and buspirone both increase  serotonin levels. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available.
nefazodone|buspirone|3|Significant - Monitor Closely|nefazodone will increase the level or effect of buspirone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Potential for dangerous interaction. Use with caution and monitor closely.
phenelzine|buspirone|33|Contraindicated|phenelzine and buspirone both increase  serotonin levels. Never use combination.
phenelzine|buspirone|33|Contraindicated|phenelzine, buspirone. Mechanism: pharmacodynamic synergism. Never use combination. Risk of acute hypertensive episode.
rasagiline|buspirone|20|Serious - Use Alternative|rasagiline, buspirone. Mechanism: pharmacodynamic synergism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available. Risk of acute hypertensive episode. Avoid combination within 14 days of MAOI use.
rifabutin|buspirone|20|Serious - Use Alternative|rifabutin will decrease the level or effect of buspirone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
ritonavir|buspirone|11|Significant - Monitor Closely|ritonavir will increase the level or effect of buspirone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
telithromycin|buspirone|11|Significant - Monitor Closely|telithromycin will increase the level or effect of buspirone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
tranylcypromine|buspirone|33|Contraindicated|tranylcypromine and buspirone both increase  serotonin levels. Never use combination.
tranylcypromine|buspirone|33|Contraindicated|tranylcypromine, buspirone. Mechanism: pharmacodynamic synergism. Never use combination. Risk of acute hypertensive episode.
trazodone|buspirone|22|Serious - Use Alternative|trazodone and buspirone both increase  serotonin levels. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available.
trimipramine|buspirone|22|Serious - Use Alternative|trimipramine and buspirone both increase  serotonin levels. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available.
venlafaxine|buspirone|22|Serious - Use Alternative|venlafaxine and buspirone both increase  serotonin levels. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available.
verapamil|buspirone|11|Significant - Monitor Closely|verapamil will increase the level or effect of buspirone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely. Consider lower buspirone doses.
voriconazole|buspirone|11|Significant - Monitor Closely|voriconazole will increase the level or effect of buspirone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
zolmitriptan|buspirone|3|Significant - Monitor Closely|zolmitriptan and buspirone both increase  serotonin levels. Potential for dangerous interaction. Use with caution and monitor closely.
itraconazole|busulfan|2|Significant - Monitor Closely|itraconazole increases levels of busulfan by decreasing hepatic clearance. Potential for interaction, monitor.
butabarbital|clomipramine|11|Significant - Monitor Closely|butabarbital will decrease the level or effect of clomipramine by  affecting hepatic enzyme CYP1A2 metabolism. Significant interaction possible, monitor closely.
butabarbital|clomipramine|3|Significant - Monitor Closely|butabarbital will decrease the level or effect of clomipramine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Potential for dangerous interaction. Use with caution and monitor closely.
butabarbital|clomipramine|2|Significant - Monitor Closely|butabarbital and clomipramine both increase  sedation. Potential for interaction, monitor.
butabarbital|clomipramine|1|Minor|butabarbital, clomipramine. Other (see comment). Minor or non-significant interaction. Comment: Barbiturates may increase adverse effects, including respiratory depression, produced by toxic doses of TCAs. With therapeutic doses of TCAs, barbiturates increase metabolism and decrease blood concentrations of TCAs.
butabarbital|conjugated estrogens|11|Significant - Monitor Closely|butabarbital will decrease the level or effect of conjugated estrogens by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
butabarbital|cyclosporine|20|Serious - Use Alternative|butabarbital decreases levels of cyclosporine by increasing metabolism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
butabarbital|cyclosporine|11|Significant - Monitor Closely|butabarbital will decrease the level or effect of cyclosporine by  affecting hepatic enzyme CYP1A2 metabolism. Significant interaction possible, monitor closely.
butabarbital|cyclosporine|11|Significant - Monitor Closely|butabarbital will decrease the level or effect of cyclosporine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
butabarbital|desipramine|3|Significant - Monitor Closely|butabarbital will decrease the level or effect of desipramine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Potential for dangerous interaction. Use with caution and monitor closely.
butabarbital|desipramine|2|Significant - Monitor Closely|butabarbital and desipramine both increase  sedation. Potential for interaction, monitor.
butabarbital|desipramine|1|Minor|butabarbital, desipramine. Other (see comment). Minor or non-significant interaction. Comment: Barbiturates may increase adverse effects, including respiratory depression, produced by toxic doses of TCAs. With therapeutic doses of TCAs, barbiturates increase metabolism and decrease blood concentrations of TCAs.
butabarbital|dexamethasone|11|Significant - Monitor Closely|butabarbital will decrease the level or effect of dexamethasone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
butabarbital|disopyramide|1|Minor|butabarbital will decrease the level or effect of disopyramide by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor or non-significant interaction.
butabarbital|doxepin|2|Significant - Monitor Closely|butabarbital and doxepin both increase  sedation. Potential for interaction, monitor.
butabarbital|doxepin|1|Minor|butabarbital, doxepin. Other (see comment). Minor or non-significant interaction. Comment: Barbiturates may increase adverse effects, including respiratory depression, produced by toxic doses of TCAs. With therapeutic doses of TCAs, barbiturates increase metabolism and decrease blood concentrations of TCAs.
butabarbital|doxycycline|11|Significant - Monitor Closely|butabarbital decreases levels of doxycycline by increasing metabolism. Significant interaction possible, monitor closely.
butabarbital|droperidol|2|Significant - Monitor Closely|butabarbital and droperidol both increase  sedation. Potential for interaction, monitor.
butabarbital|eltrombopag|11|Significant - Monitor Closely|butabarbital will decrease the level or effect of eltrombopag by  affecting hepatic enzyme CYP1A2 metabolism. Significant interaction possible, monitor closely.
butabarbital|eltrombopag|11|Significant - Monitor Closely|butabarbital will decrease the level or effect of eltrombopag by  affecting hepatic enzyme CYP2C9/10 metabolism. Significant interaction possible, monitor closely.
butabarbital|estradiol|11|Significant - Monitor Closely|butabarbital will decrease the level or effect of estradiol by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
butabarbital|felodipine|11|Significant - Monitor Closely|butabarbital will decrease the level or effect of felodipine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
butabarbital|fludrocortisone|11|Significant - Monitor Closely|butabarbital will decrease the level or effect of fludrocortisone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
butabarbital|griseofulvin|1|Minor|butabarbital decreases levels of griseofulvin by inhibition of GI absorption. Applies only to oral form of both agents. Minor or non-significant interaction.
butabarbital|hydrocortisone|11|Significant - Monitor Closely|butabarbital will decrease the level or effect of hydrocortisone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
hydroxyzine|butabarbital|2|Significant - Monitor Closely|hydroxyzine and butabarbital both increase  sedation. Potential for interaction, monitor.
butabarbital|imipramine|11|Significant - Monitor Closely|butabarbital will decrease the level or effect of imipramine by  affecting hepatic enzyme CYP1A2 metabolism. Significant interaction possible, monitor closely.
butabarbital|imipramine|11|Significant - Monitor Closely|butabarbital will decrease the level or effect of imipramine by  affecting hepatic enzyme CYP2C19 metabolism. Significant interaction possible, monitor closely.
butabarbital|imipramine|3|Significant - Monitor Closely|butabarbital will decrease the level or effect of imipramine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Potential for dangerous interaction. Use with caution and monitor closely.
butabarbital|imipramine|2|Significant - Monitor Closely|butabarbital and imipramine both increase  sedation. Potential for interaction, monitor.
butabarbital|imipramine|1|Minor|butabarbital, imipramine. Other (see comment). Minor or non-significant interaction. Comment: Barbiturates may increase adverse effects, including respiratory depression, produced by toxic doses of TCAs. With therapeutic doses of TCAs, barbiturates increase metabolism and decrease blood concentrations of TCAs.
butabarbital|methadone|11|Significant - Monitor Closely|butabarbital will decrease the level or effect of methadone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
butabarbital|methadone|2|Significant - Monitor Closely|butabarbital and methadone both increase  sedation. Potential for interaction, monitor.
butabarbital|nifedipine|1|Minor|butabarbital will decrease the level or effect of nifedipine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor or non-significant interaction.
butabarbital|nortriptyline|2|Significant - Monitor Closely|butabarbital and nortriptyline both increase  sedation. Potential for interaction, monitor.
butabarbital|nortriptyline|1|Minor|butabarbital, nortriptyline. Other (see comment). Minor or non-significant interaction. Comment: Barbiturates may increase adverse effects, including respiratory depression, produced by toxic doses of TCAs. With therapeutic doses of TCAs, barbiturates increase metabolism and decrease blood concentrations of TCAs.
butabarbital|prednisolone|11|Significant - Monitor Closely|butabarbital will decrease the level or effect of prednisolone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
butabarbital|prednisone|11|Significant - Monitor Closely|butabarbital will decrease the level or effect of prednisone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
butabarbital|protriptyline|2|Significant - Monitor Closely|butabarbital and protriptyline both increase  sedation. Potential for interaction, monitor.
butabarbital|protriptyline|1|Minor|butabarbital, protriptyline. Other (see comment). Minor or non-significant interaction. Comment: Barbiturates may increase adverse effects, including respiratory depression, produced by toxic doses of TCAs. With therapeutic doses of TCAs, barbiturates increase metabolism and decrease blood concentrations of TCAs.
butabarbital|quinidine|11|Significant - Monitor Closely|butabarbital will decrease the level or effect of quinidine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
butabarbital|theophylline|11|Significant - Monitor Closely|butabarbital will decrease the level or effect of theophylline by  affecting hepatic enzyme CYP1A2 metabolism. Significant interaction possible, monitor closely.
butabarbital|theophylline|11|Significant - Monitor Closely|butabarbital will decrease the level or effect of theophylline by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
butabarbital|triamcinolone|11|Significant - Monitor Closely|butabarbital will decrease the level or effect of triamcinolone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
butabarbital|trimipramine|2|Significant - Monitor Closely|butabarbital and trimipramine both increase  sedation. Potential for interaction, monitor.
butabarbital|trimipramine|1|Minor|butabarbital, trimipramine. Other (see comment). Minor or non-significant interaction. Comment: Barbiturates may increase adverse effects, including respiratory depression, produced by toxic doses of TCAs. With therapeutic doses of TCAs, barbiturates increase metabolism and decrease blood concentrations of TCAs.
triprolidine|butabarbital|2|Significant - Monitor Closely|triprolidine and butabarbital both increase  sedation. Potential for interaction, monitor.
butabarbital|verapamil|11|Significant - Monitor Closely|butabarbital will decrease the level or effect of verapamil by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
butabarbital|voriconazole|21|Serious - Use Alternative|butabarbital decreases levels of voriconazole by increasing metabolism. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available. Never use combination.
butabarbital|voriconazole|1|Minor|butabarbital will decrease the level or effect of voriconazole by  affecting hepatic enzyme CYP2C19 metabolism. Minor or non-significant interaction.
butabarbital|voriconazole|1|Minor|butabarbital will decrease the level or effect of voriconazole by  affecting hepatic enzyme CYP2C9/10 metabolism. Minor or non-significant interaction.
butabarbital|warfarin|20|Serious - Use Alternative|butabarbital decreases effects of warfarin by increasing metabolism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
butabarbital|warfarin|11|Significant - Monitor Closely|butabarbital will decrease the level or effect of warfarin by  affecting hepatic enzyme CYP1A2 metabolism. Significant interaction possible, monitor closely.
butabarbital|warfarin|11|Significant - Monitor Closely|butabarbital will decrease the level or effect of warfarin by  affecting hepatic enzyme CYP2C9/10 metabolism. Significant interaction possible, monitor closely.
butabarbital|warfarin|11|Significant - Monitor Closely|butabarbital will decrease the level or effect of warfarin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
butabarbital|warfarin|1|Minor|butabarbital will decrease the level or effect of warfarin by  affecting hepatic enzyme CYP2C19 metabolism. Minor or non-significant interaction.
chloramphenicol|butalbital|1|Minor|chloramphenicol increases levels of butalbital by decreasing metabolism. Minor or non-significant interaction.
butalbital|chloramphenicol|1|Minor|butalbital decreases levels of chloramphenicol by increasing metabolism. Minor or non-significant interaction.
butalbital|clomipramine|11|Significant - Monitor Closely|butalbital will decrease the level or effect of clomipramine by  affecting hepatic enzyme CYP1A2 metabolism. Significant interaction possible, monitor closely.
butalbital|clomipramine|3|Significant - Monitor Closely|butalbital will decrease the level or effect of clomipramine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Potential for dangerous interaction. Use with caution and monitor closely.
butalbital|clomipramine|2|Significant - Monitor Closely|butalbital and clomipramine both increase  sedation. Potential for interaction, monitor.
butalbital|clomipramine|1|Minor|butalbital, clomipramine. Other (see comment). Minor or non-significant interaction. Comment: Barbiturates may increase adverse effects, including respiratory depression, produced by toxic doses of TCAs. With therapeutic doses of TCAs, barbiturates increase metabolism and decrease blood concentrations of TCAs.
butalbital|conjugated estrogens|11|Significant - Monitor Closely|butalbital will decrease the level or effect of conjugated estrogens by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
butalbital|cyclosporine|20|Serious - Use Alternative|butalbital decreases levels of cyclosporine by increasing metabolism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
butalbital|cyclosporine|11|Significant - Monitor Closely|butalbital will decrease the level or effect of cyclosporine by  affecting hepatic enzyme CYP1A2 metabolism. Significant interaction possible, monitor closely.
butalbital|cyclosporine|11|Significant - Monitor Closely|butalbital will decrease the level or effect of cyclosporine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
butalbital|desipramine|3|Significant - Monitor Closely|butalbital will decrease the level or effect of desipramine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Potential for dangerous interaction. Use with caution and monitor closely.
butalbital|desipramine|2|Significant - Monitor Closely|butalbital and desipramine both increase  sedation. Potential for interaction, monitor.
butalbital|desipramine|1|Minor|butalbital, desipramine. Other (see comment). Minor or non-significant interaction. Comment: Barbiturates may increase adverse effects, including respiratory depression, produced by toxic doses of TCAs. With therapeutic doses of TCAs, barbiturates increase metabolism and decrease blood concentrations of TCAs.
butalbital|dexamethasone|11|Significant - Monitor Closely|butalbital will decrease the level or effect of dexamethasone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
butalbital|doxepin|2|Significant - Monitor Closely|butalbital and doxepin both increase  sedation. Potential for interaction, monitor.
butalbital|doxepin|1|Minor|butalbital, doxepin. Other (see comment). Minor or non-significant interaction. Comment: Barbiturates may increase adverse effects, including respiratory depression, produced by toxic doses of TCAs. With therapeutic doses of TCAs, barbiturates increase metabolism and decrease blood concentrations of TCAs.
butalbital|doxycycline|11|Significant - Monitor Closely|butalbital decreases levels of doxycycline by increasing metabolism. Significant interaction possible, monitor closely.
butalbital|droperidol|2|Significant - Monitor Closely|butalbital and droperidol both increase  sedation. Potential for interaction, monitor.
butalbital|eltrombopag|11|Significant - Monitor Closely|butalbital will decrease the level or effect of eltrombopag by  affecting hepatic enzyme CYP1A2 metabolism. Significant interaction possible, monitor closely.
butalbital|eltrombopag|11|Significant - Monitor Closely|butalbital will decrease the level or effect of eltrombopag by  affecting hepatic enzyme CYP2C9/10 metabolism. Significant interaction possible, monitor closely.
butalbital|estradiol|11|Significant - Monitor Closely|butalbital will decrease the level or effect of estradiol by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
butalbital|felodipine|11|Significant - Monitor Closely|butalbital will decrease the level or effect of felodipine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
butalbital|fludrocortisone|11|Significant - Monitor Closely|butalbital will decrease the level or effect of fludrocortisone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
butalbital|griseofulvin|1|Minor|butalbital decreases levels of griseofulvin by inhibition of GI absorption. Applies only to oral form of both agents. Minor or non-significant interaction.
butalbital|hydrocortisone|11|Significant - Monitor Closely|butalbital will decrease the level or effect of hydrocortisone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
hydroxyzine|butalbital|2|Significant - Monitor Closely|hydroxyzine and butalbital both increase  sedation. Potential for interaction, monitor.
butalbital|imipramine|11|Significant - Monitor Closely|butalbital will decrease the level or effect of imipramine by  affecting hepatic enzyme CYP1A2 metabolism. Significant interaction possible, monitor closely.
butalbital|imipramine|11|Significant - Monitor Closely|butalbital will decrease the level or effect of imipramine by  affecting hepatic enzyme CYP2C19 metabolism. Significant interaction possible, monitor closely.
butalbital|imipramine|3|Significant - Monitor Closely|butalbital will decrease the level or effect of imipramine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Potential for dangerous interaction. Use with caution and monitor closely.
butalbital|imipramine|2|Significant - Monitor Closely|butalbital and imipramine both increase  sedation. Potential for interaction, monitor.
butalbital|imipramine|1|Minor|butalbital, imipramine. Other (see comment). Minor or non-significant interaction. Comment: Barbiturates may increase adverse effects, including respiratory depression, produced by toxic doses of TCAs. With therapeutic doses of TCAs, barbiturates increase metabolism and decrease blood concentrations of TCAs.
butalbital|methadone|11|Significant - Monitor Closely|butalbital will decrease the level or effect of methadone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
butalbital|methadone|2|Significant - Monitor Closely|butalbital and methadone both increase  sedation. Potential for interaction, monitor.
butalbital|nifedipine|1|Minor|butalbital will decrease the level or effect of nifedipine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor or non-significant interaction.
butalbital|nortriptyline|2|Significant - Monitor Closely|butalbital and nortriptyline both increase  sedation. Potential for interaction, monitor.
butalbital|nortriptyline|1|Minor|butalbital, nortriptyline. Other (see comment). Minor or non-significant interaction. Comment: Barbiturates may increase adverse effects, including respiratory depression, produced by toxic doses of TCAs. With therapeutic doses of TCAs, barbiturates increase metabolism and decrease blood concentrations of TCAs.
butalbital|prednisolone|11|Significant - Monitor Closely|butalbital will decrease the level or effect of prednisolone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
butalbital|prednisone|11|Significant - Monitor Closely|butalbital will decrease the level or effect of prednisone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
butalbital|protriptyline|2|Significant - Monitor Closely|butalbital and protriptyline both increase  sedation. Potential for interaction, monitor.
butalbital|protriptyline|1|Minor|butalbital, protriptyline. Other (see comment). Minor or non-significant interaction. Comment: Barbiturates may increase adverse effects, including respiratory depression, produced by toxic doses of TCAs. With therapeutic doses of TCAs, barbiturates increase metabolism and decrease blood concentrations of TCAs.
butalbital|quinidine|11|Significant - Monitor Closely|butalbital will decrease the level or effect of quinidine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
butalbital|theophylline|11|Significant - Monitor Closely|butalbital will decrease the level or effect of theophylline by  affecting hepatic enzyme CYP1A2 metabolism. Significant interaction possible, monitor closely.
butalbital|theophylline|11|Significant - Monitor Closely|butalbital will decrease the level or effect of theophylline by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
butalbital|triamcinolone|11|Significant - Monitor Closely|butalbital will decrease the level or effect of triamcinolone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
butalbital|trimipramine|2|Significant - Monitor Closely|butalbital and trimipramine both increase  sedation. Potential for interaction, monitor.
butalbital|trimipramine|1|Minor|butalbital, trimipramine. Other (see comment). Minor or non-significant interaction. Comment: Barbiturates may increase adverse effects, including respiratory depression, produced by toxic doses of TCAs. With therapeutic doses of TCAs, barbiturates increase metabolism and decrease blood concentrations of TCAs.
triprolidine|butalbital|2|Significant - Monitor Closely|triprolidine and butalbital both increase  sedation. Potential for interaction, monitor.
butalbital|verapamil|11|Significant - Monitor Closely|butalbital will decrease the level or effect of verapamil by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
butalbital|voriconazole|21|Serious - Use Alternative|butalbital decreases levels of voriconazole by increasing metabolism. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available. Never use combination.
butalbital|voriconazole|1|Minor|butalbital will decrease the level or effect of voriconazole by  affecting hepatic enzyme CYP2C19 metabolism. Minor or non-significant interaction.
butalbital|voriconazole|1|Minor|butalbital will decrease the level or effect of voriconazole by  affecting hepatic enzyme CYP2C9/10 metabolism. Minor or non-significant interaction.
butalbital|warfarin|20|Serious - Use Alternative|butalbital decreases effects of warfarin by increasing metabolism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
butalbital|warfarin|11|Significant - Monitor Closely|butalbital will decrease the level or effect of warfarin by  affecting hepatic enzyme CYP1A2 metabolism. Significant interaction possible, monitor closely.
butalbital|warfarin|11|Significant - Monitor Closely|butalbital will decrease the level or effect of warfarin by  affecting hepatic enzyme CYP2C9/10 metabolism. Significant interaction possible, monitor closely.
butalbital|warfarin|11|Significant - Monitor Closely|butalbital will decrease the level or effect of warfarin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
butalbital|warfarin|1|Minor|butalbital will decrease the level or effect of warfarin by  affecting hepatic enzyme CYP2C19 metabolism. Minor or non-significant interaction.
butorphanol|droperidol|2|Significant - Monitor Closely|butorphanol and droperidol both increase  sedation. Potential for interaction, monitor.
triprolidine|butorphanol|2|Significant - Monitor Closely|triprolidine and butorphanol both increase  sedation. Potential for interaction, monitor.
carbamazepine|cabazitaxel|11|Significant - Monitor Closely|carbamazepine will decrease the level or effect of cabazitaxel by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely. Coadministration of strong CYP3A4 inducers may decrease cabazitaxel concentrations. Avoid coadministration.
clarithromycin|cabazitaxel|20|Serious - Use Alternative|clarithromycin will increase the level or effect of cabazitaxel by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available. Coadministration of cabazitaxel with strong CYP3A4 inhibitors should be avoided.
indinavir|cabazitaxel|3|Significant - Monitor Closely|indinavir increases levels of cabazitaxel by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Potential for dangerous interaction. Use with caution and monitor closely. Potential for increased toxicity. Avoid coadministration.
itraconazole|cabazitaxel|20|Serious - Use Alternative|itraconazole will increase the level or effect of cabazitaxel by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available. Coadministration of cabazitaxel with strong CYP3A4 inhibitors should be avoided.
ketoconazole|cabazitaxel|20|Serious - Use Alternative|ketoconazole will increase the level or effect of cabazitaxel by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available. Coadministration of cabazitaxel with strong CYP3A4 inhibitors should be avoided.
nefazodone|cabazitaxel|20|Serious - Use Alternative|nefazodone will increase the level or effect of cabazitaxel by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available. Coadministration of cabazitaxel with strong CYP3A4 inhibitors should be avoided.
nelfinavir|cabazitaxel|3|Significant - Monitor Closely|nelfinavir increases levels of cabazitaxel by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Potential for dangerous interaction. Use with caution and monitor closely. Potential for increased toxicity. Avoid coadministration.
phenobarbital|cabazitaxel|11|Significant - Monitor Closely|phenobarbital will decrease the level or effect of cabazitaxel by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely. Coadministration of strong CYP3A4 inducers may decrease cabazitaxel concentrations. Avoid coadministration.
phenytoin|cabazitaxel|11|Significant - Monitor Closely|phenytoin will decrease the level or effect of cabazitaxel by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely. Coadministration of strong CYP3A4 inducers may decrease cabazitaxel concentrations. Avoid coadministration.
rifabutin|cabazitaxel|11|Significant - Monitor Closely|rifabutin will decrease the level or effect of cabazitaxel by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely. Coadministration of strong CYP3A4 inducers may decrease cabazitaxel concentrations. Avoid coadministration.
rifapentine|cabazitaxel|11|Significant - Monitor Closely|rifapentine will decrease the level or effect of cabazitaxel by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely. Coadministration of strong CYP3A4 inducers may decrease cabazitaxel concentrations. Avoid coadministration.
ritonavir|cabazitaxel|3|Significant - Monitor Closely|ritonavir increases levels of cabazitaxel by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Potential for dangerous interaction. Use with caution and monitor closely. Potential for increased toxicity. Avoid coadministration.
saquinavir|cabazitaxel|3|Significant - Monitor Closely|saquinavir increases levels of cabazitaxel by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Potential for dangerous interaction. Use with caution and monitor closely. Potential for increased toxicity. Avoid coadministration.
telithromycin|cabazitaxel|20|Serious - Use Alternative|telithromycin will increase the level or effect of cabazitaxel by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available. Coadministration of cabazitaxel with strong CYP3A4 inhibitors should be avoided.
voriconazole|cabazitaxel|20|Serious - Use Alternative|voriconazole will increase the level or effect of cabazitaxel by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available. Coadministration of cabazitaxel with strong CYP3A4 inhibitors should be avoided.
cabergoline|zolmitriptan|33|Contraindicated|cabergoline, zolmitriptan.Either increases toxicity of the other by pharmacodynamic synergism. Never use combination. Additive vasospasm.  Sep. by 24h.
etravirine|cabozantinib|2|Significant - Monitor Closely|etravirine will decrease the level or effect of cabozantinib by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Potential for interaction, monitor.
ciprofloxacin|caffeine|2|Significant - Monitor Closely|ciprofloxacin will increase the level or effect of caffeine by  affecting hepatic enzyme CYP1A2 metabolism. Potential for interaction, monitor. The hepatic metabolism of caffeine may be decreased by ciprofloxacin; pharmacologic effects of caffeine may be increased.
clozapine|caffeine|2|Significant - Monitor Closely|clozapine increases and caffeine decreases sedation. Effect of interaction is not clear, use caution. Potential for interaction, monitor.
norfloxacin|caffeine|1|Minor|norfloxacin will increase the level or effect of caffeine by  affecting hepatic enzyme CYP1A2 metabolism. Minor or non-significant interaction.
caffeine|regadenoson|22|Serious - Use Alternative|caffeine decreases effects of regadenoson by pharmacodynamic antagonism. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available. Avoid methylxanthines for 12 hours before regadenoson administration.
ceftriaxone|calcium acetate|33|Contraindicated|ceftriaxone, calcium acetate. Other (see comment). Never use combination. Comment: Do not use ANY calcium-containing solutions (including Ringer's or Harmann's) in combination with IV ceftriaxone; risk of potentially fatal particulate precipitation in lungs, kidneys.  Separate by at least 48 hrs.
calcium acetate|ciprofloxacin|11|Significant - Monitor Closely|calcium acetate decreases effects of ciprofloxacin by inhibition of GI absorption. Applies only to oral form of both agents. Significant interaction possible, monitor closely. Ciprofloxacin should be administered 2 hr before or 6 hr after calcium salts.
calcium acetate|demeclocycline|20|Serious - Use Alternative|calcium acetate, demeclocycline.Either decreases levels of the other by inhibition of GI absorption. Applies only to oral form of both agents. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available. Separate by 2 hours.
calcium acetate|doxycycline|20|Serious - Use Alternative|calcium acetate, doxycycline.Either decreases levels of the other by inhibition of GI absorption. Applies only to oral form of both agents. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available. Separate by 2 hours.
calcium acetate|eltrombopag|21|Serious - Use Alternative|calcium acetate decreases levels of eltrombopag by inhibition of GI absorption. Applies only to oral form of both agents. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available. Never use combination. Separate by at least 4 hours.
calcium acetate|estramustine|11|Significant - Monitor Closely|calcium acetate decreases levels of estramustine by inhibition of GI absorption. Applies only to oral form of both agents. Significant interaction possible, monitor closely. Patients should take estramustine with water at least 1h before or 2h after meals.
calcium acetate|gemifloxacin|11|Significant - Monitor Closely|calcium acetate, gemifloxacin.Either decreases levels of the other by inhibition of GI absorption. Applies only to oral form of both agents. Significant interaction possible, monitor closely. Separate by 2 hours.
calcium acetate|ibandronate|11|Significant - Monitor Closely|calcium acetate decreases levels of ibandronate by inhibition of GI absorption. Applies only to oral form of both agents. Significant interaction possible, monitor closely. Separate by 30 minutes.
calcium acetate|levofloxacin|11|Significant - Monitor Closely|calcium acetate, levofloxacin.Either decreases levels of the other by inhibition of GI absorption. Applies only to oral form of both agents. Significant interaction possible, monitor closely. Separate by 2 hours.
calcium acetate|levothyroxine|11|Significant - Monitor Closely|calcium acetate decreases levels of levothyroxine by inhibition of GI absorption. Applies only to oral form of both agents. Significant interaction possible, monitor closely. Separate by 2 hours.
calcium acetate|minocycline|20|Serious - Use Alternative|calcium acetate, minocycline.Either decreases levels of the other by inhibition of GI absorption. Applies only to oral form of both agents. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available. Separate by 2 hours.
calcium acetate|norfloxacin|11|Significant - Monitor Closely|calcium acetate, norfloxacin.Either decreases levels of the other by inhibition of GI absorption. Applies only to oral form of both agents. Significant interaction possible, monitor closely. Separate by 2 hours.
calcium acetate|ofloxacin|11|Significant - Monitor Closely|calcium acetate, ofloxacin.Either decreases levels of the other by inhibition of GI absorption. Applies only to oral form of both agents. Significant interaction possible, monitor closely. Separate by 2 hours.
calcium acetate|risedronate|11|Significant - Monitor Closely|calcium acetate decreases levels of risedronate by inhibition of GI absorption. Applies only to oral form of both agents. Significant interaction possible, monitor closely. Separate by 30 minutes.
calcium acetate|tetracycline|20|Serious - Use Alternative|calcium acetate, tetracycline.Either decreases levels of the other by inhibition of GI absorption. Applies only to oral form of both agents. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available. Separate by 2 hours.
calcium acetate|tiludronate|11|Significant - Monitor Closely|calcium acetate decreases levels of tiludronate by inhibition of GI absorption. Applies only to oral form of both agents. Significant interaction possible, monitor closely. Separate by 30 minutes.
calcium carbonate|eltrombopag|21|Serious - Use Alternative|calcium carbonate decreases levels of eltrombopag by inhibition of GI absorption. Applies only to oral form of both agents. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available. Never use combination. Separate by at least 4 hours.
calcium carbonate|itraconazole|20|Serious - Use Alternative|calcium carbonate will decrease the level or effect of itraconazole by  increasing gastric pH. Applies only to oral form of both agents. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
calcium carbonate|itraconazole|11|Significant - Monitor Closely|calcium carbonate decreases levels of itraconazole by inhibition of GI absorption. Applies only to oral form of both agents. Significant interaction possible, monitor closely. Separate by 2 hours.
ceftriaxone|calcium chloride|33|Contraindicated|ceftriaxone, calcium chloride. Other (see comment). Never use combination. Comment: Contraindicated in neonates if they require (or are expected to require) treatment with calcium-containing IV solutions, including continuous calcium-containing infusions such as parenteral nutrition because of the risk of precipitation of ceftriaxone-calcium. Separate IV ceftriaxone and IV calcium by at least 48 hrs. However, in patients other than neonates, ceftriaxone and calcium-containing solutions may be administered sequentially of one another if the IV infusion lines are thoroughly flushed between infusions with a compatible fluid.
calcium chloride|demeclocycline|20|Serious - Use Alternative|calcium chloride, demeclocycline.Either decreases levels of the other by inhibition of GI absorption. Applies only to oral form of both agents. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available. Separate by 2 hours.
calcium chloride|doxycycline|20|Serious - Use Alternative|calcium chloride, doxycycline.Either decreases levels of the other by inhibition of GI absorption. Applies only to oral form of both agents. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available. Separate by 2 hours.
calcium chloride|eltrombopag|21|Serious - Use Alternative|calcium chloride decreases levels of eltrombopag by inhibition of GI absorption. Applies only to oral form of both agents. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available. Never use combination. Separate by at least 4 hours.
calcium chloride|ibandronate|11|Significant - Monitor Closely|calcium chloride decreases levels of ibandronate by inhibition of GI absorption. Applies only to oral form of both agents. Significant interaction possible, monitor closely. Separate by 30 minutes.
calcium chloride|levothyroxine|11|Significant - Monitor Closely|calcium chloride decreases levels of levothyroxine by inhibition of GI absorption. Applies only to oral form of both agents. Significant interaction possible, monitor closely. Separate by 2 hours.
calcium chloride|minocycline|20|Serious - Use Alternative|calcium chloride, minocycline.Either decreases levels of the other by inhibition of GI absorption. Applies only to oral form of both agents. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available. Separate by 2 hours.
calcium chloride|risedronate|11|Significant - Monitor Closely|calcium chloride decreases levels of risedronate by inhibition of GI absorption. Applies only to oral form of both agents. Significant interaction possible, monitor closely. Separate by 30 minutes.
calcium chloride|tetracycline|20|Serious - Use Alternative|calcium chloride, tetracycline.Either decreases levels of the other by inhibition of GI absorption. Applies only to oral form of both agents. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available. Separate by 2 hours.
calcium chloride|tiludronate|11|Significant - Monitor Closely|calcium chloride decreases levels of tiludronate by inhibition of GI absorption. Applies only to oral form of both agents. Significant interaction possible, monitor closely. Separate by 30 minutes.
canagliflozin|digoxin|3|Significant - Monitor Closely|canagliflozin increases levels of digoxin by unspecified interaction mechanism. Potential for dangerous interaction. Use with caution and monitor closely. Digoxin AUC and peak serum concentration increased when coadministered with canagliflozin.
phenobarbital|canagliflozin|11|Significant - Monitor Closely|phenobarbital decreases levels of canagliflozin by increasing metabolism. Significant interaction possible, monitor closely. Coadministration with potent UGT enzyme inducers: Consider increasing dose to 300 mg qDay if 100 mg/day tolerate and additional glycemic control required (eGFR must be >60 mL/min/1.73 m2 to increase dose); if eGFR <60 mL/min/1.73 m2, consider using a different antihyperglycemic agent.
phenytoin|canagliflozin|11|Significant - Monitor Closely|phenytoin decreases levels of canagliflozin by increasing metabolism. Significant interaction possible, monitor closely. Coadministration with potent UGT enzyme inducers: Consider increasing dose to 300 mg qDay if 100 mg/day tolerate and additional glycemic control required (eGFR must be >60 mL/min/1.73 m2 to increase dose); if eGFR <60 mL/min/1.73 m2, consider using a different antihyperglycemic agent.
ritonavir|canagliflozin|11|Significant - Monitor Closely|ritonavir decreases levels of canagliflozin by increasing metabolism. Significant interaction possible, monitor closely. Coadministration with potent UGT enzyme inducers: Consider increasing dose to 300 mg qDay if 100 mg/day tolerate and additional glycemic control required (eGFR must be >60 mL/min/1.73 m2 to increase dose); if eGFR <60 mL/min/1.73 m2, consider using a different antihyperglycemic agent.
canakinumab|etanercept|22|Serious - Use Alternative|canakinumab and etanercept both increase  immunosuppressive effects; risk of infection. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available.
canakinumab|golimumab|22|Serious - Use Alternative|canakinumab and golimumab both increase  immunosuppressive effects; risk of infection. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available.
canakinumab|infliximab|22|Serious - Use Alternative|canakinumab and infliximab both increase  immunosuppressive effects; risk of infection. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available.
canakinumab|rilonacept|22|Serious - Use Alternative|canakinumab and rilonacept both increase  immunosuppressive effects; risk of infection. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available.
candesartan|drospirenone|3|Significant - Monitor Closely|candesartan and drospirenone both increase  serum potassium. Potential for dangerous interaction. Use with caution and monitor closely.
candesartan|lithium|20|Serious - Use Alternative|candesartan increases toxicity of lithium by decreasing renal clearance. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
candesartan|spironolactone|3|Significant - Monitor Closely|candesartan and spironolactone both increase  serum potassium. Potential for dangerous interaction. Use with caution and monitor closely.
candesartan|trandolapril|20|Serious - Use Alternative|candesartan, trandolapril.Either increases toxicity of the other by pharmacodynamic synergism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available. Dual blockade of renin-angiotensin system increases risks of hypotension, hyperkalemia, and renal impairment.
treprostinil|candesartan|2|Significant - Monitor Closely|treprostinil increases effects of candesartan by pharmacodynamic synergism. Potential for interaction, monitor.
candesartan|triamterene|3|Significant - Monitor Closely|candesartan and triamterene both increase  serum potassium. Potential for dangerous interaction. Use with caution and monitor closely.
capecitabine|ethotoin|11|Significant - Monitor Closely|capecitabine increases levels of ethotoin by unknown mechanism. Significant interaction possible, monitor closely. Based on case reports.
capecitabine|fosphenytoin|11|Significant - Monitor Closely|capecitabine increases levels of fosphenytoin by unknown mechanism. Significant interaction possible, monitor closely. Based on case reports.
capecitabine|phenytoin|11|Significant - Monitor Closely|capecitabine increases levels of phenytoin by unknown mechanism. Significant interaction possible, monitor closely. Based on case reports.
capecitabine|warfarin|20|Serious - Use Alternative|capecitabine increases effects of warfarin by unspecified interaction mechanism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available. Monitor INR and prothrombin time.
captopril|drospirenone|11|Significant - Monitor Closely|captopril, drospirenone. Mechanism: pharmacodynamic synergism. Significant interaction possible, monitor closely. Risk of hyperkalemia.
icatibant|captopril|2|Significant - Monitor Closely|icatibant decreases effects of captopril by pharmacodynamic antagonism. Potential for interaction, monitor. Icatibant has potential to have a pharmacodynamic interaction with ACE inhibitors where it may attenuate the antihypertensive effect of ACE inhibitors.
captopril|lithium|11|Significant - Monitor Closely|captopril increases toxicity of lithium by unknown mechanism. Significant interaction possible, monitor closely. ACE inhibitor induced Na+ depletion may increase reabsorption of lithium from renal tubule.
captopril|spironolactone|11|Significant - Monitor Closely|captopril, spironolactone. Mechanism: pharmacodynamic synergism. Significant interaction possible, monitor closely. Risk of hyperkalemia.
tizanidine|captopril|1|Minor|tizanidine increases effects of captopril by pharmacodynamic synergism. Minor or non-significant interaction. Risk of hypotension.
treprostinil|captopril|1|Minor|treprostinil increases effects of captopril by pharmacodynamic synergism. Minor or non-significant interaction.
captopril|triamterene|11|Significant - Monitor Closely|captopril, triamterene. Mechanism: pharmacodynamic synergism. Significant interaction possible, monitor closely. Risk of hyperkalemia.
tacrine|carbachol|11|Significant - Monitor Closely|tacrine increases effects of carbachol by pharmacodynamic synergism. Significant interaction possible, monitor closely.
carbachol|tacrine|2|Significant - Monitor Closely|carbachol and tacrine both increase  cholinergic effects/transmission. Potential for interaction, monitor.
cimetidine|carbamazepine|3|Significant - Monitor Closely|cimetidine will increase the level or effect of carbamazepine by  decreasing metabolism. Potential for dangerous interaction. Use with caution and monitor closely. Monitor plasma levels when used concomitantly
clarithromycin|carbamazepine|20|Serious - Use Alternative|clarithromycin will increase the level or effect of carbamazepine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available. Monitor plasma levels when used concomitantly
carbamazepine|clozapine|20|Serious - Use Alternative|carbamazepine will decrease the level or effect of clozapine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
carbamazepine|clozapine|20|Serious - Use Alternative|carbamazepine, clozapine.Either increases toxicity of the other by pharmacodynamic synergism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available. Increased risk of agranulocytosis.
carbamazepine|clozapine|11|Significant - Monitor Closely|carbamazepine will decrease the level or effect of clozapine by  affecting hepatic enzyme CYP1A2 metabolism. Significant interaction possible, monitor closely.
carbamazepine|cyclosporine|20|Serious - Use Alternative|carbamazepine will decrease the level or effect of cyclosporine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
carbamazepine|cyclosporine|11|Significant - Monitor Closely|carbamazepine will decrease the level or effect of cyclosporine by  affecting hepatic enzyme CYP1A2 metabolism. Significant interaction possible, monitor closely.
cyclosporine|carbamazepine|11|Significant - Monitor Closely|cyclosporine will increase the level or effect of carbamazepine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
carbamazepine|dabrafenib|20|Serious - Use Alternative|carbamazepine decreases levels of dabrafenib by increasing metabolism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available. Strong CYP2C8 inducers may decrease dabrafenib levels.
carbamazepine|dabrafenib|20|Serious - Use Alternative|carbamazepine decreases levels of dabrafenib by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
dabrafenib|carbamazepine|3|Significant - Monitor Closely|dabrafenib will decrease the level or effect of carbamazepine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Potential for dangerous interaction. Use with caution and monitor closely.
danazol|carbamazepine|3|Significant - Monitor Closely|danazol will increase the level or effect of carbamazepine by  decreasing metabolism. Potential for dangerous interaction. Use with caution and monitor closely. Monitor plasma levels when used concomitantly
carbamazepine|delavirdine|33|Contraindicated|carbamazepine decreases levels of delavirdine by increasing metabolism. Never use combination.
delavirdine|carbamazepine|11|Significant - Monitor Closely|delavirdine will increase the level or effect of carbamazepine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
carbamazepine|delavirdine|2|Significant - Monitor Closely|carbamazepine will decrease the level or effect of delavirdine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Potential for interaction, monitor.
carbamazepine|desipramine|2|Significant - Monitor Closely|carbamazepine will decrease the level or effect of desipramine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Potential for interaction, monitor.
carbamazepine|desipramine|1|Minor|carbamazepine decreases levels of desipramine by increasing metabolism. Minor or non-significant interaction.
carbamazepine|diltiazem|20|Serious - Use Alternative|carbamazepine will decrease the level or effect of diltiazem by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
diltiazem|carbamazepine|3|Significant - Monitor Closely|diltiazem will increase the level or effect of carbamazepine by  decreasing metabolism. Potential for dangerous interaction. Use with caution and monitor closely. Monitor plasma levels when used concomitantly
carbamazepine|doxepin|1|Minor|carbamazepine decreases levels of doxepin by increasing metabolism. Minor or non-significant interaction.
carbamazepine|doxycycline|11|Significant - Monitor Closely|carbamazepine decreases levels of doxycycline by increasing metabolism. Significant interaction possible, monitor closely.
carbamazepine|dyphylline|20|Serious - Use Alternative|carbamazepine will decrease the level or effect of dyphylline by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
dyphylline|carbamazepine|20|Serious - Use Alternative|dyphylline decreases levels of carbamazepine by increasing metabolism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
carbamazepine|dyphylline|11|Significant - Monitor Closely|carbamazepine will decrease the level or effect of dyphylline by  affecting hepatic enzyme CYP1A2 metabolism. Significant interaction possible, monitor closely.
carbamazepine|eltrombopag|11|Significant - Monitor Closely|carbamazepine will decrease the level or effect of eltrombopag by  affecting hepatic enzyme CYP1A2 metabolism. Significant interaction possible, monitor closely.
carbamazepine|eltrombopag|11|Significant - Monitor Closely|carbamazepine will decrease the level or effect of eltrombopag by  affecting hepatic enzyme CYP2C9/10 metabolism. Significant interaction possible, monitor closely.
carbamazepine|etravirine|33|Contraindicated|carbamazepine decreases levels of etravirine by increasing metabolism. Never use combination.
carbamazepine|etravirine|20|Serious - Use Alternative|carbamazepine will decrease the level or effect of etravirine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
carbamazepine|etravirine|11|Significant - Monitor Closely|carbamazepine will decrease the level or effect of etravirine by  affecting hepatic enzyme CYP2C9/10 metabolism. Significant interaction possible, monitor closely.
etravirine|carbamazepine|11|Significant - Monitor Closely|etravirine will decrease the level or effect of carbamazepine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
carbamazepine|ezogabine|1|Minor|carbamazepine decreases levels of ezogabine by Mechanism: unknown. Minor or non-significant interaction. Upon discontinuation of  carbamazepine, ezogabine clearance decreased by approximately 30%. Consider an increase in the ezogabine dose during concurrent use.
carbamazepine|felbamate|11|Significant - Monitor Closely|carbamazepine decreases levels of felbamate by increasing metabolism. Significant interaction possible, monitor closely. Toxicity increased with combination.
carbamazepine|felodipine|20|Serious - Use Alternative|carbamazepine will decrease the level or effect of felodipine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
felodipine|carbamazepine|11|Significant - Monitor Closely|felodipine increases levels of carbamazepine by decreasing metabolism. Significant interaction possible, monitor closely.
fluconazole|carbamazepine|11|Significant - Monitor Closely|fluconazole will increase the level or effect of carbamazepine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely. Monitor plasma levels when used concomitantly
fluoxetine|carbamazepine|3|Significant - Monitor Closely|fluoxetine will increase the level or effect of carbamazepine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Potential for dangerous interaction. Use with caution and monitor closely. Monitor plasma levels when used concomitantly
fluvoxamine|carbamazepine|3|Significant - Monitor Closely|fluvoxamine will increase the level or effect of carbamazepine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Potential for dangerous interaction. Use with caution and monitor closely. Monitor plasma levels when used concomitantly
carbamazepine|haloperidol|11|Significant - Monitor Closely|carbamazepine decreases levels of haloperidol by increasing metabolism. Significant interaction possible, monitor closely.
carbamazepine|imatinib|2|Significant - Monitor Closely|carbamazepine will decrease the level or effect of imatinib by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Potential for interaction, monitor.
carbamazepine|imipramine|11|Significant - Monitor Closely|carbamazepine will decrease the level or effect of imipramine by  affecting hepatic enzyme CYP1A2 metabolism. Significant interaction possible, monitor closely.
carbamazepine|imipramine|2|Significant - Monitor Closely|carbamazepine will decrease the level or effect of imipramine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Potential for interaction, monitor.
carbamazepine|imipramine|1|Minor|carbamazepine decreases levels of imipramine by increasing metabolism. Minor or non-significant interaction.
carbamazepine|indinavir|20|Serious - Use Alternative|carbamazepine will decrease the level or effect of indinavir by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
indinavir|carbamazepine|11|Significant - Monitor Closely|indinavir will increase the level or effect of carbamazepine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely. Monitor plasma levels when used concomitantly
isoniazid|carbamazepine|11|Significant - Monitor Closely|isoniazid will increase the level or effect of carbamazepine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely. Monitor plasma levels when used concomitantly
isotretinoin|carbamazepine|1|Minor|isotretinoin decreases levels of carbamazepine by increasing renal clearance. Minor or non-significant interaction.
itraconazole|carbamazepine|20|Serious - Use Alternative|itraconazole will increase the level or effect of carbamazepine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available. Monitor plasma levels when used concomitantly
carbamazepine|itraconazole|2|Significant - Monitor Closely|carbamazepine will decrease the level or effect of itraconazole by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Potential for interaction, monitor.
carbamazepine|ivacaftor|22|Serious - Use Alternative|carbamazepine decreases levels of ivacaftor by affecting hepatic/intestinal enzyme CYP3A4 metabolism. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available. Avoid coadministration with strong CYP3A4 inducers; systemic exposure of ivacaftor substantially reduced (ie, ~9-fold).
ivacaftor|carbamazepine|20|Serious - Use Alternative|ivacaftor increases levels of carbamazepine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available. Ivacaftor and its M1 metabolite has the potential to inhibit CYP3A4, may significantly increase systemic exposure to CYP3A4 substrates.
ketoconazole|carbamazepine|20|Serious - Use Alternative|ketoconazole will increase the level or effect of carbamazepine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available. Monitor plasma levels when used concomitantly
carbamazepine|ketoconazole|2|Significant - Monitor Closely|carbamazepine will decrease the level or effect of ketoconazole by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Potential for interaction, monitor.
carbamazepine|lamotrigine|11|Significant - Monitor Closely|carbamazepine decreases levels of lamotrigine by increasing metabolism. Significant interaction possible, monitor closely.
carbamazepine|linagliptin|11|Significant - Monitor Closely|carbamazepine will decrease the level or effect of linagliptin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely. Use of alternative treatments is strongly recommended when linagliptin is to be administered with a CYP3A4 inducer.
carbamazepine|linagliptin|11|Significant - Monitor Closely|carbamazepine will decrease the level or effect of linagliptin by  P-glycoprotein (MDR1) efflux transporter. Significant interaction possible, monitor closely. Use of alternative treatments is strongly recommended when linagliptin is to be administered with a P-gp inducer.
carbamazepine|lovastatin|22|Serious - Use Alternative|carbamazepine will decrease the level or effect of lovastatin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available.
carbamazepine|lurasidone|33|Contraindicated|carbamazepine decreases levels of lurasidone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Never use combination. Contraindicated; decreases lurasidone Cmax by ~85%.
lurasidone|carbamazepine|11|Significant - Monitor Closely|lurasidone, carbamazepine.Either increases toxicity of the other by Other (see comment). Significant interaction possible, monitor closely. Comment: Potential for increased CNS depressant effects when used concurrently; monitor for increased adverse effects and toxicity.
carbamazepine|mestranol|20|Serious - Use Alternative|carbamazepine will decrease the level or effect of mestranol by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
carbamazepine|mestranol|20|Serious - Use Alternative|carbamazepine decreases levels of mestranol by increasing metabolism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available. May result in loss of contraceptive efficacy.
carbamazepine|methadone|20|Serious - Use Alternative|carbamazepine will decrease the level or effect of methadone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
methylphenidate|carbamazepine|1|Minor|methylphenidate increases effects of carbamazepine by decreasing metabolism. Minor or non-significant interaction.
metronidazole|carbamazepine|11|Significant - Monitor Closely|metronidazole will increase the level or effect of carbamazepine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
carbamazepine|midazolam|20|Serious - Use Alternative|carbamazepine will decrease the level or effect of midazolam by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
nefazodone|carbamazepine|33|Contraindicated|nefazodone will increase the level or effect of carbamazepine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Never use combination.
nefazodone|carbamazepine|33|Contraindicated|nefazodone increases levels of carbamazepine by decreasing metabolism. Never use combination.
carbamazepine|nefazodone|33|Contraindicated|carbamazepine decreases levels of nefazodone by increasing metabolism. Never use combination.
carbamazepine|nortriptyline|1|Minor|carbamazepine decreases levels of nortriptyline by increasing metabolism. Minor or non-significant interaction.
oxybutynin|carbamazepine|11|Significant - Monitor Closely|oxybutynin will increase the level or effect of carbamazepine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely. Monitor plasma levels when used concomitantly
carbamazepine|oxybutynin|2|Significant - Monitor Closely|carbamazepine will decrease the level or effect of oxybutynin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Potential for interaction, monitor.
carbamazepine|pancuronium|1|Minor|carbamazepine decreases effects of pancuronium by pharmacodynamic antagonism. Minor or non-significant interaction.
carbamazepine|pazopanib|20|Serious - Use Alternative|carbamazepine will decrease the level or effect of pazopanib by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
carbamazepine|ponatinib|20|Serious - Use Alternative|carbamazepine decreases levels of ponatinib by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available. Avoid unless the coadministration outweighs the possible risk of ponatinib underexposure; monitor for signs of reduced efficacy.
carbamazepine|praziquantel|33|Contraindicated|carbamazepine decreases levels of praziquantel by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Never use combination. Strong CYP450 inducers significantly decrease praziquantel blood levels.
carbamazepine|regorafenib|33|Contraindicated|carbamazepine, regorafenib. affecting hepatic/intestinal enzyme CYP3A4 metabolism. Never use combination. Strong CYP3A4 inducers decrease regorafenib levels and increase exposure of the active metabolite M-5.
carbamazepine|rilpivirine|33|Contraindicated|carbamazepine decreases levels of rilpivirine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Never use combination. Contraindicated. Rilpivirine should not be co-administered with strong CYP 3A4 inducers. Potential for loss of virologic response and possible resistance to rilpivirine or to the NNRTI class.
carbamazepine|risperidone|11|Significant - Monitor Closely|carbamazepine decreases levels of risperidone by increasing metabolism. Significant interaction possible, monitor closely.
carbamazepine|ritonavir|20|Serious - Use Alternative|carbamazepine will decrease the level or effect of ritonavir by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
ritonavir|carbamazepine|11|Significant - Monitor Closely|ritonavir will increase the level or effect of carbamazepine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely. Monitor plasma levels when used concomitantly
carbamazepine|roflumilast|33|Contraindicated|carbamazepine will decrease the level or effect of roflumilast by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Never use combination. Coadministration not recommended; strong cytochrome P450 enzyme inducers decrease systemic exposure to roflumilast and may reduce the therapeutic effectiveness
carbamazepine|roflumilast|33|Contraindicated|carbamazepine will decrease the level or effect of roflumilast by  affecting hepatic enzyme CYP1A2 metabolism. Never use combination.  Coadministration not recommended; strong cytochrome P450 enzyme inducers decrease systemic exposure to roflumilast and may reduce the therapeutic effectiveness
rufinamide|carbamazepine|11|Significant - Monitor Closely|rufinamide will decrease the level or effect of carbamazepine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
carbamazepine|rufinamide|11|Significant - Monitor Closely|carbamazepine decreases levels of rufinamide by increasing metabolism. Significant interaction possible, monitor closely.
sertraline|carbamazepine|1|Minor|sertraline increases levels of carbamazepine by decreasing metabolism. Minor or non-significant interaction.
carbamazepine|simvastatin|22|Serious - Use Alternative|carbamazepine will decrease the level or effect of simvastatin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available.
carbamazepine|sunitinib|20|Serious - Use Alternative|carbamazepine will decrease the level or effect of sunitinib by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
carbamazepine|tacrolimus|20|Serious - Use Alternative|carbamazepine will decrease the level or effect of tacrolimus by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available. Monitor tacrolimus levels and adjust dose accordingly
carbamazepine|telithromycin|33|Contraindicated|carbamazepine decreases levels of telithromycin by increasing metabolism. Never use combination. Separate by 2 wks.
telithromycin|carbamazepine|11|Significant - Monitor Closely|telithromycin will increase the level or effect of carbamazepine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
carbamazepine|telithromycin|2|Significant - Monitor Closely|carbamazepine will decrease the level or effect of telithromycin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Potential for interaction, monitor.
carbamazepine|temsirolimus|20|Serious - Use Alternative|carbamazepine will decrease the level or effect of temsirolimus by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
carbamazepine|theophylline|20|Serious - Use Alternative|carbamazepine will decrease the level or effect of theophylline by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
theophylline|carbamazepine|20|Serious - Use Alternative|theophylline decreases levels of carbamazepine by increasing metabolism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
carbamazepine|theophylline|11|Significant - Monitor Closely|carbamazepine will decrease the level or effect of theophylline by  affecting hepatic enzyme CYP1A2 metabolism. Significant interaction possible, monitor closely.
ticlopidine|carbamazepine|11|Significant - Monitor Closely|ticlopidine will increase the level or effect of carbamazepine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely. Monitor plasma levels when used concomitantly
carbamazepine|tipranavir|20|Serious - Use Alternative|carbamazepine will decrease the level or effect of tipranavir by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
tipranavir|carbamazepine|11|Significant - Monitor Closely|tipranavir will increase the level or effect of carbamazepine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely. Monitor plasma levels when used concomitantly
carbamazepine|tolvaptan|22|Serious - Use Alternative|carbamazepine will decrease the level or effect of tolvaptan by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available.
topiramate|carbamazepine|11|Significant - Monitor Closely|topiramate will decrease the level or effect of carbamazepine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
carbamazepine|topiramate|11|Significant - Monitor Closely|carbamazepine decreases levels of topiramate by increasing metabolism. Significant interaction possible, monitor closely.
carbamazepine|tramadol|11|Significant - Monitor Closely|carbamazepine will decrease the level or effect of tramadol by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely. Decreased AUC  of tramadol and the active metabolite (O-desmethyltramadol) when coadministered with strong CYP3A4 and CYP2B6 inducers
trazodone|carbamazepine|3|Significant - Monitor Closely|trazodone will increase the level or effect of carbamazepine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Potential for dangerous interaction. Use with caution and monitor closely. Monitor plasma levels when used concomitantly
carbamazepine|trazodone|2|Significant - Monitor Closely|carbamazepine will decrease the level or effect of trazodone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Potential for interaction, monitor.
carbamazepine|trazodone|1|Minor|carbamazepine decreases levels of trazodone by increasing metabolism. Minor or non-significant interaction.
troleandomycin|carbamazepine|11|Significant - Monitor Closely|troleandomycin will increase the level or effect of carbamazepine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely. Monitor plasma levels when used concomitantly
carbamazepine|troleandomycin|2|Significant - Monitor Closely|carbamazepine will decrease the level or effect of troleandomycin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Potential for interaction, monitor.
carbamazepine|tubocurarine|1|Minor|carbamazepine decreases effects of tubocurarine by pharmacodynamic antagonism. Minor or non-significant interaction.
carbamazepine|ulipristal|20|Serious - Use Alternative|carbamazepine will decrease the level or effect of ulipristal by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
valproic acid|carbamazepine|11|Significant - Monitor Closely|valproic acid will increase the level or effect of carbamazepine by  Mechanism: decreasing metabolism. Significant interaction possible, monitor closely. Valproic acid may increase or decrease carbamazepine levels.
carbamazepine|valproic acid|11|Significant - Monitor Closely|carbamazepine decreases levels of valproic acid by increasing metabolism. Significant interaction possible, monitor closely.
carbamazepine|vandetanib|33|Contraindicated|carbamazepine decreases levels of vandetanib by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Never use combination. Avoid coadministration with potent CYP3A4 inducers; these drugs reduce exposure to vandetanib by up to 40%.
carbamazepine|vecuronium|1|Minor|carbamazepine decreases effects of vecuronium by pharmacodynamic antagonism. Minor or non-significant interaction.
carbamazepine|vemurafenib|20|Serious - Use Alternative|carbamazepine decreases levels of vemurafenib by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
carbamazepine|vemurafenib|2|Significant - Monitor Closely|carbamazepine decreases levels of vemurafenib by P-glycoprotein (MDR1) efflux transporter. Potential for interaction, monitor.
carbamazepine|verapamil|20|Serious - Use Alternative|carbamazepine will decrease the level or effect of verapamil by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
verapamil|carbamazepine|11|Significant - Monitor Closely|verapamil will increase the level or effect of carbamazepine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely. Monitor plasma levels when used concomitantly
carbamazepine|vilazodone|11|Significant - Monitor Closely|carbamazepine decreases levels of vilazodone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely. Consider increasing vilazodone dose up to 2-fold (not to exceed 80 mg/day) when coadministered with strong CYP3A4 inducers for >14 days.
carbamazepine|voriconazole|33|Contraindicated|carbamazepine decreases levels of voriconazole by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Never use combination.
voriconazole|carbamazepine|11|Significant - Monitor Closely|voriconazole will increase the level or effect of carbamazepine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely. Monitor plasma levels when used concomitantly
carbamazepine|warfarin|20|Serious - Use Alternative|carbamazepine will decrease the level or effect of warfarin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
carbamazepine|warfarin|11|Significant - Monitor Closely|carbamazepine will decrease the level or effect of warfarin by  affecting hepatic enzyme CYP1A2 metabolism. Significant interaction possible, monitor closely.
carbamazepine|warfarin|11|Significant - Monitor Closely|carbamazepine will decrease the level or effect of warfarin by  affecting hepatic enzyme CYP2C9/10 metabolism. Significant interaction possible, monitor closely.
carbamazepine|warfarin|11|Significant - Monitor Closely|carbamazepine decreases levels of warfarin by increasing metabolism. Significant interaction possible, monitor closely.
carbamazepine|ziprasidone|2|Significant - Monitor Closely|carbamazepine will decrease the level or effect of ziprasidone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Potential for interaction, monitor.
carbinoxamine|triprolidine|2|Significant - Monitor Closely|carbinoxamine and triprolidine both increase  sedation. Potential for interaction, monitor.
carboplatin|fosphenytoin|11|Significant - Monitor Closely|carboplatin decreases levels of fosphenytoin by unknown mechanism. Significant interaction possible, monitor closely.
carboplatin|phenytoin|11|Significant - Monitor Closely|carboplatin decreases levels of phenytoin by unknown mechanism. Significant interaction possible, monitor closely.
carboplatin|tacrolimus|2|Significant - Monitor Closely|carboplatin and tacrolimus both increase  nephrotoxicity and/or ototoxicity. Potential for interaction, monitor.
carboprost tromethamine|oxytocin|11|Significant - Monitor Closely|carboprost tromethamine increases effects of oxytocin by pharmacodynamic synergism. Significant interaction possible, monitor closely.
carisoprodol|droperidol|2|Significant - Monitor Closely|carisoprodol and droperidol both increase  sedation. Potential for interaction, monitor.
cimetidine|carmustine|11|Significant - Monitor Closely|cimetidine, carmustine. Mechanism: decreasing metabolism. Significant interaction possible, monitor closely. Enhanced myelotoxicity.
carmustine|digoxin|2|Significant - Monitor Closely|carmustine decreases levels of digoxin by inhibition of GI absorption. Applies only to oral form of both agents. Potential for interaction, monitor. It is prudent to closely monitor patients for loss of clinical efficacy of digoxin while receiving antineoplastic therapy.
carmustine|fosphenytoin|11|Significant - Monitor Closely|carmustine decreases levels of fosphenytoin by unknown mechanism. Significant interaction possible, monitor closely.
carmustine|phenytoin|11|Significant - Monitor Closely|carmustine decreases levels of phenytoin by unknown mechanism. Significant interaction possible, monitor closely.
citalopram|carvedilol|2|Significant - Monitor Closely|citalopram increases levels of carvedilol by decreasing metabolism. Potential for interaction, monitor.
carvedilol|digoxin|11|Significant - Monitor Closely|carvedilol increases levels of digoxin by enhancing GI absorption. Applies only to oral form of both agents. Significant interaction possible, monitor closely.
carvedilol|digoxin|11|Significant - Monitor Closely|carvedilol increases levels of digoxin by decreasing renal clearance. Significant interaction possible, monitor closely.
carvedilol|digoxin|11|Significant - Monitor Closely|carvedilol increases effects of digoxin by pharmacodynamic synergism. Significant interaction possible, monitor closely. Enhanced bradycardia.
carvedilol|digoxin|2|Significant - Monitor Closely|carvedilol and digoxin both increase  serum potassium. Potential for interaction, monitor.
dihydroergotamine|carvedilol|1|Minor|dihydroergotamine, carvedilol. Mechanism: pharmacodynamic synergism. Minor or non-significant interaction. Additive vasospasm.
carvedilol|epinephrine|11|Significant - Monitor Closely|carvedilol decreases effects of epinephrine by pharmacodynamic antagonism. Significant interaction possible, monitor closely.
carvedilol|epinephrine|2|Significant - Monitor Closely|carvedilol increases and epinephrine decreases serum potassium. Effect of interaction is not clear, use caution. Potential for interaction, monitor.
escitalopram|carvedilol|1|Minor|escitalopram increases levels of carvedilol by decreasing metabolism. Minor or non-significant interaction.
etravirine|carvedilol|11|Significant - Monitor Closely|etravirine will increase the level or effect of carvedilol by  affecting hepatic enzyme CYP2C9/10 metabolism. Significant interaction possible, monitor closely.
fluoxetine|carvedilol|20|Serious - Use Alternative|fluoxetine will increase the level or effect of carvedilol by  affecting hepatic enzyme CYP2D6 metabolism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
fluoxetine|carvedilol|2|Significant - Monitor Closely|fluoxetine will increase the level or effect of carvedilol by  affecting hepatic enzyme CYP2C9/10 metabolism. Potential for interaction, monitor.
carvedilol|formoterol|11|Significant - Monitor Closely|carvedilol decreases effects of formoterol by pharmacodynamic antagonism. Significant interaction possible, monitor closely.
carvedilol|formoterol|2|Significant - Monitor Closely|carvedilol increases and formoterol decreases serum potassium. Effect of interaction is not clear, use caution. Potential for interaction, monitor.
ibuprofen|carvedilol|11|Significant - Monitor Closely|ibuprofen decreases effects of carvedilol by pharmacodynamic antagonism. Significant interaction possible, monitor closely. Long term (>1 wk) NSAID use.  NSAIDs decrease prostaglandin synthesis.
carvedilol|ibuprofen|2|Significant - Monitor Closely|carvedilol and ibuprofen both increase  serum potassium. Potential for interaction, monitor.
indomethacin|carvedilol|11|Significant - Monitor Closely|indomethacin decreases effects of carvedilol by pharmacodynamic antagonism. Significant interaction possible, monitor closely. Long term (>1 wk) NSAID use.  NSAIDs decrease prostaglandin synthesis.
carvedilol|indomethacin|2|Significant - Monitor Closely|carvedilol and indomethacin both increase  serum potassium. Potential for interaction, monitor.
paroxetine|carvedilol|20|Serious - Use Alternative|paroxetine will increase the level or effect of carvedilol by  affecting hepatic enzyme CYP2D6 metabolism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
carvedilol|pirbuterol|11|Significant - Monitor Closely|carvedilol decreases effects of pirbuterol by pharmacodynamic antagonism. Significant interaction possible, monitor closely.
carvedilol|pirbuterol|2|Significant - Monitor Closely|carvedilol increases and pirbuterol decreases serum potassium. Effect of interaction is not clear, use caution. Potential for interaction, monitor.
piroxicam|carvedilol|11|Significant - Monitor Closely|piroxicam decreases effects of carvedilol by pharmacodynamic antagonism. Significant interaction possible, monitor closely. Long term (>1 wk) NSAID use.  NSAIDs decrease prostaglandin synthesis.
carvedilol|piroxicam|2|Significant - Monitor Closely|carvedilol and piroxicam both increase  serum potassium. Potential for interaction, monitor.
prazosin|carvedilol|3|Significant - Monitor Closely|prazosin and carvedilol both increase  anti-hypertensive channel blocking. Potential for dangerous interaction. Use with caution and monitor closely.
carvedilol|salmeterol|11|Significant - Monitor Closely|carvedilol decreases effects of salmeterol by pharmacodynamic antagonism. Significant interaction possible, monitor closely.
carvedilol|salmeterol|2|Significant - Monitor Closely|carvedilol increases and salmeterol decreases serum potassium. Effect of interaction is not clear, use caution. Potential for interaction, monitor.
sertraline|carvedilol|11|Significant - Monitor Closely|sertraline will increase the level or effect of carvedilol by  affecting hepatic enzyme CYP2D6 metabolism. Significant interaction possible, monitor closely.
terazosin|carvedilol|3|Significant - Monitor Closely|terazosin and carvedilol both increase  anti-hypertensive channel blocking. Potential for dangerous interaction. Use with caution and monitor closely.
carvedilol|terbutaline|11|Significant - Monitor Closely|carvedilol decreases effects of terbutaline by pharmacodynamic antagonism. Significant interaction possible, monitor closely.
carvedilol|terbutaline|2|Significant - Monitor Closely|carvedilol increases and terbutaline decreases serum potassium. Effect of interaction is not clear, use caution. Potential for interaction, monitor.
carvedilol|topotecan|22|Serious - Use Alternative|carvedilol will increase the level or effect of topotecan by  P-glycoprotein (MDR1) efflux transporter. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available. Product labeling for PO topotecan recommends avoiding concomitant use of P-gp inhibitors; the interaction with IV topotecan may be less severe but is still likely of clinical significance
treprostinil|carvedilol|1|Minor|treprostinil increases effects of carvedilol by pharmacodynamic synergism. Minor or non-significant interaction.
carvedilol|verapamil|3|Significant - Monitor Closely|carvedilol and verapamil both increase  anti-hypertensive channel blocking. Potential for dangerous interaction. Use with caution and monitor closely.
cyclosporine|caspofungin|20|Serious - Use Alternative|cyclosporine increases levels of caspofungin by unknown mechanism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
caspofungin|tacrolimus|1|Minor|caspofungin decreases levels of tacrolimus by unspecified interaction mechanism. Minor or non-significant interaction.
cefaclor|probenecid|11|Significant - Monitor Closely|cefaclor will increase the level or effect of probenecid by  acidic (anionic) drug competition for renal tubular clearance. Significant interaction possible, monitor closely.
cefadroxil|probenecid|11|Significant - Monitor Closely|cefadroxil will increase the level or effect of probenecid by  acidic (anionic) drug competition for renal tubular clearance. Significant interaction possible, monitor closely.
cefamandole|probenecid|11|Significant - Monitor Closely|cefamandole will increase the level or effect of probenecid by  acidic (anionic) drug competition for renal tubular clearance. Significant interaction possible, monitor closely.
probenecid|cefazolin|11|Significant - Monitor Closely|probenecid increases levels of cefazolin by acidic (anionic) drug competition for renal tubular clearance. Significant interaction possible, monitor closely.
cimetidine|cefditoren|2|Significant - Monitor Closely|cimetidine will decrease the level or effect of cefditoren by  increasing gastric pH. Applies only to oral form of both agents. Potential for interaction, monitor.
famotidine|cefditoren|2|Significant - Monitor Closely|famotidine will decrease the level or effect of cefditoren by  increasing gastric pH. Applies only to oral form of both agents. Potential for interaction, monitor.
nizatidine|cefditoren|2|Significant - Monitor Closely|nizatidine will decrease the level or effect of cefditoren by  increasing gastric pH. Applies only to oral form of both agents. Potential for interaction, monitor.
ranitidine|cefditoren|2|Significant - Monitor Closely|ranitidine will decrease the level or effect of cefditoren by  increasing gastric pH. Applies only to oral form of both agents. Potential for interaction, monitor.
probenecid|cefepime|11|Significant - Monitor Closely|probenecid will increase the level or effect of cefepime by  acidic (anionic) drug competition for renal tubular clearance. Significant interaction possible, monitor closely.
probenecid|cefixime|11|Significant - Monitor Closely|probenecid will increase the level or effect of cefixime by  acidic (anionic) drug competition for renal tubular clearance. Significant interaction possible, monitor closely.
probenecid|cefotaxime|11|Significant - Monitor Closely|probenecid will increase the level or effect of cefotaxime by  acidic (anionic) drug competition for renal tubular clearance. Significant interaction possible, monitor closely.
probenecid|cefotetan|11|Significant - Monitor Closely|probenecid will increase the level or effect of cefotetan by  acidic (anionic) drug competition for renal tubular clearance. Significant interaction possible, monitor closely.
cefotetan|warfarin|20|Serious - Use Alternative|cefotetan increases effects of warfarin by anticoagulation. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available. cephalosporins may decrease prothrombin activity.
probenecid|cefoxitin|11|Significant - Monitor Closely|probenecid will increase the level or effect of cefoxitin by  acidic (anionic) drug competition for renal tubular clearance. Significant interaction possible, monitor closely.
cefoxitin|warfarin|20|Serious - Use Alternative|cefoxitin will increase the level or effect of warfarin by  Other (see comment). Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available. Decr vitamin K-producing intestinal flora may increase INR after a few days.
cefoxitin|warfarin|20|Serious - Use Alternative|cefoxitin increases effects of warfarin by anticoagulation. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available. cephalosporins may decrease prothrombin activity.
probenecid|cefprozil|11|Significant - Monitor Closely|probenecid will increase the level or effect of cefprozil by  acidic (anionic) drug competition for renal tubular clearance. Significant interaction possible, monitor closely.
ceftizoxime|probenecid|11|Significant - Monitor Closely|ceftizoxime will increase the level or effect of probenecid by  acidic (anionic) drug competition for renal tubular clearance. Significant interaction possible, monitor closely.
ceftriaxone|warfarin|20|Serious - Use Alternative|ceftriaxone increases effects of warfarin by anticoagulation. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available. cephalosporins may decrease prothrombin activity.
ceftriaxone|warfarin|11|Significant - Monitor Closely|ceftriaxone increases effects of warfarin by Other (see comment). Significant interaction possible, monitor closely. Comment: Decr vitamin K-producing intestinal flora may increase INR after a few days.
probenecid|cefuroxime|11|Significant - Monitor Closely|probenecid will increase the level or effect of cefuroxime by  acidic (anionic) drug competition for renal tubular clearance. Significant interaction possible, monitor closely.
eltrombopag|celecoxib|11|Significant - Monitor Closely|eltrombopag increases levels of celecoxib by decreasing metabolism. Significant interaction possible, monitor closely. UGT inhibition; significance of interaction unclear.
fluconazole|celecoxib|1|Minor|fluconazole will increase the level or effect of celecoxib by  affecting hepatic enzyme CYP2C9/10 metabolism. Minor or non-significant interaction.
celecoxib|lithium|11|Significant - Monitor Closely|celecoxib increases levels of lithium by decreasing renal clearance. Significant interaction possible, monitor closely.
celecoxib|pralatrexate|11|Significant - Monitor Closely|celecoxib increases levels of pralatrexate by decreasing renal clearance. Significant interaction possible, monitor closely. NSAIDs may delay pralatrexate clearance, increasing drug exposure. Adjust the pralatrexate dose as needed.
telmisartan|celecoxib|11|Significant - Monitor Closely|telmisartan, celecoxib.Either increases toxicity of the other by Other (see comment). Significant interaction possible, monitor closely. Comment: May result in renal function deterioration, particularly in elderly or volume depleted individuals.
celecoxib|telmisartan|3|Significant - Monitor Closely|celecoxib decreases effects of telmisartan by pharmacodynamic antagonism. Potential for dangerous interaction. Use with caution and monitor closely.  NSAIDs decrease synthesis of vasodilating renal prostaglandins, and thus affect fluid homeostasis and may diminish antihypertensive effect.
telmisartan|celecoxib|2|Significant - Monitor Closely|telmisartan and celecoxib both increase  serum potassium. Potential for interaction, monitor.
celecoxib|timolol|11|Significant - Monitor Closely|celecoxib will increase the level or effect of timolol by  affecting hepatic enzyme CYP2D6 metabolism. Significant interaction possible, monitor closely.
celecoxib|timolol|11|Significant - Monitor Closely|celecoxib decreases effects of timolol by pharmacodynamic antagonism. Significant interaction possible, monitor closely. Long term (>1 wk) NSAID use.  NSAIDs decrease prostaglandin synthesis.
timolol|celecoxib|2|Significant - Monitor Closely|timolol and celecoxib both increase  serum potassium. Potential for interaction, monitor.
celecoxib|tolbutamide|11|Significant - Monitor Closely|celecoxib increases effects of tolbutamide by unknown mechanism. Significant interaction possible, monitor closely. Risk of hypoglycemia.
trandolapril|celecoxib|11|Significant - Monitor Closely|trandolapril, celecoxib.Either increases toxicity of the other by Other (see comment). Significant interaction possible, monitor closely. Comment: May result in renal function deterioration, particularly in elderly or volume depleted individuals.
celecoxib|trandolapril|3|Significant - Monitor Closely|celecoxib decreases effects of trandolapril by pharmacodynamic antagonism. Potential for dangerous interaction. Use with caution and monitor closely. NSAIDs decrease synthesis of vasodilating renal prostaglandins, and thus affect fluid homeostasis and may diminish antihypertenisve effect.
warfarin|celecoxib|3|Significant - Monitor Closely|warfarin and celecoxib both increase  anticoagulation. Potential for dangerous interaction. Use with caution and monitor closely.
terazosin|celiprolol|3|Significant - Monitor Closely|terazosin and celiprolol both increase  anti-hypertensive channel blocking. Potential for dangerous interaction. Use with caution and monitor closely.
treprostinil|celiprolol|1|Minor|treprostinil increases effects of celiprolol by pharmacodynamic synergism. Minor or non-significant interaction.
cephalexin|probenecid|11|Significant - Monitor Closely|cephalexin will increase the level or effect of probenecid by  acidic (anionic) drug competition for renal tubular clearance. Significant interaction possible, monitor closely.
etanercept|certolizumab pegol|20|Serious - Use Alternative|etanercept and certolizumab pegol both increase  immunosuppressive effects; risk of infection. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available. Avoid combination because of an increased risk of serious infection.
golimumab|certolizumab pegol|20|Serious - Use Alternative|golimumab and certolizumab pegol both increase  immunosuppressive effects; risk of infection. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available. Avoid combination because of an increased risk of serious infection.
infliximab|certolizumab pegol|20|Serious - Use Alternative|infliximab and certolizumab pegol both increase  immunosuppressive effects; risk of infection. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available. Avoid combination because of an increased risk of serious infection.
natalizumab|certolizumab pegol|20|Serious - Use Alternative|natalizumab and certolizumab pegol both increase  immunosuppressive effects; risk of infection. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available. Avoid combination because of an increased risk of serious infection.
rituximab|certolizumab pegol|20|Serious - Use Alternative|rituximab and certolizumab pegol both increase  immunosuppressive effects; risk of infection. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available. Avoid combination because of an increased risk of serious infection.
certolizumab pegol|tofacitinib|20|Serious - Use Alternative|certolizumab pegol, tofacitinib.Either increases toxicity of the other by immunosuppressive effects; risk of infection. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
conivaptan|cevimeline|1|Minor|conivaptan will increase the level or effect of cevimeline by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor or non-significant interaction.
tacrine|cevimeline|11|Significant - Monitor Closely|tacrine increases effects of cevimeline by pharmacodynamic synergism. Significant interaction possible, monitor closely.
cevimeline|tacrine|2|Significant - Monitor Closely|cevimeline and tacrine both increase  cholinergic effects/transmission. Potential for interaction, monitor.
triprolidine|chloral hydrate|2|Significant - Monitor Closely|triprolidine and chloral hydrate both increase  sedation. Potential for interaction, monitor.
chloramphenicol|chlorpropamide|1|Minor|chloramphenicol increases levels of chlorpropamide by decreasing metabolism. Minor or non-significant interaction.
chloramphenicol|ethotoin|1|Minor|chloramphenicol increases levels of ethotoin by decreasing metabolism. Minor or non-significant interaction.
chloramphenicol|fosphenytoin|11|Significant - Monitor Closely|chloramphenicol increases levels of fosphenytoin by decreasing metabolism. Significant interaction possible, monitor closely.
chloramphenicol|glipizide|1|Minor|chloramphenicol increases levels of glipizide by decreasing metabolism. Minor or non-significant interaction.
chloramphenicol|glyburide|1|Minor|chloramphenicol increases levels of glyburide by decreasing metabolism. Minor or non-significant interaction.
chloramphenicol|lurasidone|33|Contraindicated|chloramphenicol increases levels of lurasidone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Never use combination. Coadministration of lurasidone and strong CYP3A4 inhibitors is contraindicated.
chloramphenicol|phenytoin|11|Significant - Monitor Closely|chloramphenicol increases levels of phenytoin by decreasing metabolism. Significant interaction possible, monitor closely.
chloramphenicol|tolazamide|1|Minor|chloramphenicol increases levels of tolazamide by decreasing metabolism. Minor or non-significant interaction.
chloramphenicol|tolbutamide|1|Minor|chloramphenicol increases levels of tolbutamide by decreasing metabolism. Minor or non-significant interaction.
cimetidine|chlordiazepoxide|11|Significant - Monitor Closely|cimetidine increases levels of chlordiazepoxide by decreasing metabolism. Significant interaction possible, monitor closely.
chlordiazepoxide|clozapine|2|Significant - Monitor Closely|chlordiazepoxide and clozapine both increase  sedation. Potential for interaction, monitor.
fluconazole|chlordiazepoxide|1|Minor|fluconazole increases levels of chlordiazepoxide by decreasing metabolism. Minor or non-significant interaction.
fosphenytoin|chlordiazepoxide|3|Significant - Monitor Closely|fosphenytoin will decrease the level or effect of chlordiazepoxide by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Potential for dangerous interaction. Use with caution and monitor closely.
indinavir|chlordiazepoxide|3|Significant - Monitor Closely|indinavir increases levels of chlordiazepoxide by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Potential for dangerous interaction. Use with caution and monitor closely. Potential for increased toxicity. Use alternatives if available. Consider lowering benzodiazepine dose.
itraconazole|chlordiazepoxide|1|Minor|itraconazole increases levels of chlordiazepoxide by decreasing metabolism. Minor or non-significant interaction.
ketoconazole|chlordiazepoxide|1|Minor|ketoconazole increases levels of chlordiazepoxide by decreasing metabolism. Minor or non-significant interaction.
nelfinavir|chlordiazepoxide|3|Significant - Monitor Closely|nelfinavir increases levels of chlordiazepoxide by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Potential for dangerous interaction. Use with caution and monitor closely. Potential for increased toxicity. Use alternatives if available. Consider lowering benzodiazepine dose.
omeprazole|chlordiazepoxide|1|Minor|omeprazole increases levels of chlordiazepoxide by decreasing metabolism. Minor or non-significant interaction.
phenytoin|chlordiazepoxide|3|Significant - Monitor Closely|phenytoin will decrease the level or effect of chlordiazepoxide by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Potential for dangerous interaction. Use with caution and monitor closely.
ritonavir|chlordiazepoxide|3|Significant - Monitor Closely|ritonavir increases levels of chlordiazepoxide by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Potential for dangerous interaction. Use with caution and monitor closely. Use alternatives if available. Potential for increased toxicity. Consider lowering benzodiazepine dose.
saquinavir|chlordiazepoxide|3|Significant - Monitor Closely|saquinavir increases levels of chlordiazepoxide by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Potential for dangerous interaction. Use with caution and monitor closely. Use alternatives if available. Consider lowering benzodiazepine dose.
tipranavir|chlordiazepoxide|3|Significant - Monitor Closely|tipranavir increases levels of chlordiazepoxide by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Potential for dangerous interaction. Use with caution and monitor closely. Use alternatives if available. Consider lowering benzodiazepine dose.
triprolidine|chlordiazepoxide|2|Significant - Monitor Closely|triprolidine and chlordiazepoxide both increase  sedation. Potential for interaction, monitor.
voriconazole|chlordiazepoxide|1|Minor|voriconazole increases levels of chlordiazepoxide by decreasing metabolism. Minor or non-significant interaction.
chloroquine|cyclosporine|2|Significant - Monitor Closely|chloroquine increases levels of cyclosporine by decreasing metabolism. Potential for interaction, monitor.
magnesium oxide|chloroquine|11|Significant - Monitor Closely|magnesium oxide will decrease the level or effect of chloroquine by  cation binding in GI tract. Significant interaction possible, monitor closely. Separate doses by at least 4 hr
chloroquine|praziquantel|1|Minor|chloroquine decreases levels of praziquantel by unspecified interaction mechanism. Minor or non-significant interaction.
chloroquine|tamoxifen|11|Significant - Monitor Closely|chloroquine decreases effects of tamoxifen by decreasing metabolism. Significant interaction possible, monitor closely. Inhibition of CYP2D6 metabolism to tamoxifen's active metabolite, endoxifen.
chloroquine|tamsulosin|2|Significant - Monitor Closely|chloroquine increases levels of tamsulosin by affecting hepatic enzyme CYP2D6 metabolism. Potential for interaction, monitor.
chloroquine|thioridazine|20|Serious - Use Alternative|chloroquine will increase the level or effect of thioridazine by  affecting hepatic enzyme CYP2D6 metabolism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
chloroquine|thioridazine|1|Minor|chloroquine increases levels of thioridazine by decreasing metabolism. Minor or non-significant interaction.
chloroquine|tramadol|2|Significant - Monitor Closely|chloroquine decreases effects of tramadol by affecting hepatic enzyme CYP2D6 metabolism. Potential for interaction, monitor. Decreased conversion of tramadol to active metabolite.
chloroquine|tramadol|2|Significant - Monitor Closely|chloroquine decreases effects of tramadol by decreasing metabolism. Potential for interaction, monitor. Decreased conversion of tramadol to active metabolite.
cholestyramine|chlorothiazide|11|Significant - Monitor Closely|cholestyramine decreases levels of chlorothiazide by inhibition of GI absorption. Applies only to oral form of both agents. Significant interaction possible, monitor closely.
colestipol|chlorothiazide|1|Minor|colestipol decreases levels of chlorothiazide by inhibition of GI absorption. Applies only to oral form of both agents. Minor or non-significant interaction.
chlorothiazide|digoxin|11|Significant - Monitor Closely|chlorothiazide increases effects of digoxin by pharmacodynamic synergism. Significant interaction possible, monitor closely. Hypokalemia increases digoxin effects.
digoxin|chlorothiazide|2|Significant - Monitor Closely|digoxin increases and chlorothiazide decreases serum potassium. Effect of interaction is not clear, use caution. Potential for interaction, monitor.
chlorothiazide|lithium|11|Significant - Monitor Closely|chlorothiazide increases toxicity of lithium by decreasing elimination. Significant interaction possible, monitor closely.
treprostinil|chlorothiazide|1|Minor|treprostinil increases effects of chlorothiazide by pharmacodynamic synergism. Minor or non-significant interaction.
chlorpromazine|cisapride|33|Contraindicated|chlorpromazine and cisapride both increase  QTc interval. Never use combination.
chlorpromazine|dexfenfluramine|11|Significant - Monitor Closely|chlorpromazine, dexfenfluramine. Mechanism: unknown. Significant interaction possible, monitor closely. Risk of cardiac arrhythmia or sudden death, more likely w/thioridazine than other phenothiazines.  Interaction more likely in certain predisposed pts. only.
chlorpromazine|dexfenfluramine|2|Significant - Monitor Closely|chlorpromazine increases and dexfenfluramine decreases sedation. Effect of interaction is not clear, use caution. Potential for interaction, monitor.
chlorpromazine|dextroamphetamine|11|Significant - Monitor Closely|chlorpromazine, dextroamphetamine. Mechanism: unknown. Significant interaction possible, monitor closely. Risk of cardiac arrhythmia or sudden death, more likely w/thioridazine than other phenothiazines.  Interaction more likely in certain predisposed pts. only.
chlorpromazine|dextroamphetamine|2|Significant - Monitor Closely|chlorpromazine increases and dextroamphetamine decreases sedation. Effect of interaction is not clear, use caution. Potential for interaction, monitor.
chlorpromazine|diethylpropion|11|Significant - Monitor Closely|chlorpromazine, diethylpropion. Mechanism: unknown. Significant interaction possible, monitor closely. Risk of cardiac arrhythmia or sudden death, more likely w/thioridazine than other phenothiazines.  Interaction more likely in certain predisposed pts. only.
chlorpromazine|diethylpropion|2|Significant - Monitor Closely|chlorpromazine increases and diethylpropion decreases sedation. Effect of interaction is not clear, use caution. Potential for interaction, monitor.
chlorpromazine|fenfluramine|11|Significant - Monitor Closely|chlorpromazine, fenfluramine. Mechanism: unknown. Significant interaction possible, monitor closely. Risk of cardiac arrhythmia or sudden death, more likely w/thioridazine than other phenothiazines.  Interaction more likely in certain predisposed pts. only.
chlorpromazine|fenfluramine|2|Significant - Monitor Closely|chlorpromazine increases and fenfluramine decreases sedation. Effect of interaction is not clear, use caution. Potential for interaction, monitor.
chlorpromazine|levofloxacin|3|Significant - Monitor Closely|chlorpromazine and levofloxacin both increase  QTc interval. Potential for dangerous interaction. Use with caution and monitor closely.
chlorpromazine|lumefantrine|22|Serious - Use Alternative|chlorpromazine and lumefantrine both increase  QTc interval. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available.
lumefantrine|chlorpromazine|2|Significant - Monitor Closely|lumefantrine will increase the level or effect of chlorpromazine by  affecting hepatic enzyme CYP2D6 metabolism. Potential for interaction, monitor.
chlorpromazine|methamphetamine|11|Significant - Monitor Closely|chlorpromazine, methamphetamine. Mechanism: unknown. Significant interaction possible, monitor closely. Risk of cardiac arrhythmia or sudden death, more likely w/thioridazine than other phenothiazines.  Interaction more likely in certain predisposed pts. only.
chlorpromazine|methamphetamine|2|Significant - Monitor Closely|chlorpromazine increases and methamphetamine decreases sedation. Effect of interaction is not clear, use caution. Potential for interaction, monitor.
chlorpromazine|metrizamide|33|Contraindicated|chlorpromazine, metrizamide. Mechanism: unknown. Never use combination. Risk of seizure.  D/C phenothiazine 24h before admin. of metrizamide.
meperidine|chlorpromazine|2|Significant - Monitor Closely|meperidine and chlorpromazine both increase  sedation. Potential for interaction, monitor.
chlorpromazine|phendimetrazine|11|Significant - Monitor Closely|chlorpromazine, phendimetrazine. Mechanism: unknown. Significant interaction possible, monitor closely. Risk of cardiac arrhythmia or sudden death, more likely w/thioridazine than other phenothiazines.  Interaction more likely in certain predisposed pts. only.
chlorpromazine|phendimetrazine|2|Significant - Monitor Closely|chlorpromazine increases and phendimetrazine decreases sedation. Effect of interaction is not clear, use caution. Potential for interaction, monitor.
chlorpromazine|phentermine|11|Significant - Monitor Closely|chlorpromazine, phentermine. Mechanism: unknown. Significant interaction possible, monitor closely. Risk of cardiac arrhythmia or sudden death, more likely w/thioridazine than other phenothiazines.  Interaction more likely in certain predisposed pts. only.
chlorpromazine|phentermine|2|Significant - Monitor Closely|chlorpromazine increases and phentermine decreases sedation. Effect of interaction is not clear, use caution. Potential for interaction, monitor.
propranolol|chlorpromazine|21|Serious - Use Alternative|propranolol, chlorpromazine.Either increases levels of the other by decreasing metabolism. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available. Never use combination. Not all beta blockers share this interaction (e.g., atenolol, nadolol, sotalol do not interact).
chlorpromazine|tamoxifen|11|Significant - Monitor Closely|chlorpromazine, tamoxifen. affecting hepatic enzyme CYP2D6 metabolism. Significant interaction possible, monitor closely. CYP2D6 inhibition decreases metabolism of tamoxifen to  hydroxytamoxifen, and N-desmethyl tamoxifen to endoxifen (active metabolites with 100-fold greater affinity for estrogen receptor); decreased endoxifen levels may result in poor clinical outcome.
chlorpromazine|tamsulosin|2|Significant - Monitor Closely|chlorpromazine increases levels of tamsulosin by affecting hepatic enzyme CYP2D6 metabolism. Potential for interaction, monitor.
chlorpromazine|terfenadine|33|Contraindicated|chlorpromazine and terfenadine both increase  QTc interval. Never use combination.
terfenadine|chlorpromazine|2|Significant - Monitor Closely|terfenadine and chlorpromazine both increase  sedation. Potential for interaction, monitor.
chlorpromazine|tetrabenazine|3|Significant - Monitor Closely|chlorpromazine and tetrabenazine both increase  antidopaminergic effects, including extrapyramidal symptoms and neuroleptic malignant syndrome. Potential for dangerous interaction. Use with caution and monitor closely.
chlorpromazine|thioridazine|22|Serious - Use Alternative|chlorpromazine and thioridazine both increase  QTc interval. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available.
chlorpromazine|thioridazine|2|Significant - Monitor Closely|chlorpromazine and thioridazine both increase  antidopaminergic effects, including extrapyramidal symptoms and neuroleptic malignant syndrome. Potential for interaction, monitor.
chlorpromazine|thioridazine|2|Significant - Monitor Closely|chlorpromazine and thioridazine both increase  sedation. Potential for interaction, monitor.
thioridazine|chlorpromazine|1|Minor|thioridazine will increase the level or effect of chlorpromazine by  affecting hepatic enzyme CYP2D6 metabolism. Minor or non-significant interaction.
chlorpromazine|thiothixene|2|Significant - Monitor Closely|chlorpromazine and thiothixene both increase  antidopaminergic effects, including extrapyramidal symptoms and neuroleptic malignant syndrome. Potential for interaction, monitor.
chlorpromazine|thiothixene|2|Significant - Monitor Closely|chlorpromazine and thiothixene both increase  sedation. Potential for interaction, monitor.
tolterodine|chlorpromazine|11|Significant - Monitor Closely|tolterodine decreases levels of chlorpromazine by inhibition of GI absorption. Applies only to oral form of both agents. Significant interaction possible, monitor closely.
tolterodine|chlorpromazine|11|Significant - Monitor Closely|tolterodine decreases levels of chlorpromazine by pharmacodynamic antagonism. Significant interaction possible, monitor closely.
chlorpromazine|tolterodine|11|Significant - Monitor Closely|chlorpromazine increases effects of tolterodine by pharmacodynamic synergism. Significant interaction possible, monitor closely. Additive anticholinergic effects, possible hypoglycemia.
tramadol|chlorpromazine|2|Significant - Monitor Closely|tramadol and chlorpromazine both increase  sedation. Potential for interaction, monitor.
chlorpromazine|trimipramine|22|Serious - Use Alternative|chlorpromazine and trimipramine both increase  QTc interval. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available.
chlorpromazine|trimipramine|2|Significant - Monitor Closely|chlorpromazine and trimipramine both increase  sedation. Potential for interaction, monitor.
trimipramine|chlorpromazine|1|Minor|trimipramine, chlorpromazine.Either increases levels of the other by decreasing metabolism. Minor or non-significant interaction. Additive anticholinergic effects.
trimipramine|chlorpromazine|1|Minor|trimipramine, chlorpromazine.Either increases levels of the other by pharmacodynamic synergism. Minor or non-significant interaction. Additive anticholinergic effects.
triprolidine|chlorpromazine|2|Significant - Monitor Closely|triprolidine and chlorpromazine both increase  sedation. Potential for interaction, monitor.
chlorpromazine|venlafaxine|3|Significant - Monitor Closely|chlorpromazine and venlafaxine both increase  QTc interval. Potential for dangerous interaction. Use with caution and monitor closely.
venlafaxine|chlorpromazine|2|Significant - Monitor Closely|venlafaxine will increase the level or effect of chlorpromazine by  affecting hepatic enzyme CYP2D6 metabolism. Potential for interaction, monitor.
chlorpromazine|ziprasidone|22|Serious - Use Alternative|chlorpromazine and ziprasidone both increase  QTc interval. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available.
chlorpromazine|ziprasidone|2|Significant - Monitor Closely|chlorpromazine and ziprasidone both increase  antidopaminergic effects, including extrapyramidal symptoms and neuroleptic malignant syndrome. Potential for interaction, monitor.
chlorpromazine|ziprasidone|2|Significant - Monitor Closely|chlorpromazine and ziprasidone both increase  sedation. Potential for interaction, monitor.
nadolol|chlorpropamide|11|Significant - Monitor Closely|nadolol decreases effects of chlorpropamide by pharmacodynamic antagonism. Significant interaction possible, monitor closely. Non selective beta blockers may also mask the symptoms of hypoglycemia.
pindolol|chlorpropamide|11|Significant - Monitor Closely|pindolol decreases effects of chlorpropamide by pharmacodynamic antagonism. Significant interaction possible, monitor closely. Non selective beta blockers may also mask the symptoms of hypoglycemia.
propranolol|chlorpropamide|11|Significant - Monitor Closely|propranolol decreases effects of chlorpropamide by pharmacodynamic antagonism. Significant interaction possible, monitor closely. Non selective beta blockers may also mask the symptoms of hypoglycemia.
salsalate|chlorpropamide|11|Significant - Monitor Closely|salsalate increases effects of chlorpropamide by unknown mechanism. Significant interaction possible, monitor closely. Risk of hypoglycemia.
salsalate|chlorpropamide|1|Minor|salsalate will increase the level or effect of chlorpropamide by  acidic (anionic) drug competition for renal tubular clearance. Minor or non-significant interaction.
salsalate|chlorpropamide|1|Minor|salsalate increases effects of chlorpropamide by plasma protein binding competition. Minor or non-significant interaction. Large dose of salicylate.
sulfadiazine|chlorpropamide|11|Significant - Monitor Closely|sulfadiazine increases levels of chlorpropamide by plasma protein binding competition. Significant interaction possible, monitor closely.
sulfamethoxazole|chlorpropamide|11|Significant - Monitor Closely|sulfamethoxazole increases levels of chlorpropamide by plasma protein binding competition. Significant interaction possible, monitor closely.
sulfasalazine|chlorpropamide|11|Significant - Monitor Closely|sulfasalazine increases effects of chlorpropamide by unknown mechanism. Significant interaction possible, monitor closely. Risk of hypoglycemia.
sulfasalazine|chlorpropamide|1|Minor|sulfasalazine will increase the level or effect of chlorpropamide by  acidic (anionic) drug competition for renal tubular clearance. Minor or non-significant interaction.
sulfasalazine|chlorpropamide|1|Minor|sulfasalazine increases effects of chlorpropamide by plasma protein binding competition. Minor or non-significant interaction. Large dose of salicylate.
sulfisoxazole|chlorpropamide|11|Significant - Monitor Closely|sulfisoxazole increases levels of chlorpropamide by plasma protein binding competition. Significant interaction possible, monitor closely.
timolol|chlorpropamide|11|Significant - Monitor Closely|timolol decreases effects of chlorpropamide by pharmacodynamic antagonism. Significant interaction possible, monitor closely. Non selective beta blockers may also mask the symptoms of hypoglycemia.
voriconazole|chlorpropamide|11|Significant - Monitor Closely|voriconazole increases levels of chlorpropamide by decreasing metabolism. Significant interaction possible, monitor closely.
diazoxide|chlorthalidone|1|Minor|diazoxide, chlorthalidone. Mechanism: pharmacodynamic synergism. Minor or non-significant interaction. Risk of hyperglycemia.
chlorthalidone|digoxin|11|Significant - Monitor Closely|chlorthalidone increases effects of digoxin by pharmacodynamic synergism. Significant interaction possible, monitor closely. Hypokalemia increases digoxin effects.
digoxin|chlorthalidone|2|Significant - Monitor Closely|digoxin increases and chlorthalidone decreases serum potassium. Effect of interaction is not clear, use caution. Potential for interaction, monitor.
chlorthalidone|lithium|11|Significant - Monitor Closely|chlorthalidone increases toxicity of lithium by decreasing elimination. Significant interaction possible, monitor closely.
treprostinil|chlorthalidone|1|Minor|treprostinil increases effects of chlorthalidone by pharmacodynamic synergism. Minor or non-significant interaction.
cholestyramine|vitamin d|2|Significant - Monitor Closely|cholestyramine will decrease the level or effect of vitamin d by  Other (see comment). Potential for interaction, monitor. Bile acid sequestrants may decrease the absorption of fat-soluble vitamins. Administer vitamin supplementation at least 4 hours prior to cholestyramine.
colesevelam|vitamin d|2|Significant - Monitor Closely|colesevelam will decrease the level or effect of vitamin d by  Other (see comment). Potential for interaction, monitor. Bile acid sequestrants may decrease the absorption of fat-soluble vitamins. Administer vitamin supplementation at least 4 hours prior to colesevelam.
colestipol|vitamin d|2|Significant - Monitor Closely|colestipol will decrease the level or effect of vitamin d by  Other (see comment). Potential for interaction, monitor. Bile acid sequestrants may decrease the absorption of fat-soluble vitamins. Administer vitamin supplementation at least 4 hours prior to colestipol.
orlistat|vitamin d|2|Significant - Monitor Closely|orlistat will decrease the level or effect of vitamin d by  Other (see comment). Potential for interaction, monitor. When combination must be used, may consider administering vitamin D at least 2 hours before or after administration of orlistat.
vitamin d|sucralfate|11|Significant - Monitor Closely|vitamin d increases levels of sucralfate by Other (see comment). Significant interaction possible, monitor closely. Comment: Avoid coadministration. Vitamin D analogs may increase the absorption of aluminum from sucralfate. .
cholestyramine|digoxin|11|Significant - Monitor Closely|cholestyramine decreases levels of digoxin by inhibition of GI absorption. Applies only to oral form of both agents. Significant interaction possible, monitor closely.
cholestyramine|ezetimibe|11|Significant - Monitor Closely|cholestyramine decreases levels of ezetimibe by inhibition of GI absorption. Applies only to oral form of both agents. Significant interaction possible, monitor closely. Separate by 2-4 hours.
cholestyramine|fluvastatin|11|Significant - Monitor Closely|cholestyramine decreases levels of fluvastatin by inhibition of GI absorption. Applies only to oral form of both agents. Significant interaction possible, monitor closely.
cholestyramine|hydrocortisone|11|Significant - Monitor Closely|cholestyramine decreases levels of hydrocortisone by inhibition of GI absorption. Applies only to oral form of both agents. Significant interaction possible, monitor closely.
cholestyramine|levothyroxine|11|Significant - Monitor Closely|cholestyramine decreases levels of levothyroxine by inhibition of GI absorption. Applies only to oral form of both agents. Significant interaction possible, monitor closely.
cholestyramine|liothyronine|11|Significant - Monitor Closely|cholestyramine decreases levels of liothyronine by inhibition of GI absorption. Applies only to oral form of both agents. Significant interaction possible, monitor closely.
cholestyramine|lomitapide|11|Significant - Monitor Closely|cholestyramine decreases levels of lomitapide by drug binding in GI tract. Significant interaction possible, monitor closely. Separate lomitapide and administration of bile acid sequestrants by at least 4 hours; bile acid sequestrants can interfere with the absorption of oral medications.
cholestyramine|methotrexate|11|Significant - Monitor Closely|cholestyramine decreases levels of methotrexate by inhibition of GI absorption. Applies only to oral form of both agents. Significant interaction possible, monitor closely. To minimize drug interactions, administer other drugs at least 1 hour before or at least 4-6 hours after the administration of cholestyramine.
cholestyramine|raloxifene|11|Significant - Monitor Closely|cholestyramine decreases levels of raloxifene by inhibition of GI absorption. Applies only to oral form of both agents. Significant interaction possible, monitor closely.
cholestyramine|spironolactone|2|Significant - Monitor Closely|cholestyramine, spironolactone. unspecified interaction mechanism. Potential for interaction, monitor. Hyperkalemic metabolic acidosis reported when coadministered.
cholestyramine|troglitazone|11|Significant - Monitor Closely|cholestyramine decreases levels of troglitazone by inhibition of GI absorption. Applies only to oral form of both agents. Significant interaction possible, monitor closely.
cholestyramine|warfarin|11|Significant - Monitor Closely|cholestyramine decreases levels of warfarin by inhibition of GI absorption. Applies only to oral form of both agents. Significant interaction possible, monitor closely.
diltiazem|cilostazol|11|Significant - Monitor Closely|diltiazem will increase the level or effect of cilostazol by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely. A dosing regimen of cilostazol 50 mg twice daily should be considered when administered with diltiazem.
fluconazole|cilostazol|20|Serious - Use Alternative|fluconazole increases toxicity of cilostazol by affecting hepatic enzyme CYP2C19 metabolism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available. Decrease cilostazol dose by 50%; serum levels of 3,4-dehydrocilostazol (active metabolite) increased by strong CYP2C19 inhibitors.
fluconazole|cilostazol|11|Significant - Monitor Closely|fluconazole will increase the level or effect of cilostazol by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
fluoxetine|cilostazol|3|Significant - Monitor Closely|fluoxetine increases toxicity of cilostazol by affecting hepatic enzyme CYP2C19 metabolism. Potential for dangerous interaction. Use with caution and monitor closely. Consider decreasing cilostazol dose; moderate CYP2C19 inhibitors may increase  serum levels of 3,4-dehydrocilostazol (active metabolite).
fluvoxamine|cilostazol|20|Serious - Use Alternative|fluvoxamine increases toxicity of cilostazol by affecting hepatic enzyme CYP2C19 metabolism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available. Decrease cilostazol dose by 50%; serum levels of 3,4-dehydrocilostazol (active metabolite) increased by strong CYP2C19 inhibitors.
fluvoxamine|cilostazol|11|Significant - Monitor Closely|fluvoxamine will increase the level or effect of cilostazol by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
ginkgo biloba|cilostazol|1|Minor|ginkgo biloba, cilostazol. pharmacodynamic synergism. Minor or non-significant interaction. May prolong bleeding time.  Conflicting evidence.Ã¿ Use with caution.
itraconazole|cilostazol|20|Serious - Use Alternative|itraconazole will increase the level or effect of cilostazol by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
ketoconazole|cilostazol|20|Serious - Use Alternative|ketoconazole will increase the level or effect of cilostazol by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
ketoconazole|cilostazol|3|Significant - Monitor Closely|ketoconazole increases toxicity of cilostazol by affecting hepatic enzyme CYP2C19 metabolism. Potential for dangerous interaction. Use with caution and monitor closely. Consider decreasing cilostazol dose; moderate CYP2C19 inhibitors may increase  serum levels of 3,4-dehydrocilostazol (active metabolite).
nefazodone|cilostazol|20|Serious - Use Alternative|nefazodone will increase the level or effect of cilostazol by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
omeprazole|cilostazol|20|Serious - Use Alternative|omeprazole will increase the level or effect of cilostazol by  affecting hepatic enzyme CYP2C19 metabolism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
sertraline|cilostazol|3|Significant - Monitor Closely|sertraline increases toxicity of cilostazol by affecting hepatic enzyme CYP2C19 metabolism. Potential for dangerous interaction. Use with caution and monitor closely. Consider decreasing cilostazol dose; moderate CYP2C19 inhibitors may increase  serum levels of 3,4-dehydrocilostazol (active metabolite).
telithromycin|cilostazol|11|Significant - Monitor Closely|telithromycin will increase the level or effect of cilostazol by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
ticlopidine|cilostazol|20|Serious - Use Alternative|ticlopidine increases toxicity of cilostazol by affecting hepatic enzyme CYP2C19 metabolism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available. Decrease cilostazol dose by 50%; serum levels of 3,4-dehydrocilostazol (active metabolite) increased by strong CYP2C19 inhibitors.
voriconazole|cilostazol|11|Significant - Monitor Closely|voriconazole will increase the level or effect of cilostazol by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
cimetidine|clomipramine|11|Significant - Monitor Closely|cimetidine will increase the level or effect of clomipramine by  affecting hepatic enzyme CYP1A2 metabolism. Significant interaction possible, monitor closely.
cimetidine|clomipramine|2|Significant - Monitor Closely|cimetidine will increase the level or effect of clomipramine by  affecting hepatic enzyme CYP2D6 metabolism. Potential for interaction, monitor.
cimetidine|clomipramine|2|Significant - Monitor Closely|cimetidine will increase the level or effect of clomipramine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Potential for interaction, monitor.
cimetidine|clonazepam|11|Significant - Monitor Closely|cimetidine increases levels of clonazepam by decreasing metabolism. Significant interaction possible, monitor closely.
cimetidine|clorazepate|11|Significant - Monitor Closely|cimetidine increases levels of clorazepate by decreasing metabolism. Significant interaction possible, monitor closely.
cimetidine|clozapine|20|Serious - Use Alternative|cimetidine will increase the level or effect of clozapine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
cimetidine|clozapine|11|Significant - Monitor Closely|cimetidine will increase the level or effect of clozapine by  affecting hepatic enzyme CYP1A2 metabolism. Significant interaction possible, monitor closely.
cimetidine|codeine|20|Serious - Use Alternative|cimetidine increases effects of codeine by decreasing metabolism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
cimetidine|codeine|1|Minor|cimetidine will increase the level or effect of codeine by  affecting hepatic enzyme CYP2D6 metabolism. Minor or non-significant interaction.
cimetidine|desipramine|11|Significant - Monitor Closely|cimetidine will increase the level or effect of desipramine by  affecting hepatic enzyme CYP2D6 metabolism. Significant interaction possible, monitor closely.
cimetidine|desipramine|2|Significant - Monitor Closely|cimetidine will increase the level or effect of desipramine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Potential for interaction, monitor.
cimetidine|diazepam|20|Serious - Use Alternative|cimetidine will increase the level or effect of diazepam by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
cimetidine|dofetilide|33|Contraindicated|cimetidine increases levels of dofetilide by decreasing renal clearance. Never use combination. Risk of prolonged QTc interval.
cimetidine|dofetilide|20|Serious - Use Alternative|cimetidine will increase the level or effect of dofetilide by  basic (cationic) drug competition for renal tubular clearance. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
cimetidine|donepezil|2|Significant - Monitor Closely|cimetidine will increase the level or effect of donepezil by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Potential for interaction, monitor.
cimetidine|donepezil|1|Minor|cimetidine will increase the level or effect of donepezil by  affecting hepatic enzyme CYP2D6 metabolism. Minor or non-significant interaction.
cimetidine|doxepin|11|Significant - Monitor Closely|cimetidine will increase the level or effect of doxepin by  affecting hepatic enzyme CYP2D6 metabolism. Significant interaction possible, monitor closely.
cimetidine|eltrombopag|1|Minor|cimetidine will increase the level or effect of eltrombopag by  affecting hepatic enzyme CYP1A2 metabolism. Minor or non-significant interaction.
cimetidine|eltrombopag|1|Minor|cimetidine will increase the level or effect of eltrombopag by  affecting hepatic enzyme CYP2C9/10 metabolism. Minor or non-significant interaction.
cimetidine|epirubicin|11|Significant - Monitor Closely|cimetidine increases levels of epirubicin by decreasing metabolism. Significant interaction possible, monitor closely. Cimetidine increased the AUC of epirubicin by 50%. Cimetidine treatment should be stopped during treatment with epirubicin.
cimetidine|ethotoin|11|Significant - Monitor Closely|cimetidine will increase the level or effect of ethotoin by  affecting hepatic enzyme CYP2C9/10 metabolism. Significant interaction possible, monitor closely.
cimetidine|fentanyl|20|Serious - Use Alternative|cimetidine increases effects of fentanyl by decreasing metabolism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
cimetidine|fentanyl|2|Significant - Monitor Closely|cimetidine will increase the level or effect of fentanyl by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Potential for interaction, monitor.
cimetidine|flecainide|11|Significant - Monitor Closely|cimetidine will increase the level or effect of flecainide by  affecting hepatic enzyme CYP2D6 metabolism. Significant interaction possible, monitor closely. Flecainide dosage should be carefully titrated on initiation of therapy. Careful monitoring of flecainide plasma concentration should be instituted when cimetidine is coadministered or discontinued.
cimetidine|fosphenytoin|11|Significant - Monitor Closely|cimetidine will increase the level or effect of fosphenytoin by  affecting hepatic enzyme CYP2C9/10 metabolism. Significant interaction possible, monitor closely.
cimetidine|galantamine|2|Significant - Monitor Closely|cimetidine will increase the level or effect of galantamine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Potential for interaction, monitor.
cimetidine|galantamine|1|Minor|cimetidine will increase the level or effect of galantamine by  affecting hepatic enzyme CYP2D6 metabolism. Minor or non-significant interaction.
cimetidine|imipramine|11|Significant - Monitor Closely|cimetidine will increase the level or effect of imipramine by  affecting hepatic enzyme CYP1A2 metabolism. Significant interaction possible, monitor closely.
cimetidine|imipramine|11|Significant - Monitor Closely|cimetidine will increase the level or effect of imipramine by  affecting hepatic enzyme CYP2D6 metabolism. Significant interaction possible, monitor closely.
cimetidine|imipramine|2|Significant - Monitor Closely|cimetidine will increase the level or effect of imipramine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Potential for interaction, monitor.
cimetidine|itraconazole|20|Serious - Use Alternative|cimetidine will decrease the level or effect of itraconazole by  increasing gastric pH. Applies only to oral form of both agents. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
cimetidine|itraconazole|2|Significant - Monitor Closely|cimetidine will increase the level or effect of itraconazole by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Potential for interaction, monitor.
cimetidine|ketoconazole|20|Serious - Use Alternative|cimetidine will decrease the level or effect of ketoconazole by  increasing gastric pH. Applies only to oral form of both agents. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
cimetidine|ketoconazole|2|Significant - Monitor Closely|cimetidine will increase the level or effect of ketoconazole by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Potential for interaction, monitor.
cimetidine|lidocaine|11|Significant - Monitor Closely|cimetidine will increase the level or effect of lidocaine by  affecting hepatic enzyme CYP1A2 metabolism. Significant interaction possible, monitor closely.
cimetidine|metformin|11|Significant - Monitor Closely|cimetidine will increase the level or effect of metformin by  basic (cationic) drug competition for renal tubular clearance. Significant interaction possible, monitor closely.
cimetidine|methadone|20|Serious - Use Alternative|cimetidine will increase the level or effect of methadone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
cimetidine|methadone|20|Serious - Use Alternative|cimetidine increases effects of methadone by decreasing metabolism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
cimetidine|metoprolol|11|Significant - Monitor Closely|cimetidine will increase the level or effect of metoprolol by  affecting hepatic enzyme CYP2D6 metabolism. Significant interaction possible, monitor closely.
cimetidine|midazolam|20|Serious - Use Alternative|cimetidine will increase the level or effect of midazolam by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
cimetidine|nalbuphine|20|Serious - Use Alternative|cimetidine increases effects of nalbuphine by decreasing metabolism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
cimetidine|nifedipine|2|Significant - Monitor Closely|cimetidine will increase the level or effect of nifedipine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Potential for interaction, monitor.
cimetidine|nimodipine|20|Serious - Use Alternative|cimetidine will increase the level or effect of nimodipine by  increasing gastric pH. Applies only to oral form of both agents. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
cimetidine|nimodipine|2|Significant - Monitor Closely|cimetidine will increase the level or effect of nimodipine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Potential for interaction, monitor.
cimetidine|nortriptyline|11|Significant - Monitor Closely|cimetidine will increase the level or effect of nortriptyline by  affecting hepatic enzyme CYP2D6 metabolism. Significant interaction possible, monitor closely.
cimetidine|oxycodone|20|Serious - Use Alternative|cimetidine increases effects of oxycodone by decreasing metabolism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
cimetidine|oxycodone|11|Significant - Monitor Closely|cimetidine will increase the level or effect of oxycodone by  affecting hepatic enzyme CYP2D6 metabolism. Significant interaction possible, monitor closely.
cimetidine|oxymorphone|20|Serious - Use Alternative|cimetidine increases effects of oxymorphone by decreasing metabolism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
cimetidine|oxymorphone|11|Significant - Monitor Closely|cimetidine will increase the level or effect of oxymorphone by  affecting hepatic enzyme CYP2D6 metabolism. Significant interaction possible, monitor closely.
cimetidine|pazopanib|20|Serious - Use Alternative|cimetidine will decrease the level or effect of pazopanib by  increasing gastric pH. Applies only to oral form of both agents. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available. Avoid coadministration of pazopanib with drugs that raise gastric pH; consider short-acting antacids in place of PPIs and H2 antagonists; separate antacid and pazopanib dosing by several hours
cimetidine|phenytoin|11|Significant - Monitor Closely|cimetidine will increase the level or effect of phenytoin by  affecting hepatic enzyme CYP2C9/10 metabolism. Significant interaction possible, monitor closely.
cimetidine|posaconazole|2|Significant - Monitor Closely|cimetidine will decrease the level or effect of posaconazole by  increasing gastric pH. Applies only to oral form of both agents. Potential for interaction, monitor.
cimetidine|pramipexole|11|Significant - Monitor Closely|cimetidine will increase the level or effect of pramipexole by  basic (cationic) drug competition for renal tubular clearance. Significant interaction possible, monitor closely.
cimetidine|procainamide|20|Serious - Use Alternative|cimetidine will increase the level or effect of procainamide by  basic (cationic) drug competition for renal tubular clearance. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
cimetidine|propranolol|11|Significant - Monitor Closely|cimetidine will increase the level or effect of propranolol by  affecting hepatic enzyme CYP2D6 metabolism. Significant interaction possible, monitor closely.
cimetidine|quinidine|20|Serious - Use Alternative|cimetidine will increase the level or effect of quinidine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
quinidine|cimetidine|20|Serious - Use Alternative|quinidine will increase the level or effect of cimetidine by  basic (cationic) drug competition for renal tubular clearance. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
cimetidine|roflumilast|3|Significant - Monitor Closely|cimetidine increases levels of roflumilast by Other (see comment). Potential for dangerous interaction. Use with caution and monitor closely. Comment: Coadministration with dual inhibitors of CYP3A4 and CYP1A2 may increase systemic exposure and result in increased adverse reactions.
cimetidine|sildenafil|20|Serious - Use Alternative|cimetidine will increase the level or effect of sildenafil by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
cimetidine|sufentanil|20|Serious - Use Alternative|cimetidine increases effects of sufentanil by decreasing metabolism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
cimetidine|sufentanil|2|Significant - Monitor Closely|cimetidine will increase the level or effect of sufentanil by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Potential for interaction, monitor.
cimetidine|tacrine|20|Serious - Use Alternative|cimetidine increases levels of tacrine by decreasing metabolism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
cimetidine|tacrine|1|Minor|cimetidine will increase the level or effect of tacrine by  affecting hepatic enzyme CYP1A2 metabolism. Minor or non-significant interaction.
cimetidine|tacrolimus|20|Serious - Use Alternative|cimetidine will increase the level or effect of tacrolimus by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
cimetidine|tamoxifen|11|Significant - Monitor Closely|cimetidine, tamoxifen. affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely. CYP3A4 inhibition decreases metabolism of tamoxifen to N-desmethyl tamoxifen (active metabolite with similar biologic activity).
cimetidine|tamsulosin|11|Significant - Monitor Closely|cimetidine increases levels of tamsulosin by decreasing renal clearance. Significant interaction possible, monitor closely. Decreases tamsulosin clearance by 26% resulting in increased AUC (44%).
cimetidine|tamsulosin|2|Significant - Monitor Closely|cimetidine increases levels of tamsulosin by affecting hepatic enzyme CYP2D6 metabolism. Potential for interaction, monitor.
cimetidine|terfenadine|33|Contraindicated|cimetidine increases levels of terfenadine by decreasing metabolism. Never use combination. Risk of QT interval prolongation.
cimetidine|terfenadine|22|Serious - Use Alternative|cimetidine will increase the level or effect of terfenadine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available.
cimetidine|theophylline|20|Serious - Use Alternative|cimetidine will increase the level or effect of theophylline by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
cimetidine|theophylline|11|Significant - Monitor Closely|cimetidine will increase the level or effect of theophylline by  affecting hepatic enzyme CYP1A2 metabolism. Significant interaction possible, monitor closely.
cimetidine|timolol|11|Significant - Monitor Closely|cimetidine will increase the level or effect of timolol by  affecting hepatic enzyme CYP2D6 metabolism. Significant interaction possible, monitor closely.
cimetidine|tizanidine|20|Serious - Use Alternative|cimetidine will increase the level or effect of tizanidine by  affecting hepatic enzyme CYP1A2 metabolism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
cimetidine|tolterodine|20|Serious - Use Alternative|cimetidine will increase the level or effect of tolterodine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
cimetidine|tolterodine|1|Minor|cimetidine will increase the level or effect of tolterodine by  affecting hepatic enzyme CYP2D6 metabolism. Minor or non-significant interaction.
cimetidine|tramadol|2|Significant - Monitor Closely|cimetidine decreases effects of tramadol by affecting hepatic enzyme CYP2D6 metabolism. Potential for interaction, monitor. Decreased conversion of tramadol to active metabolite.
cimetidine|tramadol|2|Significant - Monitor Closely|cimetidine decreases effects of tramadol by decreasing metabolism. Potential for interaction, monitor. Decreased conversion of tramadol to active metabolite.
cimetidine|trazodone|2|Significant - Monitor Closely|cimetidine will increase the level or effect of trazodone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Potential for interaction, monitor.
cimetidine|triazolam|20|Serious - Use Alternative|cimetidine will increase the level or effect of triazolam by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
cimetidine|vilazodone|20|Serious - Use Alternative|cimetidine increases levels of vilazodone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available. If intolerable adverse effects occur when coadministered with moderate CYP3A4 inhibitors, reduce daily dose to 20 mg.
cimetidine|warfarin|20|Serious - Use Alternative|cimetidine will increase the level or effect of warfarin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
cimetidine|warfarin|11|Significant - Monitor Closely|cimetidine will increase the level or effect of warfarin by  affecting hepatic enzyme CYP1A2 metabolism. Significant interaction possible, monitor closely.
cimetidine|warfarin|11|Significant - Monitor Closely|cimetidine will increase the level or effect of warfarin by  affecting hepatic enzyme CYP2C9/10 metabolism. Significant interaction possible, monitor closely.
cimetidine|zaleplon|2|Significant - Monitor Closely|cimetidine will increase the level or effect of zaleplon by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Potential for interaction, monitor.
itraconazole|cinacalcet|20|Serious - Use Alternative|itraconazole will increase the level or effect of cinacalcet by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
ketoconazole|cinacalcet|20|Serious - Use Alternative|ketoconazole will increase the level or effect of cinacalcet by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
cinacalcet|tamoxifen|11|Significant - Monitor Closely|cinacalcet, tamoxifen. affecting hepatic enzyme CYP2D6 metabolism. Significant interaction possible, monitor closely. CYP2D6 inhibition decreases metabolism of tamoxifen to  hydroxytamoxifen, and N-desmethyl tamoxifen to endoxifen (active metabolites with 100-fold greater affinity for estrogen receptor); decreased endoxifen levels may result in poor clinical outcome.
cinacalcet|tamsulosin|2|Significant - Monitor Closely|cinacalcet increases levels of tamsulosin by affecting hepatic enzyme CYP2D6 metabolism. Potential for interaction, monitor.
telithromycin|cinacalcet|11|Significant - Monitor Closely|telithromycin will increase the level or effect of cinacalcet by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
voriconazole|cinacalcet|11|Significant - Monitor Closely|voriconazole will increase the level or effect of cinacalcet by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
ciprofloxacin|clozapine|20|Serious - Use Alternative|ciprofloxacin will increase the level or effect of clozapine by  affecting hepatic enzyme CYP1A2 metabolism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available. Use caution when administering ciprofloxacin in patients receiving drugs that prolong the QT interval. At elevated serum concentrations, clozapine may produce clinically significant prolongation of the QTc interval.
ciprofloxacin|cyclosporine|2|Significant - Monitor Closely|ciprofloxacin will increase the level or effect of cyclosporine by  affecting hepatic enzyme CYP1A2 metabolism. Potential for interaction, monitor. Ciprofloxacin may cause transient elevations in serum creatinine in patients receiving concomitant cyclosporine and ciprofloxacin therapy. Ciprofloxacin may enhance the nephrotoxic effects of cyclosporine during concurrent use.
ciprofloxacin|duloxetine|11|Significant - Monitor Closely|ciprofloxacin will increase the level or effect of duloxetine by  affecting hepatic enzyme CYP1A2 metabolism. Significant interaction possible, monitor closely. Coadministration of CYP1A2 inhibiting quinolones with duloxetine may lead to significant increases in duloxetine levels, AUC, and half-life. Consider therapy modification if duloxetine is necessary.
ciprofloxacin|eltrombopag|2|Significant - Monitor Closely|ciprofloxacin will increase the level or effect of eltrombopag by  affecting hepatic enzyme CYP1A2 metabolism. Potential for interaction, monitor.
ciprofloxacin|foscarnet|1|Minor|ciprofloxacin, foscarnet. Mechanism: unknown. Minor or non-significant interaction. Based on 2 case reports it was reported that there is a potential for an increased risk of seizures.
ciprofloxacin|lomitapide|11|Significant - Monitor Closely|ciprofloxacin increases levels of lomitapide by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely. Lomitapide dose should not exceed 30 mg/day.
lomitapide|ciprofloxacin|3|Significant - Monitor Closely|lomitapide increases levels of ciprofloxacin by P-glycoprotein (MDR1) efflux transporter. Potential for dangerous interaction. Use with caution and monitor closely. Consider reducing dose when used concomitantly with lomitapide.
magnesium oxide|ciprofloxacin|11|Significant - Monitor Closely|magnesium oxide decreases levels of ciprofloxacin by inhibition of GI absorption. Applies only to oral form of both agents. Significant interaction possible, monitor closely. Separate by 2 hours.
ciprofloxacin|methotrexate|2|Significant - Monitor Closely|ciprofloxacin will increase the level or effect of methotrexate by  Other (see comment). Potential for interaction, monitor. Renal tubular transport of methotrexate may be inhibited by coadministration of ciprofloxacin, potentially leading to increased methotrexate plasma levels and toxicity.
ciprofloxacin|phenytoin|11|Significant - Monitor Closely|ciprofloxacin decreases effects of phenytoin by unknown mechanism. Significant interaction possible, monitor closely. Ciprofloxacin has been reported to both increase and decrease phenytoin concentrations. Additional clinical evidence is needed however; phenytoin serum concentrations should be monitored in patients.
ciprofloxacin|procainamide|2|Significant - Monitor Closely|ciprofloxacin and procainamide both increase  QTc interval. Potential for interaction, monitor. Ciprofloxacin elicits minimal effects on QT interval. Caution if used in combination with other drugs known to affect QT interval or in patients with other risk factors.
ciprofloxacin|ramelteon|11|Significant - Monitor Closely|ciprofloxacin will increase the level or effect of ramelteon by  affecting hepatic enzyme CYP1A2 metabolism. Significant interaction possible, monitor closely. Ciprofloxacin may decrease the metabolism of ramelteon; if ciprofloxacin is coadministered with ramelteon, monitor the patient closely for toxicity.
ciprofloxacin|rasagiline|20|Serious - Use Alternative|ciprofloxacin will increase the level or effect of rasagiline by  affecting hepatic enzyme CYP1A2 metabolism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available. Ciprofloxacin may increase rasagiline concentration resulting in increased adverse reactions. Patients should be closely monitored during concomitant use of these drugs.
ciprofloxacin|ropinirole|11|Significant - Monitor Closely|ciprofloxacin will increase the level or effect of ropinirole by  affecting hepatic enzyme CYP1A2 metabolism. Significant interaction possible, monitor closely. Ciprofloxacin may decrease the metabolism of ropinirole; monitor for increased effects of ropinirole.
sevelamer|ciprofloxacin|11|Significant - Monitor Closely|sevelamer decreases levels of ciprofloxacin by inhibition of GI absorption. Applies only to oral form of both agents. Significant interaction possible, monitor closely. Administer oral quinolones at least 1 hour before or 3 hours after sevelamer. .
sucralfate|ciprofloxacin|11|Significant - Monitor Closely|sucralfate decreases levels of ciprofloxacin by inhibition of GI absorption. Applies only to oral form of both agents. Significant interaction possible, monitor closely. The oral absorption of ciprofloxacin may be significantly reduced by sucralfate secondary to chelation within the GI tract. To help avoid interactions due to chelation, ciprofloxacin should be taken 2 hours before or 6 hours after administration of sucralfate.
ciprofloxacin|tacrine|1|Minor|ciprofloxacin will increase the level or effect of tacrine by  affecting hepatic enzyme CYP1A2 metabolism. Minor or non-significant interaction. Although not studied, tacrine metabolism may be reduced by coadministration with inhibitors of CYP1A2 such as ciprofloxacin.
ciprofloxacin|theophylline|20|Serious - Use Alternative|ciprofloxacin will increase the level or effect of theophylline by  affecting hepatic enzyme CYP1A2 metabolism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available. Concomitant use of theophylline and ciprofloxacin has decreased theophylline clearance and increased plasma levels and symptoms of toxicity. Serious and fatal reactions have included cardiac arrest, seizure, status epilepticus, and respiratory failure. If concomitant use cannot be avoided, monitor theophylline levels and adjust dosage as needed.
ciprofloxacin|theophylline|20|Serious - Use Alternative|ciprofloxacin will increase the level or effect of theophylline by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available. Concomitant use of theophylline and ciprofloxacin has decreased theophylline clearance and increased plasma levels and symptoms of toxicity. Serious and fatal reactions have included cardiac arrest, seizure, status epilepticus, and respiratory failure. If concomitant use cannot be avoided, monitor theophylline levels and adjust dosage as needed.
ciprofloxacin|tizanidine|22|Serious - Use Alternative|ciprofloxacin will increase the level or effect of tizanidine by  affecting hepatic enzyme CYP1A2 metabolism. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available. Coadministration of ciprofloxacin and tizanidine is contraindicated.
ciprofloxacin|warfarin|20|Serious - Use Alternative|ciprofloxacin will increase the level or effect of warfarin by  affecting hepatic enzyme CYP1A2 metabolism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available. Quinolone antibiotics such as ciprofloxacin may enhance the anticoagulant effects of warfarin.  Important to monitor INR/prothrombin time and toxic effects of warfarin. Patients receiving this combination should be closely monitored for adverse effects.
zinc|ciprofloxacin|11|Significant - Monitor Closely|zinc decreases effects of ciprofloxacin by Other (see comment). Significant interaction possible, monitor closely. Comment: Ciprofloxacin should be administered 2 hr before or 6 hr after zinc salts.
cisapride|clarithromycin|33|Contraindicated|cisapride and clarithromycin both increase  QTc interval. Never use combination.
clarithromycin|cisapride|33|Contraindicated|clarithromycin increases levels of cisapride by decreasing metabolism. Never use combination. Risk of QT interval prolongation.
clarithromycin|cisapride|22|Serious - Use Alternative|clarithromycin will increase the level or effect of cisapride by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available.
clomipramine|cisapride|33|Contraindicated|clomipramine and cisapride both increase  QTc interval. Never use combination.
crizotinib|cisapride|33|Contraindicated|crizotinib and cisapride both increase  QTc interval. Never use combination. Cisapride is contraindicated with drugs that may prolong the QT interval. Coadministration of crizotinib with CYP3A substrates with narrow therapeutic indices should be avoided.
delavirdine|cisapride|21|Serious - Use Alternative|delavirdine increases levels of cisapride by decreasing metabolism. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available. Never use combination. Risk of QT interval prolongation.
delavirdine|cisapride|20|Serious - Use Alternative|delavirdine will increase the level or effect of cisapride by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
desipramine|cisapride|33|Contraindicated|desipramine and cisapride both increase  QTc interval. Never use combination.
diltiazem|cisapride|21|Serious - Use Alternative|diltiazem increases levels of cisapride by decreasing metabolism. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available. Never use combination. Risk of QT interval prolongation.
diltiazem|cisapride|20|Serious - Use Alternative|diltiazem will increase the level or effect of cisapride by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
cisapride|disopyramide|33|Contraindicated|cisapride and disopyramide both increase  QTc interval. Never use combination.
doxepin|cisapride|33|Contraindicated|doxepin and cisapride both increase  QTc interval. Never use combination.
efavirenz|cisapride|20|Serious - Use Alternative|efavirenz will decrease the level or effect of cisapride by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
efavirenz|cisapride|20|Serious - Use Alternative|efavirenz increases levels of cisapride by decreasing metabolism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
cisapride|flecainide|22|Serious - Use Alternative|cisapride and flecainide both increase  QTc interval. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available.
cisapride|fluconazole|33|Contraindicated|cisapride and fluconazole both increase  QTc interval. Never use combination.
fluconazole|cisapride|33|Contraindicated|fluconazole increases levels of cisapride by decreasing metabolism. Never use combination. Risk of QT interval prolongation.
fluconazole|cisapride|21|Serious - Use Alternative|fluconazole will increase the level or effect of cisapride by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available. Never use combination.
fluphenazine|cisapride|33|Contraindicated|fluphenazine and cisapride both increase  QTc interval. Never use combination.
fosamprenavir|cisapride|33|Contraindicated|fosamprenavir increases levels of cisapride by decreasing metabolism. Never use combination. Risk of QT interval prolongation.
fosamprenavir|cisapride|21|Serious - Use Alternative|fosamprenavir will increase the level or effect of cisapride by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available. Never use combination.
cisapride|ibutilide|33|Contraindicated|cisapride and ibutilide both increase  QTc interval. Never use combination.
imipramine|cisapride|33|Contraindicated|imipramine and cisapride both increase  QTc interval. Never use combination.
indinavir|cisapride|21|Serious - Use Alternative|indinavir increases levels of cisapride by decreasing metabolism. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available. Never use combination. Risk of QT interval prolongation.
indinavir|cisapride|20|Serious - Use Alternative|indinavir will increase the level or effect of cisapride by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
itraconazole|cisapride|33|Contraindicated|itraconazole will increase the level or effect of cisapride by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Never use combination. Both drugs will increase QT interval
cisapride|itraconazole|33|Contraindicated|cisapride and itraconazole both increase  QTc interval. Never use combination.
itraconazole|cisapride|33|Contraindicated|itraconazole increases levels of cisapride by decreasing metabolism. Never use combination. Risk of QT interval prolongation.
cisapride|ketoconazole|33|Contraindicated|cisapride and ketoconazole both increase  QTc interval. Never use combination.
ketoconazole|cisapride|33|Contraindicated|ketoconazole increases levels of cisapride by decreasing metabolism. Never use combination. Risk of QT interval prolongation.
ketoconazole|cisapride|22|Serious - Use Alternative|ketoconazole will increase the level or effect of cisapride by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available.
cisapride|lumefantrine|33|Contraindicated|cisapride and lumefantrine both increase  QTc interval. Never use combination.
lumefantrine|cisapride|21|Serious - Use Alternative|lumefantrine will decrease the level or effect of cisapride by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available. Never use combination.
maprotiline|cisapride|33|Contraindicated|maprotiline and cisapride both increase  QTc interval. Never use combination.
mibefradil|cisapride|33|Contraindicated|mibefradil increases levels of cisapride by decreasing metabolism. Never use combination. Risk of QT interval prolongation.
mibefradil|cisapride|21|Serious - Use Alternative|mibefradil will increase the level or effect of cisapride by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available. Never use combination.
nefazodone|cisapride|33|Contraindicated|nefazodone increases levels of cisapride by decreasing metabolism. Never use combination. Risk of QT interval prolongation.
nefazodone|cisapride|22|Serious - Use Alternative|nefazodone will increase the level or effect of cisapride by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available.
nelfinavir|cisapride|33|Contraindicated|nelfinavir increases levels of cisapride by decreasing metabolism. Never use combination. Potential for serious and/or life-threatening reactions (eg, cardiac arrhythmias).
nelfinavir|cisapride|20|Serious - Use Alternative|nelfinavir will increase the level or effect of cisapride by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
nifedipine|cisapride|21|Serious - Use Alternative|nifedipine increases levels of cisapride by decreasing metabolism. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available. Never use combination. Risk of QT interval prolongation.
nifedipine|cisapride|20|Serious - Use Alternative|nifedipine will increase the level or effect of cisapride by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
cisapride|nifedipine|11|Significant - Monitor Closely|cisapride increases levels of nifedipine by enhancing GI absorption. Applies only to oral form of both agents. Significant interaction possible, monitor closely. Cisapride increases GI motility and may cause rapid absorption of extended-release nifedipine.
nortriptyline|cisapride|33|Contraindicated|nortriptyline and cisapride both increase  QTc interval. Never use combination.
perphenazine|cisapride|33|Contraindicated|perphenazine and cisapride both increase  QTc interval. Never use combination.
cisapride|posaconazole|22|Serious - Use Alternative|cisapride and posaconazole both increase  QTc interval. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available.
posaconazole|cisapride|21|Serious - Use Alternative|posaconazole increases levels of cisapride by decreasing metabolism. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available. Never use combination. Risk of QT interval prolongation.
posaconazole|cisapride|20|Serious - Use Alternative|posaconazole will increase the level or effect of cisapride by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
cisapride|procainamide|33|Contraindicated|cisapride and procainamide both increase  QTc interval. Never use combination.
prochlorperazine|cisapride|33|Contraindicated|prochlorperazine and cisapride both increase  QTc interval. Never use combination.
promazine|cisapride|33|Contraindicated|promazine and cisapride both increase  QTc interval. Never use combination.
promethazine|cisapride|33|Contraindicated|promethazine and cisapride both increase  QTc interval. Never use combination.
propafenone|cisapride|21|Serious - Use Alternative|propafenone, cisapride. Mechanism: pharmacodynamic synergism. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available. Never use combination. Risk of prolonged QTc interval.
protriptyline|cisapride|33|Contraindicated|protriptyline and cisapride both increase  QTc interval. Never use combination.
quinidine|cisapride|33|Contraindicated|quinidine and cisapride both increase  QTc interval. Never use combination.
ritonavir|cisapride|33|Contraindicated|ritonavir increases levels of cisapride by decreasing metabolism. Never use combination. Risk of QT interval prolongation.
ritonavir|cisapride|21|Serious - Use Alternative|ritonavir will increase the level or effect of cisapride by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available. Never use combination.
saquinavir|cisapride|33|Contraindicated|saquinavir increases levels of cisapride by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Never use combination. Increased risk of QT prolongation and cardiac arrhythmias.
cisapride|sotalol|33|Contraindicated|cisapride and sotalol both increase  QTc interval. Never use combination.
telaprevir|cisapride|33|Contraindicated|telaprevir increases levels of cisapride by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Never use combination. Contraindicated. Potential for cardiac arrhythmia.
cisapride|telavancin|22|Serious - Use Alternative|cisapride and telavancin both increase  QTc interval. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available.
telithromycin|cisapride|33|Contraindicated|telithromycin increases levels of cisapride by decreasing metabolism. Never use combination. Risk of QT interval prolongation.
cisapride|telithromycin|22|Serious - Use Alternative|cisapride and telithromycin both increase  QTc interval. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available.
telithromycin|cisapride|21|Serious - Use Alternative|telithromycin will increase the level or effect of cisapride by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available. Never use combination.
cisapride|terfenadine|33|Contraindicated|cisapride and terfenadine both increase  QTc interval. Never use combination.
thioridazine|cisapride|33|Contraindicated|thioridazine and cisapride both increase  QTc interval. Never use combination.
tipranavir|cisapride|33|Contraindicated|tipranavir increases levels of cisapride by decreasing metabolism. Never use combination. Risk of QT interval prolongation.
cisapride|toremifene|33|Contraindicated|cisapride and toremifene both increase  QTc interval. Never use combination. Concurrent use of cisapride with other agents that prolong QTc interval is contraindicated.
trifluoperazine|cisapride|33|Contraindicated|trifluoperazine and cisapride both increase  QTc interval. Never use combination.
trimipramine|cisapride|33|Contraindicated|trimipramine and cisapride both increase  QTc interval. Never use combination.
troleandomycin|cisapride|33|Contraindicated|troleandomycin increases levels of cisapride by decreasing metabolism. Never use combination. Risk of QT interval prolongation.
troleandomycin|cisapride|21|Serious - Use Alternative|troleandomycin will increase the level or effect of cisapride by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available. Never use combination.
voriconazole|cisapride|33|Contraindicated|voriconazole increases levels of cisapride by decreasing metabolism. Never use combination. Risk of QT interval prolongation.
cisapride|voriconazole|22|Serious - Use Alternative|cisapride and voriconazole both increase  QTc interval. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available.
voriconazole|cisapride|21|Serious - Use Alternative|voriconazole will increase the level or effect of cisapride by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available. Never use combination.
zafirlukast|cisapride|21|Serious - Use Alternative|zafirlukast increases levels of cisapride by decreasing metabolism. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available. Never use combination. Risk of QT interval prolongation.
zafirlukast|cisapride|20|Serious - Use Alternative|zafirlukast will increase the level or effect of cisapride by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
cisapride|ziprasidone|33|Contraindicated|cisapride and ziprasidone both increase  QTc interval. Never use combination.
cisplatin|fosphenytoin|11|Significant - Monitor Closely|cisplatin decreases levels of fosphenytoin by unknown mechanism. Significant interaction possible, monitor closely.
furosemide|cisplatin|11|Significant - Monitor Closely|furosemide, cisplatin.Either increases toxicity of the other by pharmacodynamic synergism. Significant interaction possible, monitor closely. Additive ototoxicity.
cisplatin|gentamicin|11|Significant - Monitor Closely|cisplatin and gentamicin both increase  nephrotoxicity and/or ototoxicity. Significant interaction possible, monitor closely.
cisplatin|methotrexate|2|Significant - Monitor Closely|cisplatin and methotrexate both increase  nephrotoxicity and/or ototoxicity. Potential for interaction, monitor.
cisplatin|paclitaxel|1|Minor|cisplatin increases levels of paclitaxel by decreasing renal clearance. Minor or non-significant interaction.
cisplatin|phenytoin|11|Significant - Monitor Closely|cisplatin decreases levels of phenytoin by unknown mechanism. Significant interaction possible, monitor closely.
cisplatin|tacrolimus|11|Significant - Monitor Closely|cisplatin and tacrolimus both increase  nephrotoxicity and/or ototoxicity. Significant interaction possible, monitor closely.
cisplatin|tobramycin|2|Significant - Monitor Closely|cisplatin and tobramycin both increase  nephrotoxicity and/or ototoxicity. Potential for interaction, monitor.
topotecan|cisplatin|3|Significant - Monitor Closely|topotecan, cisplatin.Either increases toxicity of the other by pharmacodynamic synergism. Potential for dangerous interaction. Use with caution and monitor closely. Use alternatives if available. Additive myelosuppression.
clarithromycin|citalopram|11|Significant - Monitor Closely|clarithromycin increases levels of citalopram by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely. ECG monitoring is recommended, along with drugs that may prolong the QT interval.
citalopram|clozapine|11|Significant - Monitor Closely|citalopram increases effects of clozapine by pharmacodynamic synergism. Significant interaction possible, monitor closely. Increased risk for serotonin syndrome.
citalopram|desvenlafaxine|20|Serious - Use Alternative|citalopram and desvenlafaxine both increase  serotonin levels. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
citalopram|eletriptan|20|Serious - Use Alternative|citalopram, eletriptan. Mechanism: unknown. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available. Combination may increase risk of serotonin syndrome. If concomitant treatment with citalopram and a triptan is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases.
citalopram|frovatriptan|20|Serious - Use Alternative|citalopram, frovatriptan. Mechanism: unknown. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available. Combination may increase risk of serotonin syndrome. If concomitant treatment with citalopram and a triptan is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases.
isocarboxazid|citalopram|33|Contraindicated|isocarboxazid and citalopram both increase  serotonin levels. Never use combination. At least 2 weeks should elapse between discontinuation of MAOI therapy and the start of citalopram therapy, and at least 2 weeks between discontinuation of citalopram therapy and commencement of MAOI therapy.
citalopram|ketoprofen|11|Significant - Monitor Closely|citalopram, ketoprofen.Either increases toxicity of the other by pharmacodynamic synergism. Significant interaction possible, monitor closely. Increased risk of upper GI bleeding. If possible, avoid concurrent use.
linezolid|citalopram|22|Serious - Use Alternative|linezolid and citalopram both increase  serotonin levels. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available. Linezolid may increase serotonin as a result of MAO-A inhibition. If linezolid must be administered, discontinue serotonergic drug immediately and monitor for CNS toxicity. Serotonergic therapy may be resumed 24 hours after last linezolid dose or after 2 weeks of monitoring, whichever comes first.
lumefantrine|citalopram|11|Significant - Monitor Closely|lumefantrine and citalopram both increase  QTc interval. Significant interaction possible, monitor closely. ECG monitoring is recommended, along with drugs that may prolong the QT interval.
citalopram|metoprolol|2|Significant - Monitor Closely|citalopram increases levels of metoprolol by decreasing metabolism. Potential for interaction, monitor. Increased metoprolol plasma levels have been associated with decreased cardioselectivity.
citalopram|naratriptan|20|Serious - Use Alternative|citalopram, naratriptan. Mechanism: unknown. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available. Combination may increase risk of serotonin syndrome. If concomitant treatment with citalopram and a triptan is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases.
oxycodone|citalopram|3|Significant - Monitor Closely|oxycodone increases effects of citalopram by pharmacodynamic synergism. Potential for dangerous interaction. Use with caution and monitor closely. Opioids may enhance the serotonergic effects of SSRIs and increase risk for serotonergic syndrome.
phenelzine|citalopram|33|Contraindicated|phenelzine and citalopram both increase  serotonin levels. Never use combination. At least 2 weeks should elapse between discontinuation of MAOI therapy and the start of citalopram therapy, and at least 2 weeks between discontinuation of citalopram therapy and commencement of MAOI therapy.
pimozide|citalopram|33|Contraindicated|pimozide, citalopram. Mechanism: unknown. Never use combination. Combination may increase risk of QT prolongation.
citalopram|propranolol|2|Significant - Monitor Closely|citalopram increases levels of propranolol by decreasing metabolism. Potential for interaction, monitor.
rasagiline|citalopram|20|Serious - Use Alternative|rasagiline and citalopram both increase  serotonin levels. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available. Combination may increase risk of serotonin syndrome or neuroleptic malignant syndrome-like reactions.
citalopram|rizatriptan|20|Serious - Use Alternative|citalopram, rizatriptan. Mechanism: unknown. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available. Combination may increase risk of serotonin syndrome. If concomitant treatment with citalopram and a triptan is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases.
selegiline|citalopram|33|Contraindicated|selegiline and citalopram both increase  serotonin levels. Never use combination. At least 2 weeks should elapse between discontinuation of MAOI therapy and the start of citalopram therapy, and at least 2 weeks between discontinuation of citalopram therapy and commencement of MAOI therapy.
citalopram|sumatriptan|20|Serious - Use Alternative|citalopram, sumatriptan. Mechanism: unknown. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available. Combination may increase risk of serotonin syndrome. If concomitant treatment with citalopram and a triptan is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases.
telithromycin|citalopram|11|Significant - Monitor Closely|telithromycin increases levels of citalopram by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely. ECG monitoring is recommended, along with drugs that may prolong the QT interval.
ticlopidine|citalopram|11|Significant - Monitor Closely|ticlopidine increases levels of citalopram by affecting hepatic enzyme CYP2C19 metabolism. Significant interaction possible, monitor closely. Citalopram 20 mg/day is the maximum recommended dose for patients taking CYP2C19 inhibitors because of the risk of QT prolongation.
citalopram|tolmetin|11|Significant - Monitor Closely|citalopram, tolmetin.Either increases toxicity of the other by pharmacodynamic synergism. Significant interaction possible, monitor closely. Increased risk of upper GI bleeding. If possible, avoid concurrent use.
citalopram|tramadol|11|Significant - Monitor Closely|citalopram and tramadol both increase  serotonin levels. Significant interaction possible, monitor closely. Combination may increase risk of serotonin syndrome or neuroleptic malignant syndrome-like reactions.
tranylcypromine|citalopram|33|Contraindicated|tranylcypromine and citalopram both increase  serotonin levels. Never use combination. At least 2 weeks should elapse between discontinuation of MAOI therapy and the start of citalopram therapy, and at least 2 weeks between discontinuation of citalopram therapy and commencement of MAOI therapy.
citalopram|trazodone|11|Significant - Monitor Closely|citalopram and trazodone both increase  serotonin levels. Significant interaction possible, monitor closely. Combination may increase risk of serotonin syndrome or neuroleptic malignant syndrome-like reactions.
citalopram|trimipramine|20|Serious - Use Alternative|citalopram and trimipramine both increase  serotonin levels. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available. Citalopram may increase TCA levels. Increased risk of serotonin syndrome or neuroleptic malignant syndrome. Potential risk for QT prolongation. ECG monitoring is recommended.
citalopram|venlafaxine|20|Serious - Use Alternative|citalopram and venlafaxine both increase  serotonin levels. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available. Combination may increase risk of serotonin syndrome or neuroleptic malignant syndrome-like reactions.
voriconazole|citalopram|11|Significant - Monitor Closely|voriconazole increases levels of citalopram by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely. ECG monitoring is recommended, along with drugs that may prolong the QT interval.
citalopram|warfarin|11|Significant - Monitor Closely|citalopram increases levels of warfarin by decreasing metabolism. Significant interaction possible, monitor closely. Coadministration of warfarin and citalopram increased prothrombin time by 5%. Use caution with coadministration and monitor patient.
ziprasidone|citalopram|11|Significant - Monitor Closely|ziprasidone and citalopram both increase  QTc interval. Significant interaction possible, monitor closely. ECG monitoring is recommended, along with drugs that may prolong the QT interval.
citalopram|ziprasidone|3|Significant - Monitor Closely|citalopram and ziprasidone both decrease  QTc interval. Potential for dangerous interaction. Use with caution and monitor closely.
citalopram|zolmitriptan|20|Serious - Use Alternative|citalopram, zolmitriptan. Mechanism: unknown. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available. Combination may increase risk of serotonin syndrome. If concomitant treatment with citalopram and a triptan is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases.
clarithromycin|colchicine|33|Contraindicated|clarithromycin will increase the level or effect of colchicine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Never use combination. Combination only contraindicated when coadministered in patients with renal or hepatic impairment
clarithromycin|colchicine|11|Significant - Monitor Closely|clarithromycin will increase the level or effect of colchicine by  P-glycoprotein (MDR1) efflux transporter. Significant interaction possible, monitor closely.
clarithromycin|cyclosporine|20|Serious - Use Alternative|clarithromycin will increase the level or effect of cyclosporine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
clarithromycin|cyclosporine|11|Significant - Monitor Closely|clarithromycin will increase the level or effect of cyclosporine by  P-glycoprotein (MDR1) efflux transporter. Significant interaction possible, monitor closely.
cyclosporine|clarithromycin|1|Minor|cyclosporine will increase the level or effect of clarithromycin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor or non-significant interaction.
clarithromycin|dabrafenib|20|Serious - Use Alternative|clarithromycin increases levels of dabrafenib by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
dabrafenib|clarithromycin|3|Significant - Monitor Closely|dabrafenib will decrease the level or effect of clarithromycin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Potential for dangerous interaction. Use with caution and monitor closely.
clarithromycin|darifenacin|20|Serious - Use Alternative|clarithromycin will increase the level or effect of darifenacin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
darifenacin|clarithromycin|1|Minor|darifenacin will increase the level or effect of clarithromycin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor or non-significant interaction.
clarithromycin|darunavir|20|Serious - Use Alternative|clarithromycin will increase the level or effect of darunavir by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
darunavir|clarithromycin|11|Significant - Monitor Closely|darunavir increases levels of clarithromycin by decreasing metabolism. Significant interaction possible, monitor closely. No dose adjustment necessary in normal renal function.  If ClCr = 30 60 ml/min, decr clarithromycin dose by 50%.  If ClCr < 30 ml/min, decr clarithromycin dose by 75%.
darunavir|clarithromycin|1|Minor|darunavir will increase the level or effect of clarithromycin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor or non-significant interaction.
clarithromycin|diazepam|20|Serious - Use Alternative|clarithromycin will increase the level or effect of diazepam by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
clarithromycin|digoxin|20|Serious - Use Alternative|clarithromycin will increase the level or effect of digoxin by  altering intestinal flora. Applies only to oral form of both agents. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
clarithromycin|digoxin|11|Significant - Monitor Closely|clarithromycin will increase the level or effect of digoxin by  P-glycoprotein (MDR1) efflux transporter. Significant interaction possible, monitor closely.
clarithromycin|dihydroergotamine|33|Contraindicated|clarithromycin increases toxicity of dihydroergotamine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Never use combination. Coadministration may result in vasospasm and ischemia of the extremities and other tissues including the CNS.
clarithromycin|disopyramide|20|Serious - Use Alternative|clarithromycin and disopyramide both increase  QTc interval. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
clarithromycin|disopyramide|2|Significant - Monitor Closely|clarithromycin will increase the level or effect of disopyramide by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Potential for interaction, monitor.
clarithromycin|dofetilide|20|Serious - Use Alternative|clarithromycin and dofetilide both increase  QTc interval. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
clarithromycin|dronedarone|22|Serious - Use Alternative|clarithromycin will increase the level or effect of dronedarone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available.
clarithromycin|dronedarone|22|Serious - Use Alternative|clarithromycin and dronedarone both increase  QTc interval. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available.
dronedarone|clarithromycin|1|Minor|dronedarone will increase the level or effect of clarithromycin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor or non-significant interaction.
clarithromycin|dyphylline|20|Serious - Use Alternative|clarithromycin will increase the level or effect of dyphylline by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
clarithromycin|dyphylline|1|Minor|clarithromycin increases levels of dyphylline by decreasing metabolism. Minor or non-significant interaction.
clarithromycin|efavirenz|2|Significant - Monitor Closely|clarithromycin will increase the level or effect of efavirenz by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Potential for interaction, monitor.
efavirenz|clarithromycin|1|Minor|efavirenz will decrease the level or effect of clarithromycin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor or non-significant interaction.
clarithromycin|eletriptan|21|Serious - Use Alternative|clarithromycin increases levels of eletriptan by decreasing metabolism. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available. Never use combination. Separate by 72 hours.
clarithromycin|eletriptan|20|Serious - Use Alternative|clarithromycin will increase the level or effect of eletriptan by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
clarithromycin|eplerenone|2|Significant - Monitor Closely|clarithromycin will increase the level or effect of eplerenone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Potential for interaction, monitor.
clarithromycin|ergotamine|33|Contraindicated|clarithromycin increases toxicity of ergotamine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Never use combination. Coadministration may result in vasospasm and ischemia of the extremities and other tissues including the CNS.
clarithromycin|ergotamine|21|Serious - Use Alternative|clarithromycin increases levels of ergotamine by decreasing metabolism. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available. Never use combination.
clarithromycin|erlotinib|20|Serious - Use Alternative|clarithromycin will increase the level or effect of erlotinib by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
clarithromycin|erlotinib|11|Significant - Monitor Closely|clarithromycin will increase the level or effect of erlotinib by  P-glycoprotein (MDR1) efflux transporter. Significant interaction possible, monitor closely.
clarithromycin|etravirine|20|Serious - Use Alternative|clarithromycin will increase the level or effect of etravirine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
etravirine|clarithromycin|1|Minor|etravirine will decrease the level or effect of clarithromycin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor or non-significant interaction.
clarithromycin|everolimus|22|Serious - Use Alternative|clarithromycin will increase the level or effect of everolimus by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available.
clarithromycin|everolimus|21|Serious - Use Alternative|clarithromycin will increase the level or effect of everolimus by  P-glycoprotein (MDR1) efflux transporter. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available. Never use combination.
clarithromycin|fluoxetine|3|Significant - Monitor Closely|clarithromycin and fluoxetine both increase  QTc interval. Potential for dangerous interaction. Use with caution and monitor closely.
fosphenytoin|clarithromycin|1|Minor|fosphenytoin will decrease the level or effect of clarithromycin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor or non-significant interaction.
clarithromycin|iloperidone|3|Significant - Monitor Closely|clarithromycin and iloperidone both increase  QTc interval. Potential for dangerous interaction. Use with caution and monitor closely.
iloperidone|clarithromycin|2|Significant - Monitor Closely|iloperidone increases levels of clarithromycin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Potential for interaction, monitor. Iloperidone is a time-dependent CYP3A inhibitor and may lead to increased plasma levels of drugs predominantly eliminated by CYP3A4.
clarithromycin|imatinib|11|Significant - Monitor Closely|clarithromycin will increase the level or effect of imatinib by  P-glycoprotein (MDR1) efflux transporter. Significant interaction possible, monitor closely.
clarithromycin|imatinib|2|Significant - Monitor Closely|clarithromycin will increase the level or effect of imatinib by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Potential for interaction, monitor.
clarithromycin|indinavir|20|Serious - Use Alternative|clarithromycin will increase the level or effect of indinavir by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
clarithromycin|indinavir|11|Significant - Monitor Closely|clarithromycin will increase the level or effect of indinavir by  P-glycoprotein (MDR1) efflux transporter. Significant interaction possible, monitor closely.
indinavir|clarithromycin|1|Minor|indinavir will increase the level or effect of clarithromycin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor or non-significant interaction.
clarithromycin|itraconazole|22|Serious - Use Alternative|clarithromycin and itraconazole both increase  QTc interval. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available.
clarithromycin|itraconazole|11|Significant - Monitor Closely|clarithromycin will increase the level or effect of itraconazole by  P-glycoprotein (MDR1) efflux transporter. Significant interaction possible, monitor closely.
clarithromycin|itraconazole|2|Significant - Monitor Closely|clarithromycin will increase the level or effect of itraconazole by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Potential for interaction, monitor.
ivacaftor|clarithromycin|20|Serious - Use Alternative|ivacaftor, clarithromycin.Either increases levels of the other by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available. Ivacaftor and its M1 metabolite has the potential to inhibit CYP3A4, may significantly increase systemic exposure to CYP3A4 substrates; reduce ivacaftor dose to 150 mg twice-a-week when coadministered with strong CYP3A4 inhibitors.
clarithromycin|lovastatin|33|Contraindicated|clarithromycin will increase the level or effect of lovastatin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Never use combination. Strong CYP3A4 inhibitors increase systemic statin exposure and risk of myopathy, including rhabdomyolysis
clarithromycin|lovastatin|33|Contraindicated|clarithromycin will increase the level or effect of lovastatin by  P-glycoprotein (MDR1) efflux transporter. Never use combination.
clarithromycin|lurasidone|33|Contraindicated|clarithromycin increases levels of lurasidone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Never use combination. Coadministration of lurasidone and strong CYP3A4 inhibitors is contraindicated.
clarithromycin|methylprednisolone|20|Serious - Use Alternative|clarithromycin will increase the level or effect of methylprednisolone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
clarithromycin|methylprednisolone|11|Significant - Monitor Closely|clarithromycin will increase the level or effect of methylprednisolone by  P-glycoprotein (MDR1) efflux transporter. Significant interaction possible, monitor closely.
methylprednisolone|clarithromycin|1|Minor|methylprednisolone will decrease the level or effect of clarithromycin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor or non-significant interaction.
clarithromycin|methylprednisolone|1|Minor|clarithromycin increases levels of methylprednisolone by decreasing metabolism. Minor or non-significant interaction.
clarithromycin|midazolam|20|Serious - Use Alternative|clarithromycin will increase the level or effect of midazolam by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
clarithromycin|pazopanib|20|Serious - Use Alternative|clarithromycin will increase the level or effect of pazopanib by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available. Avoid coadministration of pazopanib with strong CYP3A4 inhibitors if possible; if must coadminister, decrease pazopanib dose to 400 mg/day
clarithromycin|pazopanib|2|Significant - Monitor Closely|clarithromycin and pazopanib both increase  QTc interval. Potential for interaction, monitor.
phenytoin|clarithromycin|1|Minor|phenytoin will decrease the level or effect of clarithromycin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor or non-significant interaction.
clarithromycin|pimozide|33|Contraindicated|clarithromycin and pimozide both increase  QTc interval. Never use combination.
clarithromycin|pimozide|33|Contraindicated|clarithromycin increases levels of pimozide by decreasing metabolism. Never use combination. Risk of QT interval prolongation.
clarithromycin|pimozide|2|Significant - Monitor Closely|clarithromycin will increase the level or effect of pimozide by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Potential for interaction, monitor.
clarithromycin|ponatinib|20|Serious - Use Alternative|clarithromycin increases levels of ponatinib by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available. Decrease ponatinib starting dose to 30 mg qDay if coadministration with strong CYP3A4 inhibitors cannot be avoided.
clarithromycin|quetiapine|20|Serious - Use Alternative|clarithromycin will increase the level or effect of quetiapine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
quetiapine|clarithromycin|2|Significant - Monitor Closely|quetiapine, clarithromycin.Either increases toxicity of the other by QTc interval. Potential for interaction, monitor. Avoid use with drugs that prolong QT and in patients with risk factors for prolonged QT interval. Postmarketing cases show QT prolongation with overdose in patients with concomitant illness or with drugs known to cause electrolyte imbalance or prolong QT.
quinidine|clarithromycin|33|Contraindicated|quinidine and clarithromycin both increase  QTc interval. Never use combination.
clarithromycin|quinidine|20|Serious - Use Alternative|clarithromycin will increase the level or effect of quinidine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
clarithromycin|ranolazine|22|Serious - Use Alternative|clarithromycin will increase the level or effect of ranolazine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available.
clarithromycin|ranolazine|3|Significant - Monitor Closely|clarithromycin and ranolazine both increase  QTc interval. Potential for dangerous interaction. Use with caution and monitor closely.
clarithromycin|regorafenib|33|Contraindicated|clarithromycin, regorafenib. affecting hepatic/intestinal enzyme CYP3A4 metabolism. Never use combination. Strong CYP3A4 inhibitors increase regorafenib levels and decrease exposure of the active metabolites M-2 and M-5.
clarithromycin|repaglinide|20|Serious - Use Alternative|clarithromycin will increase the level or effect of repaglinide by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
clarithromycin|rifabutin|33|Contraindicated|clarithromycin increases levels of rifabutin by decreasing metabolism. Never use combination.
rifabutin|clarithromycin|2|Significant - Monitor Closely|rifabutin will decrease the level or effect of clarithromycin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Potential for interaction, monitor.
clarithromycin|saxagliptin|3|Significant - Monitor Closely|clarithromycin will increase the level or effect of saxagliptin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Potential for dangerous interaction. Use with caution and monitor closely. Limit saxagliptin dose to 2.5 mg/day when coadministered with strong CYP3A4 inhibitors
clarithromycin|sildenafil|20|Serious - Use Alternative|clarithromycin will increase the level or effect of sildenafil by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
clarithromycin|simvastatin|33|Contraindicated|clarithromycin will increase the level or effect of simvastatin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Never use combination. Increased risk for rhabdomyolysis with drugs that increase simvastatin systemic exposure
clarithromycin|sirolimus|22|Serious - Use Alternative|clarithromycin will increase the level or effect of sirolimus by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available.
clarithromycin|sirolimus|11|Significant - Monitor Closely|clarithromycin will increase the level or effect of sirolimus by  P-glycoprotein (MDR1) efflux transporter. Significant interaction possible, monitor closely.
clarithromycin|solifenacin|20|Serious - Use Alternative|clarithromycin will increase the level or effect of solifenacin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
clarithromycin|sotalol|20|Serious - Use Alternative|clarithromycin and sotalol both increase  QTc interval. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
clarithromycin|sunitinib|20|Serious - Use Alternative|clarithromycin will increase the level or effect of sunitinib by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
clarithromycin|tacrolimus|20|Serious - Use Alternative|clarithromycin will increase the level or effect of tacrolimus by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
clarithromycin|tacrolimus|11|Significant - Monitor Closely|clarithromycin will increase the level or effect of tacrolimus by  P-glycoprotein (MDR1) efflux transporter. Significant interaction possible, monitor closely.
clarithromycin|tadalafil|20|Serious - Use Alternative|clarithromycin will increase the level or effect of tadalafil by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available. For ED limit tadalafil to max of 2.5 mg/day (for daily use) or 10 mg dose every 72 hr (for use as needed). Avoid concurrent use of tadalafil for pulmonary HTN in patients taking strong CYP3A4 inhibitors.
clarithromycin|tamoxifen|11|Significant - Monitor Closely|clarithromycin, tamoxifen. affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely. CYP3A4 inhibition decreases metabolism of tamoxifen to N-desmethyl tamoxifen (active metabolite with similar biologic activity).
clarithromycin|tamsulosin|20|Serious - Use Alternative|clarithromycin increases levels of tamsulosin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
clarithromycin|telithromycin|3|Significant - Monitor Closely|clarithromycin and telithromycin both increase  QTc interval. Potential for dangerous interaction. Use with caution and monitor closely.
clarithromycin|telithromycin|2|Significant - Monitor Closely|clarithromycin will increase the level or effect of telithromycin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Potential for interaction, monitor.
telithromycin|clarithromycin|1|Minor|telithromycin will increase the level or effect of clarithromycin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor or non-significant interaction.
clarithromycin|temsirolimus|20|Serious - Use Alternative|clarithromycin will increase the level or effect of temsirolimus by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
clarithromycin|teniposide|2|Significant - Monitor Closely|clarithromycin will increase the level or effect of teniposide by  P-glycoprotein (MDR1) efflux transporter. Potential for interaction, monitor.
clarithromycin|terfenadine|33|Contraindicated|clarithromycin and terfenadine both increase  QTc interval. Never use combination.
clarithromycin|terfenadine|33|Contraindicated|clarithromycin increases levels of terfenadine by decreasing metabolism. Never use combination. Risk of QT interval prolongation.
clarithromycin|terfenadine|22|Serious - Use Alternative|clarithromycin will increase the level or effect of terfenadine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available.
clarithromycin|theophylline|20|Serious - Use Alternative|clarithromycin will increase the level or effect of theophylline by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
clarithromycin|theophylline|1|Minor|clarithromycin increases levels of theophylline by decreasing metabolism. Minor or non-significant interaction.
clarithromycin|tipranavir|20|Serious - Use Alternative|clarithromycin will increase the level or effect of tipranavir by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
tipranavir|clarithromycin|20|Serious - Use Alternative|tipranavir, clarithromycin.Either increases levels of the other by decreasing metabolism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available. No dose adjustment necessary in normal renal function.  If ClCr = 30 60 ml/min, decr clarithromycin dose by 50%.  If ClCr < 30 ml/min, decr clarithromycin dose by 75%.
clarithromycin|tolterodine|20|Serious - Use Alternative|clarithromycin will increase the level or effect of tolterodine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
clarithromycin|tolvaptan|22|Serious - Use Alternative|clarithromycin will increase the level or effect of tolvaptan by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available.
clarithromycin|tolvaptan|11|Significant - Monitor Closely|clarithromycin will increase the level or effect of tolvaptan by  P-glycoprotein (MDR1) efflux transporter. Significant interaction possible, monitor closely.
clarithromycin|topotecan|22|Serious - Use Alternative|clarithromycin will increase the level or effect of topotecan by  P-glycoprotein (MDR1) efflux transporter. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available. Product labeling for PO topotecan recommends avoiding concomitant use of P-gp inhibitors; the interaction with IV topotecan may be less severe but is still likely of clinical significance
clarithromycin|toremifene|20|Serious - Use Alternative|clarithromycin increases levels of toremifene by decreasing metabolism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available. Concurrent use of toremifene with agents causing  QT prolongation should be avoided. If concomitant use is required it's recommended that toremifene be interrupted. If interruption not possible, patients requiring therapy with a drug that prolongs QT should be closely monitored. ECGs should be obtained for high risk patients.
trazodone|clarithromycin|22|Serious - Use Alternative|trazodone and clarithromycin both increase  QTc interval. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available.
clarithromycin|trazodone|20|Serious - Use Alternative|clarithromycin will increase the level or effect of trazodone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
clarithromycin|triazolam|20|Serious - Use Alternative|clarithromycin will increase the level or effect of triazolam by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
trimipramine|clarithromycin|22|Serious - Use Alternative|trimipramine and clarithromycin both increase  QTc interval. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available.
clarithromycin|valproic acid|1|Minor|clarithromycin increases levels of valproic acid by decreasing metabolism. Minor or non-significant interaction.
clarithromycin|vardenafil|20|Serious - Use Alternative|clarithromycin will increase the level or effect of vardenafil by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
vemurafenib|clarithromycin|20|Serious - Use Alternative|vemurafenib and clarithromycin both increase  QTc interval. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available. Concomitant use of vemurafenib with drugs that  prolong QT interval is not recommended. Clarithromycin may also increase levels of vemurafenib.
clarithromycin|venlafaxine|3|Significant - Monitor Closely|clarithromycin and venlafaxine both increase  QTc interval. Potential for dangerous interaction. Use with caution and monitor closely.
clarithromycin|verapamil|11|Significant - Monitor Closely|clarithromycin will increase the level or effect of verapamil by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely. Increased effect of calcium channel blockers may lead to hypotension, edema, decreased HR, and acute kidney injury due to reduced renal blood flow
verapamil|clarithromycin|1|Minor|verapamil will increase the level or effect of clarithromycin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor or non-significant interaction.
clarithromycin|vilazodone|20|Serious - Use Alternative|clarithromycin increases levels of vilazodone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available. If intolerable adverse effects occur when coadministered with moderate CYP3A4 inhibitors, reduce daily dose to 20 mg.
clarithromycin|vinblastine|11|Significant - Monitor Closely|clarithromycin will increase the level or effect of vinblastine by  P-glycoprotein (MDR1) efflux transporter. Significant interaction possible, monitor closely.
clarithromycin|vinblastine|2|Significant - Monitor Closely|clarithromycin will increase the level or effect of vinblastine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Potential for interaction, monitor.
clarithromycin|vincristine|11|Significant - Monitor Closely|clarithromycin will increase the level or effect of vincristine by  P-glycoprotein (MDR1) efflux transporter. Significant interaction possible, monitor closely.
clarithromycin|vincristine|2|Significant - Monitor Closely|clarithromycin will increase the level or effect of vincristine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Potential for interaction, monitor.
clarithromycin|vinorelbine|2|Significant - Monitor Closely|clarithromycin will increase the level or effect of vinorelbine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Potential for interaction, monitor.
clarithromycin|vismodegib|2|Significant - Monitor Closely|clarithromycin will increase the level or effect of vismodegib by  P-glycoprotein (MDR1) efflux transporter. Potential for interaction, monitor. Vismodegib is a substrate of efflux transporter P-glycoprotein (P-gp); coadministration with P-gp inhibitors increase vismodegib systemic exposure
clarithromycin|voriconazole|3|Significant - Monitor Closely|clarithromycin and voriconazole both increase  QTc interval. Potential for dangerous interaction. Use with caution and monitor closely.
voriconazole|clarithromycin|1|Minor|voriconazole will increase the level or effect of clarithromycin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor or non-significant interaction.
clarithromycin|warfarin|20|Serious - Use Alternative|clarithromycin increases effects of warfarin by decreasing metabolism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
clarithromycin|warfarin|11|Significant - Monitor Closely|clarithromycin increases toxicity of warfarin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely. Increased risk of hemorrage; monitor INR and prothrombin times frequently.
clarithromycin|zidovudine|11|Significant - Monitor Closely|clarithromycin increases toxicity of zidovudine by unknown mechanism. Significant interaction possible, monitor closely. Increased risk of myelosuppression.
clarithromycin|zidovudine|11|Significant - Monitor Closely|clarithromycin, zidovudine. Mechanism: unknown. Significant interaction possible, monitor closely. Clarithromycin may increase or decrease levels of zidovudine. Literature describes conflicting reports. Separate administration by minimum 2 to 4 hours.  .
clarithromycin|ziprasidone|22|Serious - Use Alternative|clarithromycin and ziprasidone both increase  QTc interval. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available.
clarithromycin|ziprasidone|2|Significant - Monitor Closely|clarithromycin will increase the level or effect of ziprasidone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Potential for interaction, monitor.
clarithromycin|zolpidem|1|Minor|clarithromycin will increase the level or effect of zolpidem by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor or non-significant interaction.
clarithromycin|zonisamide|2|Significant - Monitor Closely|clarithromycin will increase the level or effect of zonisamide by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Potential for interaction, monitor.
clemastine|triprolidine|2|Significant - Monitor Closely|clemastine and triprolidine both increase  sedation. Potential for interaction, monitor.
treprostinil|clevidipine|1|Minor|treprostinil increases effects of clevidipine by pharmacodynamic synergism. Minor or non-significant interaction.
clindamycin|pancuronium|20|Serious - Use Alternative|clindamycin increases effects of pancuronium by pharmacodynamic synergism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available. Risk of respiratory depression.
clindamycin|rocuronium|20|Serious - Use Alternative|clindamycin increases effects of rocuronium by pharmacodynamic synergism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available. Risk of respiratory depression.
clindamycin|succinylcholine|20|Serious - Use Alternative|clindamycin increases effects of succinylcholine by pharmacodynamic synergism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available. Risk of respiratory depression.
clindamycin|tubocurarine|20|Serious - Use Alternative|clindamycin increases effects of tubocurarine by pharmacodynamic synergism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available. Risk of respiratory depression.
clindamycin|vecuronium|20|Serious - Use Alternative|clindamycin increases effects of vecuronium by pharmacodynamic synergism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available. Risk of respiratory depression.
clozapine|clobazam|2|Significant - Monitor Closely|clozapine, clobazam. Other (see comment). Potential for interaction, monitor. Comment: Concomitant administration can increase the potential for CNS effects (e.g., increased sedation or respiratory depression).
ketoconazole|clobazam|11|Significant - Monitor Closely|ketoconazole will increase the level or effect of clobazam by  affecting hepatic enzyme CYP2C19 metabolism. Significant interaction possible, monitor closely. Dosage adjustment may be required; CYP2C19 inhibitors may result in increased exposure to N-desmethylclobazam (active metabolite).
rotigotine|clobazam|2|Significant - Monitor Closely|rotigotine, clobazam. Other (see comment). Potential for interaction, monitor. Comment: Concomitant administration can increase the potential for CNS effects (e.g., increased sedation or respiratory depression).
ticlopidine|clobazam|11|Significant - Monitor Closely|ticlopidine will increase the level or effect of clobazam by  affecting hepatic enzyme CYP2C19 metabolism. Significant interaction possible, monitor closely. Dosage adjustment may be required; CYP2C19 inhibitors may result in increased exposure to N-desmethylclobazam (active metabolite).
triprolidine|clobazam|2|Significant - Monitor Closely|triprolidine, clobazam. Other (see comment). Potential for interaction, monitor. Comment: Concomitant administration can increase the potential for CNS effects (e.g., increased sedation or respiratory depression).
clomipramine|clonidine|20|Serious - Use Alternative|clomipramine decreases effects of clonidine by Other (see comment). Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available. Comment: Inhibition of uptake by adrenergic neurons.
clomipramine|desvenlafaxine|20|Serious - Use Alternative|clomipramine and desvenlafaxine both increase  serotonin levels. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
desvenlafaxine|clomipramine|2|Significant - Monitor Closely|desvenlafaxine will increase the level or effect of clomipramine by  affecting hepatic enzyme CYP2D6 metabolism. Potential for interaction, monitor. Desvenlafaxine inhibits CYP2D6; with higher desvenlafaxine doses (ie, 400 mg) decrease the CYP2D6 substrate dose by up to 50%; no dosage adjustment needed with desvenlafaxine doses <100 mg
clomipramine|dobutamine|20|Serious - Use Alternative|clomipramine, dobutamine. Other (see comment). Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available. Comment: Tricyclic antidepressants increase or decrease effects of sympathomimetics, by blocking reuptake of NE, or blocking uptake of indirect sympathomimetics into the adrenergic neuron.
clomipramine|dobutamine|2|Significant - Monitor Closely|clomipramine increases and dobutamine decreases sedation. Effect of interaction is not clear, use caution. Potential for interaction, monitor.
donepezil|clomipramine|11|Significant - Monitor Closely|donepezil increases and clomipramine decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Significant interaction possible, monitor closely.
clomipramine|dopamine|20|Serious - Use Alternative|clomipramine, dopamine. Other (see comment). Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available. Comment: Tricyclic antidepressants increase or decrease effects of sympathomimetics, by blocking reuptake of NE, or blocking uptake of indirect sympathomimetics into the adrenergic neuron.
clomipramine|dopamine|2|Significant - Monitor Closely|clomipramine increases and dopamine decreases sedation. Effect of interaction is not clear, use caution. Potential for interaction, monitor.
clomipramine|ephedrine|20|Serious - Use Alternative|clomipramine, ephedrine. Other (see comment). Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available. Comment: Tricyclic antidepressants increase or decrease effects of sympathomimetics, by blocking reuptake of NE, or blocking uptake of indirect sympathomimetics into the adrenergic neuron.
clomipramine|ephedrine|11|Significant - Monitor Closely|clomipramine increases effects of ephedrine by unknown mechanism. Significant interaction possible, monitor closely.
clomipramine|ephedrine|2|Significant - Monitor Closely|clomipramine increases and ephedrine decreases sedation. Effect of interaction is not clear, use caution. Potential for interaction, monitor.
epinephrine|clomipramine|22|Serious - Use Alternative|epinephrine and clomipramine both increase  QTc interval. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available.
clomipramine|epinephrine|20|Serious - Use Alternative|clomipramine, epinephrine. Other (see comment). Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available. Comment: Tricyclic antidepressants increase or decrease effects of sympathomimetics, by blocking reuptake of NE, or blocking uptake of indirect sympathomimetics into the adrenergic neuron.
clomipramine|epinephrine|11|Significant - Monitor Closely|clomipramine increases effects of epinephrine by unknown mechanism. Significant interaction possible, monitor closely.
clomipramine|epinephrine|2|Significant - Monitor Closely|clomipramine increases and epinephrine decreases sedation. Effect of interaction is not clear, use caution. Potential for interaction, monitor.
fluoxetine|clomipramine|22|Serious - Use Alternative|fluoxetine and clomipramine both increase  serotonin levels. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available.
fluoxetine|clomipramine|20|Serious - Use Alternative|fluoxetine will increase the level or effect of clomipramine by  affecting hepatic enzyme CYP2D6 metabolism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
clomipramine|fluoxetine|3|Significant - Monitor Closely|clomipramine and fluoxetine both increase  QTc interval. Potential for dangerous interaction. Use with caution and monitor closely.
fluvoxamine|clomipramine|22|Serious - Use Alternative|fluvoxamine and clomipramine both increase  serotonin levels. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available.
fluvoxamine|clomipramine|20|Serious - Use Alternative|fluvoxamine will increase the level or effect of clomipramine by  affecting hepatic enzyme CYP1A2 metabolism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
fluvoxamine|clomipramine|3|Significant - Monitor Closely|fluvoxamine will increase the level or effect of clomipramine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Potential for dangerous interaction. Use with caution and monitor closely.
clomipramine|fluvoxamine|3|Significant - Monitor Closely|clomipramine and fluvoxamine both increase  QTc interval. Potential for dangerous interaction. Use with caution and monitor closely.
galantamine|clomipramine|11|Significant - Monitor Closely|galantamine increases and clomipramine decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Significant interaction possible, monitor closely.
isocarboxazid|clomipramine|33|Contraindicated|isocarboxazid and clomipramine both increase  serotonin levels. Never use combination.
clomipramine|norepinephrine|20|Serious - Use Alternative|clomipramine, norepinephrine. Other (see comment). Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available. Comment: Tricyclic antidepressants increase or decrease effects of sympathomimetics, by blocking reuptake of NE, or blocking uptake of indirect sympathomimetics into the adrenergic neuron.
clomipramine|norepinephrine|11|Significant - Monitor Closely|clomipramine increases effects of norepinephrine by unknown mechanism. Significant interaction possible, monitor closely.
clomipramine|norepinephrine|2|Significant - Monitor Closely|clomipramine increases and norepinephrine decreases sedation. Effect of interaction is not clear, use caution. Potential for interaction, monitor.
phenelzine|clomipramine|33|Contraindicated|phenelzine and clomipramine both increase  serotonin levels. Never use combination.
clomipramine|phenylephrine|20|Serious - Use Alternative|clomipramine, phenylephrine. Other (see comment). Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available. Comment: Tricyclic antidepressants increase or decrease effects of sympathomimetics, by blocking reuptake of NE, or blocking uptake of indirect sympathomimetics into the adrenergic neuron.
clomipramine|phenylephrine|2|Significant - Monitor Closely|clomipramine increases and phenylephrine decreases sedation. Effect of interaction is not clear, use caution. Potential for interaction, monitor.
clomipramine|pirbuterol|20|Serious - Use Alternative|clomipramine, pirbuterol. Other (see comment). Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available. Comment: Tricyclic antidepressants increase or decrease effects of sympathomimetics, by blocking reuptake of NE, or blocking uptake of indirect sympathomimetics into the adrenergic neuron.
clomipramine|pirbuterol|2|Significant - Monitor Closely|clomipramine increases and pirbuterol decreases sedation. Effect of interaction is not clear, use caution. Potential for interaction, monitor.
clomipramine|pseudoephedrine|20|Serious - Use Alternative|clomipramine, pseudoephedrine. Other (see comment). Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available. Comment: Tricyclic antidepressants increase or decrease effects of sympathomimetics, by blocking reuptake of NE, or blocking uptake of indirect sympathomimetics into the adrenergic neuron.
clomipramine|pseudoephedrine|2|Significant - Monitor Closely|clomipramine increases and pseudoephedrine decreases sedation. Effect of interaction is not clear, use caution. Potential for interaction, monitor.
quinidine|clomipramine|33|Contraindicated|quinidine and clomipramine both increase  QTc interval. Never use combination.
quinidine|clomipramine|20|Serious - Use Alternative|quinidine will increase the level or effect of clomipramine by  affecting hepatic enzyme CYP2D6 metabolism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
rasagiline|clomipramine|20|Serious - Use Alternative|rasagiline and clomipramine both increase  serotonin levels. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available. Avoid combination within 14 days of MAOI use.
rifabutin|clomipramine|11|Significant - Monitor Closely|rifabutin decreases levels of clomipramine by increasing metabolism. Significant interaction possible, monitor closely.
rifabutin|clomipramine|2|Significant - Monitor Closely|rifabutin will decrease the level or effect of clomipramine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Potential for interaction, monitor.
ritonavir|clomipramine|11|Significant - Monitor Closely|ritonavir will increase the level or effect of clomipramine by  affecting hepatic enzyme CYP2D6 metabolism. Significant interaction possible, monitor closely.
ritonavir|clomipramine|11|Significant - Monitor Closely|ritonavir will increase the level or effect of clomipramine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
rivastigmine|clomipramine|11|Significant - Monitor Closely|rivastigmine increases and clomipramine decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Significant interaction possible, monitor closely.
tacrine|clomipramine|11|Significant - Monitor Closely|tacrine will increase the level or effect of clomipramine by  affecting hepatic enzyme CYP1A2 metabolism. Significant interaction possible, monitor closely.
tacrine|clomipramine|11|Significant - Monitor Closely|tacrine increases and clomipramine decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Significant interaction possible, monitor closely.
clomipramine|tamsulosin|2|Significant - Monitor Closely|clomipramine increases levels of tamsulosin by affecting hepatic enzyme CYP2D6 metabolism. Potential for interaction, monitor.
clomipramine|terbutaline|20|Serious - Use Alternative|clomipramine, terbutaline. Other (see comment). Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available. Comment: Tricyclic antidepressants increase or decrease effects of sympathomimetics, by blocking reuptake of NE, or blocking uptake of indirect sympathomimetics into the adrenergic neuron.
clomipramine|terbutaline|2|Significant - Monitor Closely|clomipramine increases and terbutaline decreases sedation. Effect of interaction is not clear, use caution. Potential for interaction, monitor.
clomipramine|terfenadine|33|Contraindicated|clomipramine and terfenadine both increase  QTc interval. Never use combination.
terfenadine|clomipramine|2|Significant - Monitor Closely|terfenadine and clomipramine both increase  sedation. Potential for interaction, monitor.
thiothixene|clomipramine|2|Significant - Monitor Closely|thiothixene and clomipramine both increase  sedation. Potential for interaction, monitor.
clomipramine|toremifene|20|Serious - Use Alternative|clomipramine and toremifene both increase  QTc interval. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available. Concurrent use of toremifene with agents causing  QT prolongation should be avoided. If concomitant use is required it's recommended that toremifene be interrupted. If interruption not possible, patients requiring therapy with a drug that prolongs QT should be closely monitored. ECGs should be obtained for high risk patients.
clomipramine|tramadol|3|Significant - Monitor Closely|clomipramine and tramadol both increase  serotonin levels. Potential for dangerous interaction. Use with caution and monitor closely.
tramadol|clomipramine|2|Significant - Monitor Closely|tramadol and clomipramine both increase  sedation. Potential for interaction, monitor.
tranylcypromine|clomipramine|33|Contraindicated|tranylcypromine and clomipramine both increase  serotonin levels. Never use combination.
clomipramine|trazodone|22|Serious - Use Alternative|clomipramine and trazodone both increase  QTc interval. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available.
trazodone|clomipramine|22|Serious - Use Alternative|trazodone and clomipramine both increase  serotonin levels. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available.
clomipramine|trazodone|2|Significant - Monitor Closely|clomipramine and trazodone both decrease  cholinergic effects/transmission. Potential for interaction, monitor.
clomipramine|trazodone|2|Significant - Monitor Closely|clomipramine and trazodone both increase  sedation. Potential for interaction, monitor.
clomipramine|trimipramine|22|Serious - Use Alternative|clomipramine and trimipramine both increase  QTc interval. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available.
clomipramine|trimipramine|22|Serious - Use Alternative|clomipramine and trimipramine both increase  serotonin levels. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available.
clomipramine|trimipramine|2|Significant - Monitor Closely|clomipramine and trimipramine both decrease  cholinergic effects/transmission. Potential for interaction, monitor.
clomipramine|trimipramine|2|Significant - Monitor Closely|clomipramine and trimipramine both increase  sedation. Potential for interaction, monitor.
triprolidine|clomipramine|2|Significant - Monitor Closely|triprolidine and clomipramine both increase  sedation. Potential for interaction, monitor.
venlafaxine|clomipramine|22|Serious - Use Alternative|venlafaxine and clomipramine both increase  serotonin levels. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available.
venlafaxine|clomipramine|11|Significant - Monitor Closely|venlafaxine will increase the level or effect of clomipramine by  affecting hepatic enzyme CYP2D6 metabolism. Significant interaction possible, monitor closely.
clomipramine|venlafaxine|3|Significant - Monitor Closely|clomipramine and venlafaxine both increase  QTc interval. Potential for dangerous interaction. Use with caution and monitor closely.
clomipramine|voriconazole|3|Significant - Monitor Closely|clomipramine and voriconazole both increase  QTc interval. Potential for dangerous interaction. Use with caution and monitor closely.
voriconazole|clomipramine|1|Minor|voriconazole will increase the level or effect of clomipramine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor or non-significant interaction.
clomipramine|ziprasidone|22|Serious - Use Alternative|clomipramine and ziprasidone both increase  QTc interval. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available.
ziprasidone|clomipramine|2|Significant - Monitor Closely|ziprasidone and clomipramine both increase  sedation. Potential for interaction, monitor.
zolmitriptan|clomipramine|3|Significant - Monitor Closely|zolmitriptan and clomipramine both increase  serotonin levels. Potential for dangerous interaction. Use with caution and monitor closely.
clonazepam|clozapine|2|Significant - Monitor Closely|clonazepam and clozapine both increase  sedation. Potential for interaction, monitor.
indinavir|clonazepam|3|Significant - Monitor Closely|indinavir increases levels of clonazepam by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Potential for dangerous interaction. Use with caution and monitor closely. Potential for increased toxicity. Use alternatives if available. Consider lowering benzodiazepine dose.
itraconazole|clonazepam|3|Significant - Monitor Closely|itraconazole will increase the level or effect of clonazepam by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Potential for dangerous interaction. Use with caution and monitor closely.
kava|clonazepam|2|Significant - Monitor Closely|kava and clonazepam both increase  sedation. Potential for interaction, monitor.
ketoconazole|clonazepam|3|Significant - Monitor Closely|ketoconazole will increase the level or effect of clonazepam by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Potential for dangerous interaction. Use with caution and monitor closely.
nelfinavir|clonazepam|3|Significant - Monitor Closely|nelfinavir increases levels of clonazepam by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Potential for dangerous interaction. Use with caution and monitor closely. Potential for increased toxicity. Use alternatives if available. Consider lowering benzodiazepine dose.
omeprazole|clonazepam|1|Minor|omeprazole increases levels of clonazepam by decreasing metabolism. Minor or non-significant interaction.
ritonavir|clonazepam|3|Significant - Monitor Closely|ritonavir increases levels of clonazepam by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Potential for dangerous interaction. Use with caution and monitor closely. Potential for increased toxicity. Use alternatives if available. Consider lowering benzodiazepine dose.
saquinavir|clonazepam|3|Significant - Monitor Closely|saquinavir increases levels of clonazepam by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Potential for dangerous interaction. Use with caution and monitor closely. Use alternatives if available. Consider lowering benzodiazepine dose.
tipranavir|clonazepam|3|Significant - Monitor Closely|tipranavir increases levels of clonazepam by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Potential for dangerous interaction. Use with caution and monitor closely. Use alternatives if available. Consider lowering benzodiazepine dose.
triprolidine|clonazepam|2|Significant - Monitor Closely|triprolidine and clonazepam both increase  sedation. Potential for interaction, monitor.
desipramine|clonidine|20|Serious - Use Alternative|desipramine decreases effects of clonidine by Other (see comment). Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available. Comment: Inhibition of uptake by adrenergic neurons.
doxepin|clonidine|20|Serious - Use Alternative|doxepin decreases effects of clonidine by Other (see comment). Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available. Comment: Inhibition of uptake by adrenergic neurons.
clonidine|esmolol|20|Serious - Use Alternative|clonidine, esmolol.Either increases toxicity of the other by unspecified interaction mechanism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available. Can increase risk of bradycardia.
clonidine|esmolol|11|Significant - Monitor Closely|clonidine, esmolol.Either increases toxicity of the other by pharmacodynamic synergism. Significant interaction possible, monitor closely. Additive sympatholytic action may worsen sinus node dysfunction and atrioventricular (AV) block.
esmolol|clonidine|3|Significant - Monitor Closely|esmolol, clonidine. Mechanism: pharmacodynamic synergism. Potential for dangerous interaction. Use with caution and monitor closely. Selective beta blocker administration during withdrawal from centrally acting alpha agonists may result in rebound hypertension.
imipramine|clonidine|20|Serious - Use Alternative|imipramine decreases effects of clonidine by Other (see comment). Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available. Comment: Inhibition of uptake by adrenergic neurons.
clonidine|metoprolol|20|Serious - Use Alternative|clonidine, metoprolol.Either increases toxicity of the other by unspecified interaction mechanism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available. Can increase risk of bradycardia.
clonidine|metoprolol|11|Significant - Monitor Closely|clonidine, metoprolol.Either increases toxicity of the other by pharmacodynamic synergism. Significant interaction possible, monitor closely. Additive sympatholytic action may worsen sinus node dysfunction and atrioventricular (AV) block.
metoprolol|clonidine|3|Significant - Monitor Closely|metoprolol, clonidine. Mechanism: pharmacodynamic synergism. Potential for dangerous interaction. Use with caution and monitor closely. Selective beta blocker administration during withdrawal from centrally acting alpha agonists may result in rebound hypertension.
milnacipran|clonidine|11|Significant - Monitor Closely|milnacipran decreases effects of clonidine by pharmacodynamic antagonism. Significant interaction possible, monitor closely.
mirtazapine|clonidine|20|Serious - Use Alternative|mirtazapine decreases effects of clonidine by pharmacodynamic antagonism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available. Risk of hypertensive urgency.
clonidine|nadolol|20|Serious - Use Alternative|clonidine, nadolol.Either increases toxicity of the other by unspecified interaction mechanism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available. Can increase risk of bradycardia.
nadolol|clonidine|3|Significant - Monitor Closely|nadolol, clonidine. Mechanism: pharmacodynamic synergism. Potential for dangerous interaction. Use with caution and monitor closely. Non selective beta blocker administration during withdrawal from centrally acting alpha agonists may result in rebound hypertension.
nortriptyline|clonidine|20|Serious - Use Alternative|nortriptyline decreases effects of clonidine by Other (see comment). Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available. Comment: Inhibition of uptake by adrenergic neurons.
penbutolol|clonidine|3|Significant - Monitor Closely|penbutolol, clonidine. Mechanism: pharmacodynamic synergism. Potential for dangerous interaction. Use with caution and monitor closely. Selective beta blocker administration during withdrawal from centrally acting alpha agonists may result in rebound hypertension.
pindolol|clonidine|3|Significant - Monitor Closely|pindolol, clonidine. Mechanism: pharmacodynamic synergism. Potential for dangerous interaction. Use with caution and monitor closely. Non selective beta blocker administration during withdrawal from centrally acting alpha agonists may result in rebound hypertension.
clonidine|propranolol|20|Serious - Use Alternative|clonidine, propranolol.Either increases toxicity of the other by unspecified interaction mechanism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available. Can increase risk of bradycardia.
propranolol|clonidine|3|Significant - Monitor Closely|propranolol, clonidine. Mechanism: pharmacodynamic synergism. Potential for dangerous interaction. Use with caution and monitor closely. Non selective beta blocker administration during withdrawal from centrally acting alpha agonists may result in rebound hypertension.
protriptyline|clonidine|20|Serious - Use Alternative|protriptyline decreases effects of clonidine by Other (see comment). Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available. Comment: Inhibition of uptake by adrenergic neurons.
clonidine|sotalol|20|Serious - Use Alternative|clonidine, sotalol.Either increases toxicity of the other by unspecified interaction mechanism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available. Can increase risk of bradycardia.
sotalol|clonidine|3|Significant - Monitor Closely|sotalol, clonidine. Mechanism: pharmacodynamic synergism. Potential for dangerous interaction. Use with caution and monitor closely. Selective beta blocker administration during withdrawal from centrally acting alpha agonists may result in rebound hypertension.
clonidine|timolol|20|Serious - Use Alternative|clonidine, timolol.Either increases toxicity of the other by unspecified interaction mechanism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available. Can increase risk of bradycardia.
timolol|clonidine|3|Significant - Monitor Closely|timolol, clonidine. Mechanism: pharmacodynamic synergism. Potential for dangerous interaction. Use with caution and monitor closely. Non selective beta blocker administration during withdrawal from centrally acting alpha agonists may result in rebound hypertension.
treprostinil|clonidine|1|Minor|treprostinil increases effects of clonidine by pharmacodynamic synergism. Minor or non-significant interaction.
trimipramine|clonidine|20|Serious - Use Alternative|trimipramine decreases effects of clonidine by Other (see comment). Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available. Comment: Inhibition of uptake by adrenergic neurons.
esomeprazole|clopidogrel|22|Serious - Use Alternative|esomeprazole decreases effects of clopidogrel by affecting hepatic enzyme CYP2C19 metabolism. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available. Clopidogrel efficacy may be reduced by drugs that inhibit CYP2C19. Inhibition of platelet aggregation by clopidogrel is entirely due to an active metabolite. Clopidogrel is metabolized to this active metabolite in part by CYP2C19.  .
etravirine|clopidogrel|22|Serious - Use Alternative|etravirine decreases effects of clopidogrel by affecting hepatic enzyme CYP2C19 metabolism. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available. Clopidogrel efficacy may be reduced by drugs that inhibit CYP2C19. Inhibition of platelet aggregation by clopidogrel is entirely due to an active metabolite. Clopidogrel is metabolized to this active metabolite in part by CYP2C19.  .
etravirine|clopidogrel|11|Significant - Monitor Closely|etravirine decreases effects of clopidogrel by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely. Clopidogrel efficacy may be reduced by drugs that inhibit CYP3A4. Inhibition of platelet aggregation by clopidogrel is entirely due to an active metabolite. Clopidogrel is metabolized to this active metabolite in part by CYP3A4. .
ginkgo biloba|clopidogrel|1|Minor|ginkgo biloba, clopidogrel. pharmacodynamic synergism. Minor or non-significant interaction. May prolong bleeding time.  Conflicting evidence. Use with caution.
lansoprazole|clopidogrel|2|Significant - Monitor Closely|lansoprazole decreases effects of clopidogrel by affecting hepatic enzyme CYP2C19 metabolism. Potential for interaction, monitor. Mean AUC of clopidogrel active metabolite was reduced by ~14% when lansoprazole was coadministered compared to administration of clopidogrel alone in healthy subjects who were CYP2C19 extensive metabolizers. Clopidogrel efficacy may be reduced by drugs that inhibit CYP2C19. Inhibition of platelet aggregation by clopidogrel is entirely due to the active clopidogrel metabolite. Clopidogrel is metabolized in part by CYP2C19.
omeprazole|clopidogrel|22|Serious - Use Alternative|omeprazole decreases effects of clopidogrel by affecting hepatic enzyme CYP2C19 metabolism. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available. Clopidogrel efficacy may be reduced by drugs that inhibit CYP2C19. Inhibition of platelet aggregation by clopidogrel is entirely due to an active metabolite. Clopidogrel is metabolized to this active metabolite in part by CYP2C19.  .
pantoprazole|clopidogrel|2|Significant - Monitor Closely|pantoprazole decreases effects of clopidogrel by affecting hepatic enzyme CYP2C19 metabolism. Potential for interaction, monitor. Clopidogrel efficacy may be reduced by drugs that inhibit CYP2C19. Inhibition of platelet aggregation by clopidogrel is entirely due to the active clopidogrel metabolite. Clopidogrel is metabolized in part by CYP2C19. Pantoprazole prescribing information state that coadministration with clopidogrel had no clinically important effect on exposure to clopidogrel active metabolite; no dose adjustment of clopidogrel is required .
rabeprazole|clopidogrel|22|Serious - Use Alternative|rabeprazole decreases effects of clopidogrel by affecting hepatic enzyme CYP2C19 metabolism. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available. Clopidogrel efficacy may be reduced by drugs that inhibit CYP2C19. Inhibition of platelet aggregation by clopidogrel is entirely due to an active metabolite. Clopidogrel is metabolized to this active metabolite in part by CYP2C19. .
rivaroxaban|clopidogrel|11|Significant - Monitor Closely|rivaroxaban, clopidogrel. Other (see comment). Significant interaction possible, monitor closely. Comment: Avoid concurrent administration of clopidogrel with rivaroxaban unless the benefit outweighs the risk of increased bleeding. .
warfarin|clopidogrel|3|Significant - Monitor Closely|warfarin, clopidogrel.Either increases effects of the other by pharmacodynamic synergism. Potential for dangerous interaction. Use with caution and monitor closely. Enhanced risk of hemorrhage; additive effects may occur when simultaneous use is clinically required .
clorazepate|clozapine|2|Significant - Monitor Closely|clorazepate and clozapine both increase  sedation. Potential for interaction, monitor.
fosamprenavir|clorazepate|3|Significant - Monitor Closely|fosamprenavir increases levels of clorazepate by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Potential for dangerous interaction. Use with caution and monitor closely. Use alternatives if available. Consider lowering benzodiazepine dose.
indinavir|clorazepate|3|Significant - Monitor Closely|indinavir increases levels of clorazepate by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Potential for dangerous interaction. Use with caution and monitor closely. Potential for increased toxicity. Use alternatives if available. Consider lowering benzodiazepine dose.
nelfinavir|clorazepate|3|Significant - Monitor Closely|nelfinavir increases levels of clorazepate by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Potential for dangerous interaction. Use with caution and monitor closely. Use alternatives if available. Consider lowering benzodiazepine dose.
omeprazole|clorazepate|1|Minor|omeprazole increases levels of clorazepate by decreasing metabolism. Minor or non-significant interaction.
saquinavir|clorazepate|3|Significant - Monitor Closely|saquinavir increases levels of clorazepate by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Potential for dangerous interaction. Use with caution and monitor closely. Use alternatives if available. Consider lowering benzodiazepine dose.
tipranavir|clorazepate|3|Significant - Monitor Closely|tipranavir increases levels of clorazepate by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Potential for dangerous interaction. Use with caution and monitor closely. Use alternatives if available. Consider lowering benzodiazepine dose.
triprolidine|clorazepate|2|Significant - Monitor Closely|triprolidine and clorazepate both increase  sedation. Potential for interaction, monitor.
clotrimazole|colchicine|11|Significant - Monitor Closely|clotrimazole will decrease the level or effect of colchicine by  P-glycoprotein (MDR1) efflux transporter. Significant interaction possible, monitor closely.
clotrimazole|everolimus|21|Serious - Use Alternative|clotrimazole will decrease the level or effect of everolimus by  P-glycoprotein (MDR1) efflux transporter. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available. Never use combination.
clotrimazole|tacrolimus|11|Significant - Monitor Closely|clotrimazole will decrease the level or effect of tacrolimus by  P-glycoprotein (MDR1) efflux transporter. Significant interaction possible, monitor closely.
clotrimazole|tacrolimus|1|Minor|clotrimazole increases levels of tacrolimus by decreasing metabolism. Minor or non-significant interaction.
clotrimazole|tolvaptan|11|Significant - Monitor Closely|clotrimazole will decrease the level or effect of tolvaptan by  P-glycoprotein (MDR1) efflux transporter. Significant interaction possible, monitor closely.
diazepam|clozapine|11|Significant - Monitor Closely|diazepam, clozapine. Mechanism: pharmacodynamic synergism. Significant interaction possible, monitor closely. Possible risk of cardiorespiratory collapse.
diazepam|clozapine|2|Significant - Monitor Closely|diazepam and clozapine both increase  sedation. Potential for interaction, monitor.
estazolam|clozapine|2|Significant - Monitor Closely|estazolam and clozapine both increase  sedation. Potential for interaction, monitor.
ethotoin|clozapine|11|Significant - Monitor Closely|ethotoin will decrease the level or effect of clozapine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
fluoxetine|clozapine|11|Significant - Monitor Closely|fluoxetine increases levels of clozapine by affecting hepatic enzyme CYP2D6 metabolism. Significant interaction possible, monitor closely. Plasma levels of clozapine may be increased, resulting in increased pharmacologic and toxic effects. Adjust clozapine dose as needed when initiating or discontinuing certain SSRIs. .
clozapine|fluoxetine|3|Significant - Monitor Closely|clozapine and fluoxetine both increase  QTc interval. Potential for dangerous interaction. Use with caution and monitor closely.
flurazepam|clozapine|2|Significant - Monitor Closely|flurazepam and clozapine both increase  sedation. Potential for interaction, monitor.
fluvoxamine|clozapine|20|Serious - Use Alternative|fluvoxamine will increase the level or effect of clozapine by  affecting hepatic enzyme CYP1A2 metabolism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
fluvoxamine|clozapine|3|Significant - Monitor Closely|fluvoxamine will increase the level or effect of clozapine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Potential for dangerous interaction. Use with caution and monitor closely.
fosphenytoin|clozapine|11|Significant - Monitor Closely|fosphenytoin will decrease the level or effect of clozapine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
clozapine|haloperidol|2|Significant - Monitor Closely|clozapine and haloperidol both increase  antidopaminergic effects, including extrapyramidal symptoms and neuroleptic malignant syndrome. Potential for interaction, monitor.
clozapine|haloperidol|2|Significant - Monitor Closely|clozapine and haloperidol both increase  sedation. Potential for interaction, monitor.
haloperidol|clozapine|2|Significant - Monitor Closely|haloperidol and clozapine both increase  QTc interval. Potential for interaction, monitor.
lorazepam|clozapine|11|Significant - Monitor Closely|lorazepam, clozapine. Mechanism: pharmacodynamic synergism. Significant interaction possible, monitor closely. Possible risk of cardiorespiratory collapse.
lorazepam|clozapine|2|Significant - Monitor Closely|lorazepam and clozapine both increase  sedation. Potential for interaction, monitor.
midazolam|clozapine|2|Significant - Monitor Closely|midazolam and clozapine both increase  sedation. Potential for interaction, monitor.
modafinil|clozapine|11|Significant - Monitor Closely|modafinil will decrease the level or effect of clozapine by  affecting hepatic enzyme CYP1A2 metabolism. Significant interaction possible, monitor closely.
modafinil|clozapine|11|Significant - Monitor Closely|modafinil will decrease the level or effect of clozapine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
clozapine|modafinil|2|Significant - Monitor Closely|clozapine increases and modafinil decreases sedation. Effect of interaction is not clear, use caution. Potential for interaction, monitor.
norfloxacin|clozapine|11|Significant - Monitor Closely|norfloxacin will increase the level or effect of clozapine by  affecting hepatic enzyme CYP1A2 metabolism. Significant interaction possible, monitor closely.
oxazepam|clozapine|2|Significant - Monitor Closely|oxazepam and clozapine both increase  sedation. Potential for interaction, monitor.
phenytoin|clozapine|11|Significant - Monitor Closely|phenytoin will decrease the level or effect of clozapine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.  When adding phenytoin therapy to patients stabilized on clozapine, monitor patient closely for worsening of psychotic symptoms. If needed, increase the clozapine dose cautiously on basis of psychotic symptoms. Conversely, when phenytoin is discontinued, levels of clozapine may significantly increase.
quazepam|clozapine|2|Significant - Monitor Closely|quazepam and clozapine both increase  sedation. Potential for interaction, monitor.
rifabutin|clozapine|20|Serious - Use Alternative|rifabutin will decrease the level or effect of clozapine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
ritonavir|clozapine|11|Significant - Monitor Closely|ritonavir will increase the level or effect of clozapine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
sertraline|clozapine|11|Significant - Monitor Closely|sertraline increases levels of clozapine by affecting hepatic enzyme CYP2D6 metabolism. Significant interaction possible, monitor closely. Plasma levels of clozapine may be increased, resulting in increased pharmacologic and toxic effects. Adjust clozapine dose as needed when initiating or discontinuing certain SSRIs. .
tacrine|clozapine|11|Significant - Monitor Closely|tacrine will increase the level or effect of clozapine by  affecting hepatic enzyme CYP1A2 metabolism. Significant interaction possible, monitor closely.
clozapine|tamsulosin|2|Significant - Monitor Closely|clozapine increases levels of tamsulosin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Potential for interaction, monitor. Dose reduction may be needed for coadministered drugs that are predominantly metabolized by CYP3A.
clozapine|tamsulosin|2|Significant - Monitor Closely|clozapine increases levels of tamsulosin by affecting hepatic enzyme CYP2D6 metabolism. Potential for interaction, monitor.
temazepam|clozapine|2|Significant - Monitor Closely|temazepam and clozapine both increase  sedation. Potential for interaction, monitor.
clozapine|tetrabenazine|3|Significant - Monitor Closely|clozapine and tetrabenazine both increase  antidopaminergic effects, including extrapyramidal symptoms and neuroleptic malignant syndrome. Potential for dangerous interaction. Use with caution and monitor closely.
clozapine|tofacitinib|2|Significant - Monitor Closely|clozapine increases levels of tofacitinib by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Potential for interaction, monitor. No specific dose adjustment recommended when tofacitinib coadministered with moderate CYP3A4 inhibitors; decrease tofacitinib dose if coadministered with both moderate CYP3A4 and potent CYP2C19 inhibitors.
tramadol|clozapine|2|Significant - Monitor Closely|tramadol and clozapine both increase  sedation. Potential for interaction, monitor.
triazolam|clozapine|2|Significant - Monitor Closely|triazolam and clozapine both increase  sedation. Potential for interaction, monitor.
triprolidine|clozapine|2|Significant - Monitor Closely|triprolidine and clozapine both increase  sedation. Potential for interaction, monitor.
disulfiram|cocaine|11|Significant - Monitor Closely|disulfiram increases levels of cocaine by unknown mechanism. Significant interaction possible, monitor closely.
iloperidone|cocaine|2|Significant - Monitor Closely|iloperidone increases levels of cocaine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Potential for interaction, monitor. Iloperidone is a time-dependent CYP3A inhibitor and may lead to increased plasma levels of drugs predominantly eliminated by CYP3A4.
cocaine|tamoxifen|11|Significant - Monitor Closely|cocaine, tamoxifen. affecting hepatic enzyme CYP2D6 metabolism. Significant interaction possible, monitor closely. CYP2D6 inhibition decreases metabolism of tamoxifen to  hydroxytamoxifen, and N-desmethyl tamoxifen to endoxifen (active metabolites with 100-fold greater affinity for estrogen receptor); decreased endoxifen levels may result in poor clinical outcome.
cocaine|tamsulosin|2|Significant - Monitor Closely|cocaine increases levels of tamsulosin by affecting hepatic enzyme CYP2D6 metabolism. Potential for interaction, monitor.
cocaine|tramadol|2|Significant - Monitor Closely|cocaine and tramadol both increase  serotonin levels. Potential for interaction, monitor.
trimipramine|cocaine|3|Significant - Monitor Closely|trimipramine and cocaine both increase  serotonin levels. Potential for dangerous interaction. Use with caution and monitor closely.
venlafaxine|cocaine|3|Significant - Monitor Closely|venlafaxine and cocaine both increase  serotonin levels. Potential for dangerous interaction. Use with caution and monitor closely.
quinidine|codeine|11|Significant - Monitor Closely|quinidine decreases effects of codeine by decreasing metabolism. Significant interaction possible, monitor closely. Decreased conversion of codeine to active metabolite morphine.
quinidine|codeine|2|Significant - Monitor Closely|quinidine will increase the level or effect of codeine by  affecting hepatic enzyme CYP2D6 metabolism. Potential for interaction, monitor.
triprolidine|codeine|2|Significant - Monitor Closely|triprolidine and codeine both increase  sedation. Potential for interaction, monitor.
conivaptan|colchicine|11|Significant - Monitor Closely|conivaptan will increase the level or effect of colchicine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
colchicine|cyclosporine|11|Significant - Monitor Closely|colchicine increases effects of cyclosporine by pharmacodynamic synergism. Significant interaction possible, monitor closely.
cyclosporine|colchicine|3|Significant - Monitor Closely|cyclosporine will increase the level or effect of colchicine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Potential for dangerous interaction. Use with caution and monitor closely. Coadministration significantly increases plasma levels and toxic effects of colchicine (eg, myopathy, neuropathy), especially in presence of renal impairment; prescribing information recommends reducing colchicine dose
cyclosporine|colchicine|3|Significant - Monitor Closely|cyclosporine will increase the level or effect of colchicine by  P-glycoprotein (MDR1) efflux transporter. Potential for dangerous interaction. Use with caution and monitor closely. Coadministration significantly increases plasma levels and toxic effects of colchicine (eg, myopathy, neuropathy), especially in presence of renal impairment; prescribing information recommends reducing colchicine dose
colchicine|fluvastatin|20|Serious - Use Alternative|colchicine, fluvastatin.Either increases toxicity of the other by pharmacodynamic synergism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available. Increased risk of rhabdomyolysis (incl a fatality).
colchicine|lovastatin|20|Serious - Use Alternative|colchicine, lovastatin.Either increases toxicity of the other by pharmacodynamic synergism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available. Increased risk of rhabdomyolysis (incl a fatality).
lovastatin|colchicine|11|Significant - Monitor Closely|lovastatin will increase the level or effect of colchicine by  P-glycoprotein (MDR1) efflux transporter. Significant interaction possible, monitor closely.
colchicine|pitavastatin|20|Serious - Use Alternative|colchicine, pitavastatin.Either increases toxicity of the other by pharmacodynamic synergism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available. Increased risk of rhabdomyolysis (incl a fatality).
colchicine|pravastatin|20|Serious - Use Alternative|colchicine, pravastatin.Either increases toxicity of the other by pharmacodynamic synergism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available. Increased risk of rhabdomyolysis (incl a fatality).
colchicine|rosuvastatin|20|Serious - Use Alternative|colchicine, rosuvastatin.Either increases toxicity of the other by pharmacodynamic synergism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available. Increased risk of rhabdomyolysis (incl a fatality).
colchicine|simvastatin|20|Serious - Use Alternative|colchicine, simvastatin.Either increases toxicity of the other by pharmacodynamic synergism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available. Increased risk of rhabdomyolysis (incl a fatality).
simvastatin|colchicine|11|Significant - Monitor Closely|simvastatin will increase the level or effect of colchicine by  P-glycoprotein (MDR1) efflux transporter. Significant interaction possible, monitor closely.
telithromycin|colchicine|33|Contraindicated|telithromycin will increase the level or effect of colchicine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Never use combination. Concomitant treatment with telithromycin and colchicine is contraindicated in patients with kidney or liver impairment.
troleandomycin|colchicine|11|Significant - Monitor Closely|troleandomycin will increase the level or effect of colchicine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
verapamil|colchicine|11|Significant - Monitor Closely|verapamil will increase the level or effect of colchicine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely. Colchicine toxicity may occur. Colchicine dosing adjustment may be required for patients also receiving verapamil.
verapamil|colchicine|11|Significant - Monitor Closely|verapamil will increase the level or effect of colchicine by  P-glycoprotein (MDR1) efflux transporter. Significant interaction possible, monitor closely. Colchicine toxicity may occur. Colchicine dosing adjustment may be required for patients also receiving verapamil.
voriconazole|colchicine|11|Significant - Monitor Closely|voriconazole will increase the level or effect of colchicine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
colesevelam|doxercalciferol|11|Significant - Monitor Closely|colesevelam decreases levels of doxercalciferol by inhibition of GI absorption. Applies only to oral form of both agents. Significant interaction possible, monitor closely. (Vitamin D analog).
colesevelam|vitamin d|2|Significant - Monitor Closely|colesevelam will decrease the level or effect of vitamin d by  Other (see comment). Potential for interaction, monitor. Bile acid sequestrants may decrease the absorption of fat-soluble vitamins. Administer vitamin supplementation at least 4 hours prior to colesevelam.
colesevelam|glyburide|11|Significant - Monitor Closely|colesevelam decreases levels of glyburide by drug binding in GI tract. Significant interaction possible, monitor closely. Concomitant administration decreases glyburide absorption; however, absorption is not reduced when glyburide is administered 4 hr before colesevelam.
colesevelam|norethindrone|11|Significant - Monitor Closely|colesevelam decreases levels of norethindrone by drug binding in GI tract. Significant interaction possible, monitor closely. Administer oral contraceptives containing norethindrone/ethinyl estradiol at least 4 hr before colesevelam to avoid decreased absorption.
colesevelam|paricalcitol|11|Significant - Monitor Closely|colesevelam decreases levels of paricalcitol by inhibition of GI absorption. Applies only to oral form of both agents. Significant interaction possible, monitor closely. (Vitamin D analog).
colesevelam|phenytoin|3|Significant - Monitor Closely|colesevelam will decrease the level or effect of phenytoin by  Mechanism: inhibition of GI absorption. Applies only to oral form of both agents. Potential for dangerous interaction. Use with caution and monitor closely. Administer phenytoin at least 4 hr before colesevelam
colestipol|digoxin|11|Significant - Monitor Closely|colestipol decreases levels of digoxin by inhibition of GI absorption. Applies only to oral form of both agents. Significant interaction possible, monitor closely.
colestipol|fluvastatin|1|Minor|colestipol decreases levels of fluvastatin by inhibition of GI absorption. Applies only to oral form of both agents. Minor or non-significant interaction.
colestipol|hydrocortisone|1|Minor|colestipol decreases levels of hydrocortisone by inhibition of GI absorption. Applies only to oral form of both agents. Minor or non-significant interaction.
colestipol|levothyroxine|1|Minor|colestipol decreases levels of levothyroxine by inhibition of GI absorption. Applies only to oral form of both agents. Minor or non-significant interaction.
colestipol|liothyronine|1|Minor|colestipol decreases levels of liothyronine by inhibition of GI absorption. Applies only to oral form of both agents. Minor or non-significant interaction.
colestipol|lomitapide|11|Significant - Monitor Closely|colestipol decreases levels of lomitapide by drug binding in GI tract. Significant interaction possible, monitor closely. Separate lomitapide and administration of bile acid sequestrants by at least 4 hours; bile acid sequestrants can interfere with the absorption of oral medications.
colestipol|warfarin|1|Minor|colestipol decreases levels of warfarin by inhibition of GI absorption. Applies only to oral form of both agents. Minor or non-significant interaction.
conivaptan|dronedarone|21|Serious - Use Alternative|conivaptan will increase the level or effect of dronedarone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available. Never use combination.
dronedarone|conivaptan|11|Significant - Monitor Closely|dronedarone will increase the level or effect of conivaptan by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
conivaptan|eplerenone|1|Minor|conivaptan will increase the level or effect of eplerenone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor or non-significant interaction.
conivaptan|everolimus|21|Serious - Use Alternative|conivaptan will increase the level or effect of everolimus by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available. Never use combination.
conivaptan|fentanyl|1|Minor|conivaptan will increase the level or effect of fentanyl by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor or non-significant interaction.
conivaptan|fesoterodine|11|Significant - Monitor Closely|conivaptan will increase the level or effect of fesoterodine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
fluconazole|conivaptan|11|Significant - Monitor Closely|fluconazole will increase the level or effect of conivaptan by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
conivaptan|iloperidone|11|Significant - Monitor Closely|conivaptan will increase the level or effect of iloperidone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
iloperidone|conivaptan|2|Significant - Monitor Closely|iloperidone increases levels of conivaptan by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Potential for interaction, monitor. Iloperidone is a time-dependent CYP3A inhibitor and may lead to increased plasma levels of drugs predominantly eliminated by CYP3A4.
itraconazole|conivaptan|33|Contraindicated|itraconazole will increase the level or effect of conivaptan by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Never use combination. Coadministration of conivaptan with strong CYP3A4 inhibitors is contraindicated.
conivaptan|itraconazole|1|Minor|conivaptan will increase the level or effect of itraconazole by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor or non-significant interaction.
conivaptan|ixabepilone|11|Significant - Monitor Closely|conivaptan will increase the level or effect of ixabepilone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
ketoconazole|conivaptan|33|Contraindicated|ketoconazole will increase the level or effect of conivaptan by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Never use combination. Coadministration of conivaptan with strong CYP3A4 inhibitors is contraindicated.
conivaptan|ketoconazole|1|Minor|conivaptan will increase the level or effect of ketoconazole by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor or non-significant interaction.
conivaptan|lurasidone|33|Contraindicated|conivaptan increases levels of lurasidone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Never use combination. Coadministration of lurasidone and strong CYP3A4 inhibitors is contraindicated.
conivaptan|maraviroc|11|Significant - Monitor Closely|conivaptan will increase the level or effect of maraviroc by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely. Decrease maraviroc dose to 150 mg BID when coadministered with strong CYP3A4 inhibitors
conivaptan|methylprednisolone|11|Significant - Monitor Closely|conivaptan will increase the level or effect of methylprednisolone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
methylprednisolone|conivaptan|11|Significant - Monitor Closely|methylprednisolone will decrease the level or effect of conivaptan by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
conivaptan|nilotinib|11|Significant - Monitor Closely|conivaptan will increase the level or effect of nilotinib by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
conivaptan|nisoldipine|11|Significant - Monitor Closely|conivaptan will increase the level or effect of nisoldipine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
conivaptan|paclitaxel|1|Minor|conivaptan will increase the level or effect of paclitaxel by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor or non-significant interaction.
conivaptan|pazopanib|20|Serious - Use Alternative|conivaptan will increase the level or effect of pazopanib by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available. Avoid coadministration of pazopanib with strong CYP3A4 inhibitors if possible; if must coadminister, decrease pazopanib dose to 400 mg/day
conivaptan|ponatinib|20|Serious - Use Alternative|conivaptan increases levels of ponatinib by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available. Decrease ponatinib starting dose to 30 mg qDay if coadministration with strong CYP3A4 inhibitors cannot be avoided.
posaconazole|conivaptan|33|Contraindicated|posaconazole will increase the level or effect of conivaptan by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Never use combination. Coadministration of conivaptan with strong CYP3A4 inhibitors is contraindicated.
conivaptan|ranolazine|21|Serious - Use Alternative|conivaptan will increase the level or effect of ranolazine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available. Never use combination.
conivaptan|rivaroxaban|20|Serious - Use Alternative|conivaptan increases levels of rivaroxaban by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available. Avoid concomitant use of rivaroxaban and combined Pgp and strong CYP3A4 inhibitors. Combination may lead to significant increases in rivaroxaban levels and increase bleeding risk.
conivaptan|romidepsin|2|Significant - Monitor Closely|conivaptan will increase the level or effect of romidepsin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Potential for interaction, monitor.
conivaptan|saxagliptin|3|Significant - Monitor Closely|conivaptan will increase the level or effect of saxagliptin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Potential for dangerous interaction. Use with caution and monitor closely. Limit saxagliptin dose to 2.5 mg/day when coadministered with strong CYP3A4 inhibitors
conivaptan|sildenafil|11|Significant - Monitor Closely|conivaptan will increase the level or effect of sildenafil by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
conivaptan|silodosin|21|Serious - Use Alternative|conivaptan will increase the level or effect of silodosin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available. Never use combination.
conivaptan|tacrolimus|11|Significant - Monitor Closely|conivaptan will increase the level or effect of tacrolimus by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
conivaptan|tadalafil|11|Significant - Monitor Closely|conivaptan will increase the level or effect of tadalafil by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely. For ED limit tadalafil to max of 2.5 mg/day (for daily use) or 10 mg dose every 72 hr (for use as needed). Avoid concurrent use of tadalafil for pulmonary HTN in patients taking strong CYP3A4 inhibitors.
conivaptan|tamoxifen|20|Serious - Use Alternative|conivaptan, tamoxifen. affecting hepatic/intestinal enzyme CYP3A4 metabolism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available. CYP3A4 inhibition decreases metabolism of tamoxifen to N-desmethyl tamoxifen (active metabolite with similar biologic activity).
conivaptan|tamsulosin|20|Serious - Use Alternative|conivaptan increases levels of tamsulosin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
telaprevir|conivaptan|33|Contraindicated|telaprevir will increase the level or effect of conivaptan by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Never use combination. Coadministration of conivaptan with strong CYP3A4 inhibitors is contraindicated.
telithromycin|conivaptan|33|Contraindicated|telithromycin will increase the level or effect of conivaptan by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Never use combination. Coadministration of conivaptan with strong CYP3A4 inhibitors is contraindicated.
conivaptan|telithromycin|1|Minor|conivaptan will increase the level or effect of telithromycin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor or non-significant interaction.
conivaptan|temsirolimus|11|Significant - Monitor Closely|conivaptan will increase the level or effect of temsirolimus by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
conivaptan|ticagrelor|11|Significant - Monitor Closely|conivaptan increases levels of ticagrelor by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely. Ticagrelor is metabolized by CYP3A4/5. Avoid use with strong CYP3A inhibitors.
conivaptan|tolterodine|11|Significant - Monitor Closely|conivaptan will increase the level or effect of tolterodine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
conivaptan|tolvaptan|21|Serious - Use Alternative|conivaptan will increase the level or effect of tolvaptan by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available. Never use combination.
conivaptan|toremifene|11|Significant - Monitor Closely|conivaptan, toremifene. Other (see comment). Significant interaction possible, monitor closely. Comment: Upon completion or discontinuation of conivaptan, allow 7 days before initiating therapy with drugs that are CYP3A4 substrates. Monitor for any potential adverse effects.
conivaptan|trazodone|20|Serious - Use Alternative|conivaptan will increase the level or effect of trazodone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
conivaptan|vardenafil|11|Significant - Monitor Closely|conivaptan will increase the level or effect of vardenafil by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
conivaptan|verapamil|11|Significant - Monitor Closely|conivaptan will increase the level or effect of verapamil by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
conivaptan|vilazodone|20|Serious - Use Alternative|conivaptan increases levels of vilazodone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available. Strong CYP3A4 inhibitors may increase vilazodone plasma levels by 50% - Reduce daily dose  to 20 mg.
conivaptan|vinblastine|1|Minor|conivaptan will increase the level or effect of vinblastine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor or non-significant interaction.
conivaptan|vincristine|1|Minor|conivaptan will increase the level or effect of vincristine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor or non-significant interaction.
conivaptan|vinorelbine|1|Minor|conivaptan will increase the level or effect of vinorelbine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor or non-significant interaction.
voriconazole|conivaptan|33|Contraindicated|voriconazole will increase the level or effect of conivaptan by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Never use combination. Coadministration of conivaptan with strong CYP3A4 inhibitors is contraindicated.
conivaptan|zolpidem|1|Minor|conivaptan will increase the level or effect of zolpidem by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor or non-significant interaction.
conivaptan|zonisamide|1|Minor|conivaptan will increase the level or effect of zonisamide by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor or non-significant interaction.
ethotoin|conjugated estrogens|11|Significant - Monitor Closely|ethotoin will decrease the level or effect of conjugated estrogens by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
ethotoin|conjugated estrogens|11|Significant - Monitor Closely|ethotoin will decrease the level or effect of conjugated estrogens by  P-glycoprotein (MDR1) efflux transporter. Significant interaction possible, monitor closely.
fosphenytoin|conjugated estrogens|11|Significant - Monitor Closely|fosphenytoin will decrease the level or effect of conjugated estrogens by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
fosphenytoin|conjugated estrogens|11|Significant - Monitor Closely|fosphenytoin will decrease the level or effect of conjugated estrogens by  P-glycoprotein (MDR1) efflux transporter. Significant interaction possible, monitor closely.
griseofulvin|conjugated estrogens|11|Significant - Monitor Closely|griseofulvin will decrease the level or effect of conjugated estrogens by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
hexobarbital|conjugated estrogens|11|Significant - Monitor Closely|hexobarbital will decrease the level or effect of conjugated estrogens by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
pentobarbital|conjugated estrogens|11|Significant - Monitor Closely|pentobarbital will decrease the level or effect of conjugated estrogens by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
phenobarbital|conjugated estrogens|11|Significant - Monitor Closely|phenobarbital will decrease the level or effect of conjugated estrogens by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
phenobarbital|conjugated estrogens|11|Significant - Monitor Closely|phenobarbital will decrease the level or effect of conjugated estrogens by  P-glycoprotein (MDR1) efflux transporter. Significant interaction possible, monitor closely.
phenytoin|conjugated estrogens|11|Significant - Monitor Closely|phenytoin will decrease the level or effect of conjugated estrogens by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
phenytoin|conjugated estrogens|11|Significant - Monitor Closely|phenytoin will decrease the level or effect of conjugated estrogens by  P-glycoprotein (MDR1) efflux transporter. Significant interaction possible, monitor closely.  If the estrogen is being used for contraception then loss of contraception may occur.
prednisolone|conjugated estrogens|11|Significant - Monitor Closely|prednisolone will decrease the level or effect of conjugated estrogens by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
prednisone|conjugated estrogens|11|Significant - Monitor Closely|prednisone will decrease the level or effect of conjugated estrogens by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
primidone|conjugated estrogens|11|Significant - Monitor Closely|primidone will decrease the level or effect of conjugated estrogens by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
secobarbital|conjugated estrogens|11|Significant - Monitor Closely|secobarbital will decrease the level or effect of conjugated estrogens by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
crizotinib|disopyramide|20|Serious - Use Alternative|crizotinib increases levels of disopyramide by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available. Coadministration of crizotinib with CYP3A substrates with narrow therapeutic indices should be avoided. ECG monitoring is recommended, along with drugs that may prolong the QT interval.
crizotinib|dronedarone|33|Contraindicated|crizotinib and dronedarone both increase  QTc interval. Never use combination. Dronedarone is contraindicated with drugs that may prolong the QT interval. Coadministration of crizotinib with CYP3A substrates with narrow therapeutic indices should be avoided.
ketoconazole|crizotinib|11|Significant - Monitor Closely|ketoconazole increases levels of crizotinib by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely. Concomitant use of strong CYP3A inhibitors should be avoided.  .
crizotinib|lomitapide|33|Contraindicated|crizotinib increases levels of lomitapide by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Never use combination. Increases lomitapide levels several folds.
crizotinib|midazolam|11|Significant - Monitor Closely|crizotinib increases levels of midazolam by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely. Coadministration of crizotinib with CYP3A substrates with narrow therapeutic indices should be avoided.
crizotinib|ondansetron|20|Serious - Use Alternative|crizotinib and ondansetron both decrease  QTc interval. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.  Avoid with congenital long QT syndrome; ECG monitoring recommended with concomitant medications that prolong QT interval, electrolyte abnormalities, CHF, or bradyarrhythmias.
crizotinib|ondansetron|2|Significant - Monitor Closely|crizotinib increases levels of ondansetron by P-glycoprotein (MDR1) efflux transporter. Potential for interaction, monitor.
crizotinib|quinidine|20|Serious - Use Alternative|crizotinib increases levels of quinidine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available. Coadministration of crizotinib with CYP3A substrates with narrow therapeutic indices should be avoided. ECG monitoring is recommended, along with drugs that may prolong the QT interval.
crizotinib|tacrolimus|20|Serious - Use Alternative|crizotinib increases levels of tacrolimus by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available. Coadministration of crizotinib with CYP3A substrates with narrow therapeutic indices should be avoided. ECG monitoring is recommended, along with drugs that may prolong the QT interval.
crizotinib|tacrolimus|2|Significant - Monitor Closely|crizotinib increases levels of tacrolimus by P-glycoprotein (MDR1) efflux transporter. Potential for interaction, monitor.
crizotinib|thioridazine|33|Contraindicated|crizotinib and thioridazine both increase  QTc interval. Never use combination. Thioridazine is contraindicated with drugs that may prolong the QT interval.
donepezil|cyclizine|2|Significant - Monitor Closely|donepezil increases and cyclizine decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Potential for interaction, monitor.
donepezil|cyclizine|1|Minor|donepezil decreases effects of cyclizine by pharmacodynamic antagonism. Minor or non-significant interaction.
galantamine|cyclizine|2|Significant - Monitor Closely|galantamine increases and cyclizine decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Potential for interaction, monitor.
galantamine|cyclizine|1|Minor|galantamine decreases effects of cyclizine by pharmacodynamic antagonism. Minor or non-significant interaction.
tacrine|cyclizine|2|Significant - Monitor Closely|tacrine increases and cyclizine decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Potential for interaction, monitor.
tacrine|cyclizine|1|Minor|tacrine decreases effects of cyclizine by pharmacodynamic antagonism. Minor or non-significant interaction.
cyclizine|triprolidine|2|Significant - Monitor Closely|cyclizine and triprolidine both increase  sedation. Potential for interaction, monitor.
donepezil|cyclobenzaprine|2|Significant - Monitor Closely|donepezil increases and cyclobenzaprine decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Potential for interaction, monitor.
donepezil|cyclobenzaprine|1|Minor|donepezil decreases effects of cyclobenzaprine by pharmacodynamic antagonism. Minor or non-significant interaction.
galantamine|cyclobenzaprine|2|Significant - Monitor Closely|galantamine increases and cyclobenzaprine decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Potential for interaction, monitor.
galantamine|cyclobenzaprine|1|Minor|galantamine decreases effects of cyclobenzaprine by pharmacodynamic antagonism. Minor or non-significant interaction.
rasagiline|cyclobenzaprine|3|Significant - Monitor Closely|rasagiline and cyclobenzaprine both increase  serotonin levels. Potential for dangerous interaction. Use with caution and monitor closely.
tacrine|cyclobenzaprine|2|Significant - Monitor Closely|tacrine increases and cyclobenzaprine decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Potential for interaction, monitor.
tacrine|cyclobenzaprine|1|Minor|tacrine decreases effects of cyclobenzaprine by pharmacodynamic antagonism. Minor or non-significant interaction.
tramadol|cyclobenzaprine|20|Serious - Use Alternative|tramadol and cyclobenzaprine both increase  serotonin levels. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
cyclobenzaprine|tramadol|2|Significant - Monitor Closely|cyclobenzaprine and tramadol both increase  sedation. Potential for interaction, monitor.
tranylcypromine|cyclobenzaprine|33|Contraindicated|tranylcypromine and cyclobenzaprine both increase  serotonin levels. Never use combination. Do not coadminister cyclobenzaprine with MAOIs or within 14 days of discontinuing an MAOI
cyclophosphamide|digoxin|2|Significant - Monitor Closely|cyclophosphamide decreases levels of digoxin by inhibition of GI absorption. Applies only to oral form of both agents. Potential for interaction, monitor.
etanercept|cyclophosphamide|22|Serious - Use Alternative|etanercept, cyclophosphamide. Mechanism: unspecified interaction mechanism. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available. The incidence of noncutaneous solid malignancies may be increased in patients receiving TNF blocking agents with cyclophosphamide. Coadministration is not recommended.
cyclophosphamide|succinylcholine|11|Significant - Monitor Closely|cyclophosphamide increases levels of succinylcholine by decreasing metabolism. Significant interaction possible, monitor closely. Neuromuscular blockade may be prolonged because of inhibition of cholinesterase activity. Prolonged respiratory depression with extended periods of apnea may occur. .
cyclophosphamide|thiotepa|2|Significant - Monitor Closely|cyclophosphamide, thiotepa.Either increases toxicity of the other by pharmacodynamic synergism. Potential for interaction, monitor. Additive myelosuppression.
cyclophosphamide|warfarin|11|Significant - Monitor Closely|cyclophosphamide increases effects of warfarin by unknown mechanism. Significant interaction possible, monitor closely. Anticoagulant effect is increased. Monitor coagulation parameters during and after cyclophosphamide therapy. Adjust the warfarin dose as needed.
danazol|cyclosporine|20|Serious - Use Alternative|danazol increases effects of cyclosporine by decreasing metabolism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
diclofenac|cyclosporine|3|Significant - Monitor Closely|diclofenac, cyclosporine.Either increases toxicity of the other by nephrotoxicity and/or ototoxicity. Potential for dangerous interaction. Use with caution and monitor closely. Potential for dangerous interaction. Use with caution and monitor closely.
cyclosporine|digoxin|20|Serious - Use Alternative|cyclosporine increases levels of digoxin by decreasing renal clearance. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
cyclosporine|digoxin|11|Significant - Monitor Closely|cyclosporine will increase the level or effect of digoxin by  P-glycoprotein (MDR1) efflux transporter. Significant interaction possible, monitor closely.
diltiazem|cyclosporine|11|Significant - Monitor Closely|diltiazem will increase the level or effect of cyclosporine by  affecting hepatic enzyme CYP1A2 metabolism. Significant interaction possible, monitor closely.
cyclosporine|diltiazem|11|Significant - Monitor Closely|cyclosporine will increase the level or effect of diltiazem by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
diltiazem|cyclosporine|11|Significant - Monitor Closely|diltiazem will increase the level or effect of cyclosporine by  P-glycoprotein (MDR1) efflux transporter. Significant interaction possible, monitor closely. If given concomitantly, monitor circulating cyclosporine levels and adjust cyclosporine dosage as necessary. Also monitor patients for increased cyclosporine toxicity (renal dysfunction, cholestasis, paresthesias).
diltiazem|cyclosporine|11|Significant - Monitor Closely|diltiazem increases levels of cyclosporine by unknown mechanism. Significant interaction possible, monitor closely.
cyclosporine|dronedarone|20|Serious - Use Alternative|cyclosporine will increase the level or effect of dronedarone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
dronedarone|cyclosporine|11|Significant - Monitor Closely|dronedarone will increase the level or effect of cyclosporine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
dronedarone|cyclosporine|11|Significant - Monitor Closely|dronedarone will increase the level or effect of cyclosporine by  P-glycoprotein (MDR1) efflux transporter. Significant interaction possible, monitor closely. Risk of QTc prolongation and cyclosporine toxicity.
efavirenz|cyclosporine|11|Significant - Monitor Closely|efavirenz will decrease the level or effect of cyclosporine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
cyclosporine|efavirenz|1|Minor|cyclosporine will increase the level or effect of efavirenz by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor or non-significant interaction.
ethotoin|cyclosporine|20|Serious - Use Alternative|ethotoin decreases levels of cyclosporine by increasing metabolism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
ethotoin|cyclosporine|11|Significant - Monitor Closely|ethotoin will decrease the level or effect of cyclosporine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
ethotoin|cyclosporine|11|Significant - Monitor Closely|ethotoin will decrease the level or effect of cyclosporine by  P-glycoprotein (MDR1) efflux transporter. Significant interaction possible, monitor closely.
etodolac|cyclosporine|3|Significant - Monitor Closely|etodolac, cyclosporine.Either increases toxicity of the other by nephrotoxicity and/or ototoxicity. Potential for dangerous interaction. Use with caution and monitor closely. Potential for dangerous interaction. Use with caution and monitor closely.
cyclosporine|etoposide|11|Significant - Monitor Closely|cyclosporine will increase the level or effect of etoposide by  P-glycoprotein (MDR1) efflux transporter. Significant interaction possible, monitor closely.
cyclosporine|etoposide|11|Significant - Monitor Closely|cyclosporine increases levels of etoposide by decreasing elimination. Significant interaction possible, monitor closely. Interaction seen with high dose cyclosporine. Serum etoposide concentrations may be elevated, resulting in increased toxicity. Monitor complete blood cell count and adjust the dose of etoposide as needed.
cyclosporine|ezetimibe|1|Minor|cyclosporine increases levels of ezetimibe by unknown mechanism. Minor or non-significant interaction.
fenoprofen|cyclosporine|3|Significant - Monitor Closely|fenoprofen, cyclosporine.Either increases toxicity of the other by nephrotoxicity and/or ototoxicity. Potential for dangerous interaction. Use with caution and monitor closely. Potential for dangerous interaction. Use with caution and monitor closely.
fluconazole|cyclosporine|11|Significant - Monitor Closely|fluconazole will increase the level or effect of cyclosporine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
flurbiprofen|cyclosporine|3|Significant - Monitor Closely|flurbiprofen, cyclosporine.Either increases toxicity of the other by nephrotoxicity and/or ototoxicity. Potential for dangerous interaction. Use with caution and monitor closely.
cyclosporine|fosamprenavir|11|Significant - Monitor Closely|cyclosporine will increase the level or effect of fosamprenavir by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
fosamprenavir|cyclosporine|11|Significant - Monitor Closely|fosamprenavir will increase the level or effect of cyclosporine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
cyclosporine|foscarnet|2|Significant - Monitor Closely|cyclosporine and foscarnet both increase  nephrotoxicity and/or ototoxicity. Potential for interaction, monitor.
fosphenytoin|cyclosporine|20|Serious - Use Alternative|fosphenytoin decreases levels of cyclosporine by increasing metabolism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
fosphenytoin|cyclosporine|11|Significant - Monitor Closely|fosphenytoin will decrease the level or effect of cyclosporine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
fosphenytoin|cyclosporine|11|Significant - Monitor Closely|fosphenytoin will decrease the level or effect of cyclosporine by  P-glycoprotein (MDR1) efflux transporter. Significant interaction possible, monitor closely.
glimepiride|cyclosporine|1|Minor|glimepiride increases levels of cyclosporine by unknown mechanism. Minor or non-significant interaction.
glipizide|cyclosporine|1|Minor|glipizide increases levels of cyclosporine by unknown mechanism. Minor or non-significant interaction.
glyburide|cyclosporine|1|Minor|glyburide increases levels of cyclosporine by unknown mechanism. Minor or non-significant interaction.
griseofulvin|cyclosporine|11|Significant - Monitor Closely|griseofulvin will decrease the level or effect of cyclosporine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
griseofulvin|cyclosporine|1|Minor|griseofulvin increases levels of cyclosporine by unknown mechanism. Minor or non-significant interaction.
hexobarbital|cyclosporine|20|Serious - Use Alternative|hexobarbital decreases levels of cyclosporine by increasing metabolism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
hexobarbital|cyclosporine|11|Significant - Monitor Closely|hexobarbital will decrease the level or effect of cyclosporine by  affecting hepatic enzyme CYP1A2 metabolism. Significant interaction possible, monitor closely.
hexobarbital|cyclosporine|11|Significant - Monitor Closely|hexobarbital will decrease the level or effect of cyclosporine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
ibuprofen|cyclosporine|3|Significant - Monitor Closely|ibuprofen, cyclosporine.Either increases toxicity of the other by nephrotoxicity and/or ototoxicity. Potential for dangerous interaction. Use with caution and monitor closely. Potential for dangerous interaction. Use with caution and monitor closely.
cyclosporine|imatinib|11|Significant - Monitor Closely|cyclosporine will increase the level or effect of imatinib by  P-glycoprotein (MDR1) efflux transporter. Significant interaction possible, monitor closely.
imatinib|cyclosporine|11|Significant - Monitor Closely|imatinib increases levels of cyclosporine by decreasing metabolism. Significant interaction possible, monitor closely.
cyclosporine|imatinib|1|Minor|cyclosporine will increase the level or effect of imatinib by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor or non-significant interaction.
cyclosporine|indinavir|11|Significant - Monitor Closely|cyclosporine will increase the level or effect of indinavir by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
cyclosporine|indinavir|11|Significant - Monitor Closely|cyclosporine will increase the level or effect of indinavir by  P-glycoprotein (MDR1) efflux transporter. Significant interaction possible, monitor closely.
indomethacin|cyclosporine|3|Significant - Monitor Closely|indomethacin, cyclosporine.Either increases toxicity of the other by nephrotoxicity and/or ototoxicity. Potential for dangerous interaction. Use with caution and monitor closely.
cyclosporine|itraconazole|11|Significant - Monitor Closely|cyclosporine will increase the level or effect of itraconazole by  P-glycoprotein (MDR1) efflux transporter. Significant interaction possible, monitor closely.
cyclosporine|itraconazole|1|Minor|cyclosporine will increase the level or effect of itraconazole by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor or non-significant interaction.
ketoconazole|cyclosporine|11|Significant - Monitor Closely|ketoconazole will increase the level or effect of cyclosporine by  P-glycoprotein (MDR1) efflux transporter. Significant interaction possible, monitor closely.
cyclosporine|ketoconazole|1|Minor|cyclosporine will increase the level or effect of ketoconazole by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor or non-significant interaction.
ketoprofen|cyclosporine|3|Significant - Monitor Closely|ketoprofen, cyclosporine.Either increases toxicity of the other by nephrotoxicity and/or ototoxicity. Potential for dangerous interaction. Use with caution and monitor closely.
cyclosporine|lovastatin|20|Serious - Use Alternative|cyclosporine will increase the level or effect of lovastatin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available. Do not exceed 20 mg/day of lovastatin
mefenamic acid|cyclosporine|3|Significant - Monitor Closely|mefenamic acid, cyclosporine.Either increases toxicity of the other by nephrotoxicity and/or ototoxicity. Potential for dangerous interaction. Use with caution and monitor closely.
melphalan|cyclosporine|2|Significant - Monitor Closely|melphalan increases toxicity of cyclosporine by unknown mechanism. Potential for interaction, monitor. Increased risk of nephrotoxicity.
cyclosporine|mestranol|11|Significant - Monitor Closely|cyclosporine will increase the level or effect of mestranol by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
cyclosporine|mestranol|11|Significant - Monitor Closely|cyclosporine will increase the level or effect of mestranol by  P-glycoprotein (MDR1) efflux transporter. Significant interaction possible, monitor closely.
mestranol|cyclosporine|1|Minor|mestranol increases levels of cyclosporine by unknown mechanism. Minor or non-significant interaction.
cyclosporine|methotrexate|11|Significant - Monitor Closely|cyclosporine and methotrexate both increase  nephrotoxicity and/or ototoxicity. Significant interaction possible, monitor closely. Either drug may increase the concentration of the other. Monitoring of methotrexate and cyclosporine concentrations during concurrent cyclosporine therapy is recommended.
cyclosporine|methotrexate|11|Significant - Monitor Closely|cyclosporine, methotrexate. Other (see comment). Significant interaction possible, monitor closely. Comment: Methotrexate levels were increased ~30% and 7-hydroxy methotrexate (metabolite) levels were decreased ~80%.
metoclopramide|cyclosporine|11|Significant - Monitor Closely|metoclopramide increases levels of cyclosporine by enhancing GI absorption. Applies only to oral form of both agents. Significant interaction possible, monitor closely.
modafinil|cyclosporine|11|Significant - Monitor Closely|modafinil will decrease the level or effect of cyclosporine by  affecting hepatic enzyme CYP1A2 metabolism. Significant interaction possible, monitor closely.
modafinil|cyclosporine|11|Significant - Monitor Closely|modafinil will decrease the level or effect of cyclosporine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
nabumetone|cyclosporine|3|Significant - Monitor Closely|nabumetone, cyclosporine.Either increases toxicity of the other by nephrotoxicity and/or ototoxicity. Potential for dangerous interaction. Use with caution and monitor closely.
nafcillin|cyclosporine|11|Significant - Monitor Closely|nafcillin will decrease the level or effect of cyclosporine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
naproxen|cyclosporine|3|Significant - Monitor Closely|naproxen, cyclosporine.Either increases toxicity of the other by nephrotoxicity and/or ototoxicity. Potential for dangerous interaction. Use with caution and monitor closely.
nefazodone|cyclosporine|11|Significant - Monitor Closely|nefazodone will decrease the level or effect of cyclosporine by  P-glycoprotein (MDR1) efflux transporter. Significant interaction possible, monitor closely.
cyclosporine|nelfinavir|11|Significant - Monitor Closely|cyclosporine will increase the level or effect of nelfinavir by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
cyclosporine|nelfinavir|11|Significant - Monitor Closely|cyclosporine will increase the level or effect of nelfinavir by  P-glycoprotein (MDR1) efflux transporter. Significant interaction possible, monitor closely.
cyclosporine|nicardipine|11|Significant - Monitor Closely|cyclosporine will increase the level or effect of nicardipine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
nicardipine|cyclosporine|11|Significant - Monitor Closely|nicardipine will increase the level or effect of cyclosporine by  P-glycoprotein (MDR1) efflux transporter. Significant interaction possible, monitor closely.
nicardipine|cyclosporine|11|Significant - Monitor Closely|nicardipine increases levels of cyclosporine by decreasing metabolism. Significant interaction possible, monitor closely.
nifedipine|cyclosporine|11|Significant - Monitor Closely|nifedipine will increase the level or effect of cyclosporine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
nifedipine|cyclosporine|11|Significant - Monitor Closely|nifedipine will decrease the level or effect of cyclosporine by  P-glycoprotein (MDR1) efflux transporter. Significant interaction possible, monitor closely.
cyclosporine|nifedipine|1|Minor|cyclosporine will increase the level or effect of nifedipine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor or non-significant interaction.
norfloxacin|cyclosporine|11|Significant - Monitor Closely|norfloxacin will increase the level or effect of cyclosporine by  affecting hepatic enzyme CYP1A2 metabolism. Significant interaction possible, monitor closely.
octreotide|cyclosporine|11|Significant - Monitor Closely|octreotide decreases levels of cyclosporine by inhibition of GI absorption. Applies only to oral form of both agents. Significant interaction possible, monitor closely.
omeprazole|cyclosporine|11|Significant - Monitor Closely|omeprazole will decrease the level or effect of cyclosporine by  affecting hepatic enzyme CYP1A2 metabolism. Significant interaction possible, monitor closely.
omeprazole|cyclosporine|11|Significant - Monitor Closely|omeprazole, cyclosporine.Either increases toxicity of the other by Other (see comment). Significant interaction possible, monitor closely. Comment: When used for prolonged periods of time PPIs may cause hypomagnesemia and the risk is further increased when used concomitantly with drugs that also have the same effects.
cyclosporine|omeprazole|1|Minor|cyclosporine, omeprazole.Either increases toxicity of the other by Other (see comment). Minor or non-significant interaction. Comment: Effectiveness of proton pump inhibitors may be decreased theoretically if administered with other antisecretory agents.
orlistat|cyclosporine|20|Serious - Use Alternative|orlistat decreases levels of cyclosporine by inhibition of GI absorption. Applies only to oral form of both agents. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available. Administer cyclosporine 3 hours after orlistat .
oxaprozin|cyclosporine|3|Significant - Monitor Closely|oxaprozin, cyclosporine.Either increases toxicity of the other by nephrotoxicity and/or ototoxicity. Potential for dangerous interaction. Use with caution and monitor closely.
oxcarbazepine|cyclosporine|11|Significant - Monitor Closely|oxcarbazepine will decrease the level or effect of cyclosporine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
pentobarbital|cyclosporine|20|Serious - Use Alternative|pentobarbital decreases levels of cyclosporine by increasing metabolism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
pentobarbital|cyclosporine|11|Significant - Monitor Closely|pentobarbital will decrease the level or effect of cyclosporine by  affecting hepatic enzyme CYP1A2 metabolism. Significant interaction possible, monitor closely.
pentobarbital|cyclosporine|11|Significant - Monitor Closely|pentobarbital will decrease the level or effect of cyclosporine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
phenobarbital|cyclosporine|20|Serious - Use Alternative|phenobarbital decreases levels of cyclosporine by increasing metabolism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
phenobarbital|cyclosporine|11|Significant - Monitor Closely|phenobarbital will decrease the level or effect of cyclosporine by  affecting hepatic enzyme CYP1A2 metabolism. Significant interaction possible, monitor closely.
phenobarbital|cyclosporine|11|Significant - Monitor Closely|phenobarbital will decrease the level or effect of cyclosporine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
phenobarbital|cyclosporine|11|Significant - Monitor Closely|phenobarbital will decrease the level or effect of cyclosporine by  P-glycoprotein (MDR1) efflux transporter. Significant interaction possible, monitor closely.
phenytoin|cyclosporine|20|Serious - Use Alternative|phenytoin decreases levels of cyclosporine by increasing metabolism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
phenytoin|cyclosporine|11|Significant - Monitor Closely|phenytoin will decrease the level or effect of cyclosporine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
phenytoin|cyclosporine|11|Significant - Monitor Closely|phenytoin will decrease the level or effect of cyclosporine by  P-glycoprotein (MDR1) efflux transporter. Significant interaction possible, monitor closely.
piroxicam|cyclosporine|3|Significant - Monitor Closely|piroxicam, cyclosporine.Either increases toxicity of the other by nephrotoxicity and/or ototoxicity. Potential for dangerous interaction. Use with caution and monitor closely.
cyclosporine|pitavastatin|33|Contraindicated|cyclosporine increases levels of pitavastatin by decreasing metabolism. Never use combination.
posaconazole|cyclosporine|11|Significant - Monitor Closely|posaconazole will increase the level or effect of cyclosporine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
cyclosporine|posaconazole|11|Significant - Monitor Closely|cyclosporine will increase the level or effect of posaconazole by  P-glycoprotein (MDR1) efflux transporter. Significant interaction possible, monitor closely.
primidone|cyclosporine|20|Serious - Use Alternative|primidone decreases levels of cyclosporine by increasing metabolism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
primidone|cyclosporine|11|Significant - Monitor Closely|primidone will decrease the level or effect of cyclosporine by  affecting hepatic enzyme CYP1A2 metabolism. Significant interaction possible, monitor closely.
primidone|cyclosporine|11|Significant - Monitor Closely|primidone will decrease the level or effect of cyclosporine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
cyclosporine|propafenone|1|Minor|cyclosporine will increase the level or effect of propafenone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor or non-significant interaction.
pyrazinamide|cyclosporine|1|Minor|pyrazinamide decreases levels of cyclosporine by unknown mechanism. Minor or non-significant interaction.
cyclosporine|repaglinide|11|Significant - Monitor Closely|cyclosporine will increase the level or effect of repaglinide by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
cyclosporine|repaglinide|11|Significant - Monitor Closely|cyclosporine increases levels of repaglinide by Other (see comment). Significant interaction possible, monitor closely. Comment: Repaglinide  is a substrate for active hepatic uptake transporter protein OATP1B1; cyclosporine inhibits this protein and may increase levels of repaglinide; repaglinide may require dose reduction.
rifabutin|cyclosporine|20|Serious - Use Alternative|rifabutin will decrease the level or effect of cyclosporine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
cyclosporine|rilonacept|22|Serious - Use Alternative|cyclosporine and rilonacept both increase  immunosuppressive effects; risk of infection. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available.
cyclosporine|ritonavir|11|Significant - Monitor Closely|cyclosporine will increase the level or effect of ritonavir by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
cyclosporine|ritonavir|11|Significant - Monitor Closely|cyclosporine will increase the level or effect of ritonavir by  P-glycoprotein (MDR1) efflux transporter. Significant interaction possible, monitor closely.
cyclosporine|rosuvastatin|20|Serious - Use Alternative|cyclosporine increases levels of rosuvastatin by unspecified interaction mechanism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available. Incr risk of myopathy. Limit rosuvastatin dose to 5 mg qd.
roxithromycin|cyclosporine|11|Significant - Monitor Closely|roxithromycin increases levels of cyclosporine by decreasing metabolism. Significant interaction possible, monitor closely.
cyclosporine|roxithromycin|1|Minor|cyclosporine increases levels of roxithromycin by decreasing elimination. Minor or non-significant interaction.
cyclosporine|saquinavir|11|Significant - Monitor Closely|cyclosporine will increase the level or effect of saquinavir by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
cyclosporine|saquinavir|11|Significant - Monitor Closely|cyclosporine will increase the level or effect of saquinavir by  P-glycoprotein (MDR1) efflux transporter. Significant interaction possible, monitor closely.
saquinavir|cyclosporine|11|Significant - Monitor Closely|saquinavir increases levels of cyclosporine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
secobarbital|cyclosporine|20|Serious - Use Alternative|secobarbital decreases levels of cyclosporine by increasing metabolism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
secobarbital|cyclosporine|11|Significant - Monitor Closely|secobarbital will decrease the level or effect of cyclosporine by  affecting hepatic enzyme CYP1A2 metabolism. Significant interaction possible, monitor closely.
secobarbital|cyclosporine|11|Significant - Monitor Closely|secobarbital will decrease the level or effect of cyclosporine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
cyclosporine|simvastatin|33|Contraindicated|cyclosporine will increase the level or effect of simvastatin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Never use combination. Contraindicated.  Increased risk for rhabdomyolysis with drugs that increase simvastatin systemic exposure.
cyclosporine|sirolimus|11|Significant - Monitor Closely|cyclosporine will increase the level or effect of sirolimus by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely. Simultaneous coadministration significantly increases sirolimus levels; this is minimized by administering sirolimus 4 hr after cyclosporine
cyclosporine|sirolimus|11|Significant - Monitor Closely|cyclosporine will increase the level or effect of sirolimus by  P-glycoprotein (MDR1) efflux transporter. Significant interaction possible, monitor closely. Simultaneous coadministration significantly increases sirolimus levels; this is minimized by administering sirolimus 4 hr after cyclosporine
cyclosporine|sirolimus|11|Significant - Monitor Closely|cyclosporine and sirolimus both increase  immunosuppressive effects; risk of infection. Significant interaction possible, monitor closely.
sirolimus|cyclosporine|3|Significant - Monitor Closely|sirolimus increases toxicity of cyclosporine by nephrotoxicity and/or ototoxicity. Potential for dangerous interaction. Use with caution and monitor closely. Elevations in serum creatinine, hemolytic uremic syndrome, TTP, and microangiopathy were observed when sirolimus used in combination with full-dose cyclosporine; this effect is often reversible with cyclosporine dose reduction.
sulfadiazine|cyclosporine|20|Serious - Use Alternative|sulfadiazine decreases effects of cyclosporine by unknown mechanism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available. Increased nephrotoxicity with this combination.
sulfamethoxazole|cyclosporine|20|Serious - Use Alternative|sulfamethoxazole decreases effects of cyclosporine by unknown mechanism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available. Increased nephrotoxicity with this combination.
sulfasalazine|cyclosporine|11|Significant - Monitor Closely|sulfasalazine increases toxicity of cyclosporine by pharmacodynamic antagonism. Significant interaction possible, monitor closely. NSAIDs decrease prostaglandin synthesis, increasing the risk of nephrotoxicity.
sulindac|cyclosporine|3|Significant - Monitor Closely|sulindac, cyclosporine.Either increases toxicity of the other by nephrotoxicity and/or ototoxicity. Potential for dangerous interaction. Use with caution and monitor closely.
cyclosporine|tacrolimus|22|Serious - Use Alternative|cyclosporine and tacrolimus both increase  immunosuppressive effects; risk of infection. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available.
cyclosporine|tacrolimus|22|Serious - Use Alternative|cyclosporine and tacrolimus both increase  nephrotoxicity and/or ototoxicity. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available.
cyclosporine|tacrolimus|11|Significant - Monitor Closely|cyclosporine will increase the level or effect of tacrolimus by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
cyclosporine|tacrolimus|11|Significant - Monitor Closely|cyclosporine will increase the level or effect of tacrolimus by  P-glycoprotein (MDR1) efflux transporter. Significant interaction possible, monitor closely.
cyclosporine|tamsulosin|2|Significant - Monitor Closely|cyclosporine increases levels of tamsulosin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Potential for interaction, monitor. Dose reduction may be needed for coadministered drugs that are predominantly metabolized by CYP3A.
verapamil|trazodone|2|Significant - Monitor Closely|verapamil will increase the level or effect of trazodone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Potential for interaction, monitor.
verapamil|trazodone|1|Minor|verapamil increases levels of trazodone by decreasing metabolism. Minor or non-significant interaction.
voriconazole|trazodone|22|Serious - Use Alternative|voriconazole will increase the level or effect of trazodone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available.
trazodone|voriconazole|3|Significant - Monitor Closely|trazodone and voriconazole both increase  QTc interval. Potential for dangerous interaction. Use with caution and monitor closely.
zolmitriptan|trazodone|3|Significant - Monitor Closely|zolmitriptan and trazodone both increase  serotonin levels. Potential for dangerous interaction. Use with caution and monitor closely.
trazodone|zolmitriptan|1|Minor|trazodone, zolmitriptan. Mechanism: unknown. Minor or non-significant interaction. Risk of weakness, dyspnea, chest pain.
treprostinil|triamterene|1|Minor|treprostinil increases effects of triamterene by pharmacodynamic synergism. Minor or non-significant interaction.
treprostinil|valsartan|2|Significant - Monitor Closely|treprostinil increases effects of valsartan by pharmacodynamic synergism. Potential for interaction, monitor.
treprostinil|verapamil|1|Minor|treprostinil increases effects of verapamil by pharmacodynamic synergism. Minor or non-significant interaction.
triamcinolone|warfarin|11|Significant - Monitor Closely|triamcinolone will decrease the level or effect of warfarin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
triamcinolone|warfarin|11|Significant - Monitor Closely|triamcinolone, warfarin. Other (see comment). Significant interaction possible, monitor closely. Comment: Corticosteroids may decrease anticoagulant effects by increasing blood coagulability; conversely, they may impair vascular integrity, thus increasing bleeding risk.  Monitor INR closely.
valsartan|triamterene|3|Significant - Monitor Closely|valsartan and triamterene both increase  serum potassium. Potential for dangerous interaction. Use with caution and monitor closely.
triprolidine|triazolam|2|Significant - Monitor Closely|triprolidine and triazolam both increase  sedation. Potential for interaction, monitor.
verapamil|triazolam|11|Significant - Monitor Closely|verapamil will increase the level or effect of triazolam by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
voriconazole|triazolam|11|Significant - Monitor Closely|voriconazole will increase the level or effect of triazolam by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
triprolidine|trifluoperazine|2|Significant - Monitor Closely|triprolidine and trifluoperazine both increase  sedation. Potential for interaction, monitor.
triprolidine|trimipramine|2|Significant - Monitor Closely|triprolidine and trimipramine both increase  sedation. Potential for interaction, monitor.
venlafaxine|trimipramine|22|Serious - Use Alternative|venlafaxine and trimipramine both increase  serotonin levels. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available.
trimipramine|venlafaxine|3|Significant - Monitor Closely|trimipramine and venlafaxine both increase  QTc interval. Potential for dangerous interaction. Use with caution and monitor closely.
trimipramine|voriconazole|3|Significant - Monitor Closely|trimipramine and voriconazole both increase  QTc interval. Potential for dangerous interaction. Use with caution and monitor closely.
trimipramine|ziprasidone|22|Serious - Use Alternative|trimipramine and ziprasidone both increase  QTc interval. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available.
ziprasidone|trimipramine|2|Significant - Monitor Closely|ziprasidone and trimipramine both increase  sedation. Potential for interaction, monitor.
zolmitriptan|trimipramine|3|Significant - Monitor Closely|zolmitriptan and trimipramine both increase  serotonin levels. Potential for dangerous interaction. Use with caution and monitor closely.
triprolidine|ziconotide|2|Significant - Monitor Closely|triprolidine and ziconotide both increase  sedation. Potential for interaction, monitor.
triprolidine|ziprasidone|2|Significant - Monitor Closely|triprolidine and ziprasidone both increase  sedation. Potential for interaction, monitor.
valganciclovir|zidovudine|21|Serious - Use Alternative|valganciclovir increases toxicity of zidovudine by pharmacodynamic synergism. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available. Never use combination.
voriconazole|vardenafil|11|Significant - Monitor Closely|voriconazole will increase the level or effect of vardenafil by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
vemurafenib|voriconazole|20|Serious - Use Alternative|vemurafenib and voriconazole both increase  QTc interval. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available. Concomitant use of vemurafenib with drugs that  prolong QT interval is not recommended. Voriconazole may also increase levels of vemurafenib.
vemurafenib|warfarin|2|Significant - Monitor Closely|vemurafenib will increase the level or effect of warfarin by  affecting hepatic enzyme CYP2C9/10 metabolism. Potential for interaction, monitor. Exercise caution and consider additional INR monitoring when vemurafenib is used concomitantly with warfarin.
venlafaxine|voriconazole|2|Significant - Monitor Closely|venlafaxine and voriconazole both increase  QTc interval. Potential for interaction, monitor.
zolmitriptan|venlafaxine|3|Significant - Monitor Closely|zolmitriptan and venlafaxine both increase  serotonin levels. Potential for dangerous interaction. Use with caution and monitor closely.
venlafaxine|zolmitriptan|1|Minor|venlafaxine, zolmitriptan. Mechanism: unknown. Minor or non-significant interaction. Risk of weakness, dyspnea, chest pain.
voriconazole|verapamil|11|Significant - Monitor Closely|voriconazole will increase the level or effect of verapamil by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely. Combo may increase risk of hypotension, bradycardia, AV block.
voriconazole|verapamil|11|Significant - Monitor Closely|voriconazole increases levels of verapamil by decreasing metabolism. Significant interaction possible, monitor closely.
voriconazole|vilazodone|20|Serious - Use Alternative|voriconazole increases toxicity of vilazodone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available. Strong CYP3A4 inhibitors may increase vilazodone plasma levels by 50% - Reduce daily dose  to 20 mg.
voriconazole|vinblastine|11|Significant - Monitor Closely|voriconazole increases levels of vinblastine by decreasing metabolism. Significant interaction possible, monitor closely.
voriconazole|vinblastine|1|Minor|voriconazole will increase the level or effect of vinblastine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor or non-significant interaction.
voriconazole|vincristine|11|Significant - Monitor Closely|voriconazole increases levels of vincristine by decreasing metabolism. Significant interaction possible, monitor closely.
voriconazole|vincristine|1|Minor|voriconazole will increase the level or effect of vincristine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor or non-significant interaction.
voriconazole|vinorelbine|1|Minor|voriconazole will increase the level or effect of vinorelbine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor or non-significant interaction.
voriconazole|ziprasidone|3|Significant - Monitor Closely|voriconazole and ziprasidone both increase  QTc interval. Potential for dangerous interaction. Use with caution and monitor closely.
voriconazole|ziprasidone|1|Minor|voriconazole will increase the level or effect of ziprasidone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor or non-significant interaction.
voriconazole|zolpidem|1|Minor|voriconazole will increase the level or effect of zolpidem by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor or non-significant interaction.
voriconazole|zonisamide|1|Minor|voriconazole will increase the level or effect of zonisamide by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor or non-significant interaction.
lorcaserin|thioridazine|11|Significant - Monitor Closely|lorcaserin will increase the level or effect of thioridazine by  affecting hepatic enzyme CYP2D6 metabolism. Significant interaction possible, monitor closely.
losartan|spironolactone|3|Significant - Monitor Closely|losartan and spironolactone both increase  serum potassium. Potential for dangerous interaction. Use with caution and monitor closely.
losartan|trandolapril|20|Serious - Use Alternative|losartan, trandolapril.Either increases toxicity of the other by pharmacodynamic synergism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available. Dual blockade of renin-angiotensin system increases risks of hypotension, hyperkalemia, and renal impairment.
treprostinil|losartan|2|Significant - Monitor Closely|treprostinil increases effects of losartan by pharmacodynamic synergism. Potential for interaction, monitor.
losartan|triamterene|3|Significant - Monitor Closely|losartan and triamterene both increase  serum potassium. Potential for dangerous interaction. Use with caution and monitor closely.
nefazodone|lovastatin|33|Contraindicated|nefazodone will increase the level or effect of lovastatin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Never use combination. Strong CYP3A4 inhibitors increase systemic statin exposure and risk of myopathy, including rhabdomyolysis
nefazodone|lovastatin|11|Significant - Monitor Closely|nefazodone will decrease the level or effect of lovastatin by  P-glycoprotein (MDR1) efflux transporter. Significant interaction possible, monitor closely.
nelfinavir|lovastatin|33|Contraindicated|nelfinavir will increase the level or effect of lovastatin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Never use combination. Strong CYP3A4 inhibitors increase systemic statin exposure and risk of myopathy, including rhabdomyolysis
lovastatin|nelfinavir|33|Contraindicated|lovastatin will increase the level or effect of nelfinavir by  P-glycoprotein (MDR1) efflux transporter. Never use combination.
nevirapine|lovastatin|20|Serious - Use Alternative|nevirapine will decrease the level or effect of lovastatin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
niacin|lovastatin|20|Serious - Use Alternative|niacin, lovastatin.Either increases toxicity of the other by pharmacodynamic synergism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available. Increased risk of rhabdomyolysis (>1 g/day niacin). Do not exceed 20 mg/day of lovastatin.
rifabutin|lovastatin|22|Serious - Use Alternative|rifabutin will decrease the level or effect of lovastatin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available.
ritonavir|lovastatin|33|Contraindicated|ritonavir will increase the level or effect of lovastatin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Never use combination. Strong CYP3A4 inhibitors increase systemic statin exposure and risk of myopathy, including rhabdomyolysis
lovastatin|ritonavir|33|Contraindicated|lovastatin will increase the level or effect of ritonavir by  P-glycoprotein (MDR1) efflux transporter. Never use combination.
lovastatin|saquinavir|33|Contraindicated|lovastatin will increase the level or effect of saquinavir by  P-glycoprotein (MDR1) efflux transporter. Never use combination.
saquinavir|lovastatin|33|Contraindicated|saquinavir increases levels of lovastatin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Never use combination. Strong CYP3A4 inhibitors increase systemic statin exposure and risk of myopathy, including rhabdomyolysis.
telaprevir|lovastatin|33|Contraindicated|telaprevir increases levels of lovastatin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Never use combination. Strong CYP3A4 inhibitors increase systemic statin exposure and risk of myopathy, including rhabdomyolysis.
telithromycin|lovastatin|33|Contraindicated|telithromycin will increase the level or effect of lovastatin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Never use combination. Strong CYP3A4 inhibitors increase systemic statin exposure and risk of myopathy, including rhabdomyolysis
ticagrelor|lovastatin|11|Significant - Monitor Closely|ticagrelor increases levels of lovastatin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely. Avoid lovastatin doses greater than 40 mg.
tipranavir|lovastatin|33|Contraindicated|tipranavir increases levels of lovastatin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Never use combination. This interaction is the net effect of tipranavir being coadministered with ritonavir (boosted therapy); increased risk of myopathy including rhabdomyolysis.
verapamil|lovastatin|20|Serious - Use Alternative|verapamil will increase the level or effect of lovastatin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available. Do not exceed 20 mg of lovastatin
verapamil|lovastatin|11|Significant - Monitor Closely|verapamil will increase the level or effect of lovastatin by  P-glycoprotein (MDR1) efflux transporter. Significant interaction possible, monitor closely. Avoid concomitant use of verapamil and lovastatin if possible. If used together, use lower doses of lovastatin and monitor for lovastatin toxicity (myositis, rhabdomyolysis).
voriconazole|lovastatin|33|Contraindicated|voriconazole will increase the level or effect of lovastatin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Never use combination. Strong CYP3A4 inhibitors increase systemic statin exposure and risk of myopathy, including rhabdomyolysis
lovastatin|warfarin|11|Significant - Monitor Closely|lovastatin increases effects of warfarin by unknown mechanism. Significant interaction possible, monitor closely.
loxapine|tetrabenazine|3|Significant - Monitor Closely|loxapine and tetrabenazine both increase  antidopaminergic effects, including extrapyramidal symptoms and neuroleptic malignant syndrome. Potential for dangerous interaction. Use with caution and monitor closely.
loxapine|thiothixene|2|Significant - Monitor Closely|loxapine and thiothixene both increase  antidopaminergic effects, including extrapyramidal symptoms and neuroleptic malignant syndrome. Potential for interaction, monitor.
loxapine|thiothixene|2|Significant - Monitor Closely|loxapine and thiothixene both increase  sedation. Potential for interaction, monitor.
loxapine|trimipramine|2|Significant - Monitor Closely|loxapine and trimipramine both increase  sedation. Potential for interaction, monitor.
triprolidine|loxapine|2|Significant - Monitor Closely|triprolidine and loxapine both increase  sedation. Potential for interaction, monitor.
loxapine|ziprasidone|2|Significant - Monitor Closely|loxapine and ziprasidone both increase  antidopaminergic effects, including extrapyramidal symptoms and neuroleptic malignant syndrome. Potential for interaction, monitor.
loxapine|ziprasidone|2|Significant - Monitor Closely|loxapine and ziprasidone both increase  sedation. Potential for interaction, monitor.
maprotiline|lumefantrine|22|Serious - Use Alternative|maprotiline and lumefantrine both increase  QTc interval. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available.
mefloquine|lumefantrine|22|Serious - Use Alternative|mefloquine increases toxicity of lumefantrine by QTc interval. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available. Mefloquine may enhance the QTc prolonging effect of high risk QTc prolonging agents.
mefloquine|lumefantrine|11|Significant - Monitor Closely|mefloquine decreases levels of lumefantrine by inhibition of GI absorption. Applies only to oral form of both agents. Significant interaction possible, monitor closely. Mefloquine decreases bile production; take Coartem (lumefantrine) during food consumption.
lumefantrine|methadone|11|Significant - Monitor Closely|lumefantrine will decrease the level or effect of methadone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
lumefantrine|methadone|3|Significant - Monitor Closely|lumefantrine and methadone both increase  QTc interval. Potential for dangerous interaction. Use with caution and monitor closely.
lumefantrine|moxifloxacin|22|Serious - Use Alternative|lumefantrine and moxifloxacin both increase  QTc interval. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available.
lumefantrine|nilotinib|22|Serious - Use Alternative|lumefantrine and nilotinib both increase  QTc interval. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available.
nilotinib|lumefantrine|11|Significant - Monitor Closely|nilotinib will increase the level or effect of lumefantrine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
nortriptyline|lumefantrine|22|Serious - Use Alternative|nortriptyline and lumefantrine both increase  QTc interval. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available.
lumefantrine|nortriptyline|20|Serious - Use Alternative|lumefantrine will increase the level or effect of nortriptyline by  affecting hepatic enzyme CYP2D6 metabolism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
lumefantrine|octreotide|22|Serious - Use Alternative|lumefantrine and octreotide both increase  QTc interval. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available.
lumefantrine|pazopanib|11|Significant - Monitor Closely|lumefantrine will decrease the level or effect of pazopanib by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
lumefantrine|pazopanib|2|Significant - Monitor Closely|lumefantrine and pazopanib both increase  QTc interval. Potential for interaction, monitor.
lumefantrine|pentamidine|33|Contraindicated|lumefantrine and pentamidine both increase  QTc interval. Never use combination.
lumefantrine|pimozide|33|Contraindicated|lumefantrine and pimozide both increase  QTc interval. Never use combination.
lumefantrine|pimozide|1|Minor|lumefantrine will decrease the level or effect of pimozide by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor or non-significant interaction.
lumefantrine|procainamide|33|Contraindicated|lumefantrine and procainamide both increase  QTc interval. Never use combination.
lumefantrine|propafenone|20|Serious - Use Alternative|lumefantrine will increase the level or effect of propafenone by  affecting hepatic enzyme CYP2D6 metabolism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
lumefantrine|propafenone|1|Minor|lumefantrine will decrease the level or effect of propafenone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor or non-significant interaction.
protriptyline|lumefantrine|22|Serious - Use Alternative|protriptyline and lumefantrine both increase  QTc interval. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available.
lumefantrine|quetiapine|11|Significant - Monitor Closely|lumefantrine will decrease the level or effect of quetiapine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
quetiapine|lumefantrine|2|Significant - Monitor Closely|quetiapine, lumefantrine.Either increases toxicity of the other by QTc interval. Potential for interaction, monitor. Avoid use with drugs that prolong QT and in patients with risk factors for prolonged QT interval. Postmarketing cases show QT prolongation with overdose in patients with concomitant illness or with drugs known to cause electrolyte imbalance or prolong QT.
quinidine|lumefantrine|33|Contraindicated|quinidine and lumefantrine both increase  QTc interval. Never use combination.
lumefantrine|quinidine|11|Significant - Monitor Closely|lumefantrine will decrease the level or effect of quinidine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
lumefantrine|quinine|1|Minor|lumefantrine will decrease the level or effect of quinine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor or non-significant interaction.
lumefantrine|ranolazine|21|Serious - Use Alternative|lumefantrine will decrease the level or effect of ranolazine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available. Never use combination.
lumefantrine|ranolazine|3|Significant - Monitor Closely|lumefantrine and ranolazine both increase  QTc interval. Potential for dangerous interaction. Use with caution and monitor closely.
lumefantrine|risperidone|3|Significant - Monitor Closely|lumefantrine and risperidone both increase  QTc interval. Potential for dangerous interaction. Use with caution and monitor closely.
lumefantrine|risperidone|2|Significant - Monitor Closely|lumefantrine will increase the level or effect of risperidone by  affecting hepatic enzyme CYP2D6 metabolism. Potential for interaction, monitor.
lumefantrine|romidepsin|20|Serious - Use Alternative|lumefantrine and romidepsin both increase  QTc interval. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
lumefantrine|sotalol|33|Contraindicated|lumefantrine and sotalol both increase  QTc interval. Never use combination.
lumefantrine|sunitinib|11|Significant - Monitor Closely|lumefantrine will decrease the level or effect of sunitinib by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
lumefantrine|tacrolimus|11|Significant - Monitor Closely|lumefantrine will decrease the level or effect of tacrolimus by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
lumefantrine|telavancin|3|Significant - Monitor Closely|lumefantrine and telavancin both increase  QTc interval. Potential for dangerous interaction. Use with caution and monitor closely.
telithromycin|lumefantrine|11|Significant - Monitor Closely|telithromycin will increase the level or effect of lumefantrine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
lumefantrine|telithromycin|3|Significant - Monitor Closely|lumefantrine and telithromycin both increase  QTc interval. Potential for dangerous interaction. Use with caution and monitor closely.
lumefantrine|telithromycin|1|Minor|lumefantrine will decrease the level or effect of telithromycin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor or non-significant interaction.
lumefantrine|thioridazine|22|Serious - Use Alternative|lumefantrine will increase the level or effect of thioridazine by  affecting hepatic enzyme CYP2D6 metabolism. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available.
thioridazine|lumefantrine|22|Serious - Use Alternative|thioridazine and lumefantrine both increase  QTc interval. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available.
trimipramine|lumefantrine|22|Serious - Use Alternative|trimipramine and lumefantrine both increase  QTc interval. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available.
voriconazole|lumefantrine|11|Significant - Monitor Closely|voriconazole will increase the level or effect of lumefantrine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
lumefantrine|voriconazole|3|Significant - Monitor Closely|lumefantrine and voriconazole both increase  QTc interval. Potential for dangerous interaction. Use with caution and monitor closely.
lumefantrine|ziprasidone|22|Serious - Use Alternative|lumefantrine and ziprasidone both increase  QTc interval. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available.
lumefantrine|ziprasidone|1|Minor|lumefantrine will decrease the level or effect of ziprasidone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor or non-significant interaction.
metoclopramide|lurasidone|33|Contraindicated|metoclopramide increases toxicity of lurasidone by antidopaminergic effects, including extrapyramidal symptoms and neuroleptic malignant syndrome. Never use combination. Concomitant use of metoclopramide and antipsychotics is contraindicated by the manufacturer of metoclopramide; increased risk of extrapyramidal effects. .
nafcillin|lurasidone|33|Contraindicated|nafcillin decreases levels of lurasidone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Never use combination. Contraindicated.
magnesium oxide|minocycline|20|Serious - Use Alternative|magnesium oxide decreases levels of minocycline by inhibition of GI absorption. Applies only to oral form of both agents. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
magnesium oxide|moxifloxacin|11|Significant - Monitor Closely|magnesium oxide decreases levels of moxifloxacin by inhibition of GI absorption. Applies only to oral form of both agents. Significant interaction possible, monitor closely. Separate by 2 hours.
magnesium oxide|norfloxacin|11|Significant - Monitor Closely|magnesium oxide decreases levels of norfloxacin by inhibition of GI absorption. Applies only to oral form of both agents. Significant interaction possible, monitor closely. Separate by 2 hours.
magnesium oxide|ofloxacin|11|Significant - Monitor Closely|magnesium oxide decreases levels of ofloxacin by inhibition of GI absorption. Applies only to oral form of both agents. Significant interaction possible, monitor closely. Separate by 2 hours.
rivastigmine|maprotiline|2|Significant - Monitor Closely|rivastigmine increases and maprotiline decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Potential for interaction, monitor.
tacrine|maprotiline|2|Significant - Monitor Closely|tacrine increases and maprotiline decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Potential for interaction, monitor.
thioridazine|maprotiline|22|Serious - Use Alternative|thioridazine and maprotiline both increase  QTc interval. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available.
thioridazine|maprotiline|2|Significant - Monitor Closely|thioridazine and maprotiline both increase  sedation. Potential for interaction, monitor.
maprotiline|thioridazine|1|Minor|maprotiline, thioridazine.Either increases levels of the other by decreasing metabolism. Minor or non-significant interaction. Additive anticholinergic effects.
maprotiline|thioridazine|1|Minor|maprotiline, thioridazine.Either increases levels of the other by pharmacodynamic synergism. Minor or non-significant interaction. Additive anticholinergic effects.
thiothixene|maprotiline|2|Significant - Monitor Closely|thiothixene and maprotiline both increase  sedation. Potential for interaction, monitor.
maprotiline|tramadol|3|Significant - Monitor Closely|maprotiline and tramadol both increase  serotonin levels. Potential for dangerous interaction. Use with caution and monitor closely.
tramadol|maprotiline|2|Significant - Monitor Closely|tramadol and maprotiline both increase  sedation. Potential for interaction, monitor.
tranylcypromine|maprotiline|33|Contraindicated|tranylcypromine and maprotiline both increase  serotonin levels. Never use combination.
maprotiline|trazodone|22|Serious - Use Alternative|maprotiline and trazodone both increase  QTc interval. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available.
trazodone|maprotiline|22|Serious - Use Alternative|trazodone and maprotiline both increase  serotonin levels. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available.
maprotiline|trazodone|2|Significant - Monitor Closely|maprotiline and trazodone both decrease  cholinergic effects/transmission. Potential for interaction, monitor.
maprotiline|trazodone|2|Significant - Monitor Closely|maprotiline and trazodone both increase  sedation. Potential for interaction, monitor.
maprotiline|trimipramine|22|Serious - Use Alternative|maprotiline and trimipramine both increase  QTc interval. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available.
maprotiline|trimipramine|22|Serious - Use Alternative|maprotiline and trimipramine both increase  serotonin levels. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available.
maprotiline|trimipramine|2|Significant - Monitor Closely|maprotiline and trimipramine both decrease  cholinergic effects/transmission. Potential for interaction, monitor.
maprotiline|trimipramine|2|Significant - Monitor Closely|maprotiline and trimipramine both increase  sedation. Potential for interaction, monitor.
triprolidine|maprotiline|2|Significant - Monitor Closely|triprolidine and maprotiline both increase  sedation. Potential for interaction, monitor.
venlafaxine|maprotiline|22|Serious - Use Alternative|venlafaxine and maprotiline both increase  serotonin levels. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available.
maprotiline|venlafaxine|3|Significant - Monitor Closely|maprotiline and venlafaxine both increase  QTc interval. Potential for dangerous interaction. Use with caution and monitor closely.
maprotiline|voriconazole|3|Significant - Monitor Closely|maprotiline and voriconazole both increase  QTc interval. Potential for dangerous interaction. Use with caution and monitor closely.
maprotiline|ziprasidone|22|Serious - Use Alternative|maprotiline and ziprasidone both increase  QTc interval. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available.
ziprasidone|maprotiline|2|Significant - Monitor Closely|ziprasidone and maprotiline both increase  sedation. Potential for interaction, monitor.
zolmitriptan|maprotiline|3|Significant - Monitor Closely|zolmitriptan and maprotiline both increase  serotonin levels. Potential for dangerous interaction. Use with caution and monitor closely.
telithromycin|maraviroc|11|Significant - Monitor Closely|telithromycin will increase the level or effect of maraviroc by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely. Decrease maraviroc dose to 150 mg BID when coadministered with strong CYP3A4 inhibitors
topiramate|maraviroc|11|Significant - Monitor Closely|topiramate will decrease the level or effect of maraviroc by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
voriconazole|maraviroc|11|Significant - Monitor Closely|voriconazole will increase the level or effect of maraviroc by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely. Decrease maraviroc dose to 150 mg BID when coadministered with strong CYP3A4 inhibitors
phenytoin|mebendazole|21|Serious - Use Alternative|phenytoin decreases levels of mebendazole by increasing metabolism. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available. Never use combination.
tacrine|meclizine|2|Significant - Monitor Closely|tacrine increases and meclizine decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Potential for interaction, monitor.
tacrine|meclizine|1|Minor|tacrine decreases effects of meclizine by pharmacodynamic antagonism. Minor or non-significant interaction.
mefenamic acid|methotrexate|20|Serious - Use Alternative|mefenamic acid increases levels of methotrexate by decreasing renal clearance. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available. Concomitant administration of NSAIDs with high dose methotrexate has been reported to elevate and prolong serum methotrexate levels, resulting in deaths from severe hematologic and GI toxicity. NSAIDs may reduce tubular secretion of methotrexate and enhance toxicity. .
mefenamic acid|tolbutamide|11|Significant - Monitor Closely|mefenamic acid increases effects of tolbutamide by unknown mechanism. Significant interaction possible, monitor closely. Risk of hypoglycemia.
trandolapril|mefenamic acid|11|Significant - Monitor Closely|trandolapril, mefenamic acid.Either increases toxicity of the other by Other (see comment). Significant interaction possible, monitor closely. Comment: May result in renal function deterioration, particularly in elderly or volume depleted individuals.
mefenamic acid|trandolapril|3|Significant - Monitor Closely|mefenamic acid decreases effects of trandolapril by pharmacodynamic antagonism. Potential for dangerous interaction. Use with caution and monitor closely. NSAIDs decrease synthesis of vasodilating renal prostaglandins, and thus affect fluid homeostasis and may diminish antihypertenisve effect.
warfarin|mefenamic acid|3|Significant - Monitor Closely|warfarin and mefenamic acid both increase  anticoagulation. Potential for dangerous interaction. Use with caution and monitor closely.
ritonavir|mefloquine|20|Serious - Use Alternative|ritonavir increases levels of mefloquine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available. Potential for increased toxicity. Avoid coadministration during and for 15 weeks after discontinuing mefloquine. .
ritonavir|mefloquine|20|Serious - Use Alternative|ritonavir increases toxicity of mefloquine by QTc interval. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
mefloquine|ritonavir|1|Minor|mefloquine decreases levels of ritonavir by unknown mechanism. Minor or non-significant interaction.
mefloquine|tacrolimus|20|Serious - Use Alternative|mefloquine increases toxicity of tacrolimus by QTc interval. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available. Mefloquine may enhance the QTc prolonging effect of high risk QTc prolonging agents.
telithromycin|mefloquine|20|Serious - Use Alternative|telithromycin will increase the level or effect of mefloquine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available. Potential for increased toxicity. Avoid coadministration during and for 15 weeks after discontinuing mefloquine.
mefloquine|thiothixene|20|Serious - Use Alternative|mefloquine increases toxicity of thiothixene by QTc interval. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available. Mefloquine may enhance the QTc prolonging effect of high risk QTc prolonging agents.
mefloquine|topotecan|20|Serious - Use Alternative|mefloquine increases levels of topotecan by P-glycoprotein (MDR1) efflux transporter. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
mefloquine|toremifene|20|Serious - Use Alternative|mefloquine and toremifene both increase  QTc interval. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available. Concurrent use of toremifene with agents causing  QT prolongation should be avoided. If concomitant use is required it's recommended that toremifene be interrupted. If interruption not possible, patients requiring therapy with a drug that prolongs QT should be closely monitored. ECGs should be obtained for high risk patients.
mefloquine|trimipramine|20|Serious - Use Alternative|mefloquine increases toxicity of trimipramine by QTc interval. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available. Mefloquine may enhance the QTc prolonging effect of high risk QTc prolonging agents.
voriconazole|mefloquine|20|Serious - Use Alternative|voriconazole will increase the level or effect of mefloquine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available. Potential for increased toxicity. Avoid coadministration during and for 15 weeks after discontinuing mefloquine.
mefloquine|vorinostat|20|Serious - Use Alternative|mefloquine increases toxicity of vorinostat by QTc interval. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available. Mefloquine may enhance the QTc prolonging effect of high risk QTc prolonging agents.
mefloquine|ziprasidone|22|Serious - Use Alternative|mefloquine increases toxicity of ziprasidone by QTc interval. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available. Mefloquine may enhance the QTc prolonging effect of high risk QTc prolonging agents.
melatonin|nifedipine|11|Significant - Monitor Closely|melatonin decreases effects of nifedipine by pharmacodynamic antagonism. Significant interaction possible, monitor closely.
meloxicam|pralatrexate|11|Significant - Monitor Closely|meloxicam increases levels of pralatrexate by decreasing renal clearance. Significant interaction possible, monitor closely. NSAIDs may delay pralatrexate clearance, increasing drug exposure. Adjust the pralatrexate dose as needed.
telmisartan|meloxicam|11|Significant - Monitor Closely|telmisartan, meloxicam.Either increases toxicity of the other by Other (see comment). Significant interaction possible, monitor closely. Comment: May result in renal function deterioration, particularly in elderly or volume depleted individuals.
meloxicam|telmisartan|3|Significant - Monitor Closely|meloxicam decreases effects of telmisartan by pharmacodynamic antagonism. Potential for dangerous interaction. Use with caution and monitor closely.  NSAIDs decrease synthesis of vasodilating renal prostaglandins, and thus affect fluid homeostasis and may diminish antihypertensive effect.
telmisartan|meloxicam|2|Significant - Monitor Closely|telmisartan and meloxicam both increase  serum potassium. Potential for interaction, monitor.
meloxicam|timolol|11|Significant - Monitor Closely|meloxicam decreases effects of timolol by pharmacodynamic antagonism. Significant interaction possible, monitor closely. Long term (>1 wk) NSAID use.  NSAIDs decrease prostaglandin synthesis.
timolol|meloxicam|2|Significant - Monitor Closely|timolol and meloxicam both increase  serum potassium. Potential for interaction, monitor.
trandolapril|meloxicam|11|Significant - Monitor Closely|trandolapril, meloxicam.Either increases toxicity of the other by Other (see comment). Significant interaction possible, monitor closely. Comment: May result in renal function deterioration, particularly in elderly or volume depleted individuals.
meloxicam|trandolapril|3|Significant - Monitor Closely|meloxicam decreases effects of trandolapril by pharmacodynamic antagonism. Potential for dangerous interaction. Use with caution and monitor closely. NSAIDs decrease synthesis of vasodilating renal prostaglandins, and thus affect fluid homeostasis and may diminish antihypertenisve effect.
voriconazole|meloxicam|1|Minor|voriconazole will increase the level or effect of meloxicam by  affecting hepatic enzyme CYP2C9/10 metabolism. Minor or non-significant interaction.
warfarin|meloxicam|3|Significant - Monitor Closely|warfarin and meloxicam both increase  anticoagulation. Potential for dangerous interaction. Use with caution and monitor closely.
sodium bicarbonate|memantine|11|Significant - Monitor Closely|sodium bicarbonate will increase the level or effect of memantine by  passive renal tubular reabsorption - basic urine. Significant interaction possible, monitor closely.
tacrine|mepenzolate|2|Significant - Monitor Closely|tacrine increases and mepenzolate decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Potential for interaction, monitor.
tacrine|mepenzolate|1|Minor|tacrine decreases effects of mepenzolate by pharmacodynamic antagonism. Minor or non-significant interaction.
mercaptopurine|warfarin|11|Significant - Monitor Closely|mercaptopurine decreases effects of warfarin by unknown mechanism. Significant interaction possible, monitor closely. Inhibition of the anticoagulant effect of warfarin, when given with mercaptopurine, has been reported.
minocycline|mestranol|2|Significant - Monitor Closely|minocycline will decrease the level or effect of mestranol by  altering intestinal flora. Applies only to oral forms of hormone. Low risk of contraceptive failure. Potential for interaction, monitor.
modafinil|mestranol|11|Significant - Monitor Closely|modafinil will decrease the level or effect of mestranol by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
nelfinavir|mestranol|11|Significant - Monitor Closely|nelfinavir will increase the level or effect of mestranol by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
nelfinavir|mestranol|11|Significant - Monitor Closely|nelfinavir decreases levels of mestranol by increasing metabolism. Significant interaction possible, monitor closely. May result in contraceptive failure.
oxcarbazepine|mestranol|11|Significant - Monitor Closely|oxcarbazepine will decrease the level or effect of mestranol by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
phenobarbital|mestranol|20|Serious - Use Alternative|phenobarbital decreases levels of mestranol by increasing metabolism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available. May result in contraceptive failure.
phenobarbital|mestranol|11|Significant - Monitor Closely|phenobarbital will decrease the level or effect of mestranol by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
phenobarbital|mestranol|11|Significant - Monitor Closely|phenobarbital will decrease the level or effect of mestranol by  P-glycoprotein (MDR1) efflux transporter. Significant interaction possible, monitor closely.
phenytoin|mestranol|20|Serious - Use Alternative|phenytoin decreases levels of mestranol by increasing metabolism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available. May result in contraceptive failure.
phenytoin|mestranol|11|Significant - Monitor Closely|phenytoin will decrease the level or effect of mestranol by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
phenytoin|mestranol|11|Significant - Monitor Closely|phenytoin will decrease the level or effect of mestranol by  P-glycoprotein (MDR1) efflux transporter. Significant interaction possible, monitor closely.
mestranol|phenytoin|11|Significant - Monitor Closely|mestranol decreases effects of phenytoin by decreasing metabolism. Significant interaction possible, monitor closely.
pioglitazone|mestranol|1|Minor|pioglitazone decreases levels of mestranol by unknown mechanism. Minor or non-significant interaction.
prednisolone|mestranol|11|Significant - Monitor Closely|prednisolone will decrease the level or effect of mestranol by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
prednisone|mestranol|11|Significant - Monitor Closely|prednisone will decrease the level or effect of mestranol by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
primidone|mestranol|20|Serious - Use Alternative|primidone decreases levels of mestranol by increasing metabolism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available. Contraceptive failure may result.
primidone|mestranol|11|Significant - Monitor Closely|primidone will decrease the level or effect of mestranol by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
rifabutin|mestranol|20|Serious - Use Alternative|rifabutin will decrease the level or effect of mestranol by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
rifabutin|mestranol|20|Serious - Use Alternative|rifabutin decreases levels of mestranol by increasing metabolism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available. May result in contraceptive failure.
tetracycline|mestranol|2|Significant - Monitor Closely|tetracycline will decrease the level or effect of mestranol by  altering intestinal flora. Applies only to oral forms of hormone. Low risk of contraceptive failure. Potential for interaction, monitor.
tipranavir|mestranol|20|Serious - Use Alternative|tipranavir decreases levels of mestranol by increasing metabolism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available. May result in contraceptive failure.
mestranol|tizanidine|1|Minor|mestranol increases levels of tizanidine by unspecified interaction mechanism. Minor or non-significant interaction.
topiramate|mestranol|11|Significant - Monitor Closely|topiramate will decrease the level or effect of mestranol by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
mestranol|warfarin|21|Serious - Use Alternative|mestranol decreases effects of warfarin by pharmacodynamic antagonism. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available. Never use combination. Risk of thromboembolic disorders.
nelfinavir|methadone|11|Significant - Monitor Closely|nelfinavir will increase the level or effect of methadone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
nevirapine|methadone|11|Significant - Monitor Closely|nevirapine will decrease the level or effect of methadone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
pentobarbital|methadone|11|Significant - Monitor Closely|pentobarbital will decrease the level or effect of methadone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
pentobarbital|methadone|2|Significant - Monitor Closely|pentobarbital and methadone both increase  sedation. Potential for interaction, monitor.
phenobarbital|methadone|11|Significant - Monitor Closely|phenobarbital will decrease the level or effect of methadone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
phenobarbital|methadone|2|Significant - Monitor Closely|phenobarbital and methadone both increase  sedation. Potential for interaction, monitor.
phenytoin|methadone|21|Serious - Use Alternative|phenytoin decreases levels of methadone by increasing metabolism. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available. Never use combination.
phenytoin|methadone|11|Significant - Monitor Closely|phenytoin will decrease the level or effect of methadone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
primidone|methadone|11|Significant - Monitor Closely|primidone will decrease the level or effect of methadone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
primidone|methadone|2|Significant - Monitor Closely|primidone and methadone both increase  sedation. Potential for interaction, monitor.
rifabutin|methadone|20|Serious - Use Alternative|rifabutin will decrease the level or effect of methadone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
rifapentine|methadone|11|Significant - Monitor Closely|rifapentine will decrease the level or effect of methadone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
rilpivirine|methadone|11|Significant - Monitor Closely|rilpivirine, methadone. Other (see comment). Significant interaction possible, monitor closely. Comment: No dose adjustments are required when initiating co-administration of methadone with rilpivirine. However, clinical monitoring is recommended as methadone maintenance therapy may need to be adjusted in some patients.
rilpivirine|methadone|2|Significant - Monitor Closely|rilpivirine increases toxicity of methadone by QTc interval. Potential for interaction, monitor. Rilpivirine should be used with caution when co-administered with a drug with a known risk of Torsade de Pointes.
ritonavir|methadone|11|Significant - Monitor Closely|ritonavir will increase the level or effect of methadone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
ritonavir|methadone|11|Significant - Monitor Closely|ritonavir decreases effects of methadone by Other (see comment). Significant interaction possible, monitor closely. Comment: Ritonavir may induce the metabolism of methadone and/or induce the p glycoprotein pathway that pumps drugs out of the CNS.
secobarbital|methadone|11|Significant - Monitor Closely|secobarbital will decrease the level or effect of methadone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
secobarbital|methadone|2|Significant - Monitor Closely|secobarbital and methadone both increase  sedation. Potential for interaction, monitor.
methadone|tamsulosin|2|Significant - Monitor Closely|methadone increases levels of tamsulosin by affecting hepatic enzyme CYP2D6 metabolism. Potential for interaction, monitor.
telaprevir|methadone|11|Significant - Monitor Closely|telaprevir decreases levels of methadone by Other (see comment). Significant interaction possible, monitor closely. Comment: No adjustment of methadone dose is required when initiating co-administration of telaprevir. However, clinical monitoring is recommended as the dose of methadone during maintenance therapy may need to be adjusted in some patients.
telithromycin|methadone|11|Significant - Monitor Closely|telithromycin will increase the level or effect of methadone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
methadone|telithromycin|2|Significant - Monitor Closely|methadone and telithromycin both increase  QTc interval. Potential for interaction, monitor.
methadone|thiothixene|2|Significant - Monitor Closely|methadone and thiothixene both increase  sedation. Potential for interaction, monitor.
tipranavir|methadone|11|Significant - Monitor Closely|tipranavir decreases levels of methadone by increasing metabolism. Significant interaction possible, monitor closely.
tramadol|methadone|20|Serious - Use Alternative|tramadol, methadone. Other (see comment). Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available. Comment: Tramadol may reinitiate opiate dependence in pts. previously addicted to other opiates; it may also provoke withdrawal Sx. in pts. who are currently opiate dependent.
methadone|tramadol|2|Significant - Monitor Closely|methadone and tramadol both increase  sedation. Potential for interaction, monitor.
trimipramine|methadone|3|Significant - Monitor Closely|trimipramine and methadone both increase  QTc interval. Potential for dangerous interaction. Use with caution and monitor closely.
methadone|trimipramine|2|Significant - Monitor Closely|methadone and trimipramine both increase  sedation. Potential for interaction, monitor.
triprolidine|methadone|2|Significant - Monitor Closely|triprolidine and methadone both increase  sedation. Potential for interaction, monitor.
voriconazole|methadone|11|Significant - Monitor Closely|voriconazole will increase the level or effect of methadone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
methadone|voriconazole|2|Significant - Monitor Closely|methadone and voriconazole both increase  QTc interval. Potential for interaction, monitor.
methadone|zidovudine|1|Minor|methadone increases levels of zidovudine by decreasing renal clearance. Minor or non-significant interaction.
methadone|ziprasidone|3|Significant - Monitor Closely|methadone and ziprasidone both increase  QTc interval. Potential for dangerous interaction. Use with caution and monitor closely.
methadone|ziprasidone|2|Significant - Monitor Closely|methadone and ziprasidone both increase  sedation. Potential for interaction, monitor.
paroxetine|methamphetamine|20|Serious - Use Alternative|paroxetine will increase the level or effect of methamphetamine by  affecting hepatic enzyme CYP2D6 metabolism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
perphenazine|methamphetamine|11|Significant - Monitor Closely|perphenazine will increase the level or effect of methamphetamine by  affecting hepatic enzyme CYP2D6 metabolism. Significant interaction possible, monitor closely.
perphenazine|methamphetamine|11|Significant - Monitor Closely|perphenazine, methamphetamine. Mechanism: unknown. Significant interaction possible, monitor closely. Risk of cardiac arrhythmia or sudden death, more likely w/thioridazine than other phenothiazines.  Interaction more likely in certain predisposed pts. only.
perphenazine|methamphetamine|2|Significant - Monitor Closely|perphenazine increases and methamphetamine decreases sedation. Effect of interaction is not clear, use caution. Potential for interaction, monitor.
phenelzine|methamphetamine|33|Contraindicated|phenelzine increases effects of methamphetamine by pharmacodynamic synergism. Never use combination. Risk of acute hypertensive episode.
prochlorperazine|methamphetamine|11|Significant - Monitor Closely|prochlorperazine, methamphetamine. Mechanism: unknown. Significant interaction possible, monitor closely. Risk of cardiac arrhythmia or sudden death, more likely w/thioridazine than other phenothiazines.  Interaction more likely in certain predisposed pts. only.
prochlorperazine|methamphetamine|2|Significant - Monitor Closely|prochlorperazine increases and methamphetamine decreases sedation. Effect of interaction is not clear, use caution. Potential for interaction, monitor.
promethazine|methamphetamine|11|Significant - Monitor Closely|promethazine, methamphetamine. Mechanism: unknown. Significant interaction possible, monitor closely. Risk of cardiac arrhythmia or sudden death, more likely w/thioridazine than other phenothiazines.  Interaction more likely in certain predisposed pts. only.
promethazine|methamphetamine|2|Significant - Monitor Closely|promethazine increases and methamphetamine decreases sedation. Effect of interaction is not clear, use caution. Potential for interaction, monitor.
rasagiline|methamphetamine|33|Contraindicated|rasagiline increases effects of methamphetamine by pharmacodynamic synergism. Never use combination. Risk of acute hypertensive episode. Coadministration is contraindicated during or within 14 days following the administration of MAOIs.
thioridazine|methamphetamine|11|Significant - Monitor Closely|thioridazine will increase the level or effect of methamphetamine by  affecting hepatic enzyme CYP2D6 metabolism. Significant interaction possible, monitor closely.
thioridazine|methamphetamine|11|Significant - Monitor Closely|thioridazine, methamphetamine. Mechanism: unknown. Significant interaction possible, monitor closely. Risk of cardiac arrhythmia or sudden death, more likely w/thioridazine than other phenothiazines.  Interaction more likely in certain predisposed pts. only.
thioridazine|methamphetamine|2|Significant - Monitor Closely|thioridazine increases and methamphetamine decreases sedation. Effect of interaction is not clear, use caution. Potential for interaction, monitor.
tramadol|methamphetamine|2|Significant - Monitor Closely|tramadol increases and methamphetamine decreases sedation. Effect of interaction is not clear, use caution. Potential for interaction, monitor.
tranylcypromine|methamphetamine|33|Contraindicated|tranylcypromine increases effects of methamphetamine by pharmacodynamic synergism. Never use combination. Risk of acute hypertensive episode.
trifluoperazine|methamphetamine|11|Significant - Monitor Closely|trifluoperazine, methamphetamine. Mechanism: unknown. Significant interaction possible, monitor closely. Risk of cardiac arrhythmia or sudden death, more likely w/thioridazine than other phenothiazines.  Interaction more likely in certain predisposed pts. only.
trifluoperazine|methamphetamine|2|Significant - Monitor Closely|trifluoperazine increases and methamphetamine decreases sedation. Effect of interaction is not clear, use caution. Potential for interaction, monitor.
triprolidine|methamphetamine|2|Significant - Monitor Closely|triprolidine increases and methamphetamine decreases sedation. Effect of interaction is not clear, use caution. Potential for interaction, monitor.
methazolamide|salsalate|11|Significant - Monitor Closely|methazolamide, salsalate.Either increases levels of the other by Other (see comment). Significant interaction possible, monitor closely. Comment: Carbonic anhydrase inhibitors (CAIs) and salicylates inhibit each other's renal tubular secretion, resulting in increased plasma levels.  CAIs also shift salicylates from plasma to the CNS, leading to potential neurotoxicity.
methimazole|tamsulosin|2|Significant - Monitor Closely|methimazole increases levels of tamsulosin by affecting hepatic enzyme CYP2D6 metabolism. Potential for interaction, monitor.
methimazole|warfarin|11|Significant - Monitor Closely|methimazole decreases effects of warfarin by pharmacodynamic antagonism. Significant interaction possible, monitor closely.
nabumetone|methotrexate|20|Serious - Use Alternative|nabumetone increases levels of methotrexate by decreasing renal clearance. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available. Concomitant administration of NSAIDs with high dose methotrexate has been reported to elevate and prolong serum methotrexate levels, resulting in deaths from severe hematologic and GI toxicity. NSAIDs may reduce tubular secretion of methotrexate and enhance toxicity. .
nafcillin|methotrexate|11|Significant - Monitor Closely|nafcillin increases levels of methotrexate by decreasing renal clearance. Significant interaction possible, monitor closely. Increased serum concentrations of methotrexate with concomitant hematologic and gastrointestinal toxicity have been observed with concurrent administration of high or low doses of methotrexate and penicillins.
naproxen|methotrexate|20|Serious - Use Alternative|naproxen increases levels of methotrexate by decreasing renal clearance. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available. Concomitant administration of NSAIDs with high dose methotrexate has been reported to elevate and prolong serum methotrexate levels, resulting in deaths from severe hematologic and GI toxicity. NSAIDs may reduce tubular secretion of methotrexate and enhance toxicity.
omeprazole|methotrexate|11|Significant - Monitor Closely|omeprazole increases levels of methotrexate by decreasing renal clearance. Significant interaction possible, monitor closely. Temporary withdrawal of PPI may be considered in some patients.
oxaprozin|methotrexate|20|Serious - Use Alternative|oxaprozin increases levels of methotrexate by decreasing renal clearance. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available. Concomitant administration of NSAIDs with high dose methotrexate has been reported to elevate and prolong serum methotrexate levels, resulting in deaths from severe hematologic and GI toxicity. NSAIDs may reduce tubular secretion of methotrexate and enhance toxicity. .
phenytoin|methotrexate|2|Significant - Monitor Closely|phenytoin increases toxicity of methotrexate by Other (see comment). Potential for interaction, monitor. Comment: Methotrexate is partially bound to serum albumin, and toxicity may be increased because of displacement by certain drugs, such as phenytoin.
piroxicam|methotrexate|20|Serious - Use Alternative|piroxicam increases levels of methotrexate by decreasing renal clearance. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available. Concomitant administration of NSAIDs with high dose methotrexate has been reported to elevate and prolong serum methotrexate levels, resulting in deaths from severe hematologic and GI toxicity. NSAIDs may reduce tubular secretion of methotrexate and enhance toxicity. .
probenecid|methotrexate|20|Serious - Use Alternative|probenecid increases levels of methotrexate by acidic (anionic) drug competition for renal tubular clearance. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available. If combination must be used, decrease methotrexate dose; also, methotrexate increases uric acid production and risk for uric acid neuropathy.
probenecid|methotrexate|11|Significant - Monitor Closely|probenecid will increase the level or effect of methotrexate by  Other (see comment). Significant interaction possible, monitor closely. Methotrexate plasma levels, therapeutic effects, and toxicity may be enhanced. Monitor methotrexate concentrations and adjust dose accordingly.
procarbazine|methotrexate|2|Significant - Monitor Closely|procarbazine, methotrexate.Either increases toxicity of the other by pharmacodynamic synergism. Potential for interaction, monitor. Increased risk of immunosupression.
methotrexate|rilonacept|2|Significant - Monitor Closely|methotrexate and rilonacept both increase  immunosuppressive effects; risk of infection. Potential for interaction, monitor. Combination may increase risk of myelosuppression.
salsalate|methotrexate|20|Serious - Use Alternative|salsalate increases levels of methotrexate by decreasing renal clearance. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available. Caution should be exercised when salicylates are given in combination with methotrexate.  Risk for drug interactions with methotrexate is greatest during high-dose methotrexate therapy, it has been recommended that any of these drugs be used cautiously with methotrexate even when methotrexate is used in low doses.
sulfadiazine|methotrexate|20|Serious - Use Alternative|sulfadiazine increases toxicity of methotrexate by plasma protein binding competition. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
sulfamethoxazole|methotrexate|20|Serious - Use Alternative|sulfamethoxazole increases toxicity of methotrexate by plasma protein binding competition. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available. Methotrexate concentrations may be elevated, increasing the risk of toxicity (eg, bone marrow suppression).
sulfisoxazole|methotrexate|20|Serious - Use Alternative|sulfisoxazole increases toxicity of methotrexate by plasma protein binding competition. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
sulindac|methotrexate|20|Serious - Use Alternative|sulindac increases levels of methotrexate by decreasing renal clearance. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available. Concomitant administration of NSAIDs with high dose methotrexate has been reported to elevate and prolong serum methotrexate levels, resulting in deaths from severe hematologic and GI toxicity. NSAIDs may reduce tubular secretion of methotrexate and enhance toxicity. .
tetracycline|methotrexate|2|Significant - Monitor Closely|tetracycline increases levels of methotrexate by decreasing elimination. Potential for interaction, monitor. If tetracyclines cannot be avoided in patients receiving high-dose methotrexate, closely monitor methotrexate plasma concentrations and patients for signs and symptoms of toxicity.
ticarcillin|methotrexate|11|Significant - Monitor Closely|ticarcillin increases levels of methotrexate by decreasing renal clearance. Significant interaction possible, monitor closely. Increased serum concentrations of methotrexate with concomitant hematologic and gastrointestinal toxicity have been observed with concurrent administration of high or low doses of methotrexate and penicillins.
tolmetin|methotrexate|20|Serious - Use Alternative|tolmetin increases levels of methotrexate by decreasing renal clearance. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available. Concomitant administration of NSAIDs with high dose methotrexate has been reported to elevate and prolong serum methotrexate levels, resulting in deaths from severe hematologic and GI toxicity. NSAIDs may reduce tubular secretion of methotrexate and enhance toxicity. .
trimethoprim|methotrexate|20|Serious - Use Alternative|trimethoprim, methotrexate.Either increases toxicity of the other by pharmacodynamic synergism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available. Due to an additive antifolate effect, trimethoprim has been shown to rarely increase bone marrow suppression in patients receiving methotrexate.
trimethoprim|methotrexate|11|Significant - Monitor Closely|trimethoprim increases toxicity of methotrexate by Other (see comment). Significant interaction possible, monitor closely. Comment: Trimethoprim may increase risk of methotrexate-induced bone marrow suppression and megaloblastic anemia. If this drug combination cannot be avoided, closely monitor for signs of hematologic toxicity.
minocycline|methoxyflurane|20|Serious - Use Alternative|minocycline, methoxyflurane. Mechanism: pharmacodynamic synergism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available. Risk of nephrotoxicity.
phenobarbital|methoxyflurane|21|Serious - Use Alternative|phenobarbital increases toxicity of methoxyflurane by increasing metabolism. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available. Never use combination. Increased metabolism of methoxyflurane to nephrotoxic compounds.
primidone|methoxyflurane|21|Serious - Use Alternative|primidone increases toxicity of methoxyflurane by increasing metabolism. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available. Never use combination. Increased metabolism of methoxyflurane to nephrotoxic compounds.
tetracycline|methoxyflurane|20|Serious - Use Alternative|tetracycline, methoxyflurane. Mechanism: pharmacodynamic synergism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available. Risk of nephrotoxicity.
treprostinil|methyclothiazide|1|Minor|treprostinil increases effects of methyclothiazide by pharmacodynamic synergism. Minor or non-significant interaction.
nadolol|methyldopa|11|Significant - Monitor Closely|nadolol, methyldopa. Mechanism: pharmacodynamic synergism. Significant interaction possible, monitor closely. Non selective beta blocker administration during withdrawal from methyldopa may result in rebound hypertension.
methyldopa|norepinephrine|11|Significant - Monitor Closely|methyldopa increases effects of norepinephrine by unknown mechanism. Significant interaction possible, monitor closely.
methyldopa|phenylephrine|11|Significant - Monitor Closely|methyldopa increases effects of phenylephrine by unknown mechanism. Significant interaction possible, monitor closely.
pindolol|methyldopa|11|Significant - Monitor Closely|pindolol, methyldopa. Mechanism: pharmacodynamic synergism. Significant interaction possible, monitor closely. Non selective beta blocker administration during withdrawal from methyldopa may result in rebound hypertension.
propranolol|methyldopa|11|Significant - Monitor Closely|propranolol, methyldopa. Mechanism: pharmacodynamic synergism. Significant interaction possible, monitor closely. Non selective beta blocker administration during withdrawal from methyldopa may result in rebound hypertension.
methyldopa|pseudoephedrine|11|Significant - Monitor Closely|methyldopa increases effects of pseudoephedrine by unknown mechanism. Significant interaction possible, monitor closely.
timolol|methyldopa|11|Significant - Monitor Closely|timolol, methyldopa. Mechanism: pharmacodynamic synergism. Significant interaction possible, monitor closely. Non selective beta blocker administration during withdrawal from methyldopa may result in rebound hypertension.
tranylcypromine|methyldopa|22|Serious - Use Alternative|tranylcypromine, methyldopa. Other (see comment). High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available. Comment: Tranylcypromine inhibits the hypotensive effects of methyldopa. At least 14 days should elapse between discontinuation of MAOI therapy and initiation of treatment with methyldopa.
phenelzine|methylphenidate|33|Contraindicated|phenelzine increases effects of methylphenidate by pharmacodynamic synergism. Never use combination. Risk of acute hypertensive episode.
rasagiline|methylphenidate|33|Contraindicated|rasagiline increases effects of methylphenidate by pharmacodynamic synergism. Never use combination. Risk of acute hypertensive episode. Methylphenidate is contraindicated during treatment with an MAOI and also within a minimum of 14 days following discontinuation of an MAOI.
tranylcypromine|methylphenidate|33|Contraindicated|tranylcypromine increases effects of methylphenidate by pharmacodynamic synergism. Never use combination. Risk of acute hypertensive episode.
phenobarbital|methylprednisolone|11|Significant - Monitor Closely|phenobarbital will decrease the level or effect of methylprednisolone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
phenobarbital|methylprednisolone|11|Significant - Monitor Closely|phenobarbital will decrease the level or effect of methylprednisolone by  P-glycoprotein (MDR1) efflux transporter. Significant interaction possible, monitor closely.
phenytoin|methylprednisolone|11|Significant - Monitor Closely|phenytoin will decrease the level or effect of methylprednisolone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
phenytoin|methylprednisolone|11|Significant - Monitor Closely|phenytoin will decrease the level or effect of methylprednisolone by  P-glycoprotein (MDR1) efflux transporter. Significant interaction possible, monitor closely.
primidone|methylprednisolone|11|Significant - Monitor Closely|primidone will decrease the level or effect of methylprednisolone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
methylprednisolone|tacrolimus|11|Significant - Monitor Closely|methylprednisolone will decrease the level or effect of tacrolimus by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
tacrolimus|methylprednisolone|11|Significant - Monitor Closely|tacrolimus will increase the level or effect of methylprednisolone by  P-glycoprotein (MDR1) efflux transporter. Significant interaction possible, monitor closely.
methylprednisolone|tacrolimus|1|Minor|methylprednisolone, tacrolimus.Either increases levels of the other by decreasing metabolism. Minor or non-significant interaction.
paliperidone|metoclopramide|2|Significant - Monitor Closely|paliperidone and metoclopramide both increase  antidopaminergic effects, including extrapyramidal symptoms and neuroleptic malignant syndrome. Potential for interaction, monitor.
metoclopramide|tetrabenazine|3|Significant - Monitor Closely|metoclopramide and tetrabenazine both increase  antidopaminergic effects, including extrapyramidal symptoms and neuroleptic malignant syndrome. Potential for dangerous interaction. Use with caution and monitor closely.
metoclopramide|venlafaxine|20|Serious - Use Alternative|metoclopramide and venlafaxine both increase  serotonin levels. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available. Additive effects; increased risk for serotonin syndrome, neuroleptic malignant syndrome, dystonia, or other extrapyramidal reactions
metoclopramide|vilazodone|20|Serious - Use Alternative|metoclopramide increases levels of vilazodone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available. Strong CYP3A4 inhibitors may increase vilazodone plasma levels by 50% - Reduce daily dose  to 20 mg.
treprostinil|metolazone|1|Minor|treprostinil increases effects of metolazone by pharmacodynamic synergism. Minor or non-significant interaction.
mirabegron|metoprolol|2|Significant - Monitor Closely|mirabegron will increase the level or effect of metoprolol by  affecting hepatic enzyme CYP2D6 metabolism. Potential for interaction, monitor.
paroxetine|metoprolol|20|Serious - Use Alternative|paroxetine will increase the level or effect of metoprolol by  affecting hepatic enzyme CYP2D6 metabolism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
phenobarbital|metoprolol|11|Significant - Monitor Closely|phenobarbital decreases levels of metoprolol by increasing metabolism. Significant interaction possible, monitor closely. Consider a higher beta-blocker dose during coadministration of phenobarbital.  Atenolol, sotalol, nadolol less likely to be affected than other beta blockers.
metoprolol|pirbuterol|11|Significant - Monitor Closely|metoprolol decreases effects of pirbuterol by pharmacodynamic antagonism. Significant interaction possible, monitor closely.
metoprolol|pirbuterol|2|Significant - Monitor Closely|metoprolol increases and pirbuterol decreases serum potassium. Effect of interaction is not clear, use caution. Potential for interaction, monitor.
piroxicam|metoprolol|11|Significant - Monitor Closely|piroxicam decreases effects of metoprolol by pharmacodynamic antagonism. Significant interaction possible, monitor closely. Long term (>1 wk) NSAID use.  NSAIDs decrease prostaglandin synthesis.
metoprolol|piroxicam|2|Significant - Monitor Closely|metoprolol and piroxicam both increase  serum potassium. Potential for interaction, monitor.
prazosin|metoprolol|3|Significant - Monitor Closely|prazosin and metoprolol both increase  anti-hypertensive channel blocking. Potential for dangerous interaction. Use with caution and monitor closely.
primidone|metoprolol|11|Significant - Monitor Closely|primidone decreases levels of metoprolol by increasing metabolism. Significant interaction possible, monitor closely. Consider a higher beta-blocker dose during coadministration of primidone.  Atenolol, sotalol, nadolol less likely to be affected than other beta blockers.
propafenone|metoprolol|11|Significant - Monitor Closely|propafenone will increase the level or effect of metoprolol by  affecting hepatic enzyme CYP2D6 metabolism. Significant interaction possible, monitor closely.  If concurrent therapy is required, monitor cardiac function carefully, particularly blood pressure.  A dosage adjustment for the beta blocker may be required.
metoprolol|salmeterol|11|Significant - Monitor Closely|metoprolol decreases effects of salmeterol by pharmacodynamic antagonism. Significant interaction possible, monitor closely.
metoprolol|salmeterol|2|Significant - Monitor Closely|metoprolol increases and salmeterol decreases serum potassium. Effect of interaction is not clear, use caution. Potential for interaction, monitor.
sertraline|metoprolol|11|Significant - Monitor Closely|sertraline will increase the level or effect of metoprolol by  affecting hepatic enzyme CYP2D6 metabolism. Significant interaction possible, monitor closely.
terazosin|metoprolol|3|Significant - Monitor Closely|terazosin and metoprolol both increase  anti-hypertensive channel blocking. Potential for dangerous interaction. Use with caution and monitor closely.
metoprolol|terbutaline|11|Significant - Monitor Closely|metoprolol increases effects of terbutaline by pharmacodynamic synergism. Significant interaction possible, monitor closely.
metoprolol|terbutaline|11|Significant - Monitor Closely|metoprolol decreases effects of terbutaline by pharmacodynamic antagonism. Significant interaction possible, monitor closely.
metoprolol|terbutaline|2|Significant - Monitor Closely|metoprolol increases and terbutaline decreases serum potassium. Effect of interaction is not clear, use caution. Potential for interaction, monitor.
treprostinil|metoprolol|1|Minor|treprostinil increases effects of metoprolol by pharmacodynamic synergism. Minor or non-significant interaction.
verapamil|metoprolol|20|Serious - Use Alternative|verapamil, metoprolol.Either increases toxicity of the other by unspecified interaction mechanism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available. Can increase risk of bradycardia.
metoprolol|verapamil|3|Significant - Monitor Closely|metoprolol and verapamil both increase  anti-hypertensive channel blocking. Potential for dangerous interaction. Use with caution and monitor closely.
perphenazine|metrizamide|33|Contraindicated|perphenazine, metrizamide. Mechanism: unknown. Never use combination. Risk of seizure.  D/C phenothiazine 24h before admin. of metrizamide.
prochlorperazine|metrizamide|33|Contraindicated|prochlorperazine, metrizamide. Mechanism: unknown. Never use combination. Risk of seizure.  D/C phenothiazine 24h before admin. of metrizamide.
promethazine|metrizamide|33|Contraindicated|promethazine, metrizamide. Mechanism: unknown. Never use combination. Risk of seizure.  D/C phenothiazine 24h before admin. of metrizamide.
thioridazine|metrizamide|33|Contraindicated|thioridazine, metrizamide. Mechanism: unknown. Never use combination. Risk of seizure.  D/C phenothiazine 24h before admin. of metrizamide.
trifluoperazine|metrizamide|33|Contraindicated|trifluoperazine, metrizamide. Mechanism: unknown. Never use combination. Risk of seizure.  D/C phenothiazine 24h before admin. of metrizamide.
metronidazole|tacrolimus|11|Significant - Monitor Closely|metronidazole will increase the level or effect of tacrolimus by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
metronidazole|tamsulosin|2|Significant - Monitor Closely|metronidazole increases levels of tamsulosin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Potential for interaction, monitor. Dose reduction may be needed for coadministered drugs that are predominantly metabolized by CYP3A.
metronidazole|tolterodine|11|Significant - Monitor Closely|metronidazole will increase the level or effect of tolterodine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
metronidazole|trazodone|2|Significant - Monitor Closely|metronidazole will increase the level or effect of trazodone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Potential for interaction, monitor.
metronidazole|warfarin|20|Serious - Use Alternative|metronidazole increases levels of warfarin by decreasing metabolism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
metronidazole|warfarin|11|Significant - Monitor Closely|metronidazole will increase the level or effect of warfarin by  affecting hepatic enzyme CYP2C9/10 metabolism. Significant interaction possible, monitor closely.
metronidazole|warfarin|11|Significant - Monitor Closely|metronidazole will increase the level or effect of warfarin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
phenytoin|metyrapone|11|Significant - Monitor Closely|phenytoin decreases levels of metyrapone by increasing metabolism. Significant interaction possible, monitor closely.
phenytoin|mexiletine|11|Significant - Monitor Closely|phenytoin decreases levels of mexiletine by increasing metabolism. Significant interaction possible, monitor closely.
propafenone|mexiletine|11|Significant - Monitor Closely|propafenone will increase the level or effect of mexiletine by  affecting hepatic enzyme CYP2D6 metabolism. Significant interaction possible, monitor closely.
mexiletine|ramelteon|11|Significant - Monitor Closely|mexiletine will increase the level or effect of ramelteon by  affecting hepatic enzyme CYP1A2 metabolism. Significant interaction possible, monitor closely.
tacrine|mexiletine|11|Significant - Monitor Closely|tacrine will increase the level or effect of mexiletine by  affecting hepatic enzyme CYP1A2 metabolism. Significant interaction possible, monitor closely.
mexiletine|tacrine|1|Minor|mexiletine will increase the level or effect of tacrine by  affecting hepatic enzyme CYP1A2 metabolism. Minor or non-significant interaction.
mexiletine|theophylline|11|Significant - Monitor Closely|mexiletine will increase the level or effect of theophylline by  affecting hepatic enzyme CYP1A2 metabolism. Significant interaction possible, monitor closely.
mexiletine|tizanidine|21|Serious - Use Alternative|mexiletine will increase the level or effect of tizanidine by  affecting hepatic enzyme CYP1A2 metabolism. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available. Never use combination.
mibefradil|tacrolimus|11|Significant - Monitor Closely|mibefradil will increase the level or effect of tacrolimus by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
nelfinavir|midazolam|33|Contraindicated|nelfinavir increases levels of midazolam by decreasing metabolism. Never use combination. Potential for serious and/or life threatening reactions (eg, prolonged or increased sedation, or respiratory depression).
nelfinavir|midazolam|11|Significant - Monitor Closely|nelfinavir will increase the level or effect of midazolam by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
midazolam|nelfinavir|11|Significant - Monitor Closely|midazolam will decrease the level or effect of nelfinavir by  P-glycoprotein (MDR1) efflux transporter. Significant interaction possible, monitor closely.
omeprazole|midazolam|1|Minor|omeprazole increases levels of midazolam by decreasing metabolism. Minor or non-significant interaction.
phenytoin|midazolam|11|Significant - Monitor Closely|phenytoin will decrease the level or effect of midazolam by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
ritonavir|midazolam|21|Serious - Use Alternative|ritonavir increases levels of midazolam by decreasing metabolism. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available. Never use combination.
ritonavir|midazolam|11|Significant - Monitor Closely|ritonavir will increase the level or effect of midazolam by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
midazolam|ritonavir|11|Significant - Monitor Closely|midazolam will decrease the level or effect of ritonavir by  P-glycoprotein (MDR1) efflux transporter. Significant interaction possible, monitor closely.
saquinavir|midazolam|21|Serious - Use Alternative|saquinavir increases levels of midazolam by decreasing metabolism. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available. Never use combination.
midazolam|saquinavir|11|Significant - Monitor Closely|midazolam will decrease the level or effect of saquinavir by  P-glycoprotein (MDR1) efflux transporter. Significant interaction possible, monitor closely.
telaprevir|midazolam|33|Contraindicated|telaprevir increases levels of midazolam by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Never use combination. Contraindicated. Concurrent use with oral midazolam may cause prolonged or increased sedation or respiratory depression. Concurrent use with telaprevir and IV midazolam may cause a  significant interaction; consider using a lower dose of IV midazolam especially if more than a single dose of midazolam is administered. .
telithromycin|midazolam|11|Significant - Monitor Closely|telithromycin will increase the level or effect of midazolam by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
tipranavir|midazolam|21|Serious - Use Alternative|tipranavir increases levels of midazolam by decreasing metabolism. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available. Never use combination.
triprolidine|midazolam|2|Significant - Monitor Closely|triprolidine and midazolam both increase  sedation. Potential for interaction, monitor.
verapamil|midazolam|11|Significant - Monitor Closely|verapamil will increase the level or effect of midazolam by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
voriconazole|midazolam|11|Significant - Monitor Closely|voriconazole will increase the level or effect of midazolam by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
norepinephrine|midodrine|2|Significant - Monitor Closely|norepinephrine and midodrine both decrease  sedation. Potential for interaction, monitor.
norepinephrine|midodrine|2|Significant - Monitor Closely|norepinephrine and midodrine both increase  sympathetic (adrenergic) effects, including increased blood pressure and heart rate. Potential for interaction, monitor.
phenelzine|midodrine|33|Contraindicated|phenelzine increases effects of midodrine by pharmacodynamic synergism. Never use combination. Risk of acute hypertensive episode.
midodrine|phenylephrine|2|Significant - Monitor Closely|midodrine and phenylephrine both decrease  sedation. Potential for interaction, monitor.
midodrine|phenylephrine|2|Significant - Monitor Closely|midodrine and phenylephrine both increase  sympathetic (adrenergic) effects, including increased blood pressure and heart rate. Potential for interaction, monitor.
pirbuterol|midodrine|2|Significant - Monitor Closely|pirbuterol and midodrine both decrease  sedation. Potential for interaction, monitor.
pirbuterol|midodrine|2|Significant - Monitor Closely|pirbuterol and midodrine both increase  sympathetic (adrenergic) effects, including increased blood pressure and heart rate. Potential for interaction, monitor.
midodrine|pseudoephedrine|2|Significant - Monitor Closely|midodrine and pseudoephedrine both decrease  sedation. Potential for interaction, monitor.
midodrine|pseudoephedrine|2|Significant - Monitor Closely|midodrine and pseudoephedrine both increase  sympathetic (adrenergic) effects, including increased blood pressure and heart rate. Potential for interaction, monitor.
rasagiline|midodrine|20|Serious - Use Alternative|rasagiline increases effects of midodrine by pharmacodynamic synergism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available. Midodrine should not be given concurrently with monoamine oxidase inhibitors (MAOIs). Risk of acute hypertensive episode.
terbutaline|midodrine|2|Significant - Monitor Closely|terbutaline and midodrine both decrease  sedation. Potential for interaction, monitor.
terbutaline|midodrine|2|Significant - Monitor Closely|terbutaline and midodrine both increase  sympathetic (adrenergic) effects, including increased blood pressure and heart rate. Potential for interaction, monitor.
tranylcypromine|midodrine|33|Contraindicated|tranylcypromine increases effects of midodrine by pharmacodynamic synergism. Never use combination. Risk of acute hypertensive episode.
trimipramine|midodrine|20|Serious - Use Alternative|trimipramine, midodrine. Other (see comment). Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available. Comment: Tricyclic antidepressants increase or decrease effects of sympathomimetics, by blocking reuptake of NE, or blocking uptake of indirect sympathomimetics into the adrenergic neuron.
trimipramine|midodrine|2|Significant - Monitor Closely|trimipramine increases and midodrine decreases sedation. Effect of interaction is not clear, use caution. Potential for interaction, monitor.
mifepristone|pasireotide|3|Significant - Monitor Closely|mifepristone and pasireotide both increase  QTc interval. Potential for dangerous interaction. Use with caution and monitor closely.
phenelzine|milnacipran|33|Contraindicated|phenelzine and milnacipran both increase  serotonin levels. Never use combination.
procarbazine|milnacipran|33|Contraindicated|procarbazine and milnacipran both increase  serotonin levels. Never use combination. Combination is contraindicated within 2 weeks of MAOI use.
rasagiline|milnacipran|33|Contraindicated|rasagiline and milnacipran both increase  serotonin levels. Never use combination. Concomitant use with MAOIs or within 14 days of discontinuing treatment with an MAOI is contraindicated.
tranylcypromine|milnacipran|33|Contraindicated|tranylcypromine and milnacipran both increase  serotonin levels. Never use combination.
milnacipran|venlafaxine|22|Serious - Use Alternative|milnacipran and venlafaxine both increase  serotonin levels. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available.
zolmitriptan|milnacipran|3|Significant - Monitor Closely|zolmitriptan and milnacipran both increase  serotonin levels. Potential for dangerous interaction. Use with caution and monitor closely.
milnacipran|zolmitriptan|1|Minor|milnacipran, zolmitriptan. Mechanism: unknown. Minor or non-significant interaction. Risk of weakness, dyspnea, chest pain.
minocycline|nafcillin|20|Serious - Use Alternative|minocycline decreases effects of nafcillin by pharmacodynamic antagonism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available. bacteriostatic antibiotics may interfere with the bactericidal actions of penicillins.
minocycline|oxacillin|20|Serious - Use Alternative|minocycline decreases effects of oxacillin by pharmacodynamic antagonism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available. bacteriostatic agents may inhibit the effects of bactericidal agents.
minocycline|piperacillin|11|Significant - Monitor Closely|minocycline decreases effects of piperacillin by pharmacodynamic antagonism. Significant interaction possible, monitor closely. bacteriostatic agents may inhibit the effects of bactericidal agents.
minocycline|pivmecillinam|20|Serious - Use Alternative|minocycline decreases effects of pivmecillinam by pharmacodynamic antagonism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
minocycline|ticarcillin|20|Serious - Use Alternative|minocycline decreases effects of ticarcillin by pharmacodynamic antagonism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
minocycline|tretinoin|33|Contraindicated|minocycline, tretinoin.Either increases toxicity of the other by Other (see comment). Never use combination. Comment: Both tretinoin and tetracyclines can cause increased intracranial pressure.
minocycline|tretinoin|20|Serious - Use Alternative|minocycline, tretinoin.Either increases levels of the other by Mechanism: pharmacodynamic synergism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available. Increased phototoxicity.
minocycline|warfarin|1|Minor|minocycline increases effects of warfarin by pharmacodynamic synergism. Minor or non-significant interaction.
minoxidil|treprostinil|11|Significant - Monitor Closely|minoxidil, treprostinil.Either increases effects of the other by pharmacodynamic synergism. Significant interaction possible, monitor closely.
treprostinil|minoxidil|1|Minor|treprostinil increases effects of minoxidil by pharmacodynamic synergism. Minor or non-significant interaction.
mirabegron|propafenone|2|Significant - Monitor Closely|mirabegron will increase the level or effect of propafenone by  affecting hepatic enzyme CYP2D6 metabolism. Potential for interaction, monitor.
mirabegron|thioridazine|2|Significant - Monitor Closely|mirabegron will increase the level or effect of thioridazine by  affecting hepatic enzyme CYP2D6 metabolism. Potential for interaction, monitor.
phenelzine|mirtazapine|22|Serious - Use Alternative|phenelzine and mirtazapine both increase  serotonin levels. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available.
rasagiline|mirtazapine|33|Contraindicated|rasagiline and mirtazapine both increase  serotonin levels. Never use combination. Avoid combination within 14 days of MAOI use.
tramadol|mirtazapine|2|Significant - Monitor Closely|tramadol and mirtazapine both increase  sedation. Potential for interaction, monitor.
mirtazapine|tramadol|2|Significant - Monitor Closely|mirtazapine and tramadol both increase  serotonin levels. Potential for interaction, monitor.
tranylcypromine|mirtazapine|22|Serious - Use Alternative|tranylcypromine and mirtazapine both increase  serotonin levels. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available.
trazodone|mirtazapine|3|Significant - Monitor Closely|trazodone and mirtazapine both increase  serotonin levels. Potential for dangerous interaction. Use with caution and monitor closely.
trazodone|mirtazapine|2|Significant - Monitor Closely|trazodone and mirtazapine both increase  sedation. Potential for interaction, monitor.
trimipramine|mirtazapine|3|Significant - Monitor Closely|trimipramine and mirtazapine both increase  serotonin levels. Potential for dangerous interaction. Use with caution and monitor closely.
trimipramine|mirtazapine|2|Significant - Monitor Closely|trimipramine and mirtazapine both increase  sedation. Potential for interaction, monitor.
triprolidine|mirtazapine|2|Significant - Monitor Closely|triprolidine and mirtazapine both increase  sedation. Potential for interaction, monitor.
venlafaxine|mirtazapine|3|Significant - Monitor Closely|venlafaxine and mirtazapine both increase  serotonin levels. Potential for dangerous interaction. Use with caution and monitor closely.
zolmitriptan|mirtazapine|2|Significant - Monitor Closely|zolmitriptan and mirtazapine both increase  serotonin levels. Potential for interaction, monitor.
vinblastine|mitomycin|11|Significant - Monitor Closely|vinblastine increases toxicity of mitomycin by unknown mechanism. Significant interaction possible, monitor closely. Acute shortness of breath and severe bronchospasm have occurred following use of vinca alkaloids in patients who had previously or simultaneously received mitomycin. .
vincristine|mitomycin|11|Significant - Monitor Closely|vincristine increases toxicity of mitomycin by unknown mechanism. Significant interaction possible, monitor closely. Risk of severe bronchospasm and dyspnea.  D/C mitomycin 2 wks prior to vinblastine Tx.
spironolactone|mitotane|11|Significant - Monitor Closely|spironolactone decreases effects of mitotane by pharmacodynamic antagonism. Significant interaction possible, monitor closely.
mitotane|warfarin|11|Significant - Monitor Closely|mitotane will decrease the level or effect of warfarin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely. Monitor INR for a change in anticoagulant dosage requirements when warfarin is coadministered with mitotane (strong CYP3A4 inducer)
modafinil|roflumilast|3|Significant - Monitor Closely|modafinil will decrease the level or effect of roflumilast by  affecting hepatic enzyme CYP1A2 metabolism. Potential for dangerous interaction. Use with caution and monitor closely. Concomitant therapy may reduce therapeutic effectiveness.
modafinil|telithromycin|1|Minor|modafinil will decrease the level or effect of telithromycin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor or non-significant interaction.
modafinil|triazolam|11|Significant - Monitor Closely|modafinil will decrease the level or effect of triazolam by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
triazolam|modafinil|2|Significant - Monitor Closely|triazolam increases and modafinil decreases sedation. Effect of interaction is not clear, use caution. Potential for interaction, monitor.
trimipramine|modafinil|2|Significant - Monitor Closely|trimipramine increases and modafinil decreases sedation. Effect of interaction is not clear, use caution. Potential for interaction, monitor.
modafinil|voriconazole|1|Minor|modafinil will increase the level or effect of voriconazole by  affecting hepatic enzyme CYP2C19 metabolism. Minor or non-significant interaction.
tizanidine|moexipril|1|Minor|tizanidine increases effects of moexipril by pharmacodynamic synergism. Minor or non-significant interaction. Risk of hypotension.
treprostinil|moexipril|1|Minor|treprostinil increases effects of moexipril by pharmacodynamic synergism. Minor or non-significant interaction.
moexipril|triamterene|11|Significant - Monitor Closely|moexipril, triamterene. Mechanism: pharmacodynamic synergism. Significant interaction possible, monitor closely. Risk of hyperkalemia.
triprolidine|morphine|2|Significant - Monitor Closely|triprolidine and morphine both increase  sedation. Potential for interaction, monitor.
quinidine|moxifloxacin|33|Contraindicated|quinidine and moxifloxacin both increase  QTc interval. Never use combination.
moxifloxacin|sotalol|33|Contraindicated|moxifloxacin and sotalol both increase  QTc interval. Never use combination.
sucralfate|moxifloxacin|11|Significant - Monitor Closely|sucralfate decreases levels of moxifloxacin by inhibition of GI absorption. Applies only to oral form of both agents. Significant interaction possible, monitor closely.
trimipramine|moxifloxacin|22|Serious - Use Alternative|trimipramine and moxifloxacin both increase  QTc interval. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available.
moxifloxacin|voriconazole|3|Significant - Monitor Closely|moxifloxacin and voriconazole both increase  QTc interval. Potential for dangerous interaction. Use with caution and monitor closely.
moxifloxacin|warfarin|11|Significant - Monitor Closely|moxifloxacin increases effects of warfarin by Other (see comment). Significant interaction possible, monitor closely. Comment: Decr vitamin K-producing intestinal flora may increase INR after a few days.
moxifloxacin|warfarin|11|Significant - Monitor Closely|moxifloxacin increases effects of warfarin by unknown mechanism. Significant interaction possible, monitor closely. Ciprofloxacin, norfloxacin, & ofloxacin are most likely to interact w/warfarin; data for other quinolones is conflicting.  Monitor INR closely.
moxifloxacin|ziprasidone|22|Serious - Use Alternative|moxifloxacin and ziprasidone both increase  QTc interval. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available.
triprolidine|nabilone|2|Significant - Monitor Closely|triprolidine and nabilone both increase  sedation. Potential for interaction, monitor.
nabumetone|pralatrexate|11|Significant - Monitor Closely|nabumetone increases levels of pralatrexate by decreasing renal clearance. Significant interaction possible, monitor closely. NSAIDs may delay pralatrexate clearance, increasing drug exposure. Adjust the pralatrexate dose as needed.
telmisartan|nabumetone|11|Significant - Monitor Closely|telmisartan, nabumetone.Either increases toxicity of the other by Other (see comment). Significant interaction possible, monitor closely. Comment: May result in renal function deterioration, particularly in elderly or volume depleted individuals.
nabumetone|telmisartan|3|Significant - Monitor Closely|nabumetone decreases effects of telmisartan by pharmacodynamic antagonism. Potential for dangerous interaction. Use with caution and monitor closely.  NSAIDs decrease synthesis of vasodilating renal prostaglandins, and thus affect fluid homeostasis and may diminish antihypertensive effect.
telmisartan|nabumetone|2|Significant - Monitor Closely|telmisartan and nabumetone both increase  serum potassium. Potential for interaction, monitor.
nabumetone|timolol|11|Significant - Monitor Closely|nabumetone decreases effects of timolol by pharmacodynamic antagonism. Significant interaction possible, monitor closely. Long term (>1 wk) NSAID use.  NSAIDs decrease prostaglandin synthesis.
timolol|nabumetone|2|Significant - Monitor Closely|timolol and nabumetone both increase  serum potassium. Potential for interaction, monitor.
trandolapril|nabumetone|11|Significant - Monitor Closely|trandolapril, nabumetone.Either increases toxicity of the other by Other (see comment). Significant interaction possible, monitor closely. Comment: May result in renal function deterioration, particularly in elderly or volume depleted individuals.
nabumetone|trandolapril|3|Significant - Monitor Closely|nabumetone decreases effects of trandolapril by pharmacodynamic antagonism. Potential for dangerous interaction. Use with caution and monitor closely. NSAIDs decrease synthesis of vasodilating renal prostaglandins, and thus affect fluid homeostasis and may diminish antihypertenisve effect.
warfarin|nabumetone|3|Significant - Monitor Closely|warfarin and nabumetone both increase  anticoagulation. Potential for dangerous interaction. Use with caution and monitor closely.
nadolol|pirbuterol|11|Significant - Monitor Closely|nadolol decreases effects of pirbuterol by pharmacodynamic antagonism. Significant interaction possible, monitor closely.
nadolol|pirbuterol|2|Significant - Monitor Closely|nadolol increases and pirbuterol decreases serum potassium. Effect of interaction is not clear, use caution. Potential for interaction, monitor.
piroxicam|nadolol|11|Significant - Monitor Closely|piroxicam decreases effects of nadolol by pharmacodynamic antagonism. Significant interaction possible, monitor closely. Long term (>1 wk) NSAID use.  NSAIDs decrease prostaglandin synthesis.
nadolol|piroxicam|2|Significant - Monitor Closely|nadolol and piroxicam both increase  serum potassium. Potential for interaction, monitor.
prazosin|nadolol|3|Significant - Monitor Closely|prazosin and nadolol both increase  anti-hypertensive channel blocking. Potential for dangerous interaction. Use with caution and monitor closely.
nadolol|salmeterol|11|Significant - Monitor Closely|nadolol decreases effects of salmeterol by pharmacodynamic antagonism. Significant interaction possible, monitor closely.
nadolol|salmeterol|2|Significant - Monitor Closely|nadolol increases and salmeterol decreases serum potassium. Effect of interaction is not clear, use caution. Potential for interaction, monitor.
terazosin|nadolol|3|Significant - Monitor Closely|terazosin and nadolol both increase  anti-hypertensive channel blocking. Potential for dangerous interaction. Use with caution and monitor closely.
nadolol|terbutaline|11|Significant - Monitor Closely|nadolol decreases effects of terbutaline by pharmacodynamic antagonism. Significant interaction possible, monitor closely.
nadolol|terbutaline|2|Significant - Monitor Closely|nadolol increases and terbutaline decreases serum potassium. Effect of interaction is not clear, use caution. Potential for interaction, monitor.
nadolol|theophylline|11|Significant - Monitor Closely|nadolol, theophylline. Other (see comment). Significant interaction possible, monitor closely. Comment: Beta blockers (esp. non selective) antagonize theophylline effects, while at the same time increasing theophylline levels and toxicity (mechanism: decreased theophylline metabolism). Smoking increases risk of interaction.
nadolol|tolazamide|11|Significant - Monitor Closely|nadolol decreases effects of tolazamide by pharmacodynamic antagonism. Significant interaction possible, monitor closely. Non selective beta blockers may also mask the symptoms of hypoglycemia.
nadolol|tolbutamide|11|Significant - Monitor Closely|nadolol decreases effects of tolbutamide by pharmacodynamic antagonism. Significant interaction possible, monitor closely. Non selective beta blockers may also mask the symptoms of hypoglycemia.
treprostinil|nadolol|1|Minor|treprostinil increases effects of nadolol by pharmacodynamic synergism. Minor or non-significant interaction.
verapamil|nadolol|20|Serious - Use Alternative|verapamil, nadolol.Either increases toxicity of the other by unspecified interaction mechanism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available. Can increase risk of bradycardia.
nadolol|verapamil|3|Significant - Monitor Closely|nadolol and verapamil both increase  anti-hypertensive channel blocking. Potential for dangerous interaction. Use with caution and monitor closely.
nafcillin|roflumilast|33|Contraindicated|nafcillin will decrease the level or effect of roflumilast by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Never use combination. Coadministration not recommended; strong cytochrome P450 enzyme inducers decrease systemic exposure to roflumilast and may reduce the therapeutic effectiveness
nafcillin|telithromycin|1|Minor|nafcillin will decrease the level or effect of telithromycin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor or non-significant interaction.
nafcillin|temsirolimus|11|Significant - Monitor Closely|nafcillin will decrease the level or effect of temsirolimus by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
tetracycline|nafcillin|20|Serious - Use Alternative|tetracycline decreases effects of nafcillin by pharmacodynamic antagonism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
nafcillin|tramadol|11|Significant - Monitor Closely|nafcillin will decrease the level or effect of tramadol by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely. Decreased AUC  of tramadol and the active metabolite (O-desmethyltramadol) when coadministered with strong CYP3A4 and CYP2B6 inducers
nafcillin|trazodone|11|Significant - Monitor Closely|nafcillin will decrease the level or effect of trazodone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
nafcillin|vandetanib|33|Contraindicated|nafcillin decreases levels of vandetanib by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Never use combination. Avoid coadministration with potent CYP3A4 inducers; these drugs reduce exposure to vandetanib by up to 40%.
nafcillin|verapamil|11|Significant - Monitor Closely|nafcillin will decrease the level or effect of verapamil by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
nafcillin|verapamil|11|Significant - Monitor Closely|nafcillin decreases levels of verapamil by increasing metabolism. Significant interaction possible, monitor closely.
nafcillin|warfarin|20|Serious - Use Alternative|nafcillin decreases effects of warfarin by increasing hepatic clearance. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
triprolidine|nalbuphine|2|Significant - Monitor Closely|triprolidine and nalbuphine both increase  sedation. Potential for interaction, monitor.
naproxen|pralatrexate|11|Significant - Monitor Closely|naproxen increases levels of pralatrexate by decreasing renal clearance. Significant interaction possible, monitor closely. NSAIDs may delay pralatrexate clearance, increasing drug exposure. Adjust the pralatrexate dose as needed.
telmisartan|naproxen|11|Significant - Monitor Closely|telmisartan, naproxen.Either increases toxicity of the other by Other (see comment). Significant interaction possible, monitor closely. Comment: May result in renal function deterioration, particularly in elderly or volume depleted individuals.
naproxen|telmisartan|3|Significant - Monitor Closely|naproxen decreases effects of telmisartan by pharmacodynamic antagonism. Potential for dangerous interaction. Use with caution and monitor closely.  NSAIDs decrease synthesis of vasodilating renal prostaglandins, and thus affect fluid homeostasis and may diminish antihypertensive effect.
telmisartan|naproxen|2|Significant - Monitor Closely|telmisartan and naproxen both increase  serum potassium. Potential for interaction, monitor.
naproxen|timolol|11|Significant - Monitor Closely|naproxen decreases effects of timolol by pharmacodynamic antagonism. Significant interaction possible, monitor closely. Long term (>1 wk) NSAID use.  NSAIDs decrease prostaglandin synthesis.
timolol|naproxen|2|Significant - Monitor Closely|timolol and naproxen both increase  serum potassium. Potential for interaction, monitor.
trandolapril|naproxen|11|Significant - Monitor Closely|trandolapril, naproxen.Either increases toxicity of the other by Other (see comment). Significant interaction possible, monitor closely. Comment: May result in renal function deterioration, particularly in elderly or volume depleted individuals.
naproxen|trandolapril|3|Significant - Monitor Closely|naproxen decreases effects of trandolapril by pharmacodynamic antagonism. Potential for dangerous interaction. Use with caution and monitor closely. NSAIDs decrease synthesis of vasodilating renal prostaglandins, and thus affect fluid homeostasis and may diminish antihypertenisve effect.
warfarin|naproxen|3|Significant - Monitor Closely|warfarin and naproxen both increase  anticoagulation. Potential for dangerous interaction. Use with caution and monitor closely.
naratriptan|nefazodone|3|Significant - Monitor Closely|naratriptan and nefazodone both increase  serotonin levels. Potential for dangerous interaction. Use with caution and monitor closely.
nefazodone|naratriptan|1|Minor|nefazodone, naratriptan. Mechanism: unknown. Minor or non-significant interaction. Risk of weakness, dyspnea, chest pain.
naratriptan|paroxetine|3|Significant - Monitor Closely|naratriptan and paroxetine both increase  serotonin levels. Potential for dangerous interaction. Use with caution and monitor closely.
paroxetine|naratriptan|1|Minor|paroxetine, naratriptan. Mechanism: unknown. Minor or non-significant interaction. Risk of weakness, dyspnea, chest pain.
naratriptan|phenelzine|22|Serious - Use Alternative|naratriptan and phenelzine both increase  serotonin levels. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available.
phenelzine|naratriptan|21|Serious - Use Alternative|phenelzine increases levels of naratriptan by decreasing metabolism. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available. Never use combination.
naratriptan|sertraline|3|Significant - Monitor Closely|naratriptan and sertraline both increase  serotonin levels. Potential for dangerous interaction. Use with caution and monitor closely.
sertraline|naratriptan|1|Minor|sertraline, naratriptan. Mechanism: unknown. Minor or non-significant interaction. Risk of weakness, dyspnea, chest pain.
naratriptan|tramadol|2|Significant - Monitor Closely|naratriptan and tramadol both increase  serotonin levels. Potential for interaction, monitor.
naratriptan|tranylcypromine|22|Serious - Use Alternative|naratriptan and tranylcypromine both increase  serotonin levels. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available.
tranylcypromine|naratriptan|21|Serious - Use Alternative|tranylcypromine increases levels of naratriptan by decreasing metabolism. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available. Never use combination.
naratriptan|trazodone|3|Significant - Monitor Closely|naratriptan and trazodone both increase  serotonin levels. Potential for dangerous interaction. Use with caution and monitor closely.
trazodone|naratriptan|1|Minor|trazodone, naratriptan. Mechanism: unknown. Minor or non-significant interaction. Risk of weakness, dyspnea, chest pain.
naratriptan|trimipramine|3|Significant - Monitor Closely|naratriptan and trimipramine both increase  serotonin levels. Potential for dangerous interaction. Use with caution and monitor closely.
naratriptan|venlafaxine|3|Significant - Monitor Closely|naratriptan and venlafaxine both increase  serotonin levels. Potential for dangerous interaction. Use with caution and monitor closely.
venlafaxine|naratriptan|1|Minor|venlafaxine, naratriptan. Mechanism: unknown. Minor or non-significant interaction. Risk of weakness, dyspnea, chest pain.
naratriptan|vilazodone|22|Serious - Use Alternative|naratriptan, vilazodone.Either increases toxicity of the other by serotonin levels. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available. Concomitant therapy should be discontinued immediately if signs or symptoms of serotonin syndrome emerge and supportive symptomatic treatment should be initiated.  .
naratriptan|zolmitriptan|33|Contraindicated|naratriptan, zolmitriptan.Either increases toxicity of the other by pharmacodynamic synergism. Never use combination. Additive vasospasm.  Sep. by 24h.
naratriptan|zolmitriptan|2|Significant - Monitor Closely|naratriptan and zolmitriptan both increase  serotonin levels. Potential for interaction, monitor.
nateglinide|tolbutamide|1|Minor|nateglinide will increase the level or effect of tolbutamide by  affecting hepatic enzyme CYP2C9/10 metabolism. Minor or non-significant interaction.
voriconazole|nateglinide|11|Significant - Monitor Closely|voriconazole will increase the level or effect of nateglinide by  affecting hepatic enzyme CYP2C9/10 metabolism. Significant interaction possible, monitor closely.
nateglinide|voriconazole|1|Minor|nateglinide will increase the level or effect of voriconazole by  affecting hepatic enzyme CYP2C9/10 metabolism. Minor or non-significant interaction.
terazosin|nebivolol|3|Significant - Monitor Closely|terazosin and nebivolol both increase  anti-hypertensive channel blocking. Potential for dangerous interaction. Use with caution and monitor closely.
treprostinil|nebivolol|1|Minor|treprostinil increases effects of nebivolol by pharmacodynamic synergism. Minor or non-significant interaction.
nefazodone|pazopanib|20|Serious - Use Alternative|nefazodone will increase the level or effect of pazopanib by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available. Avoid coadministration of pazopanib with strong CYP3A4 inhibitors if possible; if must coadminister, decrease pazopanib dose to 400 mg/day
phenelzine|nefazodone|33|Contraindicated|phenelzine and nefazodone both increase  serotonin levels. Never use combination.
nefazodone|pimozide|33|Contraindicated|nefazodone increases levels of pimozide by decreasing metabolism. Never use combination. Risk of QT interval prolongation.
nefazodone|pimozide|20|Serious - Use Alternative|nefazodone will increase the level or effect of pimozide by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
nefazodone|ponatinib|20|Serious - Use Alternative|nefazodone increases levels of ponatinib by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available. Decrease ponatinib starting dose to 30 mg qDay if coadministration with strong CYP3A4 inhibitors cannot be avoided.
rasagiline|nefazodone|20|Serious - Use Alternative|rasagiline and nefazodone both increase  serotonin levels. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available. Do not use nefazodone in combination with a MAOI, or within 14 days of discontinuing treatment with a MAOI. Allow at least 1 week after stopping nefazodone before starting an MAOI.
rizatriptan|nefazodone|3|Significant - Monitor Closely|rizatriptan and nefazodone both increase  serotonin levels. Potential for dangerous interaction. Use with caution and monitor closely.
nefazodone|rizatriptan|1|Minor|nefazodone, rizatriptan. Mechanism: unknown. Minor or non-significant interaction. Risk of weakness, dyspnea, chest pain.
nefazodone|saxagliptin|3|Significant - Monitor Closely|nefazodone will increase the level or effect of saxagliptin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Potential for dangerous interaction. Use with caution and monitor closely. Limit saxagliptin dose to 2.5 mg/day when coadministered with strong CYP3A4 inhibitors
nefazodone|simvastatin|33|Contraindicated|nefazodone will increase the level or effect of simvastatin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Never use combination. Contraindicated. Increased risk for rhabdomyolysis with drugs that increase simvastatin systemic exposure.
nefazodone|solifenacin|20|Serious - Use Alternative|nefazodone will increase the level or effect of solifenacin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
sumatriptan|nefazodone|3|Significant - Monitor Closely|sumatriptan and nefazodone both increase  serotonin levels. Potential for dangerous interaction. Use with caution and monitor closely.
nefazodone|sumatriptan|1|Minor|nefazodone, sumatriptan. Mechanism: unknown. Minor or non-significant interaction. Risk of weakness, dyspnea, chest pain.
nefazodone|sunitinib|20|Serious - Use Alternative|nefazodone will increase the level or effect of sunitinib by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
nefazodone|tacrolimus|20|Serious - Use Alternative|nefazodone will increase the level or effect of tacrolimus by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
nefazodone|tacrolimus|11|Significant - Monitor Closely|nefazodone will decrease the level or effect of tacrolimus by  P-glycoprotein (MDR1) efflux transporter. Significant interaction possible, monitor closely.
nefazodone|tadalafil|11|Significant - Monitor Closely|nefazodone will increase the level or effect of tadalafil by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely. For ED limit tadalafil to max of 2.5 mg/day (for daily use) or 10 mg dose every 72 hr (for use as needed). Avoid concurrent use of tadalafil for pulmonary HTN in patients taking strong CYP3A4 inhibitors.
nefazodone|tamoxifen|20|Serious - Use Alternative|nefazodone, tamoxifen. affecting hepatic/intestinal enzyme CYP3A4 metabolism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available. CYP3A4 inhibition decreases metabolism of tamoxifen to N-desmethyl tamoxifen (active metabolite with similar biologic activity).
nefazodone|tamsulosin|20|Serious - Use Alternative|nefazodone increases levels of tamsulosin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
nefazodone|tamsulosin|2|Significant - Monitor Closely|nefazodone increases levels of tamsulosin by affecting hepatic enzyme CYP2D6 metabolism. Potential for interaction, monitor.
nefazodone|telithromycin|20|Serious - Use Alternative|nefazodone will increase the level or effect of telithromycin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
nefazodone|temsirolimus|20|Serious - Use Alternative|nefazodone will increase the level or effect of temsirolimus by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
nefazodone|terfenadine|33|Contraindicated|nefazodone increases levels of terfenadine by decreasing metabolism. Never use combination. Risk of QT interval prolongation.
nefazodone|terfenadine|22|Serious - Use Alternative|nefazodone will increase the level or effect of terfenadine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available.
nefazodone|tolterodine|20|Serious - Use Alternative|nefazodone will increase the level or effect of tolterodine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
nefazodone|tolvaptan|20|Serious - Use Alternative|nefazodone will increase the level or effect of tolvaptan by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
nefazodone|tolvaptan|11|Significant - Monitor Closely|nefazodone will decrease the level or effect of tolvaptan by  P-glycoprotein (MDR1) efflux transporter. Significant interaction possible, monitor closely.
nefazodone|tramadol|3|Significant - Monitor Closely|nefazodone and tramadol both increase  serotonin levels. Potential for dangerous interaction. Use with caution and monitor closely.
tranylcypromine|nefazodone|33|Contraindicated|tranylcypromine and nefazodone both increase  serotonin levels. Never use combination.
nefazodone|trazodone|22|Serious - Use Alternative|nefazodone and trazodone both increase  serotonin levels. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available.
nefazodone|trazodone|20|Serious - Use Alternative|nefazodone will increase the level or effect of trazodone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
nefazodone|triazolam|20|Serious - Use Alternative|nefazodone will increase the level or effect of triazolam by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
nefazodone|trimipramine|22|Serious - Use Alternative|nefazodone and trimipramine both increase  serotonin levels. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available.
nefazodone|vardenafil|3|Significant - Monitor Closely|nefazodone will increase the level or effect of vardenafil by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Potential for dangerous interaction. Use with caution and monitor closely.
nefazodone|vemurafenib|20|Serious - Use Alternative|nefazodone increases levels of vemurafenib by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
nefazodone|venlafaxine|22|Serious - Use Alternative|nefazodone and venlafaxine both increase  serotonin levels. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available.
nefazodone|verapamil|20|Serious - Use Alternative|nefazodone will increase the level or effect of verapamil by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
nefazodone|vinblastine|20|Serious - Use Alternative|nefazodone will increase the level or effect of vinblastine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
nefazodone|vinblastine|11|Significant - Monitor Closely|nefazodone will decrease the level or effect of vinblastine by  P-glycoprotein (MDR1) efflux transporter. Significant interaction possible, monitor closely.
nefazodone|vincristine|20|Serious - Use Alternative|nefazodone will increase the level or effect of vincristine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
nefazodone|vincristine|11|Significant - Monitor Closely|nefazodone will decrease the level or effect of vincristine by  P-glycoprotein (MDR1) efflux transporter. Significant interaction possible, monitor closely.
nefazodone|vinorelbine|20|Serious - Use Alternative|nefazodone will increase the level or effect of vinorelbine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
zolmitriptan|nefazodone|3|Significant - Monitor Closely|zolmitriptan and nefazodone both increase  serotonin levels. Potential for dangerous interaction. Use with caution and monitor closely.
nefazodone|zolmitriptan|1|Minor|nefazodone, zolmitriptan. Mechanism: unknown. Minor or non-significant interaction. Risk of weakness, dyspnea, chest pain.
nefazodone|zolpidem|20|Serious - Use Alternative|nefazodone will increase the level or effect of zolpidem by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
nefazodone|zonisamide|20|Serious - Use Alternative|nefazodone will increase the level or effect of zonisamide by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
nevirapine|nelfinavir|11|Significant - Monitor Closely|nevirapine will decrease the level or effect of nelfinavir by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
nelfinavir|nevirapine|2|Significant - Monitor Closely|nelfinavir and nevirapine both increase  risk of immune reconstitution syndrome. Potential for interaction, monitor.
nelfinavir|pimozide|33|Contraindicated|nelfinavir increases levels of pimozide by decreasing metabolism. Never use combination. Potential for serious and/or life-threatening reactions (eg, cardiac arrhythmias).
nelfinavir|pimozide|1|Minor|nelfinavir will increase the level or effect of pimozide by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor or non-significant interaction.
nelfinavir|ponatinib|20|Serious - Use Alternative|nelfinavir increases levels of ponatinib by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available. Decrease ponatinib starting dose to 30 mg qDay if coadministration with strong CYP3A4 inhibitors cannot be avoided.
ponatinib|nelfinavir|2|Significant - Monitor Closely|ponatinib increases levels of nelfinavir by P-glycoprotein (MDR1) efflux transporter. Potential for interaction, monitor.
nelfinavir|quinidine|21|Serious - Use Alternative|nelfinavir increases levels of quinidine by decreasing metabolism. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available. Never use combination.
quinidine|nelfinavir|20|Serious - Use Alternative|quinidine will increase the level or effect of nelfinavir by  P-glycoprotein (MDR1) efflux transporter. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
nelfinavir|quinidine|11|Significant - Monitor Closely|nelfinavir will increase the level or effect of quinidine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
nelfinavir|ranolazine|20|Serious - Use Alternative|nelfinavir will increase the level or effect of ranolazine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
ranolazine|nelfinavir|11|Significant - Monitor Closely|ranolazine will increase the level or effect of nelfinavir by  P-glycoprotein (MDR1) efflux transporter. Significant interaction possible, monitor closely.
nelfinavir|saxagliptin|3|Significant - Monitor Closely|nelfinavir will increase the level or effect of saxagliptin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Potential for dangerous interaction. Use with caution and monitor closely. Limit saxagliptin dose to 2.5 mg/day when coadministered with strong CYP3A4 inhibitors
nelfinavir|sildenafil|33|Contraindicated|nelfinavir will increase the level or effect of sildenafil by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Never use combination.
nelfinavir|simvastatin|33|Contraindicated|nelfinavir will increase the level or effect of simvastatin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Never use combination.
simvastatin|nelfinavir|33|Contraindicated|simvastatin will increase the level or effect of nelfinavir by  P-glycoprotein (MDR1) efflux transporter. Never use combination.
nelfinavir|solifenacin|11|Significant - Monitor Closely|nelfinavir will increase the level or effect of solifenacin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
nelfinavir|sunitinib|11|Significant - Monitor Closely|nelfinavir will increase the level or effect of sunitinib by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
nelfinavir|tacrolimus|11|Significant - Monitor Closely|nelfinavir will increase the level or effect of tacrolimus by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
tacrolimus|nelfinavir|11|Significant - Monitor Closely|tacrolimus will increase the level or effect of nelfinavir by  P-glycoprotein (MDR1) efflux transporter. Significant interaction possible, monitor closely.
nelfinavir|tadalafil|20|Serious - Use Alternative|nelfinavir will increase the level or effect of tadalafil by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available. Stop tadalafil >24 hours prior to protease inhibitor (PI) initiation, restart 7 days after PI initiation at 20 mg once daily, and increase to 40 mg once daily based on tolerability.
nelfinavir|tamoxifen|20|Serious - Use Alternative|nelfinavir, tamoxifen. affecting hepatic/intestinal enzyme CYP3A4 metabolism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available. CYP3A4 inhibition decreases metabolism of tamoxifen to N-desmethyl tamoxifen (active metabolite with similar biologic activity).
nelfinavir|tamsulosin|20|Serious - Use Alternative|nelfinavir increases levels of tamsulosin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
nelfinavir|telaprevir|33|Contraindicated|nelfinavir, telaprevir.Either increases levels of the other by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Never use combination.
telithromycin|nelfinavir|11|Significant - Monitor Closely|telithromycin will increase the level or effect of nelfinavir by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
nelfinavir|telithromycin|1|Minor|nelfinavir will increase the level or effect of telithromycin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor or non-significant interaction.
nelfinavir|temsirolimus|11|Significant - Monitor Closely|nelfinavir will increase the level or effect of temsirolimus by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
nelfinavir|teniposide|2|Significant - Monitor Closely|nelfinavir will increase the level or effect of teniposide by  P-glycoprotein (MDR1) efflux transporter. Potential for interaction, monitor.
nelfinavir|terfenadine|21|Serious - Use Alternative|nelfinavir increases levels of terfenadine by decreasing metabolism. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available. Never use combination. Risk of QT interval prolongation.
nelfinavir|terfenadine|20|Serious - Use Alternative|nelfinavir will increase the level or effect of terfenadine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
nelfinavir|tolterodine|11|Significant - Monitor Closely|nelfinavir will increase the level or effect of tolterodine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
nelfinavir|topotecan|22|Serious - Use Alternative|nelfinavir will increase the level or effect of topotecan by  P-glycoprotein (MDR1) efflux transporter. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available. Product labeling for PO topotecan recommends avoiding concomitant use of P-gp inhibitors; the interaction with IV topotecan may be less severe but is still likely of clinical significance
nelfinavir|tramadol|11|Significant - Monitor Closely|nelfinavir increases levels of tramadol by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely. Potential for increased toxicity. .
nelfinavir|trazodone|11|Significant - Monitor Closely|nelfinavir will increase the level or effect of trazodone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
trazodone|nelfinavir|11|Significant - Monitor Closely|trazodone will decrease the level or effect of nelfinavir by  P-glycoprotein (MDR1) efflux transporter. Significant interaction possible, monitor closely.
nelfinavir|triazolam|33|Contraindicated|nelfinavir increases levels of triazolam by decreasing metabolism. Never use combination. Potential for serious and/or life threatening reactions (eg, prolonged or increased sedation, or respiratory depression).
nelfinavir|triazolam|11|Significant - Monitor Closely|nelfinavir will increase the level or effect of triazolam by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
nelfinavir|vardenafil|11|Significant - Monitor Closely|nelfinavir will increase the level or effect of vardenafil by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
nelfinavir|vemurafenib|20|Serious - Use Alternative|nelfinavir increases levels of vemurafenib by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
nelfinavir|vemurafenib|2|Significant - Monitor Closely|nelfinavir increases levels of vemurafenib by P-glycoprotein (MDR1) efflux transporter. Potential for interaction, monitor.
vemurafenib|nelfinavir|2|Significant - Monitor Closely|vemurafenib increases levels of nelfinavir by P-glycoprotein (MDR1) efflux transporter. Potential for interaction, monitor.
nelfinavir|verapamil|11|Significant - Monitor Closely|nelfinavir will increase the level or effect of verapamil by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
verapamil|nelfinavir|11|Significant - Monitor Closely|verapamil will increase the level or effect of nelfinavir by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
verapamil|nelfinavir|11|Significant - Monitor Closely|verapamil will increase the level or effect of nelfinavir by  P-glycoprotein (MDR1) efflux transporter. Significant interaction possible, monitor closely.
nelfinavir|vinblastine|1|Minor|nelfinavir will increase the level or effect of vinblastine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor or non-significant interaction.
nelfinavir|vincristine|1|Minor|nelfinavir will increase the level or effect of vincristine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor or non-significant interaction.
nelfinavir|vinorelbine|1|Minor|nelfinavir will increase the level or effect of vinorelbine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor or non-significant interaction.
voriconazole|nelfinavir|20|Serious - Use Alternative|voriconazole will increase the level or effect of nelfinavir by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
nelfinavir|warfarin|11|Significant - Monitor Closely|nelfinavir will increase the level or effect of warfarin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
nelfinavir|zolpidem|1|Minor|nelfinavir will increase the level or effect of zolpidem by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor or non-significant interaction.
nelfinavir|zonisamide|1|Minor|nelfinavir will increase the level or effect of zonisamide by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor or non-significant interaction.
netilmicin|pancuronium|20|Serious - Use Alternative|netilmicin increases effects of pancuronium by pharmacodynamic synergism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available. Risk of apnea.
netilmicin|rocuronium|20|Serious - Use Alternative|netilmicin increases effects of rocuronium by pharmacodynamic synergism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available. Risk of apnea.
netilmicin|succinylcholine|20|Serious - Use Alternative|netilmicin increases effects of succinylcholine by pharmacodynamic synergism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available. Risk of apnea.
tacrolimus|netilmicin|11|Significant - Monitor Closely|tacrolimus will increase the level or effect of netilmicin by  P-glycoprotein (MDR1) efflux transporter. Significant interaction possible, monitor closely.
netilmicin|tacrolimus|2|Significant - Monitor Closely|netilmicin and tacrolimus both increase  nephrotoxicity and/or ototoxicity. Potential for interaction, monitor.
netilmicin|tubocurarine|20|Serious - Use Alternative|netilmicin increases effects of tubocurarine by pharmacodynamic synergism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available. Risk of apnea.
netilmicin|vecuronium|20|Serious - Use Alternative|netilmicin increases effects of vecuronium by pharmacodynamic synergism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available. Risk of apnea.
nevirapine|roflumilast|33|Contraindicated|nevirapine will decrease the level or effect of roflumilast by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Never use combination. Coadministration not recommended; strong cytochrome P450 enzyme inducers decrease systemic exposure to roflumilast and may reduce the therapeutic effectiveness
nevirapine|saquinavir|11|Significant - Monitor Closely|nevirapine will decrease the level or effect of saquinavir by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
saquinavir|nevirapine|2|Significant - Monitor Closely|saquinavir and nevirapine both increase  risk of immune reconstitution syndrome. Potential for interaction, monitor.
nevirapine|simvastatin|20|Serious - Use Alternative|nevirapine will decrease the level or effect of simvastatin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
nevirapine|telithromycin|1|Minor|nevirapine will decrease the level or effect of telithromycin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor or non-significant interaction.
nevirapine|temsirolimus|11|Significant - Monitor Closely|nevirapine will decrease the level or effect of temsirolimus by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
nevirapine|tipranavir|11|Significant - Monitor Closely|nevirapine will decrease the level or effect of tipranavir by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
tipranavir|nevirapine|2|Significant - Monitor Closely|tipranavir and nevirapine both increase  risk of immune reconstitution syndrome. Potential for interaction, monitor.
nevirapine|tramadol|11|Significant - Monitor Closely|nevirapine will decrease the level or effect of tramadol by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely. Decreased AUC  of tramadol and the active metabolite (O-desmethyltramadol) when coadministered with strong CYP3A4 and CYP2B6 inducers
nevirapine|trazodone|20|Serious - Use Alternative|nevirapine will decrease the level or effect of trazodone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
nevirapine|vandetanib|33|Contraindicated|nevirapine decreases levels of vandetanib by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Never use combination. Avoid coadministration with potent CYP3A4 inducers; these drugs reduce exposure to vandetanib by up to 40%.
nevirapine|warfarin|11|Significant - Monitor Closely|nevirapine will decrease the level or effect of warfarin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
niacin|pitavastatin|20|Serious - Use Alternative|niacin, pitavastatin.Either increases toxicity of the other by pharmacodynamic synergism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available. Increased risk of rhabdomyolysis (>1 g/day niacin).
nicardipine|tacrolimus|11|Significant - Monitor Closely|nicardipine will increase the level or effect of tacrolimus by  P-glycoprotein (MDR1) efflux transporter. Significant interaction possible, monitor closely.
nicardipine|tadalafil|20|Serious - Use Alternative|nicardipine will increase the level or effect of tadalafil by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available. CYP3A4 inhibitors may reduce tadalafil clearance increasing systemic exposure to tadalafil; significantly increased levels may result in significant adverse events including severe hypotension, syncope, visual changes, and priapism.
nicardipine|tamsulosin|20|Serious - Use Alternative|nicardipine increases levels of tamsulosin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
nicardipine|tamsulosin|2|Significant - Monitor Closely|nicardipine increases levels of tamsulosin by affecting hepatic enzyme CYP2D6 metabolism. Potential for interaction, monitor.
telithromycin|nicardipine|11|Significant - Monitor Closely|telithromycin will increase the level or effect of nicardipine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
nicardipine|teniposide|2|Significant - Monitor Closely|nicardipine will increase the level or effect of teniposide by  P-glycoprotein (MDR1) efflux transporter. Potential for interaction, monitor.
tipranavir|nicardipine|11|Significant - Monitor Closely|tipranavir, nicardipine. Other (see comment). Significant interaction possible, monitor closely. Comment: Nicardipine levels may incr or decr, due to contradictory effects of tipranavir on hepatic CYP3A4 and P glycoprotein.
nicardipine|topotecan|22|Serious - Use Alternative|nicardipine will increase the level or effect of topotecan by  P-glycoprotein (MDR1) efflux transporter. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available. Product labeling for PO topotecan recommends avoiding concomitant use of P-gp inhibitors; the interaction with IV topotecan may be less severe but is still likely of clinical significance
treprostinil|nicardipine|1|Minor|treprostinil increases effects of nicardipine by pharmacodynamic synergism. Minor or non-significant interaction.
verapamil|nicardipine|11|Significant - Monitor Closely|verapamil will increase the level or effect of nicardipine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
nicardipine|verapamil|2|Significant - Monitor Closely|nicardipine and verapamil both increase  anti-hypertensive channel blocking. Potential for interaction, monitor.
nicardipine|vinblastine|11|Significant - Monitor Closely|nicardipine will increase the level or effect of vinblastine by  P-glycoprotein (MDR1) efflux transporter. Significant interaction possible, monitor closely.
nicardipine|vincristine|11|Significant - Monitor Closely|nicardipine will increase the level or effect of vincristine by  P-glycoprotein (MDR1) efflux transporter. Significant interaction possible, monitor closely.
voriconazole|nicardipine|11|Significant - Monitor Closely|voriconazole will increase the level or effect of nicardipine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
voriconazole|nicardipine|11|Significant - Monitor Closely|voriconazole increases levels of nicardipine by decreasing metabolism. Significant interaction possible, monitor closely.
zafirlukast|nicardipine|11|Significant - Monitor Closely|zafirlukast will increase the level or effect of nicardipine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
pentobarbital|nifedipine|3|Significant - Monitor Closely|pentobarbital will decrease the level or effect of nifedipine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Potential for dangerous interaction. Use with caution and monitor closely.
phenobarbital|nifedipine|3|Significant - Monitor Closely|phenobarbital will decrease the level or effect of nifedipine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Potential for dangerous interaction. Use with caution and monitor closely.
primidone|nifedipine|3|Significant - Monitor Closely|primidone will decrease the level or effect of nifedipine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Potential for dangerous interaction. Use with caution and monitor closely.
nifedipine|quinidine|11|Significant - Monitor Closely|nifedipine will increase the level or effect of quinidine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
nifedipine|quinidine|11|Significant - Monitor Closely|nifedipine decreases levels of quinidine by increasing elimination. Significant interaction possible, monitor closely.
quinidine|nifedipine|11|Significant - Monitor Closely|quinidine increases levels of nifedipine by decreasing metabolism. Significant interaction possible, monitor closely.
secobarbital|nifedipine|1|Minor|secobarbital will decrease the level or effect of nifedipine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor or non-significant interaction.
nifedipine|tacrolimus|11|Significant - Monitor Closely|nifedipine will increase the level or effect of tacrolimus by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
nifedipine|tacrolimus|11|Significant - Monitor Closely|nifedipine will decrease the level or effect of tacrolimus by  P-glycoprotein (MDR1) efflux transporter. Significant interaction possible, monitor closely.
nifedipine|telithromycin|1|Minor|nifedipine will increase the level or effect of telithromycin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor or non-significant interaction.
telithromycin|nifedipine|1|Minor|telithromycin will increase the level or effect of nifedipine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor or non-significant interaction.
nifedipine|tipranavir|11|Significant - Monitor Closely|nifedipine will increase the level or effect of tipranavir by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
tizanidine|nifedipine|1|Minor|tizanidine increases effects of nifedipine by pharmacodynamic synergism. Minor or non-significant interaction. Risk of hypotension.
treprostinil|nifedipine|1|Minor|treprostinil increases effects of nifedipine by pharmacodynamic synergism. Minor or non-significant interaction.
voriconazole|nifedipine|11|Significant - Monitor Closely|voriconazole increases levels of nifedipine by decreasing metabolism. Significant interaction possible, monitor closely.
voriconazole|nifedipine|1|Minor|voriconazole will increase the level or effect of nifedipine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor or non-significant interaction.
nilotinib|tacrolimus|11|Significant - Monitor Closely|nilotinib will increase the level or effect of tacrolimus by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
nilotinib|tacrolimus|11|Significant - Monitor Closely|nilotinib will increase the level or effect of tacrolimus by  P-glycoprotein (MDR1) efflux transporter. Significant interaction possible, monitor closely.
nilotinib|tamoxifen|11|Significant - Monitor Closely|nilotinib, tamoxifen. affecting hepatic enzyme CYP2C9/10 metabolism. Significant interaction possible, monitor closely. CYP2C9/10 inhibition decreases tamoxifen metabolism to active metabolites.
nilotinib|tamoxifen|11|Significant - Monitor Closely|nilotinib, tamoxifen. affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely. CYP3A4 inhibition decreases metabolism of tamoxifen to N-desmethyl tamoxifen (active metabolite with similar biologic activity).
telithromycin|nilotinib|11|Significant - Monitor Closely|telithromycin will increase the level or effect of nilotinib by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
nilotinib|telithromycin|3|Significant - Monitor Closely|nilotinib and telithromycin both increase  QTc interval. Potential for dangerous interaction. Use with caution and monitor closely.
nilotinib|telithromycin|1|Minor|nilotinib will increase the level or effect of telithromycin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor or non-significant interaction.
nilotinib|topotecan|22|Serious - Use Alternative|nilotinib will increase the level or effect of topotecan by  P-glycoprotein (MDR1) efflux transporter. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available. Product labeling for PO topotecan recommends avoiding concomitant use of P-gp inhibitors; the interaction with IV topotecan may be less severe but is still likely of clinical significance
nilotinib|toremifene|33|Contraindicated|nilotinib and toremifene both increase  QTc interval. Never use combination. Avoid concurrent use of nilotinib with other QTc prolonging agents.
nilotinib|tramadol|1|Minor|nilotinib will increase the level or effect of tramadol by  affecting hepatic enzyme CYP2D6 metabolism. Minor or non-significant interaction.
trimipramine|nilotinib|22|Serious - Use Alternative|trimipramine and nilotinib both increase  QTc interval. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available.
voriconazole|nilotinib|11|Significant - Monitor Closely|voriconazole will increase the level or effect of nilotinib by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
nilotinib|voriconazole|3|Significant - Monitor Closely|nilotinib and voriconazole both increase  QTc interval. Potential for dangerous interaction. Use with caution and monitor closely.
nilotinib|voriconazole|1|Minor|nilotinib will increase the level or effect of voriconazole by  affecting hepatic enzyme CYP2C9/10 metabolism. Minor or non-significant interaction.
nilotinib|ziprasidone|22|Serious - Use Alternative|nilotinib and ziprasidone both increase  QTc interval. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available.
nilotinib|ziprasidone|1|Minor|nilotinib will increase the level or effect of ziprasidone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor or non-significant interaction.
telithromycin|nimodipine|1|Minor|telithromycin will increase the level or effect of nimodipine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor or non-significant interaction.
tipranavir|nimodipine|11|Significant - Monitor Closely|tipranavir increases levels of nimodipine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely. Potential for increased toxicity. .
voriconazole|nimodipine|1|Minor|voriconazole will increase the level or effect of nimodipine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor or non-significant interaction.
phenytoin|nisoldipine|11|Significant - Monitor Closely|phenytoin will decrease the level or effect of nisoldipine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
telithromycin|nisoldipine|11|Significant - Monitor Closely|telithromycin will increase the level or effect of nisoldipine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
tipranavir|nisoldipine|11|Significant - Monitor Closely|tipranavir, nisoldipine. Other (see comment). Significant interaction possible, monitor closely. Comment: Nisoldipine levels may incr or decr, due to contradictory effects of tipranavir on hepatic CYP3A4 and P glycoprotein.
tipranavir|nisoldipine|11|Significant - Monitor Closely|tipranavir increases levels of nisoldipine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely. Potential for increased toxicity. .
treprostinil|nisoldipine|1|Minor|treprostinil increases effects of nisoldipine by pharmacodynamic synergism. Minor or non-significant interaction.
voriconazole|nisoldipine|11|Significant - Monitor Closely|voriconazole will increase the level or effect of nisoldipine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
voriconazole|nisoldipine|11|Significant - Monitor Closely|voriconazole increases levels of nisoldipine by decreasing metabolism. Significant interaction possible, monitor closely.
telithromycin|nitrendipine|1|Minor|telithromycin will increase the level or effect of nitrendipine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor or non-significant interaction.
voriconazole|nitrendipine|1|Minor|voriconazole will increase the level or effect of nitrendipine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor or non-significant interaction.
nortriptyline|norepinephrine|20|Serious - Use Alternative|nortriptyline, norepinephrine. Other (see comment). Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available. Comment: Tricyclic antidepressants increase or decrease effects of sympathomimetics, by blocking reuptake of NE, or blocking uptake of indirect sympathomimetics into the adrenergic neuron.
nortriptyline|norepinephrine|11|Significant - Monitor Closely|nortriptyline increases effects of norepinephrine by unknown mechanism. Significant interaction possible, monitor closely.
nortriptyline|norepinephrine|2|Significant - Monitor Closely|nortriptyline increases and norepinephrine decreases sedation. Effect of interaction is not clear, use caution. Potential for interaction, monitor.
phenelzine|norepinephrine|33|Contraindicated|phenelzine increases effects of norepinephrine by pharmacodynamic synergism. Never use combination. Risk of acute hypertensive episode.
rasagiline|norepinephrine|11|Significant - Monitor Closely|rasagiline increases effects of norepinephrine by pharmacodynamic synergism. Significant interaction possible, monitor closely. Risk of acute hypertensive episode.
trimipramine|norepinephrine|20|Serious - Use Alternative|trimipramine, norepinephrine. Other (see comment). Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available. Comment: Tricyclic antidepressants increase or decrease effects of sympathomimetics, by blocking reuptake of NE, or blocking uptake of indirect sympathomimetics into the adrenergic neuron.
trimipramine|norepinephrine|11|Significant - Monitor Closely|trimipramine increases effects of norepinephrine by unknown mechanism. Significant interaction possible, monitor closely.
trimipramine|norepinephrine|2|Significant - Monitor Closely|trimipramine increases and norepinephrine decreases sedation. Effect of interaction is not clear, use caution. Potential for interaction, monitor.
rufinamide|norethindrone|11|Significant - Monitor Closely|rufinamide decreases effects of norethindrone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely. Rufinamide is a weak inducer of the CYP 3A4 enzyme and can decrease exposure of drugs that are substrates of CYP3A4. .
sucralfate|norfloxacin|11|Significant - Monitor Closely|sucralfate decreases levels of norfloxacin by inhibition of GI absorption. Applies only to oral form of both agents. Significant interaction possible, monitor closely.
norfloxacin|tacrine|1|Minor|norfloxacin will increase the level or effect of tacrine by  affecting hepatic enzyme CYP1A2 metabolism. Minor or non-significant interaction.
quetiapine|vorinostat|2|Significant - Monitor Closely|quetiapine, vorinostat.Either increases toxicity of the other by QTc interval. Potential for interaction, monitor. Avoid use with drugs that prolong QT and in patients with risk factors for prolonged QT interval. Postmarketing cases show QT prolongation with overdose in patients with concomitant illness or with drugs known to cause electrolyte imbalance or prolong QT.
quetiapine|ziprasidone|2|Significant - Monitor Closely|quetiapine and ziprasidone both increase  antidopaminergic effects, including extrapyramidal symptoms and neuroleptic malignant syndrome. Potential for interaction, monitor.
quetiapine|ziprasidone|2|Significant - Monitor Closely|quetiapine and ziprasidone both increase  sedation. Potential for interaction, monitor.
quetiapine|ziprasidone|2|Significant - Monitor Closely|quetiapine, ziprasidone.Either increases toxicity of the other by QTc interval. Potential for interaction, monitor. Avoid use with drugs that prolong QT and in patients with risk factors for prolonged QT interval. Postmarketing cases show QT prolongation with overdose in patients with concomitant illness or with drugs known to cause electrolyte imbalance or prolong QT.
quinapril|spironolactone|11|Significant - Monitor Closely|quinapril, spironolactone. Mechanism: pharmacodynamic synergism. Significant interaction possible, monitor closely. Risk of hyperkalemia.
tizanidine|quinapril|1|Minor|tizanidine increases effects of quinapril by pharmacodynamic synergism. Minor or non-significant interaction. Risk of hypotension.
treprostinil|quinapril|1|Minor|treprostinil increases effects of quinapril by pharmacodynamic synergism. Minor or non-significant interaction.
quinapril|triamterene|11|Significant - Monitor Closely|quinapril, triamterene. Mechanism: pharmacodynamic synergism. Significant interaction possible, monitor closely. Risk of hyperkalemia.
quinidine|ranolazine|22|Serious - Use Alternative|quinidine and ranolazine both increase  QTc interval. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available.
ritonavir|quinidine|21|Serious - Use Alternative|ritonavir increases levels of quinidine by decreasing metabolism. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available. Never use combination.
quinidine|ritonavir|20|Serious - Use Alternative|quinidine will increase the level or effect of ritonavir by  P-glycoprotein (MDR1) efflux transporter. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
ritonavir|quinidine|11|Significant - Monitor Closely|ritonavir will increase the level or effect of quinidine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
secobarbital|quinidine|11|Significant - Monitor Closely|secobarbital will decrease the level or effect of quinidine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
sodium bicarbonate|quinidine|11|Significant - Monitor Closely|sodium bicarbonate will increase the level or effect of quinidine by  passive renal tubular reabsorption - basic urine. Significant interaction possible, monitor closely. Elevated quinidine plasma levels, possibly with cardiac conduction disturbances and arrhythmias, may occur.
quinidine|succinylcholine|1|Minor|quinidine increases effects of succinylcholine by pharmacodynamic synergism. Minor or non-significant interaction.
quinidine|tacrolimus|20|Serious - Use Alternative|quinidine will increase the level or effect of tacrolimus by  P-glycoprotein (MDR1) efflux transporter. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
quinidine|tamoxifen|11|Significant - Monitor Closely|quinidine decreases effects of tamoxifen by decreasing metabolism. Significant interaction possible, monitor closely. Inhibition of CYP2D6 metabolism to tamoxifen's active metabolite, endoxifen.
quinidine|tamsulosin|20|Serious - Use Alternative|quinidine increases levels of tamsulosin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
quinidine|tamsulosin|2|Significant - Monitor Closely|quinidine increases levels of tamsulosin by affecting hepatic enzyme CYP2D6 metabolism. Potential for interaction, monitor.
quinidine|telavancin|22|Serious - Use Alternative|quinidine and telavancin both increase  QTc interval. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available.
quinidine|telithromycin|22|Serious - Use Alternative|quinidine and telithromycin both increase  QTc interval. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available.
telithromycin|quinidine|11|Significant - Monitor Closely|telithromycin will increase the level or effect of quinidine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely. The rare occurrence of arrhythmias resulting from the potential for additive QT prolongation should be considered as a possibility when quinidine and telithromycin are coadministered. Telithromycin should be avoided if possible in patients that are treated with quinidine.
quinidine|teniposide|2|Significant - Monitor Closely|quinidine will increase the level or effect of teniposide by  P-glycoprotein (MDR1) efflux transporter. Potential for interaction, monitor.
quinidine|terfenadine|33|Contraindicated|quinidine and terfenadine both increase  QTc interval. Never use combination.
quinidine|tetrabenazine|11|Significant - Monitor Closely|quinidine increases effects of tetrabenazine by affecting hepatic enzyme CYP2D6 metabolism. Significant interaction possible, monitor closely. Decrease tetrabenazine dose by 50% when coadministered with strong CYP2D6 inhibitors.
thioridazine|quinidine|33|Contraindicated|thioridazine and quinidine both increase  QTc interval. Never use combination.
quinidine|thioridazine|22|Serious - Use Alternative|quinidine will increase the level or effect of thioridazine by  affecting hepatic enzyme CYP2D6 metabolism. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available.
quinidine|thioridazine|20|Serious - Use Alternative|quinidine, thioridazine.Either increases effects of the other by pharmacodynamic synergism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available. Additive cardiac effects.
tipranavir|quinidine|33|Contraindicated|tipranavir increases levels of quinidine by decreasing metabolism. Never use combination.
quinidine|tolterodine|2|Significant - Monitor Closely|quinidine will increase the level or effect of tolterodine by  affecting hepatic enzyme CYP2D6 metabolism. Potential for interaction, monitor.
quinidine|topotecan|22|Serious - Use Alternative|quinidine will increase the level or effect of topotecan by  P-glycoprotein (MDR1) efflux transporter. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available. Product labeling for PO topotecan recommends avoiding concomitant use of P-gp inhibitors; the interaction with IV topotecan may be less severe but is still likely of clinical significance
quinidine|toremifene|20|Serious - Use Alternative|quinidine and toremifene both increase  QTc interval. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available. Concurrent use of toremifene with agents causing  QT prolongation should be avoided. If concomitant use is required it's recommended that toremifene be interrupted. If interruption not possible, patients requiring therapy with a drug that prolongs QT should be closely monitored. ECGs should be obtained for high risk patients.
quinidine|tramadol|2|Significant - Monitor Closely|quinidine decreases effects of tramadol by affecting hepatic enzyme CYP2D6 metabolism. Potential for interaction, monitor. Decreased conversion of tramadol to active metabolite.
quinidine|tramadol|2|Significant - Monitor Closely|quinidine decreases effects of tramadol by decreasing metabolism. Potential for interaction, monitor. Decreased conversion of tramadol to active metabolite.
quinidine|trazodone|33|Contraindicated|quinidine and trazodone both increase  QTc interval. Never use combination.
quinidine|trimipramine|33|Contraindicated|quinidine and trimipramine both increase  QTc interval. Never use combination.
quinidine|vecuronium|1|Minor|quinidine increases effects of vecuronium by pharmacodynamic synergism. Minor or non-significant interaction.
quinidine|venlafaxine|22|Serious - Use Alternative|quinidine and venlafaxine both increase  QTc interval. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available.
verapamil|quinidine|11|Significant - Monitor Closely|verapamil will increase the level or effect of quinidine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
quinidine|verapamil|11|Significant - Monitor Closely|quinidine will increase the level or effect of verapamil by  basic (cationic) drug competition for renal tubular clearance. Significant interaction possible, monitor closely.
quinidine|vilazodone|20|Serious - Use Alternative|quinidine increases levels of vilazodone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available. Strong CYP3A4 inhibitors may increase vilazodone plasma levels by 50% - Reduce daily dose  to 20 mg.
quinidine|vinblastine|20|Serious - Use Alternative|quinidine will increase the level or effect of vinblastine by  P-glycoprotein (MDR1) efflux transporter. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
quinidine|vincristine|20|Serious - Use Alternative|quinidine will increase the level or effect of vincristine by  P-glycoprotein (MDR1) efflux transporter. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
voriconazole|quinidine|33|Contraindicated|voriconazole will increase the level or effect of quinidine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Never use combination. Elevated and toxic levels of quinidine may occur potentiating the risk for QT prolongation and cardiac arrhythmias.
quinidine|voriconazole|33|Contraindicated|quinidine and voriconazole both increase  QTc interval. Never use combination.
quinidine|warfarin|11|Significant - Monitor Closely|quinidine increases effects of warfarin by decreasing metabolism. Significant interaction possible, monitor closely. Dosage reduction of warfarin may be needed during concurrent administration of quinidine. Monitor INR and adjust the dosage accordingly.
quinidine|ziprasidone|33|Contraindicated|quinidine and ziprasidone both increase  QTc interval. Never use combination.
quinine|succinylcholine|21|Serious - Use Alternative|quinine increases effects of succinylcholine by pharmacodynamic synergism. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available. Never use combination. Risk of resp. depression.
quinine|tamsulosin|2|Significant - Monitor Closely|quinine increases levels of tamsulosin by affecting hepatic enzyme CYP2D6 metabolism. Potential for interaction, monitor.
telithromycin|quinine|11|Significant - Monitor Closely|telithromycin and quinine both increase  QTc interval. Significant interaction possible, monitor closely.
telithromycin|quinine|1|Minor|telithromycin will increase the level or effect of quinine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor or non-significant interaction.
thioridazine|quinine|33|Contraindicated|thioridazine and quinine both increase  QTc interval. Never use combination.
thiothixene|quinine|11|Significant - Monitor Closely|thiothixene and quinine both increase  QTc interval. Significant interaction possible, monitor closely.
toremifene|quinine|11|Significant - Monitor Closely|toremifene and quinine both increase  QTc interval. Significant interaction possible, monitor closely.
quinine|vecuronium|21|Serious - Use Alternative|quinine increases effects of vecuronium by pharmacodynamic synergism. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available. Never use combination. Risk of resp. depression.
voriconazole|quinine|11|Significant - Monitor Closely|voriconazole and quinine both increase  QTc interval. Significant interaction possible, monitor closely.
voriconazole|quinine|1|Minor|voriconazole will increase the level or effect of quinine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor or non-significant interaction.
vorinostat|quinine|11|Significant - Monitor Closely|vorinostat and quinine both increase  QTc interval. Significant interaction possible, monitor closely.
quinine|warfarin|20|Serious - Use Alternative|quinine increases effects of warfarin by unknown mechanism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
ziprasidone|quinine|11|Significant - Monitor Closely|ziprasidone and quinine both increase  QTc interval. Significant interaction possible, monitor closely.
rabeprazole|rilpivirine|33|Contraindicated|rabeprazole decreases levels of rilpivirine by increasing gastric pH. Applies only to oral form of both agents. Never use combination. Contraindicated. Concurrent use may cause treatment failure and/or the development of rilpivirine or NNRTI resistance. Coadministration of a PPI and rilpivirine may result in decreased rilpivirine plasma concentrations, which could cause impaired virologic response to rilpivirine.
tacrine|ramelteon|11|Significant - Monitor Closely|tacrine will increase the level or effect of ramelteon by  affecting hepatic enzyme CYP1A2 metabolism. Significant interaction possible, monitor closely.
triprolidine|ramelteon|2|Significant - Monitor Closely|triprolidine and ramelteon both increase  sedation. Potential for interaction, monitor.
zileuton|ramelteon|11|Significant - Monitor Closely|zileuton will increase the level or effect of ramelteon by  affecting hepatic enzyme CYP1A2 metabolism. Significant interaction possible, monitor closely.
ramipril|spironolactone|11|Significant - Monitor Closely|ramipril, spironolactone. Mechanism: pharmacodynamic synergism. Significant interaction possible, monitor closely. Risk of hyperkalemia.
tizanidine|ramipril|1|Minor|tizanidine increases effects of ramipril by pharmacodynamic synergism. Minor or non-significant interaction. Risk of hypotension.
treprostinil|ramipril|1|Minor|treprostinil increases effects of ramipril by pharmacodynamic synergism. Minor or non-significant interaction.
ramipril|triamterene|11|Significant - Monitor Closely|ramipril, triamterene. Mechanism: pharmacodynamic synergism. Significant interaction possible, monitor closely. Risk of hyperkalemia.
ranitidine|rilpivirine|11|Significant - Monitor Closely|ranitidine, rilpivirine. increasing gastric pH. Applies only to oral form of both agents. Significant interaction possible, monitor closely. Combination of rilpivirine and H2-receptor antagonists should be used with caution as co-administration may cause significant decreases in rilpivirine plasma concentrations (increase in gastric pH). H2-receptor antagonists should only be administered at least 12 hours before or at least 4 hours after rilpivirine.
ranitidine|vismodegib|2|Significant - Monitor Closely|ranitidine will decrease the level or effect of vismodegib by  Other (see comment). Potential for interaction, monitor. Drugs that increase gastric pH alter vismodegib solubility and therefore reduce bioavailability; effect on efficacy unknown
ritonavir|ranolazine|21|Serious - Use Alternative|ritonavir will increase the level or effect of ranolazine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available. Never use combination.
ranolazine|ritonavir|11|Significant - Monitor Closely|ranolazine will increase the level or effect of ritonavir by  P-glycoprotein (MDR1) efflux transporter. Significant interaction possible, monitor closely.
ranolazine|saquinavir|11|Significant - Monitor Closely|ranolazine will increase the level or effect of saquinavir by  P-glycoprotein (MDR1) efflux transporter. Significant interaction possible, monitor closely.
ranolazine|simvastatin|20|Serious - Use Alternative|ranolazine increases levels of simvastatin by Other (see comment). Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available. Comment: Benefits of combination therapy should be carefully weighed against the potential risks of combination. Potential for increased risk of myopathy/rhabdomyolysis. Limit simvastatin dose to no more than 20 mg/day when used concurrently. .
ranolazine|sotalol|22|Serious - Use Alternative|ranolazine and sotalol both increase  QTc interval. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available.
ranolazine|tacrolimus|11|Significant - Monitor Closely|ranolazine will increase the level or effect of tacrolimus by  P-glycoprotein (MDR1) efflux transporter. Significant interaction possible, monitor closely.
ranolazine|tamsulosin|2|Significant - Monitor Closely|ranolazine increases levels of tamsulosin by affecting hepatic enzyme CYP2D6 metabolism. Potential for interaction, monitor.
telithromycin|ranolazine|21|Serious - Use Alternative|telithromycin will increase the level or effect of ranolazine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available. Never use combination.
ranolazine|telithromycin|2|Significant - Monitor Closely|ranolazine and telithromycin both increase  QTc interval. Potential for interaction, monitor.
ranolazine|thioridazine|21|Serious - Use Alternative|ranolazine will increase the level or effect of thioridazine by  affecting hepatic enzyme CYP2D6 metabolism. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available. Never use combination.
thioridazine|ranolazine|3|Significant - Monitor Closely|thioridazine and ranolazine both increase  QTc interval. Potential for dangerous interaction. Use with caution and monitor closely.
ranolazine|tolterodine|1|Minor|ranolazine will increase the level or effect of tolterodine by  affecting hepatic enzyme CYP2D6 metabolism. Minor or non-significant interaction.
ranolazine|topotecan|22|Serious - Use Alternative|ranolazine will increase the level or effect of topotecan by  P-glycoprotein (MDR1) efflux transporter. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available. Product labeling for PO topotecan recommends avoiding concomitant use of P-gp inhibitors; the interaction with IV topotecan may be less severe but is still likely of clinical significance
ranolazine|tramadol|1|Minor|ranolazine will increase the level or effect of tramadol by  affecting hepatic enzyme CYP2D6 metabolism. Minor or non-significant interaction.
trimipramine|ranolazine|3|Significant - Monitor Closely|trimipramine and ranolazine both increase  QTc interval. Potential for dangerous interaction. Use with caution and monitor closely.
verapamil|ranolazine|21|Serious - Use Alternative|verapamil will increase the level or effect of ranolazine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available. Never use combination.
voriconazole|ranolazine|21|Serious - Use Alternative|voriconazole will increase the level or effect of ranolazine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available. Never use combination.
ranolazine|voriconazole|2|Significant - Monitor Closely|ranolazine and voriconazole both increase  QTc interval. Potential for interaction, monitor.
ranolazine|ziprasidone|3|Significant - Monitor Closely|ranolazine and ziprasidone both increase  QTc interval. Potential for dangerous interaction. Use with caution and monitor closely.
rasagiline|sertraline|20|Serious - Use Alternative|rasagiline and sertraline both increase  serotonin levels. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available. Severe CNS toxicity associated with hyperpyrexia has been reported with the combined treatment of an antidepressant and rasagiline. Avoid combination within 14 days of MAOI use.
rasagiline|tapentadol|33|Contraindicated|rasagiline increases toxicity of tapentadol by unknown mechanism. Never use combination. Concomitant MAOI therapy within the last 14 days is contraindicated. Risk of hypotension, hyperpyrexia, somnolence, or death. .
rasagiline|tapentadol|3|Significant - Monitor Closely|rasagiline and tapentadol both increase  serotonin levels. Potential for dangerous interaction. Use with caution and monitor closely.
tetrabenazine|rasagiline|33|Contraindicated|tetrabenazine, rasagiline. Other (see comment). Never use combination. Comment: Risk of acute hypertensive episode; separate by 14 d. .
rasagiline|tramadol|33|Contraindicated|rasagiline and tramadol both increase  serotonin levels. Never use combination.
rasagiline|tranylcypromine|33|Contraindicated|rasagiline and tranylcypromine both increase  serotonin levels. Never use combination. At least 14 days should elapse between discontinuation of rasagiline and initiation of another MAOI or discontinuation of another MAOI and initiation of rasagiline.
rasagiline|trazodone|20|Serious - Use Alternative|rasagiline and trazodone both increase  serotonin levels. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available. Trazodone should not be coadministered with a MAOI or within 14 days of discontinuing a MAOI. Similarly, a MAOI should not be given within 14 days of stopping trazodone.
rasagiline|trimipramine|20|Serious - Use Alternative|rasagiline and trimipramine both increase  serotonin levels. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available. Severe CNS toxicity associated with hyperpyrexia has been reported with the combined treatment of an antidepressant and rasagiline. Avoid combination within 14 days of MAOI use.
rasagiline|venlafaxine|20|Serious - Use Alternative|rasagiline and venlafaxine both increase  serotonin levels. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available. Severe CNS toxicity associated with hyperpyrexia has been reported with the combined treatment of an antidepressant and rasagiline. Avoid combination within 14 days of MAOI use.
zolmitriptan|rasagiline|20|Serious - Use Alternative|zolmitriptan and rasagiline both increase  serotonin levels. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available. Avoid combination within 14 days of MAOI use
theophylline|regadenoson|22|Serious - Use Alternative|theophylline decreases effects of regadenoson by pharmacodynamic antagonism. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available. Avoid methylxanthines for 12 hours before regadenoson administration.
telithromycin|regorafenib|33|Contraindicated|telithromycin, regorafenib. affecting hepatic/intestinal enzyme CYP3A4 metabolism. Never use combination. Strong CYP3A4 inhibitors increase regorafenib levels and decrease exposure of the active metabolites M-2 and M-5.
voriconazole|regorafenib|33|Contraindicated|voriconazole, regorafenib. affecting hepatic/intestinal enzyme CYP3A4 metabolism. Never use combination. Strong CYP3A4 inhibitors increase regorafenib levels and decrease exposure of the active metabolites M-2 and M-5.
telithromycin|repaglinide|11|Significant - Monitor Closely|telithromycin will increase the level or effect of repaglinide by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
voriconazole|repaglinide|11|Significant - Monitor Closely|voriconazole will increase the level or effect of repaglinide by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
tetrabenazine|reserpine|33|Contraindicated|tetrabenazine, reserpine. Other (see comment). Never use combination. Comment: Tetrabenazine reversibly inhibits VMAT2 while reserpine binds irreversibly to VMAT2 and the duration of its effect is several days; caution when switching from reserpine to tetrabenazine; wait for chorea to re-emerge before administering tetrabenazine to avoid overdosage and major CNS depletion of serotonin and norepinephrine; at least 20 days should elapse after stopping reserpine before starting tetrabenazine.
tranylcypromine|reserpine|21|Serious - Use Alternative|tranylcypromine, reserpine. Other (see comment). High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available. Never use combination. Comment: If reserpine given after MAOI Tx, risk of acute hypertensive episode.  Mechanism: MAOI causes accumulation of NE in neuron, and reserpine stimulates NE release.
treprostinil|reserpine|1|Minor|treprostinil increases effects of reserpine by pharmacodynamic synergism. Minor or non-significant interaction.
ribavirin|zidovudine|20|Serious - Use Alternative|ribavirin decreases effects of zidovudine by Other (see comment). Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available. Comment: Mechanism: Competition for thymidine kinase for conversion to active form.
rifabutin|rilpivirine|20|Serious - Use Alternative|rifabutin decreases levels of rilpivirine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available. If coadministered, increase rilpivirine dose to 50 mg PO once daily; when rifabutin coadministration is stopped, decrease rilpivirine dose to 25 mg once daily.
rifabutin|ritonavir|20|Serious - Use Alternative|rifabutin will decrease the level or effect of ritonavir by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
ritonavir|rifabutin|11|Significant - Monitor Closely|ritonavir increases levels of rifabutin by decreasing metabolism. Significant interaction possible, monitor closely.
rifabutin|roflumilast|33|Contraindicated|rifabutin will decrease the level or effect of roflumilast by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Never use combination. Coadministration not recommended; strong cytochrome P450 enzyme inducers decrease systemic exposure to roflumilast and may reduce the therapeutic effectiveness
saquinavir|rifabutin|20|Serious - Use Alternative|saquinavir will decrease the level or effect of rifabutin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available. Dosage reduction of rifabutin by at least 75% of the usual dose of 300 mg/day is recommended (ie, a maximum dose of 150 mg every other day or 3 times/week). Increased monitoring for adverse events is warranted in patients receiving the combination. Consider monitoring rifabutin concentrations to ensure adequate exposure.
rifabutin|saquinavir|2|Significant - Monitor Closely|rifabutin decreases levels of saquinavir by increasing metabolism. Potential for interaction, monitor. If saquinavir administered with ritonavir as boosted therapy, interaction not clinically significant.
rifabutin|simvastatin|22|Serious - Use Alternative|rifabutin will decrease the level or effect of simvastatin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available.
rifabutin|sirolimus|22|Serious - Use Alternative|rifabutin will decrease the level or effect of sirolimus by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available.
rifabutin|sunitinib|20|Serious - Use Alternative|rifabutin will decrease the level or effect of sunitinib by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
rifabutin|tacrolimus|20|Serious - Use Alternative|rifabutin will decrease the level or effect of tacrolimus by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
rifabutin|tamoxifen|2|Significant - Monitor Closely|rifabutin will decrease the level or effect of tamoxifen by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Potential for interaction, monitor.
rifabutin|telithromycin|2|Significant - Monitor Closely|rifabutin will decrease the level or effect of telithromycin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Potential for interaction, monitor.
rifabutin|temsirolimus|20|Serious - Use Alternative|rifabutin will decrease the level or effect of temsirolimus by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
rifabutin|tipranavir|20|Serious - Use Alternative|rifabutin will decrease the level or effect of tipranavir by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
tipranavir|rifabutin|20|Serious - Use Alternative|tipranavir increases levels of rifabutin by decreasing metabolism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
rifabutin|tolvaptan|22|Serious - Use Alternative|rifabutin will decrease the level or effect of tolvaptan by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available.
rifabutin|toremifene|11|Significant - Monitor Closely|rifabutin decreases levels of toremifene by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely. CYP3A4 inducers increase rate of toremifene metabolism, lowering the steady-state concentration in serum.
rifabutin|tramadol|11|Significant - Monitor Closely|rifabutin will decrease the level or effect of tramadol by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely. Decreased AUC  of tramadol and the active metabolite (O-desmethyltramadol) when coadministered with strong CYP3A4 and CYP2B6 inducers
rifabutin|trazodone|20|Serious - Use Alternative|rifabutin will decrease the level or effect of trazodone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
rifabutin|trazodone|11|Significant - Monitor Closely|rifabutin decreases levels of trazodone by increasing metabolism. Significant interaction possible, monitor closely.
rifabutin|trimipramine|11|Significant - Monitor Closely|rifabutin decreases levels of trimipramine by increasing metabolism. Significant interaction possible, monitor closely.
rifabutin|vandetanib|33|Contraindicated|rifabutin decreases levels of vandetanib by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Never use combination. Avoid coadministration with potent CYP3A4 inducers; these drugs reduce exposure to vandetanib by up to 40%.
rifabutin|vemurafenib|20|Serious - Use Alternative|rifabutin decreases levels of vemurafenib by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
rifabutin|verapamil|20|Serious - Use Alternative|rifabutin will decrease the level or effect of verapamil by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
rifabutin|voriconazole|33|Contraindicated|rifabutin decreases levels of voriconazole by increasing metabolism. Never use combination. Voriconazole may also increase levels of rifabutin.
rifabutin|warfarin|20|Serious - Use Alternative|rifabutin will decrease the level or effect of warfarin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
rifabutin|warfarin|11|Significant - Monitor Closely|rifabutin decreases levels of warfarin by increasing metabolism. Significant interaction possible, monitor closely.
rifabutin|zidovudine|2|Significant - Monitor Closely|rifabutin will decrease the level or effect of zidovudine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Potential for interaction, monitor.
rifapentine|rilpivirine|33|Contraindicated|rifapentine decreases levels of rilpivirine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Never use combination. Contraindicated. Rilpivirine should not be co-administered with strong CYP 3A4 inducers. Potential for loss of virologic response and possible resistance to rilpivirine or to the NNRTI class.
rifapentine|roflumilast|33|Contraindicated|rifapentine will decrease the level or effect of roflumilast by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Never use combination. Coadministration not recommended; strong cytochrome P450 enzyme inducers decrease systemic exposure to roflumilast and may reduce the therapeutic effectiveness
rifapentine|telithromycin|1|Minor|rifapentine will decrease the level or effect of telithromycin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor or non-significant interaction.
rifapentine|temsirolimus|11|Significant - Monitor Closely|rifapentine will decrease the level or effect of temsirolimus by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
rifapentine|tipranavir|21|Serious - Use Alternative|rifapentine decreases levels of tipranavir by increasing metabolism. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available. Never use combination.
rifapentine|tipranavir|11|Significant - Monitor Closely|rifapentine will decrease the level or effect of tipranavir by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
rifapentine|tramadol|11|Significant - Monitor Closely|rifapentine will decrease the level or effect of tramadol by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely. Decreased AUC  of tramadol and the active metabolite (O-desmethyltramadol) when coadministered with strong CYP3A4 and CYP2B6 inducers
rifapentine|trazodone|20|Serious - Use Alternative|rifapentine will decrease the level or effect of trazodone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
rifapentine|vandetanib|33|Contraindicated|rifapentine decreases levels of vandetanib by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Never use combination. Avoid coadministration with potent CYP3A4 inducers; these drugs reduce exposure to vandetanib by up to 40%.
rifapentine|vemurafenib|20|Serious - Use Alternative|rifapentine decreases levels of vemurafenib by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
rifapentine|verapamil|11|Significant - Monitor Closely|rifapentine will decrease the level or effect of verapamil by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
rifapentine|voriconazole|1|Minor|rifapentine will decrease the level or effect of voriconazole by  affecting hepatic enzyme CYP2C9/10 metabolism. Minor or non-significant interaction.
rilonacept|sipuleucel-t|3|Significant - Monitor Closely|rilonacept decreases effects of sipuleucel-t by pharmacodynamic antagonism. Potential for dangerous interaction. Use with caution and monitor closely.
rilonacept|sirolimus|22|Serious - Use Alternative|rilonacept and sirolimus both increase  immunosuppressive effects; risk of infection. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available.
rilonacept|tacrolimus|22|Serious - Use Alternative|rilonacept and tacrolimus both increase  immunosuppressive effects; risk of infection. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available.
rilonacept|temsirolimus|22|Serious - Use Alternative|rilonacept and temsirolimus both increase  immunosuppressive effects; risk of infection. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available.
tocilizumab|rilonacept|22|Serious - Use Alternative|tocilizumab and rilonacept both increase  immunosuppressive effects; risk of infection. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available.
tacrolimus|risperidone|11|Significant - Monitor Closely|tacrolimus will increase the level or effect of risperidone by  P-glycoprotein (MDR1) efflux transporter. Significant interaction possible, monitor closely.
risperidone|tetrabenazine|3|Significant - Monitor Closely|risperidone and tetrabenazine both increase  antidopaminergic effects, including extrapyramidal symptoms and neuroleptic malignant syndrome. Potential for dangerous interaction. Use with caution and monitor closely.
risperidone|thiothixene|2|Significant - Monitor Closely|risperidone and thiothixene both increase  antidopaminergic effects, including extrapyramidal symptoms and neuroleptic malignant syndrome. Potential for interaction, monitor.
risperidone|thiothixene|2|Significant - Monitor Closely|risperidone and thiothixene both increase  sedation. Potential for interaction, monitor.
trimipramine|risperidone|3|Significant - Monitor Closely|trimipramine and risperidone both increase  QTc interval. Potential for dangerous interaction. Use with caution and monitor closely.
risperidone|trimipramine|2|Significant - Monitor Closely|risperidone and trimipramine both increase  sedation. Potential for interaction, monitor.
triprolidine|risperidone|2|Significant - Monitor Closely|triprolidine and risperidone both increase  sedation. Potential for interaction, monitor.
risperidone|voriconazole|2|Significant - Monitor Closely|risperidone and voriconazole both increase  QTc interval. Potential for interaction, monitor.
risperidone|ziprasidone|3|Significant - Monitor Closely|risperidone and ziprasidone both increase  QTc interval. Potential for dangerous interaction. Use with caution and monitor closely.
risperidone|ziprasidone|2|Significant - Monitor Closely|risperidone and ziprasidone both increase  antidopaminergic effects, including extrapyramidal symptoms and neuroleptic malignant syndrome. Potential for interaction, monitor.
risperidone|ziprasidone|2|Significant - Monitor Closely|risperidone and ziprasidone both increase  sedation. Potential for interaction, monitor.
ritonavir|rivaroxaban|20|Serious - Use Alternative|ritonavir increases levels of rivaroxaban by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available. Avoid concomitant use of rivaroxaban and combined Pgp and strong CYP3A4 inhibitors. Combination may lead to significant increases in rivaroxaban levels and increase bleeding risk.
ritonavir|roflumilast|3|Significant - Monitor Closely|ritonavir will decrease the level or effect of roflumilast by  affecting hepatic enzyme CYP1A2 metabolism. Potential for dangerous interaction. Use with caution and monitor closely. Concomitant therapy may reduce therapeutic effectiveness.
ritonavir|saxagliptin|3|Significant - Monitor Closely|ritonavir will increase the level or effect of saxagliptin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Potential for dangerous interaction. Use with caution and monitor closely. Limit saxagliptin dose to 2.5 mg/day when coadministered with strong CYP3A4 inhibitors
ritonavir|silodosin|21|Serious - Use Alternative|ritonavir will increase the level or effect of silodosin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available. Never use combination.
ritonavir|silodosin|11|Significant - Monitor Closely|ritonavir will increase the level or effect of silodosin by  P-glycoprotein (MDR1) efflux transporter. Significant interaction possible, monitor closely.
ritonavir|tacrolimus|11|Significant - Monitor Closely|ritonavir will increase the level or effect of tacrolimus by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
ritonavir|tacrolimus|11|Significant - Monitor Closely|ritonavir will increase the level or effect of tacrolimus by  P-glycoprotein (MDR1) efflux transporter. Significant interaction possible, monitor closely.
ritonavir|tadalafil|20|Serious - Use Alternative|ritonavir will increase the level or effect of tadalafil by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available. Stop tadalafil >24 hours prior to protease inhibitor (PI) initiation, restart 7 days after PI initiation at 20 mg once daily, and increase to 40 mg once daily based on tolerability.
ritonavir|tamoxifen|20|Serious - Use Alternative|ritonavir, tamoxifen. affecting hepatic/intestinal enzyme CYP3A4 metabolism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available. CYP3A4 inhibition decreases metabolism of tamoxifen to N-desmethyl tamoxifen (active metabolite with similar biologic activity).
ritonavir|tamoxifen|11|Significant - Monitor Closely|ritonavir, tamoxifen. affecting hepatic enzyme CYP2D6 metabolism. Significant interaction possible, monitor closely. CYP2D6 inhibition decreases metabolism of tamoxifen to  hydroxytamoxifen, and N-desmethyl tamoxifen to endoxifen (active metabolites with 100-fold greater affinity for estrogen receptor); decreased endoxifen levels may result in poor clinical outcome.
ritonavir|tamsulosin|20|Serious - Use Alternative|ritonavir increases levels of tamsulosin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
ritonavir|tamsulosin|2|Significant - Monitor Closely|ritonavir increases levels of tamsulosin by affecting hepatic enzyme CYP2D6 metabolism. Potential for interaction, monitor.
ritonavir|telaprevir|33|Contraindicated|ritonavir, telaprevir.Either increases levels of the other by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Never use combination.
ritonavir|telaprevir|11|Significant - Monitor Closely|ritonavir, telaprevir. Other (see comment). Significant interaction possible, monitor closely. Comment: Concomitant administration of telaprevir and fosamprenavir/ritonavir resulted in reduced steady-state exposures to telaprevir and amprenavir. It is not recommended to co-administer fosamprenavir/ritonavir and telaprevir.
telithromycin|ritonavir|11|Significant - Monitor Closely|telithromycin will increase the level or effect of ritonavir by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
ritonavir|telithromycin|1|Minor|ritonavir will increase the level or effect of telithromycin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor or non-significant interaction.
ritonavir|temsirolimus|11|Significant - Monitor Closely|ritonavir will increase the level or effect of temsirolimus by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
ritonavir|teniposide|2|Significant - Monitor Closely|ritonavir will increase the level or effect of teniposide by  P-glycoprotein (MDR1) efflux transporter. Potential for interaction, monitor.
ritonavir|terfenadine|33|Contraindicated|ritonavir increases levels of terfenadine by decreasing metabolism. Never use combination. Risk of QT interval prolongation.
ritonavir|terfenadine|21|Serious - Use Alternative|ritonavir will increase the level or effect of terfenadine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available. Never use combination.
ritonavir|theophylline|11|Significant - Monitor Closely|ritonavir will increase the level or effect of theophylline by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
ritonavir|tolterodine|11|Significant - Monitor Closely|ritonavir will increase the level or effect of tolterodine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
ritonavir|tolterodine|1|Minor|ritonavir will increase the level or effect of tolterodine by  affecting hepatic enzyme CYP2D6 metabolism. Minor or non-significant interaction.
ritonavir|tolvaptan|21|Serious - Use Alternative|ritonavir will increase the level or effect of tolvaptan by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available. Never use combination.
ritonavir|tolvaptan|11|Significant - Monitor Closely|ritonavir will increase the level or effect of tolvaptan by  P-glycoprotein (MDR1) efflux transporter. Significant interaction possible, monitor closely.
tolvaptan|ritonavir|11|Significant - Monitor Closely|tolvaptan will increase the level or effect of ritonavir by  P-glycoprotein (MDR1) efflux transporter. Significant interaction possible, monitor closely.
ritonavir|topotecan|22|Serious - Use Alternative|ritonavir will increase the level or effect of topotecan by  P-glycoprotein (MDR1) efflux transporter. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available. Product labeling for PO topotecan recommends avoiding concomitant use of P-gp inhibitors; the interaction with IV topotecan may be less severe but is still likely of clinical significance
ritonavir|tramadol|11|Significant - Monitor Closely|ritonavir will increase the level or effect of tramadol by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely. May require decreased tramadol dose or adjustment of dosing interval; increased risk for serious adverse events including seizures and serotonin syndrome
trazodone|ritonavir|11|Significant - Monitor Closely|trazodone will decrease the level or effect of ritonavir by  P-glycoprotein (MDR1) efflux transporter. Significant interaction possible, monitor closely.
ritonavir|trazodone|3|Significant - Monitor Closely|ritonavir will increase the level or effect of trazodone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Potential for dangerous interaction. Use with caution and monitor closely.
ritonavir|triazolam|21|Serious - Use Alternative|ritonavir increases levels of triazolam by decreasing metabolism. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available. Never use combination.
ritonavir|triazolam|11|Significant - Monitor Closely|ritonavir will increase the level or effect of triazolam by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
ritonavir|vardenafil|11|Significant - Monitor Closely|ritonavir will increase the level or effect of vardenafil by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
vemurafenib|ritonavir|20|Serious - Use Alternative|vemurafenib and ritonavir both increase  QTc interval. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available. Concomitant use of vemurafenib with drugs that  prolong QT interval is not recommended.
ritonavir|vemurafenib|20|Serious - Use Alternative|ritonavir increases levels of vemurafenib by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
ritonavir|vemurafenib|2|Significant - Monitor Closely|ritonavir increases levels of vemurafenib by P-glycoprotein (MDR1) efflux transporter. Potential for interaction, monitor.
vemurafenib|ritonavir|2|Significant - Monitor Closely|vemurafenib increases levels of ritonavir by P-glycoprotein (MDR1) efflux transporter. Potential for interaction, monitor.
ritonavir|venlafaxine|11|Significant - Monitor Closely|ritonavir increases levels of venlafaxine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely. Potential for increased toxicity. .
ritonavir|verapamil|11|Significant - Monitor Closely|ritonavir will increase the level or effect of verapamil by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
verapamil|ritonavir|11|Significant - Monitor Closely|verapamil will increase the level or effect of ritonavir by  P-glycoprotein (MDR1) efflux transporter. Significant interaction possible, monitor closely.
ritonavir|vinblastine|11|Significant - Monitor Closely|ritonavir will increase the level or effect of vinblastine by  P-glycoprotein (MDR1) efflux transporter. Significant interaction possible, monitor closely.
ritonavir|vinblastine|1|Minor|ritonavir will increase the level or effect of vinblastine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor or non-significant interaction.
ritonavir|vincristine|11|Significant - Monitor Closely|ritonavir will increase the level or effect of vincristine by  P-glycoprotein (MDR1) efflux transporter. Significant interaction possible, monitor closely.
ritonavir|vincristine|1|Minor|ritonavir will increase the level or effect of vincristine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor or non-significant interaction.
ritonavir|vinorelbine|1|Minor|ritonavir will increase the level or effect of vinorelbine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor or non-significant interaction.
voriconazole|ritonavir|33|Contraindicated|voriconazole will increase the level or effect of ritonavir by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Never use combination.
ritonavir|voriconazole|33|Contraindicated|ritonavir decreases levels of voriconazole by increasing metabolism. Never use combination. Ritonavir 400 mg BID decreases voriconazole levels; lower ritonavir doses have unknown effect.
ritonavir|zolpidem|1|Minor|ritonavir will increase the level or effect of zolpidem by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor or non-significant interaction.
ritonavir|zonisamide|1|Minor|ritonavir will increase the level or effect of zonisamide by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor or non-significant interaction.
tamoxifen|rivaroxaban|11|Significant - Monitor Closely|tamoxifen increases levels of rivaroxaban by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely. Patients with renal impairment receiving rivaroxaban with drugs that are combined P-gp and weak or moderate CYP3A4 inhibitors may have significant increases in exposure compared with patients with normal renal function and no inhibitor use, since both pathways of rivaroxaban elimination are affected. Since these increases may increase bleeding risk, use rivaroxaban in this situation only if the potential benefit justifies the potential risk.
rivastigmine|trazodone|1|Minor|rivastigmine increases and trazodone decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Minor or non-significant interaction.
rizatriptan|tramadol|2|Significant - Monitor Closely|rizatriptan and tramadol both increase  serotonin levels. Potential for interaction, monitor.
rizatriptan|tranylcypromine|22|Serious - Use Alternative|rizatriptan and tranylcypromine both increase  serotonin levels. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available. Concomitant use or use within 2 wks following the discontinuation of tranylcypromine is contraindicated.
tranylcypromine|rizatriptan|21|Serious - Use Alternative|tranylcypromine increases levels of rizatriptan by decreasing metabolism. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available. Never use combination.
rizatriptan|trazodone|3|Significant - Monitor Closely|rizatriptan and trazodone both increase  serotonin levels. Potential for dangerous interaction. Use with caution and monitor closely.
trazodone|rizatriptan|1|Minor|trazodone, rizatriptan. Mechanism: unknown. Minor or non-significant interaction. Risk of weakness, dyspnea, chest pain.
rizatriptan|trimipramine|3|Significant - Monitor Closely|rizatriptan and trimipramine both increase  serotonin levels. Potential for dangerous interaction. Use with caution and monitor closely.
rizatriptan|venlafaxine|3|Significant - Monitor Closely|rizatriptan and venlafaxine both increase  serotonin levels. Potential for dangerous interaction. Use with caution and monitor closely.
venlafaxine|rizatriptan|1|Minor|venlafaxine, rizatriptan. Mechanism: unknown. Minor or non-significant interaction. Risk of weakness, dyspnea, chest pain.
rizatriptan|zolmitriptan|33|Contraindicated|rizatriptan, zolmitriptan.Either increases toxicity of the other by pharmacodynamic synergism. Never use combination. Additive vasospasm.  Sep. by 24h.
rizatriptan|zolmitriptan|2|Significant - Monitor Closely|rizatriptan and zolmitriptan both increase  serotonin levels. Potential for interaction, monitor.
tobramycin|rocuronium|20|Serious - Use Alternative|tobramycin increases effects of rocuronium by pharmacodynamic synergism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available. Risk of apnea.
zafirlukast|roflumilast|3|Significant - Monitor Closely|zafirlukast increases levels of roflumilast by Other (see comment). Potential for dangerous interaction. Use with caution and monitor closely. Comment: Coadministration with dual inhibitors of CYP3A4 and CYP1A2 may increase systemic exposure and result in increased adverse reactions.
romidepsin|ziprasidone|3|Significant - Monitor Closely|romidepsin and ziprasidone both increase  QTc interval. Potential for dangerous interaction. Use with caution and monitor closely. Avoid using ziprasidone with other QTc prolonging agents.
thiothixene|ropinirole|21|Serious - Use Alternative|thiothixene decreases effects of ropinirole by pharmacodynamic antagonism. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available. Never use combination.
ziprasidone|ropinirole|21|Serious - Use Alternative|ziprasidone decreases effects of ropinirole by pharmacodynamic antagonism. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available. Never use combination.
tipranavir|rosuvastatin|3|Significant - Monitor Closely|tipranavir increases levels of rosuvastatin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Potential for dangerous interaction. Use with caution and monitor closely. This interaction is the net effect of tipranavir being coadministered with ritonavir (boosted therapy); increased risk of myopathy including rhabdomyolysis; do not exceed rosuvastatin dose of 10 mg/day.
valproic acid|rufinamide|11|Significant - Monitor Closely|valproic acid increases levels of rufinamide by decreasing metabolism. Significant interaction possible, monitor closely. Initiate rufinamide at a dose <10 mg/kg/day in pediatric patients or <400 mg/day in adults.
voriconazole|ruxolitinib|20|Serious - Use Alternative|voriconazole will increase the level or effect of ruxolitinib by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available. Reduce ruxolitinib starting dose to 10 mg BID with platelet count 100 X 10^9/L or more and concurrent use of strong CYP3A4 inhibitors; avoid with platelet counts <100 X 10^9/L
timolol|salmeterol|11|Significant - Monitor Closely|timolol decreases effects of salmeterol by pharmacodynamic antagonism. Significant interaction possible, monitor closely.
timolol|salmeterol|2|Significant - Monitor Closely|timolol increases and salmeterol decreases serum potassium. Effect of interaction is not clear, use caution. Potential for interaction, monitor.
salsalate|sulindac|2|Significant - Monitor Closely|salsalate and sulindac both increase  anticoagulation. Potential for interaction, monitor.
salsalate|sulindac|2|Significant - Monitor Closely|salsalate and sulindac both increase  serum potassium. Potential for interaction, monitor.
salsalate|sulindac|1|Minor|salsalate will increase the level or effect of sulindac by  acidic (anionic) drug competition for renal tubular clearance. Minor or non-significant interaction.
salsalate|tolmetin|2|Significant - Monitor Closely|salsalate and tolmetin both increase  anticoagulation. Potential for interaction, monitor.
salsalate|tolmetin|2|Significant - Monitor Closely|salsalate and tolmetin both increase  serum potassium. Potential for interaction, monitor.
salsalate|tolmetin|1|Minor|salsalate will increase the level or effect of tolmetin by  acidic (anionic) drug competition for renal tubular clearance. Minor or non-significant interaction.
salsalate|trandolapril|1|Minor|salsalate decreases effects of trandolapril by pharmacodynamic antagonism. Minor or non-significant interaction. NSAIDs decrease prostaglandin synthesis.
salsalate|triamcinolone|11|Significant - Monitor Closely|salsalate, triamcinolone.Either increases toxicity of the other by pharmacodynamic synergism. Significant interaction possible, monitor closely. Increased risk of GI ulceration.
triamcinolone|salsalate|1|Minor|triamcinolone decreases levels of salsalate by increasing renal clearance. Minor or non-significant interaction.
tacrolimus|saquinavir|11|Significant - Monitor Closely|tacrolimus will increase the level or effect of saquinavir by  P-glycoprotein (MDR1) efflux transporter. Significant interaction possible, monitor closely.
saquinavir|tadalafil|11|Significant - Monitor Closely|saquinavir increases levels of tadalafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely. Potential for increased toxicity. .
saquinavir|tamoxifen|20|Serious - Use Alternative|saquinavir, tamoxifen. affecting hepatic/intestinal enzyme CYP3A4 metabolism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available. CYP3A4 inhibition decreases metabolism of tamoxifen to N-desmethyl tamoxifen (active metabolite with similar biologic activity).
saquinavir|tamoxifen|11|Significant - Monitor Closely|saquinavir, tamoxifen.Either increases effects of the other by QTc interval. Significant interaction possible, monitor closely.
saquinavir|tamsulosin|20|Serious - Use Alternative|saquinavir increases levels of tamsulosin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
saquinavir|telavancin|22|Serious - Use Alternative|saquinavir, telavancin.Either increases toxicity of the other by QTc interval. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available.
telithromycin|saquinavir|11|Significant - Monitor Closely|telithromycin will increase the level or effect of saquinavir by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
saquinavir|teniposide|2|Significant - Monitor Closely|saquinavir will increase the level or effect of teniposide by  P-glycoprotein (MDR1) efflux transporter. Potential for interaction, monitor.
tipranavir|saquinavir|20|Serious - Use Alternative|tipranavir decreases levels of saquinavir by unspecified interaction mechanism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
saquinavir|tipranavir|2|Significant - Monitor Closely|saquinavir and tipranavir both increase  risk of immune reconstitution syndrome. Potential for interaction, monitor.
tolvaptan|saquinavir|11|Significant - Monitor Closely|tolvaptan will increase the level or effect of saquinavir by  P-glycoprotein (MDR1) efflux transporter. Significant interaction possible, monitor closely.
saquinavir|topotecan|22|Serious - Use Alternative|saquinavir will increase the level or effect of topotecan by  P-glycoprotein (MDR1) efflux transporter. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available. Product labeling for PO topotecan recommends avoiding concomitant use of P-gp inhibitors; the interaction with IV topotecan may be less severe but is still likely of clinical significance
trazodone|saquinavir|33|Contraindicated|trazodone will decrease the level or effect of saquinavir by  P-glycoprotein (MDR1) efflux transporter. Never use combination.
saquinavir|triazolam|21|Serious - Use Alternative|saquinavir increases levels of triazolam by decreasing metabolism. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available. Never use combination.
saquinavir|vardenafil|22|Serious - Use Alternative|saquinavir increases levels of vardenafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available. Potential for increased toxicity. .
vemurafenib|saquinavir|20|Serious - Use Alternative|vemurafenib and saquinavir both increase  QTc interval. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available. Concomitant use of vemurafenib with drugs that  prolong QT interval is not recommended. Saquinavir may also increase levels of vemurafenib.
saquinavir|venlafaxine|22|Serious - Use Alternative|saquinavir, venlafaxine.Either increases toxicity of the other by affecting hepatic/intestinal enzyme CYP3A4 metabolism. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available. May increase risk for QT prolongation.
verapamil|saquinavir|11|Significant - Monitor Closely|verapamil will increase the level or effect of saquinavir by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
verapamil|saquinavir|11|Significant - Monitor Closely|verapamil will increase the level or effect of saquinavir by  P-glycoprotein (MDR1) efflux transporter. Significant interaction possible, monitor closely.
voriconazole|saquinavir|20|Serious - Use Alternative|voriconazole will increase the level or effect of saquinavir by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
voriconazole|saxagliptin|3|Significant - Monitor Closely|voriconazole will increase the level or effect of saxagliptin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Potential for dangerous interaction. Use with caution and monitor closely. Limit saxagliptin dose to 2.5 mg/day when coadministered with strong CYP3A4 inhibitors
tacrine|scopolamine|2|Significant - Monitor Closely|tacrine increases and scopolamine decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Potential for interaction, monitor.
tacrine|scopolamine|1|Minor|tacrine decreases effects of scopolamine by pharmacodynamic antagonism. Minor or non-significant interaction.
secobarbital|theophylline|11|Significant - Monitor Closely|secobarbital will decrease the level or effect of theophylline by  affecting hepatic enzyme CYP1A2 metabolism. Significant interaction possible, monitor closely.
secobarbital|theophylline|11|Significant - Monitor Closely|secobarbital will decrease the level or effect of theophylline by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
secobarbital|triamcinolone|11|Significant - Monitor Closely|secobarbital will decrease the level or effect of triamcinolone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
secobarbital|trimipramine|2|Significant - Monitor Closely|secobarbital and trimipramine both increase  sedation. Potential for interaction, monitor.
secobarbital|trimipramine|1|Minor|secobarbital, trimipramine. Other (see comment). Minor or non-significant interaction. Comment: Barbiturates may increase adverse effects, including respiratory depression, produced by toxic doses of TCAs. With therapeutic doses of TCAs, barbiturates increase metabolism and decrease blood concentrations of TCAs.
triprolidine|secobarbital|2|Significant - Monitor Closely|triprolidine and secobarbital both increase  sedation. Potential for interaction, monitor.
secobarbital|verapamil|11|Significant - Monitor Closely|secobarbital will decrease the level or effect of verapamil by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
secobarbital|warfarin|20|Serious - Use Alternative|secobarbital decreases effects of warfarin by increasing metabolism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
secobarbital|warfarin|11|Significant - Monitor Closely|secobarbital will decrease the level or effect of warfarin by  affecting hepatic enzyme CYP1A2 metabolism. Significant interaction possible, monitor closely.
secobarbital|warfarin|11|Significant - Monitor Closely|secobarbital will decrease the level or effect of warfarin by  affecting hepatic enzyme CYP2C9/10 metabolism. Significant interaction possible, monitor closely.
secobarbital|warfarin|11|Significant - Monitor Closely|secobarbital will decrease the level or effect of warfarin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
secobarbital|warfarin|1|Minor|secobarbital will decrease the level or effect of warfarin by  affecting hepatic enzyme CYP2C19 metabolism. Minor or non-significant interaction.
selegiline|tapentadol|33|Contraindicated|selegiline increases toxicity of tapentadol by unknown mechanism. Never use combination. At least 14 days should elapse between the discontinuation of a MAO-inhibiting drug and the initiation of tapentadol.
selegiline|tapentadol|3|Significant - Monitor Closely|selegiline and tapentadol both increase  serotonin levels. Potential for dangerous interaction. Use with caution and monitor closely.
tetrabenazine|selegiline|33|Contraindicated|tetrabenazine, selegiline.Either increases effects of the other by pharmacodynamic synergism. Never use combination. Risk of acute hypertensive episode; separate by 14 days. Mechanism: MAOI causes accumulation of norepinephrine in neuron and tetrabenazine stimulates norepinephrine release.
selegiline|tramadol|33|Contraindicated|selegiline and tramadol both increase  serotonin levels. Never use combination. At least 14 days should elapse between discontinuation of selegiline and initiation of analgesic.
selegiline|tranylcypromine|33|Contraindicated|selegiline and tranylcypromine both increase  serotonin levels. Never use combination.
selegiline|trazodone|20|Serious - Use Alternative|selegiline and trazodone both increase  serotonin levels. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
selegiline|trimipramine|33|Contraindicated|selegiline and trimipramine both increase  serotonin levels. Never use combination. Concurrent use or use within 14 days of selegiline treatment is contraindicated
selegiline|venlafaxine|33|Contraindicated|selegiline and venlafaxine both increase  serotonin levels. Never use combination. At least 14 days should elapse between discontinuation of selegiline and initiation of treatment with a serotonergic drug.
selegiline|vilazodone|33|Contraindicated|selegiline, vilazodone.Either increases toxicity of the other by serotonin levels. Never use combination. Coadministration with MAO inhibitors are contraindicated. Do not prescribe vilazodone within 14 days of discontinuing or starting an MAO inhibitor.
zolmitriptan|selegiline|3|Significant - Monitor Closely|zolmitriptan and selegiline both increase  serotonin levels. Potential for dangerous interaction. Use with caution and monitor closely.
thioridazine|sertindole|22|Serious - Use Alternative|thioridazine and sertindole both increase  QTc interval. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available.
thioridazine|sertindole|11|Significant - Monitor Closely|thioridazine will increase the level or effect of sertindole by  affecting hepatic enzyme CYP2D6 metabolism. Significant interaction possible, monitor closely.
sertindole|thioridazine|2|Significant - Monitor Closely|sertindole and thioridazine both increase  antidopaminergic effects, including extrapyramidal symptoms and neuroleptic malignant syndrome. Potential for interaction, monitor.
sertindole|thioridazine|2|Significant - Monitor Closely|sertindole and thioridazine both increase  sedation. Potential for interaction, monitor.
sertraline|tamoxifen|11|Significant - Monitor Closely|sertraline decreases effects of tamoxifen by decreasing metabolism. Significant interaction possible, monitor closely. Inhibition of CYP2D6 metabolism to tamoxifen's active metabolite, endoxifen.
sertraline|tamsulosin|2|Significant - Monitor Closely|sertraline increases levels of tamsulosin by affecting hepatic enzyme CYP2D6 metabolism. Potential for interaction, monitor.
sertraline|tolmetin|11|Significant - Monitor Closely|sertraline, tolmetin.Either increases toxicity of the other by pharmacodynamic synergism. Significant interaction possible, monitor closely. Increased risk of upper GI bleeding. SSRIs inhib. serotonin uptake by platelets.
sertraline|tolterodine|1|Minor|sertraline will increase the level or effect of tolterodine by  affecting hepatic enzyme CYP2D6 metabolism. Minor or non-significant interaction.
sertraline|tramadol|3|Significant - Monitor Closely|sertraline and tramadol both increase  serotonin levels. Potential for dangerous interaction. Use with caution and monitor closely.
sertraline|tramadol|2|Significant - Monitor Closely|sertraline decreases effects of tramadol by affecting hepatic enzyme CYP2D6 metabolism. Potential for interaction, monitor. Decreased conversion of tramadol to active metabolite.
sertraline|tramadol|2|Significant - Monitor Closely|sertraline decreases effects of tramadol by decreasing metabolism. Potential for interaction, monitor. Decreased conversion of tramadol to active metabolite.
tranylcypromine|sertraline|33|Contraindicated|tranylcypromine and sertraline both increase  serotonin levels. Never use combination.
sertraline|trazodone|22|Serious - Use Alternative|sertraline and trazodone both increase  serotonin levels. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available.
sertraline|trimipramine|22|Serious - Use Alternative|sertraline and trimipramine both increase  serotonin levels. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available.
sertraline|venlafaxine|22|Serious - Use Alternative|sertraline and venlafaxine both increase  serotonin levels. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available.
zolmitriptan|sertraline|3|Significant - Monitor Closely|zolmitriptan and sertraline both increase  serotonin levels. Potential for dangerous interaction. Use with caution and monitor closely.
sertraline|zolmitriptan|1|Minor|sertraline, zolmitriptan. Mechanism: unknown. Minor or non-significant interaction. Risk of weakness, dyspnea, chest pain.
telithromycin|sildenafil|11|Significant - Monitor Closely|telithromycin will increase the level or effect of sildenafil by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
sildenafil|terazosin|20|Serious - Use Alternative|sildenafil increases effects of terazosin by pharmacodynamic synergism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available. Risk of hypotension; separate sildenafil >25mg from alpha blocker by 4hr.
tipranavir|sildenafil|11|Significant - Monitor Closely|tipranavir increases levels of sildenafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely. Potential for increased toxicity. Increased risk of priapism, hypotension, and other adverse effects.
voriconazole|sildenafil|11|Significant - Monitor Closely|voriconazole will increase the level or effect of sildenafil by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
tacrolimus|silodosin|11|Significant - Monitor Closely|tacrolimus will increase the level or effect of silodosin by  P-glycoprotein (MDR1) efflux transporter. Significant interaction possible, monitor closely.
silodosin|tamsulosin|20|Serious - Use Alternative|silodosin, tamsulosin.Either increases effects of the other by additive vasodilation. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available. Risk of hypotension.
silodosin|terazosin|2|Significant - Monitor Closely|silodosin and terazosin both increase  anti-hypertensive channel blocking. Potential for interaction, monitor.
vardenafil|silodosin|21|Serious - Use Alternative|vardenafil increases effects of silodosin by pharmacodynamic synergism. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available. Never use combination. Risk of hypotension.
verapamil|silodosin|21|Serious - Use Alternative|verapamil will increase the level or effect of silodosin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available. Never use combination.
verapamil|silodosin|11|Significant - Monitor Closely|verapamil will increase the level or effect of silodosin by  P-glycoprotein (MDR1) efflux transporter. Significant interaction possible, monitor closely.
silodosin|verapamil|2|Significant - Monitor Closely|silodosin and verapamil both increase  anti-hypertensive channel blocking. Potential for interaction, monitor.
voriconazole|silodosin|21|Serious - Use Alternative|voriconazole will increase the level or effect of silodosin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available. Never use combination.
telaprevir|simvastatin|33|Contraindicated|telaprevir increases levels of simvastatin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Never use combination. Contraindicated. Potential for myopathy including rhabdomyolysis.
telithromycin|simvastatin|33|Contraindicated|telithromycin will increase the level or effect of simvastatin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Never use combination. Contraindicated. Increased risk for rhabdomyolysis with drugs that increase simstatin systemic exposure
simvastatin|telithromycin|33|Contraindicated|simvastatin will increase the level or effect of telithromycin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Never use combination. Contraindicated. Increased risk for rhabdomyolysis with drugs that increase simvastatin systemic exposure
ticagrelor|simvastatin|11|Significant - Monitor Closely|ticagrelor increases levels of simvastatin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely. Avoid simvastatin doses greater than 40 mg.
tipranavir|simvastatin|33|Contraindicated|tipranavir increases levels of simvastatin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Never use combination. This interaction is the net effect of tipranavir being coadministered with ritonavir (boosted therapy); increased risk of myopathy including rhabdomyolysis.
verapamil|simvastatin|20|Serious - Use Alternative|verapamil will increase the level or effect of simvastatin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available. Do not exceed simvastatin 10 mg daily when given concurrently. Potential for increased risk of myopathy/rhabdomyolysis.
voriconazole|simvastatin|20|Serious - Use Alternative|voriconazole will increase the level or effect of simvastatin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available. Simvastatin prescribing information recommends a reduced simvastatin dose be considered when coadministered with voriconazole to reduce the risk of myopathy, including rhabdomyolysis
sirolimus|tacrolimus|22|Serious - Use Alternative|sirolimus and tacrolimus both increase  immunosuppressive effects; risk of infection. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available.
sirolimus|tacrolimus|11|Significant - Monitor Closely|sirolimus will increase the level or effect of tacrolimus by  P-glycoprotein (MDR1) efflux transporter. Significant interaction possible, monitor closely.
telithromycin|sirolimus|21|Serious - Use Alternative|telithromycin will increase the level or effect of sirolimus by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available. Never use combination.
tipranavir|sirolimus|11|Significant - Monitor Closely|tipranavir, sirolimus. Other (see comment). Significant interaction possible, monitor closely. Comment: Sirolimus levels may incr or decr, due to contradictory effects of tipranavir on hepatic CYP3A4 and P glycoprotein.
trandolapril|sirolimus|2|Significant - Monitor Closely|trandolapril, sirolimus.Either increases toxicity of the other by Other (see comment). Potential for interaction, monitor. Comment: Coadministration increases risk of angioedema.
voriconazole|sirolimus|33|Contraindicated|voriconazole will increase the level or effect of sirolimus by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Never use combination.
voriconazole|sirolimus|33|Contraindicated|voriconazole increases levels of sirolimus by decreasing metabolism. Never use combination.
sitaxentan|tamoxifen|11|Significant - Monitor Closely|sitaxentan, tamoxifen. affecting hepatic enzyme CYP2C9/10 metabolism. Significant interaction possible, monitor closely. CYP2C9/10 inhibition decreases tamoxifen metabolism to active metabolites.
sitaxentan|tamoxifen|1|Minor|sitaxentan will increase the level or effect of tamoxifen by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor or non-significant interaction.
sitaxentan|tolbutamide|1|Minor|sitaxentan will increase the level or effect of tolbutamide by  affecting hepatic enzyme CYP2C9/10 metabolism. Minor or non-significant interaction.
sitaxentan|tolterodine|11|Significant - Monitor Closely|sitaxentan will increase the level or effect of tolterodine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
sitaxentan|trazodone|11|Significant - Monitor Closely|sitaxentan will increase the level or effect of trazodone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
sitaxentan|voriconazole|1|Minor|sitaxentan will increase the level or effect of voriconazole by  affecting hepatic enzyme CYP2C9/10 metabolism. Minor or non-significant interaction.
sitaxentan|warfarin|11|Significant - Monitor Closely|sitaxentan will increase the level or effect of warfarin by  affecting hepatic enzyme CYP2C9/10 metabolism. Significant interaction possible, monitor closely.
sitaxentan|warfarin|11|Significant - Monitor Closely|sitaxentan will increase the level or effect of warfarin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
sodium bicarbonate|trandolapril|11|Significant - Monitor Closely|sodium bicarbonate decreases effects of trandolapril by unspecified interaction mechanism. Significant interaction possible, monitor closely.
tacrine|solifenacin|2|Significant - Monitor Closely|tacrine increases and solifenacin decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Potential for interaction, monitor.
tacrine|solifenacin|1|Minor|tacrine decreases effects of solifenacin by pharmacodynamic antagonism. Minor or non-significant interaction.
telithromycin|solifenacin|11|Significant - Monitor Closely|telithromycin will increase the level or effect of solifenacin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
voriconazole|solifenacin|11|Significant - Monitor Closely|voriconazole will increase the level or effect of solifenacin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
sotalol|telavancin|22|Serious - Use Alternative|sotalol and telavancin both increase  QTc interval. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available.
sotalol|telithromycin|22|Serious - Use Alternative|sotalol and telithromycin both increase  QTc interval. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available.
telithromycin|sotalol|1|Minor|telithromycin decreases levels of sotalol by unspecified interaction mechanism. Minor or non-significant interaction.
terazosin|sotalol|3|Significant - Monitor Closely|terazosin and sotalol both increase  anti-hypertensive channel blocking. Potential for dangerous interaction. Use with caution and monitor closely. Additive hypotensive effects may occur when terazosin is used in combination with sotalol.
sotalol|terbutaline|11|Significant - Monitor Closely|sotalol decreases effects of terbutaline by pharmacodynamic antagonism. Significant interaction possible, monitor closely.
sotalol|terbutaline|2|Significant - Monitor Closely|sotalol increases and terbutaline decreases serum potassium. Effect of interaction is not clear, use caution. Potential for interaction, monitor.
sotalol|terfenadine|33|Contraindicated|sotalol and terfenadine both increase  QTc interval. Never use combination.
sotalol|theophylline|11|Significant - Monitor Closely|sotalol, theophylline. Other (see comment). Significant interaction possible, monitor closely. Comment: Beta blockers (esp. non selective) antagonize theophylline effects, while at the same time increasing theophylline levels and toxicity (mechanism: decreased theophylline metabolism). Smoking increases risk of interaction.
thioridazine|sotalol|33|Contraindicated|thioridazine and sotalol both increase  QTc interval. Never use combination.
sotalol|toremifene|20|Serious - Use Alternative|sotalol and toremifene both increase  QTc interval. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available. Concurrent use of toremifene with agents causing  QT prolongation should be avoided. If concomitant use is required it's recommended that toremifene be interrupted. If interruption not possible, patients requiring therapy with a drug that prolongs QT should be closely monitored. ECGs should be obtained for high risk patients.
treprostinil|sotalol|1|Minor|treprostinil increases effects of sotalol by pharmacodynamic synergism. Minor or non-significant interaction.
trimipramine|sotalol|33|Contraindicated|trimipramine and sotalol both increase  QTc interval. Never use combination.
sotalol|voriconazole|22|Serious - Use Alternative|sotalol and voriconazole both increase  QTc interval. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available.
sotalol|ziprasidone|33|Contraindicated|sotalol and ziprasidone both increase  QTc interval. Never use combination.
telmisartan|spironolactone|3|Significant - Monitor Closely|telmisartan and spironolactone both increase  serum potassium. Potential for dangerous interaction. Use with caution and monitor closely.
spironolactone|tobramycin|11|Significant - Monitor Closely|spironolactone will increase the level or effect of tobramycin by  P-glycoprotein (MDR1) efflux transporter. Significant interaction possible, monitor closely.
trandolapril|spironolactone|11|Significant - Monitor Closely|trandolapril, spironolactone. Mechanism: pharmacodynamic synergism. Significant interaction possible, monitor closely. Risk of hyperkalemia.
treprostinil|spironolactone|1|Minor|treprostinil increases effects of spironolactone by pharmacodynamic synergism. Minor or non-significant interaction.
zidovudine|stavudine|21|Serious - Use Alternative|zidovudine decreases effects of stavudine by Other (see comment). High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available. Never use combination. Comment: Mechanism: Competition for thymidine kinase for conversion to active form.
stavudine|zidovudine|2|Significant - Monitor Closely|stavudine and zidovudine both increase  risk of immune reconstitution syndrome. Potential for interaction, monitor.
tacrolimus|streptomycin|11|Significant - Monitor Closely|tacrolimus will increase the level or effect of streptomycin by  P-glycoprotein (MDR1) efflux transporter. Significant interaction possible, monitor closely.
streptomycin|tacrolimus|2|Significant - Monitor Closely|streptomycin and tacrolimus both increase  nephrotoxicity and/or ototoxicity. Potential for interaction, monitor.
ticarcillin|streptomycin|1|Minor|ticarcillin decreases effects of streptomycin by altering metabolism. Minor or non-significant interaction. Increased risk in renal impairment.
tacrine|succinylcholine|11|Significant - Monitor Closely|tacrine increases effects of succinylcholine by pharmacodynamic synergism. Significant interaction possible, monitor closely.
succinylcholine|tacrine|2|Significant - Monitor Closely|succinylcholine and tacrine both increase  cholinergic effects/transmission. Potential for interaction, monitor.
tobramycin|succinylcholine|20|Serious - Use Alternative|tobramycin increases effects of succinylcholine by pharmacodynamic synergism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available. Risk of apnea.
sucralfate|warfarin|1|Minor|sucralfate decreases levels of warfarin by inhibition of GI absorption. Applies only to oral form of both agents. Minor or non-significant interaction.
telithromycin|sufentanil|1|Minor|telithromycin will increase the level or effect of sufentanil by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor or non-significant interaction.
tranylcypromine|sufentanil|20|Serious - Use Alternative|tranylcypromine increases toxicity of sufentanil by unknown mechanism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available. Risk of hypotension, hyperpyrexia, somnolence, or death; separate by 14 d.
triprolidine|sufentanil|2|Significant - Monitor Closely|triprolidine and sufentanil both increase  sedation. Potential for interaction, monitor.
voriconazole|sufentanil|1|Minor|voriconazole will increase the level or effect of sufentanil by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor or non-significant interaction.
sulfadiazine|tolbutamide|11|Significant - Monitor Closely|sulfadiazine increases levels of tolbutamide by plasma protein binding competition. Significant interaction possible, monitor closely.
sulfadiazine|warfarin|20|Serious - Use Alternative|sulfadiazine increases effects of warfarin by decreasing metabolism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
sulfadiazine|warfarin|20|Serious - Use Alternative|sulfadiazine increases effects of warfarin by plasma protein binding competition. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
sulfamethoxazole|tolbutamide|11|Significant - Monitor Closely|sulfamethoxazole increases levels of tolbutamide by plasma protein binding competition. Significant interaction possible, monitor closely.
sulfamethoxazole|tolbutamide|1|Minor|sulfamethoxazole will increase the level or effect of tolbutamide by  affecting hepatic enzyme CYP2C9/10 metabolism. Minor or non-significant interaction.
sulfamethoxazole|warfarin|20|Serious - Use Alternative|sulfamethoxazole increases effects of warfarin by decreasing metabolism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
sulfamethoxazole|warfarin|20|Serious - Use Alternative|sulfamethoxazole increases effects of warfarin by plasma protein binding competition. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
sulfamethoxazole|warfarin|11|Significant - Monitor Closely|sulfamethoxazole will increase the level or effect of warfarin by  affecting hepatic enzyme CYP2C9/10 metabolism. Significant interaction possible, monitor closely.
sulfisoxazole|tolbutamide|11|Significant - Monitor Closely|sulfisoxazole increases levels of tolbutamide by plasma protein binding competition. Significant interaction possible, monitor closely.
sulfisoxazole|warfarin|20|Serious - Use Alternative|sulfisoxazole increases effects of warfarin by decreasing metabolism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
sulfisoxazole|warfarin|20|Serious - Use Alternative|sulfisoxazole increases effects of warfarin by plasma protein binding competition. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
telmisartan|sulindac|11|Significant - Monitor Closely|telmisartan, sulindac.Either increases toxicity of the other by Other (see comment). Significant interaction possible, monitor closely. Comment: May result in renal function deterioration, particularly in elderly or volume depleted individuals.
sulindac|telmisartan|3|Significant - Monitor Closely|sulindac decreases effects of telmisartan by pharmacodynamic antagonism. Potential for dangerous interaction. Use with caution and monitor closely.  NSAIDs decrease synthesis of vasodilating renal prostaglandins, and thus affect fluid homeostasis and may diminish antihypertensive effect.
telmisartan|sulindac|2|Significant - Monitor Closely|telmisartan and sulindac both increase  serum potassium. Potential for interaction, monitor.
sulindac|timolol|11|Significant - Monitor Closely|sulindac decreases effects of timolol by pharmacodynamic antagonism. Significant interaction possible, monitor closely. Long term (>1 wk) NSAID use.  NSAIDs decrease prostaglandin synthesis.
timolol|sulindac|2|Significant - Monitor Closely|timolol and sulindac both increase  serum potassium. Potential for interaction, monitor.
trandolapril|sulindac|11|Significant - Monitor Closely|trandolapril, sulindac.Either increases toxicity of the other by Other (see comment). Significant interaction possible, monitor closely. Comment: May result in renal function deterioration, particularly in elderly or volume depleted individuals.
sulindac|trandolapril|3|Significant - Monitor Closely|sulindac decreases effects of trandolapril by pharmacodynamic antagonism. Potential for dangerous interaction. Use with caution and monitor closely. NSAIDs decrease synthesis of vasodilating renal prostaglandins, and thus affect fluid homeostasis and may diminish antihypertenisve effect.
warfarin|sulindac|3|Significant - Monitor Closely|warfarin and sulindac both increase  anticoagulation. Potential for dangerous interaction. Use with caution and monitor closely.
sumatriptan|tramadol|2|Significant - Monitor Closely|sumatriptan and tramadol both increase  serotonin levels. Potential for interaction, monitor.
sumatriptan|tranylcypromine|22|Serious - Use Alternative|sumatriptan and tranylcypromine both increase  serotonin levels. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available. Concomitant use or use within 2 wks following the discontinuation of tranylcypromine is contraindicated.
tranylcypromine|sumatriptan|21|Serious - Use Alternative|tranylcypromine increases levels of sumatriptan by decreasing metabolism. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available. Never use combination.
sumatriptan|trazodone|3|Significant - Monitor Closely|sumatriptan and trazodone both increase  serotonin levels. Potential for dangerous interaction. Use with caution and monitor closely.
trazodone|sumatriptan|1|Minor|trazodone, sumatriptan. Mechanism: unknown. Minor or non-significant interaction. Risk of weakness, dyspnea, chest pain.
sumatriptan|trimipramine|3|Significant - Monitor Closely|sumatriptan and trimipramine both increase  serotonin levels. Potential for dangerous interaction. Use with caution and monitor closely.
sumatriptan|venlafaxine|3|Significant - Monitor Closely|sumatriptan and venlafaxine both increase  serotonin levels. Potential for dangerous interaction. Use with caution and monitor closely.
venlafaxine|sumatriptan|1|Minor|venlafaxine, sumatriptan. Mechanism: unknown. Minor or non-significant interaction. Risk of weakness, dyspnea, chest pain.
sumatriptan|vilazodone|22|Serious - Use Alternative|sumatriptan, vilazodone.Either increases toxicity of the other by serotonin levels. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available. Concomitant therapy should be discontinued immediately if signs or symptoms of serotonin syndrome emerge and supportive symptomatic treatment should be initiated.  .
sumatriptan|zolmitriptan|33|Contraindicated|sumatriptan, zolmitriptan.Either increases toxicity of the other by pharmacodynamic synergism. Never use combination. Additive vasospasm.  Sep. by 24h.
sumatriptan|zolmitriptan|2|Significant - Monitor Closely|sumatriptan and zolmitriptan both increase  serotonin levels. Potential for interaction, monitor.
telithromycin|sunitinib|11|Significant - Monitor Closely|telithromycin will increase the level or effect of sunitinib by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
temsirolimus|sunitinib|20|Serious - Use Alternative|temsirolimus, sunitinib.Either increases toxicity of the other by Mechanism: unspecified interaction mechanism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available. Combo may cause severe rash, gout, cellulitis.
sunitinib|toremifene|20|Serious - Use Alternative|sunitinib and toremifene both increase  QTc interval. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available. Concurrent use of toremifene with agents causing  QT prolongation should be avoided. If concomitant use is required it's recommended that toremifene be interrupted. If interruption not possible, patients requiring therapy with a drug that prolongs QT should be closely monitored. ECGs should be obtained for high risk patients.
voriconazole|sunitinib|11|Significant - Monitor Closely|voriconazole will increase the level or effect of sunitinib by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
tacrine|theophylline|20|Serious - Use Alternative|tacrine increases levels of theophylline by decreasing metabolism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
tacrine|theophylline|11|Significant - Monitor Closely|tacrine will increase the level or effect of theophylline by  affecting hepatic enzyme CYP1A2 metabolism. Significant interaction possible, monitor closely.
tacrine|tiotropium|2|Significant - Monitor Closely|tacrine increases and tiotropium decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Potential for interaction, monitor.
tacrine|tiotropium|1|Minor|tacrine decreases effects of tiotropium by pharmacodynamic antagonism. Minor or non-significant interaction.
tacrine|tolterodine|2|Significant - Monitor Closely|tacrine increases and tolterodine decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Potential for interaction, monitor.
tacrine|tolterodine|1|Minor|tacrine decreases effects of tolterodine by pharmacodynamic antagonism. Minor or non-significant interaction.
tacrine|trihexyphenidyl|2|Significant - Monitor Closely|tacrine decreases effects of trihexyphenidyl by pharmacodynamic antagonism. Potential for interaction, monitor.
tacrine|trimipramine|2|Significant - Monitor Closely|tacrine increases and trimipramine decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Potential for interaction, monitor.
telaprevir|tacrolimus|11|Significant - Monitor Closely|telaprevir increases levels of tacrolimus by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely. Significant dose reductions and prolongation of the dosing interval of the immunosuppressant to achieve the desired blood levels should be anticipated. Close monitoring of the immunosuppressant blood levels, and frequent assessments of renal function and immunosuppressant-related side effects are recommended when co-administered with telaprevir. Tacrolimus may prolong the QT interval. The use of telaprevir in organ transplant patients has not been studied.
telithromycin|tacrolimus|11|Significant - Monitor Closely|telithromycin will increase the level or effect of tacrolimus by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
tacrolimus|temsirolimus|22|Serious - Use Alternative|tacrolimus and temsirolimus both increase  immunosuppressive effects; risk of infection. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available.
tipranavir|tacrolimus|11|Significant - Monitor Closely|tipranavir, tacrolimus. Other (see comment). Significant interaction possible, monitor closely. Comment: Tacrolimus levels may incr or decr, due to contradictory effects of tipranavir on hepatic CYP3A4 and P glycoprotein.
tacrolimus|tobramycin|11|Significant - Monitor Closely|tacrolimus will increase the level or effect of tobramycin by  P-glycoprotein (MDR1) efflux transporter. Significant interaction possible, monitor closely.
tacrolimus|tobramycin|3|Significant - Monitor Closely|tacrolimus and tobramycin both increase  nephrotoxicity and/or ototoxicity. Potential for dangerous interaction. Use with caution and monitor closely.
tacrolimus|tofacitinib|20|Serious - Use Alternative|tacrolimus, tofacitinib.Either increases toxicity of the other by immunosuppressive effects; risk of infection. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
tacrolimus|topotecan|22|Serious - Use Alternative|tacrolimus will increase the level or effect of topotecan by  P-glycoprotein (MDR1) efflux transporter. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available. Product labeling for PO topotecan recommends avoiding concomitant use of P-gp inhibitors; the interaction with IV topotecan may be less severe but is still likely of clinical significance
tacrolimus|toremifene|20|Serious - Use Alternative|tacrolimus and toremifene both increase  QTc interval. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available. Concurrent use of toremifene with agents causing  QT prolongation should be avoided. If concomitant use is required it's recommended that toremifene be interrupted. If interruption not possible, patients requiring therapy with a drug that prolongs QT should be closely monitored. ECGs should be obtained for high risk patients.
troleandomycin|tacrolimus|11|Significant - Monitor Closely|troleandomycin will increase the level or effect of tacrolimus by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
verapamil|tacrolimus|11|Significant - Monitor Closely|verapamil will increase the level or effect of tacrolimus by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
verapamil|tacrolimus|11|Significant - Monitor Closely|verapamil will increase the level or effect of tacrolimus by  P-glycoprotein (MDR1) efflux transporter. Significant interaction possible, monitor closely.
voriconazole|tacrolimus|11|Significant - Monitor Closely|voriconazole will increase the level or effect of tacrolimus by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
tadalafil|tamsulosin|11|Significant - Monitor Closely|tadalafil, tamsulosin.Either increases effects of the other by additive vasodilation. Significant interaction possible, monitor closely. Risk of hypotension.
telaprevir|tadalafil|33|Contraindicated|telaprevir increases levels of tadalafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Never use combination. Contraindicated with chronic use for PAH. Telaprevir can be used with tadalafil for ED; dose should be limited to 10 mg every 72 hr with increased monitoring for adverse reactions.
telithromycin|tadalafil|11|Significant - Monitor Closely|telithromycin will increase the level or effect of tadalafil by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely. For ED limit tadalafil to max of 2.5 mg/day (for daily use) or 10 mg dose every 72 hr (for use as needed). Avoid concurrent use of tadalafil for pulmonary HTN in patients taking strong CYP3A4 inhibitors.
tadalafil|terazosin|11|Significant - Monitor Closely|tadalafil increases effects of terazosin by pharmacodynamic synergism. Significant interaction possible, monitor closely. Risk of hypotension.
tipranavir|tadalafil|11|Significant - Monitor Closely|tipranavir will increase the level or effect of tadalafil by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely. For ED limit tadalafil to max of 2.5 mg/day (for daily use) or 10 mg dose every 72 hr (for use as needed). Avoid concurrent use of tadalafil for pulmonary HTN in patients taking strong CYP3A4 inhibitors.
voriconazole|tadalafil|11|Significant - Monitor Closely|voriconazole will increase the level or effect of tadalafil by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
telithromycin|tamoxifen|11|Significant - Monitor Closely|telithromycin, tamoxifen. affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely. CYP3A4 inhibition decreases metabolism of tamoxifen to N-desmethyl tamoxifen (active metabolite with similar biologic activity).
tamoxifen|topotecan|22|Serious - Use Alternative|tamoxifen will increase the level or effect of topotecan by  P-glycoprotein (MDR1) efflux transporter. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available. Product labeling for PO topotecan recommends avoiding concomitant use of P-gp inhibitors; the interaction with IV topotecan may be less severe but is still likely of clinical significance
voriconazole|tamoxifen|11|Significant - Monitor Closely|voriconazole, tamoxifen. affecting hepatic enzyme CYP2C9/10 metabolism. Significant interaction possible, monitor closely. CYP2C9/10 inhibition decreases tamoxifen metabolism to active metabolites.
voriconazole|tamoxifen|11|Significant - Monitor Closely|voriconazole, tamoxifen. affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely. CYP3A4 inhibition decreases metabolism of tamoxifen to N-desmethyl tamoxifen (active metabolite with similar biologic activity).
tamoxifen|warfarin|20|Serious - Use Alternative|tamoxifen increases effects of warfarin by unknown mechanism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
telithromycin|tamsulosin|20|Serious - Use Alternative|telithromycin increases levels of tamsulosin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
terazosin|tamsulosin|20|Serious - Use Alternative|terazosin, tamsulosin.Either increases effects of the other by additive vasodilation. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available. Risk of hypotension.
terbinafine|tamsulosin|2|Significant - Monitor Closely|terbinafine increases levels of tamsulosin by affecting hepatic enzyme CYP2D6 metabolism. Potential for interaction, monitor.
thioridazine|tamsulosin|2|Significant - Monitor Closely|thioridazine increases levels of tamsulosin by affecting hepatic enzyme CYP2D6 metabolism. Potential for interaction, monitor.
ticlopidine|tamsulosin|2|Significant - Monitor Closely|ticlopidine increases levels of tamsulosin by affecting hepatic enzyme CYP2D6 metabolism. Potential for interaction, monitor.
tranylcypromine|tamsulosin|2|Significant - Monitor Closely|tranylcypromine increases levels of tamsulosin by affecting hepatic enzyme CYP2D6 metabolism. Potential for interaction, monitor.
trazodone|tamsulosin|2|Significant - Monitor Closely|trazodone increases levels of tamsulosin by affecting hepatic enzyme CYP2D6 metabolism. Potential for interaction, monitor.
vardenafil|tamsulosin|11|Significant - Monitor Closely|vardenafil, tamsulosin.Either increases effects of the other by additive vasodilation. Significant interaction possible, monitor closely. Risk of hypotension.
voriconazole|tamsulosin|20|Serious - Use Alternative|voriconazole increases levels of tamsulosin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
zolmitriptan|tapentadol|3|Significant - Monitor Closely|zolmitriptan and tapentadol both increase  serotonin levels. Potential for dangerous interaction. Use with caution and monitor closely.
telaprevir|triazolam|33|Contraindicated|telaprevir increases levels of triazolam by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Never use combination. Contraindicated. Prolonged or increased sedation or respiratory depression. .
telavancin|terfenadine|22|Serious - Use Alternative|telavancin and terfenadine both increase  QTc interval. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available.
telavancin|ziprasidone|3|Significant - Monitor Closely|telavancin and ziprasidone both increase  QTc interval. Potential for dangerous interaction. Use with caution and monitor closely.
telithromycin|temsirolimus|11|Significant - Monitor Closely|telithromycin will increase the level or effect of temsirolimus by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
telithromycin|terfenadine|33|Contraindicated|telithromycin increases levels of terfenadine by decreasing metabolism. Never use combination. Risk of QT interval prolongation.
telithromycin|terfenadine|22|Serious - Use Alternative|telithromycin and terfenadine both increase  QTc interval. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available.
telithromycin|terfenadine|21|Serious - Use Alternative|telithromycin will increase the level or effect of terfenadine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available. Never use combination.
telithromycin|theophylline|11|Significant - Monitor Closely|telithromycin will increase the level or effect of theophylline by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
theophylline|telithromycin|1|Minor|theophylline, telithromycin. pharmacodynamic synergism. Minor or non-significant interaction. Risk of GI side effects; separate by 1 hr.
thioridazine|telithromycin|3|Significant - Monitor Closely|thioridazine and telithromycin both increase  QTc interval. Potential for dangerous interaction. Use with caution and monitor closely.
telithromycin|tolterodine|11|Significant - Monitor Closely|telithromycin will increase the level or effect of tolterodine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
telithromycin|toremifene|11|Significant - Monitor Closely|telithromycin increases levels of toremifene by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely. Metabolism of toremifene may be inhibited by drugs known to inhibit CYP3A4 hepatic enzymes.
telithromycin|trazodone|11|Significant - Monitor Closely|telithromycin will increase the level or effect of trazodone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
trazodone|telithromycin|3|Significant - Monitor Closely|trazodone and telithromycin both increase  QTc interval. Potential for dangerous interaction. Use with caution and monitor closely.
telithromycin|triazolam|11|Significant - Monitor Closely|telithromycin will increase the level or effect of triazolam by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
trimipramine|telithromycin|3|Significant - Monitor Closely|trimipramine and telithromycin both increase  QTc interval. Potential for dangerous interaction. Use with caution and monitor closely.
telithromycin|vardenafil|11|Significant - Monitor Closely|telithromycin will increase the level or effect of vardenafil by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
vemurafenib|telithromycin|20|Serious - Use Alternative|vemurafenib and telithromycin both increase  QTc interval. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available. Concomitant use of vemurafenib with drugs that  prolong QT interval is not recommended. Telithromycin may also increase levels of vemurafenib.
telithromycin|venlafaxine|2|Significant - Monitor Closely|telithromycin and venlafaxine both increase  QTc interval. Potential for interaction, monitor.
telithromycin|verapamil|11|Significant - Monitor Closely|telithromycin will increase the level or effect of verapamil by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
verapamil|telithromycin|1|Minor|verapamil will increase the level or effect of telithromycin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor or non-significant interaction.
telithromycin|vinblastine|1|Minor|telithromycin will increase the level or effect of vinblastine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor or non-significant interaction.
telithromycin|vincristine|1|Minor|telithromycin will increase the level or effect of vincristine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor or non-significant interaction.
telithromycin|vinorelbine|1|Minor|telithromycin will increase the level or effect of vinorelbine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor or non-significant interaction.
telithromycin|voriconazole|2|Significant - Monitor Closely|telithromycin and voriconazole both increase  QTc interval. Potential for interaction, monitor.
voriconazole|telithromycin|1|Minor|voriconazole will increase the level or effect of telithromycin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor or non-significant interaction.
telithromycin|warfarin|11|Significant - Monitor Closely|telithromycin will increase the level or effect of warfarin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
telithromycin|ziprasidone|3|Significant - Monitor Closely|telithromycin and ziprasidone both increase  QTc interval. Potential for dangerous interaction. Use with caution and monitor closely.
telithromycin|ziprasidone|1|Minor|telithromycin will increase the level or effect of ziprasidone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor or non-significant interaction.
telithromycin|zolpidem|1|Minor|telithromycin will increase the level or effect of zolpidem by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor or non-significant interaction.
telithromycin|zonisamide|1|Minor|telithromycin will increase the level or effect of zonisamide by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor or non-significant interaction.
telmisartan|tolmetin|11|Significant - Monitor Closely|telmisartan, tolmetin.Either increases toxicity of the other by Other (see comment). Significant interaction possible, monitor closely. Comment: May result in renal function deterioration, particularly in elderly or volume depleted individuals.
tolmetin|telmisartan|3|Significant - Monitor Closely|tolmetin decreases effects of telmisartan by pharmacodynamic antagonism. Potential for dangerous interaction. Use with caution and monitor closely.  NSAIDs decrease synthesis of vasodilating renal prostaglandins, and thus affect fluid homeostasis and may diminish antihypertensive effect.
telmisartan|tolmetin|2|Significant - Monitor Closely|telmisartan and tolmetin both increase  serum potassium. Potential for interaction, monitor.
telmisartan|trandolapril|20|Serious - Use Alternative|telmisartan, trandolapril.Either increases toxicity of the other by pharmacodynamic synergism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available. Dual blockade of renin-angiotensin system increases risks of hypotension, hyperkalemia, and renal impairment.
treprostinil|telmisartan|2|Significant - Monitor Closely|treprostinil increases effects of telmisartan by pharmacodynamic synergism. Potential for interaction, monitor.
telmisartan|triamterene|3|Significant - Monitor Closely|telmisartan and triamterene both increase  serum potassium. Potential for dangerous interaction. Use with caution and monitor closely.
triprolidine|temazepam|2|Significant - Monitor Closely|triprolidine and temazepam both increase  sedation. Potential for interaction, monitor.
trandolapril|temsirolimus|2|Significant - Monitor Closely|trandolapril, temsirolimus.Either increases toxicity of the other by Other (see comment). Potential for interaction, monitor. Comment: Coadministration increases risk of angioedema.
voriconazole|temsirolimus|11|Significant - Monitor Closely|voriconazole will increase the level or effect of temsirolimus by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
terazosin|timolol|3|Significant - Monitor Closely|terazosin and timolol both increase  anti-hypertensive channel blocking. Potential for dangerous interaction. Use with caution and monitor closely.
treprostinil|terazosin|1|Minor|treprostinil increases effects of terazosin by pharmacodynamic synergism. Minor or non-significant interaction.
vardenafil|terazosin|21|Serious - Use Alternative|vardenafil increases effects of terazosin by pharmacodynamic synergism. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available. Never use combination. Risk of hypotension.
timolol|terbutaline|11|Significant - Monitor Closely|timolol decreases effects of terbutaline by pharmacodynamic antagonism. Significant interaction possible, monitor closely.
timolol|terbutaline|2|Significant - Monitor Closely|timolol increases and terbutaline decreases serum potassium. Effect of interaction is not clear, use caution. Potential for interaction, monitor.
tranylcypromine|terbutaline|21|Serious - Use Alternative|tranylcypromine increases effects of terbutaline by pharmacodynamic synergism. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available. Never use combination. Risk of acute hypertensive episode.
trimipramine|terbutaline|20|Serious - Use Alternative|trimipramine, terbutaline. Other (see comment). Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available. Comment: Tricyclic antidepressants increase or decrease effects of sympathomimetics, by blocking reuptake of NE, or blocking uptake of indirect sympathomimetics into the adrenergic neuron.
trimipramine|terbutaline|2|Significant - Monitor Closely|trimipramine increases and terbutaline decreases sedation. Effect of interaction is not clear, use caution. Potential for interaction, monitor.
thioridazine|terfenadine|33|Contraindicated|thioridazine and terfenadine both increase  QTc interval. Never use combination.
terfenadine|thioridazine|2|Significant - Monitor Closely|terfenadine and thioridazine both increase  sedation. Potential for interaction, monitor.
tipranavir|terfenadine|33|Contraindicated|tipranavir increases levels of terfenadine by decreasing metabolism. Never use combination. Risk of QT interval prolongation.
trifluoperazine|terfenadine|33|Contraindicated|trifluoperazine and terfenadine both increase  QTc interval. Never use combination.
terfenadine|trifluoperazine|2|Significant - Monitor Closely|terfenadine and trifluoperazine both increase  sedation. Potential for interaction, monitor.
trimipramine|terfenadine|33|Contraindicated|trimipramine and terfenadine both increase  QTc interval. Never use combination.
terfenadine|trimipramine|2|Significant - Monitor Closely|terfenadine and trimipramine both increase  sedation. Potential for interaction, monitor.
troleandomycin|terfenadine|33|Contraindicated|troleandomycin increases levels of terfenadine by decreasing metabolism. Never use combination. Risk of QT interval prolongation.
troleandomycin|terfenadine|21|Serious - Use Alternative|troleandomycin will increase the level or effect of terfenadine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available. Never use combination.
verapamil|terfenadine|33|Contraindicated|verapamil increases levels of terfenadine by decreasing metabolism. Never use combination. Risk of QT interval prolongation.
verapamil|terfenadine|21|Serious - Use Alternative|verapamil will increase the level or effect of terfenadine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available. Never use combination.
voriconazole|terfenadine|33|Contraindicated|voriconazole increases levels of terfenadine by decreasing metabolism. Never use combination. Risk of QT interval prolongation.
terfenadine|voriconazole|22|Serious - Use Alternative|terfenadine and voriconazole both increase  QTc interval. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available.
voriconazole|terfenadine|21|Serious - Use Alternative|voriconazole will increase the level or effect of terfenadine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available. Never use combination.
testosterone|warfarin|20|Serious - Use Alternative|testosterone increases levels of warfarin by decreasing metabolism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
thioridazine|tetrabenazine|3|Significant - Monitor Closely|thioridazine and tetrabenazine both increase  antidopaminergic effects, including extrapyramidal symptoms and neuroleptic malignant syndrome. Potential for dangerous interaction. Use with caution and monitor closely.
thiothixene|tetrabenazine|3|Significant - Monitor Closely|thiothixene and tetrabenazine both increase  antidopaminergic effects, including extrapyramidal symptoms and neuroleptic malignant syndrome. Potential for dangerous interaction. Use with caution and monitor closely.
tetrabenazine|tranylcypromine|33|Contraindicated|tetrabenazine, tranylcypromine. Other (see comment). Never use combination. Comment: Risk of acute hypertensive episode; separate by 14 d.  Mechanism: MAOI causes accumulation of NE in neuron and tetrabenazine stimulates NE release.
trifluoperazine|tetrabenazine|3|Significant - Monitor Closely|trifluoperazine and tetrabenazine both increase  antidopaminergic effects, including extrapyramidal symptoms and neuroleptic malignant syndrome. Potential for dangerous interaction. Use with caution and monitor closely.
ziprasidone|tetrabenazine|3|Significant - Monitor Closely|ziprasidone and tetrabenazine both increase  antidopaminergic effects, including extrapyramidal symptoms and neuroleptic malignant syndrome. Potential for dangerous interaction. Use with caution and monitor closely.
tetracycline|ticarcillin|20|Serious - Use Alternative|tetracycline decreases effects of ticarcillin by pharmacodynamic antagonism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
tetracycline|tretinoin|33|Contraindicated|tetracycline, tretinoin.Either increases toxicity of the other by unspecified interaction mechanism. Never use combination. Both tretinoin and tetracyclines can cause increased intracranial pressure.
tetracycline|tretinoin|20|Serious - Use Alternative|tetracycline, tretinoin. Mechanism: pharmacodynamic synergism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available. Increased phototoxicity.
tetracycline|warfarin|1|Minor|tetracycline increases effects of warfarin by pharmacodynamic synergism. Minor or non-significant interaction.
ticlopidine|theophylline|1|Minor|ticlopidine increases levels of theophylline by decreasing metabolism. Minor or non-significant interaction.
timolol|theophylline|11|Significant - Monitor Closely|timolol, theophylline. Other (see comment). Significant interaction possible, monitor closely. Comment: Beta blockers (esp. non selective) antagonize theophylline effects, while at the same time increasing theophylline levels and toxicity (mechanism: decreased theophylline metabolism). Smoking increases risk of interaction.
troleandomycin|theophylline|11|Significant - Monitor Closely|troleandomycin will increase the level or effect of theophylline by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
verapamil|theophylline|11|Significant - Monitor Closely|verapamil will increase the level or effect of theophylline by  affecting hepatic enzyme CYP1A2 metabolism. Significant interaction possible, monitor closely.
verapamil|theophylline|11|Significant - Monitor Closely|verapamil will increase the level or effect of theophylline by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
voriconazole|theophylline|11|Significant - Monitor Closely|voriconazole will increase the level or effect of theophylline by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
zafirlukast|theophylline|11|Significant - Monitor Closely|zafirlukast will increase the level or effect of theophylline by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
theophylline|zafirlukast|1|Minor|theophylline decreases levels of zafirlukast by unknown mechanism. Minor or non-significant interaction.
zileuton|theophylline|11|Significant - Monitor Closely|zileuton will increase the level or effect of theophylline by  affecting hepatic enzyme CYP1A2 metabolism. Significant interaction possible, monitor closely.
thioridazine|thiothixene|2|Significant - Monitor Closely|thioridazine and thiothixene both increase  antidopaminergic effects, including extrapyramidal symptoms and neuroleptic malignant syndrome. Potential for interaction, monitor.
thioridazine|thiothixene|2|Significant - Monitor Closely|thioridazine and thiothixene both increase  sedation. Potential for interaction, monitor.
thioridazine|toremifene|33|Contraindicated|thioridazine and toremifene both increase  QTc interval. Never use combination. Concurrent use of thioridazine with other agents that prolong QTc interval is contraindicated.
thioridazine|tramadol|2|Significant - Monitor Closely|thioridazine decreases effects of tramadol by affecting hepatic enzyme CYP2D6 metabolism. Potential for interaction, monitor. Decreased conversion of tramadol to active metabolite.
tramadol|thioridazine|2|Significant - Monitor Closely|tramadol and thioridazine both increase  sedation. Potential for interaction, monitor.
thioridazine|tramadol|2|Significant - Monitor Closely|thioridazine decreases effects of tramadol by decreasing metabolism. Potential for interaction, monitor. Decreased conversion of tramadol to active metabolite.
thioridazine|trimipramine|22|Serious - Use Alternative|thioridazine and trimipramine both increase  QTc interval. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available.
thioridazine|trimipramine|2|Significant - Monitor Closely|thioridazine and trimipramine both increase  sedation. Potential for interaction, monitor.
trimipramine|thioridazine|1|Minor|trimipramine, thioridazine.Either increases levels of the other by decreasing metabolism. Minor or non-significant interaction. Additive anticholinergic effects.
trimipramine|thioridazine|1|Minor|trimipramine, thioridazine.Either increases levels of the other by pharmacodynamic synergism. Minor or non-significant interaction. Additive anticholinergic effects.
triprolidine|thioridazine|2|Significant - Monitor Closely|triprolidine and thioridazine both increase  sedation. Potential for interaction, monitor.
thioridazine|voriconazole|3|Significant - Monitor Closely|thioridazine and voriconazole both increase  QTc interval. Potential for dangerous interaction. Use with caution and monitor closely.
thioridazine|ziprasidone|22|Serious - Use Alternative|thioridazine and ziprasidone both increase  QTc interval. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available.
thioridazine|ziprasidone|2|Significant - Monitor Closely|thioridazine and ziprasidone both increase  antidopaminergic effects, including extrapyramidal symptoms and neuroleptic malignant syndrome. Potential for interaction, monitor.
thioridazine|ziprasidone|2|Significant - Monitor Closely|thioridazine and ziprasidone both increase  sedation. Potential for interaction, monitor.
thiothixene|trimipramine|2|Significant - Monitor Closely|thiothixene and trimipramine both increase  sedation. Potential for interaction, monitor.
triprolidine|thiothixene|2|Significant - Monitor Closely|triprolidine and thiothixene both increase  sedation. Potential for interaction, monitor.
thiothixene|ziprasidone|2|Significant - Monitor Closely|thiothixene and ziprasidone both increase  antidopaminergic effects, including extrapyramidal symptoms and neuroleptic malignant syndrome. Potential for interaction, monitor.
thiothixene|ziprasidone|2|Significant - Monitor Closely|thiothixene and ziprasidone both increase  sedation. Potential for interaction, monitor.
ticarcillin|tobramycin|1|Minor|ticarcillin decreases effects of tobramycin by altering metabolism. Minor or non-significant interaction. Increased risk in renal impairment.
warfarin|ticlopidine|21|Serious - Use Alternative|warfarin, ticlopidine.Either increases effects of the other by pharmacodynamic synergism. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available. Never use combination. Enhanced risk of hemorrhage.
ticlopidine|warfarin|11|Significant - Monitor Closely|ticlopidine will increase the level or effect of warfarin by  affecting hepatic enzyme CYP2C9/10 metabolism. Significant interaction possible, monitor closely.
tigecycline|warfarin|11|Significant - Monitor Closely|tigecycline increases levels of warfarin by decreasing elimination. Significant interaction possible, monitor closely. Minimal effect on INR; monitor.
timolol|tolazamide|11|Significant - Monitor Closely|timolol decreases effects of tolazamide by pharmacodynamic antagonism. Significant interaction possible, monitor closely. Non selective beta blockers may also mask the symptoms of hypoglycemia.
timolol|tolbutamide|11|Significant - Monitor Closely|timolol decreases effects of tolbutamide by pharmacodynamic antagonism. Significant interaction possible, monitor closely. Non selective beta blockers may also mask the symptoms of hypoglycemia.
tolmetin|timolol|11|Significant - Monitor Closely|tolmetin decreases effects of timolol by pharmacodynamic antagonism. Significant interaction possible, monitor closely. Long term (>1 wk) NSAID use.  NSAIDs decrease prostaglandin synthesis.
timolol|tolmetin|2|Significant - Monitor Closely|timolol and tolmetin both increase  serum potassium. Potential for interaction, monitor.
treprostinil|timolol|1|Minor|treprostinil increases effects of timolol by pharmacodynamic synergism. Minor or non-significant interaction.
verapamil|timolol|20|Serious - Use Alternative|verapamil, timolol.Either increases toxicity of the other by unspecified interaction mechanism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available. Can increase risk of bradycardia.
timolol|verapamil|3|Significant - Monitor Closely|timolol and verapamil both increase  anti-hypertensive channel blocking. Potential for dangerous interaction. Use with caution and monitor closely.
tipranavir|triazolam|21|Serious - Use Alternative|tipranavir increases levels of triazolam by decreasing metabolism. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available. Never use combination.
tipranavir|vardenafil|11|Significant - Monitor Closely|tipranavir increases levels of vardenafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely. Potential for increased toxicity. .
verapamil|tipranavir|11|Significant - Monitor Closely|verapamil will increase the level or effect of tipranavir by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
tipranavir|verapamil|11|Significant - Monitor Closely|tipranavir, verapamil. Other (see comment). Significant interaction possible, monitor closely. Comment: Verapamil levels may incr or decr, due to contradictory effects of tipranavir on hepatic CYP3A4 and P glycoprotein.
voriconazole|tipranavir|20|Serious - Use Alternative|voriconazole will increase the level or effect of tipranavir by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
tipranavir|zidovudine|11|Significant - Monitor Closely|tipranavir decreases levels of zidovudine by unspecified interaction mechanism. Significant interaction possible, monitor closely.
tipranavir|zidovudine|2|Significant - Monitor Closely|tipranavir and zidovudine both increase  risk of immune reconstitution syndrome. Potential for interaction, monitor.
tizanidine|trandolapril|1|Minor|tizanidine increases effects of trandolapril by pharmacodynamic synergism. Minor or non-significant interaction. Risk of hypotension.
tizanidine|treprostinil|1|Minor|tizanidine increases effects of treprostinil by pharmacodynamic synergism. Minor or non-significant interaction. Risk of hypotension.
tobramycin|tubocurarine|20|Serious - Use Alternative|tobramycin increases effects of tubocurarine by pharmacodynamic synergism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available. Risk of apnea.
tobramycin|vancomycin|1|Minor|tobramycin and vancomycin both increase  nephrotoxicity and/or ototoxicity. Minor or non-significant interaction.
tobramycin|vecuronium|20|Serious - Use Alternative|tobramycin increases effects of vecuronium by pharmacodynamic synergism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available. Risk of apnea.
voriconazole|tolbutamide|11|Significant - Monitor Closely|voriconazole increases levels of tolbutamide by decreasing metabolism. Significant interaction possible, monitor closely.
voriconazole|tolbutamide|1|Minor|voriconazole will increase the level or effect of tolbutamide by  affecting hepatic enzyme CYP2C9/10 metabolism. Minor or non-significant interaction.
zafirlukast|tolbutamide|1|Minor|zafirlukast will increase the level or effect of tolbutamide by  affecting hepatic enzyme CYP2C9/10 metabolism. Minor or non-significant interaction.
tolcapone|tranylcypromine|21|Serious - Use Alternative|tolcapone increases effects of tranylcypromine by pharmacodynamic synergism. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available. Never use combination.
trandolapril|tolmetin|11|Significant - Monitor Closely|trandolapril, tolmetin.Either increases toxicity of the other by Other (see comment). Significant interaction possible, monitor closely. Comment: May result in renal function deterioration, particularly in elderly or volume depleted individuals.
tolmetin|trandolapril|3|Significant - Monitor Closely|tolmetin decreases effects of trandolapril by pharmacodynamic antagonism. Potential for dangerous interaction. Use with caution and monitor closely. NSAIDs decrease synthesis of vasodilating renal prostaglandins, and thus affect fluid homeostasis and may diminish antihypertenisve effect.
warfarin|tolmetin|3|Significant - Monitor Closely|warfarin and tolmetin both increase  anticoagulation. Potential for dangerous interaction. Use with caution and monitor closely.
verapamil|tolterodine|11|Significant - Monitor Closely|verapamil will increase the level or effect of tolterodine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
voriconazole|tolterodine|11|Significant - Monitor Closely|voriconazole will increase the level or effect of tolterodine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
verapamil|tolvaptan|21|Serious - Use Alternative|verapamil will increase the level or effect of tolvaptan by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available. Never use combination.
verapamil|tolvaptan|11|Significant - Monitor Closely|verapamil will increase the level or effect of tolvaptan by  P-glycoprotein (MDR1) efflux transporter. Significant interaction possible, monitor closely. Coadministration of moderate CYP 3A inhibitors, such as Verapamil with Tolvaptan should be avoided.
voriconazole|tolvaptan|21|Serious - Use Alternative|voriconazole will increase the level or effect of tolvaptan by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available. Never use combination.
triprolidine|topiramate|3|Significant - Monitor Closely|triprolidine and topiramate both increase  sedation. Potential for dangerous interaction. Use with caution and monitor closely.
topiramate|ulipristal|20|Serious - Use Alternative|topiramate will decrease the level or effect of ulipristal by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
verapamil|topotecan|22|Serious - Use Alternative|verapamil will increase the level or effect of topotecan by  P-glycoprotein (MDR1) efflux transporter. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available. Product labeling for PO topotecan recommends avoiding concomitant use of P-gp inhibitors; the interaction with IV topotecan may be less severe but is still likely of clinical significance
voriconazole|toremifene|11|Significant - Monitor Closely|voriconazole increases levels of toremifene by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely. Metabolism of toremifene may be inhibited by drugs known to inhibit CYP3A4 hepatic enzymes.
ziprasidone|toremifene|33|Contraindicated|ziprasidone and toremifene both increase  QTc interval. Never use combination. Concurrent use of ziprasidone with other agents that prolong QTc interval is contraindicated.
tranylcypromine|tramadol|22|Serious - Use Alternative|tranylcypromine and tramadol both increase  serotonin levels. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available.
tranylcypromine|tramadol|20|Serious - Use Alternative|tranylcypromine increases toxicity of tramadol by unknown mechanism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available. Risk of hypotension, hyperpyrexia, somnolence, or death; separate by 14 d.
trazodone|tramadol|3|Significant - Monitor Closely|trazodone and tramadol both increase  serotonin levels. Potential for dangerous interaction. Use with caution and monitor closely.
tramadol|trazodone|2|Significant - Monitor Closely|tramadol and trazodone both increase  sedation. Potential for interaction, monitor.
trimipramine|tramadol|3|Significant - Monitor Closely|trimipramine and tramadol both increase  serotonin levels. Potential for dangerous interaction. Use with caution and monitor closely.
tramadol|trimipramine|2|Significant - Monitor Closely|tramadol and trimipramine both increase  sedation. Potential for interaction, monitor.
triprolidine|tramadol|2|Significant - Monitor Closely|triprolidine and tramadol both increase  sedation. Potential for interaction, monitor.
venlafaxine|tramadol|3|Significant - Monitor Closely|venlafaxine and tramadol both increase  serotonin levels. Potential for dangerous interaction. Use with caution and monitor closely.
zolmitriptan|tramadol|2|Significant - Monitor Closely|zolmitriptan and tramadol both increase  serotonin levels. Potential for interaction, monitor.
treprostinil|trandolapril|1|Minor|treprostinil increases effects of trandolapril by pharmacodynamic synergism. Minor or non-significant interaction.
trandolapril|triamterene|11|Significant - Monitor Closely|trandolapril, triamterene. Mechanism: pharmacodynamic synergism. Significant interaction possible, monitor closely. Risk of hyperkalemia.
trimethoprim|trandolapril|2|Significant - Monitor Closely|trimethoprim and trandolapril both increase  serum potassium. Potential for interaction, monitor. Trimethoprim decreases urinary potassium excretion. May cause hyperkalemia, particularly with high doses, renal insufficiency, or when combined with other drugs that cause hyperkalemia.
valsartan|trandolapril|20|Serious - Use Alternative|valsartan, trandolapril.Either increases toxicity of the other by pharmacodynamic synergism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available. Dual blockade of renin-angiotensin system increases risks of hypotension, hyperkalemia, and renal impairment.
tranylcypromine|trazodone|33|Contraindicated|tranylcypromine and trazodone both increase  serotonin levels. Never use combination.
tranylcypromine|trimipramine|33|Contraindicated|tranylcypromine and trimipramine both increase  serotonin levels. Never use combination.
tranylcypromine|venlafaxine|33|Contraindicated|tranylcypromine and venlafaxine both increase  serotonin levels. Never use combination.
tranylcypromine|vilazodone|33|Contraindicated|tranylcypromine, vilazodone.Either increases toxicity of the other by serotonin levels. Never use combination. Coadministration with MAO-A inhibitors are contraindicated. Do not prescribe vilazodone within 14 days of discontinuing or starting an MAO inhibitor.
zolmitriptan|tranylcypromine|22|Serious - Use Alternative|zolmitriptan and tranylcypromine both increase  serotonin levels. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available.
tranylcypromine|zolmitriptan|21|Serious - Use Alternative|tranylcypromine increases levels of zolmitriptan by decreasing metabolism. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available. Never use combination.
trazodone|trimipramine|22|Serious - Use Alternative|trazodone and trimipramine both increase  QTc interval. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available.
trazodone|trimipramine|22|Serious - Use Alternative|trazodone and trimipramine both increase  serotonin levels. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available.
trazodone|trimipramine|2|Significant - Monitor Closely|trazodone and trimipramine both decrease  cholinergic effects/transmission. Potential for interaction, monitor.
trazodone|trimipramine|2|Significant - Monitor Closely|trazodone and trimipramine both increase  sedation. Potential for interaction, monitor.
triprolidine|trazodone|2|Significant - Monitor Closely|triprolidine and trazodone both increase  sedation. Potential for interaction, monitor.
trazodone|venlafaxine|22|Serious - Use Alternative|trazodone and venlafaxine both increase  serotonin levels. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available.
trazodone|venlafaxine|3|Significant - Monitor Closely|trazodone and venlafaxine both increase  QTc interval. Potential for dangerous interaction. Use with caution and monitor closely.
norfloxacin|tamsulosin|2|Significant - Monitor Closely|norfloxacin increases levels of tamsulosin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Potential for interaction, monitor. Dose reduction may be needed for coadministered drugs that are predominantly metabolized by CYP3A.
norfloxacin|theophylline|11|Significant - Monitor Closely|norfloxacin will increase the level or effect of theophylline by  affecting hepatic enzyme CYP1A2 metabolism. Significant interaction possible, monitor closely.
norfloxacin|tizanidine|20|Serious - Use Alternative|norfloxacin will increase the level or effect of tizanidine by  affecting hepatic enzyme CYP1A2 metabolism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
norfloxacin|warfarin|11|Significant - Monitor Closely|norfloxacin will increase the level or effect of warfarin by  affecting hepatic enzyme CYP1A2 metabolism. Significant interaction possible, monitor closely.
norfloxacin|warfarin|11|Significant - Monitor Closely|norfloxacin increases effects of warfarin by Other (see comment). Significant interaction possible, monitor closely. Comment: Decr vitamin K-producing intestinal flora may increase INR after a few days.
norfloxacin|warfarin|11|Significant - Monitor Closely|norfloxacin increases effects of warfarin by unknown mechanism. Significant interaction possible, monitor closely. Ciprofloxacin, norfloxacin, & ofloxacin are most likely to interact w/warfarin; data for other quinolones is conflicting.  Monitor INR closely.
phenelzine|nortriptyline|33|Contraindicated|phenelzine and nortriptyline both increase  serotonin levels. Never use combination.
nortriptyline|phenylephrine|20|Serious - Use Alternative|nortriptyline, phenylephrine. Other (see comment). Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available. Comment: Tricyclic antidepressants increase or decrease effects of sympathomimetics, by blocking reuptake of NE, or blocking uptake of indirect sympathomimetics into the adrenergic neuron.
nortriptyline|phenylephrine|2|Significant - Monitor Closely|nortriptyline increases and phenylephrine decreases sedation. Effect of interaction is not clear, use caution. Potential for interaction, monitor.
nortriptyline|pirbuterol|20|Serious - Use Alternative|nortriptyline, pirbuterol. Other (see comment). Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available. Comment: Tricyclic antidepressants increase or decrease effects of sympathomimetics, by blocking reuptake of NE, or blocking uptake of indirect sympathomimetics into the adrenergic neuron.
nortriptyline|pirbuterol|2|Significant - Monitor Closely|nortriptyline increases and pirbuterol decreases sedation. Effect of interaction is not clear, use caution. Potential for interaction, monitor.
nortriptyline|pseudoephedrine|20|Serious - Use Alternative|nortriptyline, pseudoephedrine. Other (see comment). Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available. Comment: Tricyclic antidepressants increase or decrease effects of sympathomimetics, by blocking reuptake of NE, or blocking uptake of indirect sympathomimetics into the adrenergic neuron.
nortriptyline|pseudoephedrine|2|Significant - Monitor Closely|nortriptyline increases and pseudoephedrine decreases sedation. Effect of interaction is not clear, use caution. Potential for interaction, monitor.
quinidine|nortriptyline|33|Contraindicated|quinidine and nortriptyline both increase  QTc interval. Never use combination.
quinidine|nortriptyline|20|Serious - Use Alternative|quinidine will increase the level or effect of nortriptyline by  affecting hepatic enzyme CYP2D6 metabolism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
quinidine|nortriptyline|20|Serious - Use Alternative|quinidine will increase the level or effect of nortriptyline by  P-glycoprotein (MDR1) efflux transporter. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
rasagiline|nortriptyline|20|Serious - Use Alternative|rasagiline and nortriptyline both increase  serotonin levels. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available. Severe CNS toxicity associated with hyperpyrexia has been reported with the combined treatment of an antidepressant and rasagiline. Avoid combination within 14 days of MAOI use.
rifabutin|nortriptyline|11|Significant - Monitor Closely|rifabutin decreases levels of nortriptyline by increasing metabolism. Significant interaction possible, monitor closely.
ritonavir|nortriptyline|11|Significant - Monitor Closely|ritonavir will increase the level or effect of nortriptyline by  affecting hepatic enzyme CYP2D6 metabolism. Significant interaction possible, monitor closely.
ritonavir|nortriptyline|11|Significant - Monitor Closely|ritonavir will increase the level or effect of nortriptyline by  P-glycoprotein (MDR1) efflux transporter. Significant interaction possible, monitor closely.
tacrine|nortriptyline|2|Significant - Monitor Closely|tacrine increases and nortriptyline decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Potential for interaction, monitor.
tacrolimus|nortriptyline|11|Significant - Monitor Closely|tacrolimus will increase the level or effect of nortriptyline by  P-glycoprotein (MDR1) efflux transporter. Significant interaction possible, monitor closely.
nortriptyline|terbutaline|20|Serious - Use Alternative|nortriptyline, terbutaline. Other (see comment). Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available. Comment: Tricyclic antidepressants increase or decrease effects of sympathomimetics, by blocking reuptake of NE, or blocking uptake of indirect sympathomimetics into the adrenergic neuron.
nortriptyline|terbutaline|2|Significant - Monitor Closely|nortriptyline increases and terbutaline decreases sedation. Effect of interaction is not clear, use caution. Potential for interaction, monitor.
nortriptyline|terfenadine|33|Contraindicated|nortriptyline and terfenadine both increase  QTc interval. Never use combination.
terfenadine|nortriptyline|2|Significant - Monitor Closely|terfenadine and nortriptyline both increase  sedation. Potential for interaction, monitor.
thiothixene|nortriptyline|2|Significant - Monitor Closely|thiothixene and nortriptyline both increase  sedation. Potential for interaction, monitor.
nortriptyline|toremifene|20|Serious - Use Alternative|nortriptyline and toremifene both increase  QTc interval. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available. Concurrent use of toremifene with agents causing  QT prolongation should be avoided. If concomitant use is required it's recommended that toremifene be interrupted. If interruption not possible, patients requiring therapy with a drug that prolongs QT should be closely monitored. ECGs should be obtained for high risk patients.
nortriptyline|tramadol|3|Significant - Monitor Closely|nortriptyline and tramadol both increase  serotonin levels. Potential for dangerous interaction. Use with caution and monitor closely.
tramadol|nortriptyline|2|Significant - Monitor Closely|tramadol and nortriptyline both increase  sedation. Potential for interaction, monitor.
tranylcypromine|nortriptyline|33|Contraindicated|tranylcypromine and nortriptyline both increase  serotonin levels. Never use combination.
nortriptyline|trazodone|22|Serious - Use Alternative|nortriptyline and trazodone both increase  QTc interval. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available.
trazodone|nortriptyline|22|Serious - Use Alternative|trazodone and nortriptyline both increase  serotonin levels. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available.
trazodone|nortriptyline|11|Significant - Monitor Closely|trazodone will decrease the level or effect of nortriptyline by  P-glycoprotein (MDR1) efflux transporter. Significant interaction possible, monitor closely.
nortriptyline|trazodone|2|Significant - Monitor Closely|nortriptyline and trazodone both decrease  cholinergic effects/transmission. Potential for interaction, monitor.
nortriptyline|trazodone|2|Significant - Monitor Closely|nortriptyline and trazodone both increase  sedation. Potential for interaction, monitor.
nortriptyline|trimipramine|22|Serious - Use Alternative|nortriptyline and trimipramine both increase  QTc interval. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available.
nortriptyline|trimipramine|22|Serious - Use Alternative|nortriptyline and trimipramine both increase  serotonin levels. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available.
nortriptyline|trimipramine|2|Significant - Monitor Closely|nortriptyline and trimipramine both decrease  cholinergic effects/transmission. Potential for interaction, monitor.
nortriptyline|trimipramine|2|Significant - Monitor Closely|nortriptyline and trimipramine both increase  sedation. Potential for interaction, monitor.
triprolidine|nortriptyline|2|Significant - Monitor Closely|triprolidine and nortriptyline both increase  sedation. Potential for interaction, monitor.
venlafaxine|nortriptyline|22|Serious - Use Alternative|venlafaxine and nortriptyline both increase  serotonin levels. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available.
venlafaxine|nortriptyline|20|Serious - Use Alternative|venlafaxine will increase the level or effect of nortriptyline by  affecting hepatic enzyme CYP2D6 metabolism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
nortriptyline|venlafaxine|3|Significant - Monitor Closely|nortriptyline and venlafaxine both increase  QTc interval. Potential for dangerous interaction. Use with caution and monitor closely.
nortriptyline|vilazodone|22|Serious - Use Alternative|nortriptyline, vilazodone.Either increases toxicity of the other by serotonin levels. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available. Concomitant therapy should be discontinued immediately if signs or symptoms of serotonin syndrome emerge and supportive symptomatic treatment should be initiated.  .
nortriptyline|voriconazole|3|Significant - Monitor Closely|nortriptyline and voriconazole both increase  QTc interval. Potential for dangerous interaction. Use with caution and monitor closely.
nortriptyline|ziprasidone|22|Serious - Use Alternative|nortriptyline and ziprasidone both increase  QTc interval. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available.
ziprasidone|nortriptyline|2|Significant - Monitor Closely|ziprasidone and nortriptyline both increase  sedation. Potential for interaction, monitor.
zolmitriptan|nortriptyline|3|Significant - Monitor Closely|zolmitriptan and nortriptyline both increase  serotonin levels. Potential for dangerous interaction. Use with caution and monitor closely.
trimipramine|octreotide|22|Serious - Use Alternative|trimipramine and octreotide both increase  QTc interval. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available.
octreotide|voriconazole|3|Significant - Monitor Closely|octreotide and voriconazole both increase  QTc interval. Potential for dangerous interaction. Use with caution and monitor closely.
octreotide|ziprasidone|22|Serious - Use Alternative|octreotide and ziprasidone both increase  QTc interval. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available.
ofloxacin|procainamide|22|Serious - Use Alternative|ofloxacin and procainamide both increase  QTc interval. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available.
ofloxacin|procainamide|11|Significant - Monitor Closely|ofloxacin will increase the level or effect of procainamide by  basic (cationic) drug competition for renal tubular clearance. Significant interaction possible, monitor closely.
quinidine|ofloxacin|22|Serious - Use Alternative|quinidine and ofloxacin both increase  QTc interval. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available.
quinidine|ofloxacin|11|Significant - Monitor Closely|quinidine will increase the level or effect of ofloxacin by  basic (cationic) drug competition for renal tubular clearance. Significant interaction possible, monitor closely.
sucralfate|ofloxacin|11|Significant - Monitor Closely|sucralfate decreases levels of ofloxacin by inhibition of GI absorption. Applies only to oral form of both agents. Significant interaction possible, monitor closely.
ofloxacin|warfarin|11|Significant - Monitor Closely|ofloxacin increases effects of warfarin by Other (see comment). Significant interaction possible, monitor closely. Comment: Decr vitamin K-producing intestinal flora may increase INR after a few days.
ofloxacin|warfarin|11|Significant - Monitor Closely|ofloxacin increases effects of warfarin by unknown mechanism. Significant interaction possible, monitor closely. Ciprofloxacin, norfloxacin, & ofloxacin are most likely to interact w/warfarin; data for other quinolones is conflicting.  Monitor INR closely.
ritonavir|olanzapine|11|Significant - Monitor Closely|ritonavir decreases levels of olanzapine by increasing metabolism. Significant interaction possible, monitor closely.
tacrine|olanzapine|11|Significant - Monitor Closely|tacrine will increase the level or effect of olanzapine by  affecting hepatic enzyme CYP1A2 metabolism. Significant interaction possible, monitor closely.
olanzapine|tetrabenazine|3|Significant - Monitor Closely|olanzapine and tetrabenazine both increase  antidopaminergic effects, including extrapyramidal symptoms and neuroleptic malignant syndrome. Potential for dangerous interaction. Use with caution and monitor closely.
triprolidine|olanzapine|2|Significant - Monitor Closely|triprolidine and olanzapine both increase  sedation. Potential for interaction, monitor.
olmesartan|trandolapril|20|Serious - Use Alternative|olmesartan, trandolapril.Either increases toxicity of the other by pharmacodynamic synergism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available. Dual blockade of renin-angiotensin system increases risks of hypotension, hyperkalemia, and renal impairment.
treprostinil|olmesartan|2|Significant - Monitor Closely|treprostinil increases effects of olmesartan by pharmacodynamic synergism. Potential for interaction, monitor.
omalizumab|sipuleucel-t|3|Significant - Monitor Closely|omalizumab decreases effects of sipuleucel-t by pharmacodynamic antagonism. Potential for dangerous interaction. Use with caution and monitor closely.
omeprazole|ospemifene|1|Minor|omeprazole increases levels of ospemifene by affecting hepatic enzyme CYP2C19 metabolism. Minor or non-significant interaction.
omeprazole|phenytoin|11|Significant - Monitor Closely|omeprazole will increase the level or effect of phenytoin by  affecting hepatic enzyme CYP2C9/10 metabolism. Significant interaction possible, monitor closely.
omeprazole|quazepam|1|Minor|omeprazole increases levels of quazepam by decreasing metabolism. Minor or non-significant interaction.
omeprazole|rilpivirine|33|Contraindicated|omeprazole decreases levels of rilpivirine by increasing gastric pH. Applies only to oral form of both agents. Never use combination. Contraindicated. Concurrent use may cause treatment failure and/or the development of rilpivirine or NNRTI resistance. Coadministration of a PPI and rilpivirine may result in decreased rilpivirine plasma concentrations, which could cause impaired virologic response to rilpivirine.
omeprazole|roflumilast|3|Significant - Monitor Closely|omeprazole will decrease the level or effect of roflumilast by  affecting hepatic enzyme CYP1A2 metabolism. Potential for dangerous interaction. Use with caution and monitor closely. Concomitant therapy may reduce therapeutic effectiveness.
omeprazole|tacrolimus|2|Significant - Monitor Closely|omeprazole will increase the level or effect of tacrolimus by  affecting hepatic enzyme CYP2C19 metabolism. Potential for interaction, monitor. Concomitant administration may increase tacrolimus whole blood concentrations, particularly in intermediate or poor metabolizers of CYP2C19
omeprazole|triazolam|1|Minor|omeprazole increases levels of triazolam by decreasing metabolism. Minor or non-significant interaction.
omeprazole|vismodegib|2|Significant - Monitor Closely|omeprazole will decrease the level or effect of vismodegib by  Other (see comment). Potential for interaction, monitor. Drugs that increase gastric pH alter vismodegib solubility and therefore reduce bioavailability; effect on efficacy unknown
voriconazole|omeprazole|11|Significant - Monitor Closely|voriconazole will increase the level or effect of omeprazole by  affecting hepatic enzyme CYP2C19 metabolism. Significant interaction possible, monitor closely.
omeprazole|voriconazole|1|Minor|omeprazole will increase the level or effect of voriconazole by  affecting hepatic enzyme CYP2C19 metabolism. Minor or non-significant interaction.
pazopanib|ondansetron|20|Serious - Use Alternative|pazopanib and ondansetron both increase  QTc interval. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.  Avoid with congenital long QT syndrome; ECG monitoring recommended with concomitant medications that prolong QT interval, electrolyte abnormalities, CHF, or bradyarrhythmias.
ondansetron|telavancin|20|Serious - Use Alternative|ondansetron and telavancin both increase  QTc interval. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available. Avoid with congenital long QT syndrome; ECG monitoring recommended with concomitant medications that prolong QT interval, electrolyte abnormalities, CHF, or bradyarrhythmias.
orlistat|vitamin a|1|Minor|orlistat decreases levels of vitamin a by inhibition of GI absorption. Applies only to oral form of both agents. Minor or non-significant interaction. Separate by 2 hours.
orlistat|vitamin e|1|Minor|orlistat decreases levels of vitamin e by inhibition of GI absorption. Applies only to oral form of both agents. Minor or non-significant interaction. May cause fat-soluble vitamin malabsorption. Separate by 2 hours.
orlistat|warfarin|2|Significant - Monitor Closely|orlistat decreases effects of warfarin by Other (see comment). Potential for interaction, monitor. Comment: Orlistat may decrease vitamin K absorption; patients on chronic stable doses of warfarin who are prescribed orlistat should be monitored closely for changes in coagulation parameters.
tacrine|orphenadrine|2|Significant - Monitor Closely|tacrine increases and orphenadrine decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Potential for interaction, monitor.
tetracycline|oxacillin|20|Serious - Use Alternative|tetracycline decreases effects of oxacillin by pharmacodynamic antagonism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available. bacteriostatic agents may inhibit the effects of bactericidal agents.
oxandrolone|warfarin|20|Serious - Use Alternative|oxandrolone increases levels of warfarin by decreasing metabolism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
oxaprozin|pralatrexate|11|Significant - Monitor Closely|oxaprozin increases levels of pralatrexate by decreasing renal clearance. Significant interaction possible, monitor closely. NSAIDs may delay pralatrexate clearance, increasing drug exposure. Adjust the pralatrexate dose as needed.
telmisartan|oxaprozin|11|Significant - Monitor Closely|telmisartan, oxaprozin.Either increases toxicity of the other by Other (see comment). Significant interaction possible, monitor closely. Comment: May result in renal function deterioration, particularly in elderly or volume depleted individuals.
oxaprozin|telmisartan|3|Significant - Monitor Closely|oxaprozin decreases effects of telmisartan by pharmacodynamic antagonism. Potential for dangerous interaction. Use with caution and monitor closely.  NSAIDs decrease synthesis of vasodilating renal prostaglandins, and thus affect fluid homeostasis and may diminish antihypertensive effect.
telmisartan|oxaprozin|2|Significant - Monitor Closely|telmisartan and oxaprozin both increase  serum potassium. Potential for interaction, monitor.
oxaprozin|timolol|11|Significant - Monitor Closely|oxaprozin decreases effects of timolol by pharmacodynamic antagonism. Significant interaction possible, monitor closely. Long term (>1 wk) NSAID use.  NSAIDs decrease prostaglandin synthesis.
timolol|oxaprozin|2|Significant - Monitor Closely|timolol and oxaprozin both increase  serum potassium. Potential for interaction, monitor.
trandolapril|oxaprozin|11|Significant - Monitor Closely|trandolapril, oxaprozin.Either increases toxicity of the other by Other (see comment). Significant interaction possible, monitor closely. Comment: May result in renal function deterioration, particularly in elderly or volume depleted individuals.
oxaprozin|trandolapril|3|Significant - Monitor Closely|oxaprozin decreases effects of trandolapril by pharmacodynamic antagonism. Potential for dangerous interaction. Use with caution and monitor closely. NSAIDs decrease synthesis of vasodilating renal prostaglandins, and thus affect fluid homeostasis and may diminish antihypertenisve effect.
warfarin|oxaprozin|3|Significant - Monitor Closely|warfarin and oxaprozin both increase  anticoagulation. Potential for dangerous interaction. Use with caution and monitor closely.
triprolidine|oxazepam|2|Significant - Monitor Closely|triprolidine and oxazepam both increase  sedation. Potential for interaction, monitor.
oxcarbazepine|phenytoin|2|Significant - Monitor Closely|oxcarbazepine increases levels of phenytoin by affecting hepatic enzyme CYP2C9/10 metabolism. Potential for interaction, monitor.
phenytoin|oxcarbazepine|1|Minor|phenytoin decreases levels of oxcarbazepine by increasing metabolism. Minor or non-significant interaction.
oxcarbazepine|rilpivirine|33|Contraindicated|oxcarbazepine decreases levels of rilpivirine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Never use combination. Contraindicated. Rilpivirine should not be co-administered with strong CYP 3A4 inducers. Potential for loss of virologic response and possible resistance to rilpivirine or to the NNRTI class.
oxcarbazepine|roflumilast|33|Contraindicated|oxcarbazepine will decrease the level or effect of roflumilast by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Never use combination. Coadministration not recommended; strong cytochrome P450 enzyme inducers decrease systemic exposure to roflumilast and may reduce the therapeutic effectiveness
oxcarbazepine|telithromycin|1|Minor|oxcarbazepine will decrease the level or effect of telithromycin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor or non-significant interaction.
oxcarbazepine|temsirolimus|11|Significant - Monitor Closely|oxcarbazepine will decrease the level or effect of temsirolimus by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
oxcarbazepine|tramadol|11|Significant - Monitor Closely|oxcarbazepine will decrease the level or effect of tramadol by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely. Decreased AUC  of tramadol and the active metabolite (O-desmethyltramadol) when coadministered with strong CYP3A4 and CYP2B6 inducers
oxcarbazepine|trazodone|11|Significant - Monitor Closely|oxcarbazepine will decrease the level or effect of trazodone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
oxcarbazepine|ulipristal|20|Serious - Use Alternative|oxcarbazepine will decrease the level or effect of ulipristal by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
tacrine|oxybutynin|2|Significant - Monitor Closely|tacrine increases and oxybutynin decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Potential for interaction, monitor.
tacrine|oxybutynin|1|Minor|tacrine decreases effects of oxybutynin by pharmacodynamic antagonism. Minor or non-significant interaction.
paroxetine|oxycodone|20|Serious - Use Alternative|paroxetine will increase the level or effect of oxycodone by  affecting hepatic enzyme CYP2D6 metabolism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
oxycodone|paroxetine|3|Significant - Monitor Closely|oxycodone increases effects of paroxetine by pharmacodynamic synergism. Potential for dangerous interaction. Use with caution and monitor closely. Opioids may enhance the serotonergic effects of SSRIs and increase risk for serotonergic syndrome.
paroxetine|oxycodone|1|Minor|paroxetine decreases effects of oxycodone by decreasing metabolism. Minor or non-significant interaction. Decreased conversion of oxycodone to active metabolite morphine.
sertraline|oxycodone|11|Significant - Monitor Closely|sertraline will increase the level or effect of oxycodone by  affecting hepatic enzyme CYP2B6 metabolism. Significant interaction possible, monitor closely.
oxycodone|sertraline|3|Significant - Monitor Closely|oxycodone increases effects of sertraline by pharmacodynamic synergism. Potential for dangerous interaction. Use with caution and monitor closely. Opioids may enhance the serotonergic effects of SSRIs and increase risk for serotonergic syndrome.
triprolidine|oxycodone|2|Significant - Monitor Closely|triprolidine and oxycodone both increase  sedation. Potential for interaction, monitor.
oxymetholone|warfarin|20|Serious - Use Alternative|oxymetholone increases levels of warfarin by decreasing metabolism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
triprolidine|oxymorphone|2|Significant - Monitor Closely|triprolidine and oxymorphone both increase  sedation. Potential for interaction, monitor.
oxytetracycline|pivmecillinam|20|Serious - Use Alternative|oxytetracycline decreases effects of pivmecillinam by pharmacodynamic antagonism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
oxytetracycline|ticarcillin|20|Serious - Use Alternative|oxytetracycline decreases effects of ticarcillin by pharmacodynamic antagonism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
oxytocin|phenylephrine|11|Significant - Monitor Closely|oxytocin increases effects of phenylephrine by pharmacodynamic synergism. Significant interaction possible, monitor closely.
pazopanib|paclitaxel|11|Significant - Monitor Closely|pazopanib increases levels of paclitaxel by decreasing metabolism. Significant interaction possible, monitor closely.
tacrolimus|paclitaxel|11|Significant - Monitor Closely|tacrolimus will increase the level or effect of paclitaxel by  P-glycoprotein (MDR1) efflux transporter. Significant interaction possible, monitor closely.
telithromycin|paclitaxel|1|Minor|telithromycin will increase the level or effect of paclitaxel by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor or non-significant interaction.
paclitaxel|trastuzumab|3|Significant - Monitor Closely|paclitaxel increases levels of trastuzumab by unknown mechanism. Potential for dangerous interaction. Use with caution and monitor closely. Coadministration increased trastuzumab levels 1.5-fold.
voriconazole|paclitaxel|1|Minor|voriconazole will increase the level or effect of paclitaxel by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor or non-significant interaction.
palifermin|pralatrexate|22|Serious - Use Alternative|palifermin increases toxicity of pralatrexate by Other (see comment). High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available. Comment: Palifermin should not be administered within 24 hours before, during infusion of, or within 24 hours after administration of antineoplastic agents. .
paliperidone|pramipexole|21|Serious - Use Alternative|paliperidone decreases effects of pramipexole by pharmacodynamic antagonism. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available. Never use combination.
paliperidone|risperidone|2|Significant - Monitor Closely|paliperidone and risperidone both increase  antidopaminergic effects, including extrapyramidal symptoms and neuroleptic malignant syndrome. Potential for interaction, monitor.
paliperidone|risperidone|2|Significant - Monitor Closely|paliperidone and risperidone both increase  QTc interval. Potential for interaction, monitor.
paliperidone|risperidone|2|Significant - Monitor Closely|paliperidone and risperidone both increase  sedation. Potential for interaction, monitor.
paliperidone|ropinirole|21|Serious - Use Alternative|paliperidone decreases effects of ropinirole by pharmacodynamic antagonism. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available. Never use combination.
paliperidone|tetrabenazine|3|Significant - Monitor Closely|paliperidone and tetrabenazine both increase  antidopaminergic effects, including extrapyramidal symptoms and neuroleptic malignant syndrome. Potential for dangerous interaction. Use with caution and monitor closely.
triprolidine|paliperidone|2|Significant - Monitor Closely|triprolidine and paliperidone both increase  sedation. Potential for interaction, monitor.
phenytoin|pancuronium|3|Significant - Monitor Closely|phenytoin decreases effects of pancuronium by pharmacodynamic antagonism. Potential for dangerous interaction. Use with caution and monitor closely. Monitor closely for more rapid recovery from neuromuscular blockade than expected; infusion rate requirements may be higher.
quinidine|pancuronium|1|Minor|quinidine increases effects of pancuronium by pharmacodynamic synergism. Minor or non-significant interaction.
quinine|pancuronium|21|Serious - Use Alternative|quinine increases effects of pancuronium by pharmacodynamic synergism. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available. Never use combination. Risk of resp. depression.
tobramycin|pancuronium|20|Serious - Use Alternative|tobramycin increases effects of pancuronium by pharmacodynamic synergism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available. Risk of apnea.
pantoprazole|rilpivirine|33|Contraindicated|pantoprazole decreases levels of rilpivirine by increasing gastric pH. Applies only to oral form of both agents. Never use combination. Contraindicated. Concurrent use may cause treatment failure and/or the development of rilpivirine or NNRTI resistance. Coadministration of a PPI and rilpivirine may result in decreased rilpivirine plasma concentrations, which could cause impaired virologic response to rilpivirine.
phenelzine|paroxetine|33|Contraindicated|phenelzine and paroxetine both increase  serotonin levels. Never use combination.
paroxetine|phentermine|20|Serious - Use Alternative|paroxetine, phentermine.Either increases toxicity of the other by Mechanism: unknown. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available. Risk of serotonin syndrome.
paroxetine|pimozide|33|Contraindicated|paroxetine increases levels of pimozide by affecting hepatic enzyme CYP2D6 metabolism. Never use combination. Contraindicated. Coadministration increases pimozide AUC and Cmax and may result in prolonged QT interval.
paroxetine|propafenone|20|Serious - Use Alternative|paroxetine will increase the level or effect of propafenone by  affecting hepatic enzyme CYP2D6 metabolism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
propafenone|paroxetine|20|Serious - Use Alternative|propafenone will increase the level or effect of paroxetine by  affecting hepatic enzyme CYP2D6 metabolism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available. Monitor heart rate and EKG in patients receiving concurrent paroxetine and propafenone. Doses may need to be reduced.
paroxetine|propranolol|20|Serious - Use Alternative|paroxetine will increase the level or effect of propranolol by  affecting hepatic enzyme CYP2D6 metabolism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
rasagiline|paroxetine|20|Serious - Use Alternative|rasagiline and paroxetine both increase  serotonin levels. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available. Severe CNS toxicity associated with hyperpyrexia has been reported with the combined treatment of an antidepressant and rasagiline. Avoid combination within 14 days of MAOI use.
paroxetine|risperidone|11|Significant - Monitor Closely|paroxetine increases levels of risperidone by decreasing metabolism. Significant interaction possible, monitor closely.
paroxetine|risperidone|2|Significant - Monitor Closely|paroxetine will increase the level or effect of risperidone by  affecting hepatic enzyme CYP2D6 metabolism. Potential for interaction, monitor.
paroxetine|risperidone|2|Significant - Monitor Closely|paroxetine and risperidone both increase  QTc interval. Potential for interaction, monitor.
rizatriptan|paroxetine|3|Significant - Monitor Closely|rizatriptan and paroxetine both increase  serotonin levels. Potential for dangerous interaction. Use with caution and monitor closely.
paroxetine|rizatriptan|1|Minor|paroxetine, rizatriptan. Mechanism: unknown. Minor or non-significant interaction. Risk of weakness, dyspnea, chest pain.
selegiline|paroxetine|33|Contraindicated|selegiline and paroxetine both increase  serotonin levels. Never use combination. At least 14 days should elapse between discontinuation of selegiline and initiation of treatment with a serotonergic drug.
sumatriptan|paroxetine|3|Significant - Monitor Closely|sumatriptan and paroxetine both increase  serotonin levels. Potential for dangerous interaction. Use with caution and monitor closely.
paroxetine|sumatriptan|1|Minor|paroxetine, sumatriptan. Mechanism: unknown. Minor or non-significant interaction. Risk of weakness, dyspnea, chest pain.
paroxetine|tamoxifen|11|Significant - Monitor Closely|paroxetine decreases effects of tamoxifen by decreasing metabolism. Significant interaction possible, monitor closely. Inhibition of CYP2D6 metabolism to tamoxifen's active metabolite, endoxifen.
paroxetine|tamsulosin|2|Significant - Monitor Closely|paroxetine increases levels of tamsulosin by affecting hepatic enzyme CYP2D6 metabolism. Potential for interaction, monitor.
paroxetine|tetrabenazine|11|Significant - Monitor Closely|paroxetine increases effects of tetrabenazine by affecting hepatic enzyme CYP2D6 metabolism. Significant interaction possible, monitor closely. Decrease tetrabenazine dose by 50% when coadministered with strong CYP2D6 inhibitors.
paroxetine|thioridazine|33|Contraindicated|paroxetine increases levels of thioridazine by decreasing metabolism. Never use combination. Risk of long QT syndrome.
paroxetine|thioridazine|22|Serious - Use Alternative|paroxetine will increase the level or effect of thioridazine by  affecting hepatic enzyme CYP2D6 metabolism. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available.
thioridazine|paroxetine|22|Serious - Use Alternative|thioridazine will increase the level or effect of paroxetine by  affecting hepatic enzyme CYP2D6 metabolism. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available.
thioridazine|paroxetine|22|Serious - Use Alternative|thioridazine and paroxetine both increase  QTc interval. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available.
tipranavir|paroxetine|20|Serious - Use Alternative|tipranavir will increase the level or effect of paroxetine by  affecting hepatic enzyme CYP2D6 metabolism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
paroxetine|tolmetin|11|Significant - Monitor Closely|paroxetine, tolmetin.Either increases toxicity of the other by pharmacodynamic synergism. Significant interaction possible, monitor closely. Increased risk of upper GI bleeding. SSRIs inhib. serotonin uptake by platelets.
paroxetine|tolterodine|20|Serious - Use Alternative|paroxetine will increase the level or effect of tolterodine by  affecting hepatic enzyme CYP2D6 metabolism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
paroxetine|tramadol|3|Significant - Monitor Closely|paroxetine and tramadol both increase  serotonin levels. Potential for dangerous interaction. Use with caution and monitor closely.
paroxetine|tramadol|2|Significant - Monitor Closely|paroxetine decreases effects of tramadol by affecting hepatic enzyme CYP2D6 metabolism. Potential for interaction, monitor. Decreased conversion of tramadol to active metabolite.
paroxetine|tramadol|1|Minor|paroxetine decreases effects of tramadol by decreasing metabolism. Minor or non-significant interaction. Decreased conversion of tramadol to active metabolite.
tranylcypromine|paroxetine|33|Contraindicated|tranylcypromine and paroxetine both increase  serotonin levels. Never use combination.
paroxetine|trazodone|22|Serious - Use Alternative|paroxetine and trazodone both increase  serotonin levels. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available.
trazodone|paroxetine|3|Significant - Monitor Closely|trazodone and paroxetine both increase  QTc interval. Potential for dangerous interaction. Use with caution and monitor closely.
paroxetine|trimipramine|22|Serious - Use Alternative|paroxetine and trimipramine both increase  serotonin levels. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available.
trimipramine|paroxetine|3|Significant - Monitor Closely|trimipramine and paroxetine both increase  QTc interval. Potential for dangerous interaction. Use with caution and monitor closely.
paroxetine|venlafaxine|22|Serious - Use Alternative|paroxetine and venlafaxine both increase  serotonin levels. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available.
paroxetine|venlafaxine|2|Significant - Monitor Closely|paroxetine and venlafaxine both increase  QTc interval. Potential for interaction, monitor.
venlafaxine|paroxetine|1|Minor|venlafaxine will increase the level or effect of paroxetine by  affecting hepatic enzyme CYP2D6 metabolism. Minor or non-significant interaction.
paroxetine|warfarin|20|Serious - Use Alternative|paroxetine increases levels of warfarin by decreasing metabolism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
zolmitriptan|paroxetine|3|Significant - Monitor Closely|zolmitriptan and paroxetine both increase  serotonin levels. Potential for dangerous interaction. Use with caution and monitor closely.
paroxetine|zolmitriptan|1|Minor|paroxetine, zolmitriptan. Mechanism: unknown. Minor or non-significant interaction. Risk of weakness, dyspnea, chest pain.
rifabutin|pazopanib|20|Serious - Use Alternative|rifabutin will decrease the level or effect of pazopanib by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
ritonavir|pazopanib|20|Serious - Use Alternative|ritonavir will increase the level or effect of pazopanib by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available. Avoid coadministration of pazopanib with strong CYP3A4 inhibitors if possible; if must coadminister, decrease pazopanib dose to 400 mg/day
saquinavir|pazopanib|22|Serious - Use Alternative|saquinavir increases levels of pazopanib by affecting hepatic/intestinal enzyme CYP3A4 metabolism. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available. Potential for increased toxicity. Increased risk of QT prolongation and cardiac arrhythmias.
simvastatin|pazopanib|11|Significant - Monitor Closely|simvastatin increases toxicity of pazopanib by Other (see comment). Significant interaction possible, monitor closely. Comment: Increased risk of elevated LFTs with pazopanib when coadministered with simvastatin.
pazopanib|toremifene|20|Serious - Use Alternative|pazopanib and toremifene both increase  QTc interval. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available. Concurrent use of toremifene with agents causing  QT prolongation should be avoided. If concomitant use is required it's recommended that toremifene be interrupted. If interruption not possible, patients requiring therapy with a drug that prolongs QT should be closely monitored. ECGs should be obtained for high risk patients.
pazopanib|ziprasidone|2|Significant - Monitor Closely|pazopanib and ziprasidone both increase  QTc interval. Potential for interaction, monitor.
pefloxacin|theophylline|20|Serious - Use Alternative|pefloxacin will increase the level or effect of theophylline by  affecting hepatic enzyme CYP1A2 metabolism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
sulindac|pemetrexed|20|Serious - Use Alternative|sulindac increases levels of pemetrexed by unspecified interaction mechanism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available. Interrupt dosing in all patients taking NSAIDs with long elimination half-lives for at least 5d before, the day of, and 2d following pemetrexed administration. If coadministration of an NSAID is necessary, closely monitor patients for toxicity, especially myelosuppression, renal toxicity, and GI toxicity.
tolmetin|pemetrexed|20|Serious - Use Alternative|tolmetin increases levels of pemetrexed by unspecified interaction mechanism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available. Interrupt dosing in all patients taking NSAIDs with long elimination half-lives for at least 5d before, the day of, and 2d following pemetrexed administration. If coadministration of an NSAID is necessary, closely monitor patients for toxicity, especially myelosuppression, renal toxicity, and GI toxicity.
piroxicam|penbutolol|11|Significant - Monitor Closely|piroxicam decreases effects of penbutolol by pharmacodynamic antagonism. Significant interaction possible, monitor closely. Long term (>1 wk) NSAID use.  NSAIDs decrease prostaglandin synthesis.
penbutolol|piroxicam|2|Significant - Monitor Closely|penbutolol and piroxicam both increase  serum potassium. Potential for interaction, monitor.
prazosin|penbutolol|3|Significant - Monitor Closely|prazosin and penbutolol both increase  anti-hypertensive channel blocking. Potential for dangerous interaction. Use with caution and monitor closely.
terazosin|penbutolol|3|Significant - Monitor Closely|terazosin and penbutolol both increase  anti-hypertensive channel blocking. Potential for dangerous interaction. Use with caution and monitor closely.
penbutolol|terbutaline|11|Significant - Monitor Closely|penbutolol decreases effects of terbutaline by pharmacodynamic antagonism. Significant interaction possible, monitor closely.
penbutolol|terbutaline|2|Significant - Monitor Closely|penbutolol increases and terbutaline decreases serum potassium. Effect of interaction is not clear, use caution. Potential for interaction, monitor.
penbutolol|theophylline|11|Significant - Monitor Closely|penbutolol, theophylline. Other (see comment). Significant interaction possible, monitor closely. Comment: Beta blockers (esp. non selective) antagonize theophylline effects, while at the same time increasing theophylline levels and toxicity (mechanism: decreased theophylline metabolism). Smoking increases risk of interaction.
treprostinil|penbutolol|1|Minor|treprostinil increases effects of penbutolol by pharmacodynamic synergism. Minor or non-significant interaction.
pentaerythritol tetranitrate|tadalafil|22|Serious - Use Alternative|pentaerythritol tetranitrate, tadalafil. Mechanism: additive vasodilation. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available. Potentially fatal hypotension.
pentaerythritol tetranitrate|vardenafil|22|Serious - Use Alternative|pentaerythritol tetranitrate, vardenafil. Mechanism: additive vasodilation. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available. Potentially fatal hypotension.
pentamidine|tacrolimus|2|Significant - Monitor Closely|pentamidine and tacrolimus both increase  nephrotoxicity and/or ototoxicity. Potential for interaction, monitor.
pentamidine|telavancin|22|Serious - Use Alternative|pentamidine and telavancin both increase  QTc interval. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available.
thioridazine|pentamidine|33|Contraindicated|thioridazine and pentamidine both increase  QTc interval. Never use combination.
trimipramine|pentamidine|33|Contraindicated|trimipramine and pentamidine both increase  QTc interval. Never use combination.
pentamidine|voriconazole|22|Serious - Use Alternative|pentamidine and voriconazole both increase  QTc interval. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available.
pentamidine|ziprasidone|33|Contraindicated|pentamidine and ziprasidone both increase  QTc interval. Never use combination.
triprolidine|pentazocine|2|Significant - Monitor Closely|triprolidine and pentazocine both increase  sedation. Potential for interaction, monitor.
pentobarbital|prednisolone|11|Significant - Monitor Closely|pentobarbital will decrease the level or effect of prednisolone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
pentobarbital|prednisone|11|Significant - Monitor Closely|pentobarbital will decrease the level or effect of prednisone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
pentobarbital|quinidine|11|Significant - Monitor Closely|pentobarbital will decrease the level or effect of quinidine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
pentobarbital|roflumilast|33|Contraindicated|pentobarbital will decrease the level or effect of roflumilast by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Never use combination. Coadministration not recommended; strong cytochrome P450 enzyme inducers decrease systemic exposure to roflumilast and may reduce the therapeutic effectiveness
pentobarbital|telithromycin|1|Minor|pentobarbital will decrease the level or effect of telithromycin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor or non-significant interaction.
pentobarbital|temsirolimus|11|Significant - Monitor Closely|pentobarbital will decrease the level or effect of temsirolimus by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
pentobarbital|theophylline|11|Significant - Monitor Closely|pentobarbital will decrease the level or effect of theophylline by  affecting hepatic enzyme CYP1A2 metabolism. Significant interaction possible, monitor closely.
pentobarbital|theophylline|11|Significant - Monitor Closely|pentobarbital will decrease the level or effect of theophylline by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
pentobarbital|tramadol|11|Significant - Monitor Closely|pentobarbital will decrease the level or effect of tramadol by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely. Decreased AUC  of tramadol and the active metabolite (O-desmethyltramadol) when coadministered with strong CYP3A4 and CYP2B6 inducers
pentobarbital|tramadol|2|Significant - Monitor Closely|pentobarbital and tramadol both increase  sedation. Potential for interaction, monitor.
pentobarbital|trazodone|11|Significant - Monitor Closely|pentobarbital will decrease the level or effect of trazodone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
pentobarbital|trazodone|2|Significant - Monitor Closely|pentobarbital and trazodone both increase  sedation. Potential for interaction, monitor.
pentobarbital|trazodone|1|Minor|pentobarbital, trazodone. Other (see comment). Minor or non-significant interaction. Comment: Barbiturates may increase adverse effects, including respiratory depression, produced by toxic doses of TCAs. With therapeutic doses of TCAs, barbiturates increase metabolism and decrease blood concentrations of TCAs.
pentobarbital|triamcinolone|11|Significant - Monitor Closely|pentobarbital will decrease the level or effect of triamcinolone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
pentobarbital|trimipramine|2|Significant - Monitor Closely|pentobarbital and trimipramine both increase  sedation. Potential for interaction, monitor.
pentobarbital|trimipramine|1|Minor|pentobarbital, trimipramine. Other (see comment). Minor or non-significant interaction. Comment: Barbiturates may increase adverse effects, including respiratory depression, produced by toxic doses of TCAs. With therapeutic doses of TCAs, barbiturates increase metabolism and decrease blood concentrations of TCAs.
triprolidine|pentobarbital|2|Significant - Monitor Closely|triprolidine and pentobarbital both increase  sedation. Potential for interaction, monitor.
pentobarbital|vandetanib|33|Contraindicated|pentobarbital decreases levels of vandetanib by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Never use combination. Avoid coadministration with potent CYP3A4 inducers; these drugs reduce exposure to vandetanib by up to 40%.
pentobarbital|verapamil|11|Significant - Monitor Closely|pentobarbital will decrease the level or effect of verapamil by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
pentobarbital|warfarin|20|Serious - Use Alternative|pentobarbital decreases effects of warfarin by increasing metabolism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
pentobarbital|warfarin|11|Significant - Monitor Closely|pentobarbital will decrease the level or effect of warfarin by  affecting hepatic enzyme CYP1A2 metabolism. Significant interaction possible, monitor closely.
pentobarbital|warfarin|11|Significant - Monitor Closely|pentobarbital will decrease the level or effect of warfarin by  affecting hepatic enzyme CYP2C9/10 metabolism. Significant interaction possible, monitor closely.
pentobarbital|warfarin|11|Significant - Monitor Closely|pentobarbital will decrease the level or effect of warfarin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
pentobarbital|warfarin|1|Minor|pentobarbital will decrease the level or effect of warfarin by  affecting hepatic enzyme CYP2C19 metabolism. Minor or non-significant interaction.
pentoxifylline|theophylline|1|Minor|pentoxifylline increases levels of theophylline by decreasing metabolism. Minor or non-significant interaction.
pentoxifylline|warfarin|11|Significant - Monitor Closely|pentoxifylline increases effects of warfarin by pharmacodynamic synergism. Significant interaction possible, monitor closely.
phenytoin|perampanel|20|Serious - Use Alternative|phenytoin will decrease the level or effect of perampanel by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
perindopril|spironolactone|11|Significant - Monitor Closely|perindopril, spironolactone. Mechanism: pharmacodynamic synergism. Significant interaction possible, monitor closely. Risk of hyperkalemia.
tizanidine|perindopril|1|Minor|tizanidine increases effects of perindopril by pharmacodynamic synergism. Minor or non-significant interaction. Risk of hypotension.
treprostinil|perindopril|1|Minor|treprostinil increases effects of perindopril by pharmacodynamic synergism. Minor or non-significant interaction.
perindopril|triamterene|11|Significant - Monitor Closely|perindopril, triamterene. Mechanism: pharmacodynamic synergism. Significant interaction possible, monitor closely. Risk of hyperkalemia.
perphenazine|phendimetrazine|11|Significant - Monitor Closely|perphenazine, phendimetrazine. Mechanism: unknown. Significant interaction possible, monitor closely. Risk of cardiac arrhythmia or sudden death, more likely w/thioridazine than other phenothiazines.  Interaction more likely in certain predisposed pts. only.
perphenazine|phendimetrazine|2|Significant - Monitor Closely|perphenazine increases and phendimetrazine decreases sedation. Effect of interaction is not clear, use caution. Potential for interaction, monitor.
perphenazine|phentermine|11|Significant - Monitor Closely|perphenazine, phentermine. Mechanism: unknown. Significant interaction possible, monitor closely. Risk of cardiac arrhythmia or sudden death, more likely w/thioridazine than other phenothiazines.  Interaction more likely in certain predisposed pts. only.
perphenazine|phentermine|2|Significant - Monitor Closely|perphenazine increases and phentermine decreases sedation. Effect of interaction is not clear, use caution. Potential for interaction, monitor.
perphenazine|terfenadine|33|Contraindicated|perphenazine and terfenadine both increase  QTc interval. Never use combination.
terfenadine|perphenazine|2|Significant - Monitor Closely|terfenadine and perphenazine both increase  sedation. Potential for interaction, monitor.
perphenazine|tetrabenazine|3|Significant - Monitor Closely|perphenazine and tetrabenazine both increase  antidopaminergic effects, including extrapyramidal symptoms and neuroleptic malignant syndrome. Potential for dangerous interaction. Use with caution and monitor closely.
triprolidine|perphenazine|2|Significant - Monitor Closely|triprolidine and perphenazine both increase  sedation. Potential for interaction, monitor.
phenelzine|meperidine|33|Contraindicated|phenelzine and meperidine both increase  serotonin levels. Never use combination.
phenelzine|meperidine|33|Contraindicated|phenelzine increases toxicity of meperidine by unknown mechanism. Never use combination.
rasagiline|meperidine|33|Contraindicated|rasagiline and meperidine both increase  serotonin levels. Never use combination. Risk of serious, sometimes fatal reactions from serotonin syndrome.
ritonavir|meperidine|11|Significant - Monitor Closely|ritonavir increases levels of meperidine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely. Potential for increased toxicity.
ritonavir|meperidine|1|Minor|ritonavir decreases levels of meperidine by increasing metabolism. Minor or non-significant interaction. Ritonavir induces the metabolism of meperidine to normeperidine, increasing CNS toxicity.
selegiline|meperidine|33|Contraindicated|selegiline and meperidine both increase  serotonin levels. Never use combination. At least 14 days should elapse between discontinuation of selegiline and initiation of analgesic.
tipranavir|meperidine|20|Serious - Use Alternative|tipranavir, meperidine. Mechanism: unspecified interaction mechanism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available. Meperidine levels decrease, but metabolite normeperidine levels increase, increasing risk of seizure.
tramadol|meperidine|20|Serious - Use Alternative|tramadol, meperidine. Other (see comment). Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available. Comment: Tramadol may reinitiate opiate dependence in pts. previously addicted to other opiates; it may also provoke withdrawal Sx. in pts. who are currently opiate dependent.
meperidine|tramadol|3|Significant - Monitor Closely|meperidine and tramadol both increase  serotonin levels. Potential for dangerous interaction. Use with caution and monitor closely.
meperidine|tramadol|2|Significant - Monitor Closely|meperidine and tramadol both increase  sedation. Potential for interaction, monitor.
tranylcypromine|meperidine|33|Contraindicated|tranylcypromine and meperidine both increase  serotonin levels. Never use combination.
tranylcypromine|meperidine|33|Contraindicated|tranylcypromine increases toxicity of meperidine by unknown mechanism. Never use combination.
trazodone|meperidine|22|Serious - Use Alternative|trazodone and meperidine both increase  serotonin levels. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available.
meperidine|trazodone|2|Significant - Monitor Closely|meperidine and trazodone both increase  sedation. Potential for interaction, monitor.
trimipramine|meperidine|22|Serious - Use Alternative|trimipramine and meperidine both increase  serotonin levels. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available.
meperidine|trimipramine|2|Significant - Monitor Closely|meperidine and trimipramine both increase  sedation. Potential for interaction, monitor.
triprolidine|meperidine|2|Significant - Monitor Closely|triprolidine and meperidine both increase  sedation. Potential for interaction, monitor.
venlafaxine|meperidine|22|Serious - Use Alternative|venlafaxine and meperidine both increase  serotonin levels. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available.
zolmitriptan|meperidine|3|Significant - Monitor Closely|zolmitriptan and meperidine both increase  serotonin levels. Potential for dangerous interaction. Use with caution and monitor closely.
phenelzine|phendimetrazine|33|Contraindicated|phenelzine increases effects of phendimetrazine by pharmacodynamic synergism. Never use combination. Risk of acute hypertensive episode.
prochlorperazine|phendimetrazine|11|Significant - Monitor Closely|prochlorperazine, phendimetrazine. Mechanism: unknown. Significant interaction possible, monitor closely. Risk of cardiac arrhythmia or sudden death, more likely w/thioridazine than other phenothiazines.  Interaction more likely in certain predisposed pts. only.
prochlorperazine|phendimetrazine|2|Significant - Monitor Closely|prochlorperazine increases and phendimetrazine decreases sedation. Effect of interaction is not clear, use caution. Potential for interaction, monitor.
promethazine|phendimetrazine|11|Significant - Monitor Closely|promethazine, phendimetrazine. Mechanism: unknown. Significant interaction possible, monitor closely. Risk of cardiac arrhythmia or sudden death, more likely w/thioridazine than other phenothiazines.  Interaction more likely in certain predisposed pts. only.
promethazine|phendimetrazine|2|Significant - Monitor Closely|promethazine increases and phendimetrazine decreases sedation. Effect of interaction is not clear, use caution. Potential for interaction, monitor.
rasagiline|phendimetrazine|20|Serious - Use Alternative|rasagiline increases effects of phendimetrazine by pharmacodynamic synergism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available. Phendimetrazine should not be administered during or within 14 days following the use of most MAOIs or drugs with MAO-inhibiting activity. Risk of acute hypertensive episode.
thioridazine|phendimetrazine|11|Significant - Monitor Closely|thioridazine, phendimetrazine. Mechanism: unknown. Significant interaction possible, monitor closely. Risk of cardiac arrhythmia or sudden death, more likely w/thioridazine than other phenothiazines.  Interaction more likely in certain predisposed pts. only.
thioridazine|phendimetrazine|2|Significant - Monitor Closely|thioridazine increases and phendimetrazine decreases sedation. Effect of interaction is not clear, use caution. Potential for interaction, monitor.
tramadol|phendimetrazine|2|Significant - Monitor Closely|tramadol increases and phendimetrazine decreases sedation. Effect of interaction is not clear, use caution. Potential for interaction, monitor.
tranylcypromine|phendimetrazine|33|Contraindicated|tranylcypromine increases effects of phendimetrazine by pharmacodynamic synergism. Never use combination. Risk of acute hypertensive episode.
trifluoperazine|phendimetrazine|11|Significant - Monitor Closely|trifluoperazine, phendimetrazine. Mechanism: unknown. Significant interaction possible, monitor closely. Risk of cardiac arrhythmia or sudden death, more likely w/thioridazine than other phenothiazines.  Interaction more likely in certain predisposed pts. only.
trifluoperazine|phendimetrazine|2|Significant - Monitor Closely|trifluoperazine increases and phendimetrazine decreases sedation. Effect of interaction is not clear, use caution. Potential for interaction, monitor.
triprolidine|phendimetrazine|2|Significant - Monitor Closely|triprolidine increases and phendimetrazine decreases sedation. Effect of interaction is not clear, use caution. Potential for interaction, monitor.
phenelzine|phentermine|33|Contraindicated|phenelzine increases effects of phentermine by pharmacodynamic synergism. Never use combination. Risk of acute hypertensive episode.
phenelzine|phenylephrine|33|Contraindicated|phenelzine increases effects of phenylephrine by pharmacodynamic synergism. Never use combination. Risk of acute hypertensive episode.
phenelzine|pirbuterol|21|Serious - Use Alternative|phenelzine increases effects of pirbuterol by pharmacodynamic synergism. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available. Never use combination. Risk of acute hypertensive episode.
phenelzine|protriptyline|33|Contraindicated|phenelzine and protriptyline both increase  serotonin levels. Never use combination.
phenelzine|pseudoephedrine|33|Contraindicated|phenelzine increases effects of pseudoephedrine by pharmacodynamic synergism. Never use combination. Risk of acute hypertensive episode.
rizatriptan|phenelzine|22|Serious - Use Alternative|rizatriptan and phenelzine both increase  serotonin levels. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available.
phenelzine|rizatriptan|21|Serious - Use Alternative|phenelzine increases levels of rizatriptan by decreasing metabolism. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available. Never use combination.
phenelzine|sertraline|33|Contraindicated|phenelzine and sertraline both increase  serotonin levels. Never use combination.
sumatriptan|phenelzine|22|Serious - Use Alternative|sumatriptan and phenelzine both increase  serotonin levels. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available.
phenelzine|sumatriptan|21|Serious - Use Alternative|phenelzine increases levels of sumatriptan by decreasing metabolism. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available. Never use combination.
phenelzine|terbutaline|21|Serious - Use Alternative|phenelzine increases effects of terbutaline by pharmacodynamic synergism. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available. Never use combination. Risk of acute hypertensive episode.
tetrabenazine|phenelzine|33|Contraindicated|tetrabenazine, phenelzine. Other (see comment). Never use combination. Comment: Risk of acute hypertensive episode; separate by 14 d.  Mechanism: MAOI causes accumulation of NE in neuron and tetrabenazine stimulates NE release.
tolcapone|phenelzine|21|Serious - Use Alternative|tolcapone increases effects of phenelzine by pharmacodynamic synergism. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available. Never use combination.
phenelzine|tramadol|22|Serious - Use Alternative|phenelzine and tramadol both increase  serotonin levels. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available.
phenelzine|tramadol|20|Serious - Use Alternative|phenelzine increases toxicity of tramadol by unknown mechanism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available. Risk of hypotension, hyperpyrexia, somnolence, or death; separate by 14 d.
phenelzine|tranylcypromine|33|Contraindicated|phenelzine and tranylcypromine both increase  serotonin levels. Never use combination.
phenelzine|trazodone|33|Contraindicated|phenelzine and trazodone both increase  serotonin levels. Never use combination.
phenelzine|trimipramine|33|Contraindicated|phenelzine and trimipramine both increase  serotonin levels. Never use combination.
phenelzine|venlafaxine|33|Contraindicated|phenelzine and venlafaxine both increase  serotonin levels. Never use combination.
phenelzine|vilazodone|33|Contraindicated|phenelzine, vilazodone.Either increases toxicity of the other by serotonin levels. Never use combination. Coadministration with MAO-A inhibitors are contraindicated. Do not prescribe vilazodone within 14 days of discontinuing or starting an MAO inhibitor.
zolmitriptan|phenelzine|22|Serious - Use Alternative|zolmitriptan and phenelzine both increase  serotonin levels. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available.
phenelzine|zolmitriptan|21|Serious - Use Alternative|phenelzine increases levels of zolmitriptan by decreasing metabolism. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available. Never use combination.
phenobarbital|prednisolone|11|Significant - Monitor Closely|phenobarbital will decrease the level or effect of prednisolone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
phenobarbital|prednisolone|11|Significant - Monitor Closely|phenobarbital will decrease the level or effect of prednisolone by  P-glycoprotein (MDR1) efflux transporter. Significant interaction possible, monitor closely.
phenobarbital|prednisone|11|Significant - Monitor Closely|phenobarbital will decrease the level or effect of prednisone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
phenobarbital|prednisone|11|Significant - Monitor Closely|phenobarbital will decrease the level or effect of prednisone by  P-glycoprotein (MDR1) efflux transporter. Significant interaction possible, monitor closely.
phenobarbital|propranolol|11|Significant - Monitor Closely|phenobarbital decreases levels of propranolol by increasing metabolism. Significant interaction possible, monitor closely. Consider a higher beta-blocker dose during coadministration of phenobarbital.  Atenolol, sotalol, nadolol less likely to be affected than other beta blockers.
phenobarbital|quinidine|11|Significant - Monitor Closely|phenobarbital will decrease the level or effect of quinidine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
phenobarbital|regorafenib|33|Contraindicated|phenobarbital, regorafenib. affecting hepatic/intestinal enzyme CYP3A4 metabolism. Never use combination. Strong CYP3A4 inducers decrease regorafenib levels and increase exposure of the active metabolite M-5.
phenobarbital|rilpivirine|33|Contraindicated|phenobarbital decreases levels of rilpivirine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Never use combination. Contraindicated. Rilpivirine should not be co-administered with strong CYP 3A4 inducers. Potential for loss of virologic response and possible resistance to rilpivirine or to the NNRTI class.
phenobarbital|roflumilast|33|Contraindicated|phenobarbital will decrease the level or effect of roflumilast by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Never use combination. Coadministration not recommended; strong cytochrome P450 enzyme inducers decrease systemic exposure to roflumilast and may reduce the therapeutic effectiveness
phenobarbital|roflumilast|33|Contraindicated|phenobarbital will decrease the level or effect of roflumilast by  affecting hepatic enzyme CYP1A2 metabolism. Never use combination. Coadministration not recommended; strong cytochrome P450 enzyme inducers decrease systemic exposure to roflumilast and may reduce the therapeutic effectiveness
phenobarbital|rufinamide|11|Significant - Monitor Closely|phenobarbital decreases levels of rufinamide by increasing metabolism. Significant interaction possible, monitor closely.
phenobarbital|sunitinib|11|Significant - Monitor Closely|phenobarbital will decrease the level or effect of sunitinib by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
phenobarbital|tacrolimus|11|Significant - Monitor Closely|phenobarbital will decrease the level or effect of tacrolimus by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
phenobarbital|tacrolimus|11|Significant - Monitor Closely|phenobarbital will decrease the level or effect of tacrolimus by  P-glycoprotein (MDR1) efflux transporter. Significant interaction possible, monitor closely.
phenobarbital|telithromycin|1|Minor|phenobarbital will decrease the level or effect of telithromycin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor or non-significant interaction.
phenobarbital|temsirolimus|11|Significant - Monitor Closely|phenobarbital will decrease the level or effect of temsirolimus by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
phenobarbital|theophylline|11|Significant - Monitor Closely|phenobarbital will decrease the level or effect of theophylline by  affecting hepatic enzyme CYP1A2 metabolism. Significant interaction possible, monitor closely.
phenobarbital|theophylline|11|Significant - Monitor Closely|phenobarbital will decrease the level or effect of theophylline by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
phenobarbital|tipranavir|11|Significant - Monitor Closely|phenobarbital will decrease the level or effect of tipranavir by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
phenobarbital|tramadol|11|Significant - Monitor Closely|phenobarbital will decrease the level or effect of tramadol by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely. Decreased AUC  of tramadol and the active metabolite (O-desmethyltramadol) when coadministered with strong CYP3A4 and CYP2B6 inducers
phenobarbital|tramadol|2|Significant - Monitor Closely|phenobarbital and tramadol both increase  sedation. Potential for interaction, monitor.
phenobarbital|trazodone|11|Significant - Monitor Closely|phenobarbital will decrease the level or effect of trazodone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
phenobarbital|trazodone|2|Significant - Monitor Closely|phenobarbital and trazodone both increase  sedation. Potential for interaction, monitor.
phenobarbital|trazodone|1|Minor|phenobarbital, trazodone. Other (see comment). Minor or non-significant interaction. Comment: Barbiturates may increase adverse effects, including respiratory depression, produced by toxic doses of TCAs. With therapeutic doses of TCAs, barbiturates increase metabolism and decrease blood concentrations of TCAs.
phenobarbital|triamcinolone|11|Significant - Monitor Closely|phenobarbital will decrease the level or effect of triamcinolone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
phenobarbital|triamcinolone|11|Significant - Monitor Closely|phenobarbital will decrease the level or effect of triamcinolone by  P-glycoprotein (MDR1) efflux transporter. Significant interaction possible, monitor closely.
phenobarbital|trimipramine|2|Significant - Monitor Closely|phenobarbital and trimipramine both increase  sedation. Potential for interaction, monitor.
phenobarbital|trimipramine|1|Minor|phenobarbital, trimipramine. Other (see comment). Minor or non-significant interaction. Comment: Barbiturates may increase adverse effects, including respiratory depression, produced by toxic doses of TCAs. With therapeutic doses of TCAs, barbiturates increase metabolism and decrease blood concentrations of TCAs.
triprolidine|phenobarbital|2|Significant - Monitor Closely|triprolidine and phenobarbital both increase  sedation. Potential for interaction, monitor.
phenobarbital|ulipristal|20|Serious - Use Alternative|phenobarbital will decrease the level or effect of ulipristal by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
phenobarbital|vandetanib|33|Contraindicated|phenobarbital decreases levels of vandetanib by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Never use combination. Avoid coadministration with potent CYP3A4 inducers; these drugs reduce exposure to vandetanib by up to 40%.
phenobarbital|vemurafenib|20|Serious - Use Alternative|phenobarbital decreases levels of vemurafenib by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
phenobarbital|verapamil|11|Significant - Monitor Closely|phenobarbital will decrease the level or effect of verapamil by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
phenobarbital|voriconazole|33|Contraindicated|phenobarbital decreases levels of voriconazole by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Never use combination.
phenobarbital|warfarin|20|Serious - Use Alternative|phenobarbital decreases effects of warfarin by increasing metabolism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
phenobarbital|warfarin|11|Significant - Monitor Closely|phenobarbital will decrease the level or effect of warfarin by  affecting hepatic enzyme CYP1A2 metabolism. Significant interaction possible, monitor closely.
phenobarbital|warfarin|11|Significant - Monitor Closely|phenobarbital will decrease the level or effect of warfarin by  affecting hepatic enzyme CYP2C9/10 metabolism. Significant interaction possible, monitor closely.
phenobarbital|warfarin|11|Significant - Monitor Closely|phenobarbital will decrease the level or effect of warfarin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
phenobarbital|warfarin|1|Minor|phenobarbital will decrease the level or effect of warfarin by  affecting hepatic enzyme CYP2C19 metabolism. Minor or non-significant interaction.
tadalafil|phenoxybenzamine|11|Significant - Monitor Closely|tadalafil increases effects of phenoxybenzamine by pharmacodynamic synergism. Significant interaction possible, monitor closely. Risk of hypotension.
phenoxybenzamine|tamsulosin|20|Serious - Use Alternative|phenoxybenzamine, tamsulosin.Either increases effects of the other by additive vasodilation. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available. Risk of hypotension.
treprostinil|phenoxybenzamine|1|Minor|treprostinil increases effects of phenoxybenzamine by pharmacodynamic synergism. Minor or non-significant interaction.
vardenafil|phenoxybenzamine|21|Serious - Use Alternative|vardenafil increases effects of phenoxybenzamine by pharmacodynamic synergism. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available. Never use combination. Risk of hypotension.
prochlorperazine|phentermine|11|Significant - Monitor Closely|prochlorperazine, phentermine. Mechanism: unknown. Significant interaction possible, monitor closely. Risk of cardiac arrhythmia or sudden death, more likely w/thioridazine than other phenothiazines.  Interaction more likely in certain predisposed pts. only.
prochlorperazine|phentermine|2|Significant - Monitor Closely|prochlorperazine increases and phentermine decreases sedation. Effect of interaction is not clear, use caution. Potential for interaction, monitor.
promazine|phentermine|11|Significant - Monitor Closely|promazine, phentermine. Mechanism: unknown. Significant interaction possible, monitor closely. Risk of cardiac arrhythmia or sudden death, more likely w/thioridazine than other phenothiazines.  Interaction more likely in certain predisposed pts. only.
promethazine|phentermine|11|Significant - Monitor Closely|promethazine, phentermine. Mechanism: unknown. Significant interaction possible, monitor closely. Risk of cardiac arrhythmia or sudden death, more likely w/thioridazine than other phenothiazines.  Interaction more likely in certain predisposed pts. only.
promethazine|phentermine|2|Significant - Monitor Closely|promethazine increases and phentermine decreases sedation. Effect of interaction is not clear, use caution. Potential for interaction, monitor.
rasagiline|phentermine|20|Serious - Use Alternative|rasagiline increases effects of phentermine by pharmacodynamic synergism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available. Phentermine should not be administered during or within 14 days following the use of most MAOIs or drugs with MAO-inhibiting activity. Risk of acute hypertensive episode. .
thioridazine|phentermine|11|Significant - Monitor Closely|thioridazine, phentermine. Mechanism: unknown. Significant interaction possible, monitor closely. Risk of cardiac arrhythmia or sudden death, more likely w/thioridazine than other phenothiazines.  Interaction more likely in certain predisposed pts. only.
thioridazine|phentermine|2|Significant - Monitor Closely|thioridazine increases and phentermine decreases sedation. Effect of interaction is not clear, use caution. Potential for interaction, monitor.
tramadol|phentermine|2|Significant - Monitor Closely|tramadol increases and phentermine decreases sedation. Effect of interaction is not clear, use caution. Potential for interaction, monitor.
tranylcypromine|phentermine|33|Contraindicated|tranylcypromine increases effects of phentermine by pharmacodynamic synergism. Never use combination. Risk of acute hypertensive episode.
trifluoperazine|phentermine|11|Significant - Monitor Closely|trifluoperazine, phentermine. Mechanism: unknown. Significant interaction possible, monitor closely. Risk of cardiac arrhythmia or sudden death, more likely w/thioridazine than other phenothiazines.  Interaction more likely in certain predisposed pts. only.
trifluoperazine|phentermine|2|Significant - Monitor Closely|trifluoperazine increases and phentermine decreases sedation. Effect of interaction is not clear, use caution. Potential for interaction, monitor.
triprolidine|phentermine|2|Significant - Monitor Closely|triprolidine increases and phentermine decreases sedation. Effect of interaction is not clear, use caution. Potential for interaction, monitor.
venlafaxine|phentermine|20|Serious - Use Alternative|venlafaxine, phentermine.Either increases toxicity of the other by Mechanism: unknown. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available. Risk of serotonin syndrome.
tadalafil|phentolamine|11|Significant - Monitor Closely|tadalafil increases effects of phentolamine by pharmacodynamic synergism. Significant interaction possible, monitor closely. Risk of hypotension.
phentolamine|tamsulosin|20|Serious - Use Alternative|phentolamine, tamsulosin.Either increases effects of the other by additive vasodilation. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available. Risk of hypotension.
treprostinil|phentolamine|1|Minor|treprostinil increases effects of phentolamine by pharmacodynamic synergism. Minor or non-significant interaction.
vardenafil|phentolamine|21|Serious - Use Alternative|vardenafil increases effects of phentolamine by pharmacodynamic synergism. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available. Never use combination. Risk of hypotension.
protriptyline|phenylephrine|20|Serious - Use Alternative|protriptyline, phenylephrine. Other (see comment). Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available. Comment: Tricyclic antidepressants increase or decrease effects of sympathomimetics, by blocking reuptake of NE, or blocking uptake of indirect sympathomimetics into the adrenergic neuron.
protriptyline|phenylephrine|2|Significant - Monitor Closely|protriptyline increases and phenylephrine decreases sedation. Effect of interaction is not clear, use caution. Potential for interaction, monitor.
rasagiline|phenylephrine|11|Significant - Monitor Closely|rasagiline increases effects of phenylephrine by pharmacodynamic synergism. Significant interaction possible, monitor closely. Risk of acute hypertensive episode.
tranylcypromine|phenylephrine|33|Contraindicated|tranylcypromine increases effects of phenylephrine by pharmacodynamic synergism. Never use combination. Risk of acute hypertensive episode.
trimipramine|phenylephrine|20|Serious - Use Alternative|trimipramine, phenylephrine. Other (see comment). Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available. Comment: Tricyclic antidepressants increase or decrease effects of sympathomimetics, by blocking reuptake of NE, or blocking uptake of indirect sympathomimetics into the adrenergic neuron.
trimipramine|phenylephrine|2|Significant - Monitor Closely|trimipramine increases and phenylephrine decreases sedation. Effect of interaction is not clear, use caution. Potential for interaction, monitor.
phenytoin|ponatinib|20|Serious - Use Alternative|phenytoin decreases levels of ponatinib by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available. Avoid unless the coadministration outweighs the possible risk of ponatinib underexposure; monitor for signs of reduced efficacy.
phenytoin|posaconazole|22|Serious - Use Alternative|phenytoin will decrease the level or effect of posaconazole by  P-glycoprotein (MDR1) efflux transporter. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available.
phenytoin|posaconazole|11|Significant - Monitor Closely|phenytoin decreases levels of posaconazole by increasing metabolism. Significant interaction possible, monitor closely.
phenytoin|praziquantel|33|Contraindicated|phenytoin decreases levels of praziquantel by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Never use combination. Strong CYP450 inducers significantly decrease praziquantel blood levels.
phenytoin|prednisolone|11|Significant - Monitor Closely|phenytoin will decrease the level or effect of prednisolone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
phenytoin|prednisolone|11|Significant - Monitor Closely|phenytoin will decrease the level or effect of prednisolone by  P-glycoprotein (MDR1) efflux transporter. Significant interaction possible, monitor closely.
phenytoin|prednisone|11|Significant - Monitor Closely|phenytoin will decrease the level or effect of prednisone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
phenytoin|prednisone|11|Significant - Monitor Closely|phenytoin will decrease the level or effect of prednisone by  P-glycoprotein (MDR1) efflux transporter. Significant interaction possible, monitor closely.
phenytoin|quetiapine|11|Significant - Monitor Closely|phenytoin will decrease the level or effect of quetiapine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely. Increased doses of quetiapine may be required to maintain control of psychotic symptoms in patients receiving quetiapine and phenytoin. Caution should be taken if phenytoin is withdrawn from therapy or replaced with a non-inducing anticonvulsant.
phenytoin|quinidine|11|Significant - Monitor Closely|phenytoin will decrease the level or effect of quinidine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
phenytoin|quinidine|11|Significant - Monitor Closely|phenytoin decreases levels of quinidine by increasing metabolism. Significant interaction possible, monitor closely.
phenytoin|regorafenib|33|Contraindicated|phenytoin, regorafenib. affecting hepatic/intestinal enzyme CYP3A4 metabolism. Never use combination. Strong CYP3A4 inducers decrease regorafenib levels and increase exposure of the active metabolite M-5.
phenytoin|rilpivirine|33|Contraindicated|phenytoin decreases levels of rilpivirine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Never use combination. Contraindicated. Rilpivirine should not be co-administered with strong CYP 3A4 inducers. Potential for loss of virologic response and possible resistance to rilpivirine or to the NNRTI class.
rufinamide|phenytoin|11|Significant - Monitor Closely|rufinamide increases levels of phenytoin by decreasing renal clearance. Significant interaction possible, monitor closely.
phenytoin|rufinamide|11|Significant - Monitor Closely|phenytoin decreases levels of rufinamide by increasing metabolism. Significant interaction possible, monitor closely.
sertraline|phenytoin|2|Significant - Monitor Closely|sertraline increases levels of phenytoin by decreasing metabolism. Potential for interaction, monitor.
phenytoin|sirolimus|21|Serious - Use Alternative|phenytoin will decrease the level or effect of sirolimus by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available. Never use combination.
phenytoin|sirolimus|11|Significant - Monitor Closely|phenytoin will decrease the level or effect of sirolimus by  P-glycoprotein (MDR1) efflux transporter. Significant interaction possible, monitor closely.
sucralfate|phenytoin|1|Minor|sucralfate decreases levels of phenytoin by inhibition of GI absorption. Applies only to oral form of both agents. Minor or non-significant interaction.
sulfadiazine|phenytoin|1|Minor|sulfadiazine increases levels of phenytoin by decreasing metabolism. Minor or non-significant interaction.
phenytoin|sunitinib|11|Significant - Monitor Closely|phenytoin will decrease the level or effect of sunitinib by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
phenytoin|tacrolimus|11|Significant - Monitor Closely|phenytoin will decrease the level or effect of tacrolimus by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
phenytoin|tacrolimus|11|Significant - Monitor Closely|phenytoin will decrease the level or effect of tacrolimus by  P-glycoprotein (MDR1) efflux transporter. Significant interaction possible, monitor closely. Tacrolimus dosage requirements may be greater when administered concurrently with phenytoin.
phenytoin|telithromycin|33|Contraindicated|phenytoin decreases levels of telithromycin by increasing metabolism. Never use combination. Separate by 2 wks.
phenytoin|telithromycin|1|Minor|phenytoin will decrease the level or effect of telithromycin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor or non-significant interaction.
phenytoin|temsirolimus|11|Significant - Monitor Closely|phenytoin will decrease the level or effect of temsirolimus by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
phenytoin|theophylline|11|Significant - Monitor Closely|phenytoin will decrease the level or effect of theophylline by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
ticlopidine|phenytoin|11|Significant - Monitor Closely|ticlopidine will increase the level or effect of phenytoin by  affecting hepatic enzyme CYP2C9/10 metabolism. Significant interaction possible, monitor closely.
phenytoin|tipranavir|11|Significant - Monitor Closely|phenytoin will decrease the level or effect of tipranavir by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
phenytoin|tobramycin|11|Significant - Monitor Closely|phenytoin will decrease the level or effect of tobramycin by  P-glycoprotein (MDR1) efflux transporter. Significant interaction possible, monitor closely.
phenytoin|tofacitinib|11|Significant - Monitor Closely|phenytoin will decrease the level or effect of tofacitinib by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely. Loss of, or decreased response to tofacitinib may occur when coadministered with potent CYP3A4 inducers
tolbutamide|phenytoin|1|Minor|tolbutamide increases levels of phenytoin by plasma protein binding competition. Minor or non-significant interaction.
phenytoin|tolbutamide|1|Minor|phenytoin decreases effects of tolbutamide by pharmacodynamic antagonism. Minor or non-significant interaction.
phenytoin|tolvaptan|21|Serious - Use Alternative|phenytoin will decrease the level or effect of tolvaptan by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available. Never use combination.
phenytoin|tolvaptan|11|Significant - Monitor Closely|phenytoin will decrease the level or effect of tolvaptan by  P-glycoprotein (MDR1) efflux transporter. Significant interaction possible, monitor closely.
phenytoin|topiramate|11|Significant - Monitor Closely|phenytoin decreases levels of topiramate by increasing metabolism. Significant interaction possible, monitor closely.
topiramate|phenytoin|1|Minor|topiramate increases levels of phenytoin by decreasing metabolism. Minor or non-significant interaction.
phenytoin|tramadol|11|Significant - Monitor Closely|phenytoin will decrease the level or effect of tramadol by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely. Decreased AUC  of tramadol and the active metabolite (O-desmethyltramadol) when coadministered with strong CYP3A4 and CYP2B6 inducers
trazodone|phenytoin|1|Minor|trazodone increases levels of phenytoin by unspecified interaction mechanism. Minor or non-significant interaction.
phenytoin|triamcinolone|11|Significant - Monitor Closely|phenytoin will decrease the level or effect of triamcinolone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
phenytoin|triamcinolone|11|Significant - Monitor Closely|phenytoin will decrease the level or effect of triamcinolone by  P-glycoprotein (MDR1) efflux transporter. Significant interaction possible, monitor closely.
phenytoin|triazolam|11|Significant - Monitor Closely|phenytoin will decrease the level or effect of triazolam by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
phenytoin|tubocurarine|1|Minor|phenytoin decreases effects of tubocurarine by pharmacodynamic antagonism. Minor or non-significant interaction.
phenytoin|ulipristal|20|Serious - Use Alternative|phenytoin will decrease the level or effect of ulipristal by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
phenytoin|vandetanib|33|Contraindicated|phenytoin decreases levels of vandetanib by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Never use combination. Avoid coadministration with potent CYP3A4 inducers; these drugs reduce exposure to vandetanib by up to 40%.
phenytoin|vecuronium|3|Significant - Monitor Closely|phenytoin decreases effects of vecuronium by pharmacodynamic antagonism. Potential for dangerous interaction. Use with caution and monitor closely. Monitor closely for more rapid recovery from neuromuscular blockade than expected; infusion rate requirements may be higher.
phenytoin|vemurafenib|20|Serious - Use Alternative|phenytoin decreases levels of vemurafenib by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
phenytoin|vemurafenib|2|Significant - Monitor Closely|phenytoin decreases levels of vemurafenib by P-glycoprotein (MDR1) efflux transporter. Potential for interaction, monitor.
phenytoin|verapamil|11|Significant - Monitor Closely|phenytoin will decrease the level or effect of verapamil by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
vigabatrin|phenytoin|1|Minor|vigabatrin decreases levels of phenytoin by unknown mechanism. Minor or non-significant interaction.
vinblastine|phenytoin|11|Significant - Monitor Closely|vinblastine decreases levels of phenytoin by inhibition of GI absorption. Applies only to oral form of both agents. Significant interaction possible, monitor closely.
vinblastine|phenytoin|11|Significant - Monitor Closely|vinblastine decreases levels of phenytoin by increasing metabolism. Significant interaction possible, monitor closely.
vinblastine|phenytoin|11|Significant - Monitor Closely|vinblastine will decrease the level or effect of phenytoin by  P-glycoprotein (MDR1) efflux transporter. Significant interaction possible, monitor closely. Concurrent use of vinblastine and phenytoin may reduce phenytoin plasma levels and increase seizure activity.
phenytoin|vinblastine|1|Minor|phenytoin will decrease the level or effect of vinblastine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor or non-significant interaction.
phenytoin|vinblastine|1|Minor|phenytoin will decrease the level or effect of vinblastine by  P-glycoprotein (MDR1) efflux transporter. Minor or non-significant interaction. Phenytoin may be less likely to interact with vinblastine. Careful monitoring of patients for seizure activity is recommended, as is monitoring of plasma phenytoin levels.
voriconazole|phenytoin|11|Significant - Monitor Closely|voriconazole will increase the level or effect of phenytoin by  affecting hepatic enzyme CYP2C9/10 metabolism. Significant interaction possible, monitor closely.
phenytoin|voriconazole|1|Minor|phenytoin decreases levels of voriconazole by increasing metabolism. Minor or non-significant interaction.
phenytoin|warfarin|11|Significant - Monitor Closely|phenytoin will decrease the level or effect of warfarin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
warfarin|phenytoin|11|Significant - Monitor Closely|warfarin increases levels of phenytoin by unknown mechanism. Significant interaction possible, monitor closely.
phenytoin|warfarin|11|Significant - Monitor Closely|phenytoin, warfarin. Other (see comment). Significant interaction possible, monitor closely. Comment: Hydantoin anticonvulsants increase anticoagulant effects at first, then decrease those effects with continued use (2+ wks).  There are multiple mechanisms involved, including enzyme induction, plasma protein binding site competition, and additive effects on prothrombin time.
tacrine|pilocarpine|11|Significant - Monitor Closely|tacrine increases effects of pilocarpine by pharmacodynamic synergism. Significant interaction possible, monitor closely.
pilocarpine|tacrine|2|Significant - Monitor Closely|pilocarpine and tacrine both increase  cholinergic effects/transmission. Potential for interaction, monitor.
pimozide|posaconazole|22|Serious - Use Alternative|pimozide and posaconazole both increase  QTc interval. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available.
posaconazole|pimozide|21|Serious - Use Alternative|posaconazole increases levels of pimozide by decreasing metabolism. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available. Never use combination. Risk of QT interval prolongation.
posaconazole|pimozide|1|Minor|posaconazole will increase the level or effect of pimozide by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor or non-significant interaction.
ritonavir|pimozide|33|Contraindicated|ritonavir increases levels of pimozide by decreasing metabolism. Never use combination. Risk of QT interval prolongation.
ritonavir|pimozide|1|Minor|ritonavir will increase the level or effect of pimozide by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor or non-significant interaction.
saquinavir|pimozide|21|Serious - Use Alternative|saquinavir increases levels of pimozide by decreasing metabolism. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available. Never use combination. Risk of prolonged QTc interval.
sertraline|pimozide|33|Contraindicated|sertraline increases levels of pimozide by decreasing metabolism. Never use combination. Risk of prolonged QTc interval.
telaprevir|pimozide|33|Contraindicated|telaprevir increases levels of pimozide by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Never use combination. Contraindicated. Potential for serious and/or life-threatening adverse reactions such as cardiac arrhythmias secondary to increases in plasma concentrations of antiarrhythmics.
pimozide|telavancin|22|Serious - Use Alternative|pimozide and telavancin both increase  QTc interval. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available.
telithromycin|pimozide|33|Contraindicated|telithromycin increases levels of pimozide by decreasing metabolism. Never use combination. Risk of QT interval prolongation.
pimozide|telithromycin|22|Serious - Use Alternative|pimozide and telithromycin both increase  QTc interval. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available.
telithromycin|pimozide|1|Minor|telithromycin will increase the level or effect of pimozide by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor or non-significant interaction.
pimozide|tetrabenazine|3|Significant - Monitor Closely|pimozide and tetrabenazine both increase  antidopaminergic effects, including extrapyramidal symptoms and neuroleptic malignant syndrome. Potential for dangerous interaction. Use with caution and monitor closely.
thioridazine|pimozide|33|Contraindicated|thioridazine and pimozide both increase  QTc interval. Never use combination.
pimozide|thioridazine|2|Significant - Monitor Closely|pimozide and thioridazine both increase  antidopaminergic effects, including extrapyramidal symptoms and neuroleptic malignant syndrome. Potential for interaction, monitor.
pimozide|thioridazine|2|Significant - Monitor Closely|pimozide and thioridazine both increase  sedation. Potential for interaction, monitor.
pimozide|thiothixene|2|Significant - Monitor Closely|pimozide and thiothixene both increase  antidopaminergic effects, including extrapyramidal symptoms and neuroleptic malignant syndrome. Potential for interaction, monitor.
pimozide|thiothixene|2|Significant - Monitor Closely|pimozide and thiothixene both increase  sedation. Potential for interaction, monitor.
tipranavir|pimozide|33|Contraindicated|tipranavir increases levels of pimozide by decreasing metabolism. Never use combination. Risk of QT interval prolongation.
pimozide|toremifene|33|Contraindicated|pimozide and toremifene both increase  QTc interval. Never use combination. Concurrent use of pimozide with other agents that prolong QTc interval is contraindicated.
trimipramine|pimozide|33|Contraindicated|trimipramine and pimozide both increase  QTc interval. Never use combination.
pimozide|trimipramine|2|Significant - Monitor Closely|pimozide and trimipramine both increase  sedation. Potential for interaction, monitor.
triprolidine|pimozide|2|Significant - Monitor Closely|triprolidine and pimozide both increase  sedation. Potential for interaction, monitor.
troleandomycin|pimozide|33|Contraindicated|troleandomycin increases toxicity of pimozide by decreasing metabolism. Never use combination. Risk of prolonged QTc interval.
troleandomycin|pimozide|1|Minor|troleandomycin will increase the level or effect of pimozide by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor or non-significant interaction.
voriconazole|pimozide|33|Contraindicated|voriconazole will increase the level or effect of pimozide by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Never use combination.
voriconazole|pimozide|33|Contraindicated|voriconazole increases levels of pimozide by decreasing metabolism. Never use combination. Risk of QT interval prolongation.
pimozide|voriconazole|22|Serious - Use Alternative|pimozide and voriconazole both increase  QTc interval. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available.
zileuton|pimozide|21|Serious - Use Alternative|zileuton increases levels of pimozide by decreasing metabolism. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available. Never use combination. May prolong QTc interval.
pimozide|ziprasidone|33|Contraindicated|pimozide and ziprasidone both increase  QTc interval. Never use combination.
pimozide|ziprasidone|2|Significant - Monitor Closely|pimozide and ziprasidone both increase  antidopaminergic effects, including extrapyramidal symptoms and neuroleptic malignant syndrome. Potential for interaction, monitor.
pimozide|ziprasidone|2|Significant - Monitor Closely|pimozide and ziprasidone both increase  sedation. Potential for interaction, monitor.
pindolol|pirbuterol|11|Significant - Monitor Closely|pindolol decreases effects of pirbuterol by pharmacodynamic antagonism. Significant interaction possible, monitor closely.
pindolol|pirbuterol|2|Significant - Monitor Closely|pindolol increases and pirbuterol decreases serum potassium. Effect of interaction is not clear, use caution. Potential for interaction, monitor.
piroxicam|pindolol|11|Significant - Monitor Closely|piroxicam decreases effects of pindolol by pharmacodynamic antagonism. Significant interaction possible, monitor closely. Long term (>1 wk) NSAID use.  NSAIDs decrease prostaglandin synthesis.
pindolol|piroxicam|2|Significant - Monitor Closely|pindolol and piroxicam both increase  serum potassium. Potential for interaction, monitor.
prazosin|pindolol|3|Significant - Monitor Closely|prazosin and pindolol both increase  anti-hypertensive channel blocking. Potential for dangerous interaction. Use with caution and monitor closely.
pindolol|salmeterol|11|Significant - Monitor Closely|pindolol decreases effects of salmeterol by pharmacodynamic antagonism. Significant interaction possible, monitor closely.
pindolol|salmeterol|2|Significant - Monitor Closely|pindolol increases and salmeterol decreases serum potassium. Effect of interaction is not clear, use caution. Potential for interaction, monitor.
terazosin|pindolol|3|Significant - Monitor Closely|terazosin and pindolol both increase  anti-hypertensive channel blocking. Potential for dangerous interaction. Use with caution and monitor closely.
pindolol|terbutaline|11|Significant - Monitor Closely|pindolol decreases effects of terbutaline by pharmacodynamic antagonism. Significant interaction possible, monitor closely.
pindolol|terbutaline|2|Significant - Monitor Closely|pindolol increases and terbutaline decreases serum potassium. Effect of interaction is not clear, use caution. Potential for interaction, monitor.
pindolol|theophylline|11|Significant - Monitor Closely|pindolol, theophylline. Other (see comment). Significant interaction possible, monitor closely. Comment: Beta blockers (esp. non selective) antagonize theophylline effects, while at the same time increasing theophylline levels and toxicity (mechanism: decreased theophylline metabolism). Smoking increases risk of interaction.
pindolol|tolazamide|11|Significant - Monitor Closely|pindolol decreases effects of tolazamide by pharmacodynamic antagonism. Significant interaction possible, monitor closely. Non selective beta blockers may also mask the symptoms of hypoglycemia.
pindolol|tolbutamide|11|Significant - Monitor Closely|pindolol decreases effects of tolbutamide by pharmacodynamic antagonism. Significant interaction possible, monitor closely. Non selective beta blockers may also mask the symptoms of hypoglycemia.
treprostinil|pindolol|1|Minor|treprostinil increases effects of pindolol by pharmacodynamic synergism. Minor or non-significant interaction.
pindolol|verapamil|3|Significant - Monitor Closely|pindolol and verapamil both increase  anti-hypertensive channel blocking. Potential for dangerous interaction. Use with caution and monitor closely.
tetracycline|piperacillin|11|Significant - Monitor Closely|tetracycline decreases effects of piperacillin by pharmacodynamic antagonism. Significant interaction possible, monitor closely. bacteriostatic agents may inhibit the effects of bactericidal agents.
propranolol|pirbuterol|11|Significant - Monitor Closely|propranolol decreases effects of pirbuterol by pharmacodynamic antagonism. Significant interaction possible, monitor closely.
propranolol|pirbuterol|2|Significant - Monitor Closely|propranolol increases and pirbuterol decreases serum potassium. Effect of interaction is not clear, use caution. Potential for interaction, monitor.
timolol|pirbuterol|11|Significant - Monitor Closely|timolol decreases effects of pirbuterol by pharmacodynamic antagonism. Significant interaction possible, monitor closely.
timolol|pirbuterol|2|Significant - Monitor Closely|timolol increases and pirbuterol decreases serum potassium. Effect of interaction is not clear, use caution. Potential for interaction, monitor.
piroxicam|pralatrexate|11|Significant - Monitor Closely|piroxicam increases levels of pralatrexate by decreasing renal clearance. Significant interaction possible, monitor closely. NSAIDs may delay pralatrexate clearance, increasing drug exposure. Adjust the pralatrexate dose as needed.
piroxicam|propranolol|11|Significant - Monitor Closely|piroxicam decreases effects of propranolol by pharmacodynamic antagonism. Significant interaction possible, monitor closely. Long term (>1 wk) NSAID use.  NSAIDs decrease prostaglandin synthesis.
propranolol|piroxicam|2|Significant - Monitor Closely|propranolol and piroxicam both increase  serum potassium. Potential for interaction, monitor.
piroxicam|sotalol|11|Significant - Monitor Closely|piroxicam decreases effects of sotalol by pharmacodynamic antagonism. Significant interaction possible, monitor closely. Long term (>1 wk) NSAID use.  NSAIDs decrease prostaglandin synthesis.
sotalol|piroxicam|2|Significant - Monitor Closely|sotalol and piroxicam both increase  serum potassium. Potential for interaction, monitor.
telmisartan|piroxicam|11|Significant - Monitor Closely|telmisartan, piroxicam.Either increases toxicity of the other by Other (see comment). Significant interaction possible, monitor closely. Comment: May result in renal function deterioration, particularly in elderly or volume depleted individuals.
piroxicam|telmisartan|3|Significant - Monitor Closely|piroxicam decreases effects of telmisartan by pharmacodynamic antagonism. Potential for dangerous interaction. Use with caution and monitor closely.  NSAIDs decrease synthesis of vasodilating renal prostaglandins, and thus affect fluid homeostasis and may diminish antihypertensive effect.
telmisartan|piroxicam|2|Significant - Monitor Closely|telmisartan and piroxicam both increase  serum potassium. Potential for interaction, monitor.
piroxicam|timolol|11|Significant - Monitor Closely|piroxicam decreases effects of timolol by pharmacodynamic antagonism. Significant interaction possible, monitor closely. Long term (>1 wk) NSAID use.  NSAIDs decrease prostaglandin synthesis.
timolol|piroxicam|2|Significant - Monitor Closely|timolol and piroxicam both increase  serum potassium. Potential for interaction, monitor.
piroxicam|tolbutamide|11|Significant - Monitor Closely|piroxicam increases effects of tolbutamide by unknown mechanism. Significant interaction possible, monitor closely. Risk of hypoglycemia.
trandolapril|piroxicam|11|Significant - Monitor Closely|trandolapril, piroxicam.Either increases toxicity of the other by Other (see comment). Significant interaction possible, monitor closely. Comment: May result in renal function deterioration, particularly in elderly or volume depleted individuals.
piroxicam|trandolapril|3|Significant - Monitor Closely|piroxicam decreases effects of trandolapril by pharmacodynamic antagonism. Potential for dangerous interaction. Use with caution and monitor closely. NSAIDs decrease synthesis of vasodilating renal prostaglandins, and thus affect fluid homeostasis and may diminish antihypertenisve effect.
voriconazole|piroxicam|1|Minor|voriconazole will increase the level or effect of piroxicam by  affecting hepatic enzyme CYP2C9/10 metabolism. Minor or non-significant interaction.
warfarin|piroxicam|3|Significant - Monitor Closely|warfarin and piroxicam both increase  anticoagulation. Potential for dangerous interaction. Use with caution and monitor closely.
tetracycline|pivmecillinam|20|Serious - Use Alternative|tetracycline decreases effects of pivmecillinam by pharmacodynamic antagonism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
posaconazole|ponatinib|20|Serious - Use Alternative|posaconazole increases levels of ponatinib by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available. Decrease ponatinib starting dose to 30 mg qDay if coadministration with strong CYP3A4 inhibitors cannot be avoided.
ponatinib|posaconazole|2|Significant - Monitor Closely|ponatinib increases levels of posaconazole by P-glycoprotein (MDR1) efflux transporter. Potential for interaction, monitor.
ritonavir|ponatinib|20|Serious - Use Alternative|ritonavir increases levels of ponatinib by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available. Decrease ponatinib starting dose to 30 mg qDay if coadministration with strong CYP3A4 inhibitors cannot be avoided.
ponatinib|ritonavir|2|Significant - Monitor Closely|ponatinib increases levels of ritonavir by P-glycoprotein (MDR1) efflux transporter. Potential for interaction, monitor.
saquinavir|ponatinib|20|Serious - Use Alternative|saquinavir increases levels of ponatinib by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available. Decrease ponatinib starting dose to 30 mg qDay if coadministration with strong CYP3A4 inhibitors cannot be avoided.
ponatinib|saquinavir|2|Significant - Monitor Closely|ponatinib increases levels of saquinavir by P-glycoprotein (MDR1) efflux transporter. Potential for interaction, monitor.
telaprevir|ponatinib|20|Serious - Use Alternative|telaprevir increases levels of ponatinib by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available. Decrease ponatinib starting dose to 30 mg qDay if coadministration with strong CYP3A4 inhibitors cannot be avoided.
ponatinib|telaprevir|2|Significant - Monitor Closely|ponatinib increases levels of telaprevir by P-glycoprotein (MDR1) efflux transporter. Potential for interaction, monitor.
telithromycin|ponatinib|20|Serious - Use Alternative|telithromycin increases levels of ponatinib by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available. Decrease ponatinib starting dose to 30 mg qDay if coadministration with strong CYP3A4 inhibitors cannot be avoided.
voriconazole|ponatinib|20|Serious - Use Alternative|voriconazole increases levels of ponatinib by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available. Decrease ponatinib starting dose to 30 mg qDay if coadministration with strong CYP3A4 inhibitors cannot be avoided.
quinidine|posaconazole|22|Serious - Use Alternative|quinidine and posaconazole both increase  QTc interval. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available.
posaconazole|quinidine|21|Serious - Use Alternative|posaconazole will increase the level or effect of quinidine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available. Never use combination. Use of posaconazole in combination with drugs that both prolong the QT interval and are substrates for CYP3A4 is contraindicated
quinidine|posaconazole|20|Serious - Use Alternative|quinidine will increase the level or effect of posaconazole by  P-glycoprotein (MDR1) efflux transporter. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
posaconazole|regorafenib|33|Contraindicated|posaconazole, regorafenib. affecting hepatic/intestinal enzyme CYP3A4 metabolism. Never use combination. Strong CYP3A4 inhibitors increase regorafenib levels and decrease exposure of the active metabolites M-2 and M-5.
rifabutin|posaconazole|11|Significant - Monitor Closely|rifabutin decreases levels of posaconazole by increasing metabolism. Significant interaction possible, monitor closely.
posaconazole|rifabutin|1|Minor|posaconazole increases levels of rifabutin by decreasing metabolism. Minor or non-significant interaction.
posaconazole|tacrolimus|11|Significant - Monitor Closely|posaconazole will increase the level or effect of tacrolimus by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
tacrolimus|posaconazole|11|Significant - Monitor Closely|tacrolimus will increase the level or effect of posaconazole by  P-glycoprotein (MDR1) efflux transporter. Significant interaction possible, monitor closely.
posaconazole|tadalafil|11|Significant - Monitor Closely|posaconazole will increase the level or effect of tadalafil by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
posaconazole|tamoxifen|11|Significant - Monitor Closely|posaconazole, tamoxifen. affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely. CYP3A4 inhibition decreases metabolism of tamoxifen to N-desmethyl tamoxifen (active metabolite with similar biologic activity).
posaconazole|tamsulosin|20|Serious - Use Alternative|posaconazole increases levels of tamsulosin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
posaconazole|telithromycin|2|Significant - Monitor Closely|posaconazole and telithromycin both increase  QTc interval. Potential for interaction, monitor.
posaconazole|telithromycin|1|Minor|posaconazole will increase the level or effect of telithromycin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor or non-significant interaction.
posaconazole|temsirolimus|11|Significant - Monitor Closely|posaconazole will increase the level or effect of temsirolimus by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
posaconazole|terfenadine|22|Serious - Use Alternative|posaconazole and terfenadine both increase  QTc interval. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available.
posaconazole|terfenadine|21|Serious - Use Alternative|posaconazole increases levels of terfenadine by decreasing metabolism. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available. Never use combination. Risk of QT interval prolongation.
posaconazole|terfenadine|20|Serious - Use Alternative|posaconazole will increase the level or effect of terfenadine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
posaconazole|tipranavir|11|Significant - Monitor Closely|posaconazole will increase the level or effect of tipranavir by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
posaconazole|tolterodine|11|Significant - Monitor Closely|posaconazole will increase the level or effect of tolterodine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
posaconazole|trazodone|20|Serious - Use Alternative|posaconazole will increase the level or effect of trazodone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
trazodone|posaconazole|11|Significant - Monitor Closely|trazodone will decrease the level or effect of posaconazole by  P-glycoprotein (MDR1) efflux transporter. Significant interaction possible, monitor closely.
trazodone|posaconazole|3|Significant - Monitor Closely|trazodone and posaconazole both increase  QTc interval. Potential for dangerous interaction. Use with caution and monitor closely.
trimipramine|posaconazole|3|Significant - Monitor Closely|trimipramine and posaconazole both increase  QTc interval. Potential for dangerous interaction. Use with caution and monitor closely.
posaconazole|vardenafil|11|Significant - Monitor Closely|posaconazole will increase the level or effect of vardenafil by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
posaconazole|venlafaxine|2|Significant - Monitor Closely|posaconazole and venlafaxine both increase  QTc interval. Potential for interaction, monitor.
posaconazole|verapamil|11|Significant - Monitor Closely|posaconazole will increase the level or effect of verapamil by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
verapamil|posaconazole|11|Significant - Monitor Closely|verapamil will increase the level or effect of posaconazole by  P-glycoprotein (MDR1) efflux transporter. Significant interaction possible, monitor closely.
posaconazole|vinblastine|1|Minor|posaconazole will increase the level or effect of vinblastine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor or non-significant interaction.
posaconazole|vincristine|1|Minor|posaconazole will increase the level or effect of vincristine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor or non-significant interaction.
posaconazole|vinorelbine|1|Minor|posaconazole will increase the level or effect of vinorelbine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor or non-significant interaction.
posaconazole|zolpidem|1|Minor|posaconazole will increase the level or effect of zolpidem by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor or non-significant interaction.
posaconazole|zonisamide|1|Minor|posaconazole will increase the level or effect of zonisamide by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor or non-significant interaction.
telmisartan|potassium chloride|11|Significant - Monitor Closely|telmisartan and potassium chloride both increase  serum potassium. Significant interaction possible, monitor closely.
trandolapril|potassium chloride|11|Significant - Monitor Closely|trandolapril increases levels of potassium chloride by decreasing elimination. Significant interaction possible, monitor closely. Risk of hyperkalemia.
probenecid|pralatrexate|11|Significant - Monitor Closely|probenecid increases levels of pralatrexate by decreasing renal clearance. Significant interaction possible, monitor closely.
sulfamethoxazole|pralatrexate|11|Significant - Monitor Closely|sulfamethoxazole increases levels of pralatrexate by decreasing renal clearance. Significant interaction possible, monitor closely.
sulindac|pralatrexate|11|Significant - Monitor Closely|sulindac increases levels of pralatrexate by decreasing renal clearance. Significant interaction possible, monitor closely. NSAIDs may delay pralatrexate clearance, increasing drug exposure. Adjust the pralatrexate dose as needed.
tolmetin|pralatrexate|11|Significant - Monitor Closely|tolmetin increases levels of pralatrexate by decreasing renal clearance. Significant interaction possible, monitor closely. NSAIDs may delay pralatrexate clearance, increasing drug exposure. Adjust the pralatrexate dose as needed.
thiothixene|pramipexole|21|Serious - Use Alternative|thiothixene decreases effects of pramipexole by pharmacodynamic antagonism. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available. Never use combination.
ziprasidone|pramipexole|21|Serious - Use Alternative|ziprasidone decreases effects of pramipexole by pharmacodynamic antagonism. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available. Never use combination.
pramlintide|tiotropium|21|Serious - Use Alternative|pramlintide, tiotropium.Either increases effects of the other by pharmacodynamic synergism. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available. Never use combination. Synergistic inhibition of GI motility.
pramlintide|tolterodine|21|Serious - Use Alternative|pramlintide, tolterodine.Either increases effects of the other by pharmacodynamic synergism. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available. Never use combination. Synergistic inhibition of GI motility.
pramlintide|trihexyphenidyl|11|Significant - Monitor Closely|pramlintide, trihexyphenidyl.Either increases effects of the other by pharmacodynamic synergism. Significant interaction possible, monitor closely. Synergistic inhibition of GI motility.
warfarin|prasugrel|21|Serious - Use Alternative|warfarin, prasugrel.Either increases effects of the other by pharmacodynamic synergism. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available. Never use combination. Enhanced risk of hemorrhage.
prazosin|propranolol|3|Significant - Monitor Closely|prazosin and propranolol both increase  anti-hypertensive channel blocking. Potential for dangerous interaction. Use with caution and monitor closely. The severity and duration of hypotension following the first dose of prazosin may be enhanced.
prazosin|sotalol|3|Significant - Monitor Closely|prazosin and sotalol both increase  anti-hypertensive channel blocking. Potential for dangerous interaction. Use with caution and monitor closely. The severity and duration of hypotension following the first dose of prazosin may be enhanced.
tadalafil|prazosin|11|Significant - Monitor Closely|tadalafil increases effects of prazosin by pharmacodynamic synergism. Significant interaction possible, monitor closely. Risk of hypotension.
prazosin|tamsulosin|20|Serious - Use Alternative|prazosin, tamsulosin.Either increases effects of the other by additive vasodilation. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available. Risk of hypotension.
prazosin|timolol|3|Significant - Monitor Closely|prazosin and timolol both increase  anti-hypertensive channel blocking. Potential for dangerous interaction. Use with caution and monitor closely.
treprostinil|prazosin|1|Minor|treprostinil increases effects of prazosin by pharmacodynamic synergism. Minor or non-significant interaction.
vardenafil|prazosin|21|Serious - Use Alternative|vardenafil increases effects of prazosin by pharmacodynamic synergism. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available. Never use combination. Risk of hypotension.
prazosin|verapamil|2|Significant - Monitor Closely|prazosin and verapamil both increase  anti-hypertensive channel blocking. Potential for interaction, monitor.
primidone|prednisolone|11|Significant - Monitor Closely|primidone will decrease the level or effect of prednisolone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
salsalate|prednisolone|11|Significant - Monitor Closely|salsalate, prednisolone.Either increases toxicity of the other by pharmacodynamic synergism. Significant interaction possible, monitor closely. Increased risk of GI ulceration.
prednisolone|salsalate|1|Minor|prednisolone decreases levels of salsalate by increasing renal clearance. Minor or non-significant interaction.
secobarbital|prednisolone|11|Significant - Monitor Closely|secobarbital will decrease the level or effect of prednisolone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
prednisolone|warfarin|11|Significant - Monitor Closely|prednisolone will decrease the level or effect of warfarin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
prednisolone|warfarin|11|Significant - Monitor Closely|prednisolone, warfarin. Other (see comment). Significant interaction possible, monitor closely. Comment: Corticosteroids may decrease anticoagulant effects by increasing blood coagulability; conversely, they may impair vascular integrity, thus increasing bleeding risk.  Monitor INR closely.
primidone|prednisone|11|Significant - Monitor Closely|primidone will decrease the level or effect of prednisone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
salsalate|prednisone|11|Significant - Monitor Closely|salsalate, prednisone.Either increases toxicity of the other by pharmacodynamic synergism. Significant interaction possible, monitor closely. Increased risk of GI ulceration.
prednisone|salsalate|1|Minor|prednisone decreases levels of salsalate by increasing renal clearance. Minor or non-significant interaction.
secobarbital|prednisone|11|Significant - Monitor Closely|secobarbital will decrease the level or effect of prednisone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
prednisone|warfarin|11|Significant - Monitor Closely|prednisone will decrease the level or effect of warfarin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
prednisone|warfarin|11|Significant - Monitor Closely|prednisone, warfarin. Other (see comment). Significant interaction possible, monitor closely. Comment: Corticosteroids may decrease anticoagulant effects by increasing blood coagulability; conversely, they may impair vascular integrity, thus increasing bleeding risk.  Monitor INR closely.
primidone|propranolol|11|Significant - Monitor Closely|primidone decreases levels of propranolol by increasing metabolism. Significant interaction possible, monitor closely. Consider a higher beta-blocker dose during coadministration of primidone.  Atenolol, sotalol, nadolol less likely to be affected than other beta blockers.
primidone|quinidine|11|Significant - Monitor Closely|primidone will decrease the level or effect of quinidine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
primidone|roflumilast|33|Contraindicated|primidone will decrease the level or effect of roflumilast by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Never use combination. Coadministration not recommended; strong cytochrome P450 enzyme inducers decrease systemic exposure to roflumilast and may reduce the therapeutic effectiveness
primidone|roflumilast|33|Contraindicated|primidone will decrease the level or effect of roflumilast by  affecting hepatic enzyme CYP1A2 metabolism. Never use combination. Coadministration not recommended; strong cytochrome P450 enzyme inducers decrease systemic exposure to roflumilast and may reduce the therapeutic effectiveness
primidone|rufinamide|11|Significant - Monitor Closely|primidone decreases levels of rufinamide by increasing metabolism. Significant interaction possible, monitor closely.
primidone|telithromycin|1|Minor|primidone will decrease the level or effect of telithromycin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor or non-significant interaction.
primidone|temsirolimus|11|Significant - Monitor Closely|primidone will decrease the level or effect of temsirolimus by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
primidone|theophylline|11|Significant - Monitor Closely|primidone will decrease the level or effect of theophylline by  affecting hepatic enzyme CYP1A2 metabolism. Significant interaction possible, monitor closely.
primidone|theophylline|11|Significant - Monitor Closely|primidone will decrease the level or effect of theophylline by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
primidone|tramadol|11|Significant - Monitor Closely|primidone will decrease the level or effect of tramadol by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely. Decreased AUC  of tramadol and the active metabolite (O-desmethyltramadol) when coadministered with strong CYP3A4 and CYP2B6 inducers
primidone|tramadol|2|Significant - Monitor Closely|primidone and tramadol both increase  sedation. Potential for interaction, monitor.
primidone|trazodone|11|Significant - Monitor Closely|primidone will decrease the level or effect of trazodone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
primidone|trazodone|2|Significant - Monitor Closely|primidone and trazodone both increase  sedation. Potential for interaction, monitor.
primidone|trazodone|1|Minor|primidone, trazodone. Other (see comment). Minor or non-significant interaction. Comment: Barbiturates may increase adverse effects, including respiratory depression, produced by toxic doses of TCAs. With therapeutic doses of TCAs, barbiturates increase metabolism and decrease blood concentrations of TCAs.
primidone|triamcinolone|11|Significant - Monitor Closely|primidone will decrease the level or effect of triamcinolone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
triprolidine|primidone|2|Significant - Monitor Closely|triprolidine and primidone both increase  sedation. Potential for interaction, monitor.
primidone|vandetanib|33|Contraindicated|primidone decreases levels of vandetanib by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Never use combination. Avoid coadministration with potent CYP3A4 inducers; these drugs reduce exposure to vandetanib by up to 40%.
primidone|verapamil|11|Significant - Monitor Closely|primidone will decrease the level or effect of verapamil by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
primidone|voriconazole|21|Serious - Use Alternative|primidone decreases levels of voriconazole by increasing metabolism. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available. Never use combination.
primidone|voriconazole|1|Minor|primidone will decrease the level or effect of voriconazole by  affecting hepatic enzyme CYP2C19 metabolism. Minor or non-significant interaction.
primidone|voriconazole|1|Minor|primidone will decrease the level or effect of voriconazole by  affecting hepatic enzyme CYP2C9/10 metabolism. Minor or non-significant interaction.
primidone|warfarin|20|Serious - Use Alternative|primidone decreases effects of warfarin by increasing metabolism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
primidone|warfarin|11|Significant - Monitor Closely|primidone will decrease the level or effect of warfarin by  affecting hepatic enzyme CYP1A2 metabolism. Significant interaction possible, monitor closely.
primidone|warfarin|11|Significant - Monitor Closely|primidone will decrease the level or effect of warfarin by  affecting hepatic enzyme CYP2C9/10 metabolism. Significant interaction possible, monitor closely.
primidone|warfarin|11|Significant - Monitor Closely|primidone will decrease the level or effect of warfarin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
primidone|warfarin|1|Minor|primidone will decrease the level or effect of warfarin by  affecting hepatic enzyme CYP2C19 metabolism. Minor or non-significant interaction.
salsalate|probenecid|11|Significant - Monitor Closely|salsalate will increase the level or effect of probenecid by  acidic (anionic) drug competition for renal tubular clearance. Significant interaction possible, monitor closely.
salsalate|probenecid|11|Significant - Monitor Closely|salsalate decreases effects of probenecid by unknown mechanism. Significant interaction possible, monitor closely.
probenecid|valganciclovir|11|Significant - Monitor Closely|probenecid will increase the level or effect of valganciclovir by  acidic (anionic) drug competition for renal tubular clearance. Significant interaction possible, monitor closely.
probenecid|zidovudine|11|Significant - Monitor Closely|probenecid increases levels of zidovudine by decreasing metabolism. Significant interaction possible, monitor closely.
quinidine|procainamide|33|Contraindicated|quinidine and procainamide both increase  QTc interval. Never use combination.
quinidine|procainamide|20|Serious - Use Alternative|quinidine will increase the level or effect of procainamide by  basic (cationic) drug competition for renal tubular clearance. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
ranitidine|procainamide|3|Significant - Monitor Closely|ranitidine will increase the level or effect of procainamide by  basic (cationic) drug competition for renal tubular clearance. Potential for dangerous interaction. Use with caution and monitor closely.
procainamide|ranolazine|22|Serious - Use Alternative|procainamide and ranolazine both increase  QTc interval. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available.
procainamide|telavancin|22|Serious - Use Alternative|procainamide and telavancin both increase  QTc interval. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available.
procainamide|terfenadine|33|Contraindicated|procainamide and terfenadine both increase  QTc interval. Never use combination.
thioridazine|procainamide|33|Contraindicated|thioridazine and procainamide both increase  QTc interval. Never use combination.
procainamide|toremifene|20|Serious - Use Alternative|procainamide and toremifene both increase  QTc interval. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available. Concurrent use of toremifene with agents causing  QT prolongation should be avoided. If concomitant use is required it's recommended that toremifene be interrupted. If interruption not possible, patients requiring therapy with a drug that prolongs QT should be closely monitored. ECGs should be obtained for high risk patients.
procainamide|trimethoprim|22|Serious - Use Alternative|procainamide and trimethoprim both increase  QTc interval. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available.
procainamide|trimethoprim|11|Significant - Monitor Closely|procainamide will increase the level or effect of trimethoprim by  basic (cationic) drug competition for renal tubular clearance. Significant interaction possible, monitor closely.
trimipramine|procainamide|33|Contraindicated|trimipramine and procainamide both increase  QTc interval. Never use combination.
procainamide|voriconazole|22|Serious - Use Alternative|procainamide and voriconazole both increase  QTc interval. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available.
procainamide|ziprasidone|33|Contraindicated|procainamide and ziprasidone both increase  QTc interval. Never use combination.
tetrabenazine|procarbazine|33|Contraindicated|tetrabenazine, procarbazine. Other (see comment). Never use combination. Comment: Risk of acute hypertensive episode; separate by 14 d.  Mechanism: MAOI causes accumulation of NE in neuron and tetrabenazine stimulates NE release.
tolcapone|procarbazine|22|Serious - Use Alternative|tolcapone increases effects of procarbazine by pharmacodynamic synergism. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available.
procarbazine|tramadol|33|Contraindicated|procarbazine and tramadol both increase  serotonin levels. Never use combination.
procarbazine|tramadol|20|Serious - Use Alternative|procarbazine increases toxicity of tramadol by unknown mechanism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available. MAOIs may potentiate CNS depression and hypotension. Do not use within 14 days of MAOI use. .
procarbazine|tranylcypromine|33|Contraindicated|procarbazine and tranylcypromine both increase  serotonin levels. Never use combination. At least 2 weeks should elapse between discontinuation of one MAOI and initiation of therapy with the other.
procarbazine|trazodone|33|Contraindicated|procarbazine and trazodone both increase  serotonin levels. Never use combination. Combination is contraindicated within 2 weeks of MAOI use.
procarbazine|trimipramine|33|Contraindicated|procarbazine and trimipramine both increase  serotonin levels. Never use combination. Combination is contraindicated within 2 weeks of MAOI use.
procarbazine|venlafaxine|33|Contraindicated|procarbazine and venlafaxine both increase  serotonin levels. Never use combination. Combination is contraindicated within 2 weeks of MAOI use.
zolmitriptan|procarbazine|33|Contraindicated|zolmitriptan and procarbazine both increase  serotonin levels. Never use combination. Combination is contraindicated within 2 weeks of MAOI use.
procarbazine|zolmitriptan|22|Serious - Use Alternative|procarbazine increases levels of zolmitriptan by decreasing metabolism. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available.
prochlorperazine|terfenadine|33|Contraindicated|prochlorperazine and terfenadine both increase  QTc interval. Never use combination.
terfenadine|prochlorperazine|2|Significant - Monitor Closely|terfenadine and prochlorperazine both increase  sedation. Potential for interaction, monitor.
prochlorperazine|tetrabenazine|3|Significant - Monitor Closely|prochlorperazine and tetrabenazine both increase  antidopaminergic effects, including extrapyramidal symptoms and neuroleptic malignant syndrome. Potential for dangerous interaction. Use with caution and monitor closely.
triprolidine|prochlorperazine|2|Significant - Monitor Closely|triprolidine and prochlorperazine both increase  sedation. Potential for interaction, monitor.
promazine|terfenadine|33|Contraindicated|promazine and terfenadine both increase  QTc interval. Never use combination.
promethazine|terfenadine|33|Contraindicated|promethazine and terfenadine both increase  QTc interval. Never use combination.
promethazine|terfenadine|2|Significant - Monitor Closely|promethazine and terfenadine both increase  sedation. Potential for interaction, monitor.
promethazine|tramadol|2|Significant - Monitor Closely|promethazine and tramadol both increase  sedation. Potential for interaction, monitor.
tranylcypromine|promethazine|22|Serious - Use Alternative|tranylcypromine increases effects of promethazine by Other (see comment). High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available. Comment: Tranylcypromine should not be administered in combination with antihistamines because of potential additive CNS depressant effects.  MAO inhibitors also prolong and intensify anticholinergic effects of antihistamines. Combination of tranylcypromine and promethazine may result in additive hypotensive effects.
promethazine|trazodone|11|Significant - Monitor Closely|promethazine and trazodone both increase  QTc interval. Significant interaction possible, monitor closely.
promethazine|trazodone|2|Significant - Monitor Closely|promethazine and trazodone both increase  sedation. Potential for interaction, monitor.
trazodone|promethazine|1|Minor|trazodone, promethazine.Either increases toxicity of the other by pharmacodynamic synergism. Minor or non-significant interaction. Additive hypotensive effects.
trazodone|promethazine|1|Minor|trazodone, promethazine.Either increases levels of the other by decreasing metabolism. Minor or non-significant interaction. Additive anticholinergic effects.
promethazine|trimipramine|22|Serious - Use Alternative|promethazine and trimipramine both increase  QTc interval. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available.
promethazine|trimipramine|2|Significant - Monitor Closely|promethazine and trimipramine both increase  sedation. Potential for interaction, monitor.
trimipramine|promethazine|1|Minor|trimipramine, promethazine.Either increases levels of the other by decreasing metabolism. Minor or non-significant interaction. Additive anticholinergic effects.
trimipramine|promethazine|1|Minor|trimipramine, promethazine.Either increases levels of the other by pharmacodynamic synergism. Minor or non-significant interaction. Additive anticholinergic effects.
promethazine|triprolidine|2|Significant - Monitor Closely|promethazine and triprolidine both increase  sedation. Potential for interaction, monitor.
venlafaxine|promethazine|20|Serious - Use Alternative|venlafaxine will increase the level or effect of promethazine by  affecting hepatic enzyme CYP2D6 metabolism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
promethazine|venlafaxine|11|Significant - Monitor Closely|promethazine and venlafaxine both increase  QTc interval. Significant interaction possible, monitor closely.
propafenone|propranolol|11|Significant - Monitor Closely|propafenone will increase the level or effect of propranolol by  affecting hepatic enzyme CYP2D6 metabolism. Significant interaction possible, monitor closely. If concurrent therapy is required, monitor cardiac function carefully, particularly blood pressure. A dosage adjustment for the beta blocker may be required.
quinidine|propafenone|20|Serious - Use Alternative|quinidine will increase the level or effect of propafenone by  affecting hepatic enzyme CYP2D6 metabolism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available.
rifabutin|propafenone|2|Significant - Monitor Closely|rifabutin will decrease the level or effect of propafenone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Potential for interaction, monitor.
rifabutin|propafenone|1|Minor|rifabutin decreases levels of propafenone by increasing metabolism. Minor or non-significant interaction.
ritonavir|propafenone|22|Serious - Use Alternative|ritonavir will increase the level or effect of propafenone by  affecting hepatic enzyme CYP2D6 metabolism. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available. Concurrent use of propafenone and ritonavir is contraindicated.
ritonavir|propafenone|21|Serious - Use Alternative|ritonavir increases levels of propafenone by decreasing metabolism. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available. Never use combination.
ritonavir|propafenone|1|Minor|ritonavir will increase the level or effect of propafenone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor or non-significant interaction.
sertraline|propafenone|1|Minor|sertraline will increase the level or effect of propafenone by  affecting hepatic enzyme CYP2D6 metabolism. Minor or non-significant interaction. Monitor the EKG in patients receiving concurrent propafenone and sertraline. Doses of propafenone may need to be reduced.
propafenone|theophylline|1|Minor|propafenone increases levels of theophylline by decreasing renal clearance. Minor or non-significant interaction.
propafenone|thioridazine|22|Serious - Use Alternative|propafenone will increase the level or effect of thioridazine by  affecting hepatic enzyme CYP2D6 metabolism. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available. The concurrent administration of thioridazine and agents that prolong the QT interval, such as Class I antiarrhythmic agents, is contraindicated.
thioridazine|propafenone|22|Serious - Use Alternative|thioridazine will increase the level or effect of propafenone by  affecting hepatic enzyme CYP2D6 metabolism. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available. The concurrent administration of thioridazine and agents that prolong the QT interval, such as Class I antiarrhythmic agents, is contraindicated.
tipranavir|propafenone|33|Contraindicated|tipranavir increases levels of propafenone by decreasing metabolism. Never use combination.
tipranavir|propafenone|11|Significant - Monitor Closely|tipranavir will increase the level or effect of propafenone by  affecting hepatic enzyme CYP2D6 metabolism. Significant interaction possible, monitor closely.
propafenone|toremifene|20|Serious - Use Alternative|propafenone and toremifene both increase  QTc interval. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available. Concurrent use of toremifene with agents causing  QT prolongation should be avoided. If concomitant use is required it's recommended that toremifene be interrupted. If interruption not possible, patients requiring therapy with a drug that prolongs QT should be closely monitored. ECGs should be obtained for high risk patients.
venlafaxine|propafenone|2|Significant - Monitor Closely|venlafaxine will increase the level or effect of propafenone by  affecting hepatic enzyme CYP2D6 metabolism. Potential for interaction, monitor.
voriconazole|propafenone|1|Minor|voriconazole will increase the level or effect of propafenone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor or non-significant interaction.
propafenone|warfarin|11|Significant - Monitor Closely|propafenone increases effects of warfarin by decreasing metabolism. Significant interaction possible, monitor closely.
tacrine|propantheline|2|Significant - Monitor Closely|tacrine increases and propantheline decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Potential for interaction, monitor.
tacrine|propantheline|1|Minor|tacrine decreases effects of propantheline by pharmacodynamic antagonism. Minor or non-significant interaction.
propranolol|rizatriptan|2|Significant - Monitor Closely|propranolol increases levels of rizatriptan by unknown mechanism. Potential for interaction, monitor. Do not exceed rizatriptan 5 mg/dose, up to a maximum of 3 doses in 24 hr .
propranolol|salmeterol|11|Significant - Monitor Closely|propranolol decreases effects of salmeterol by pharmacodynamic antagonism. Significant interaction possible, monitor closely.
propranolol|salmeterol|2|Significant - Monitor Closely|propranolol increases and salmeterol decreases serum potassium. Effect of interaction is not clear, use caution. Potential for interaction, monitor.
sertraline|propranolol|11|Significant - Monitor Closely|sertraline will increase the level or effect of propranolol by  affecting hepatic enzyme CYP2D6 metabolism. Significant interaction possible, monitor closely.  Sertraline is a moderate to weak inhibitor of the hepatic (CYP2D6) which may be involved in the metabolism of propranolol.  Monitor patients receiving propranolol and sertraline cotherapy for an increased incidence of chest pain. This effect may be more pronounced in patients with preexisting coronary artery disease.
terazosin|propranolol|3|Significant - Monitor Closely|terazosin and propranolol both increase  anti-hypertensive channel blocking. Potential for dangerous interaction. Use with caution and monitor closely. Additive hypotensive effects may occur when terazosin is used in combination with propranolol.
propranolol|terbutaline|11|Significant - Monitor Closely|propranolol decreases effects of terbutaline by pharmacodynamic antagonism. Significant interaction possible, monitor closely.
propranolol|terbutaline|2|Significant - Monitor Closely|propranolol increases and terbutaline decreases serum potassium. Effect of interaction is not clear, use caution. Potential for interaction, monitor.
propranolol|theophylline|11|Significant - Monitor Closely|propranolol, theophylline. Other (see comment). Significant interaction possible, monitor closely. Comment: Beta blockers (esp. non selective) antagonize theophylline effects, while at the same time increasing theophylline levels and toxicity (mechanism: decreased theophylline metabolism). Smoking increases risk of interaction.
thioridazine|propranolol|22|Serious - Use Alternative|thioridazine will increase the level or effect of propranolol by  affecting hepatic enzyme CYP2D6 metabolism. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available. Due to the potential for significant, possibly life-threatening, proarrhythmic effects, concurrent administration of thioridazine and propranolol is contraindicated.
propranolol|thioridazine|21|Serious - Use Alternative|propranolol, thioridazine.Either increases levels of the other by decreasing metabolism. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available. Never use combination. Not all beta blockers share this interaction (e.g., atenolol, nadolol, sotalol do not interact).
propranolol|tolazamide|11|Significant - Monitor Closely|propranolol decreases effects of tolazamide by pharmacodynamic antagonism. Significant interaction possible, monitor closely. Non selective beta blockers may also mask the symptoms of hypoglycemia.
propranolol|tolbutamide|11|Significant - Monitor Closely|propranolol decreases effects of tolbutamide by pharmacodynamic antagonism. Significant interaction possible, monitor closely. Non selective beta blockers may also mask the symptoms of hypoglycemia.
verapamil|propranolol|20|Serious - Use Alternative|verapamil, propranolol.Either increases toxicity of the other by unspecified interaction mechanism. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available. Can increase risk of bradycardia.
propranolol|verapamil|3|Significant - Monitor Closely|propranolol and verapamil both increase  anti-hypertensive channel blocking. Potential for dangerous interaction. Use with caution and monitor closely.
propylthiouracil|warfarin|11|Significant - Monitor Closely|propylthiouracil decreases effects of warfarin by pharmacodynamic antagonism. Significant interaction possible, monitor closely.
protriptyline|pseudoephedrine|20|Serious - Use Alternative|protriptyline, pseudoephedrine. Other (see comment). Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available. Comment: Tricyclic antidepressants increase or decrease effects of sympathomimetics, by blocking reuptake of NE, or blocking uptake of indirect sympathomimetics into the adrenergic neuron.
protriptyline|pseudoephedrine|2|Significant - Monitor Closely|protriptyline increases and pseudoephedrine decreases sedation. Effect of interaction is not clear, use caution. Potential for interaction, monitor.
quinidine|protriptyline|33|Contraindicated|quinidine and protriptyline both increase  QTc interval. Never use combination.
rasagiline|protriptyline|20|Serious - Use Alternative|rasagiline and protriptyline both increase  serotonin levels. Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available. Severe CNS toxicity associated with hyperpyrexia has been reported with the combined treatment of an antidepressant and rasagiline. Avoid combination within 14 days of MAOI use.
rifabutin|protriptyline|11|Significant - Monitor Closely|rifabutin decreases levels of protriptyline by increasing metabolism. Significant interaction possible, monitor closely.
protriptyline|terbutaline|20|Serious - Use Alternative|protriptyline, terbutaline. Other (see comment). Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available. Comment: Tricyclic antidepressants increase or decrease effects of sympathomimetics, by blocking reuptake of NE, or blocking uptake of indirect sympathomimetics into the adrenergic neuron.
protriptyline|terbutaline|2|Significant - Monitor Closely|protriptyline increases and terbutaline decreases sedation. Effect of interaction is not clear, use caution. Potential for interaction, monitor.
protriptyline|terfenadine|33|Contraindicated|protriptyline and terfenadine both increase  QTc interval. Never use combination.
terfenadine|protriptyline|2|Significant - Monitor Closely|terfenadine and protriptyline both increase  sedation. Potential for interaction, monitor.
thiothixene|protriptyline|2|Significant - Monitor Closely|thiothixene and protriptyline both increase  sedation. Potential for interaction, monitor.
protriptyline|tramadol|3|Significant - Monitor Closely|protriptyline and tramadol both increase  serotonin levels. Potential for dangerous interaction. Use with caution and monitor closely.
tramadol|protriptyline|2|Significant - Monitor Closely|tramadol and protriptyline both increase  sedation. Potential for interaction, monitor.
tranylcypromine|protriptyline|33|Contraindicated|tranylcypromine and protriptyline both increase  serotonin levels. Never use combination.
protriptyline|trazodone|22|Serious - Use Alternative|protriptyline and trazodone both increase  QTc interval. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available.
trazodone|protriptyline|22|Serious - Use Alternative|trazodone and protriptyline both increase  serotonin levels. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available.
protriptyline|trazodone|2|Significant - Monitor Closely|protriptyline and trazodone both decrease  cholinergic effects/transmission. Potential for interaction, monitor.
protriptyline|trazodone|2|Significant - Monitor Closely|protriptyline and trazodone both increase  sedation. Potential for interaction, monitor.
protriptyline|trimipramine|22|Serious - Use Alternative|protriptyline and trimipramine both increase  QTc interval. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available.
protriptyline|trimipramine|22|Serious - Use Alternative|protriptyline and trimipramine both increase  serotonin levels. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available.
protriptyline|trimipramine|2|Significant - Monitor Closely|protriptyline and trimipramine both decrease  cholinergic effects/transmission. Potential for interaction, monitor.
protriptyline|trimipramine|2|Significant - Monitor Closely|protriptyline and trimipramine both increase  sedation. Potential for interaction, monitor.
triprolidine|protriptyline|2|Significant - Monitor Closely|triprolidine and protriptyline both increase  sedation. Potential for interaction, monitor.
venlafaxine|protriptyline|22|Serious - Use Alternative|venlafaxine and protriptyline both increase  serotonin levels. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available.
protriptyline|venlafaxine|3|Significant - Monitor Closely|protriptyline and venlafaxine both increase  QTc interval. Potential for dangerous interaction. Use with caution and monitor closely.
protriptyline|voriconazole|3|Significant - Monitor Closely|protriptyline and voriconazole both increase  QTc interval. Potential for dangerous interaction. Use with caution and monitor closely.
protriptyline|ziprasidone|22|Serious - Use Alternative|protriptyline and ziprasidone both increase  QTc interval. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available.
ziprasidone|protriptyline|2|Significant - Monitor Closely|ziprasidone and protriptyline both increase  sedation. Potential for interaction, monitor.
zolmitriptan|protriptyline|3|Significant - Monitor Closely|zolmitriptan and protriptyline both increase  serotonin levels. Potential for dangerous interaction. Use with caution and monitor closely.
rasagiline|pseudoephedrine|33|Contraindicated|rasagiline increases effects of pseudoephedrine by pharmacodynamic synergism. Never use combination. Risk of acute hypertensive episode.
tranylcypromine|pseudoephedrine|33|Contraindicated|tranylcypromine increases effects of pseudoephedrine by pharmacodynamic synergism. Never use combination. Risk of acute hypertensive episode.
trimipramine|pseudoephedrine|20|Serious - Use Alternative|trimipramine, pseudoephedrine. Other (see comment). Possible serious or life-threatening interaction. Monitor closely. Use alternatives if available. Comment: Tricyclic antidepressants increase or decrease effects of sympathomimetics, by blocking reuptake of NE, or blocking uptake of indirect sympathomimetics into the adrenergic neuron.
trimipramine|pseudoephedrine|2|Significant - Monitor Closely|trimipramine increases and pseudoephedrine decreases sedation. Effect of interaction is not clear, use caution. Potential for interaction, monitor.
pyrimethamine|tamsulosin|2|Significant - Monitor Closely|pyrimethamine increases levels of tamsulosin by affecting hepatic enzyme CYP2D6 metabolism. Potential for interaction, monitor.
triprolidine|quazepam|2|Significant - Monitor Closely|triprolidine and quazepam both increase  sedation. Potential for interaction, monitor.
quetiapine|tacrolimus|2|Significant - Monitor Closely|quetiapine, tacrolimus.Either increases toxicity of the other by QTc interval. Potential for interaction, monitor. Avoid use with drugs that prolong QT and in patients with risk factors for prolonged QT interval. Postmarketing cases show QT prolongation with overdose in patients with concomitant illness or with drugs known to cause electrolyte imbalance or prolong QT.
telithromycin|quetiapine|11|Significant - Monitor Closely|telithromycin will increase the level or effect of quetiapine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
quetiapine|telithromycin|2|Significant - Monitor Closely|quetiapine, telithromycin.Either increases toxicity of the other by QTc interval. Potential for interaction, monitor. Avoid use with drugs that prolong QT and in patients with risk factors for prolonged QT interval. Postmarketing cases show QT prolongation with overdose in patients with concomitant illness or with drugs known to cause electrolyte imbalance or prolong QT.
quetiapine|tetrabenazine|3|Significant - Monitor Closely|quetiapine and tetrabenazine both increase  antidopaminergic effects, including extrapyramidal symptoms and neuroleptic malignant syndrome. Potential for dangerous interaction. Use with caution and monitor closely.
quetiapine|thiothixene|2|Significant - Monitor Closely|quetiapine and thiothixene both increase  antidopaminergic effects, including extrapyramidal symptoms and neuroleptic malignant syndrome. Potential for interaction, monitor.
quetiapine|thiothixene|2|Significant - Monitor Closely|quetiapine and thiothixene both increase  sedation. Potential for interaction, monitor.
quetiapine|thiothixene|2|Significant - Monitor Closely|quetiapine, thiothixene.Either increases toxicity of the other by QTc interval. Potential for interaction, monitor. Avoid use with drugs that prolong QT and in patients with risk factors for prolonged QT interval. Postmarketing cases show QT prolongation with overdose in patients with concomitant illness or with drugs known to cause electrolyte imbalance or prolong QT.
quetiapine|toremifene|2|Significant - Monitor Closely|quetiapine, toremifene.Either increases toxicity of the other by QTc interval. Potential for interaction, monitor. Avoid use with drugs that prolong QT and in patients with risk factors for prolonged QT interval. Postmarketing cases show QT prolongation with overdose in patients with concomitant illness or with drugs known to cause electrolyte imbalance or prolong QT.
quetiapine|trimipramine|2|Significant - Monitor Closely|quetiapine and trimipramine both increase  sedation. Potential for interaction, monitor.
quetiapine|trimipramine|2|Significant - Monitor Closely|quetiapine, trimipramine.Either increases toxicity of the other by QTc interval. Potential for interaction, monitor. Avoid use with drugs that prolong QT and in patients with risk factors for prolonged QT interval. Postmarketing cases show QT prolongation with overdose in patients with concomitant illness or with drugs known to cause electrolyte imbalance or prolong QT.
triprolidine|quetiapine|2|Significant - Monitor Closely|triprolidine and quetiapine both increase  sedation. Potential for interaction, monitor.
voriconazole|quetiapine|11|Significant - Monitor Closely|voriconazole will increase the level or effect of quetiapine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely.
quetiapine|voriconazole|2|Significant - Monitor Closely|quetiapine, voriconazole.Either increases toxicity of the other by QTc interval. Potential for interaction, monitor. Avoid use with drugs that prolong QT and in patients with risk factors for prolonged QT interval. Postmarketing cases show QT prolongation with overdose in patients with concomitant illness or with drugs known to cause electrolyte imbalance or prolong QT.
